2019 Science Program by American Academy of Neurology

2019 SCIENCE PROGRAM REGISTRATION  ANNUAL MEETING SCHEDULE  ABSTRACTS Also available at AAN.com and the

AAN Conferences App

May 4–May 10  Philadelphia Advance Registration Deadline: April 11, 2019

ADVANCING NEUROLOGY. ADVANCING YOU.

The

Philly Spectacular Kick-off the Annual Meeting at Reading Terminal Market! Embrace the city’s rich history and enjoy an incredible selection of locally grown produce, locally sourced meats, plus the finest seafood, cheeses, baked goods, and confections. Eat and drink, play games, and check out the award-winning local 12-piece band, Jellyroll, in action on Sunday, May 5, from 7:00 p.m.–10:00 p.m. Tickets include: • All-you-can-eat food and beverage • Entertainment • Transportation • Private access to the Field House sports bar The first 4,000 Annual Meeting registered attendees who RSVP for a ticket get one free, all-inclusive event ticket and additional tickets may be purchased for $115 through registration.

WHAT'S INSIDE Introduction

Whatâ&#x20AC;&#x2122;s New for 2019 . . . . . . . . . . . . . . . . 3 How to Get the Most from This Guide . . . . . . . . 5 Registration . . . . . . . . . . . . . . . . . . . . 8

Annual Meeting Overviews Meeting-at-a-Glance Tear Out . . . . . . . . . . 17 Annual Meeting Schedule Overview Saturday, May 4 . . . . . . . . . . . . . 19 Sunday, May 5 . . . . . . . . . . . . . . 21 Monday, May 6 . . . . . . . . . . . . . . 24 Tuesday, May 7 . . . . . . . . . . . . . . 27 Wednesday, May 8 . . . . . . . . . . . . 30 Thursday, May 9 . . . . . . . . . . . . . 33 Friday, May 10 . . . . . . . . . . . . . . 35 Programs Listed by Topic . . . . . . . . . . . . . 39 Program Tracks . . . . . . . . . . . . . . . . . 58

Annual Meeting Sessions Plenary Sessions . . . . . . . . . . . . . . . Hot Topics . . . . . . . . . . . . . . . . 68 Presidential . . . . . . . . . . . . . . . 69 Contemporary Clinical Issues . . . . . . . . 70 Clinical Trials . . . . . . . . . . . . . . . 71 Frontiers in Neuroscience . . . . . . . . . 72 Controversies in Neurology . . . . . . . . . 73 Neurology Year in Review . . . . . . . . . 74 Experiential Learning Areas . . . . . . . . . . HeadTalks . . . . . . . . . . . . . . . . 76 Live Well . . . . . . . . . . . . . . . . 78 Maximize Your Value/Advocacy to Action . . . 80 The Grand Experience . . . . . . . . . . . 82 Navigating Your Career . . . . . . . . 84 Research Corner . . . . . . . . . . . 85 Innovation Hub . . . . . . . . . . . . . . 86 Experience the AAN: Make the Most of Your Membership . . . . . . . . . . . . . . . 88 Neuroscience in the Clinic Sessions . . . . . . Sunday, May 5 . . . . . . . . . . . . . . 90 Monday, May 6 . . . . . . . . . . . . . 90 Tuesday, May 7 . . . . . . . . . . . . . . 91 Wednesday, May 8 . . . . . . . . . . . . 91 Thursday, May 9 . . . . . . . . . . . . . 92 Invited Science Sessions . . . . . . . . . . . Sunday, May 5 . . . . . . . . . . . . . . 94 Tuesday, May 7 . . . . . . . . . . . . . . 95 Thursday, May 9 . . . . . . . . . . . . . 95

. . 67

. 75

Scientific Sessions . . . . . . . . . . . . . . . . 97 Sunday, May 5 . . . . . . . . . . . . . . 99 Monday, May 6 . . . . . . . . . . . . . 103 Tuesday, May 7 . . . . . . . . . . . . . 108 Wednesday, May 8 . . . . . . . . . . . . 112 Thursday, May 9 . . . . . . . . . . . . . 116 Friday, May 10 . . . . . . . . . . . . . 120 Poster Sessions . . . . . . . . . . . . . . . . . 123 Poster Session 1 . . . . . . . . . . . . . 124 Poster Session 2 . . . . . . . . . . . . . 142 Poster Session 3 . . . . . . . . . . . . . 160 Poster Session 4 . . . . . . . . . . . . . 178 Poster Session 5 . . . . . . . . . . . . . 195 st 71 Annual Meeting Exhibitors . . . . . . . . . . 215 2019 Award Recipients . . . . . . . . . . . . . . 216 2019 Research Program Recipients . . . . . . . . 220

Annual Meeting Information General Information . . . . . . . . . . . . . . . 222 Hotels and Reservations . . . . . . . . . . . . . 226 Hotels and Amenities . . . . . . . . . . . . . . 228 Travel Information . . . . . . . . . . . . . . . . 238

The 71st AAN Annual Meeting Deadlines-at-a-Glance March 7, 2019 Early Registration Deadline

April 2, 2019 Hotel Reservation Deadline

April 11, 2019 . . 89

Advance Registration Deadline

Location Pennsylvania Convention Center

Headquarter Hotel . . 93

Philadelphia Marriott Downtown

AAN.com/view/AM19Sci

Current as of February 1, 2019. Program subject to change.

AAN.com/view/AM19Sci

“

Whoever you are and no matter what your career path, you will find what you are looking for at the Annual Meeting—and then some. Whether you are looking to discover cutting-edge neuroscience, an unparalleled educational experience, the latest practice-enhancing tools and tips, or top careerdevelopment advice, the Annual Meeting has you covered. One of the secrets to the Annual Meeting’s enduring success is its ability to evolve, and the Annual Meeting Science Program is a prime example: • We are bigger and more diverse than ever in the way we represent various neurology subspecialties and areas of neuroscience research • We constantly innovate with new delivery formats and forums • We are continually striving to create opportunities for budding young researchers, women, and other diverse segments of the AAN membership For 2019 we’ve built a robust program that I’m excited to share with you throughout the following pages, and I hope it will assist you in planning your Annual Meeting experience. From Plenary Sessions to Neuroscience in the Clinic Sessions, and from Invited Science Sessions to Poster Sessions—you’ll notice that the program is bigger and more innovative than ever. This is all just a few months away—so register today, and I’ll see you in Philly! —Natalia S. Rost, MD, MPH, FAHA, FAAN Chair, AAN Science Committee

2019 AAN Annual Meeting

“

Education and Science Formats

The AAN recognizes and celebrates differences in preferred learning styles, which is why the Annual Meeting offers nine unique formats.

Advancing Medicine: Inspiration and Innovation Tune into a new series of three talks that explore subjects like medicine and the water crisis in Flint, MI; how neurology interfaces with AI and robotics; and what happens when neuroscience and philosophy collide. See page 7 for more detail on these topics and speakers.

BrainDome Immerse yourself in the brainâ&#x20AC;&#x2122;s inner workings with a guided audio-visual tour through a larger-than-life brain. See page 38 for more details.

Friday Grand Finale Be sure and stay through the end of the week for a not-to-be-missed, enhanced Friday experience, including: Neurology Year in Review Plenary Session Science Innovation Lunch Neurology Update Programs and Scientific Sessions Education Blitz Programs Closing Party Celebrating May Day .

Advancing Medicine: Inspiration and Innovation Talks

Invited Science Sessions

Poster Sessions

Neuroscience in the Clinic Sessions

Plenary Sessions

Experiential Learning Areas with 300+ Talks

Leadership University Courses

Scientific Sessions

259

Didactive, Case-based, Hands-on, and Interactive Courses Learn more about each learning format on page 5.

AAN.com/view/AM19Sci

Things to Discover in the Neuro Center: Scientific Poster Presentations

Visit the Poster Neighborhoods and network with colleagues while learning about the latest breakthroughs in neurologic research.

ePoster Presentations

Interactive presentations on digital monitors feature videos, 3D models/graphics, and more.

Alternate Viewing Area

Neuro Center

Enjoy daily Wine and Paint Sessions and innovative physician-led presentations in this experiential learning area.

A place to go, a place to learn, a place to stay.

Charging Areas

Exhibit Halls B-E

Catch live streams of plenary sessions, education programs, and other unique and encore programming.

Innovation Hub

Relax and recharge–both yourself and your phone–before your next course.

Buzz Cafes

Take a break with your colleagues with complimentary coffee and comfy seating.

Exhibits

Hear about the latest in the field, learn about career opportunities, find patient resources, and more.

Lunch and Picnic Space

Registered attendees can select from nutritious lunch options, and the AAN’s picnic space offers fun each day the Exhibit Hall is open.

HOW TO GET THE MOST FROM THIS GUIDE

This guide brings you the most up-to-date schedule of the 2019 AAN Annual Meeting courses, sessions, and events, with more robust details on the Science Program. Summaries provide a fast path to what is available by neurology topic, time, or program category.

Registration Learn about the advantages of registering early, and the additional savings that come with AAN membership.

Meeting-at-a-Glance and Meeting Overview This tear-out guide provides a high-level overview of the daily schedule of courses, sessions, and events to help you plan your schedule.

Meeting Schedule Colors All Annual Meeting programs all color-coded throughout the book to make it easier to spot presentations of interest.

Plenary Session

Program Session types are indicated by one of the letter codes below, followed by sequential numbers. C = Course: An education program using one or more teaching methods, including didactic, interactive, and case-based. N = Neuroscience in the Clinic Session: A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic and end with a panel discussion. P = Poster Session: A series of thematic abstract presentations in poster format presented Sunday through Thursday with 5:30 p.m.–6:30 p.m. standby times for authors.

S = Scientific Session: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length and immediately followed by a three-minute Q&A with the author. Each Scientific Session concludes with a Q&A panel with all authors. IS = Invited Science Session: An AAN scientific session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting, including Alzheimer’s Association and International Parkinson and Movement Disorder Society.

A premier session highlighting the latest advances in neuroscience presented by some of the most cutting-edge and well-known thought leaders in the field of neurology.

Experiential Learning Area An interactive way of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.

Event A must-see entertainment or social event to complement the meeting’s science and education programming.

Session Icons Provide additional at-a-glance information about programming. = Experiential Learning Area = Leadership University = Additional Fee Required

CME

= Abstract of Distinction

= Research

= CME Credit

= Technology

= New Offering in 2019

= Clinical Knowledge

AAN.com/view/AM19Sci

MAKING THE MOST OF THE ANNUAL MEETING A Schedule of Events Specifically Designed for Students, Residents, and Fellows Special Registration Rate

Featured Events

• FREE for Medical Students who are AAN members (complimentary membership at AAN.com/view/membership) • Registration only $270 for Intern and Junior members • Reduced hotel and travel costs through the AAN

We’ve made the conference affordable for volunteers!

NEW! Trainee Experience

Saturday, May 4–Friday, May 10 Kick-off your Annual Meeting experience and connect with your peers during these daily activities.

Experiential Learning Areas

We need Student, Junior, and Intern AAN members to help check registration for attendees, manage space in rooms based on the number of attendees, handle technical issues, and more.

Education & Scientific Program Monitors

Monitors are needed for all education program offerings and scientific sessions to assist directors, faculty, session co-chairs, and staff. You will receive FREE Annual Meeting registration.

Skills Workshop Volunteers

Saturday, May 4–Friday, May 10 Take your learning outside of the classroom and experience the various Experiential Learning Areas to supplement your conference education.

NEW! Futures in Neurological Research Track Saturday, May 4–Friday, May 10 Grow your future career in research with a curated set of courses and learning opportunities that will improve your knowledge and skills.

Subspecialty Mentoring Sessions

Monday evening, May 6–Thursday afternoon, May 9

Volunteers are needed for some Skills Workshops throughout the Annual Meeting. Limited space is available, and you will receive: FREE Annual Meeting registration, a waived workshop fee, and payment of at least $40 per session.

Digital Scavenger Hunt

Find information at: AAN.com/view/AMTrainee

During various poster sessions, tour the poster hall in a small group with a neurologist.

Participate in this digital scavenger hunt daily throughout the Annual Meeting for the opportunity to win prizes.

Poster Hall Tour

Schedule Highlights for Trainees Saturday, May 4

Sunday, May 5

Monday, May 6

Resident Basic Science I: Neuropathology 12:00 p.m.–4:00 p.m.

NEW! Chief Resident Leadership Program 12:00 p.m.–4:00 p.m.

REVAMPED! Student Interest Group in Neurology (SIGN) Meeting 7:30 a.m.–9:00 a.m.

NEW! Futures in Neurological Research Boot Camp 12:00 p.m.–5:00 p.m.

Medical Student Symposium 12:30 p.m.–5:30 p.m.

Futures in Neurological Research Luncheon 12:30 p.m.–2:00 p.m.

Resident Basic Science II: Neuropharmacology 1:00 p.m.–5:30 p.m.

Resident Basic Science III: Neuroanatomy: All the Lesions 1:00 p.m.–5:30 p.m. Brainstorming Competition 4:00 p.m.–5:30 p.m. REVAMPED! Early Career Reception 6:00 p.m.–9:00 p.m.

ADVANCING MEDICINE:

INSPIRATION AND INNOVATION THIS NEW SERIES OF TALKS EXPLORES SUBJECTS WHERE NEUROSCIENCE INTERSECTS WITH GLOBAL THEMES.

OPENING RECEPTION Free food and beverages will be available immediately following Dr. Herr’s talk.

The New Era of Extreme Bionics Saturday, May 4, at 5:45 p.m. - Terrace Ballroom Dr. Hugh Herr, who heads the Biomechatronics group at the MIT Media Lab, is creating bionic limbs that emulate the function of natural limbs. In 2011, TIME magazine coined him the “Leader of the Bionic Age” because of his revolutionary work in the emerging field of biomechatronics–technology that marries human physiology with electromechanics.

Dr. Hugh Herr

NEW IN

2019

Dr. Mona Hanna-Attisha

Ms. Patricia Churchland

What the Eyes Don’t See: Stories from the Frontlines of the Flint Water Crisis

The Origin of Moral Intuitions

Monday, May 6, at 1:00 p.m. - Ballroom A

Wednesday, May 8, at 1:00 p.m. - Ballroom A

Dr. Mona Hanna-Attisha is a pediatrician, professor, and public health advocate whose research exposed the Flint water crisis. Her bestselling book, What the Eyes Don’t See: A Story of Crisis, Resistance, and Hope in an American City, is a fascinating account of a shameful disaster that became a tale of activism and hope. A limited number of free books will be available to attendees along with copies for purchase.

Ms. Patricia Churchland has contributed to the fields of neurophilosophy, philosophy of the mind, and neuroethics. Her research has centered on the interface between neuroscience and philosophy with a current focus on the association of morality and the social brain. Ms. Churchland is a professor Emeritus of Philosophy at the University of California, San Diego and adjunct professor at the Salk Institute.

REGISTRATION PLANNING YOUR WEEK IS EASY AS 1-2-3: 1 Register and book your hotel quickly and easily online. 2 Use the convenient Meeting-at-a-Glance, starting on page 17 of this book, to plan your schedule, incorporating your

favorite education and science programs, and other Annual Meeting social and informational events.

Show up and experience the excellence of the world’s largest and most vibrant gathering of neurologists!

WAYS TO REGISTER

SPECIAL ACCOMMODATIONS

ONLINE AAN.com/view/register TELEPHONE (CMR) US/Canada: (800) 676-4226 International: (415) 979-2283 FOR QUESTIONS, CALL CMR OR GO TO AANAM.CMRUSHELP.COM.

The Pennsylvania Convention Center and the AAN strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, submit your request while registering online or contact Brooke Halvorson at bhalvorson@aan.com.

WAYS TO SAVE • Renew your AAN membership or join the AAN for maximum registration savings. Visit AAN.com/view/ membership. • Register by the March 7, 2019, early registration deadline to avoid increased rates.

Kosher meals may be provided at any lunch for $50 per meal and must be arranged through the registration website or by contacting CMR.

GROUP REGISTRATION Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. Special registration instructions are available through online registration or by contacting CMR. See page 226 for housing information.

IMPORTANT DEADLINES* Early Registration Deadline: March 7, 2019 Hotel Reservation Deadline: April 2, 2019 Advance Registration Deadline: April 11, 2019 *Registrations received after these dates will be processed at a higher rate.

Look for this seal to ensure you are booking through the AAN’s official housing vendor, CMR, and avoid fraudulent sites by only booking on sites where you see this seal.

ESSENTIAL EDUCATION. INCOMPARABLE SUPPORT. THAT’S AAN MEMBERSHIP. See the full listing of exclusive member benefits, including reduced cost registration to the Annual Meeting, and apply or renew at AAN.com/view/membership. 8

2019 AAN Annual Meeting

WHAT’S INCLUDED IN REGISTRATION? The AAN’s single registration rate offers exceptional value, providing access to 250+ expert-led courses, sessions, experiential learning areas—and even networking and social events. Some courses or social events require pre-registration, may have a separate registration fee, or have a limited capacity. For information on pricing, visit AAN.com/view/register.

GOLD REGISTRATION All Annual Meeting attendees are required to register. Upgrade to Gold Registration to include access to Annual Meeting On Demand (see page 225 for more information).

Early Rates Note: All prices (By March 7, 2019) in US dollars Gold Registration Registration Student Members and Nonmember Students Honorary and Senior Members Intern and Junior Members Non-physician Members (Advanced Practice Provider, Business Administrator, Researcher) Neurologist and Physician Affiliate Members Nonmembers

Advance Rates (March 8-April 11, 2019)

On-site Rates (After April 11, 2019)

Registration

Gold Registration

Registration

Gold Registration

$99

$279

$270

$369

$300

$399

$360

$459

$445

$544

$495

$594

$595

$694

$745

$1,024

$830

$1,109

$1,005

$1,284

$1,270

$1,689

$1,415

$1,834

$1,710

$2,129

IN CONJUNCTION WITH MEETINGS Connect, reunite, and collaborate with colleagues. An In Conjunction With (ICW) meeting is any event affecting Annual Meeting attendees that is outside the official AAN Annual Meeting program—from staff meetings to board meetings and alumni reunions to social dinners. If you are interested in hosting an ICW meeting during the 2019 AAN Annual Meeting, reserve your spot today at AAN.com/view/ICW or by contacting Grace Henderson at ghenderson@aan.com or (612) 928-6103.

AAN.com/view/AM19Sci

AN OPPORTUNITY TO GIVE BACK DURING THE ANNUAL MEETING Volunteer During the Brain Health Fair Designed to connect neurology patients, families, caregivers, and students throughout the Philadelphia area to local and national experts to learn the latest research advances and get their toughest questions answered. While this is a free day-long event for the general public, we are looking for volunteers–including Spanish-speaking physicians–to help out in many different ways throughout the day. Contact wvokaty@aan.com if you’re interested. Learn more BrainHealthFair.com

NEW DAY!

Thursday, May 9, 2019 10:00 a.m. – 4:00 p.m. PENNSYLVANIA CONVENTION CENTER

“

I’ve volunteered at the Brain Health Fair since 2011. It’s a rewarding experience and a pleasure to bring our work to the community we serve. Brenda Banwell, MD, FAAN Chief of the Division of Neurology at Children’s Hospital of Philadelphia

”

Descubra nuestro creciente currículo en español Encuentre programación en español en torno a una amplia variedad de temas, incluyendo: • Consejos prácticos para educadores médicos • Cuidados neurocríticos • Dolor de cabeza y trastornos neuromusculares • Esclerosis múltiple

• Lesiónes cerebrales traumáticas e ictus isquémico • Oportunidades de colaboración internacional • Teleneurología • Trastornos del movimiento • ¡Y más!

Vaya a la página 65 para enterarse de los detalles.

Brain Health Fair—Ahora el Jueves, 9 de mayo— Buscamos médicos que hablen español ¿Le interesa ofrecer información importante al público hispanohablante de Brain Health Fair? Póngase en contacto con Wendy Vokaty escribiendo a wvokaty@aan.com ofrecerse como voluntario.

ADVANCING NEUROLOGY. ADVANCING YOU.

NEW First in a New Class of Antiepileptic Drugs (AEDs) for the Treatment of Seizures Associated With LennoxGastaut Syndrome (LGS) or Dravet Syndrome in Patients 2 Years and Older1

FIRST FDA-APPROVED TREATMENT FOR DRAVET SYNDROME 1

Grace, age 5 EPIDIOLEX patient living with Dravet syndrome

IMPORTANT SAFETY INFORMATION & INDICATIONS Contraindication: Hypersensitivity EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

Warnings & Precautions Hepatocellular Injury: EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Transaminase and bilirubin levels should be obtained prior to starting treatment, at one, three, and six months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of EPIDIOLEX and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of EPIDIOLEX or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury.

Somnolence and Sedation: EPIDIOLEX can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

Withdrawal of Antiepileptic Drugs: As with most AEDs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

Adverse Reactions: The most common adverse reactions in patients receiving EPIDIOLEX (â&#x2030;Ľ10% and greater than placebo) include somnolence; decreased appetite; diarrhea; transaminase

Introducing the first and only FDA-approved prescription cannabidiol1

FINALLY, THERE’S A WHOLE NEW PATH TO EXPLORE EPIDIOLEX® (CANNABIDIOL) PROVIDES A NOVEL TREATMENT APPROACH

Structurally distinct from other AEDs2

Significantly reduces seizures in both LGS and Dravet syndrome*2

Safety and tolerability profile has been established in 3 clinical trials2

Eligible for insurance and delivered to patients via specialty pharmacies. Please see Important Safety Information below and brief summary of full Prescribing Information. *Demonstrated in three 14-week, randomized, double-blind, placebo-controlled, multicenter trials (N=516). The primary efficacy measure was the median percent change from baseline in frequency of drop seizures (LGS) or convulsive seizures (Dravet syndrome) per 28 days over the treatment period for the EPIDIOLEX groups vs placebo groups when added to current treatment. Drop seizures were defined as atonic, tonic, or tonic-clonic seizures that led to or could have led to a fall or injury. Convulsive seizures were defined as all countable atonic, tonic, clonic, and tonic-clonic seizures.2-5 References: 1. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Food and Drug Administration website. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm. Accessed June 29, 2018. 2. EPIDIOLEX [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc.; 2018. 3. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018. doi:10.1016/S0140-6736(18)30136-3. 4. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888-1897. 5. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020.

Visit E P I D I O L E X h c p . c o m for more details.

elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.

valproate increases the incidence of liver enzyme elevations. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.

Pregnancy:

Drug Abuse:

EPIDIOLEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Drug Interactions: Moderate or strong inhibitors or inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam) or others. Concomitant use of EPIDIOLEX and

EPIDIOLEX is a Schedule V controlled substance and has a low potential for abuse.

Indications: EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older. Please refer to the EPIDIOLEX full Prescribing Information for additional important information.

EPIDIOLEX® (cannabidiol) oral solution, C Brief Summary of Prescribing Information See package insert for full Prescribing Information or visit www.EpidiolexHCP.com Rx only INDICATIONS AND USAGE - EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older. CONTRAINDICATION - EPIDIOLEX is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product [see Description and Warnings and Precautions in full PI]. WARNINGS AND PRECAUTIONS Hepatocellular Injury - EPIDIOLEX causes dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]). In controlled studies for LGS and DS, the incidence of ALT elevations above 3 times the upper limit of normal (ULN) was 13% in EPIDIOLEX-treated patients compared with 1% in patients on placebo. Less than 1% of EPIDIOLEX-treated patients had ALT or AST levels greater than 20 times the ULN. There were cases of transaminase elevations associated with hospitalization in patients taking EPIDIOLEX. In clinical trials, serum transaminase elevations typically occurred in the first two months of treatment initiation; however, there were some cases observed up to 18 months after initiation of treatment, particularly in patients taking concomitant valproate. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX or reduction of EPIDIOLEX and/or concomitant valproate in about two-thirds of the cases. In about one-third of the cases, transaminase elevations resolved during continued treatment with EPIDIOLEX, without dose reduction. Risk Factors for Transaminase Elevation: Concomitant Valproate and Clobazam - The majority of ALT elevations occurred in patients taking concomitant valproate. Concomitant use of clobazam also increased the incidence of transaminase elevations, although to a lesser extent than valproate [see Drug Interactions in full PI]. In EPIDIOLEX-treated patients, the incidence of ALT elevations greater than 3 times the ULN was 30% in patients taking both concomitant valproate and clobazam, 21% in patients taking concomitant valproate (without clobazam), 4% in patients taking concomitant clobazam (without valproate), and 3% in patients taking neither drug. Consider discontinuation or dose adjustment of valproate or clobazam if liver enzyme elevations occur. Dose - Transaminase elevations are dose-related. Overall, ALT elevations greater than 3 times the ULN were reported in 17% of patients taking EPIDIOLEX 20 mg/kg/day compared with 1% in patients taking EPIDIOLEX 10 mg/kg/day. Baseline Transaminase Elevations - Patients with baseline transaminase levels above the ULN had higher rates of transaminase elevations when taking EPIDIOLEX. In controlled trials (Studies 1, 2, and 3) in patients taking EPIDIOLEX 20 mg/kg/day, the frequency of treatment-emergent ALT elevations greater than 3 times the ULN was 30% when ALT was above the ULN at baseline, compared to 12% when ALT was within the normal range at baseline. No patients taking EPIDIOLEX 10 mg/kg/day experienced ALT elevations greater than 3 times the ULN when ALT was above the ULN at baseline, compared with 2% of patients in whom ALT was within the normal range at baseline. Monitoring: In general, transaminase elevations of greater than 3 times the ULN in the presence of elevated bilirubin without an alternative explanation are an important predictor of severe liver injury. Early identification of elevated liver enzymes may decrease the risk of a serious outcome. Patients with elevated baseline transaminase levels above 3 times the ULN, accompanied by elevations in bilirubin above 2 times the ULN, should be evaluated prior to initiation of EPIDIOLEX treatment. Prior to starting treatment with EPIDIOLEX, obtain serum transaminases (ALT and AST) and total bilirubin levels. Serum transaminases and total bilirubin levels should be obtained at 1 month, 3 months, and 6 months after initiation of treatment with EPIDIOLEX, and periodically thereafter or as clinically indicated. Serum transaminases and total bilirubin levels should also be obtained within 1 month following changes in EPIDIOLEX dosage and addition of or changes in medications that are known to impact the liver. Consider more frequent monitoring of serum transaminases and bilirubin in patients who are taking valproate or who have elevated liver enzymes at baseline. If a patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine), promptly measure serum transaminases and total bilirubin and interrupt or discontinue treatment with EPIDIOLEX, as appropriate. Discontinue EPIDIOLEX in any patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Consider dosage adjustment of any co-administered medication that is known to affect the liver (e.g., valproate and clobazam). Somnolence and Sedation - EPIDIOLEX can cause somnolence and sedation. In controlled studies for LGS and DS, the incidence of somnolence and sedation (including lethargy) was 32% in EPIDIOLEX-treated patients, compared with 11% in patients on placebo and was dose-related (34% of patients taking EPIDIOLEX 20 mg/kg/day, compared with 27% in patients taking EPIDIOLEX 10 mg/kg/day). The rate was higher in patients on concomitant clobazam (46% in EPIDIOLEX-treated patients taking clobazam compared with 16% in EPIDIOLEX-treated patients not on clobazam). In general, these effects were more common early in treatment and may diminish with continued treatment. Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on EPIDIOLEX to gauge whether it adversely affects their ability to drive or operate machinery. V

Suicidal Behavior and Ideation - Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27863 AED-treated patients was 0.43%, compared to 0.24% among 16029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5–100 years) in the clinical trials analyzed [see Warnings and Precautions in full PI for absolute and relative risk by indication for all evaluated AEDs]. The relative risk for suicidal thoughts or behavior was higher in clinical trials in patients with epilepsy than in clinical trials in patients with psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing EPIDIOLEX or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Hypersensitivity Reactions - EPIDIOLEX can cause hypersensitivity reactions. One subject in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment with antihistamines. Patients with known or suspected hypersensitivity to any ingredients of EPIDIOLEX were excluded from the clinical trials. If a patient develops hypersensitivity reactions after treatment with EPIDIOLEX, the drug should be discontinued. EPIDIOLEX is contraindicated in patients with a prior hypersensitivity reaction to cannabidiol or any of the ingredients in the product, which includes sesame seed oil [see Description in full PI]. Withdrawal of Antiepileptic Drugs (AEDs) - As with most antiepileptic drugs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus [see Dosage and Administration and Clinical Studies in full PI]. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. ADVERSE REACTIONS The following important adverse reactions are described elsewhere [see Warnings and Precautions in full PI]: • Hepatocellular Injury • Somnolence and Sedation • Suicidal Behavior and Ideation • Hypersensitivity Reactions • Withdrawal of Antiepileptic Drugs Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In controlled and uncontrolled trials in patients with LGS and DS, 689 patients were treated with EPIDIOLEX, including 533 patients treated for more than 6 months, and 391 patients treated for more than 1 year. In an expanded access program and other compassionate use programs, 161 patients with DS and LGS were treated with EPIDIOLEX, including 109 patients treated for more than 6 months, 91 patients treated for more than 1 year, and 50 patients treated for more than 2 years. In placebo controlled trials of patients with LGS or DS (includes Studies 1, 2, 3, and a Phase 2 controlled study in DS), 323 patients received EPIDIOLEX. Adverse reactions are presented below; the duration of treatment in these trials was up to 14 weeks. Approximately 46% of patients were female, 83% were Caucasian, and the mean age was 14 years (range 2 to 48 years). All patients were taking other AEDs. In controlled trials, the rate of discontinuation as a result of any adverse reaction was 2.7% for patients taking EPIDIOLEX 10 mg/kg/day, 11.8% for patients taking EPIDIOLEX 20 mg/kg/day, and 1.3% for patients on placebo. The most frequent cause of discontinuations was transaminase elevation. Discontinuation for transaminase elevation occurred at an incidence of 1.3% in patients taking EPIDIOLEX 10 mg/kg/day, 5.9% in patients taking EPIDIOLEX 20 mg/kg/day, and 0.4% in patients on placebo. Somnolence, sedation, and lethargy led to discontinuation in 3% of patients taking EPIDIOLEX 20 mg/kg/day compared to 0% of patients taking EPIDIOLEX 10 mg/kg/day or on placebo. The most common adverse reactions that occurred in EPIDIOLEX-treated patients (incidence at least 10% and greater than placebo) were somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. The table below lists the adverse reactions that were reported in ≥3% of EPIDIOLEX-treated patients, and at a rate greater than those on placebo in the placebo-controlled trials in LGS and DS. Adverse reactions were similar across LGS and DS in pediatric and adult patients.

Adverse Reactions in Patients Treated with EPIDIOLEX in Controlled Trials Adverse Reactions Hepatic Disorders Transaminases elevated Gastrointestinal Disorders Decreased appetite Diarrhea Weight decreased Gastroenteritis Abdominal pain, discomfort Nervous System Disorders Somnolence Sedation Lethargy Fatigue, malaise, asthenia Insomnia, sleep disorder, poor quality sleep Irritability, agitation Aggression, anger Drooling, salivary hypersecretion Gait disturbance Infections Infection, all Infection, viral Pneumonia Infection, fungal Infection, other Other Rash Hypoxia, respiratory failure

EPIDIOLEX 10 mg/kg/day 20 mg/kg/day N=75 N=238 % %

Placebo N=227 %

16 9 3 0 3

22 20 5 4 3

5 9 1 1 1

23 3 4 11

25 6 8 12

8 1 2 4

9 3 1 3

5 5 4 2

2 <1 <1 <1

41 7 8 1 25

40 11 5 3 21

31 6 1 0 24

7 3

13 3

3 1

Decreased Weight - EPIDIOLEX can cause weight loss. In the controlled trials of patients with LGS or DS, based on measured weights, 16% of EPIDIOLEX-treated patients had a decrease in weight of ≥5% from their baseline weight, compared to 8% of patients on placebo. The decrease in weight appeared to be dose-related, with 18% of patients on EPIDIOLEX 20 mg/kg/day experiencing a decrease in weight ≥5%, compared to 9% in patients on EPIDIOLEX 10 mg/kg/day. In some cases, the decreased weight was reported as an adverse event (see Table above). Hematologic Abnormalities - EPIDIOLEX can cause decreases in hemoglobin and hematocrit. In controlled trials of patients with LGS or DS, the mean decrease in hemoglobin from baseline to end of treatment was -0.42 g/dL in EPIDIOLEX-treated patients and -0.03 g/dL in patients on placebo. A corresponding decrease in hematocrit was also observed, with a mean change of -1.5% in EPIDIOLEX-treated patients, and -0.4% in patients on placebo. There was no effect on red blood cell indices. Thirty percent (30%) of EPIDIOLEX-treated patients developed a new laboratory-defined anemia during the course of the study (defined as a normal hemoglobin concentration at baseline, with a reported value less than the lower limit of normal at a subsequent time point), versus 13% of patients on placebo. Increases in Creatinine - EPIDIOLEX can cause elevations in serum creatinine. The mechanism has not been determined. In controlled studies in healthy adults and in patients with LGS and DS, an increase in serum creatinine of approximately 10% was observed within 2 weeks of starting EPIDIOLEX. The increase was reversible in healthy adults. Reversibility was not assessed in studies in LGS and DS. DRUG INTERACTIONS Effect of Other Drugs on EPIDIOLEX Moderate or Strong Inhibitors of CYP3A4 or CYP2C19: EPIDIOLEX is metabolized by CYP3A4 and CYP2C19. Therefore, coadministration with a moderate or strong inhibitor of CYP3A4 or CYP2C19 will increase cannabidiol plasma concentrations, which may result in a greater risk of adverse reactions. Consider a reduction in EPIDIOLEX dosage when coadministered with a moderate or strong inhibitor of CYP3A4 or CYP2C19 [see Clinical Pharmacology in full PI]. Strong CYP3A4 or CYP2C19 Inducers: Coadministration with a strong CYP3A4 or CYP2C19 inducer will decrease cannabidiol plasma concentrations, which may lower the efficacy of EPIDIOLEX. Consider an increase in EPIDIOLEX dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 or CYP2C19 inducer [see Clinical Pharmacology in full PI]. Effect of EPIDIOLEX on Other Drugs UGT1A9, UGT2B7, CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 Substrates: In vitro data predict drug-drug interactions with CYP1A2 substrates (e.g., theophylline, caffeine), CYP2B6 substrates (e.g., bupropion, efavirenz), uridine 5’ diphosphoglucuronosyltransferase 1A9 (UGT1A9) (e.g., diflunisal, propofol, fenofibrate), and UGT2B7 (e.g., gemfibrozil, lamotrigine, morphine, lorazepam) when coadministered with EPIDIOLEX. Coadministration of EPIDIOLEX is also predicted to cause clinically significant interactions with CYP2C8 and CYP2C9 (e.g., phenytoin) substrates. Because of potential inhibition of enzyme activity, consider a reduction in dosage of substrates of UGT1A9, UGT2B7, CYP2C8, and CYP2C9, as clinically appropriate, if adverse reactions are experienced when

administered concomitantly with EPIDIOLEX. Because of potential for both induction and inhibition of enzyme activity, consider adjusting dosage of substrates of CYP1A2 and CYP2B6, as clinically appropriate [see Clinical Pharmacology in full PI]. Sensitive CYP2C19 Substrates: In vivo data show that coadministration of EPIDIOLEX increases plasma concentrations of drugs that are metabolized by (i.e., are substrates of) CYP2C19 (e.g., diazepam) and may increase the risk of adverse reactions with these substrates [see Clinical Pharmacology in full PI)]. Consider a reduction in dosage of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with EPIDIOLEX. Clobazam: Coadministration of EPIDIOLEX produces a 3-fold increase in plasma concentrations of N-desmethylclobazam, the active metabolite of clobazam (a substrate of CYP2C19) [see Clinical Pharmacology in full PI]. This may increase the risk of clobazamrelated adverse reactions [see Warnings and Precautions in full PI]. Consider a reduction in dosage of clobazam if adverse reactions known to occur with clobazam are experienced when co-administered with EPIDIOLEX. Concomitant Use of EPIDIOLEX and Valproate - Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations [see Warnings and Precautions in full PI]. Discontinuation or reduction of EPIDIOLEX and/or concomitant valproate should be considered. Insufficient data are available to assess the risk of concomitant administration of other hepatotoxic drugs and EPIDIOLEX. CNS Depressants and Alcohol - Concomitant use of EPIDIOLEX with other CNS depressants may increase the risk of sedation and somnolence [see Warnings and Precautions in full PI]. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as EPIDIOLEX, during pregnancy. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. Risk Summary: There are no adequate data on the developmental risks associated with the use of EPIDIOLEX in pregnant women. Administration of cannabidiol to pregnant animals produced evidence of developmental toxicity (increased embryofetal mortality in rats and decreased fetal body weights in rabbits; decreased growth, delayed sexual maturation, long-term neurobehavioral changes, and adverse effects on the reproductive system in rat offspring) at maternal plasma exposures similar to (rabbit) or greater than (rat) that in humans at therapeutic doses (see Animal Data in full PI). Lactation Risk Summary: There are no data on the presence of cannabidiol or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EPIDIOLEX and any potential adverse effects on the breastfed infant from EPIDIOLEX or from the underlying maternal condition. Pediatric Use - Safety and effectiveness of EPIDIOLEX for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome have been established in patients 2 years of age and older. Safety and effectiveness of EPIDIOLEX in pediatric patients below 2 years of age have not been established. Geriatric Use - Clinical trials of EPIDIOLEX in the treatment of LGS and DS did not include any patients aged above 55 years to determine whether or not they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Dosage and Administration, Warnings and Precautions, and Clinical Pharmacology in full PI]. Hepatic Impairment - Because of an increase in exposure to EPIDIOLEX, dosage adjustments are necessary in patients with moderate or severe hepatic impairment [see Dosage and Administration, Warnings and Precautions, and Clinical Pharmacology in full PI]. EPIDIOLEX does not require dosage adjustments in patients with mild hepatic impairment. DRUG ABUSE AND DEPENDENCE - Controlled Substance: EPIDIOLEX is controlled in Schedule V of the Controlled Substances Act. Abuse - Animal abuse-related studies show that cannabidiol does not produce cannabinoid-like behavioral responses, including generalization to delta-9tetrahydrocannabinol (THC) in a drug discrimination study. Cannabidiol also does not produce animal self-administration, suggesting it does not produce rewarding effects. In a human abuse potential study, acute administration of cannabidiol to non-dependent adult recreational drug users at therapeutic and supratherapeutic doses of 750, 1500, and 4500 mg in the fasted state (equivalent respectively to 10, 20, and 60 mg/kg in a 75 kg adult) produced responses on positive subjective measures such as Drug Liking and Take Drug Again that were within the acceptable placebo range. In contrast, 10 and 30 mg of dronabinol (synthetic THC) and 2 mg alprazolam produced large increases on positive subjective measures compared to placebo that were statistically significantly greater than those produced by cannabidiol. In other Phase 1 clinical studies conducted with cannabidiol, there were no reports of abuse-related adverse events. Dependence - In a human physical dependence study, administration of cannabidiol 1500 mg/day (750 mg twice daily) to adults for 28 days did not produce signs or symptoms of withdrawal over a 6-week assessment period beginning three days after following drug discontinuation. This suggests that cannabidiol likely does not produce physical dependence. Please see the full PI for Patient Counseling Information See full Prescribing Information at www.EpidiolexHCP.com. Marketed by Greenwich Biosciences, Inc., Carlsbad, CA 92008 USA © 2018 Greenwich Biosciences, Inc. All rights reserved.

Bring Your Career Into Focus with Annual Meeting Program Tracks Educational Programs Designed For You

Donâ&#x20AC;&#x2122;t miss these specially curated course lineups, designed to help maximize your time at the Annual Meeting based on your career path and interests. NEW! Academic Medicine Track Provides a variety of offerings for academic neurologists across career roles and stages. Visit the Academic Branded Room - Located in Room 202 - for Academic Medicine Track programs and other events created specifically for academics!

Business of Neurology Track

Perfect for individuals interested in starting a new practice or learning the fundamentals of neurology business.

NEW! Career Essentials Track Offering help with early career and development or if you are looking to launch into private practice or academics.

Foundations of Clinical Neurology for APPs Track

Created for advanced practice providers who are new to neurology.

Neurohospitalist Track

Created specifically for neurohospitalists whose primary focus is inpatient care.

Spanish-language Track

Look for education courses, scientific updates, and experiential learning area talks on a wide range of topics.

NEW! Futures in Neurological Research Track This track offers both formal coursework and learning sessions to round out research-interested traineesâ&#x20AC;&#x2122; Annual Meeting experience. See page 58 for the full track listings. You can also filter for tracks within the

AAN Conferences App or at AAN.com/view/AM19Sci.

MEETING-AT-A-GLANCE

Sat May 4

C = Course

Sun May 5

N = Neuroscience in the Clinic Session

Mon May 6

P = Poster Session

S = Scientific Platform Session

Tue May 7

IS = Invited Science Session

= Experiential Learning Area

Wed May 8

Thur May 9

Fri May 10

Friday GRAND Finale

C1-C35 7:00 a.m.-4:00 p.m.

8:00 a.m.

7:00 a.m.8:45 a.m.

C36-C46

7:00 a.m.8:45 a.m.

7:00 a.m.-9:00 a.m.

C78-C88

7:00 a.m.9:00 a.m.

7:00 a.m.-9:00 a.m.

C121-C130

Moderator: Eric Klawiter, MD, FAAN

Member, AAN Science Committee Massachusetts General Hospital, Boston, MA

Michael D. Fox, MD, PhD

Beth Israel Deaconess Medical School, Boston, MA

7:00 a.m.9:00 a.m.

7:00 a.m.-9:00 a.m.

Hot Topics Plenary Session

University of Pennsylvania, Philadelphia, PA

5K Run/1K Walk for Brain Research 6:30 a.m.-8:30 a.m.

Saturday, May 4 4:15 p.m.–5:30 p.m.

Virginia Lee, PhD

6:00 a.m. 7:00 a.m.

2019 PLENARY SPEAKERS

C165-C174

7:00 a.m.8:45a.m.

7:00 a.m.-9:00 a.m.

C205-C214

7:00 a.m.8:45a.m.

7:00 a.m.-9:00 a.m.

Sripriya Ravindra Kumar

C243-C249

7:00 a.m.8:45a.m.

7:00 a.m.-9:00 a.m.

Gradinaru Lab, California Institute of Technology, Pasadena, CA

Timothy W. Yu, MD, PhD

Boston Children’s Hospital, Boston, MA

Sunday, May 5 9:15 a.m.–12:00 p.m.

9:00 a.m.

Presidential Plenary Session

Contemporary Clinical Issues Plenary Session

9:15 a.m.-12:15 p.m.

10:00 a.m.

Clinical Trials Plenary Session 9:15 a.m.-11:30 a.m.

9:15 a.m.-11:30 a.m.

Frontiers in Neuroscience Plenary Session

Controversies in Neurology Plenary Session

Neurology Year in Review Plenary Session

9:15 a.m.-11:30 a.m.

6:00 p.m.

8:00 p.m.

Industry Therapuetic Updates 7:00 p.m.-10:00 p.m.

3:30 p.m.-5:30 p.m.

1:00 p.m.-3:00 p.m. 1:00 p.m.-5:30 p.m.

N5 3:30 p.m.-5:30 p.m.

N6 3:30 p.m.-5:30 p.m.

IS3

Invited Science Session

3:30 p.m.-5:30 p.m.

S56-S59

1:00 pm.-3:00 p.m.

1:00 p.m.-3:00 p.m.

Education Blitz: C254-C259 3:30 p.m.-4:30 p.m.

Early Career Reception The Philly Spectacular - At Reading Terminal Market!

5:30 p.m.-7:00 p.m.

Commitment to Cures 6:00 p.m.-10:00 p.m.

6:00 p.m.-9:00 p.m.

Industry Therapuetic Updates

7:00 p.m.-10:00 p.m.

12:00 p.m.-5:30 p.m.

11:45 a.m.-5:45 p.m.

1:00 p.m.-5:30 p.m.

11:30 a.m.-6:30 p.m.

11:30 a.m.-6:15 p.m.

11:30 a.m.-6:30 p.m.

11:30 a.m.-4:00 p.m.

Exhibit Hall

11:30 a.m.-6:30 p.m.

11:30 a.m.-4:00 p.m.

11:45 a.m.-6:00 p.m.

S33-S43

1:00 p.m.-5:30 p.m.

Mayo Clinic, Rochester, MN

Monday, May 6 9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session Moderator: Randolph S. Marshall MD, FAAN Vice-Chair, AAN Science Committee Columbia University, New York, NY

Lindsay Ross, MD

Cleveland Clinic Foundation, Cleveland, OH

Lawrence R. Wechsler MD, FAAN

Clinical Trials Plenary Session Moderators: Holly E. Hinson, MD, MCR, FAAN Member, AAN Science Committee Oregon Health & Science University, Portland, OR

Deborah Hall, MD, PhD, FAAN Member, AAN Science Committee Rush University, Chicago, IL

Jeff Williamson, MD

Wake Forest Baptist Health, Wake Forest, NC

Bruce A. C. Cree, MD, PhD, MCR, FAAN University of California San Francisco, Multiple Sclerosis Center, San Francisco, CA Hospital Universitari Vall D’Hebron, Barcelona, Spain Wills Eye Hospital, Philadelphia, PA

David W. Dodick, MD, FAAN

Mayo Clinic Arizona, Scottsdale, AZ

Susan Rowell, MD, MCR

Oregon Health & Science University, Portland, OR

Vinai Gondi, MD

Radiation Oncology Consultants, Chicago, IL

Wednesday, May 8 9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session Moderator: Paul M. George MD, PhD, MSE Member, AAN Science Committee Stanford Hospital, Stanford, CA

Burkhard Becher, PhD

Gil Dan Rabinovici, MD

Beverly L. Davidson, PhD

University of California San Francisco Memory & Aging Center, San Francisco, CA

Eric M. Reiman, MD

Banner Alzheimer’s Institute, Phoenix, AZ

C237-C242

Irene CM Cortese, MD

7:00 p.m.-10:00 p.m.

Carolyn B. Britton, MD

National Institutes of Health, Bethesda, MD Columbia University Irving Medical Center, New York, NY University of Pennsylvania, Philadelphia, PA

Member, AAN Science Committee MGH Neurological Clinical Research Institute, Boston, MA

Lee H. Schwamm, MD

Massachusetts General Hospital Department of Neurology, Boston, MA

Johanna Therese Fifi, MD Mount Sinai Hospital, New York, NY

Joseph R. Berger, MD, FAAN

University of Pennsylvania, Philadelphia, PA

David E. Newman-Toker, MD, PhD, FAAN Johns Hopkins University, Baltimore, MD

Emily Jean Gilmore, MD

Yale University School of Medicine, New Haven, CT

Brandon P. Foreman, MD

University of Cincinnati, Cincinnati, OH

Friday, May 10 9:15 a.m.–11:30 a.m.

Neurology Year in Review Plenary Session Moderator: Martinson K. Arnan, MD

Member, AAN Science Committee Bronson Neuroscience Center/Western Michigan University, Kalamazoo, MIA

Jinsy Andrews, MD, FAAN

Columbia University Medical Center, New York, NY

University of Pittsburgh School of Medicine, Pittsburgh, PA

Denise Y. Harvey, PhD

9:00 p.m.

Aleksandar Videnovic, MD, MSc, FAAN

Michelle Monje, MD, PhD

C250-C253

Moderators: Amy R. Brooks-Kayal, MD, FAAN

Tuesday, May 7 9:15 a.m.–11:30 a.m.

11:30 a.m.-1:00 p.m.

Claudia F. Lucchinetti, MD, FAAN

Controversies in Neurology Plenary Session Member, AAN Science Committee Children’s Hospital Colorado, Aurora, CO

Innovation Lunch

University of Rochester, Rochester, NY

Thursday, May 9 9:15 a.m.–11:30 a.m.

Medstar Georgetown Neurology, McLean, VA

Mark L. Moster, MD, FAAN

Closing Party

Advancing Medicine: Inspiration and Innovation and Opening Reception 5:45 p.m.-6:45 p.m.

7:00 p.m.

Invited Science Session

1:00 p.m.-5:30 p.m.

Jessica Ailani, MD

Jonathan W. Mink, MD, PhD, FAAN

Experiential Learning

5:00 p.m.

IS2

1:00 p.m.-2:00 p.m.

S44-S55

Children’s Hospital Colorado/Department of Neurology, Aurora, CO

Josep Gamez, MD, PhD

Stanford University, Stanford, CA

Experiential Learning

4:15 p.m.-5:30 p.m.

1:00 p.m.5:30 p.m.

C215-C236

Poster Session 5

Hot Topics Plenary Session

3:30 p.m.-5:30 p.m.

1:00 p.m.3:00 p.m.

C175-C204

Experiential Learning

4:00 p.m.

1:00 p.m.5:30 p.m.

1:00 p.m.-5:30 p.m.

Advancing Medicine: Inspiration and Innovation

Poster Session 4

3:00 p.m.-4:00 p.m.

Experiential Learning

AAN Business Meeting

Poster Session 1

3:00 p.m.

Experiential Learning

1:00 p.m.-3:00 p.m.

S12-S23

S24-S32

Experiential Learning

Poster Session 3

1:00 p.m.-3:00 p.m.

1:00 p.m.5:30 p.m.

1:00 p.m.-2:00 p.m.

C131-C164

Exhibit Hall

1:00 p.m.-5:30 p.m.

Advancing Medicine: C89-C120 Inspiration and Innovation

11:45 a.m.-5:45 p.m.

Invited Science Session

S1-S11

Exhibit Hall Networking Reception 4:00 p.m.-6:00 p.m.

Experiential Learning

2:00 p.m.

IS1

11:30 a.m.-4:00 p.m.

11:30 a.m.-6:30 p.m.

1:00 p.m.

Exhibit Hall

Poster Session 2

12:00 p.m.-5:45 p.m.

12:00 p.m.-5:30 p.m.

Exhibit Hall Opening Luncheon 11:30 a.m.-1:00 p.m.

12:00 p.m.-6:15 p.m.

C47-C77

Chair, AAN Science Committee Massachusetts General Hospital, Boston, MA

Miller School of Medicine, University of Miami, Miami, FL

11:30 a.m.-6:30 p.m.

11:30 a.m.-4:00 p.m.

12:00 p.m.

Moderator: Natalia S. Rost, MD, MPH, FAAN, FAHA

Teri Schreiner, MD, MPH

Ralph L. Sacco, MD, MS, FAHA, FAAN

11:00 a.m.

Exhibit Hall

Presidential Plenary Session

Contemporary Clinical Issues Plenary Session

University of Zurich, Zurich, Switzerland

Annette M. Langer-Gould, MD, PhD Kaiser Permanente Southern California, Pasadena, CA

Alberto Ramos, MD

Miller School of Medicine, Miami, FL

Lauren R. Moo, MD

Massachusetts General Hospital, Boston, MA

Leif A. Havton, MD, PhD

UCLA School of Medicine, Los Angeles, CA

Stacey Clardy, MD, PhD

University of Utah, Salt Lake City, UT

The Children’s Hospital of Philadelphia, Philadelphia, PA

Jed Hartings, PhD

University of Cincinnati, Cincinnati, OH

Ronald Melki, PhD

Paris-Saclay Institute of Neuroscience, Paris, France

Helen Tremlett, PhD, BPharm

University of British Columbia, Vancouver, BC, Canada

J. Paul Taylor, MD, PhD

St. Jude Children’s Research Hospital, Memphis, TN

Eric M. Wassermann, MD

National Institutes of Health, Bethesda, MD

10:00 p.m. Current as of February 1, 2019. Programs subject to change.

AAN.com/view/AM19Sci 17

C = Course N = Neuroscience in the Clinic Session P = Poster Session S = Scientific Platform Session IS = Invited Science Session = Experiential Learning Area

MEETING OVERVIEW Saturday, May 4

11:00 a.m.-11:45 a.m.

Yoga - Vinyasa

7:00 a.m.-9:00 a.m. C1 What Do I Do Now?: Assessment and C2 C3 C4 C5 C6 C7 C8

Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Using Sleep Medicine to Help Solve Difficult Neurologic Cases Clinical EEG: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Pediatric Neuro-ophthalmology Update What Do I Do Now?: Neurologic Consultations in Cancer Patients I Therapy of Movement Disorders: A Casebased Approach Clinical Pearls in Autoimmune Neurology: Real World Cases Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors?

7:00 a.m.-12:30 p.m. C9 Clerkship and Program Directors

Conference: Let’s Build an Educational Scholarly Product

7:00 a.m.-3:30 p.m. C10

C11 Neurology MOC Prep Course

8:00 a.m.-8:30 a.m. Are you My Mentor? How to Select a Good Mentor for Your Research Center

8:00 a.m.-8:45 a.m. Laughter Yoga Session

9:00 a.m.-9:30 a.m. What Should Applicants Look For in a Program? How to Successfully Publish Quality Improvement Projects

9:15 a.m.-10:00 a.m. Circle Talk: Mindfulness-based Stress Reduction (MBSR)

9:30 a.m.-11:30 a.m. C12 Clinical Approach to Muscle Disease I: C13 C14 C15 C16 C17 C18 C19 C20 C21

Role of Antibodies, Muscle Imaging, and Genetic Testing Clinicopathological Correlation Session in Dementia Child Neurology: Headache Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults Cerebrovascular Disease I: Prevention What Do I Do Now?: Neurologic Consultations in Cancer Patients II Cerebellar and Afferent Ataxias: Diagnosis and Management Multiple Sclerosis Overview I: Clinical Pearls Neurologic Complications of Medical Disease Tick-based Infections

10:00 a.m.-10:30 a.m. How to Be a Chief Resident Research Careers in Industry

10:30 a.m.-11:15 a.m. Music Therapy

11:00 a.m.-11:30 a.m. Your CV Is Talking About You Behind Your Back, and Your LORs Are Too!

Hot Topics Plenary Session

12:00 p.m.-12:30 p.m.

5:00 p.m.-5:45 p.m.

Navigating the Annual Meeting App

Telestroke Across the Continuum

12:00 p.m.-4:00 p.m.

5:45 p.m.-6:45 p.m.

C22 Resident Basic Science I: Neuropathology C23 Skills Workshop: Neuro-ophthalmology

Advancing Medicine: Inspiration and Innovation Featuring Hugh Herr, PhD

and Neurovestibular Exam Lab

7:00 p.m.-10:00 p.m.

Leadership Challenges in Practice

Industry Therapeutic Updates

12:00 p.m.-5:00 p.m. Futures in Neurological Research Boot Camp

Sunday, May 5 Yoga - Vinyasa

Transcending Opiate-based Pain Management

Resident Evaluation of Faculty: A New Approach

1:00 p.m.-1:30 p.m.

Skills in Just Two Hours! C37 Chronic Traumatic Encephalopathy: Update C38 Infections of the Nervous System I: Diagnostic Testing of Neurological Infections C39 How to Design Meaningful Clinical Trials

Mind-body Approaches to Chronic Pain Tips and Tools for Successful Recruitment

1:30 p.m.-3:30 p.m. C25 Clinical Approach to Muscle Disease II:

C40 Child Neurology: Stroke C41 Neuro-oncology in 2019: Navigating

Inflammatory Myopathies and Muscle Pathology C26 Clinical EEG: Neonatal and Pediatric C27 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke

Current Trends C42 The Dystonias: Diagnosis, Treatment and Update on Etiologies

C43 Residents in Private Practice C44 Multiple Sclerosis Therapy: Symptom

Sleep-Disordered Breathing in Neurology Populations: From Lab to Clinic Multiple Sclerosis Overview II: Clinical Advances Neurologic Complications of Medical and Surgical Therapies Mitochondrial Disorders in Neurology The Neurology of Social Behavior

Management C45 Status Epilepticus

C46

C31 C32 C33 Teleneurología (Teleneurology) C34 Evaluating Tremor in the Office

Top Ten Clinical, Educational, and Leadership Pearls

8:00 a.m.-8:45 a.m. Coding for Residents

Educators’ Leadership Program

Circle Talk: Growth Mindset

(application required)

9:15 a.m.-12:00 p.m.

1:45 p.m.-2:30 p.m.

Presidential Plenary Session

The Experience of Music Therapy in the Interdisciplinary Treatment of TBI

2:00 p.m.-2:45 p.m. How to Become a Leader in Your Health System A Career in Neuroimaging

2:45 p.m.-3:30 p.m. Case Studies: Ethical Conundrums in Neurology

3:00 p.m.-3:30 p.m. Funding Clinically Oriented/Translational Research Before R01 – Consortium and Foundation Opportunities

3:00 p.m.-3:45 p.m. Using Technology to Get Real Answers from Your Patients J-1 and H-1B Visas in Graduate Medical Education

3:00 p.m.-4:00 p.m. AAN Business Meeting

3:45 p.m.-4:45 p.m. Women in Neurology

Actualización en Dolor de Cabeza y Trastornos Neuromusculares (Update: Headache and Neuromuscular Disorder)

8:00 a.m.-8:30 a.m.

1:30 p.m.-4:00 p.m. C35

C48 C49 C50 C51 C52 C53

11:30 a.m.-4:00 p.m. Exhibit Hall 11:30 a.m.-1:00 p.m. Exhibit Hall Opening Luncheon

11:30 a.m.-6:30 p.m. P1 Poster Session 1

12:00 p.m.-1:00 p.m. Neurology Pictionary

12:00 p.m.-4:00 p.m. C62

Chief Resident Leadership Program

12:00 p.m.-5:00 p.m. BrainDome

12:30 p.m.-1:00 p.m. A Novel Clinical Practice Model in Neurology Clinics: Practice Transformation

12:30 p.m.-5:30 p.m. Medical Student Symposium

1:00 p.m.-1:30 p.m. Telemedicine FAILs: What Not to Do in a Telemedicine Encounter

C54 C55

C56 C57 C58

Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Infections of the Nervous System II: NeuroID Emergencies Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Balance and Gait Disorders Introduction to Integrative Neurology Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine Neuro-otology: The Common Peripheral Vestibular Disorders Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence Multiple Sclerosis Therapy: Diseasemodifying Treatment I Drugs and Toxin-induced Neurologic Emergencies Business Strategies for Payer Negotiations and/or How to Go off the Grid

C59

Cuidados Neurocríticos (Neurocritical Care) C60 Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases IS1 Invited Science: Infectious Diseases and Global Health S2 Neurocritical Care S3 Epilepsy/Clinical Neurophysiology (EEG) I S4 Clinical Trials in Movement Disorders S5 Therapeutics in ALS and SMA S6 MS and CNS Inflammatory Disease: Clinical Considerations I Women in Leadership: 2019, Why Are We Still Talking About This?

1:00 p.m.-5:30 p.m. C63 Resident Basic Science II:

Neuropharmacology C64 Skills Workshop: Neurophysiologic Intraoperative Monitoring

1:30 p.m.-2:00 p.m. Utilizing Wearable Technology to Improve Neurological Care

1:30 p.m.-2:30 p.m. AAN Leadership: Using Experiences to Answer the Tough Questions

2:00 p.m.-2:45 p.m. Teaching the Next Generation of Physician Advocates: Advocacy Curriculum for Neurology Residents Navigating a Career in Academics

2:30 p.m.-3:00 p.m. Level Up: How Video Games Change the Brain

Remote and Team-based Care How to be a Teacher as a Resident

3:00 p.m.-3:30 p.m.

7:00 p.m.-10:00 p.m.

The Philly Spectacular—At Reading Terminal Market! Reserve Your Ticket Through Registration

3:00 p.m.-4:00 p.m. Blind Spots: The Impact of Conscious and Unconscious Biases

Monday, May 6

7:00 a.m.-7:45 a.m.

3:30 p.m.-4:45 p.m.

Yoga - Vinyasa

S8 Neuro Trauma and Sports Neurology

Relationship Building: The Importance of the Program Director/Program Coordinator Relationship

3:30 p.m.-5:30 p.m. C65 Evaluation and Management of Autonomic C66 C67 C68 C69

C70

C71 C72 C73 C74 C75 C76 N1 S9 S10 S11

Disorders II: Diagnostic Approach and Treatments for Dysautonomia Infections of the Nervous System III: Advanced Topics in Infectious Neurology Neurology Update II: Behavioral Neurology, Movement Disorders, and Neuroophthalmology Cerebrovascular Disease IV: Telestroke The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Lifelimiting Neurological Disorders Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Neuro-otology: Diagnosis and Treatment of Nuanced Causes of Dizziness Disordered Sleep in Common Neurologic Diseases: Traumatic Brain Injury, Stroke, and Parkinson’s Disease Multiple Sclerosis Therapy: Diseasemodifying Treatment II CNS Toxicities How to Run a Practice: Business Strategies for Neurology Private Practices and the Future Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions Neuroscience in the Clinic: Child Neurology: Movement Disorders: Transition from Child to Adult Aging and Dementia: Clinical Trials and Novel Therapies Biomarkers in Movement Disorders Autoimmune CNS Inflammatory Disorders: Clinical Advances

7:00 a.m.-9:00 a.m. C77 C78

4:00 p.m.-4:45 p.m. A “How to and Why” of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time Work Life Balance in Research and Academics

4:15 p.m.-5:00 p.m. The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults

5:00 p.m.-5:30 p.m. Happiness Hour

1:00 p.m.-1:30 p.m. Using Strategic Partnerships to Grow Your Practice

Addiction

Controversies in Neuroimaging The Ripple Effect of Positive Psychology

7:30 a.m.-9:00 a.m. Student Interest Group in Neurology (SIGN) Meeting

8:00 a.m.-8:30 a.m. Crafting Meaningful Research Questions

8:00 a.m.-8:45 a.m. Physical Exercise and Cognitive Training in Neurology-Application in Aging & Neurodegenerative Disease Personal Finances for Residents Chief Resident and Program Coordinator Discussion: Choosing, Forging, Training and Mentoring Relationships

9:15 a.m.-11:30 a.m. Contemporary Clinical Issues Plenary Session

11:30 a.m.-6:00 p.m. Exhibit Hall 4:00 p.m.-6:00 p.m. Exhibit Hall Networking Reception

11:30 a.m.-6:30 p.m. P2 Poster Session 2

11:45 a.m.-12:30 p.m. Self Management in Neurologic Disease

12:00 p.m.-12:30 p.m. AI in Health Care: A Bridge to Physician Wellness

12:00 p.m.-1:00 p.m. Would You Fly With This Pilot? Meet a Member of Congress: U.S. Representative Brendan Boyle (D-PA)

2:00 p.m.-2:45 p.m. Using EHR to Close Referral Loops A Career in Clinical Practice

2:00 p.m.-3:00 p.m. Maintenance of Certification Information Session

2:30 p.m.-3:00 p.m. There’s An App for That! Using Technology to Enhance Learning and Patient Care

Advancing Medicine: Inspiration and Innovation Featuring Mona HannaAttisha, MD, MPH, FAAP

1:00 p.m.-3:00 p.m.

The Role of Integrative Medicine in Epilepsy

C93 C94 C95 C96

for Clinicians Tuberculosis of the Central Nervous System Clinical Epilepsy I: Basics Neurology Update III: Headache, Neurootology, and Epilepsy Autism Spectrum Disorders What We Know and Where We Are Going Paroxysmal Movement Disorders Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings

C100

Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders) C101 Clinical EMG I: Principles and Practice of NCS and Needle EMG N2 Neuroscience in the Clinic: Interpretations of Genetic Results S12 Progressive Multiple Sclerosis S13 Behavioral and Cognitive Neurology: Behavioral Neurology, Aging, and Dementia S14 Translational and Clinical Advances in Neuro-oncology S15 Intracerebral Hemorrhage and SAH S16 Huntington’s Disease: From Bench to Clinical Trials S17 Headache: Clinical Trials I

1:00 p.m.-4:00 p.m. C102

Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader

1:00 p.m.-5:30 p.m. C103 Resident Basic Science III: Neuroanatomy: All the Lesions

C104 Research Career Symposium C105 Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia

1:30 p.m.-2:00 p.m. Streamlining the Office Visit for Mild TBI Patients

3:45 p.m.-4:30 p.m. Nutrition, Lifestyle, and Neuropathic Pain

3:45 p.m.-4:45 p.m. 4:00 p.m.-4:45 p.m. Navigating Prior Authorizations #MeanReviews: Flipping Imposter Syndrome on Its Head

4:00 p.m.-5:30 p.m. Brainstorm: A Competition for the Innovator in All of Us

5:00 p.m.-5:45 p.m. Defining, Evaluating, and Promoting Healthy Cognitive Aging Safety and Quality Awards Careers in Movement Disorders

Medical Improv

3:00 p.m.-3:45 p.m. Research Outputs from the Axon Registry Child Neurology for Trainees

6:00 p.m.-9:00 p.m.

3:30 p.m.-5:30 p.m. C106 Cognitive Impairment Due to Alzheimer’s

Disease: Using Old Skills and New Tools for Diagnosis and Treatment C107 Emergency Room Neuro-ophthalmology C108 Clinical Epilepsy II: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly C109 Neurology Update IV: Stroke, Neuroinfectious Disease, and Autoimmune Encephalopathies C110 Adult and Pediatric Neuro-Oncology for the Neurohospitalist

C111

Sleep for Resiliency, Recovery and Performance C112 Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

C113

Concussion: Chronic Symptoms -- Selected Considerations for Why Your Patient May Not be Getting Better C114 The Global Burden of Neurologic Diseases

C115

Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease C116 LGBTQI Health in Neurology

C117 C118 C119

Tourette Syndrome: Assessment and Management How to Understand and Incorporate Medical Cannabis into Clinical Practice

Actualización en Lesión Cerebral Traumática e Ictus Isquémico (Update: TBI and Stroke) C120 Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography S19 Child Neurology: Updates in Autism, Migraine, MS, and Stroke

11:30 a.m.-12:00 p.m. Scribes: How to Do It Write

11:30 a.m.-4:00 p.m.

Exhibit Hall

11:30 a.m.-6:30 p.m. P3 Poster Session 3

11:45 a.m.-12:30 p.m. Treatment of Neuropathy Symptoms Without Medication

12:00 p.m.-12:30 p.m. Advancements in Real-time Clinical Practice Innovations

12:00 p.m.-1:00 p.m. Neuro Game Show: Localize the Lesion

12:00 p.m.-5:00 p.m. BrainDome

12:30 p.m.-1:00 p.m. Potential Pitfalls in Telemedicine

1:00 p.m.-1:30 p.m. Innovative Technologies in Assessment of Sports Concussion and Head Trauma

1:00 p.m.-1:45 p.m. Virtual Reality for Chronic Pain Women in Neurology: Thriving Through Challenges How to Create a Department That Promotes Wellness

Early Career Reception

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates

Tuesday, May 7 6:30 a.m.-8:30 a.m. 5k Run/1K Walk for Brain Research

7:00 a.m.-7:30 a.m. Diversifying Your Funding Sources with NIH and Other Sources

7:00 a.m.-7:45 a.m. Yoga - Vinyasa Pursuing a Career in Industry

7:00 a.m.-9:00 a.m. C121 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches C122 Neurocognitive Assessment for Neurologists

C123

Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy C124 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease C125 Circadian Rhythm Disorders: Implications for Neurology

C126

Active Management of Professionalism Lapses: A New Way of Thinking C127 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment C128 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy C129 Critical Care Consultations for Neurohospitalists

C130

Diagnostic Pearls in Myelitis: a Casebased Approach

8:00 a.m.-8:45 a.m. Advocacy for Residents Turning the “Diversity Tax” into Currency in Neurology

S27 General Neurology: Improving Neurologic Care and the Impact of Therapeutics

1:00 p.m.-4:00 p.m. C145

Clinical Trials Plenary Session

Standing on the Shoulders of Giants

3:30 p.m.-4:45 p.m. S18 Autonomic Disorders

9:15 a.m.-11:30 a.m.

5:00 p.m.-6:00 p.m.

3:30 p.m.-4:00 p.m. 2018 Brainstorm Competition Winner

Mind Over Matter: Meditation for the Practicing Neurologist

Philadelphia: The City of Neurology Love

3:00 p.m.-3:30 p.m.

Concussion: Topics in Acute Concussion

Everything You Need to Know to Practice Neuro-rehabilitation C97 Neuroendocrine Update: Nuts and Bolts of What You Need to Know C98 Faculty Development: Enhancing Your Role in Student and Resident Training C99 Starting a Practice From the Ground Up: A Guide for Early Career Neurologists

Episodic Syndromes Associated with Migraine S21 Autoimmune Neurology: Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease S22 Stroke Genetics, Cellular Responses, and Animal Models S23 Genetic Muscle Disorders Presentation of the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases

2:45 p.m.-3:30 p.m. Self Reflected: Deeply Fusing Art and Science to Create the World’s Most Complex Artistic Depiction of the Human Brain

8:00 a.m.-9:00 a.m.

S20 Headache Imaging and Physiology and

2:30 p.m.-3:15 p.m.

C88 Mild Cognitive Impairment: Implications

C92

C85 C86 C87

1:00 p.m.-2:00 p.m.

C80

C84

Leveraging Technology to Reduce Implicit Bias and Improve Population Health Metrics

Interviewing Skills

C89 C90 C91

Epileptologists’ Secrets for the Busy General Neurologist: Localization, Imaging, and Fear of Surgery Core Principles of Brain Tumors Stroke in Young Adults and Women Diagnosis and Treatment of Functional Movement Disorders Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist Severe TBI: From ICU to Rehabilitation Neuromyelitis Optica Spectrum Disorders Skills Workshop: Clinical Usefulness of Botulinum Toxin for Spasticity

2:00 p.m.-2:30 p.m.

1:00 p.m.-1:45 p.m.

Young Onset and Atypical Alzheimer’s Dementia C79 Differential Diagnosis of Neurologic Infections

C81 C82 C83

3:45 p.m.-4:30 p.m. Introduction to Acupuncture II - Evidencebased Applications for Acupuncture in the Treatment of Painful Neurologic Conditions

Innovations and New Technologies in Neurology: Improving Patient Care and Optimizing Clinical Practice

Tips to Sail Through The IRB

S7 Global Health

Lost in Translation: Acknowledging and Respecting Cultural Differences With Your Patients

12:30 p.m.-1:00 p.m.

7:00 a.m.-7:30 a.m.

3:30 p.m.-4:15 p.m.

1:30 p.m.-2:15 p.m.

BrainDome

Standing on the Shoulders of Giants

3:00 p.m.-3:45 p.m. Practice Innovation in Epilepsy

12:00 p.m.-5:00 p.m.

5:15 p.m.-6:15 p.m.

Medical Improv

1:00 p.m.-4:00 p.m. C61

5:00 p.m.-5:45 p.m.

Introduction to Acupuncture 1 - Conceptual Framework and Mechanism of Action

C47 Evaluation and Management of Autonomic

C36 Mastering EMG Waveform Recognition

1:00 p.m.-1:45 p.m.

C30

1:00 p.m.-3:00 p.m.

7:00 a.m.-9:00 a.m.

Statistics: Sample Size

C29

1:00 p.m.-2:15 p.m.

2:30 p.m.-3:15 p.m.

S1 Neuroepidemiology

7:00 a.m.-7:45 a.m.

12:45 p.m.-1:30 p.m.

C28

Tip of the Iceberg: Ultra-high Cost Neurology Drugs Medical Marijuana: What Do Neurologists Need to Know? Negotiation Skills

4:15 p.m.-5:30 p.m.

Art Therapy

C24

1:00 p.m.-1:45 p.m.

Opioids: What Is Your State Doing to Confront This Epidemic?

11:45 a.m.-12:30 p.m.

Women in Leadership

7:00 a.m.-4:00 p.m.

4:00 p.m.-4:45 p.m.

Fellowship as a Springboard to Junior Faculty

7:00 a.m.-7:45 a.m.

1:00 p.m.-2:00 p.m. S24 Lost Connections: From Functional

Connectivity to Needs in Pain and Palliative Care

1:00 p.m.-3:00 p.m. C131 Small Fiber Neuropathies: Sensory,

Autonomic, and Both I: Focus on Autonomic Nervous System

C132 Frontotemporal Dementias C133 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG)

C134 Continuum® Test Your Knowledge: A Multiple-choice Question Review I

C135

Case Studies: Challenging Acute Ischemic Stroke Cases C136 Neuroimaging for the General Neurologist I: Brain C137 Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders C138 Hot Topics in Headaches and Related Disorders I: Unusual Headaches, Childhood Headaches, and Concussion Management C139 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia C140 Sports Neurology: Enhancing Athletic Performance C141 Rehabilitation in Neurology C142 Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS

C143 Education Research Methodology Course C144 Actualización Científica I (Scientific Update

I - Spanish) N3 Neuroscience in the Clinic: Stem Cells S25 Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes S26 MS and CNS Inflammatory Disease: Clinical Considerations II

Mitigating the Impact of Unconscious Bias

1:00 p.m.-5:00 p.m. C146 C147

Strengths Spotting: Using Strengths to Help Improve Communication with Patients, Colleagues, and Leaders The Doctor’s Lounge…Helping Physicians in Mid-career Renew and Repurpose Their Work/Lives

1:00 p.m.-5:30 p.m. C148 Skills Workshop: EMG: Basic

1:30 p.m.-2:00 p.m. Remote Monitoring of Neurological Patients Via Mobile Health Platform

1:30 p.m.-2:30 p.m. Neuro Exam Tricks and Tips

2:00 p.m.-2:30 p.m. How to Build Clinical Research Studies in Private Practice

2:00 p.m.-2:45 p.m.

C158 Sports Concussion: Event Coverage

Foundational Skills and Sport Specific Pearls

Mid-Level Faculty Career Development Course C160 Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

C161 Child Neurology: Metabolic C162 Coding 101: E&M, Basic Procedures, Non Face-to-Face, and New Codes

Creating a Roadmap for a Diverse Workforce in Academic Neurology C164 Update on Medical Management of Stroke IS2 Invited Science: Movement Disorders S29 NeuroHIV: Pathophysiology and Clinical Phenotypes S30 Brain Cancer: From Epidemiology to Quality of Life S31 MS and CNS Inflammatory Disease: Imaging S32 General Neurology: Advances in Neurology: From the Clinic to the Bench Presentation of the Sheila Essey Award: An Award for ALS Research

3:45 p.m.-4:30 p.m. 4:00 p.m.-4:45 p.m. So You’ve Had an EHR for 10 Years, Now What? Healthcare Disparities in Populations

5:00 p.m.-5:45 p.m. Guided Meditation What is the Neurologist Compensation and Productivity Survey, and How Can it Increase My Value? From Private Practice to Academics

What Can the AAN’s Compensation and Productivity Survey Do For You?

Oportunidades de Colaboración Internacional para Realizar Proyectos de Investigación en Enfermedades Neurodegenerativas (Opportunities for International Collaborations to Conduct Research on Neurodegenerative Diseases)

Standing on the Shoulders of Giants

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates

Wednesday, May 8

3:30 p.m.-4:45 p.m. S28 Neuro-ophthalmology/Neuro-otology

3:30 p.m.-5:30 p.m. C149 Clinical Neurology for Advanced Practice

Providers C150 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System

C151 Lewy Body Dementias C152 Clinical Epilepsy IV: Surgery C153 Continuum® Test Your Knowledge: A

Multiple-choice Question Review II C154 Neuroimaging for the General Neurologist II: Brain C155 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders C156 Hot Topics in Headaches and Related Disorders II: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances C157 Evaluation and Treatment of Common Spine Disorders

Frontiers in Neuroscience Plenary Session

11:30 a.m.-6:30 p.m. P4 Poster Session 4

11:45 a.m.-12:30 p.m. Eating Your Way to Fewer Migraines

How to Write and Publish Research Papers, Reviews, and Other Scientific Communication

7:00 a.m.-7:45 a.m. Simulation in Neurology Education Yoga - Vinyasa

7:00 a.m.-9:00 a.m. C165 Current Management of Incidental and

Asymptomatic Cerebrovascular Lesions C166 Neuroimaging Biomarkers Across the Dementia Spectrum C167 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome C168 Parkinson’s Disease Update C169 Neurological Intensive Care I: The Essentials C170 Video EEG: Name That Spell

C171

Child Neurology: Neuromuscular/ Autoimmune Neurology C172 Advances in Neurogenetics C173 Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders C174 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema

8:00 a.m.-8:30 a.m. Recruiting Underrepresented Populations into Trials

Current as of February 1, 2019. Programs subject to change.

C186

Women Founders of Neurology and Neuroscience I C187 Comprehensive Migraine Update I: Migraine Diagnosis, Pathophysiology, and Comorbidities C188 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria N4 Neuroscience in the Clinic: Immunotherapies in Neurological Disease S34 Aging and Dementia: Risk Factors, Biomarkers, and Neuropathology S35 Stroke Prevention Strategies S36 Epilepsy/Clinical Neurophysiology (EEG) II S37 MS Biomarkers S38 Headache: Clinical Trials II

Relaxation Tools: See One, Do One, Teach One

12:00 p.m.-1:00 p.m. Neuro-Jeopardy: Telencephalon Twisters

12:00 p.m.-5:00 p.m. BrainDome

1:00 p.m.-1:30 p.m. Acupuncture: Beyond Meridians, Into Medicine

1:00 p.m.-1:45 p.m.

Neuromuscular Recovery

1:00 p.m.-2:00 p.m.

C177

Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach C178 Therapy in Neurology I: Neurological Infectious Diseases and Neuro-oncology C179 Nonmotor Manifestations of Parkinson’s Disease I C180 Neurological Intensive Care II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction C181 Treatment of Pediatric Multiple Sclerosis in the Current Era

C182

Neuroimaging for the General Neurologist: Spine

C183

Reading, Critiquing, and Reviewing the Neurologic Literature: An Evidence-based Approach and Case-based Presentation of Peer Reviews in Neurology

C184 C185

Business Efficiencies for Academic Neurology Departments: Business Strategies for Success Actualización en Trastornos del Movimiento (Update in Movement Disorders)

4:15 p.m.-5:00 p.m. Is There a Neurologist in the Stands?

5:00 p.m.-5:45 p.m.

Skills Workshop: Neurostimulation

Case Studies: When to Refer Patients for Cognitive Behavioral or Mindfulness Based Psychotherapies: Expanding the Neurologist’s Toolbox Succeeding in Small and Solo Practice Perspectivas profesionales para neurólogos en los Estados Unidos y América Latina (Professional Perspective for Neurologist in the United States and Latin America)

Animal Neurology

5:15 p.m.-6:15 p.m.

2:00 p.m.-2:30 p.m.

Standing on the Shoulders of Giants

A Career in Autoimmune Neurology

7:00 p.m.-10:00 p.m.

2:00 p.m.-2:45 p.m.

Industry Therapeutic Updates

Being a Neurologist at a VA Hospital

Thursday, May 9

2:30 p.m.-3:15 p.m.

7:00 a.m.-7:30 a.m.

Unlocking Purpose for a Vital Life

So Your Paper Didn’t Get Accepted, Now What?

3:00 p.m.-3:30 p.m.

7:00 a.m.-7:45 a.m.

Medical Improv

Yoga - Vinyasa

3:00 p.m.-3:45 p.m.

7:00 a.m.-9:00 a.m.

Foundations in Success in the AAN Understanding the AAN’s Toolkit for Advanced Practice Providers How to Successfully Incorporate APP’s into Your Practice

1:00 p.m.-3:00 p.m. Myasthenia Gravis, Ocular, and MuSK Myasthenia C176 Behavioral Neurology I: Network Anatomy of Behavior and Language

Digital Marketing for Your Practice

1:30 p.m.-2:30 p.m.

Advancing Medicine: Inspiration and Innovation Featuring Patricia Churchland, BPhil

C175 Neuromuscular Junction Disorders I:

Update on the Complementary Therapies for MS: An Evidence-based Review

Immersive Environments to Assess and Treat Traumatic Brain Injury: Reversing a Maladaptive Cortical Response to Injury

S33 Neuro-rehabilitation: Brain and

3:30 p.m.-5:30 p.m. C192 Neuromuscular Junction Disorders II:

Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission C193 Behavioral Neurology II: Memory and Attention C194 CANCELED C195 Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease C196 Nonmotor Manifestations of Parkinson’s Disease II C197 Neurological Intensive Care III: Vascular Diseases C198 Integrating Sleep Medicine Concepts into Your Child Neurology Practice

C199

Neuroimaging for the General Neurologist: Peripheral Nerve C200 Neurologic Case Studies in Pregnancy

C201 C202

Technology Education Research and Research Methodology Stroke Risk Factors and Epidemiology Imaging in Movement Disorders Neuromuscular Disorders Immunotherapies and Drug Trials in Autoimmune Neurological Disorders Presentation of the John Dystel Prize for Multiple Sclerosis Research

3:45 p.m.-4:15 p.m.

1:30 p.m.-2:00 p.m.

Headache Neuromodulation Therapy

1:00 p.m.-2:00 p.m.

S40 S41 S42 S43

Ultrasound

Understanding the AAN’s Latest Guidelines How to Deal with Difficult Family, Communications, Medical/Legal

S39

C191 Skills Workshop: Neuromuscular

12:30 p.m.-1:00 p.m. The Why and How of Getting a Billion Dollar EHR to Make Their System Work Better for Neurologists

Team Building in Medicine: How to Incorporate Strengths Training into Medical Teams

1:00 p.m.-5:30 p.m. C190

N5 Neuroscience in the Clinic: Wearable

4:00 p.m.-4:45 p.m.

1:00 p.m.-5:00 p.m. C189

12:00 p.m.-12:30 p.m.

7:00 a.m.-7:30 a.m.

3:30 p.m.-4:00 p.m. Fitness to Drive Testing… Warp Speed Ahead

9:15 a.m.-11:30 a.m.

5:00 p.m.-6:00 p.m.

Medical Improv The New Congress: How Will It Impact Neurology Live Intraoperative Monitoring

Consejos Prácticos para Educadores Médicos (Practical Advice for Medical Educators)

Outsmart Stress

2:30 p.m.-3:00 p.m.

3:00 p.m.-3:45 p.m.

8:00 a.m.-8:45 p.m.

C163

Treating Pain with Herbs, Supplements, and Marijuana

3:00 p.m.-3:30 p.m.

Complementary Therapies in Parkinson’s Disease Contract Negotiations for Residents

C159

The HSR Game Show A Career in Teleneurology: A Panel Discussion

2:15 p.m.-3:30 p.m.

8:00 a.m.-8:45 a.m.

Academic Neurology Departments 2020 and beyond: Succeeding in the Tripartite Mission

Women Founders of Neurology and Neuroscience II C203 Comprehensive Migraine Update II: Pharmacologic and Non-Pharmacologic Therapies C204 Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus

C205 Peripheral Neuropathy I: Anatomical Basis

and Acquired Demyelinating Neuropathies

C206 Vascular Cognitive Impairment and

Dementia: Current Status and Future C207 Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

C208

Contemporary Concerns About Brain Death Determination C209 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease C210 Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management C211 Nystagmus and Saccadic Intrusions Made Simple C212 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease

C213

Communication Skills: From Good to Great C214 Child Neurology: A Case-based Approach

8:00 a.m.-8:30 a.m. Neuroscience of Bias

8:00 a.m.-8:45 a.m. Magnifying Your Life Through Poetry Creating, Evaluating, and Publishing Your Active Learning Modules A Migraine in Room 3: Patient Centered Care for Residents

18 2019 AAN Annual Meeting

9:15 a.m.-11:30 a.m.

3:00 p.m.-3:45 p.m.

Controversies in Neurology Plenary Session

11:30 a.m.-6:30 p.m.

How to Navigate the Demands of the First Years of Your Academic Career

3:00 p.m.-4:00 p.m.

P5 Poster Session 5

11:45 a.m.-12:30 p.m. How Your Social Life Might Be Helping (or Harming) Your Brain

12:00 p.m.-1:00 p.m. Who Wants to Be a Millionaire

1:00 p.m.-1:45 p.m. Acupuncture Demonstration - 4 Gates

1:00 p.m.-2:30 p.m. S44 History of Neurology Robin’s Wish: Preview Film on Robin Williams’ Journey with LBD with His Wife Susan Schneider Williams

1:00 p.m.-3:00 p.m. C215 Peripheral Neuropathy II: Update on

Diabetic, Immune Axonal, and Hematologicrelated Neuropathies C216 Higher Cortical Visual Disorders: Casebased Review C217 Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids C218 Critical Care EEG Monitoring C219 Therapy in Neurology III: Epilepsy and Headache C220 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia C221 Functional Neurologic Disorders I: Movement, Seizures, and Multiple Sclerosis C222 Good Neurology in Challenging Conditions: Lessons from Military Neurology C223 United We Stand: Enhancing Your Practice with APPs C224 Burnout and Resilience: Strategies and Evidence for Enhancing Wellbeing C225 Actualización Científica II (Scientific Update II) C226 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I S45 Neuroinfectious Disease: Treatments, Diagnostics, and Outcomes S46 Sleep Science and Therapy Updates S47 Stroke Outcomes and Recurrence S48 Epilepsy/Clinical Neurophysiology (EEG) III S49 MS Epidemiology and Risk Stratification

1:00 p.m.-5:30 p.m. C227 Genomic Neurology: Developing Practical

Knowledge of Tools and Concepts Through Case Studies C228 Skills Workshop: Brain Death: How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family

1:30 p.m.-2:30 p.m. Rocky’s Legacy: Historical Controversies of Boxing Related Concussions

2:00 p.m.-2:45 p.m. Innovative Ways to Decrease Wait Times in Your Practice Neurohospitalist Career Choices: A Growing Landscape

2:30 p.m.-3:15 p.m. Circle Talk: Mindfulness in the Practice of Clinical Neurology

Consejos Prácticos para un Buen Examen Neurológico (Neuro Exam Tips and Tricks)

3:30 p.m.-5:15 p.m. S50 Practice, Policy, and Ethics

C247 What Do I Do Now?: Emergency and

Inpatient Management of Migraine and Other Headache Disorders C248 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making C249 Clinical Pearls: Learning from Complex Cases Simple Lessons that Apply to Everyday Problems

8:00 a.m.-8:30 a.m.

3:30 p.m.-5:30 p.m.

How to Put Together an Effective Research Presentations

C229 Peripheral Neuropathy III: Genetic

Neuropathies: Molecular Diagnosis and Treatment Perspectives C230 Disparities in Care C231 Safe and Appropriate Opioid Prescribing in Neurology C232 Women With Epilepsy (WWE): Beyond Seizure Control C233 Therapy in Neurology IV: Movement Disorders and Stroke C234 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics C235 Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders C236 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II IS3 Invited Science: Aging and Dementia N6 Neuroscience in the Clinic: The Brain Across the Menstrual Cycle S51 Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders S52 Acute Non-Interventional Stroke Care S53 Movement Disorders: Genetics and Clinical Features S54 Motor Neuron Disease S55 MS Basic Science

3:45 p.m.-4:30 p.m. Lifestyle Medicine: What It Is and Why It Should Be Your First Recourse in Patient Care

4:30 p.m.-5:30 p.m.

8:00 a.m.-8:45 a.m. How to Give Effective Feedback

9:15 a.m.-11:30 a.m. Neurology Year in Review Plenary Session

12:00 p.m.-1:00 p.m. The Neurology of Creativity at the Keyboard

12:00 p.m.-4:00 p.m. BrainDome

1:00 p.m.-1:45 p.m. Acupuncture Demonstration Auriculotherapy Growing Research in Medical Marijuana Racial, Ethnic, and Gender Disparities in Early and Mid-Career

1:00 p.m.-3:00 p.m. C250 Update in Epilepsy C251 Neuro-ophthalmology: Overview and Update

C252 Update in Aging and Dementia C253 Update in Movement Disorders S56 MS Trials and Treatment S57 Acute Treatment and Imaging of Ischemic Stroke

S58 Therapeutics in Neuromuscular Disorders S59 Migraine: Impact, Treatment Patterns and Resource Utilization

1:30 p.m.-2:15 p.m. Movement Disorder Case Studies: What I Have Learned from My Patients

Standing on the Shoulders of Giants

5:00 p.m.-5:45 p.m. Influence of a Comprehensive Lifestyle Intervention on Prevention of Dementia

7:00 p.m.-10:00 p.m.

2:00 p.m.-2:30 p.m. Choosing a Career in Neuro-oncology

2:45 p.m.-3:30 p.m. Neuroanatomy of the Zombie Brain: A Year in Review

C237 Case Studies: Diagnosis and Management

of Unusual Cases in Neuromuscular Disease C238 Case Studies in the ICU C239 Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging C240 Case Studies: Unusual Movement Disorders C241 Case Studies: Challenging Headache Cases

C242

Case Studies: Dementia

Friday, May 10 7:00 a.m.-7:30 a.m. Grant Writing 101: Getting Started

7:00 a.m.-7:45 a.m. Yoga - Vinyasa

7:00 a.m.-9:00 a.m. C243 Therapy of Neuromuscular Disease:

ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis C244 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases C245 Controversies in Stroke Treatment and Prevention C246 Hot Topics and Controversies in Parkinson’s Disease

3:00 p.m.-3:45 p.m. Global Health Opportunities

3:30 p.m.-4:30 p.m. C254

Education Blitz: Child Neurology: Concussion C255 Education Blitz: Normal Pressure Hydrocephalus C256 Education Blitz: Emerging Infectious Diseases of the Central Nervous System C257 Education Blitz: Evolution of Autoimmune Neurology C258 Education Blitz: Multiple Sclerosis C259 Education Blitz: Sleep

4:30 p.m.-5:30 p.m. NeuroZone

5:30 p.m.-7:00 p.m. Closing Party

7:00 a.m.-7:45 a.m. Yoga - Vinyasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

7:00 a.m.-9:00 a.m. What Do I Do Now?: Assessment and Management of C1 C2 C3 C4 C5 C6 C7 C8

Neuropsychiatric Symptoms in Neurocognitive Disorders Using Sleep Medicine to Help Solve Difficult Neurologic Cases Clinical EEG: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Pediatric Neuro-ophthalmology Update What Do I Do Now?: Neurologic Consultations in Cancer Patients I Therapy of Movement Disorders: A Case-based Approach Clinical Pearls in Autoimmune Neurology: Real World Cases Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors?

7:00 a.m.-12:30 p.m. Clerkship and Program Directors Conference: Letâ&#x20AC;&#x2122;s Build C9 an Educational Scholarly Product

7:00 a.m.-3:30 p.m. C10 Women in Leadership 7:00 a.m.-4:00 p.m. Neurology MOC Prep Course C11

9:30 a.m.-11:30 a.m. Clinical Approach to Muscle Disease I: Role of C12 C13 C14 C15 C16 C17 C18 C19 C20 C21

10:30 a.m.-11:15 a.m. Music Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

11:00 a.m.-11:30 a.m. Your CV Is Talking About You Behind Your Back, and Your LORs Are Too! . . . . . . . . . . . . . . . . . . 85

11:00 a.m.-11:45 a.m. Fellowship as a Springboard to Junior Faculty . .84

11:45 a.m.-12:30 p.m. Art Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

12:00 p.m.-12:30 p.m. Navigating the Annual Meeting App . . . . . . . . . . . . 77

9:15 a.m.-10:00 a.m. Circle Talk: Mindfulness-based Stress Reduction (MBSR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

12:00 p.m.-4:00 p.m. Resident Basic Science I: Neuropathology C22 Skills Workshop: Neuro-ophthalmology and C23 C24

Neurovestibular Exam Lab Leadership Challenges in Practice

12:00 p.m.-5:00 p.m. Futures in Neurological Research Boot Camp

AAN.com/view/AM19Sci 19

Saturday

How to Successfully Publish Quality Improvement Projects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85

Tick-based Infections

Research Careers in Industry . . . . . . . . . . . . . . . . . . . 85

9:00 a.m.-9:30 a.m. What Should Applicants Look For in a Program? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults Cerebrovascular Disease I: Prevention What Do I Do Now?: Neurologic Consultations in Cancer Patients II Cerebellar and Afferent Ataxias: Diagnosis and Management Multiple Sclerosis Overview I: Clinical Pearls Neurologic Complications of Medical Disease

How to Be a Chief Resident . . . . . . . . . . . . . . . . . 84

8:00 a.m.-8:45 a.m. Laughter Yoga Session . . . . . . . . . . . . . . . . . . . . . . . . 79

Child Neurology: Headache

10:00 a.m.-10:30 a.m.

8:00 a.m.-8:30 a.m. Are you My Mentor? How to Select a Good Mentor for Your Research Center . . . . . . . . . . . . . . . . . . . . . . 85

Antibodies, Muscle Imaging, and Genetic Testing Clinicopathological Correlation Session in Dementia

ANNUAL MEETING SCHEDULE

SATURDAY, MAY 4

ANNUAL MEETING SCHEDULE

SATURDAY, MAY 4 12:45 p.m.-1:30 p.m. Transcending Opiate-based Pain Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

1:00 p.m.-1:30 p.m. Statistics: Sample Size . . . . . . . . . . . . . . . . . . . . 85

1:00 p.m.-1:45 p.m. Mind-body Approaches to Chronic Pain . . . . . . . 79

Funding Clinically Oriented/Translational Research Before R01 – Consortium and Foundation Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85

3:00 p.m.-3:45 p.m. Using Technology to Get Real Answers from Your Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 J-1 and H-1B Visas in Graduate Medical Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

Tips and Tools for Successful Recruitment . . . . . . . . 84

3:00 p.m.-4:00 p.m. 1:30 p.m.-3:30 p.m. Clinical Approach to Muscle Disease II: Inflammatory C25 C26 C27 C28 C29 C30 C31 C32 C33 C34

Myopathies and Muscle Pathology Clinical EEG: Neonatal and Pediatric Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Sleep-Disordered Breathing in Neurology Populations: From Lab to Clinic Multiple Sclerosis Overview II: Clinical Advances Neurologic Complications of Medical and Surgical Therapies Mitochondrial Disorders in Neurology The Neurology of Social Behavior Teleneurología (Teleneurology) Evaluating Tremor in the Office

1:30 p.m.-4:00 p.m. Educators’ Leadership Program C35 (application required)

Saturday Text

3:00 p.m.-3:30 p.m.

1:45 p.m.-2:30 p.m. The Experience of Music Therapy in the Interdisciplinary Treatment of TBI . . . . . . . . . . . . . . . 77

2:00 p.m.-2:45 p.m. How to Become a Leader in Your Health System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 A Career in Neuroimaging . . . . . . . . . . . . . . . . . . . . . 84

2:45 p.m.-3:30 p.m. Case Studies: Ethical Conundrums in Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

20 2019 AAN Annual Meeting

AAN Business Meeting

3:45 p.m.-4:45 p.m. Women in Neurology . . . . . . . . . . . . . . . . . . . . . . . . . 77

4:00 p.m.-4:45 p.m. Opioids: What Is Your State Doing to Confront This Epidemic? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81

4:15 p.m.-5:30 p.m. Hot Topics Plenary Session . . . . . . . . . . . . . . . . . 68

5:00 p.m.-5:45 p.m. Telestroke Across the Continuum . . . . . . . . . . . . . . . 81

5:45 p.m.-6:45 p.m. Advancing Medicine: Inspiration and Innovation Featuring Hugh Herr, PhD

7:00 p.m.-10:00 p.m. Industry Therapeutic Updates

7:00 a.m.-7:45 a.m. Yoga - Vinyasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Resident Evaluation of Faculty: A New Approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

7:00 a.m.-9:00 a.m. Mastering EMG Waveform Recognition Skills in Just C36 C37 C38 C39 C40 C41 C42 C43 C44 C45 C46

Two Hours! Chronic Traumatic Encephalopathy: Update Infections of the Nervous System I: Diagnostic Testing of Neurological Infections How to Design Meaningful Clinical Trials

12:00 p.m.-4:00 p.m. C62 Chief Resident Leadership Program 12:00 p.m.-5:00 p.m. BrainDome

12:30 p.m.-1:00 p.m. A Novel Clinical Practice Model in Neurology Clinics: Practice Transformation . . . . . . . . . . . . . . . . 87

12:30 p.m.-5:30 p.m. Medical Student Symposium

Child Neurology: Stroke Neuro-oncology in 2019: Navigating Current Trends The Dystonias: Diagnosis, Treatment and Update on Etiologies

1:00 p.m.-1:30 p.m. Telemedicine FAILs: What Not to Do in a Telemedicine Encounter . . . . . . . . . . . . . . . . . . . . . . . 87

Residents in Private Practice Multiple Sclerosis Therapy: Symptom Management Status Epilepticus

1:00 p.m.-1:45 p.m. Tip of the Iceberg: Ultra-high Cost Neurology Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Medical Marijuana: What Do Neurologists Need to Know? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Negotiation Skills . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

Actualizaciรณn en Dolor de Cabeza y Trastornos Neuromusculares (Update: Headache and Neuromuscular Disorder)

8:00 a.m.-8:30 a.m. Top Ten Clinical, Educational, and Leadership Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

8:00 a.m.-8:45 a.m. Coding for Residents . . . . . . . . . . . . . . . . . . . . . . 81 Circle Talk: Growth Mindset . . . . . . . . . . . . . . . . 79

9:15 a.m.-12:00 p.m. 11:30 a.m.-4:00 p.m. Exhibit Hall Sponsored by: 11:30 a.m.-1:00 p.m. Exhibit Hall Opening Luncheon

11:30 a.m.-6:30 p.m. Poster Session 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 P1 12:00 p.m.-1:00 p.m. Neurology Pictionary . . . . . . . . . . . . . . . . . . . . . . . . . 77

1:00 p.m.-2:15 p.m. Neuroepidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 S1 1:00 p.m.-3:00 p.m. Evaluation and Management of Autonomic Disorders I: C47 C48 C49 C50 C51 C52 C53

C54 C55

Autonomic Testing, Failure, and Peripheral Neuropathies Infections of the Nervous System II: Neuro-ID Emergencies Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Balance and Gait Disorders Introduction to Integrative Neurology Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine Neuro-otology: The Common Peripheral Vestibular Disorders Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence

AAN.com/view/AM19Sci 21

Sunday

Presidential Plenary Session . . . . . . . . . . . . . . . 69

ANNUAL MEETING SCHEDULE

SUNDAY, MAY 5

ANNUAL MEETING SCHEDULE

SUNDAY, MAY 5 1:00 p.m.-3:00 p.m. Multiple Sclerosis Therapy: Disease-modifying C56 C57 C58 C59

Treatment I Drugs and Toxin-induced Neurologic Emergencies Business Strategies for Payer Negotiations and/or How to Go off the Grid

Cuidados NeurocrĂticos (Neurocritical Care) Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases Invited Science: Infectious Diseases and Global Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 Neurocritical Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

Epilepsy/Clinical Neurophysiology (EEG) I . . . . . . . . . 99

Clinical Trials in Movement Disorders . . . . . . . . . . . 100

Therapeutics in ALS and SMA . . . . . . . . . . . . . . . . 100

MS and CNS Inflammatory Disease: Clinical Considerations I . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101

C60 IS1

1:00 p.m.-4:00 p.m. C61 Women in Leadership: 2019, Why Are We Still Talking About This?

1:00 p.m.-5:30 p.m. Resident Basic Science II: Neuropharmacology C63 C64

Skills Workshop: Neurophysiologic Intraoperative Monitoring

1:30 p.m.-2:00 p.m. Utilizing Wearable Technology to Improve Neurological Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

Sunday Text

1:30 p.m.-2:30 p.m. AAN Leadership: Using Experiences to Answer the Tough Questions . . . . . . . . . . . . . . . . . . . . . . . . . . 77

2:00 p.m.-2:45 p.m. Teaching the Next Generation of Physician Advocates: Advocacy Curriculum for Neurology Residents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Navigating a Career in Academics . . . . . . . . . . . 84

2:30 p.m.-3:00 p.m. Level Up: How Video Games Change the Brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

22 2019 AAN Annual Meeting

2:30 p.m.-3:15 p.m. Introduction to Acupuncture 1 - Conceptual Framework and Mechanism of Action . . . . . . . . . . . . . . . . . . . . . 79

3:00 p.m.-3:30 p.m. Medical Improv . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

3:00 p.m.-3:45 p.m. Practice Innovation in Epilepsy . . . . . . . . . . . . . . 81

3:00 p.m.-4:00 p.m. Blind Spots: The Impact of Conscious and Unconscious Biases . . . . . . . . . . . . . . . . . . . . . . . . . . 77

3:30 p.m.-4:15 p.m. Global Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .101 S7 3:30 p.m.-4:45 p.m. Neuro Trauma and Sports Neurology . . . . . . . . . . . 101 S8 3:30 p.m.-5:30 p.m. Evaluation and Management of Autonomic Disorders II: C65 C66 C67 C68 C69

C70

C71 C72 C73 C74 C75 C76

Diagnostic Approach and Treatments for Dysautonomia Infections of the Nervous System III: Advanced Topics in Infectious Neurology Neurology Update II: Behavioral Neurology, Movement Disorders, and Neuro-ophthalmology Cerebrovascular Disease IV: Telestroke The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Lifelimiting Neurological Disorders Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Neuro-otology: Diagnosis and Treatment of Nuanced Causes of Dizziness Disordered Sleep in Common Neurologic Diseases: Traumatic Brain Injury, Stroke, and Parkinsonâ&#x20AC;&#x2122;s Disease Multiple Sclerosis Therapy: Disease-modifying Treatment II CNS Toxicities How to Run a Practice: Business Strategies for Neurology Private Practices and the Future Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions

SUNDAY, MAY 5 3:30 p.m.-5:30 p.m. Neuroscience in the Clinic: Child Neurology: Emerging N1

4:15 p.m.-5:00 p.m.

5:00 p.m.-5:30 p.m.

S10 S11

Understanding of the Epilepsy-Movement Disorder Spectrum Across the Lifespan . . . . . . . . . . . . . . . . . . 90 Aging and Dementia: Clinical Trials and Novel Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 Biomarkers in Movement Disorders . . . . . . . . . . . . 102 Autoimmune CNS Inflammatory Disorders: Clinical Advances . . . . . . . . . . . . . . . . . . . . . . . . . . . 102

The Teenage Brain: A Neuroscientist’s Survival Guide to Raising Adolescents and Young Adults . . . . . . . . 77

Happiness Hour . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

5:00 p.m.-5:45 p.m. Remote and Team-based Care . . . . . . . . . . . . . . 81

3:45 p.m.-4:30 p.m. Introduction to Acupuncture II - Evidence-based Applications for Acupuncture in the Treatment of Painful Neurologic Conditions . . . . . . . . . . . . . . . . . . 79

How to be a Teacher as a Resident . . . . . . . . . . 84

5:15 p.m.-6:15 p.m. Standing on the Shoulders of Giants . . . . . . . . . 77

4:00 p.m.-4:45 p.m. A “How to and Why” of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time . . . . . 81

7:00 p.m.-10:00 p.m.

Work Life Balance in Research and Academics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

The Philly Spectacular—At Reading Terminal Market! Reserve Your Ticket Through Registration

EdScience: 19AM NeuroSAE Ad—Half Page Horizontal> AN Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C

Make the Most of Your Annual Meeting Experience and Measure Your Success

Annual Meeting Edition

Earn 10 free self-assessment CME credits upon completion.

PRE-TEST

Assess your knowledge. Take pre-test before May 3, 2019 to receive Annual Meeting course recommendations

AAN.com/view/NeuroSAEAM

ANNUAL MEETING

Attend Annual Meeting May 4–10, 2019 to get access to post-test

POST-TEST

Take post-test before August 9, 2019 to earn 10 self-assessment CME credits

Available on the AAN Conferences App!

ANNUAL MEETING SCHEDULE

MONDAY, MAY 6 7:00 a.m.-7:30 a.m.

11:30 a.m.-4:00 p.m

Tips to Sail Through The IRB . . . . . . . . . . . . . . . . 85

7:00 a.m.-7:45 a.m. Yoga - Vinyasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Relationship Building: The Importance of the Program Director/Program Coordinator Relationship . . . . . . . 84

7:00 a.m.-9:00 a.m. C77 Addiction C78 Young Onset and Atypical Alzheimerâ&#x20AC;&#x2122;s Dementia Differential Diagnosis of Neurologic Infections C79 C80 Epileptologistsâ&#x20AC;&#x2122; Secrets for the Busy General C81 C82 C83 C84 C85 C86 C87

Neurologist: Localization, Imaging, and Fear of Surgery Core Principles of Brain Tumors Stroke in Young Adults and Women Diagnosis and Treatment of Functional Movement Disorders Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist Severe TBI: From ICU to Rehabilitation Neuromyelitis Optica Spectrum Disorders Skills Workshop: Clinical Usefulness of Botulinum Toxin for Spasticity

7:30 a.m.-9:00 a.m. Student Interest Group in Neurology (SIGN) Meeting

8:00 a.m.-8:30 a.m. Crafting Meaningful Research Questions . . . . . 85

Exhibit Hall 4:00 p.m.-6:00 p.m. Exhibit Hall Networking Reception

Sponsored by:

ADVANCING NEUROLOGY. ADVANCING YOU.

SCIENTIFIC SESSIONS

e’re refreshing the look of Scientific Sessions in 2019. The updated format will consist of eight-minute presentations that are immediately followed by a threeminute Q&A with the author before concluding the entire session with a question and answer panel with all authors. Moderators will also be tasked with guiding the discussion portions of the presentation. With a continued focus on identifying any potential biases to the audience, author disclosures will be made more clearly available during the presentations. Sunday, May 5 1:00 p.m.–2:15 p.m. S1 Neuroepidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 1:00 p.m.–3:00 p.m. S2 Neurocritical Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 S3

Epilepsy/Clinical Neurophysiology (EEG) I. . . . . . . . . . . . . . . . 99

Clinical Trials in Movement Disorders. . . . . . . . . . . . . . . . . . . 100

Therapeutics in ALS and SMA. . . . . . . . . . . . . . . . . . . . . . . . . 100

MS and CNS Inflammatory Disease: Clinical Considerations I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101

3:30 p.m.–4:15 p.m. S7 Global Health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101

3:30 p.m.–5:30 p.m. S19 Child Neurology: Updates in Autism, Migraine, MS, and Stroke. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 S20 Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine. . . . . . . . . . . . . . . . . . 106 S21 Autoimmune Neurology: Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 S22 Stroke Genetics, Cellular Responses, and Animal Models. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 S23 Genetic Muscle Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107

Tuesday, May 7

3:30 p.m.–4:45 p.m. S8 Neuro Trauma and Sports Neurology. . . . . . . . . . . . . . . . . . . 101

1:00 p.m.–2:00 p.m. S24 Lost Connections: From Functional Connectivity to Needs in Pain and Palliative Care. . . . . . . . . . . . . . . . . . . . . . . 108

3:30 p.m.–5:30 p.m. S9 Aging and Dementia: Clinical Trials and Novel Therapies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102

1:00 p.m.–3:00 p.m. S25 Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108

S10 Biomarkers in Movement Disorders . . . . . . . . . . . . . . . . . . . . 102

S26 MS and CNS Inflammatory Disease: Clinical Considerations II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109

S11 Autoimmune CNS Inflammatory Disorders: Clinical Advances. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102

Monday, May 6 1:00 p.m.–3:00 p.m. S12 Progressive Multiple Sclerosis. . . . . . . . . . . . . . . . . . . . . . . . . 103 S13 Behavioral and Cognitive Neurology: Behavioral Neurology, Aging, and Dementia. . . . . . . . . . . . . . . . . . . . . . . 103 S14 Translational and Clinical Advances in Neuro-oncology. . . . 104 S15 Intracerebral Hemorrhage and SAH. . . . . . . . . . . . . . . . . . . . 104 S16 Huntington’s Disease: From Bench to Clinical Trials. . . . . . . 105 S17 Headache: Clinical Trials I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 3:30 p.m.–4:45 p.m. S18 Autonomic Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105

S27 General Neurology: Improving Neurologic Care and t he Impact of Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109 3:30 p.m.–4:45 p.m. S28 Neuro-ophthalmology/Neuro-otology . . . . . . . . . . . . . . . . . . 110 3:30 p.m.–5:30 p.m. S29 NeuroHIV: Pathophysiology and Clinical Phenotypes. . . . . . 110 S30 Brain Cancer: From Epidemiology to Quality of Life. . . . . . . . 110 S31 MS and CNS Inflammatory Disease: Imaging. . . . . . . . . . . . 111 S32 General Neurology: Advances in Neurology: From the Clinic to the Bench. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111

Wednesday, May 8 1:00 p.m.–2:00 p.m. S33 Neuro-rehabilitation: Brain and Neuromuscular Recovery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112

AAN.com/view/AM19Sci 97

1:00 p.m.–3:00 p.m. S34 Aging and Dementia: Risk Factors, Biomarkers, and Neuropathology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 S35 Stroke Prevention Strategies. . . . . . . . . . . . . . . . . . . . . . . . . . 112 S36 Epilepsy/Clinical Neurophysiology (EEG) II. . . . . . . . . . . . . . . 113 S37 MS Biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 S38 Headache: Clinical Trials II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 3:30 p.m.–5:30 p.m. S39 Education Research and Research Methodology. . . . . . . . . 114 S40 Stroke Risk Factors and Epidemiology. . . . . . . . . . . . . . . . . . . 114 S41 Imaging in Movement Disorders. . . . . . . . . . . . . . . . . . . . . . . 115 S42 Neuromuscular Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 S43 Immunotherapies and Drug Trials in Autoimmune Neurological Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115

Thursday, May 9 1:00 p.m.–2:30 p.m. S44 History of Neurology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 1:00 p.m.–3:00 p.m. S45 Neuroinfectious Disease: Treatments, Diagnostics, and Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 S46 Sleep Science and Therapy Updates. . . . . . . . . . . . . . . . . . . . 116 S47 Stroke Outcomes and Recurrence. . . . . . . . . . . . . . . . . . . . . . 117 S48 Epilepsy/Clinical Neurophysiology (EEG) III. . . . . . . . . . . . . . 117 S49 MS Epidemiology and Risk Stratification. . . . . . . . . . . . . . . . 117 3:30 p.m.–5:15 p.m. S50 Practice, Policy, and Ethics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 3:30 p.m.–5:30 p.m. S51 Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 S52 Acute Non-Interventional Stroke Care. . . . . . . . . . . . . . . . . . 118 S53 Movement Disorders: Genetics and Clinical Features. . . . . 119 S54 Motor Neuron Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 S55 MS Basic Science. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119

Friday, May 10 1:00 p.m.–3:00 p.m. S56 MS Trials and Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 S57 Acute Treatment and Imaging of Ischemic Stroke. . . . . . . . . 120 S58 Therapeutics in Neuromuscular Disorders. . . . . . . . . . . . . . . 121 S59 Migraine: Impact, Treatment Patterns and Resource Utilization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

98 2019 AAN Annual Meeting

1:00 p.m.-2:15 p.m. S1

Neuroepidemiology

Sunday, May 5

1:00 p.m.-3:00 p.m. CME

1:00 p.m. S1.001 Is Soccer a Risk Factor for ALS?–Ettore Beghi, Elisabetta Pupillo, Letizia Mazzini, Nicola Vanacore 1:11 p.m. S1.002 Incidence of Epilepsy Among Medicare Beneficiaries Diagnosed with Alzheimer Dementia or Parkinson Disease–Leah Blank, Allison Wright Willis 1:22 p.m. S1.003 The Association between Elevated Depressive Symptoms and Risk of Incident Ischemic Stroke: the Northern Manhattan Study (NOMAS)– Marialaura Simonetto, Michelle Rae Caunca, Janet T. DeRosa, Ken Cheung, Dalila Varela, Mitchell S. V. Elkind, Ralph L. Sacco, Tatjana Rundek, Clinton B. Wright 1:33 p.m. S1.004 Causes and Predictors of 30-Day Readmission in Elderly Patients with Delirium–Hsien Lee Lau, Smit D. Patel, Neeta Garg 1:44 p.m. S1.005 Acute motor recovery in an acute flaccid paralysis cohort of Canadian children in 2018–Carmen Yea, Ari Bitnun, Joley Johnstone, Helen Branson, Mubeen Rafay, Daniela Pohl, Sunita Venkateswaran, Jason Brophy, Michelle Barton, Myriam Srour, Guillaume Sebire, Aleksandra Mineyko, Colin Wilbur, Maryam Nabavi Nouri, E. Ann Yeh 1:55 p.m. Q&A Panel with Authors

Neurocritical Care

1:00 p.m.-3:00 p.m. CME

1:00 p.m. S2.001 Admission Hemoglobin Level is Associated with Hematoma Expansion and Poor Outcome after Intracerebral Hemorrhage–Jessica Magid-Bernstein, David Albers, Kevin Doyle, Eldad Hod, Andrew Eisenberger, Santosh Bhaskar Murthy, Soojin Park, Sachin Agarwal, Sander Connolly, Mitchell S. V. Elkind, Jan Claassen, David J. Roh 1:11 p.m. S2.002 Genetic Risk Loci for Cholesterol Levels are Associated with Risk of Spontaneous Intracerebral Hemorrhage–Elayna Kirsch, Audrey Leasure, Rommell Noche, Charles Matouk, Lauren Hachmann Sansing, Katherine Crawford, Christina Kourkoulis, Daniel Woo, Jonathan Rosand, Christopher D. Anderson, Kevin N. Sheth, Guido Jose Falcone 1:22 p.m. S2.003 Liver Fibrosis and Outcomes after Primary Intracerebral Hemorrhage–Neal S. Parikh, Hooman Kamel, Babak Navi, Alexander Merkler, Arun Jesudian, Jesse Dawson, Guido Jose Falcone, Kevin N. Sheth, Mitchell S. V. Elkind, Daniel F. Hanley, Wendy C. Ziai, Santosh Bhaskar Murthy 1:33 p.m. S2.004 Rates and Predictors of Stroke in Medically Managed Patients with Unruptured Arteriovenous Malformations in ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)– Adnan I. Qureshi, Omar Saeed, Sindhu Sahito 1:44 p.m. S2.005 Functional Reorganization of the Language Network During Recovery from Severe Traumatic Brain Injury: A Longitudinal fMRI Study–Brian Coffey, Zachary D. Threlkeld, Yelena Bodien, Brian Edlow 1:55 p.m. S2.006 Analysis of Regional Brain Volumes After Traumatic Brain Injury and Correlation with Clinical Features– James Joseph Rock, Kodiak Carb, Margalit Haber, Jeffrey Ware, Erika Silverman, Nimay Kulkarni, Megan Moyer, Danielle Sandsmark, Ramon R. Diaz-Arrastia

Your One-Stop Shop for the AAN’s Online Learning Offerings. Check out the Online Learning Center in action with AAN staff available to answer your questions; learn more about the Academy’s new Neurobytes program; network with your peers; and enter for the chance to win Annual Meeting On Demand or other branded giveaways. The eLearning Networking and Innovation space is located on Level 100 (Street) near 13 th Street and Arch Street. = Abstract of Distinction

2:06 p.m. S2.007 Anatomical Explanation of a Dilated Optic Nerve Sheath Supports Clinical Research Focused on the Use of Ultrasound to Diagnose Mild Traumatic Brain Injury–Zulqar Islam, Lauren East, Parth Pradeep Agrawal, Meagan Newell, Tyler Hockman, Ian M. Heger, Hongyan Xu, Lifang Zhang, Anne-Marie Kuchinski, Robert W. Gibson, Matt Lyon 2:17 p.m. S2.008 Intracranial Injuries in the Burn ICU and Effect of Fluid Resuscitation–Brian Stephens, Anthony Robert Frattalone, Kevin Chung, Leopoldo Cancio, Julie Rizzo 2:28 p.m. S2.009 Neurological outcomes of Extracorporeal Cardiopulmonary Resuscitation (ECPR): A Systematic Review–Ibrahim Migdady, Cory J. Rice, Ken Uchino, Sung Min Cho 2:40 p.m. Q&A Panel with Authors

Epilepsy/Clinical Neurophysiology (EEG) I

CME

1:00 p.m. S3.001 Successful Expansion of Self-Management Practices: A Replication Trial of HOBSCOTCH for Memory Problems in Epilepsy–Samantha Schmidt, Wenyan Zhao, Robert Roth, Lindsay Schommer, Harold Yang, Morgan Mazanec, Felicia Chu, Heidi L. Henninger, Barbara C. Jobst 1:11 p.m. S3.002 Glioma-Related Seizures: Beyond Glioma Grade and Histopathology–Anteneh Mekonnen Feyissa, Gregory A. Worrell, William O. Tatum, George Koshy Vilanilam, Nilufer Taner, Steven S. Rosenfeld, Hugo Guerrero Cazares, Mark Jentoft, Mariet Allen, Elizabeth Martin, Kirsten Yelvington, Alfredo Quinones-Hinojosa 1:22 p.m. S3.003 Drug-drug Interaction (DDI) Studies with Coadministration of Cannabidiol (CBD) and Clobazam (CLB), Valproate (VPA), Stiripentol (STP) or Midazolam (MDZ) in Healthy Volunteers (HVTs) and Adults with Epilepsy–Jerzy P. Szaflarski, Philip Patsalos, Barry E. Gidal, Kevan VanLandingham, Dave Critchley, Gilmour Morrison 1:33 p.m. S3.004 How Effective is Standard Mental Health Treatment for the Prevention of PNES: a Preliminary Study?– Daniela Galluzzo, Stephanie Argraves, Ebony JacksonShaheed, Joseph Goulet, Cynthia A Brandt, Mary Jo Pugh, Hamada Hamid Altalib 1:44 p.m. S3.005 Stertorous Respiratory Pattern is Associated with Symmetric and Asymmetric Tonic-Clonic Seizures, Postictal Generalized EEG Suppression and Postictal Encephalopathy.–Erie Gonzalez, Yaretson Carmenate, Joon Kang, Gregory L. Krauss 1:55 p.m. S3.006 High-density 360-degree Circle Grid for Detection of After Discharges During Functional Brain Mapping in Patients with Glioma–Anvita Potluri, Jake McKay, Rana Hanna AL-Shaikh, Anteneh Mekonnen Feyissa, Karim ReFaey, Alfredo Quinones-Hinojosa, William O. Tatum 2:06 p.m. S3.007 Cortical atrophyin First-Degree Asymptomatic Relatives of non-familial-TLE Patients–Marilise Katsurayama, Jose Carlos Moreira, Vitória Ferraz, Tamires Zanão, Mateus Nogueira, Marina Koutsodontis Alvim, Leticia Franceschet Ribeiro, Iscia Lopes-Cendes, Fernando Cendes, Clarissa L. Yasuda 2:17 p.m. S3.008 Long-term Tolerability of Lacosamide and Controlledrelease Carbamazepine Monotherapy by Number of Additional Medical Conditions: A Post Hoc Analysis–Elinor Ben-Menachem, Hans Peter Grebe, Kiyohito Terada, Lori Jensen, Ting Li, Marc De Backer, Teresa De Jesus Gasalla, Melissa Brock, Victor Biton 2:28 p.m. S3.009 Interictal Spike Propagation Patterns in Adults with Epilepsy Evolve Over Time–Erin Caitlin Conrad, Samuel Tomlinson, Jeremy Wong, Kathryn A. Davis, Brian Litt, Eric D. Marsh 2:40 p.m. Q&A Panel with Authors

AAN.com/view/AM19Sci 99

Sunday

VISIT THE ELEARNING NETWORKING AND INNOVATION SPACE.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS

Sunday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS

Sunday, May 5

1:00 p.m.-3:00 p.m.

1:00 p.m.-3:00 p.m. S4

Clinical Trials in Movement Disorders

1:00 p.m. S4.001 A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of a-Synuclein Aggregation–David A. Stamler, Margaret Bradbury, Cynthia Wong, Elliot Offman 1:11 p.m. S4.002 Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation–Tanya Fischer, Thomas Gasser, Stuart H. Isaacson, Jaime Kulisevsky, Pablo Mir, Tanya Simuni, Anne Marie A. Wills, Leonor Correia Guedes, Per Svenningsson, Cheryl H. Waters, Allena Ji, Jian Li, Pacal Minini, Blandine Nembo, S. Pablo Sardi, Stephane Saubadu, Jyoti Sharma, M. Judith Peterschmitt 1:22 p.m. S4.003 Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies–Peter A. LeWitt, Daniel O. Claassen, Kurt Olson, Khodayar Farahmand, Scott Siegert, Mena Alrais, Francisco Rocha, Patricio Soares-da-Silva, Grace Lin Liang 1:33 p.m. S4.004 Levodopa-Carbidopa Intestinal Gel for the Treatment of Motor Fluctuations and Dyskinesia in Patients with Advanced Parkinson’s Disease in a ‘Real World’ Setting: Results of an Interim Analysis of the Multinational Observational Long-term Study DUOGLOBE–David G. Standaert, Jason Lamar Aldred, Marieta Anca-Herschkovitsch, Thomas L. Davis, Robert Iansek, Norbert Kovacs, Mustafa S. Siddiqui, Francesco Pontieri, Mihaela A. Simu, Lars Bergmann, Pavnit Kukreja, Mei Li, Kallol Ray Chaudhuri 1:44 p.m. S4.005 SYN120 (a dual 5-HT6/5-HT2A antagonist) study to evaluate safety, tolerability, and efficacy in Parkinson’s disease dementia (SYNAPSE): Phase 2a study results–Hubert H. Fernandez 1:55 p.m. S4.006 Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy–Farwa Ali, Peter Martin, Hugo Botha, J. Eric Ahlskog, James H. Bower, Joseph Y. Matsumoto, Robert D. Fealey, Anhar Hassan, Scott D. Eggers, Bradley F. Boeve, David S. Knopman, Erika Driver-Dunckley, Jay A. Van Gerpen, Ryan J. Uitti, Jennifer Louise Whitwell, Dennis W. Dickson, Keith A. Josephs 2:06 p.m. S4.007 Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea– Fernando L. Pagan, Wolfgang H. Jost, Christian Oehlwein, Jaroslaw Slawek, Andrzej Bogucki, Stanislaw Ochudlo, Marta Banach, Janos Csikós, Andrew Blitzer 2:17 p.m. S4.008 Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a StateDependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)–Spiridon Papapetropoulos, Margaret S. Lee, Stacey Boyer, Andrew Krouse, Rajesh Pahwa, Kelly E. Lyons, William G. Ondo, H. A. Jinnah, Rodger J. Elble

100 2019 AAN Annual Meeting

CME

2:28 p.m. S4.009 Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study–Robert A. Hauser, Hadas Barkay, Hubert H. Fernandez, Stewart A. Factor, Joohi Jimenez Shahed, Nicholas Gross, Juha M. Savola, Karen E. Anderson 2:40 p.m. Q&A Panel with Authors

Therapeutics in ALS and SMA

CME

1:00 p.m. S5.001 Intrathecal nusinersen in older children and adults with spinal muscular atrophy–Aravindhan Veerapandiyan, Katy Eichinger, Debra Guntrum, Erin Collins, Jennifer M. Kwon, Emma Ciafaloni 1:11 p.m. S5.002 Update of FORTITUDE-ALS: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis–Jeremy M. Shefner, Jinsy Andrews, Angela L. Genge, Carlayne E. Jackson, Noah Lechtzin, Timothy M. Miller, Bettina Cockroft, Fady I. Malik, Jenny Wei, Andrew A. Wolff, Stacy A. Rudnicki 1:22 p.m. S5.003 Intrathecal AAV9-SOD1-shRNA Administration for Amyotrophic Lateral Sclerosis–Gretchen Thomsen, Shibi Likhite, Sarah Corcoran, Allan Kaspar, Kevin Foust, Martin Fugere, Lyndsey Braun, Stephanie Solano, Petra Kaufmann, Kathrin Meyer, Brian Kaspar 1:33 p.m. S5.004 Cancer Drug Repurposing for Treating Amyotrophic Lateral Sclerosis (ALS)–Thomas Lukas, Teepu Siddique 1:44 p.m. S5.005 A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers– Irfan Qureshi, Vlad Coric, Kimberly Gentile, Richard Larouche, Mario Tanguay, Robert Berman 1:55 p.m. S5.006 General Characteristics of edaravone Use in the Natural History of ALS and Other Motor Neuron Disorders Consortium Dataset (NeuroBANK™)– Ximena Arcila-Londono, David Walk, Scott Vota, Alexander Sherman, Kimberly L. Goslin, Ghazala Hayat, Christian Lunetta, Daniel S. Newman, Kara L. Steijlen, James P. Wymer, Nicholas Thompson Olney, Megan Somers, Hong Yu, Lucia Alvarado, Jacqueline Jones, Prathosh Velpuri, Kenneth Faulconer, Claudi Tarlanini, Francesca Gerardi, Eric A. Macklin 2:06 p.m. S5.007 Nusinersen Treatment in Adults with SMA - the First Year Experience at a Large Center–Vivian E. Drory, Yaara Feinmesser, Alon Abraham, Batel Vainer, Anat Lavon, Beatrice Nefussy 2:17 p.m. S5.008 Outcome measures for Nusinersen efficacy in Adults with Spinal Muscular Atrophy–Crystal Jing Jing Yeo, Sarah Simeone, Ren Zhe Zhang, Kendall Trautman, Bailey Damron, Pann Nwe, Jennifer Siranosian, Alec Johnstone, Helen Chen, Elise Townsend, Flavia Nery, Maria Herrmann, Kathryn J. Swoboda 2:28 p.m. S5.009 Prospective open-label study of Nusinersen treatment for adults with Spinal Muscular Atrophy–Bakri Elsheikh, Steven Severyn, William D. Arnold, Stephen J. Kolb, John T. Kissel 2:40 p.m. Q&A Panel with Authors

MS and CNS Inflammatory Disease: Clinical Considerations I

3:30 p.m.-4:15 p.m. CME

1:00 p.m. S6.001 Challenges in Multiple Sclerosis Diagnosis: Misapplication and Misunderstanding of the McDonald Criteria–Andrew Solomon, Roman Pettigrew, Robert T. Naismith, Salim Chahin, Stephen Krieger, Brian G. Weinshenker 1:11 p.m. S6.002 Evaluation of the “Three Lesions with a Central Vein Sign” Criteria for the Differentiation between Multiple Sclerosis and its Imaging Mimics–Tim Sinnecker, Margareta Clarke, Dominik S. Meier, Christian Enzinger, Massimiliano Calabrese, Nicola De Stefano, Alain Pitiot, Antonio Giorgio, Menno M Schoonheim, Friedemann Paul, Mikolaj Pawlak, Ludwig Kappos, Alex Rovira, Nikolaos Evangelou, Jens Würfel 1:22 p.m. S6.003 The Central Vein Sign and Paramagnetic Rim Sign in White Matter Lesions of Radiolog-ically Isolated Syndrome–Jiwon Oh, Suradech Suthiphosuwan, Melanie Guenette, Martina Absinta, Daniel Reich, Aditya Bharatha, Pascal Sati 1:33 p.m. S6.004 Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria–Nicholas L. Zalewski, Alejandro A. Rabinstein, Karl Krecke, Robert D. Brown, Eelco F. M. Wijdicks, Brian G. Weinshenker, Timothy Kaufmann, Jonathan Morris, Allen J. Aksamit, J. D. Bartleson, Giuseppe Lanzino, Melissa Blessing, Eoin P. Flanagan

Global Health

3:30 p.m.-4:45 p.m. CME

0.75

Neuro Trauma and Sports Neurology

CME

1.25

3:30 p.m. S7.001 Evaluating the Relationship Between Depression and HIV-associated Cognitive Impairment Among Children and Adolescents in Zambia–Maria Elise Molinaro, Sylvia Mwanza-Kabaghe, Milimo Mweemba, Beauty Matoka, Esau G. Mbewe, Pelekelo Kabundula, Heather Adams, Gretchen L. Birbeck, David Bearden

3:30 p.m. S8.001 Resting State Functional Connectivity is Directly Related to Clinical Presentation of Mild Traumatic Brain Injury–Teena Shetty, Joseph T Nguyen, Esther Kim, Matthew Garvey, Taylor Cogsil, Apostolos Tsiouris, Sumit Niogi, Aashka Dalal, Kristin Halvorsen, Tianhao Zhang, Joseph C. Masdeu, Pratik Mukherjee, Luca Marinelli

3:41 p.m. S7.002 Beliefs Regarding Epilepsy in the Republic of Guinea Contribute to Lost Opportunities and Delay Presentation to Medical Care–Pria Anand, Nana Rahamatou Tassiou, Foksuna Sakadi, Guelngar Carlos Othon, Abdoul Bachir Djibo Hamani, Aissatou Kenda Bah, Hugues Ghislain Atakla, Mohamed Lamine Conde, Beindé Tertus Allaramadji, Amadou Talibé Balde, Djenabou Negue Barry, Arcel Woga Nitcheu, Andre Vogel, Fode Abass Cisse, Farrah J. Mateen

3:41 p.m. S8.002 Age of First Exposure to Football and Neurocognitive Performance Amongst NCAA Student-Athletes– Jaclyn B. Caccese, Ryan DeWolf, Thomas Kaminski, Thomas A. Buckley

3:55 p.m. Q&A Panel with Authors

3:52 p.m. S8.003 Relationship Between Sub-Concussive Head Impacts and Changes In Brain Metabolism in Ice Hockey Athletes–Katherine Breedlove, Alexander Peter Lin, Tyler Starr, Melissa Suzanne DiFabio, Monica Lininger, Thomas A. Buckley 4:03 p.m. S8.004 Females have a Higher Post-Concussion Subsequent Injury Rate than Male Collegiate Athletes–Thomas A. Buckley, Jessie Oldham 4:14 p.m. S8.005 Magnetic Resonance Spectroscopy of Sports-related Head Injury: A Cross-Sectional Comparison– Alexander Peter Lin, Inga Koerte 4:25 p.m. Q&A Panel with Authors

1:44 p.m. S6.005 Higher Efficacy Therapies Appear to have a Disproportionately Larger Effect in Younger Patients with Multiple Sclerosis–Brandi L. Vollmer, Kavita Nair, Stefan Sillau, Timothy L. Vollmer, John Corboy, Enrique Alvarez 1:55 p.m. S6.006 Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice–Carrie Michelle Hersh, Haleigh Harris, Devon Conway, Le Hua

Sunday

2:06 p.m. S6.007 Pregnancy-related Relapses in a Large, Contemporary Multiple Sclerosis Cohort: No Increased Risk in the Postpartum Period–Annette M. Langer-Gould, Jessica Betty Smith, Kathleen Albers, Jun Wu, Eric Kerezsi, Keeli McClearnen, Amethyst Leimpeter, Stephen K. Van Den Eeden 2:17 p.m. S6.008 Cognitive Signatures of Depression and Anxiety in Multiple Sclerosis–Victoria Leavitt, Gabriele Tosto, Claire Riley 2:28 p.m. S6.009 Age and relapse location: Critical determinants in recovery from multiple sclerosis relapses–Burcu Zeydan, Brittani L. Conway, Ugur Uygunoglu, Martina Novotna, Aksel Siva, Sean J. Pittock, Elizabeth Atkinson, Moses Rodriguez, Orhun H. Kantarci 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.-3:00 p.m.

AAN.com/view/AM19Sci 101

Sunday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 3:30 p.m.-5:30 p.m. S9

Aging and Dementia: Clinical Trials and Novel Therapies

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S9.001 Bi-directional Analysis of Tau Propagation between Braak Stages along Functional Connectivity Pathways–Joseph Seemiller, Gerard Bischof, Merle Hoenig, Masoud Tahmasian, Thilo Van Eimeren, Alexander Drzezga 3:41 p.m. S9.002 Different Rates of Lobar Atrophy Between Symptomatic and Asymptomatic MAPT Mutation Carriers–Bradley F. Boeve, Qin Chen, Matthew Senjem, Timothy Lesnick, Scott Przybelski, Nirubol Tosakulwong, Danielle Brushaber, Julie Fields, Leah Forsberg, Ralitza H. Gavrilova, Jonathan GraffRadford, Neill R. Graff-Radford, David T. Jones, David S. Knopman, Walter Kremers, Jeremy Syrjanen, Adam L. Boxer, Howard J. Rosen, Zbigniew K. Wszolek, Kejal Kantarci 3:52 p.m. S9.003 The Brain Health Champion Study: Promoting Non-Pharmacological Interventions in Cognitive Disorders–Seth Gale, Hope Schwartz, Kirk R. Daffner 4:03 p.m. S9.004 Development of antisense oligonucleotides for prion disease–Sonia Vallabh, Eric Minikel, Hien Zhao, Holly Kordasiewcz, Byron Caughey, Steven E. Arnold 4:14 p.m. S9.005 AAV-Mediated Progranulin Delivery to a Mouse Model of FTD/CNL Causes T Cell-Mediated Toxicity–Defne Amado, Julianne Rieders, Fortunay Diatta, Pilar Hernandez Con, Adina Singer, Jordan Mak, Junxian Zhang, Eric Lancaster, Beverly Davidson, Alice Chen-Plotkin 4:25 p.m. S9.006 Interim Analyses of Fixed-Dose and Titration Cohorts from PRIME: A Randomized, Double-Blind, PlaceboControlled Phase 1b Study of Aducanumab–Carmen Castrillo-Viguera, Samantha Budd Haeberlein, Philipp Von Rosenstiel, Tianle Chen, John O’Gorman, Raj Rajagovindan, Dakshaben Patel, Guanfang Wang, Spyridon Chalkias, LeAnn Skordos, Claudia Prada, Christoph Hock, Roger Nitsch, Alfred W. Sandrock 4:36 p.m. S9.007 Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies–Gregory Klein, Paul Delmar, Sunita Rehal, Mirjana Adjelkovic, Danielle Abi-Saab, Szofia S. Bullain, Smilijana Ristic, Monika Baudler, Paulo Pacheco Fontoura, Rachelle Doody 4:47 p.m. S9.008 The Effects of Memantine Added to Cholinesterase Inhibitors on NPI Behavioral Domains: Pooled Post Hoc Analysis of 3 Randomized Controlled Trials in Patients With Moderate to Severe AD–Jeffrey L. Cummings, George Grossberg, Anton P. Porsteinsson, Suzanne Hendrix, Noel Ellison, Majid Kerolous 4:58 p.m. S9.009 Identifying Factors that Predict Complications and Influence Participation in Longitudinal Cerebrospinal Fluid Biomarker Studies–Gregory S. Day, Tracy Rappai, Sushila Sathyan 5:10 p.m. Q&A Panel with Authors

Sunday, May 5

S10

Biomarkers in Movement Disorders

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S10.001 Identifying Biomarkers for Parkinson’s Disease with Reflex Tears–Mark F. Lew, Danielle Feigenbaum, Dan Freire, Srikanth Janga, Wendy Mack, Maria Edman, Curtis Okamoto, Sarah Hamm-Alvarez 3:41 p.m. S10.002 Repeat Submandibular Gland Biopsies as a Progression Marker in Parkinson’s Disease–Charles H. Adler, Michael Hinni, Geidy Serrano, Anthony Intorcia, Shyamal Mehta, David Lott, Lucia Sue, Thomas Beach 3:52 p.m. S10.003 Deep Immunophenotyping Reveals ‘Older’ T cell And B cell Compartments in Patients with Parkinson’s Disease–Rui Li, Laura Barratta, Maria Eugenina Diaz Ortiz, Roy Alcalay, Thomas F. Tropea, Alice ChenPlotkin, Amit Bar-Or 4:03 p.m. S10.004 Cortical Phase Amplitude Coupling and Pathologic Synchronization during Sleep in Parkinson’s Disease–Lenora A. Higginbotham, LynnMarie Trotti, Donald Biwise, Svjetlana Miocinovic 4:14 p.m. S10.005 Longitudinal Characterization of the Clinical and DAT Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort–Kenneth L. Marek, Tanya Simuni, Andrew D. Siderowf, David-Eirck Lafontant, Chelsea CaspellGarcia, Christopher Coffey, Brit Mollenhauer, Caroline M. Tanner, Karl D. Kieburtz, Lana Chahine, John P. Seibyl 4:25 p.m. S10.006 Capturing Parkinson’s disease heterogeneity with quantitative mobility measures–Emily J. Hill, Isabel Alfradique-Dunham, C. Grant Mangleburg, Brittany Ripperger, Amanda Stillwell, Sindhu Rao, Hiba Saade, Arjun Tarakad, Joohi Jimenez Shahed, Joseph Jankovic, Aron S. Buchman, Robert Dawe, Joshua M. Shulman 4:36 p.m. S10.007 Nilotinib is a Multi Kinase Inhibitor that Alters Cerebrospinal Fluid (CSF) Biomarkers and Increases TREM2 Levels in Individuals with Parkinson Disease.–Charbel E H Moussa, Fernando L. Pagan, Michaeline Hebron, Barbara Wilmarth, Yasar Alejandro Torres-Yaghi, Abigail Catherine Lawler, Elizabeth E. Mundel, Nadia Yusuf, Nathan Starr, Ashot Shekoyan, Sandeep Pamula, Joy Arellano, Helen Howard, Sara Matar 4:47 p.m. S10.008 Unbiased Phenotype-Based Chemical Modifier Screen In Vivo Reveals Novel Small Molecule Modulators Of Tauopathy–Qing Bai, Edward Burton 4:58 p.m. S10.009 Cerebrospinal Fluid AD Biomarkers and Regional [18F]-Flortaucipir Uptake in Lewy Body Disorders– David Gerhard Coughlin, Jeffrey Scott Phillips, Emily Roll, David A. Wolk, Sandhitsu Das, Ilya Nasrallah, Sanjeev Vaishnavi, Andrew D. Siderowf, Daniel Weintraub, Leslie Michael Shaw, John Q. Trojanowski, Murray Grossman, David Irwin, Corey McMillan 5:10 p.m. Q&A Panel with Authors

S11

Autoimmune CNS Inflammatory Disorders: Clinical Advances

3:30 p.m. S11.001 Neuronal antibodies in a prospective, multicenter cohort of patients with focal epilepsy of unknown origin–Marienke De Bruijn, Roland Thijs, Marian Majoie, Rob Rouhl, Thies van Asseldonk, Cees van Donselaar, Frans Leijten, Paul Wirtz, Anna Bastiaansen, Agnes Van Sonderen, Marco Schreurs, Peter Sillevis Smitt, Maarten Jan Titulaer 3:41 p.m. S11.002 The Spectrum of Inflammatory CNS Disorders Occurring During TNF-alpha Inhibitory Therapy–Amy Kunchok, Andrew McKeon 3:52 p.m. S11.003 Long-term clinical and cognitive evolution of children with n-methyl-d-aspartate anti-body receptor encephalitis: a French cohort study–Lorraine Flet-Berliac, Géraldine Picard, Nicolas Tchitchek, Anne Lepine, Frédéric Villega, Veronique Rogemond, Bastien Joubert, Hélène Maurey, Anca Florea, Jerome Honnorat, Seongjin Choi 4:03 p.m. S11.004 A Clinically-Based Score that predicts Cryptogenic New-Onset Refractory Status Epilepticus (C-NORSE)–Takahiro Iizuka, Juntaro Kaneko, Atsushi Kaneko, Atsuko Yanagida, Yutaka Nonoda, Yuya Onozawa, Naomi Kanazawa, Josep O. Dalmau, Kazutoshi Nishiyama 4:14 p.m. S11.005 Late-onset Neuromyelitis Optica Spectrum Disorder: The Importance of the Serostatus–Guillermo Delgado-García, Maria Sepúlveda, Yolanda Blanco, Nuria Sola-Valls, Elena H. Martinez-Lapiscina, Irene Pulido Valdeolivas, Eugenia Martinez-Hernandez, Helena Ariño, Sara Llufriu, Francesc R. Graus, Albert Saiz 4:25 p.m. S11.006 Atypical Clinical Manifestations and Overlapping Immunities associated with NMDA Receptor Antibodies–Atsushi Kaneko, Takahiro Iizuka, Hiroki Suga, Juntaro Kaneko, Yukio Yamaguchi, Hisatoshi Arai, Yushi Matsumoto, Ryo Tokimura, Takenobu Murakami, Setsu Nakatani-Enomoto, Kazuaki Kanai, Yoshikazu Ugawa, Eiichiro Amano, Eiji Kitamura, Naomi Kanazawa, Josep O. Dalmau, Kazutoshi Nishiyama 4:36 p.m. S11.007 A Population-Based Study of Idiopathic Transverse Myelitis with Aquaporin-4-IgG and MyelinOligodendrocyte-Glycoprotein-IgG Assessment–Elia Sechi, Eslam Hamdy Shosha, Jonathan Williams, Sean J. Pittock, Brian G. Weinshenker, Mark Keegan, Nicholas L. Zalewski, Sebastian Lopez, Jiraporn Jitprapaikulsan, Eoin P. Flanagan 4:47 p.m. S11.008 Evaluation of seizure treatment in anti-LGI1, antiNMDAR, and anti-GABABbR encephalitis–Marienke De Bruijn, Agnes Van Sonderen, Marleen van Coevorden-Hameete, Anna Bastiaansen, Marco Schreurs, Rob Rouhl, Cees van Donselaar, Marian Majoie, Rinze F Neuteboom, Peter Sillevis Smitt, Roland Thijs, Maarten Jan Titulaer 4:58 p.m. S11.009 Pediatric autoimmune encephalitis in Denmark during 2011–17: A nationwide multicenter population-based incidence study–Magnus Spangsberg Boesen, Alfred Peter Born, Magnus Christian Lydolph, Morten Blaabjerg, Malene Landbo Børresen 5:10 p.m. Q&A Panel with Authors

102 2019 AAN Annual Meeting

CME

1:00 p.m.-3:00 p.m.

1:00 p.m.-3:00 p.m. S12

Progressive Multiple Sclerosis

1:00 p.m. S12.001 Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis–Antje Bischof, Nico Papinutto, Anisha Keshavan, Xinheng Zhang, Anand Rajesh, Simone Sacco, Gina Kirkish, Tristan Gundel, William Stern, Eduardo Caverzasi, Chao Zhao, Yifan Zhou, Ying Lu, Refujia Gomez, Nicholas Ragan, Adam Santaniello, Alyssa Zhu, Jeremy Juwono, Carolyn J. Bevan, Riley Bove, Elizabeth Crabtree-Hartman, Jeffrey Marc Gelfand, Douglas S. Goodin, Jennifer Graves, Jorge Oksenberg, Emmanuelle Waubant, Michael R. Wilson, Scott S. Zamvil, Ari Green, Bruce A. C. Cree, Stephen L. Hauser, Roland G. Henry 1:11 p.m. S12.002 A Mouse Model of Meningeal Inflammation and Subpial Demyelination Identifies an IL-17-mediated Mechanism of Cortical Injury that is Inhibited by Siponimod Therapy–Lesley Ward, Dennis Lee, Anshu Sharma, Angela Wang, Ikbel Naouar, Xianjie Ma, Natalia Pikor, Barbara Nuesslein-Hildesheim, Jennifer L. Gommerman, Valeria Ramaglia 1:22 p.m. S12.003 Microglial Activation in the Deep Grey Matter is Associated with Regional Atrophy and Physical Disability in Multiple Sclerosis–Tarun Singhal, Steven Cicero, Renxin Chu, Shipra Dubey, Kelsey O’Connor, Shahamat Tauhid, Marie Kijewski, Howard L. Weiner, Rohit Bakshi 1:33 p.m. S12.004 Atrophied T2 lesion volume is Associated with Disability Progression and Conversion to SecondaryProgressive Multiple Sclerosis–Robert Zivadinov, Jesper Hagemeier, Valentina Genovese, Niels Bergsland, Dejan Jakimovski, Deepa Ramasamy, David Hojnacki, Channa Kolb, Michael G. Dwyer, Bianca Weinstock-Guttman 1:44 p.m. S12.005 Axonal Integrity in Primary and Secondary Progressive Multiple Sclerosis: a Baseline Subgroup Analysis of Sex, Age, and Disease Severity from the Phase III SPI2 Study–Sridar Narayanan, Gary Raymond Cutter, Jerry S. Wolinsky, Mark S. Freedman, Giancarlo Comi, Gavin Giovannoni, HansPeter Hartung, Frederic Sedel, Fred D. Lublin, Samson B. Antel, Bruce A. C. Cree, Douglas L. Arnold

2:06 p.m. S12.007 Response to Treatment According to Progressive Disease Type: Analysis from a Phase II Progressive MS Trial of Ibudilast–Andrew D. Goodman, Janel Barnes, Jon Yankey, Elizabeth Klinger, Sneha Natarajan, Robert A. Bermel, Christopher Coffey, Eric Klawiter, Kazuko Matsuda, Robert T. Naismith, Robert J. Fox, On behalf of NN102 SPRINT MS Investigators

= Abstract of Distinction

2:17 p.m. S12.008 Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study–Raju Kapoor, Finn Sellebjerg, Hans-Peter Hartung, Douglas L. Arnold, Mark S. Freedman, Douglas R. Jeffery, Aaron E. Miller, Keith R. Edwards, Carol Singh, Ih Chang, Zhang Ren, Dipen P. Sangurdekar, Bing Zhu, Devangi S. Mehta, Pei-Ran Ho, Nolan Campbell, Michael Edwards, Elizabeth Fisher, Bernd Kieseier, Richard A. Rudick, Tatiana Plavina 2:28 p.m. S12.009 The Predictive Value of Neurofilament Light Chain Levels in Blood for Cognitive Impairment in Patients with Secondary Progressive Multiple Sclerosis–Jens Kuhle, Harald Kropshofer, Christian Barro, Rolf Meinert, Dieter Haering, David Leppert, Frank Dahlke, Davorka Tomic, Ludwig Kappos 2:40 p.m. Q&A Panel with Authors

S13

CME Behavioral and Cognitive 2 Neurology: Behavioral Neurology, Aging, and Dementia

1:00 p.m. Norman Geschwind Prize in Behavioral Neurology Presentation This prize is awarded to an individual for outstanding research in the field of behavioral neurology. Applicants should have a strong desire to expand the field of behavioral neurology through research.

Recipient: Sonja Scholz, MD, PhD Bethesda, MD 1:11 p.m. S13.002 Recurrent Transient Global Amnesia–Kenneth Allen Morris, Alejandro A. Rabinstein, Nathan P. Young 1:22 p.m. S13.003 Functional Performance and Alzheimer’s Disease Neuroimaging Biomarkers–Maria Vassilaki, Jeremiah Aakre, Walter Kremers, Michelle M. Mielke, Yonas E. Geda, Mary M. Machulda, David S. Knopman, Lesley Butler, Martin Traber, Prashanthi Vemuri, Val John Lowe, Clifford R. Jack, Rosebud O. Roberts, Ronald C. Petersen 1:33 p.m. S13.004 Late Onset Semantic Dementia vs. Alzheimer’s Disease–Mario F. Mendez, Randy Desarzant, Oleg Yerokhin 1:44 p.m. S13.005 Dissociating Object and Number Knowledge in Temporal and Parietal Disease: Partitioning Semantic Memory and its Functional Consequences–Molly Ungrady, Caroline Wong, Katheryn Cousins, Murray Grossman 1:55 p.m. S13.006 Self- and Informant-Reported Subjective Memory Complaints: Association with Depression, Cognitive Impairment, and Decline–Leah Zuroff, Jessica Bove, David A. Wolk, Dawn MechanicHamilton 2:06 p.m. S13.007 Hoarding and Obsessive-Compulsive Behaviours in Frontotemporal Dementia: Clinical and Neuroanatomical Associations–Eric Mitchell, Tamara Tavares, Lena Palaniyappan, Elizabeth Finger 2:17 p.m. S13.008 The National Prion Disease Pathology Surveillance Center’s Experience and Diagnostic Accuracy of CSF RT-QuIC for Diagnosing Prion Disease in a Large Autopsy Confirmed Sample–Brian Appleby, Aleksandra Wrona, Janis Blevins, Curtis Tatsuoka, Aaron Foutz, Mark Cohen, Daniel Rhoads 2:28 p.m. S13.009 Multimodal Characterization of Delayed Diagnosis in ALS–Pilar M. Ferraro, Josephine Cooke, Laura Hennessy, Katerina Placek, Murray Grossman, Colin Quinn, Leo McCluskey, Lauren B. Elman, Corey McMillan 2:40 p.m. Q&A Panel with Authors

AAN.com/view/AM19Sci 103

Monday

1:55 p.m. S12.006 A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis–Ludwig Kappos, Patrick Vermesch, Bruce A. C. Cree, Ralph H. B. Benedict, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Sophie Arnould, Nicolas Rouyrre, Goeril Karlsson, Daniela Piani Meier, Frank Dahlke, Christian Wolf, Davorka Tomic, Robert J. Fox

CME

SCIENTIFIC PLATFORM SESSIONS

Monday, May 6

Monday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS

Monday, May 6

1:00 p.m.-3:00 p.m. S14

1:00 p.m.-3:00 p.m.

Translational and Clinical Advances in Neuro-oncology

1:00 p.m. Neuro-oncology Investigator Award Presentation This award recognizes young investigators who have advanced the field of neuro-oncology.

Recipient: Jorg Dietrich, MD, PhD Boston, MA 1:11 p.m. Neuro-oncology Scientific Award This award recognizes an individual from any discipline and of any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology..

Recipient: Andreas von Deimling, MD Heidelberg, Germany 1:22 p.m. S14.003 Accelerated progression of IDH mutant glioma after first recurrence–Julie JoAnn Miller, Franziska Loebel, Tareq Juratli, Shilpa Tummala, Erik Williams, Tracy T. Batchelor, Isabel Arrillaga-Romany, Daniel P Cahill 1:33 p.m. S14.004 Clinical and pathological characteristics of 52 adults with H3 K27M-mutant diffuse midline gliomas at UCSF–Robin A. Buerki, Sarah Lapointe, David Solomon, Joanna Phillips, Arie Perry, Javier VIllanueva-Meyer, Annette Molinaro, Nancy Ann Oberheim Bush, Jennie W. Taylor, Nicholas A. Butowski, Susan Chang, Jennifer L. Clarke 1:44 p.m. S14.005 Randomized Prospective Trial of Stereotactic Radiosurgery versus Chemotherapy for Recurrent Malignant Glioma after Second-line Chemotherapy– Tobias Walbert, Ankit Modh, David Bergman, Lonni Schultz, James Snyder, Tom Mikkelsen, Samuel Ryu, Salim Siddiqui 1:55 p.m. S14.006 The Prevalence, Timing, and Prognostic Significance of Glycemic Control as Assessed By Serial Hemoglobin A1c Measurements in Patients with Newly Diagnosed Glioma–Logan Williams, Juan Carlos Martinez-Gutierrez, Fang-Chi Hsu, Christina Cramer, Michael Chan, Adrian Laxton, Stephen B. Tatter, Glenn Lesser, Roy E. Strowd 2:06 p.m. S14.007 Diffuse Midline and Histone-Mutated Gliomas in Adults: Clinical, Molecular and Radiographic Features–Orwa Aboud, Elizabeth Vera, Kenneth Aldape, Terri Armstrong, Nicole Briceno, Hye-Jung Chung, Christine Cordova, Sonja Crandon, Ming Ji, Jason Levine, Snehal Patel, Marta Penas-Prados, Martha Quezado, Mark Raffeld, Abhik Ray-Chaudhury, Jennifer Reyes, Christine Siegel, Jing Wu, Liqiang Xi, Mark Gilbert, Brett J. Theeler 2:17 p.m. S14.008 Primary dural lymphomas: clinical presentation, management, and outcome in a bi-institutional study–Philipp Karschnia, Frank J. Barbiero, Justin T. Jordan, Tracy T. Batchelor, Brian Shaw, Anita J Huttner, Robert K. Fulbright, Jorg Dietrich, Joachim M. Baehring

104 2019 AAN Annual Meeting

CME

2:28 p.m. S14.009 Validating Advanced Volumetric Techniques for Cutaneous Neurofibromas in Clinical Trials–Raquel D. Thalheimer, Vanessa Merker, Ina Ly, Sharad Verma, Amanda Champlain, Jennifer Sawaya, Naomi Askenazi, Justin T. Jordan, Alona Muzikansky, Fernanda Sakamoto, Jaishri Blakeley, R. Rox Anderson, Scott R. Plotkin 2:40 p.m. Q&A Panel with Authors

S15

Intracerebral Hemorrhage and SAH

CME

1:00 p.m. S15.001 Warfarin use, intensity of anticoagulation, and occurrence of intracerebral hemorrhage in stroke patients: An analysis of Taiwan Stroke Registry data–Adnan I. Qureshi, Mushtaq H. Qureshi, Chung Hsu, Chung Hsu 1:11 p.m. S15.002 Risk of Intracerebral Hemorrhage in Pregnancy and the Postpartum Period: A Population Based Analysis using a Cohort–Cross Over Design–Jennifer Meeks, Arvind Bambhoroliya, Katie Alex, Sunil Sheth, Farhaan S. Vahidy 1:22 p.m. S15.003 Soluble ST2 Predicts Functional Outcome after Spontaneous Intracerebral Hemorrhage–Karen Li, Matthew Bradford Bevers, Zoe Wolcott, Christina Hansen, Audrey Leasure, Guido Jose Falcone, Lauren Hachmann Sansing, Kevin N. Sheth, W. Taylor Kimberly 1:33 p.m. S15.004 CSF Inflammatory and Vasoactive Mediators Associated with Poor Functional Outcome in Subarachnoid Hemorrhage (SAH) Patients.–Aisha Rasool Saand, Fang Yu, Jong Woo Lee, Liangge Hsu, MingMing Ning, Eng Lo, Sherry Chou 1:44 p.m. S15.005 Racial/Ethnic Disparities in the Risk of Intracerebral Hemorrhage Recurrence–Audrey Leasure, Zachary King, Victor Torres-Lopez, Santosh Bhaskar Murthy, Hooman Kamel, Ashkan Shoamanesh, Rustam Al-Shahi Salman, Jonathan Rosand, Wendy C. Ziai, Daniel F. Hanley, Daniel Woo, Charles Matouk, Lauren Hachmann Sansing, Guido Jose Falcone, Kevin N. Sheth 1:55 p.m. S15.006 Effect of Age In The Outcomes Of Patients Undergoing Treatment Of Unruptured Intracranial Aneurysms: A Study Of the National Inpatient Sample 2009-2014–Rakesh Khatri, Mohammad Rauf Afzal, Shayan Ul Haque, Ihtesham A. Qureshi, Harathi Bandaru, Anantha Vellipuram, Paisith Piriyawat, Alberto Maud, Salvador Cruz-Flores, Gustavo J. Rodriguez 2:06 p.m. S15.007 Baseline Characteristics and Readmissions Analysis in Younger and Older Adults with Intracerebral Hemorrhage–Brian Kim, Christeena Kurian, Laura Stein, Stanley Tuhrim, Mandip Singh Dhamoon 2:17 p.m. S15.008 Predicting Functional Outcomes Using Radiographic Characteristics of Spontaneous ICH-Mediated Encephalomalacia (IME) in the MISTIE-II Cohort– Hasan Ali, Ayushi Gautam, Radhika Avadhani, William Andrew Mould, Daniel F. Hanley 2:28 p.m. S15.009 In-hospital Delirium and Long-Term Cognitive Outcomes among Patients with Intracerebral Hemorrhage: A population-based cohort analysis– Jennifer Meeks, Arvind Bambhoroliya, Katie Alex, Babar Khan, Sunil Sheth, Farhaan S. Vahidy 2:40 p.m. Q&A Panel with Authors

S16

Huntington’s Disease: From Bench to Clinical Trials

1:00 p.m.-3:00 p.m. CME

1:00 p.m. Movement Disorders Research Award Presentation This award recognizes an individual for outstanding work in the field of Parkinson’s disease or other movement disorders for either a single, outstanding contribution or for lifetime achievement.

Recipient: Guenther Deuschl, MD, PhD Kiel, Germany 1:22 p.m. S16.003 Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease–Filipe B Rodrigues, Lauren M Byrne, Eileanoir Johnson, Peter Wijeratne, Enrico de Vita, Daniel Alexander, Giuseppe Palermo, Christian Czech, Scott Schobel, Rachael Scahill, Amanda Heslegrave, Henrik Zetterberg, Edward J. Wild 1:33 p.m. S16.004 Understanding HD Psychosis: An Analysis from the ENROLL-HD Database–Ashwin Jaini, Chen Yeh, Danny Bega 1:44 p.m. S16.005 Translational Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Strategy to Support RG6042 Dose Selection in Huntington’s Disease (HD)–Patricia Sanwald Ducray, Nicolas Frances, Kevin Smart, Daniel A. Norris, Holly Kordasiewcz, Andreas Guenther, Edward J. Wild, Scott Schobel 1:55 p.m. S16.006 The Biodistribution and Tolerability of rAAV5-miHTT after Bilateral Intra-striatal Delivery to Non-human Primates–Martin de Haan, Bas Blits, Lisa Spronck, Astrid Valles-sanchez, Melvin Evers, Sander van Deventer, Pavlina Konstantinova, Joseph J. Higgins 2:06 p.m. S16.007 The Efficacy and Safety Results of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)–Ralf Reilmann, Mark Forrest Gordon, Karen E. Anderson, Andrew S. Feigin, Sarah J. Tabrizi, Blair Leavitt, Julie C. Stout, Paola Piccini, Beth Borowsky, Gail Rynkowski, Rita Volkinstein, Juha M. Savola, Michael Hayden

2:28 p.m. S16.009 Innovative Recruitment Strategies Increase Diversity of Participation in the Fox Insight Longitudinal Cohort–Roseanne Dobkin, Ninad Amondikar, Chelsea Caspell-Garcia, Janel Barnes, Lauren Bataille, Lana Chahine, Andrea Katz, Catherine Kopil, Connie C. Marras, Amanda Melnick, Traci Schwieger, Bernadette Siddiqi, Luba Smolensky, David G. Standaert, Caroline M. Tanner 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

Headache: Clinical Trials I

1:00 p.m. S17.001 Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study–Peter Goadsby, David W. Dodick, Joel M. Trugman, Michelle Finnegan, Hassan Likis, Kaifeng Lu, Armin Szegedi 1:11 p.m. S17.002 Erenumab (AMG334) An Antagonist to Canonical CGRP-Receptor Does Not Impair Vasodilatory or Contractile Responses to Other Agents In Human Isolated Cerebral Arteries–Lena Ohlsson, Erik Kronvall, Cen Xu, Josefin Snellman, Lars Edvinsson 1:22 p.m. S17.003 Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low- Versus High-Frequency of Migraine Headaches–Stephen D. Silberstein, Virginia L. Stauffer, Kathleen Day, Sarah Lipsius, Maria-Carmen B. Wilson 1:33 p.m. S17.004 Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials–David W. Dodick, Timothy Smith, Roger Cady, Barbara Schaeffler, Jeff Smith, David M. Biondi, Joe Hirman 1:44 p.m. S17.005 Fremanezumab Cardiovascular and Cerebrovascular Safety Profile: Pooled Data From Placebo-Controlled and Long-Term Studies–Xiaoping Ning, Nicola Faulhaber, Nicole Lang, Paul P. Yeung, Jimmy Schiemann, Joshua T. Cohen, Ernesto Aycardi 1:55 p.m. S17.006 Long-Term Efficacy of Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification–Richard B. Lipton, Joshua T. Cohen, Paul P. Yeung, Ronghua Yang, Michael Seminerio, Verena Ramirez Campos, Rashmi B. Halker, Jessica Ailani

S18

Autonomic Disorders

CME

1.25

3:30 p.m. Irwin Schatz Award for Autonomic Disorders Presentation This award recognizes young investigators who have advanced the field of autonomic disorders, or senior investigators that have made major contributions to the field.

Recipient: Roy Freeman, MD Boston, MA 3:41 p.m. S18.002 Patient-Reported Falls and Fear of Falling in a Prospective Study of Droxidopa for Treatment of Neurogenic Orthostatic Hypotension–Steven Kymes, Clement Francois, Kim McLeod, Amy M. Duhig, Augustina Ogbonnaya, Apryl Quillen, Joan Cannon, Cyndya Shibao, Binglin Yue, Robert A. Hauser, Italo Biaggioni 3:52 p.m. S18.003 Cutaneous Alpha-Synuclein Deposition in Multiple System Atrophy–Christopher H. Gibbons, Ningshan Wang, Drew S. Kern, Jose-Alberto Palma, Horacio C. Kaufmann, Roy L. Freeman 4:03 p.m. S18.004 Long-term Administration of Intrathecal Mesenchymal Stem Cells in Multiple System Atrophy – A Compassionate Use Experience–Wolfgang Singer, Allan Dietz, Anita Zeller, Tonette Gehrking, James Schmelzer, David Michael Sletten, Jade Gehrking, Elizabeth A. Coon, Paola Sandroni, Eduardo E. Benarroch, James H. Bower, Anhar Hassan, Andrew McKeon, Ann M. Schmeichel, Karla Minota, Phillip A. Low 4:14 p.m. S18.005 Epidemiology of Postural Tachycardia Syndrome– Mahmoud A. AbdelRazek, Phillip A. Low, Walter A. Rocca, Wolfgang Singer 4:25 p.m. Q&A Panel with Authors

2:06 p.m. S17.007 Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine– Messoud Ashina, Raghavendra Vasudeva, Leah Jin, Louise Lombard, Elizabeth Gray, Erin G. Doty, Laura Yunes-Medina, Cristina Tassorelli 2:17 p.m. S17.008 Conversion from Chronic Migraine (CM) to Episodic Migraine (EM) With Long-Term Erenumab Treatment– Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein, David B. Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Sunfa Cheng, Gregory A. Rippon, Feng Zhang, Daniel D. Mikol

Monday

2:17 p.m. S16.008 Preliminary Report on the Safety and Tolerability of Bone marrow-derived Allogeneic Mesenchymal Stem Cells infused intravenously in Parkinson’s disease Patients–Mya C. Schiess, Jessika Suescun, Timothy M. Ellmore, Marie-Francoise Doursout, Erin FurrStimming, Hongyu Miao, Zhuyong Mei, Adrian Gee

S17

3:30 p.m.-4:45 p.m. CME

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.-3:00 p.m.

2:28 p.m. S17.009 Safety and Tolerability of Ubrogepant Following Intermittent, High Frequency Dosing–Joel M. Trugman, Peter Goadsby, Stewart J. Tepper, Paul Watkins, Girma Ayele, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Armin Szegedi, Abhijeet Jakate 2:40 p.m. Q&A Panel with Authors

AAN.com/view/AM19Sci 105

Monday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 3:30 p.m.-5:30 p.m. S19

Child Neurology: Updates in Autism, Migraine, MS, and Stroke

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S19.001 Yield of Etiologic and Actionable Findings in Sedated Brain MRI in Children with New Onset Seizures or Global Developmental Delay: Interim Data Analysis–Andres Jimenez Gomez, Rachelle Herring, Marcia Kukreja, Huirong Zhu, Sarah R. Risen, Jamie Sinton 3:41 p.m. S19.002 Screening for Sleep Disorders Improves Outcomes in Children with Epilepsy–Anh Huan Vo, Sejal V. Jain 3:52 p.m. S19.003 Pediatric Stroke Alert System for Quality Improvement of Stroke Recanalization–Alyssa Smith, Stephanie Morris, Michael J. Noetzel, Shannon Agner, Jennifer L. Griffith, Rejean M. Guerriero, Kristin Guilliams 4:03 p.m. S19.004 Healing Headaches: Evidence-Based Care to Accelerate Pain-Free Time for Children with Migraines in the Emergency Department–Anna Wilson Bunker, Elizabeth Rende, Clay Bordley, KlausGeorg E. Werner, Emily Sterrett 4:14 p.m. S19.005 Anti-MOG IgG1 Antibodies in Children–Giulia Fadda, Patrick Waters, Mark Woodhall, Sarosh Irani, Julia O’Mahony, Robert Allan Brown, Denise Castro, Giulia Longoni, E. Ann Yeh, Ruth-Ann Marrie, Douglas L. Arnold, Brenda Banwell, Amit Bar-Or 4:25 p.m. S19.006 In-Vivo Mapping of Thalamic Pathological Mechanisms in Pediatric Patients With MS– Ermelinda De Meo, Loredana Storelli, Lucia Moiola, Maria Pia Amato, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Maria Assunta Rocca, Massimo Filippi 4:36 p.m. S19.007 Relationship between Skin Pigmentation, HLA, Vitamin D Status and Pediatric-Onset Multiple Sclerosis–Candice Dunn, Julia O’Mahony, Heather Hanwell, E. Ann Yeh, Elena H. Martinez-Lapiscina, Amit Bar-Or, Brenda Banwell 4:47 p.m. S19.008 Anterior Cingulate Cortex Glutamate Activity in Autism Spectrum Disorder with and without Emotional Dysregulation–Gagan Joshi, Atilla Gönenç, Scott Lukas, Janet Wozniak, Nina Dallenbach, Barbora Hoskova, Rose Castle, Joseph Biederman 4:58 p.m. S19.009 Adaptor Protein Complex 4 Deficiency: A Paradigm of Complex Hereditary Spastic Paraplegia Associated With Defective Protein Trafficking–Darius EbrahimiFakhari, Robert Behne, Julian Teinert, Miriam Wimmer, Amelia Diplock, Erin Carmody, Kira Dies, Pin-Fang Chen, Elizabeth Buttermore, Mustafa Sahin 5:10 p.m. Q&A Panel with Authors

Monday, May 6

S20 Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine

3:30 p.m.-5:30 p.m. CME

3:30 p.m. Harold Wolff-John Graham Award: An Award for Headache/Facial Pain Research Presentation This award recognizes individuals who have submitted research results in the field of headache and facial pain.

Recipient: Jelena Pavlovic, MD, PhD New York, NY 3:41 p.m. S20.002 Noninvasive Vagal Nerve Stimulation (nVNS) and the Trigeminal Autonomic Reflex: An FMRI Study–Maike Moeller, Celina Schroeder, Arne May 3:52 p.m. S20.003 Characterization of the Effects of the Calcitonin Gene–Related Peptide (CGRP) Receptor Antagonists, Atogepant and Ubrogepant, on Isolated Human Coronary, Cerebral, and Middle Meningeal Arteries– Eloísa Rubio-Beltran, Kayi Chan, Antoon van den Bogaerdt, Ad Bogers, Alexander Danser, Antoinette MaassenVanDenBrink, Lars Edvinsson 4:03 p.m. S20.004 The Time Sequences of Brain MRI Findings in Spontaneous Intracranial Hypotension–Jr-Wei Wu, Yen-Feng Wang, Shu-Shya Hseu, Jong-Ling Fuh, Jiing-Feng Lirng, ShuTing Chen, Wei-Ta Chen, ShihPin Chen, Shuu-Jiun Wang 4:14 p.m. S20.005 Visual contrast threshold at 15 Hz is able to confirm visual snow syndrome in individual patients–Ozan Eren, Thomas Eggert, Ruth Ruscheweyh, Andreas Straube, Christoph J. Schankin 4:25 p.m. S20.006 Recurrent Episodic Cortical Spreading Depressions Induce Trigeminal Allodynia and Anxiety Behavior– Andrea Harriott, David Young Chung, Tsubasa Takizawa, Tao Qin, Cenk Ayata 4:36 p.m. S20.007 Brain Volume is Decreased in Spontaneous Intracranial Hypotension.–Jr-Wei Wu, Yen-Feng Wang, Shu-Shya Hseu, Jong-Ling Fuh, Jiing-Feng Lirng, ShuTing Chen, Yung-Lin Chen, Wei-Ta Chen, Shih-Pin Chen, Shuu-Jiun Wang 4:47 p.m. S20.008 Benign Paroxysmal Torticollis: Phenotype and Patient Perspectives–Kaitlin Greene, Vivien Lu, William F. Qubty, Barbara Grimes, Marta San Luciano, Amy Gelfand 4:58 p.m. S20.009 Vestibular Migraine: Symptoms, Triggers, Exam Findings & Co-morbid Disorders–Shin Chien Beh, Shamin Masrour, Stacy Victoria Smith, Deborah I. Friedman 5:10 p.m. Q&A Panel with Authors

S21

CME Autoimmune Neurology: 2 Novel Diagnostic and Predictive Biomarkers and Immunopathologic Mechanisms of Disease

3:30 p.m. S21.001 Cerebroventricular infusion of patients’ antibodies cause memory loss and anxiety in a mice model of anti-metabotropic glutamate receptor 5 (mGluR5) encephalitis–Marianna Spatola, Estibaliz Maudes, Francesco Mannara, Marija Radosevic, Lidia Sabater, Jesùs Planagumà, Myrna R. Rosenfeld, Josep O. Dalmau 3:41 p.m. S21.002 Paraneoplastic Phosphodiesterase 10A Neurological Autoimmunity Unmasked by Immune Checkpoint Inhibitor Therapy–Anastasia Zekeridou, Thomas Kryzer, Yong Guo, Anhar Hassan, Vanda A. Lennon, Claudia F. Lucchinetti, Sean J. Pittock, Andrew McKeon 3:52 p.m. S21.003 Immune checkpoint inhibitor related neurologic adverse events: clinical spectrum, management and outcomes–Divyanshu Dubey, William S. David, Kerry Reynolds, Donald Chute, Nathan Floyd Clement, Justine Cohen, Donald Lawrence, Meghan Mooradian, Ryan Sullivan, Amanda C. Guidon 4:03 p.m. S21.004 Mechanisms underlying contribution of IgG4 autoantibodies to neurofascins in autoimmune demyelinating neuropathies–Kristina Rae Patterson, Elisabeth Burnor, Amit Bar-Or, Eric Lancaster 4:14 p.m. S21.005 Myelin Oligodendrocyte Glycoprotein Autoantibody Myelitis; Clinical characteristics, MRI clues and discriminators from other demyelinating myelitis etiologies–Divyanshu Dubey, Sean J. Pittock, Karl Krecke, Padraig Morris, Elia Sechi, Nicholas L. Zalewski, Brian G. Weinshenker, Eslam Hamdy Shosha, Claudia F. Lucchinetti, James Fryer, Alfonso Sebastian Lopez, John Chen, Jiraporn Jitprapaikulsan, Andrew McKeon, Avi Gadoth, Mark Keegan, JanMendelt Tillema, Elie Naddaf, Marc C. Patterson, Kevin Messacar, Kenneth L. Tyler, Eoin P. Flanagan 4:25 p.m. S21.006 FDG-PET findings in stiff person syndrome and other anti-glutamic acid decarboxylase associated neurologic disorders–Yujie Wang, Michael Comisac, Scott Douglas Newsome 4:36 p.m. S21.007 Clinical and immunological studies in a 3-generation family with very high titers of anti-GAD antibodies– Popianna Tsiortou, Harry Alexopoulos, Sofia Akrivou, Chrysanthi Barba, Michail Kosmidis, Marinos C. Dalakas 4:47 p.m. S21.008 Predictors of outcome after a first attack of NMOSD– Maxime Guillaume, Bertrand Bourre, Bertrand Audoin, Elisabeth Maillard, Caroline Papeix, Mickael Cohen, Christine Lebrun-Frenay, Jonathan Ciron, Laure Michel, Romain Marignier, Nicolas Collongues 4:58 p.m. S21.009 MOG-IgG is associated with better visual outcomes after optic neuritis than AQP4-IgG seropositivity, despite similar severity of inner retinal layer thinning–Elias S. Sotirchos, Angeliki Filippatou, Sara Salama, Santiago Pardo, Maureen A. Mealy, Kathryn Fitzgerald, Olwen Murphy, Esther Ogbuokiri, Jerry Prince, Michael Levy, Peter A. Calabresi, Shiv Saidha 5:10 p.m. Q&A Panel with Authors

106 2019 AAN Annual Meeting

S22

Stroke Genetics, Cellular Responses, and Animal Models

CME

3:30 p.m. Michael S. Pessin Stroke Leadership Prize Presentation This prize is awarded to emerging neurologists who have a strong interest in, and have demonstrated a passion for, learning and expanding the field of stroke research.

Recipient: Alessandro Biffi, MD Boston, MA 3:41 p.m. S22.002 Novel Transcripts miR-1301, miR-130, and miR-629 Influence Early Neurologic Outcome in Acute Ischemic Stroke Patients–Alexis N. Simpkins, Kory Johnson, Zurab G. Nadareishvili, Devon Kelley, Richard Leigh, Marie Luby, Richard T. Benson, Amie W. Hsia, John K. Lynch, John M. Hallenbeck, Lawrence Latour 3:52 p.m. S22.003 Higher Coated-Platelet Levels in Patients with Lacunar Stroke are Associated with Lower Cognitive Performance at 3 Months–Angelia Kirkpatrick, Andrea Vincent, Meheroz H. Rabadi, George Dale, Calin I. Prodan 4:03 p.m. S22.004 Histone Deacetylase 3 as a Novel Therapeutic Target for Ischemic Stroke–Rudy Matheson, Kohei Chida, Eng Lo, Magdy H. Selim, Amjad Shehadah 4:14 p.m. S22.005 Effect of Abrupt Discontinuation of Chronic Aspirin Therapy on Platelet Aggregability–Erica Westphal, Rachael Wojcik, Michelle Rainka, Kaitlin Landolf, Jessica Greger, Traci Aladeen, Francis Michael Gengo 4:25 p.m. S22.006 The Matrix Gla Protein (MGP) rs1800801 is Associated With First Year Recurrence of Ischemic Stroke in Caucasians–Saran Kunaprayoon, Philipp Hendrix, Nelson Sofoluke, Matthew Daniel Adams, Ramin Zand, Amy N. Kolinovsky, Thomas N. Person, Mudit Gupta, Oded Goren, Clemens M. Schirmer, Natalia Sana Rost, James E. Faber, Christoph J. Griessenauer

4:47 p.m. S22.008 Effects of Rupture of Intracranial Aneurysms on Small RNAs in Peripheral Blood–Michal Korostynski, Marcin Piechota, Dzesika Hoinkis, Slawomir Golda, Magdalena Zygmunt, Tomasz Dziedzic, Rafal Morga, Marek Moskala, Agnieszka Slowik, Joanna Pera 4:58 p.m. S22.009 Assessing Post-Stroke Cardiac Dysfunction in the Insular Ischemic Stroke Rat Model–Victoria Jaremek, Stella Iankov, Thomas Milazzo, Lynn Wang, Shawn Whitehead, Luciano A. Sposato 5:10 p.m. Q&A Panel with Authors

Genetic Muscle Disorders

CME

3:30 p.m. Alliance Awards: S. Weir Mitchell Award Presentation This award is designed to encourage basic research in neuroscience by physicians in clinical neurology training programs.

Recipient: Andrew Findlay, MD Saint Louis, MO 3:41 p.m. S23.002 Sensitive Assessment of Duchenne Muscular Dystrophy Progression with a Dedicated Electrical Impedance Myography Device–Seward B. Rutkove, Basil T. Darras, Michele Yang, Brenda L Y Wong, Martin Buck, Laura Freedman, Melanie Leitner, Laura Dalle Pazze, Craig M. Zaidman 3:52 p.m. S23.003 Genetic Prevalence of Myotonic Dystrophy Type 1–Nicholas Elwood Johnson, Carina Imbrugia, Diane Dunn, Brett Duvall, Russell Butterfield, Marcia Feldkamp, Robert B. Weiss 4:03 p.m. S23.004 Breaking the sound barrier of randomized, controlled trials in congenital myopathies: results of the N-acetylcysteine trial in RYR1-related disorders– Joshua Todd, Jessica Witherspoon, Irene Chrismer, Sonia Razaqyar, Monal Punjabi, Jeff Elliott, Fatoumata Tounkara, Anna Kuo, Monique Shelton, Tokunbor Lawal, Carolyn Allen, Molly Cosgrove, Melody Linton, Tanya Jarca Lehky, Minal Jain, Waite Melissa, Bart Drinkard, Paul Wakim, James Dowling, Carsten G. Bonnemann, Magalie Emile-Backer, Katherine G. Meilleur

CHECK OUT A NEW WAY TO CELEBRATE AWARDS! Join us at The Grand Experience stage for special award presentations, each followed by a panel Q&A discussion with past award recipients. Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Monday, May 6 at 3:30 p.m. Recipient: Randall Bateman, MD Sheila Essey Award: An Award for ALS Research Tuesday, May 7 at 3:30 p.m. Recipient: Aaron Gitler, PhD John Dystel Prize for Multiple Sclerosis Research Wednesday, May 8 at 3:30 p.m. Recipient: Anne Cross, MD

4:14 p.m. S23.005 An Instrumented Timed Up and Go is Sensitive to Progression in Facioscapulohumeral Dystrophy– Jeffrey Statland, Adam Bruetsch, Jessie Huisinga 4:25 p.m. S23.006 FTX-1821 for Treatment of FSHD at its Root Cause: Results of a Clinical Trial in a Dish–Michelle L. Mellion, Erin Valentine, Anthony Accorsi, Joseph Maglio, Ning Shen, Alan Robertson, Richard Barnes, Steven Kazmirski, Aaron Chang, David Eyerman, Lorin Thompson, Lucienne Ronco, Peter Rahl, Owen Wallace, Alrabi Tawil, Angela Cacace, Diego Cadavid, Alejandro Rojas 4:36 p.m. S23.007 Comparison of Symptom Profile in Patients with SCN4A and CLCN1 Nondystrophic Myotonias– Alayne Meyer, Samantha Jo LoRusso, Jennifer A. Roggenbuck, William D. Arnold

Monday

4:36 p.m. S22.007 Excessive glutamate transport causes rapid astrocytic mitochondrial loss and dysfunction following focal ischemic stroke–Evelyn Kim Shih, Sabrina DaSilva, Elizabeth Krizman, Meredith Lee, Michael Robinson

S23

4:47 p.m. S23.008 Open-Label Phase 2 Clinical Trial of ManNAc for GNE Myopathy–Nuria Carillo-Carrasco, Marjan Huizing, Petcharat Leoyklang, Melanie Quintana, Joseph Shrader, Kennan Bradley, Christina Slota, John Perreault, Bradley Class, Carla Ciccone, Rebecca Parks, Galen Joe, John Heiss, Scott Berry, May Christine Malicdan, William Gahl 4:58 p.m. S23.009 Progressive Degenerative Myofibrillar Myopathy in Knock-In Mice Expressing LDB3 p.A165V Protein: A Mouse Model for Markesbery-Griggs Distal Myopathy–Yotam Blech-Hermoni, Pankaj Pathak, Kalpana Subedi, Charissa Obeng-Nyarko, Jessica Mpamugo, Ami K. Mankodi 5:10 p.m. Q&A Panel with Authors

= Abstract of Distinction

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.-5:30 p.m.

AAN.com/view/AM19Sci 107

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 1:00 p.m.-2:00 p.m. S24

CME Lost Connections: From 1 Functional Connectivity to Needs in Pain and Palliative Care

1:00 p.m. Mitchell B. Max Award for Neuropathic Pain Presentation This award recognizes an individual for outstanding work in the field of neuropathic pain for either a single contribution or for lifetime achievement.

Recipient: Troels Staehelin Jensen, MD, DMSc Aarhus, Denmark 1:11 p.m. S24.002 Aberrant Functional Connectivity of the Dorsolateral Prefrontal Cortex and the Insula During Cognitive Control in Chronic Low Back Pain Patients on Opioids–Behnaz Jarrahi, Sean Mackey 1:22 p.m. S24.003 Affective pain processing disrupted in children with posterior cerebellar tumor resection–Katie Silva, Julie Rosner, Nicole Ullrich, Christine Chordas, Peter Manley, Eric A. Moulton 1:33 p.m. S24.004 The palliative needs of individuals with Parkinson disease–Christopher Tarolli, Grace A. Zimmerman, Peggy Auinger, Scott McIntosh, Robert Horowitz, Benzi Kluger, E. Ray Dorsey, Robert G. Holloway 1:45 p.m. Q&A Panel with Authors

1:00 p.m.-3:00 p.m. S25

Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes

1:00 p.m. S25.001 Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study–Darryl C. De Vivo, Haluk Topaloglu, Kathryn J. Swoboda, Enrico Silvio Bertini, Wuh-Liang Hwu, Thomas O. Crawford, Richard Foster, Ishir Bhan, Stephanie Fradette, Wildon Farwell, Sandra P. Reyna 1:11 p.m. S25.002 Early Diagnosis and Speed to Effect in Spinal Muscular Atrophy Type 1 (SMA1)–Marcus Droege, Omar Dabbous, Douglas Feltner, Aaron Novack, Melissa Menier, Douglas M. Sproule 1:22 p.m. S25.003 FIREFISH Part 1: 1-Year Results on Motor Function in Babies with Type 1 SMA–Giovanni Baranello, Laurent Servais, John W. Day, Nicolas Deconinck, Eugenio Mercuri, Andrea Klein, Basil T. Darras, Ricardo Masson, Heidemarie Kletzl, Yumi Cleary, Muna ElKhairi, Timothy Seabrook, Christian Czech, Marianne Gerber, Coralie Nguyen, Kristina Gelblin, Ksenija Gorni, Omar Khwaja 1:33 p.m. S25.004 Interim Report on the Safety and Efficacy of LongerTerm Treatment With Nusinersen in Infantile-Onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study–Richard S. Finkel, Diana Castro, Michelle Farrar, Mar Tulinius, Kristin J. Krosschell, Kyoko Saito, Yiwei Zhang, Ishir Bhan, Wildon Farwell, Sandra P. Reyna 1:44 p.m. S25.005 Event-Free Survival and Motor Milestone Achievement Following AVXS-101 and Nusinersen Interventions Contrasted to Natural History for Type I Spinal Muscular Atrophy Patients–Omar Dabbous, Douglas M. Sproule, Douglas Feltner, Francis Ogrinc, Melissa Menier, Marcus Droege, Benit Maru, Khan Farid, Ramesh Arjunji 1:55 p.m. S25.006 AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term FollowUp From the Phase 1 Clinical Trial–Jerry R. Mendell, Kelly Lehman, Markus McColly, Linda Pax Lowes, Lindsay N. Alfano, Natalie Miller, Megan Iammarino, Kathleen Church, Francis Ogrinc, James L’Italien, Courtney Wells, Douglas M. Sproule, Douglas Feltner

Tuesday

2:06 p.m. S25.007 Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916)–Eugenio Mercuri, Giovanni Baranello, Jan Kirschner, Laurent Servais, Nathalie M. Goemans, Maria Carmela Pera, Jeppe Buchbjerg, Wai Yin Yeung, Heidemarie Kletzl, Marianne Gerber, Christian Czech, Yumi Cleary, Ksenija Gorni, Omar Khwaja

108 2019 AAN Annual Meeting

Tuesday, May 7 CME

2:17 p.m. S25.008 FIREFISH Part 1: Survival, Ventilation and Swallowing Ability in Babies with Type 1 SMA Receiving Risdiplam (RG7916)–Laurent Servais, Giovanni Baranello, John W. Day, Nicolas Deconinck, Eugenio Mercuri, Andrea Klein, Basil T. Darras, Ricardo Masson, Heidemarie Kletzl, Yumi Cleary, Muna ElKhairi, Timothy Seabrook, Christian Czech, Marianne Gerber, Coralie Nguyen, Kristina Gelblin, Ksenija Gorni, Omar Khwaja 2:28 p.m. S25.009 Serum Neurofilament Light Chain as a Potential Biomarker for Spinal Muscular Atrophy Type I Disease Activity and Therapy Response–Nicolas Deconinck, Thomas Peters, Agnieszka Kieloch, Marie-Anne Valentin, Diethilde Theil, Thomas Faller, Herve Jullien De Pommerol, Algirdas Kakarieka 2:40 p.m. Q&A Panel with Authors

S26

MS and CNS Inflammatory Disease: Clinical Considerations II

1:00 p.m.-3:00 p.m. CME

1:00 p.m. S26.001 Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients:Towards Implementation into Clinical Care–Peter A. Calabresi, Jens Kuhle, Douglas L. Arnold, Revere P. Kinkel, Ludwig Kappos, Carol Singh, Dipen P. Sangurdekar, Carl DeMoor, Bob Engle, Ray Su, Aaron Deykin, Elizabeth Fisher, Alfred W. Sandrock, Bernd Kieseier, Richard A. Rudick, Tatiana Plavina 1:11 p.m. S26.002 Timing of MRI Cervical Spine and Finding Asymptomatic T2 Hyperintensities in Multiple Sclerosis Patients–Muhammad Taimur Ahmad Malik, Peter A. Calabresi, Izlem Izbudak, Ellen M. Mowry 1:22 p.m. S26.003 Trends in the use of Highly Effective Disease Modifying Treatments in Multiple Sclerosis over 12 years across 10 Sites–Marisa P. McGinley, Nicholas Thompson, Malory Weber, Robert A. Bermel, Daniel Ontaneda 1:33 p.m. S26.004 Functional Characterization of Reappearing B cells After Anti-CD20 Mediated B cell Depletion in Two Animal Models of Multiple Sclerosis–Darius Häusler, Silke Häusser-Kinzel, Linda Feldmann, Sebastian Torke, Gildas Lepennetier, Claude Bernard, Scott S. Zamvil, Wolfgang Brueck, Klaus Lehmann-Horn, Martin Weber 1:44 p.m. S26.005 Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series–Christina Azevedo, Christen Kutz, Amy L. Dix, Aaron L. Boster, Nerses Sanossian, Jeffrey Marc Kaplan 1:55 p.m. S26.006 Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database–Lana Zhovtis Ryerson, John F. Foley, Ih Chang, Ilya Kister, Gary Raymond Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Rachna Kasliwal, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell

2:17 p.m. S26.008 Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients–Stefania De Trane, Zhifeng Mao, Cesar Alvarez-Gonzalez, Kimberley Allen-Philbey, Ozlem Yildiz, Tom Campion, Ashok Adams, Benjamin Turner, Lucia Bianchi, Monica Marta, Sharmilee Gnanapavan, Maria Espasandin, Joela Mathews, Gavin Giovannoni, David Baker, Klaus Schmierer

General Neurology: Improving Neurologic Care and the Impact of Therapeutics

1:00 p.m. S27.001 Dural Venous Sinus Stenting for Idiopathic Intracranial Hypertension: An Updated Review and The Comprehensive Meta-analysis–Lakshmi Leishangthem, Pooja SirDeshpande, Sudhakar R. Satti 1:11 p.m. S27.002 Risk of Thrombotic Events after Exposure to Intravenous Immunoglobulin or Plasma Exchange for Treatment of Neurologic Disease–Peter Jin, Laura Stein, Susan Shin, Mandip Singh Dhamoon 1:22 p.m. S27.003 EXPLORE: A prospective, multinational natural history study of acute hepatic porphyria patients with recurrent attacks–Hetanshi Naik, Robert Desnick, Laurent Gouya, Manisha Balwani, Montgomery Bissell, David Rees, Ulrich Stolzel, John P. Phillips, Raili Kauppinen, Janneke Langendonk, Laurent Deybach, Herbert Bonkovsky, Charles Parker, Michael Badminton, Penny Stein, Elisabeth Minder, Jerzy Windyga, Pavel Martasek, Maria Domenica Cappellini, Paulo Ventura, Eliane Sardh, Pauline Harper, Sverre Sandberg, Aasne Aarsand, Felix Alegre, Aneta Ivanova, Amy Chan, Quinn Dinh, William Querbes, Craig Penz, Amy Simon, Karl Anderson

CME

2:28 p.m. S27.009 Association of Phosphorylated Neurofilament Heavy Chain (pNF-H) Levels With Motor Function Achievement in Individuals With Spinal Muscular Atrophy (SMA) Treated With Nusinersen–Charlotte J. Sumner, Basil T. Darras, Francesco Muntoni, Thomas O. Crawford, Richard S. Finkel, Eugenio Mercuri, Darryl C. De Vivo, Maryam Oskoui, Eduardo Tizzano, Monique M. Ryan, Guolin Zhao, Marco Petrillo, Christopher Stebbins, Stephanie Fradette, Wildon Farwell 2:40 p.m. Q&A Panel with Authors

1:33 p.m. S27.004 Clinical Characteristics of the First 500 Subjects in the Adult Hydrocephalus Clinical Research Network Registry–Michael A. Williams, Mark Luciano, Sean Nagel, Norman Relkin, Thomas Zwimpfer, Heather Katzen, Richard Holubkov, Mark Hamilton 1:44 p.m. S27.005 Reality or Myth: Serotonin Syndrome in Migraineurs with Triptan Use–Michelle Linn Kerr, Daniel Krashin, Natalia Murinova 1:55 p.m. S27.006 Pregnancies in Women with Multiple Sclerosis: Perception of High Risk Among Health Care Providers. Interim Data from PREG-MS Cohort–Maria Claudia Manieri, Tatenda Mahlanza, Maria K. Houtchens 2:06 p.m. S27.007 Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial–Senda Ajroud-Driss, David Adams, Teresa Coelho, Michael J. Polydefkis, Alejandra Gonzalez-Duarte, Dianna Quan, Arnt Kristen, John L. Berk, Annie Partisano, Jared Gollob, Marianne T. Sweetser, Jihong Chen, Sonalee Agarwal, Ole Suhr

Tuesday

2:06 p.m. S26.007 Serious Infections in Two Large US and Swedish Rituximab-treated Multiple Sclerosis Cohorts– Annette M. Langer-Gould, Jessica Betty Smith, Fredrik L. Piehl, Bonnie Li, Thomas Frisell

S27

2:17 p.m. S27.008 Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update–Thomas H. Brannagan, Marcia Waddington Cruz, Annabel K. Wang, Michael J. Polydefkis, Peter J. Dyck, Sami L. Khella, Violaine Plante-Bordeneuve, John L. Berk, Fabio Adrian Barroso, Giampaolo Merlini, Isabel Conceicao, Steven G. Hughes, Jesse Kwoh, Shiangtung W. Jung, Spenser Guthrie, Michael Pollock, Merrill Benson, Morie A. Gertz, Teresa Coelho

2:28 p.m. S26.009 Longitudinal study of symptom botheration in Multiple Sclerosis patients–Ilya Kister, Tamar Bacon, Lingling Wang, Gary Raymond Cutter 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.-3:00 p.m.

AAN.com/view/AM19Sci 109

3:30 p.m.-4:45 p.m. S28

Neuro-ophthalmology/Neurootology

1.25

3:41 p.m. S28.002 A Novel Tele-Dizzy Consultation Program in the Emergency Department Using Portable VideoOculography to Improve Peripheral Vestibular and Stroke Diagnosis–Daniel R. Gold, Roksolyana Romana Tourkevich, Ari Shemesh, Anthony Joseph Brune, Woo Choi, Susan Peterson, Justin Bosely, Barbara Maliszewski, Mehdi Fanai, Jorge Otero-Millan, Dale Roberts, David S. Zee, David E. Newman-Toker 3:52 p.m. S28.003 Examining referral patterns to neuroophthalmologists–Leanne Stunkel, Devin Dean Mackay, Beau Benjamin Bruce, Nancy J. Newman, Valerie Biousse 4:03 p.m. S28.004 The Caudal Vermis and the Dentate Nucleus are Critical Structures for Determining the Directional Asymmetry in Gaze-Evoked Nystagmus in Unilateral Cerebellar Lesions–Alexander A. Tarnutzer, Fausto Romano, Christopher Bockisch, Bernhard Schuknecht, Giovanni Bertolini 4:14 p.m. S28.005 Long-term Safety and Efficacy of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-naive Subjects: Results of a Phase III Study–Dimos Dimitrios D. Mitsikostas, Andrzej Dekundy, Kati Sternberg, Michael Althaus, Fernando L. Pagan 4:25 p.m. Q&A Panel with Authors

Tuesday, May 7

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S28.001 Oculomotor Function In Amyotrophic Lateral Sclerosis–Saloua Mrabet, Imen Kacem, Aroua Rekik, Amira Nasri, Amina Gargouri, Mouna Ben Djebara, Riadh Gouider

S29

NeuroHIV: Pathophysiology and Clinical Phenotypes

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S29.001 Regional Brain Injury in the SIV Macaque Model of HIV is Linked to the Host Antioxidant Response– Yoelvis Garcia-Mesa, Brandon Bastien, Rolando Garza, Analise Gruenewald, Michael R. Betts, Guido Silvestri, Dennis L. Kolson 3:41 p.m. S29.002 A common (GT)n repeat polymorphism in the heme oxygenase-1 promoter associates with neuroinflammation and cognitive impairment in HIV infection–Rolando Garza, Alexander J. Gill, Benjamin Gelman, Scott L. Letendre, Dennis L. Kolson 3:52 p.m. S29.003 Basal ganglia neuronal injury correlates with antioxidant & endothelial adhesion markers in HIVinfected brain–Analise Gruenewald, Rolando Garza, Yoelvis Garcia-Mesa, Benjamin Gelman, Dennis L. Kolson 4:03 p.m. S29.004 Association of Inflammation and Neurocognitive Impairment in Older Hispanics Living with HIV– Monica M. Diaz, Ronald J. Ellis, Jennifer Iudicello, Robert K Heaton, Scott L. Letendre, Igor Grant, Maria Marquine

Brain Cancer: From Epidemiology to Quality of Life

CME

3:30 p.m. S30.001 Incidence and Natural History of H3 K27M-mutated Midline Gliomas in Adults–Karisa C. Schreck, Surabhi Ranjan, Nebojsa Skorupan, Matthias Holdhoff, Heather Ames 3:41 p.m. S30.002 Absolute Lymphocyte Count in Patients with Glioblastoma Treated with Temozolomide Chemoradiation.–Anas Ahmed Moahmmed Saeed Bamashmos, Asad Ali, Addison Barnett, Soumya Sagar, Konrad Knusel, Manmeet Ahluwalia 3:52 p.m. S30.003 Treatment-related adverse effects in patients with brain cancer: identification of distinctive features for pseudoprogression and treatment-induced necrosis.–Sebastian Friedrich Winter, Eugene Vaios, Alona Muzikansky, Marc Bussière, Helen Shih, Maria Martinez-Lage, Franziska Loebel, Peter Vajkoczy, Jorg Dietrich 4:03 p.m. S30.004 Primary Brain and Central Nervous System Tumor Treatment and Survival in the United States, 2004-2014–Catherine Garcia, Stacey Slone, Therese Dolecek, Bin Huang, Janna Neltner, John L. Villano 4:14 p.m. S30.005 Prognostic Awareness and Illness Understanding in Patients with Malignant Glioma and their Caregivers–Sophia Landay, Maya Anand, Katharine Quain, Areej El-Jawahri, Joseph Greer, Jennifer Temel, Deborah A. Forst

4:25 p.m. S29.006 A novel pathogenic role for “Junk DNA” in neurodegenerative diseases and neurodevelopmental tumors–Avindra Nath, Wenxue Li, Tongguang Wang, Tara Doucet-O’Hare, Myoung-Hwa Lee

4:25 p.m. S30.006 A Non-interventional Study of Adjunctive Lacosamide Therapy in Patients With Brain Tumor-related Epilepsy–Roberto Ruda, Scarlett Hellot, Marc De Backer, Jane Chan, Lars Joeres, Iryna Leunikava, Robin Grant, Lars Joeres

4:47 p.m. S29.008 Cross-sectional and cumulative longitudinal CPE scores are not associated with neurocognitive impairment in a well-treated aging HIV-positive population in Switzerland–Galia Santos, Isabella Locatelli, Melanie Metral, Alexandra Calmy, Thanh Lecompte, Christoph Hauser, Alexia Cusini, barbara hasse, Helen Kovari, Philip Tarr, Marcel Stoeckle, Christoph Fux, Caroline di Benedetto, Patrick Schmid, Katharine Darling, Matthias Cavassini, Renaud A. Du Pasquier 4:58 p.m. S29.009 Electroencephalogram-Based Brain Age in People Living With HIV–Michael J. Leone, Haoqi Sun, Luis Paixao, Gregory Robbins, Shibani Sharon Mukerji, M. Brandon Westover 5:10 p.m. Q&A Panel with Authors

110 2019 AAN Annual Meeting

S30

4:14 p.m. S29.005 The Association Between Chronic Distal Sensory Polyneuropathy and Balance Disturbances in Persons Living with HIV–Duaa Sakabumi, Raeanne Moore, Bin Tang, Patrick A. Delaney, John L. Keltner, Ronald J. Ellis

4:36 p.m. S29.007 Distinct Neurodegenerative and Neuroinflammatory Subtypes of HIV-associated Neurocognitive Disorders (HAND)–Bryan Smith, Ulisses Santamaria, Elizabeth Horne, Ankit Saxena, Philip McCoy, Joseph Snow, Avindra Nath

Tuesday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS

4:36 p.m. S30.007 Longer Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups– Sharon Yu, Amie Patel, Sylvia A. Crispino, Minerva Utate, Sylvia C. Kurz 4:47 p.m. S30.008 Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study–Jessica Occhiogrosso, Lauryn Hemminger, Joy Ellen Burke, Chinazom Uchenna Ibegbu, Jennifer N. Serventi, Nimish A. Mohile 4:58 p.m. S30.009 Impact of Travel Distance to Care Facility on Survival in Patients with Glioblastoma: A Retrospective Study Using the National Cancer Database–Jay-Jiguang Zhu, Ping Zhu, Xianglin Du, Yoshua Esquenazi 5:10 p.m. Q&A Panel with Authors

S31

MS and CNS Inflammatory Disease: Imaging

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.-5:30 p.m.

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S31.001 The contribution of white matter lesions to whole brain and deep grey matter atrophy in patients with MS–Kedar Mahajan, Kunio Nakamura, Jenny J. Feng, Gabrielle Macaron, Brandon P. Moss, Marisa P. McGinley, Hong Li, Stephen Jones, Mark Lowe, Adrienne Boissy, Devon Conway, Robert J. Fox, Alexander D. Rae-Grant, Mary R. Rensel, Mary Alissa Willis, Robert A. Bermel, Jeffrey Alan Cohen, Daniel Ontaneda 3:41 p.m. S31.002 Cerebral leptomeningeal enhancement is common and associated with cortical and thalamic lesions in relapsing-remitting multiple sclerosis: A 7T MRI study–Jonathan D. Zurawski, Shahamat Tauhid, Renxin Chu, Fariha Khalid, Brian Curran Healy, Howard L. Weiner, Rohit Bakshi 3:52 p.m. S31.003 Modulation of Large-Scale Functional Networks Occurs in MS Patients Starting Fingolimod or Natalizumab: A 2-Year Resting State Functional Connectivity Study–Maria Assunta Rocca, Carlotta Marchetti, Paola Valsasina, Paolo Preziosa, Gianna Carla Riccitelli, Mariaemma Rodegher, Lucia Moiola, Giancarlo Comi, Massimo Filippi 4:03 p.m. S31.004 Structural and Functional Connectivity Influence Regional Cortical Atrophy in Multiple Sclerosis– Andrew Russo, Kevin Patel, Sean Tobyne, Natalya K. Machado, Constantina Andrada Treaba, Caterina Mainero, Eric Klawiter 4:14 p.m. S31.005 Local GM Demyelination and Remote Microstructural Damage in Connected WM Tracts both Contribute to Cortical Neurodegeneration in MS–Paolo Preziosa, Svenja Kiljan, Laura Jonkman, Wilma van de Berg, Geert Schenk, Maria Assunta Rocca, Massimo Filippi, Jeroen JG Geurts, Martijn D Steenwijk 4:25 p.m. S31.006 Restricted diffusion and fiber fraction are two important parameters for identifying subtypes of multiple sclerosis using diffusion basis spectrum imaging–Afsaneh Shirani, Peng Sun, Kathryn Trinkaus, Ajit George, Dana Perantie, Robert T. Naismith, Robert Schmidt, Sheng-Kwei Song, Anne H. Cross

General Neurology: Advances in Neurology: From the Clinic to the Bench

CME

3:30 p.m. S32.001 Neurologic Presentation of Hemophagocytic Lymphohistiocytosis–Micah Drew Yost, Derek William Stitt, Michel Toledano, Sameer Parikh, Neeraj Kumar 3:41 p.m. S32.002 Could Sleep Disorders Cause Increased Readmission Following Hospitalization for Migraine? Analysis from Nationwide Readmission Database 2010-2014–Jose R. Rodriguez, Chirag Narshibhai Savani, Varun Kumar, Luiz De Souza, Tigran Kesayan, Grace Kim, Matthew Chung, James Ray Ghattas, Martin Anthony Myers, Charles W. Brock 3:52 p.m. S32.003 Morphometric Analysis of Peripheral Nerve through Deep Learning–Daniel Moiseev, Bo Hu, Jun Li 4:03 p.m. S32.004 Regulation of Locomotion and Cortical State through Optogenetic Stimulation of the Pedunculopontine Nucleus (PPN)–Ana Collazo, Justin Moreno, Thaddeus Thomas, Cameron Good, Tsung-Ming Shih 4:14 p.m. S32.005 Optogenetic Induction of TDP-43 Proteinopathy In Vivo–Charlton Graham Otte, Jacob Mann, Udai Pandey, Christopher Donnelly 4:25 p.m. S32.006 White and Gray Matter Brain Volumes in Early-Onset Alexander Disease–Jack Sollee, Ritobrato Datta, Christina Minkoff, Geraldine Liu, Hannah Cooper, Adeline Vanderver, Brenda Banwell, Amy T. Waldman 4:36 p.m. S32.007 EXOS Stratospheric Vital Sign Monitoring with Oxehealth Camera: A Pilot Feasibility Study–William David Freeman, Neethu Gopal, Rabih G. Tawk, Lawrence Harvey, Oliver Gibson, Hugh Lyod Jukes, Michelle Freeman 4:47 p.m. S32.008 Occupational Exposure to Hypobaria Results in Accelerated Cerebral White Matter Aging in Cohort of U-2 pilots and Air Force Physiologists/Chamber Technicians.–Kelsey Cacic, Paul Sherman, John H. Sladky 4:58 p.m. S32.009 Development of a minimally invasive muscle O2 nanosensor for Mitochondrial Myopathy–Zarazuela Zolkipli-Cunningham, Didi She, Katherine Mitchell, Douglas Wallace, Mark Allen, Marni Falk

Tuesday

4:36 p.m. S31.007 Measuring White Matter Axonal Injury in Patients with Multiple Sclerosis–Amalie Chen, Giulia Franco, Seth A. Smith, Richard Darrell Dortch, Junzhong Xu, Francesca Bagnato

S32

5:10 p.m. Q&A Panel with Authors

4:47 p.m. S31.008 The Association Between Cortical Gray Matter Lesions and Leptomeningeal Enhancement on 7-Tesla MRI in Multiple Sclerosis–Mehrnaz Ighani, Samuel Jonas, Izlem Izbudak, Erin O’Connor, Seongjin Choi, Jun Hua, Daniel Harrison 4:58 p.m. S31.009 Patterns of regional changes in thalamic shape and volume are related to performance in specific cognitive domains in Multiple Sclerosis–Alvino Bisecco, Rocco Capuano, Giuseppina Caiazzo, Alessandro D’Ambrosio, Renato Docimo, Simona Bonavita, Mario Ciriillo, Antonio Russo, Francesca Trojsi, Maria Assunta Rocca, Gioacchino Tedeschi, Ivan Rocha Ferreria Da Silva, Antonio Gallo 5:10 p.m. Q&A Panel with Authors

= Abstract of Distinction

AAN.com/view/AM19Sci 111

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 1:00 p.m.-2:00 p.m. S33

Neuro-rehabilitation: Brain and Neuromuscular Recovery

1:00 p.m.-3:00 p.m. CME

1:00 p.m. S33.001 Improvements in Spatial Bias and Functional Outcomes in Chronic Hemispatial Neglect: Results of a Multi-Site Phase II Efficacy Trial of a Novel Computerized Attention Training Program.–Tom Van Vleet, Joseph DeGutis, Maurizio Corbetta, Paolo Bonato, Eric Fabara 1:11 p.m. S33.002 Preserved Brain Functional Plasticity After Upper Limb Task-Oriented Rehabilitation in Progressive Multiple Sclerosis–Giacomo Boffa, Andrea Tacchino, Elvira Sbragia, Simona Schiavi, Amgad Droby, Nicolò Piaggio, Giulia Bommarito, Gaia Girardi, Giovanni Luigi Mancardi, Giampaolo Brichetto, Matilde Inglese 1:22 p.m. S33.003 Clinically meaningful change on the 100 meter timed test in neuromuscular diseases–Lindsay N. Alfano, Natalie Fae Miller, Megan Iammarino, Melissa Moore-Clingenpeel, Margaret Dugan, Chang-Yong Tsao, Louise R. Rodino-Klapac, Megan A. Waldrop, Kevin M. Flanigan, Jerry R. Mendell, Linda Pax Lowes 1:33 p.m. S33.004 Transcranial Direct Current Stimulation (tDCS) Induces Acute Changes in Brain Metabolism–Claire Choi, Michael Shaw, Natalie Pawlak, Lauren B. Krupp, Yulin Ge, Leigh Elkins Charvet 1:45 p.m. Q&A Panel with Authors

Wednesday, May 8

S34

Aging and Dementia: Risk Factors, Biomarkers, and Neuropathology

1:00 p.m.-3:00 p.m. CME

1:00 p.m. S34.001 Long-term Exposure to Ambient Air Pollution and Trajectories of Cognitive Decline among Older Adults in Northern Manhattan–Erin Ryan Kulick, Greg Wellenius, Amelia Katharine Boehme, Nicole Schupf, Richard P. Mayeux, Ralph L. Sacco, Jennifer J. Manly, Mitchell S. V. Elkind 1:11 p.m. S34.002 Factors Related to Higher Neurobiological Capital Across the Lifespan: Mayo Clinic Study of Aging–Bryan Joseph Neth, Jonathan Graff-Radford, Scott Przybelski, Christopher Schwarz, Robert Reid, Michelle M. Mielke, Ronald C. Petersen, Clifford R. Jack, David S. Knopman, Prashanthi Vemuri 1:22 p.m. S34.003 Is Mild Traumatic Brain Injury associated with Early Onset Dementia when evaluating only validated cases of Dementia?–Hari Krishna Raju Sagiraju, Janice Marceaux, Jason R Soble, Justin O’Rourke, Alicia Swan, Margaret Wells, Megan Amuan, Blessen Eapen, Mary Jo Pugh 1:33 p.m. S34.004 An inflammatory marker panel provides insight into white matter abnormalities: the Northern Manhattan Study–Mitchell S. V. Elkind, Yeseon Moon, Janet T. DeRosa, Daysi Guerrero, Tatjana Rundek, Clinton B. Wright, Ralph L. Sacco, Mady Hornig, Ken Cheung 1:44 p.m. S34.005 White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study– Nienke Legdeur, Dana E. Greenia, Davis Woodworth, Evan Fletcher, Charles S. DeCarli, Claudia Kawas, Maria M. Corrada 1:55 p.m. S34.006 APOE and Education: Effects on Regional Tau and FDG Metabolism in Older Adults–Vijay K. Ramanan, Anna Castillo, David S. Knopman, Val John Lowe, Michelle M. Mielke, Ronald C. Petersen, Clifford R. Jack, Prashanthi Vemuri 2:06 p.m. S34.007 Convergent Evidence for a Longevity Genetic Locus Associated with Tau Load in PART–Kyra JeffersonGeorge, David A. Wolk, Edward Lee, Sandhitsu Das, Laura Wisse, Philip De Jager, Julie A. Schneider, David A. Bennett, Corey McMillan

Wednesday

2:17 p.m. S34.008 A/T/N Criteria are Inconsistent in Autopsy-Confirmed Non-Amnestic Alzheimer’s Disease–Jeffrey Scott Phillips, David Irwin, Emily Roll, Corey McMillan, Fulvio Da Re, Edward Lee, Leslie Michael Shaw, John Q. Trojanowski, David A. Wolk, Murray Grossman 2:28 p.m. S34.009 Distribution of Hippocampal Tau Pathology in Amnestic and Non-Amnestic Forms of Alzheimer’s Disease–Simon Miller, Jeffrey Scott Phillips, Ranjit Ittyerah, Claire Peterson, Edward Lee, John Q. Trojanowski, David A. Wolk, Paul Yushkevich, Murray Grossman, David Irwin 2:40 p.m. Q&A Panel with Authors

112 2019 AAN Annual Meeting

S35

Stroke Prevention Strategies

CME

1:00 p.m. S35.001 Anticoagulation Choice and Timing in Stroke Due to Atrial Fibrillation: A Survey of US Stroke Specialists (ACT-SAFe)–Igor Rybinnik, Deviyani Mehta, Michael T. Mullen, Steven R. Messe, Scott E. Kasner, Ronen R. Leker, Brett L. Cucchiara 1:11 p.m. S35.002 The Use Of Oral Anticoagulants In Patients With Atrial Fibrillation In The Emergency Department– Hope Hua, Nicole Beaton Sur, Allison Choi, Sai Prasant Polineni, Lilly Lee, Seemant Chaturvedi 1:22 p.m. S35.003 The Proportion of Thrombectomy Cases That Could Be Avoided With Improved Atrial Fibrillation Stroke Prevention–Nicole Beaton Sur, Vasu Saini, Luis F. Torres, Kunakorn Atchaneeyasakul, Amer Malik, Dileep R. Yavagal, Seemant Chaturvedi 1:33 p.m. S35.004 Comparative Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Non-valvular Atrial Fibrillation Patients: The Dose Subgroup Analysis of the ARISTOPHANES Study–Steve Deitelzweig, Allison Keshishian, Xiaoyan Li, Melissa Hamilton, Cristina Masseria, Amol Dhamane, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Onur Baser, Gregory Y.H. Lip 1:44 p.m. S35.005 Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy–Eliza Cushman Miller, Amelia Katharine Boehme, Nadia Chung, Sophia Wang, James Lacey, Kamakshi Lakshminarayan, Charlie Zhong, Daniel Woo, Natalie Bello, Ronald Wapner, Mitchell S. V. Elkind, Joshua Z. Willey 1:55 p.m. S35.006 Aspirin as a Primary Prevention of Cardiovascular Disease in High-Risk New Diabetes Patients: A Retrospective Cohort Study in Taiwan–Chiawei Chiang, Ta-Cheng Chen, Yi-Chun Yeh, Yen-Yu Chen 2:06 p.m. S35.007 Direct oral anticoagulants versus Vitamin K antagonists after a recent ischemic stroke or TIA– a pooled individual patient data analysis–David Seiffge, Maurizio Paciaroni, Duncan Wilson, Masatoshi Koga, Kosmas Macha, Manuel Cappellari, Sabine Schaedelin, Clare Shakeshaft, Masahito Takagi, Georgios Tsivgoulis, Bruno Bonetti, Bernd Kallmünzer, Shoji Arihiro, Andrea Alberti, Alexandros Polymeris, Gareth Ambler, Sohei Yoshimura, Michele Venti, Leo Bonati, Keith W. Muir, Hiroshi Yamagami, Sebastian Thilemann, Riccardo Altavilla, Nils Peters, Manabu Inoue, Tobias Bobinger, Giancarlo Agnelli, Martin Brown, Shoichiro Sato, Monica Acciarresi, Hans Rolf Jager, Paolo Bovi, Stefan Schwab, Philippe A. Lyrer, Valeria Caso, Kazunori Toyoda, David Werring, Stefan T. Engelter, Gian Marco De Marchis 2:17 p.m. S35.008 Association of Carotid Arterial Atherosclerosis, Dilation, and Stiffness with Cerebral Small Vessel Disease–Fei-Fei Zhai, Meng Yang, Fei Han, Lixin Zhou, Jun Ni, Ming Yao, Shu-Yang Zhang, Zheng-Yu Jin, Liying Cui, Qing Dai, Yi-Cheng Zhu 2:28 p.m. S35.009 Caregiver Burden Among Informal Caregivers of Stroke Survivors–Saviour Achilike, Jennifer SannerBeauchamp, Munachi Nkiru Okpala, Samuel Payen, Lyric Baldridge, Mary Love, Anjail Sharrief, Sean I. Savitz 2:40 p.m. Q&A Panel with Authors

S36

Epilepsy/Clinical Neurophysiology (EEG) II

1:00 p.m.-3:00 p.m. CME

1:00 p.m. Dreifuss-Penry Epilepsy Award Presentation The intent of this award is to recognize physicians in the early stages of their careers who have made an independent contribution to epilepsy research.

Recipient: Daniel Friedman, MD, MS New York, NY 1:11 p.m. S36.002 Focal mGluR5 Abnormalities Identified in vivo in Mesial Temporal Lobe Epilepsy (MTLE) by [11C] ABP688 Positron Emission Tomography (PET)–Jack Lam, Jonathan DuBois, Jared Rowley, Karina Gonzalez Otarula, Jean-Paul Soucy, Gassan Massarweh, Jeffery A. Hall, Marie-Christine Guiot, Pedro Rosa Neto, Eliane Kobayashi 1:22 p.m. S36.003 Virtual Cortical Resection Reveals Epileptic Network Characteristics in Pediatric Patients with Focal Cortical Dysplasia.–Jeremy Wong, Samuel Tomlinson, Erin Caitlin Conrad, Ankit Khambhati, Eric D. Marsh 1:33 p.m. S36.004 Prevalence and clinico-radiological characteristics of Hippocampal Mal-Rotation (HIMAL) in an Epilepsy Clinic Population; A Retrospective Chart Review– Najib I. Murr, Rebecca Jane Thompson, Abdullah Al Sawaf, Sanaz Karimi, Matthew Omojola 1:44 p.m. S36.005 Nine-year Prospective Safety and Effectiveness Outcomes from the Long-Term Treatment Trial of the RNS® System–Dileep R. Nair, Martha Morrell 1:55 p.m. S36.006 How Often And What Predicts…30-Day Hospital Readmissions After Generalized Convulsive Status Epilepticus?–Mohamad Rahwan, Alain Zingraff Lekoubou Looti, Kinfe Bishu, Bruce I. Ovbiagele 2:06 p.m. S36.007 Characterization of Multidien Rhythms in Patients with Epilepsy–Joline M. Fan, Maxime Baud, Vikram Rao

2:28 p.m. S36.009 Bilateral and Left Hippocampal Atrophy Several Distrupt Functional Connectivity in Temporal Lobe Epilepsy–Lucas Silva, Leticia Franceschet Ribeiro, Guilherme Artoni, Fernando Cendes, Clarissa L. Yasuda 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

MS Biomarkers

1:00 p.m. S37.001 CSF kappa Free Light Chains as a Potential Quantitative Alternative to Oligoclonal Bands in Multiple Sclerosis–Ruba Shihadeh Saadeh, Sean J. Pittock, Sandra Bryant, David Murray, Melissa Post, Jody Frinack, Andrew McKeon, Maria Alice Willrich 1:11 p.m. S37.002 Serum neurofilament light chain levels and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study–Dejan Jakimovski, Robert Zivadinov, Murali Ramanathan, Jesper Hagemeier, Bianca Weinstock-Guttman, Davorka Tomic, Harald Kropshofer, Christian Barro, David Leppert, Özgür Yaldizli, Jens Kuhle, Ralph H. B. Benedict

CME

2:28 p.m. S37.009 Leukocyte telomere length is associated with disability progression in multiple sclerosis independent of chronological age–Kristen M. Krysko, Roland G. Henry, Bruce A. C. Cree, Jue Lin, Jennifer Graves, Stacy Caillier, Adam Santaniello, Chao Zhao, Refujia Gomez, Carolyn J. Bevan, Dana Smith, William Stern, Gina Kirkish, Stephen L. Hauser, Jorge Oksenberg, Jennifer Graves 2:40 p.m. Q&A Panel with Authors

1:22 p.m. S37.003 Neurofilament-Light Chain Levels Are Predictive of On-going Disease Activity in Radiologically Isolated Syndrome–Eric Thouvenot, Christophe Demattei, Ugur Uygunoglu, Sophie Pittion, Giovanni Castelnovo, Luciel Du Trieu de Terdonck, Mikael Cohen, Darin T. Okuda, Orhun H. Kantarci, Daniel Pelletier, Philippe Marin, Sylvain Lehmann, Aksel Siva, Christine Lebrun Frenay 1:33 p.m. S37.004 Serum Neurofilamant, GFAP and Tau in Patients with Aggressive Multiple Sclerosis Before and After Haematopoietic Stem Cell Transplant–Simon Thebault, Daniel Tessier, Marjorie Bowman, Hyunwoo Lee, Douglas L. Arnold, Amit Bar-Or, Vincent TabardCossa, Mark S. Freedman 1:44 p.m. S37.005 Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis–Tomas Uher, Barbora Hoskova, Christian Barro, Niels Bergsland, Michael G. Dwyer, Michaela Tyblova, Karolina Kucerova, Pascal Benkert, Zuzanna Michalak, David Leppert, Jan Krasensky, Zdenek Seidl, Manuela Vaneckova, Eva Havrdova, Robert Zivadinov, Jens Kuhle, Tomas Kalincik, Dana Horakova 1:55 p.m. S37.006 The Correlation of Blood Neurofilament Light Chain with Brain Atrophy is Partly Independent from Inflammation–Maria Pia Sormani, Ludwig Kappos, Dieter Haering, Harald Kropshofer, Christian Barro, David Leppert, Davorka Tomic, Jens Kuhle 2:06 p.m. S37.007 The association between serum neurofilament light chain and OCT measures in multiple sclerosis–Jesper Hagemeier, Eleonora Tavazzi, Murali Ramanathan, Dejan Jakimovski, Niels Bergsland, Davorka Tomic, Harald Kropshofer, David Leppert, Zuzanna Michalak, Michael G. Dwyer, Ralph H. B. Benedict, Bianca Weinstock-Guttman, Jens Kuhle, Robert Zivadinov

Wednesday

2:17 p.m. S36.008 Efficacy and Safety of Intravenous Brivaracetam as a Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit–Jerzy P. Szaflarski, Ahmed Sadek, Bernhard Greve, Paulette Williams, Julie Varner, Brian Darryl Moseley

S37

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.-3:00 p.m.

2:17 p.m. S37.008 Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness– Angeliki Filippatou, Thomas Jack Shoemaker, Megan E. Esch, Madiha Qutab, Natalia Gonzalez Caldito, Jerry Prince, Ellen M. Mowry, Peter A. Calabresi, Shiv Saidha, Elias S. Sotirchos

AAN.com/view/AM19Sci 113

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 1:00 p.m.-3:00 p.m. S38

Headache: Clinical Trials II

3:30 p.m.-5:30 p.m. CME

1:00 p.m. S38.001 Long-Term Impact of Fremanezumab on Response Rates: Results of a 1-Year Study–Lawrence C. Newman, Joshua T. Cohen, Paul P. Yeung, Ronghua Yang, Xiaoping Ning 1:11 p.m. S38.002 Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure–David W. Dodick, Stewart J. Tepper, H. Christoph Diener, Cristina Tassorelli, Sylvia M. Lucas, Stefan Evers, Feng Zhang, Denise Chou, Nadia Tenenbaum, Jan Klatt, Daniel D. Mikol, Gabriel Paiva da Silva Lima 1:22 p.m. S38.003 Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy?1) Trial–Joel R. Saper, Kerri L. Wilks, George Chakhava, Roger Cady, Barbara Schaeffler, David M. Biondi, Joe Hirman, Jeff Smith 1:33 p.m. S38.004 Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study–Peter Goadsby, Teshamae Monteith, Paul P. Yeung, Joshua M. Cohen, Ronghua Yang 1:44 p.m. S38.005 Sustained Efficacy Over 1 Year of Treatment With Erenumab: Results From the Extension Phase of the STRIVE Study in Episodic Migraine–Denise Elaine Chou, Peter Goadsby, Uwe Reuter, Yngve Hallstrom, Gregor Broessner, Jo Jaeger Bonner, Feng Zhang, Sandhya Sapra, Jan Klatt, Hernan Picard, Daniel D. Mikol 1:55 p.m. S38.006 Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache Attacks: Results From a Patient Registry–Abraham J. Nagy, Mkaya Mwamburi, Candace McClure, Eric J. Liebler, Jessica Ailani

Wednesday

2:06 p.m. S38.007 Reduction in Healthcare Resource Utilization in Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the REPOSE Study–Katja Kollewe, Angela Antonakakis, Michael Kiszka, Katherine Sommer, Justin S. Yu 2:17 p.m. S38.008 Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II–Joel M. Trugman, David W. Dodick, Jessica Ailani, Kaifeng Lu, Hassan Likis, Michelle Finnegan, Armin Szegedi, Richard B. Lipton 2:28 p.m. S38.009 Patient Global Impression of Change Related to Improvement in Most Bothersome Symptom Following Treatment With Eptinezumab–Roger Cady, Lora J. McGill, Joe Hirman, David M. Biondi, Richard B. Lipton 2:40 p.m. Q&A Panel with Authors

114 2019 AAN Annual Meeting

Wednesday, May 8

S39

Education Research and Research Methodology

3:30 p.m.-5:30 p.m. CME

3:30 p.m. S39.001 Why Do Medical Students Choose to Become Neurologists? ?A Computational Linguistics Analysis of Residency Personal Statements–Helen Cheung, Sarah Grzebinski, Charles Sanky, Jessica Ouyang, Stephen Krieger 3:41 p.m. S39.002 Diagnostic Accuracy Among Neurology Residents: Six-year Data from the Close the Loop Resident Clinical Acumen Assessment Project–Emily Schorr, Rachel Brandstadter, Peter Jin, Christine Stahl, Stephen Krieger 3:52 p.m. S39.003 Development and Validation of Simulation Scenarios for Performance Assessment in Neurological Emergencies–Nicholas Allen Morris, WanTsu Chang, Ali Tabatabai, Oliver Bates, Samuel Tisherman 4:03 p.m. S39.004 Identifying and Addressing Impaired Co-Residents in the Era of Physician Burnout–Rebecca Stainman, Ariane Lewis, Aaron Lane Nelson, Perrin A. Pleninger, Arielle Marisa Kurzweil

S40

Stroke Risk Factors and Epidemiology

CME

3:30 p.m. Alliance Awards: Founders Award Presentation This award is designed to encourage clinical and translational research in neuroscience by physicians in clinical neurology training programs.

Recipient: Lily Zhou, BHSc, MD Vancouver, BC, Canada 3:41 p.m. S40.002 Abdominal Obesity Predicts Stroke Risk in the Framingham Study–Hugo Javier Aparicio, Serkalem Demissie, Jayandra J. Himali, Matthew Pase, Claudia L. Satizabal, Kimberly Dukes, Vasileios-Arsenios Lioutas, Jose Rafael Romero, Vasan Ramachandran, Alexa Beiser, Sudha Seshadri 3:52 p.m. S40.003 CADASIL is a significant cause of small vessel occlusion stroke in Taiwan–Yi-Chu Liao, Yi-Chung Lee

4:14 p.m. S39.005 Subspecialization in Clinical Neurophysiology (CNP): A Twenty-Five Year Retrospective–Dorthea Juul, Kerry H. Levin, Laurie Gutmann, Kalea Lynn Colletta, Larry R. Faulkner

4:03 p.m. S40.004 The Inverse Relationship Between Cerebral Microbleed Burden and Migraine-Related Disability in CADASIL–Eric Goldstein, Mohammed Badi, James P. Klaas, Elizabeth R. Lesser, David O. Hodge, Robert D. Brown, David W. Dodick, Todd D. Rozen, David J. Capobianco, Michelle P. Lin, Josephine F. Huang, James F. Meschia

4:25 p.m. S39.006 The Impact of a Novel Clinic Block System on Resident and Faculty Satisfaction, Work-Life Balance, and Subspecialty Exposure–Justine E. Cormier, Bryce Buchowicz, Jeffrey Dewey, Caitlin Loomis, Sara Maguire Schaefer, Darren Volpe, Jeremy Moeller

4:14 p.m. S40.005 Long-term premorbid blood pressure and cerebral small vessel disease burden on imaging in TIA and ischaemic stroke: population-based study–Gary KK Lau, Linxin Li, Michela Simonia, Ziyah Mehta, Wilhelm Kuker, Peter Rothwell

4:36 p.m. S39.007 The Influence of Research Continuity on Neurologist’s Career Success as Physician-Scientists–Jenna Brownrout, Alexandra Hansen, Wyatt Peter Bensken, Gina Norato, John Heiss, Avindra Nath, Omar Iqbal Khan

4:25 p.m. S40.006 TBI and PTSD are associated with higher risk of Ischemic Stroke in veteran population: VA retrospective study–Shamik Shah, Olurinde Oni, Hemant Thakur, Salwa Maalouf, Ram Sharma, Mukut Sharma, Mary Oehlert, Vikas Singh

4:47 p.m. S39.008 Development and Assessment of a Novel Peer Concussion Education Program for College Athletes– Meredith Kneavel, William Ernst, Kevin McCarthy

4:36 p.m. S40.007 Regional Trends in Modifiable Vascular Risk Factors Among Patients Hospitalized for Stroke or TIA in the United States, 2005 to 2014–Melanie R. F. Greenway, Daniela Markovic, Thomas G. Brott, James F. Meschia, Kevin M. Barrett, Josephine F. Huang, Michelle P. Lin

4:58 p.m. S39.009 The PD Buddy Program: Experience from a Community-based Outreach Program–Diksha Mohanty, Denise Cumberland, Megan Church-Nally, Susan Sawning, Monica Ann Shaw, Erika Branch, Kathrin LaFaver 5:10 p.m. Q&A Panel with Authors

4:47 p.m. S40.008 Trends in Endovascular and Surgical Treatments for Aneurysmal Subarachnoid Hemorrhage in United States–Mohsain Gill, Mohammad Rauf Afzal, Saqib A. Chaudhry, Baljinder Singh, Adnan I. Qureshi 4:58 p.m. S40.009 Population-based study of Stroke-related Cardiovascular Events. Is Stroke the Culprit of Ensuing Heart Disease?–Luciano A. Sposato, Melody Lam, Britney Allen, Lucie Richard, Salimah Shariff, Gustavo Saposnik 5:10 p.m. Q&A Panel with Authors

S41

Imaging in Movement Disorders

3:30 p.m.-5:30 p.m. CME

3:30 p.m. Jon Stolk Award in Movement Disorders for Young Investigators Presentation This award recognizes young investigators who have made significant contributions to movement disorders research. The award is named for Dr. Jon Stolk, a driving force in the drug development field for Parkinson’s disease.

Recipient: Sheng-Han Kuo, MD New York, NY 3:41 p.m. S41.002 Predictors of change in cholinergic basal forebrain volume in early Parkinson disease–Matthew J. Barrett, Jeffrey Zhang, Justin Murphy, Joseph Flanigan, Jamie Blair, Jason Druzgal 3:52 p.m. S41.003 Longitudinal Connectivity Outperforms Volumetric Change As A Marker For Prodromal Parkinson’s Disease–Danilo Pena, Jessika Suescun, Óscar PeñaNogales, Rodrigo Luis-Garcia, Timothy M. Ellmore, Mya C. Schiess, Luca Giancardo 4:03 p.m. S41.004 Imaging Identifies Distinct Brainstem Phenotypes in Early Parkinson’s Disease–Frank Michael Skidmore, Thomas Anthony, William Monroe, Jon Marstrander, Yuliang Liu, Gary Raymond Cutter, Anthony P. Nicholas, David Odaibo, Mark William Albers, Glenn Brook, Mitch Horton, Elizabeth Disbrow, Rand Swenson, Hemant Tiwari, Allison Fialkowski, David G. Standaert 4:14 p.m. S41.005 Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort–Andrew D. Siderowf, Tanya Simuni, Liz Uribe, Chelsea Caspell-Garcia, Christopher Coffey, Tatiana Foroud, Brit Mollenhauer, Caroline M. Tanner, Karl D. Kieburtz, Lana Chahine, Kenneth L. Marek 4:25 p.m. S41.006 MRI Signature of Neuromelanin and Iron Pathology in Parkinson’s Disease–Daniel Huddleston, Babak Mahmoudi, Jason Langley, Stewart A. Factor, Bruce Crosson, Xiaoping Hu 4:36 p.m. S41.007 Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease– Baijayanta Maiti, Jonathan Koller, Abraham Z. Snyder, Scott Norris, Meghan C. Campbell, Joel S. Perlmutter

4:58 p.m. S41.009 Exploring the relationship between brain atrophy and clinical symptoms in Huntington’s disease–Erin Furr-Stimming, Gabriela D. Colpo, Natalia Pessoa Rocha, Leigh Latham, Odelin Charron, George Papadimitropoulos, Leorah Aude Emmanuelle Freeman, Antonio Teixeira 5:10 p.m. Q&A Panel with Authors

Neuromuscular Disorders

CME

3:30 p.m. S42.001 Natural History of Lumbosacral Radiculoplexus Neuropathy–Marcus Vinicius Rocha Pinto, Peng Soon Ng, Prabin Thapa, Ruple S. Laughlin, Peter J. Dyck, P. James B. Dyck 3:41 p.m. S42.002 MicroRNAs as potential biomarkers for lipid storage myopathies due to ETFDH and PNPLA2 mutations– Sara Missaglia, Daniela Tavian, Valentina Pegoraro, Corrado Angelini 3:52 p.m. S42.003 Premature Labor in the Domestic Sow in Response to in utero Delivery of AAV9 to Fetal Piglets–Christopher Wier, Jessica Russo, Mehmet Emir Yalvac, Anthony Reynolds, Amy Knapp, Elizabeth Powers, Lori Mattox, Catalin Buhimschi, Raphael Malbrue, Stephen J. Kolb 4:03 p.m. S42.004 Validation of a New Functional Dyspnea Score in Amyotrophic Lateral Sclerosis: ALS Functional Dyspnea Score–Terry D. Heiman-Patterson, Carlayne E. Jackson, Michael Sherman, Jeremy M. Shefner, Daniel S. Newman, Stephen N. Scelsa, Ashok Verma, Yvonne Rollins, Edward J. Kasarskis, Edward J. Kasarskis 4:14 p.m. S42.005 Myopathy: An Underrecognized Presentation of Transthyretin Amyloidosis–Marcus Vinicius Rocha Pinto, Margherita Milone, Michelle L. Mauermann, Reem M. Alhammad, Ellen McPhail, Teerin Liewluck 4:25 p.m. S42.006 Arg225Cys Mutation in SCN11A Causes Nociceptive Pain without Detectable Peripheral Nerve Pathology– Ryan Castoro, Jun Li, Christopher David Lee, Lan Zhou 4:36 p.m. S42.007 Benefits of a Small Gene Panel for CMT in the Era of Genomics–Houda Elloumi, Courtney Downtain Pickersgill, Dianalee McKnight, Tracy Brandt 4:47 p.m. S42.008 Neuromuscular Complications of Graft Versus Host Disease–Jacqui-Lyn Saw, M Hasib Sidiqi, Hassan Alkhateeb, Elie Naddaf 4:58 p.m. S42.009 The clinical spectrum of acute nutritional axonal neuropathy (ANAN)–Johanna Hamel, Eric L. Logigian 5:10 p.m. Q&A Panel with Authors

S43

Immunotherapies and Drug Trials in Autoimmune Neurological Disorders

CME

3:30 p.m. S43.001 Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderateto-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study–Vera Bril, Michael G. Benatar, Melissa Brock, Bernhard Greve, Peter Kiessling, Franz Woltering, Peter Y.K. Van den Bergh 3:41 p.m. S43.002 Depletion of memory B cells is effective to prevent relapses in AQP4 antibody NMOSD but not in MOG antibody disorder–Pierre Durozard, Audrey Rico Lamy, Clémence Boutiere, Romaric Lacroix, Corinne Brunet, Shirley Fritz, Adil Maarouf, Jean Pelletier, Bertrand Audoin 3:52 p.m. S43.003 Autologous Haematopoietic Stem Cell Transplantation (Auto-HSCT) in Stiff Person Syndrome (SPS): The UK Experience–Alice Thorpe, Lewis Kass-Iliyya, Helen Jessop, Andrew Chantry, Marios Hadjivassiliou, John Snowden, Basil Sharrack 4:03 p.m. S43.004 Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in CIDP: the PATH Study–Amgad Shebl, Billie Durn, Vera Bril, Ingemar S.J. Merkies, Hans-Peter Hartung, Richard A. Lewis, Gen Sobue, John-Philip Lawo, David R. Cornblath, Orell Mielke, Ivo N. Van Schaik 4:14 p.m. S43.005 Long-term Safety and Efficacy of Subcutaneous Immunoglobulin IgPro20 in CIDP: the PATH Extension Study.–Ivo N. Van Schaik, Orell Mielke, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A. Lewis, Gen Sobue, John-Philip Lawo, Micheala Praus, Billie Durn, David R. Cornblath, Ingemar S.J. Merkies 4:25 p.m. S43.006 Placebo Effect in the PATH Study of Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy–Richard A. Lewis, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Gen Sobue, Orell Mielke, John-Philip Lawo, Billie Durn, David R. Cornblath, Ingemar S.J. Merkies, Ivo N. Van Schaik 4:36 p.m. S43.007 Phase II Randomized Controlled Trial Evaluating Scrambler Therapy for Central Neuropathic Pain Treatment in Patients with Neuromyelitis Optica Spectrum Disorder–Maureen A. Mealy, Sharon Kozachik, Ruth Andrea Salazar Camelo, Lauren Totonis, Lawrence Cook, Thomas Smith, Michael Levy 4:47 p.m. S43.008 Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD)– Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin M. Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching Piao Tsai, Albert Saiz, Masayuki Haramura, Yusuke Terada, Yuichi Kawata, Jerome De Seze 4:58 p.m. S43.009 Neurological toxicity in cancer patients treated with immune check-point inhibitor therapy–Lauren N. Reoma, Ram Narendra Narayan, Julie Albert, Aashrai Sai Venkat Gudlavalleti, Bryan Smith, Matthew K. Schindler, Daniel Reich, Andrea Apolo, Fatima Karzai, Arun B. Rajan, James Gulley, Omar Iqbal Khan, Avindra Nath 5:10 p.m. Q&A Panel with Authors

= Abstract of Distinction

AAN.com/view/AM19Sci 115

Wednesday

4:47 p.m. S41.008 Neural Correlates Associated with Executive Function in Patients with ATP1A3 Mutations– Caroline Wilson, Jared Cook, Beverly M. Snively, Youngkyoo Jung, Jeongchul Kim, Kathleen J. Sweadner, Ihtsham Haq, Laurie J. Ozelius, Allison Brashear, Christopher T. Whitlow

S42

3:30 p.m.-5:30 p.m.

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.-5:30 p.m.

1:00 p.m.–2:30 p.m. S44

History of Neurology

1.5

Selected by the Lawrence C. McHenry Award Workgroup, this award recognizes excellence in research in the history of neurology.

Recipient: Stefano Sandrone, PhD Milan, Italy 1:55 p.m. S44.006 Sir Henry Head’s Lesser Known Self-Experiment in Sensory Physiology–Stephen G. Reich 1:22 p.m. S44.003 Robert Wartenberg and the American Academy of Neurology–David B. Burkholder, Christopher J. Boes 1:33 p.m. S44.004 Historical studies indicating a prognostic significance of herpes labialis in bacterial meningitis–Peter J. Koehler 1:44 p.m. S44.005 The American Contribution to Surgical Treatment of Trigeminal Neuralgia–Edward J. Fine 2:10 p.m. Q&A Panel with Authors

Thursday, May 9

1:00 p.m.–3:00 p.m. CME

1:00 p.m. Lawrence C. McHenry Award: An Award for the History of Neurology Presentation

S45

Neuroinfectious Disease: Treatments, Diagnostics, and Outcomes

1:00 p.m.–3:00 p.m. CME

1:00 p.m. S45.001 The spectrum of JC-virus infection: JCV encephalopathy variant associated with cerebral edema and herniation–Lauren N. Reoma, Maria Chiara Monaco, Jamie Solis, Marta Garcia Montojo, Phuong Vo, Omar Iqbal Khan, Christopher Trindade, Daniel Reich, William Richard Childs, Avindra Nath 1:11 p.m. S45.002 Acute Flaccid Myelitis: Analysis of Outbreaks and Outcomes in a Tertiary Center–Benjamin M. Greenberg, Patricia Plumb, Cynthia X. Wang, Kyle Matthew Blackburn 1:22 p.m. S45.003 Misdiagnosis of AFM: Establishing the need for first line provider education–Sarah E. Hopkins, Anusha Yeshokumar, Leslie Hayes, Raquel Farias-Moeller, Leslie A. Benson 1:33 p.m. S45.004 Prevalence and Healthcare Resource Utilization of Community-acquired and Nosocomial Bacterial Meningitis Infections in the United States–Sarah D. Hodges, Musa Kiyani, Syed M Adil, Lefko Charalambous, Promila Pagadala, Beth Parente, Hui-Jie Lee, Beiyu Liu, Christopher Paul Eckstein, Shivanand Pramod Lad 1:44 p.m. S45.005 Illuminating Tuberculosis Meningitis with Metagenomics and FLASH Enrichment–Prashanth Ramachandran, Fiona Cresswell, Charles Langelier, Saharai Caldera, Amy Lyden, Aaron McGeever, Josh Batson, Rene Sit, Norma Neff, Katherine Travisano, Lillian Khan, Joseph DeRisi, David R. Boulware, Emily Crawford, Michael R. Wilson

Sleep Science and Therapy Updates

CME

1:00 p.m. Sleep Science Award Presentation This award is intended to recognize distinguished academic contributions by neurologists to the field of sleep medicine or the contributions of non-neurologists to the interface area of sleep neurology.

Recipient: Clifford Saper, MD, PhD Boston, MA 1:22 p.m. Wayne A. Hening Sleep Medicine Investigator Award Presentation This award recognizes scientific contributions in sleep from promising young investigators. The goal of this award is to reward productive young investigators and to emphasize the essential role of neurology in sleep medicine.

Recipient: Diego Carvalho, MD Rochester, MN 1:33 p.m. S46.004 Gender differences in sleep homeostasis: Pharmacogenetic approach to examine the role of melanin concentrating hormone–Mahesh M. Thakkar, Rishi Sharma, Pradeep K. Sahota 1:44 p.m. S46.005 Autonomic Symptom Burden in Idiopathic Hypersomnia–Paul Kim, Joseph Cheung, Logan D. Schneider, LynnMarie Trotti, Mitchell G. Miglis 1:55 p.m. S46.006 Establishing True Polysomnographic Normative Values: A Systematic Review and Meta-Analysis– Brian James Murray, Tetyana Kendzerska, Trevor Jairam, Anastasia Mekhael, James Im, Mark Boulos 2:06 p.m. S46.007 Effects of Lemborexant in the Morning: Results From 3 Randomized Studies–Patricia Murphy, Dinesh Kumar, Kate Pinner, Margaret Moline

2:06 p.m. S45.007 Zoster vasculopathy surveillance using intracranial vessel wall imaging–Ivan D. Carabenciov, Stephen W. English, Vance Lehman, George W. Petty, Eugene L. Scharf

2:17 p.m. S46.008 A Long-Term Study of the Safety and Maintenance of Efficacy of Solriamfetol (JZP-110) for Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea–Nancy R. Foldvary-Schaefer, Colin Shapiro, Richard Schwab, Jean-Louis Pepin, Jan Hedner, Mansoor Ahmed, Patrick Strollo, Geert K. Mayer, Kathleen Sarmiento, Michelle Baladi, Patricia Chandler, Lawrence Lee, Atul Malhotra

2:28 p.m. S45.009 Clinical and pathological characteristics of adults with central nervous system nocardiosis–Matthew Mikhail, Sara LaHue, Yi Li, Soonme Cha, Megan Richie 2:40 p.m. Q&A Panel with Authors

116 2019 AAN Annual Meeting

S46

1:55 p.m. S45.006 Influenza-Related Neurologic Complications in Hospitalized Children–Sarah Frankl, Susan Coffin, Sanjeev Swami, Jennifer McGuire

2:17 p.m. S45.008 Long-term Outcome in Neurozika: When Biological Diagnosis Matters–Annie Lannuzel, Jean-Louis Ferge, Quentin Lobjois, Aissatou Signate, Benoit Roze, Benoit Tressières, Yoann Madec, Pascale Poullain, Cecile Herrmann, Fatiha Najioullah, Eavan Mary McGovern, Anne-Charlotte Savigan, Ruddy Valentino, Sébastien Breurec, Raymond Cesaire, Etienne Hirsch, PierreMarie Lledo, Guillaume Thiery, André Cabie, Francoise Lazarini, Emmanuel Roze

Thursday

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS

2:28 p.m. S46.009 Long-Term Evaluation of Safety and Efficacy of Pitolisant in Narcolepsy: HARMONY 3 Study–Yves Dauvilliers, Isabelle Arnulf, Zoltan Szakács, Catherine Scart-Grès, Isabelle Lecomte, Christian Causse, JeanCharles Schwartz 2:40 p.m. Q&A Panel with Authors

S47

Stroke Outcomes and Recurrence

1:00 p.m.–3:00 p.m. CME

1:00 p.m. S47.001 A Novel, Biomarker-Based Prognostic Score in Acute Ischemic Stroke: the CoRisk Score–Gian Marco De Marchis, Theresa Dankwoski, Inke König, Joachim Fladt, Felix Fluri, Henrik Gensicke, Christian Foerch, Oliver Findling, Rebekka Kurmann, Urs Fischer, Andreas R. Luft, Daniela Buhl, Stefan T. Engelter, Philippe A. Lyrer, Mirjam Christ-Crain, Marcel Arnold, Mira Katan 1:11 p.m. S47.002 Estimates and Temporal Trend for Nationwide 30-day Hospital Readmission Among Patients with Ischemic and Hemorrhagic Stroke: A Contemporary Population Based Analysis of 6-Year Nationwide Data–Farhaan S. Vahidy, Arvind Bambhoroliya, John Donnelly, Eric Thomas, Jon Tyson, Charles Miller, Louise D. McCullough, Sean I. Savitz 1:22 p.m. S47.003 Association of Late Functional Improvement With 5-Year Post-stroke Outcomes: A Population-based Cohort Study–Aravind Ganesh, Ramon LuengoFernandez, Peter Rothwell 1:33 p.m. S47.004 Outcomes Of Acute Ischemic Stroke In Patients With Alcohol Abuse: 10 Year National Estimate–Weizhe Li, Chirag Narshibhai Savani, Varun Kumar, Xiyan Yi, Tejinder Singh, Sukriye Damla Kara, William Scott Burgin, Swetha Renati 1:44 p.m. S47.005 Risk of First Time Seizure After Stroke: A Large-Scale Controlled Cohort Study–Vivek Mehta, Shaun O. Smart, Arvind Bambhroliya, Sean I. Savitz, Louise D. McCullough, Farhaan S. Vahidy, Sunil Sheth 1:55 p.m. S47.006 Impact of History of Treated Depression on Stroke Outcomes–Elizabeth A. Baraban, Lindsay Lucas 2:06 p.m. S47.007 Slow Blood-Brain Barrier Leakage Is Associated with Acute Brain Ischemia and Portends Increased Risk for Delayed Stroke–Yonatan Serlin, Jonathan Ofer, Gal Ben-Arie, Ronel Veksler, Gal Ifergane, Ilan Shelef, Jeffrey Minuk, Anat Horev, Alon Friedman

2:28 p.m. S47.009 Baseline Perfusion Imaging Collateral Scores Predict Infarct Growth in DEFUSE 3–Adam MacLellan, Michael Mlynash, Jeremy Heit, Michael Marks, Maarten G. Lansberg, Gregory W. Albers 2:40 p.m. Q&A Panel with Authors

Epilepsy/Clinical Neurophysiology (EEG) III

1:00 p.m. S48.001 Interictal Electrographic Features Differentiate MTL Responders And Nonresponders–Sharanya Desai, Thomas K. Tcheng, Martha Morrell 1:11 p.m. S48.002 The Risk Optimizing the Antiseizure Medication Regimen for Pregnancy Planning–Paula Emanuela Voinescu, Alexa Ehlert, Barbara A. Dworetzky, Page B. Pennell 1:22 p.m. S48.003 Automatic Seizure Detection Using Multi-Resolution Dynamic Mode Decomposition–Muhammad Fawad Bilal, Muhammad Rizwan Khan, Muhammad Ehtisham 1:33 p.m. S48.004 Individual Prediction of Postoperative Verbal Memory in Temporal Lobe Epilepsy: the Contribution of Postictal Memory Testing–Lukas Sveikata, Nicole Kavan, Alan Pegna, Margitta Seeck, Shahan Momjian, Karl Schaller, Serge Vulliemoz 1:44 p.m. S48.005 Mapping EEG to Structural Brain MRI for Epilepsy Localization after Surgical Deformation–Benjamin Speidel, Edward F. Chang, Robert C. Knowlton 1:55 p.m. S48.006 Sociodemographic Characteristics and Mortality Associated with Incident Epilepsy Among Medicare Beneficiaries–Emily Acton, Leah Blank, Kathryn A. Davis, Allison Wright Willis 2:06 p.m. S48.007 Widespread Pattern of White Matter Dysfunction Associates with Pharmacoresistant Seizures in Temporal Lobe Epilepsy–Leticia Franceschet Ribeiro, Jose Carlos Moreira, Marina Koutsodontis Alvim, Marilise Katsurayama, Lucas Silva, Fernando Cendes, Clarissa L. Yasuda 2:17 p.m. S48.008 Incidence and predictors of in hospital mortality associated with status epilepticus: an estimate using the Nationwide Inpatient Sample (NIS) database (2011-2014)–Sheyar Amin, Chirag Narshibhai Savani, Colby Allen Richardson, Varun Kumar, Stephanie Elizabeth MacIver, Alfred T. Frontera, Selim R. Benbadis 2:28 p.m. S48.009 Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials–Maria Bronislawa MazurkiewiczBeldzin, Michael D. Privitera, Eric D. Marsh, Vicente Villanueva, Kevan VanLandingham, Daniel Checketts, Volker A. Knappertz 2:40 p.m. Q&A Panel with Authors

S49

MS Epidemiology and Risk Stratification

CME CME

1:00 p.m. S49.001 Multiple sclerosis genetic risk burden confers earlier onset.–Farren Briggs, Mary Davis 1:11 p.m. S49.002 The Relationship between Obstructive Sleep Apnea and Age, Gender, EDSS, Disease Duration, and BMI in People with Multiple Sclerosis Who Report Fatigue: More than Size Matters–Arianna Cascone, Annina Giannuzzi, Jared Srinivasan, Lori Fafard, Barbara Bumstead, Myassar Zarif, Marijean Buhse, Mark Gudesblatt 1:22 p.m. S49.003 Amyloid PET in multiple sclerosis predicts cognitive decline at 18 months–Jordi A. Matias-Guiu, Vanesa Pytel, Maria Nieves Cabrera-Martín, Ana CortesMartinez, Teresa Moreno-Ramos, Jose Luis Carreras, Jorge Matias Guiu Guia 1:33 p.m. S49.004 Structural and Functional Damage of the Sensorimotor Network Contribute to Predict Disability Progression and Phenotype Evolution in Patients with Multiple Sclerosis: A 6.5-Year FollowUp Study–Massimo Filippi, Alessandro Meani, Chiara Cervellin, Paola Valsasina, Claudio Cordani, Elisabetta Pagani, Paolo Preziosa, Maria Assunta Rocca 1:44 p.m. S49.005 Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and Sweden–Kerstin Hellwig, Yvonne Geissbuhler, Meritxell Sabidó Espin, Catrinel Popescu, Alessandra Adamo, Joachim Klinger, Peter Huppke, Asher Ornoy, Pasi Korhonen, Kjell-Morten Myhr, Scott Montgomery, Sarah Burkill, Mayra Mori 1:55 p.m. S49.006 Executive Control of Attention Predicts Risk for Future Depression in Early Multiple Sclerosis–Lisa Glukhovsky, Michelle Fabian, Ilana B. Katz Sand, Sylvia Klineova, Stephen Krieger, Fred D. Lublin, Aaron E. Miller, Claire Riley, James F. Sumowski 2:06 p.m. S49.007 Early Life Nutrition and Risk of Pediatric Multiple Sclerosis–Claudia Gambrah Sampaney, Brenda Banwell, Julia O’Mahony, Elena H. Martinez-Lapiscina 2:17 p.m. S49.008 Distribution and predictors of disease severity in pediatric multiple sclerosisInvestigate the distribution of disease severity in pediatric-onset multiple sclerosis (MS).–Jonathan Santoro, Michael Waltz, Theron Charles Casper, Tanuja Chitnis, Gregory S. Aaen, Anita L. Belman, Leslie A. Benson, Meghan Candee, Mark Gorman, Manu S. Goyal, Jennifer Graves, Benjamin M. Greenberg, Yolanda C. Harris, Ilana L. Kahn, Lauren B. Krupp, Timothy E. Lotze, Soe Soe Mar, Manikum Moodley, Jayne Ness, Mary R. Rensel, Moses Rodriguez, John W. Rose, Jennifer Rubin, Teri Schreiner, Jan-Mendelt Tillema, Amy T. Waldman, Emmanuelle Waubant, Bianca WeinstockGuttman 2:28 p.m. S49.009 Assessment of Baseline Imaging Features as Predictors of Poor Disease Course in Pediatric Onset Multiple Sclerosis–Robert Allan Brown, Giulia Fadda, Giulia Longoni, Denise Castro, Julia O’Mahony, Amit Bar-Or, Ruth-Ann Marrie, E. Ann Yeh, Douglas L. Arnold, Brenda Banwell 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

AAN.com/view/AM19Sci 117

Thursday

2:17 p.m. S47.008 Factors Associated with Discrepancy Between Post-treatment Infarct Volume and 90-day Functional Outcome in the ESCAPE Randomized Controlled Trial–Aravind Ganesh, Bijoy Menon, Zarina Assis, Andrew M. Demchuk, Fahad Saad Al-Ajlan, Mohammed Almekhlafi, Jeremy Rempel, Blaise Baxter, John Thornton, Nima Kashani, Michael D. Hill, Mayank Goyal, M Goyal

S48

1:00 p.m.–3:00 p.m. CME

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 3:30 p.m.–5:15 p.m. S50

Practice, Policy, and Ethics

3:30 p.m.–5:30 p.m. CME

1.75

3:30 p.m. S50.001 Characteristics and Predictors of 7-Day and 30-Day Hospital Readmissions to Pediatric Neurology–Annie Hong, Yash Shah, Kanwaljit Singh, Shefali Karkare, Sanjeev V. Kothare 3:41 p.m. S50.002 A novel practice model incorporating extended rooming and scribing assistance in an academic neurology practice–Enrique Alvarez, Peter Smith, Kathy A. Deanda, Herbert Sudfeld, Laura Palmer, Jennifer Simpson, Drew S. Kern 3:52 p.m. S50.003 Neuroscience Patient Readmissions: Are Medical Prediction Models Accurate for Neurology and Neuro Intensive Care Unit Patients?–Sarah Peacock, Ami Grek, Emily Harmer, William David Freeman, Launia White, Tonja Hartjes, James Naessens 4:03 p.m. S50.004 Perspectives of Participants in a Multisite Canadian CCSVI Clinical Trial–Cody Lo, Shelly Benjaminy, J M. Girard, Reza Vosoghi, Anthony Traboulsee, Judy Illes 4:14 p.m. S50.005 Digital Decision Support Tool and Education to Optimize Primary Care Referral Process and Increase Access to Outpatient Headache Neurologists–Sana Ghafoor, Jonathan Slotkin, Mary Connell, Neil R. Holland 4:25 p.m. S50.006 The Gender Gap in Neurology from the American Academy of Neurology Work Force Task Force Report: Implications by 2025–Tasneem Fatema Hasan, Marion Toni Turnbull, Kenneth A. Vatz, Maisha T. Robinson, Elizabeth Ann Mauricio, William David Freeman 4:36 p.m. S50.007 Axon Registry Data Validation: Accuracy Assessment of Data Extraction and Measure Specification– Christine B. Baca, Sarah M. Benish, Aleksandar Videnovic, Karen Lundgren, Brandon Magliocco, Becky Schierman, Laura Palmer, Lyell K. Jones 4:50 p.m. Q&A Panel with Authors

Thursday, May 9

S51

Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders

3:30 p.m.–5:30 p.m. CME

3:30 p.m. S51.001 MGTA-456, A First-in-Class Cell Therapy, Enhances Speed and Level of Human Microglia Engraftment in the Brains of Transplanted Mice–Kevin Goncalves, Shuping Li, Melissa Brooks, Sharon Hyzy, Anthony E. Boitano, Michael P. Cooke 3:41 p.m. S51.002 Rett syndrome gene therapy improves survival and ameliorates behavioral phenotypes in MeCP2 null–Samantha Powers, Carlos Miranda, Cassandra Dennys-Rivers, Amy Huffenberger, Lyndsey Braun, Federica Rinaldi, Nicolas Wein, Kathrin Meyer, Stephanie Solano, Katherine Nguyen, Elle Lang, Allan A. Kaspar, Kevin D. Foust, Gretchen Thomsen, Martin Fugere, Brian Kaspar 3:52 p.m. S51.003 Reversal of Paralysis and Prevention of Premature Death in a Mouse Germline Model of Leigh Syndrome Caused by a Mutation in Mitochondrial ATP Synathse–John R. Guy, Huijuan Yuan 4:03 p.m. S51.004 Preservation of Function over time as Measured by North Star Ambulatory Assessment in Ambulatory Boys with Nonsense Mutation Muscular Dystrophy Treated with Ataluren–Craig McDonald, Lee-Jen Wei, G. L. Elfring, Traci Schilling, Panayiota Trifillis, Joseph McIntosh, Marcio Nattan Portes Souza, Stuart Peltz, Francesco Muntoni 4:14 p.m. S51.005 Eteplirsen-Treatment Attenuates Respiratory Decline in Ambulatory and Non-ambulatory Patients With Duchenne Muscular Dystrophy: Comparison With Natural History Cohorts–Navid Khan, Lixin Han, Bernard Kinane, Heather Gordish-Dressman, Linda Pax Lowes, Craig McDonald 4:25 p.m. S51.006 Edasalonexent, an NF-kB Inhibitor, Slows LongerTerm Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy–Richard S. Finkel, Krista H. Elvire Vandenborne, H. Lee Sweeney, Erika L. Finanger, Gihan Tennekoon, Perry Shieh, Rebecca J. Willcocks, Glenn Walter, William Rooney, Sean Forbes, William Triplett, Sabrina Yum, Maria Mancini, James MacDougall, Angelika Fretzen, Pradeep Bista, Andrew Nichols, Joanne Donovan

Thursday

4:36 p.m. S51.007 A Novel Mouse Model with Tubb4a (D249N/D249N) for classical Hypomyelination and atrophy of basal ganglia and cerebellum–Sunetra Sase, Akshata Almad, Asako Takanohashi, Akshilkumar Patel, Joel Li, Steven Scherer, Adeline Vanderver 4:47 p.m. S51.008 Cellular models of Hypomyelination and Atrophy of Basal Ganglia and Cerebellum using rodent and human induced pluripotent stem cells–Akshata Almad, Alex Boecker, Sunetra Sase, Heta Patel, Divya Sirdespande, Asako Takanohashi, Erika L.F. Holzbaur, Adeline Vanderver 4:58 p.m. S51.009 15q11.2 Deletion Results in Altered Excitability and Connectivity in Human Induced Pluripotent Stem Cell Derived Neurons–Christa Habela, Arens Taga, Raha Dastgheyb, Ki-jun Yoon, Norman Haughey, Carl E. Stafstrom, Bergles Dwight, Hongjun Song, Nicholas J. Maragakis

118 2019 AAN Annual Meeting

5:10 p.m. Q&A Panel with Authors

S52

Acute Non-Interventional Stroke Care

CME

3:30 p.m. S52.001 Development and validation of a risk score to estimate outcomes after feeding tube placement in acute stroke–Raed Joundi, Gustavo Saposnik, Rosemary Martino, Jimming Fang, Moira Kapral 3:41 p.m. S52.002 Blood Pressure Management Outside Individualized Limits of Autoregulation is Associated with Neurologic Deterioration and Worse Functional Outcomes in Patients with Large-Vessel Occlusion (LVO) Ischemic Stroke–Andrew Silverman, Anson Wang, Sumita Strander, Sreeja Kodali, Lauren Hachmann Sansing, Joseph Schindler, Emily Jean Gilmore, Kevin N. Sheth, Nils Petersen 3:52 p.m. S52.003 Low Volume non-PSC Hospitals Are More Likely to Transfer Whites but Not Blacks for a Higher Level of Stroke Care–Michael J. Lyerly, Karen C. Albright, Farhaan S. Vahidy, George Howard, John Donnelly 4:03 p.m. S52.004 A Travel Time and Efficiency Simulation for Patient Transport to Primary and Comprehensive Stroke Centers–Haitham Hussein, Morgan M. Brown, Amanda Herrmann 4:14 p.m. S52.005 Central Retinal Artery Occlusion Patient Characteristics And Inpatient Management: Nationally Representative Data–Emily Schorr, Kyle Rossi, Laura Stein, Mandip Singh Dhamoon 4:25 p.m. S52.006 Readmissions After Central Retinal Artery Occlusion versus Acute Ischemic Stroke: Nationally Representative Data–Emily Schorr, Kyle Rossi, Laura Stein, Mandip Singh Dhamoon 4:36 p.m. S52.007 Maternal morbidity outcomes in idiopathic moyamoya syndrome in New York State–Hajere Gatollari, Amelia Katharine Boehme, E. Sander Connolly, Alexander Friedman, Mitchell S. V. Elkind, Joshua Z. Willey, Eliza Cushman Miller 4:47 p.m. S52.008 Cerebrospinal Fluid Contributes to Edema Formation after Cerebral Ischemia–Humberto Mestre, Ting Du, Andrew Samson, Benjamin Kress, Amanda Sweeney, Martin Kaag Rasmussen, Kristian Nygaard Mortensen, Yuki Mori, Maiken Nedergaard 4:58 p.m. S52.009 Early Cerebral ischemic events in Symptomatic Carotid Stenosis are related to Plaque Inflammation– Surya Sharma, Prakash Rameshchandra Paliwal, Hock Luen Teoh, Bernard PL Chan, Arvind Sinha, Vijay K. Sharma 5:10 p.m. Q&A Panel with Authors

S53

Movement Disorders: Genetics and Clinical Features

3:30 p.m.–5:30 p.m. CME

3:30 p.m. S53.001 Genome-wide Association Studies of Tourette Syndrome (TS) Confirm a Shared Spectrum of Polygenic Risk across TS and Other Tic Disorders– Jeremiah M. Scharf, Dongmei Yu, Jae Hoon Sul, Fotis Tsetsos, Muhammad Nawaz, Hreinn Stefansson, Lea Davis, Peristera Paschou, Giovanni Coppola, Carol Mathews 3:41 p.m. S53.002 RDP is associated with bulbar and limb weakness: broadening the phenotype of ATP1A3+ Rapid-Onset Dystonia-Parkinsonism (RDP).–Ihtsham Haq, Beverly M. Snively, Kathleen J. Sweadner, Cynthia Suerken, Jared Cook, Laurie J. Ozelius, Charlotte Miller, Christopher T. Whitlow, Allison Brashear 3:52 p.m. S53.003 Association between glucocerebrosidase mutations and Parkinson’s disease in Ireland–Diana Angelika Olszewska, Allan McCarthy, Alexandra Soto, Ronald Walton, Russel McLaughlin, Brian Magennis, Orla Hardiman, Owen A. Ross, Timothy Lynch 4:03 p.m. S53.004 Glucocerebrosidase Deficiency Mediates Propagation of Protein Aggregation in a Drosophila Model of Neurodegeneration via Modification of Extracellular Vesicles–Kathryn Jewett, Ruth Thomas, Evelyn Vincow, Selina Yu, Leo Pallanck, Marie Ynez Davis 4:14 p.m. S53.005 Genome-Wide Association Study Meta-Analysis For Parkinson Disease Motor Subtypes–Isabel Alfradique-Dunham, Cornelis Blauwendraat, Rami AlOuran, Rainer von Coelln, Manuela Tan, Emily J. Hill, Lan Luo, Emily Young, Amanda Stillwell, Zhandong Liu, Kathrin Brockmann, Claudia Schulte, Thomas Gasser, Lasse Pihlstrom, Johan Marinus, J.J. Van Hilten, Peter Heutink, Lisa M. Shulman, Joseph Jankovic, Michael Nalls, Andrew Singleton, Huw R. Morris, Joshua M. Shulman 4:25 p.m. S53.006 Functional MAOB Gene Intron 13 Polymorphism Predicts Levodopa-induced Dyskinesia in Parkinson’s Disease–Matthias Lohle, Graziella Mangone, Wiebke Hermann, Denise Hausbrand, Martin Wolz, Julia Mende, Heinz Reichmann, Andreas Hermann, Jean Christophe Corvol, Alexander Storch

4:47 p.m. S53.008 Impaired Action Control in Patients with Functional Movement Disorders–Diksha Mohanty, Nelleke Van Wouwe, Scott Wiley, Alexandra Elaine Jacob, Kathrin LaFaver 4:58 p.m. S53.009 Phenotype and Neuropathology of FMR1 Gray Zone Carriers in Community-Dwelling Older Subjects– Deborah Hall, Sukriti Nag, Elizabeth M. Berry-Kravis, Aisha Ali, Bichum Ouyang, Yuanping Liu, Aron S. Buchman, Lili Zhou, David A. Bennett

Motor Neuron Disease

3:30 p.m. S54.001 Heritability of ALS: A Population-based study over 24 years.–Marie Ryan, Mark Heverin, Niall Pender, Russel McLaughlin, Orla Hardiman 3:41 p.m. S54.002 The Clinical and Neuroimaging Features of Primary Lateral Sclerosis–Eoin Finegan, Rangariroyashe Chipika, Stacey Li Hi Shing, Mark A Doherty, Russel McLaughlin, Colette G. Donaghy, Orla Hardiman, Peter Bede 3:52 p.m. S54.003 Clinical findings in amyotrophic lateral sclerosis type 4–Christopher Grunseich, Isabel Wang, Aneesh Patankar, Alice Schindler, Kenneth H. Fischbeck, Vivian Cheung 4:03 p.m. S54.004 Pathological and Behavioral Characterization of Transgenic Mice Expressing ALS-Associated CHCHD10-R15L–Eanna Barra Ryan, Jianhua Yan, HanXiang Deng, Teepu Siddique 4:14 p.m. S54.005 Distinct patterns of cerebellar damage in sporadic and C9ORF72-related ALS–Fabricio Castro Borba, Paula Rebello, Thiago Rezende, Lucas De Melo Teixeira Branco, Antonio Dos Santos, Wilson M. Junior, Marcondes C. Franca 4:25 p.m. S54.006 A Novel Muscle Cramp Scale for Patients with ALS–Hiroshi Mitsumoto, Madison Gilmore, Codruta Chiuzan, Camila Ibagon, Yuan Zhang, Brittany McHale, Marie-France Likanje, Jonathan Hupf 4:36 p.m. S54.007 Correlation of cognitive impairment and KING’s and MiTos staging in ALS: a cross-sectional populationbased study.–Rosario Vasta, Debora Pain, Laura Peotta, Andrea Calvo, Cristina Moglia, Antonio Canosa, Umberto Manera, Jean Pierre Zucchetti, Gabriele Mora, Enrica Bersano, Maria Francesca Sarnelli, Valentina Solara, Letizia Mazzini, Barbara Iazzolino, Adriano Chio 4:47 p.m. S54.008 Differentially Expressed microRNA Profile in Skeletal Muscle Tissue of Sporadic ALS Patients–Can Ebru Kurt, Evrim Aksu-Menges, Burcu Balci-Hayta, Ayse Tulay Aydinoglu, Sevim Erdem-Ozdamar, Ersin Tan 4:58 p.m. S54.009 Retrospective review of respiratory function in the Amyotrophic Lateral Sclerosis(ALS) veteran population with and without Edaravone therapy.– Manisha Thakore-James, Mohammad Salajegheh, Nikita James 5:10 p.m. Q&A Panel with Authors

S55

MS Basic Science

CME

3:30 p.m. S55.001 Vascular Disease Risk Factors (VDRF) in MS is Associated with Brain ATP Abnormalities: Dysmetabolism May Drive MS Disease Progression.– Vijayshree Yadav, Allison Fryman, Michael A. Lane, Frank Bittner, Manoj K. Sammi, William Rooney 3:41 p.m. S55.002 Bile Acid Metabolism is Altered in Multiple Sclerosis and Supplementation Leads to Amelioration of Neuroinflammation–Pavan Bhargava, Leah Mische, Matthew Smith, Bardia Nourbakhsh, Arthur Reyes, Kyle Martin, Emmanuelle Waubant, Ellen M. Mowry, Peter A. Calabresi 3:52 p.m. S55.003 Metabolic interference protects against a mouse model of multiple sclerosis.–Stefan Jordan, Miriam Merad, Sam H. Horng 4:03 p.m. S55.004 mTORc1 but not JNK Inhibition Augments Glucocorticosteroid Efficacy in Multiple Sclerosis– Robert Hoepner, Maud Bagnoud, Maximilian Pistor, Anke Salmen, Myriam Briner, Lisa Schrewe, Kirsten Guse, Farhad Ahmadi, Seray Demir, Louise Laverick, Melissa Gresle, Paul F. Worley, Holger Reichardt, Helmut Butzkueven, Ralf Gold, Fred Luhder, Andrew Chan 4:14 p.m. S55.005 Circular RNA of Blood Leukocytes Contribute To Proinflammatory Changes in Relapsing-Remitting Multiple Sclerosis–Marcin P. Mycko, Anna Zurawska, Krzysztof Selmaj 4:25 p.m. S55.006 Assessing the Balance Between Effector and Regulatory T cell Subsets in Pediatric Multiple Sclerosis–Ina Mexhitaj, Mukanthu Nyirenda, Rui Li, Julia O’Mahony, Ayman Rezk, Ayal Rosenberg, Craig S. Moore, Trina Johnson, Dessa Sadovnick, Louis Collins, Douglas L. Arnold, Bruno Gran, E. Ann Yeh, Ruth-Ann Marrie, Brenda Banwell, Amit Bar-Or 4:36 p.m. S55.007 Abnormal Frequency and Function of MR1-defined MAIT cells in Pediatric Multiple Sclerosis–Ina Mexhitaj, Mukanthu Nyirenda, Rui Li, Julia O’Mahony, Ayman Rezk, Ayal Rosenberg, Craig S. Moore, Trina Johnson, Dessa Sadovnick, Louis Collins, Douglas L. Arnold, Bruno Gran, E. Ann Yeh, Ruth-Ann Marrie, Brenda Banwell, Amit Bar-Or 4:47 p.m. S55.008 Human induced pluripotent Stem Cell-derived Astrocytes are differentially activated by Multiple Sclerosis-associated Cytokines–Sylvain Perriot, Amandine Mathias, Guillaume Perriard, Mathieu Canales, Nils Jonkmans, Nicolas Mérienne, Cécile Meunier, Lina El Kassar, Anselme Perrier, David Laplaud, Myriam Schluep, Nicole Déglon, Renaud A. Du Pasquier 4:58 p.m. S55.009 Oligodendrogenesis following cortical demyelination generates a novel myelination pattern–Jennifer Lauren Orthmann Murphy, Cody Call, Ethan Hughes, Peter A. Calabresi, Dwight Bergles 5:10 p.m. Q&A Panel with Authors

5:10 p.m. Q&A Panel with Authors

= Abstract of Distinction

AAN.com/view/AM19Sci 119

Thursday

4:36 p.m. S53.007 Factors contributing to the sustainment of exercise in patients with Parkinson’s Disease. The Parkinson’s Foundation Quality Improvement Initiative (PF-QII) dataset–Margaret Yu, Danielle Larson, Angela Roberts, Tanya Simuni, Alan Sadural, Bridget Fowler, Hanzi Gao, Sam Wu, Miriam R. Rafferty

S54

3:30 p.m.–5:30 p.m. CME

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.–5:30 p.m.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC SESSIONS 1:00 p.m.–3:00 p.m.

1:00 p.m.–3:00 p.m. S56

MS Trials and Treatment

1:00 p.m. S56.001 A Phase 1, Multiple-dose Study of Elezanumab (ABT555) in Patients with Relapsing Forms of Multiple Sclerosis–Adam Ziemann, Matthew Rosebraugh, Bruce Barger, Bruce A. C. Cree 1:11 p.m. S56.002 Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension–Irati Zubizarreta, Georgina Florez-Grau, Gemma Vila, Raquel Cabezon, Carolina Espana, Magi Andorrá, Albert Saiz, Sara Llufriu, Maria Sepulveda, Nuria Sola, Elena H. Martinez-Lapiscina, Irene Pulido Valdeolivas, Bonaventura Casanova, Maria Luisa Martinez Ginés, Nieves Tellez, Celia Oreja-Guevara, Marta Español, Joan Cid, Manuel Juan, Miguel Lozano, Yolanda Blanco Morgado, Lawrence Steinman, Daniel Benitez, Pablo Villoslada 1:22 p.m. S56.003 A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis–Scott Douglas Newsome, Thomas Jack Shoemaker, Pavan Bhargava, Sarah Snoops, David Cooper, Jennifer Mammen, Ellen M. Mowry, Peter A. Calabresi 1:33 p.m. S56.004 Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study–Xavier Montalban, Douglas L. Arnold, Martin Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Emily Martin, Fernando Dangond, Jerry S. Wolinsky 1:44 p.m. S56.005 Short-term brain damage accrual in African Americans with Multiple Sclerosis: MRI Findings from the CombiRx trial–Maria Petracca, Sirio Cocozza, Leorah Aude Emmanuelle Freeman, MohamedMounir El Mendili, Amgad Droby, Gary Raymond Cutter, Jerry S. Wolinsky, Fred D. Lublin, Matilde Inglese 1:55 p.m. S56.006 Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials–Sarah Harris, Giancarlo Comi, Bruce A. C. Cree, Lawrence Steinman, James K. Sheffield, Diego Silva, Harry Southworth, Ludwig Kappos

Friday

Friday, May 10

2:06 p.m. S56.007 One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments–Thomas Leist, Anthony Reder, Robert A. Bermel, Bianca WeinstockGuttman, Mark S. Freedman, Gary Raymond Cutter, James M. Stankiewicz, Xiaoye Ma, Bruno C. Musch, Csilla Csoboth, Jerry S. Wolinsky

120 2019 AAN Annual Meeting

CME

2:17 p.m. S56.008 Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study–Anne H. Cross, Jeffrey L. Bennett, H. Christian Von Budingen, Robert L. Carruthers, Keith R. Edwards, Robert J. Fallis, Damian Fiore, Jeffrey Marc Gelfand, Paul Giacomini, Benjamin M. Greenberg, David A. Hafler, Christopher Harp, Beverly Assman, Ann Herman, Carolina Ionete, Ulrike Kaunzner, Christopher Lock, Xiaoye Ma, Bruno C. Musch, Gabriel Pardo, Fredrik L. Piehl, Martin Weber, Tjalf Ziemssen, Amit Bar-Or 2:28 p.m. S56.009 Efficacy and Safety of Fingolimod 0.5 mg and 0.25 mg Versus Glatiramer Acetate 20 mg in Patients with Relapsing-Remitting Multiple Sclerosis - ASSESS Study Group–Bruce A. C. Cree, Myla D. Goldman, John Corboy, Barry A. Singer, Edward J. Fox, Douglas L. Arnold, Corey C. Ford, Bianca Weinstock-Guttman, Amit Bar-Or, Susanne Mientus, Daniel Sienkiewicz, Ying Zhang, Rajesh Karan, Nadia Tenenbaum 2:40 p.m. Q&A Panel with Authors

S57

Acute Treatment and Imaging of Ischemic Stroke

CME

1:00 p.m. S57.001 DAWN versus modified Clinical-ASPECTS Mismatch Selection for Stroke Endovascular Therapy in Late Presenting Strokes–Mehdi Bouslama, Diogo Casarin Haussen, Jonathan Grossberg, Gabriel M. Rodrigues, Clara Barreira, Michael R. Frankel, Raul G. Nogueira 1:11 p.m. S57.002 Poor Collaterals and Malignant CT Perfusion Profiles Are Associated with Increased Vulnerability to Blood Pressure Reductions during Endovascular Therapy–Sumita Strander, Seyedmehdi Payabvash, Anson Wang, Sreeja Kodali, Andrew Silverman, Tijil Agarwal, Christoph Stretz, Binbin Zheng-Lin, Gloria Lopez Cardenas, Lauren Hachmann Sansing, Joseph Schindler, Charles Matouk, Ryan Hebert, Kevin N. Sheth, Santiago Ortega Gutierrez, Nils Petersen 1:22 p.m. S57.003 Timing invariant CTA derived from CTP preserves high diagnostic yield for MCA-M2 occlusions–Kaustubh S. Limaye, Girish Bathla, Adam Bryant, Bruno Policeni, Sami Alkasab, Sudeepta Dandapat, Waldo Guerrero, Minako Hayakawa, Edgar A. Samaniego, David Hasan, Enrique C. Leira, Colin Derdeyn, Santiago Ortega-Gutierrez 1:33 p.m. S57.004 Clinical Outcomes After Pre-hospital Thrombolysis on a Mobile Stroke Unit–Andrew Russman, Daisuke Shimbo, Lila Emily Sheikhi, Kerri Maselli, Nicholas Thompson, Andrew Reimer, Muhammad Shazam Hussain, Ken Uchino 1:44 p.m. S57.005 In-Hospital Stroke Treated with IV-tPA within a Tertiary Hospital with Neurology Residents versus Hospitals without Neurology Residents–Manya Khrlobyan, Jiaxiao Shi, Zahra A. Ajani, Duy Le, Howard Rho, An Ly, Denise Gaffney, Navdeep Sangha 1:55 p.m. S57.006 Targets for Thrombolysis in Stroke Patients who Present in an Extended Time Window–Parisa Heidari, Sarah Spreadborough, Jarrhett Butler, Richard Leigh 2:06 p.m. S57.007 Mechanical Thrombectomy for Large-VesselOcclusion Strokes in Patients With Infective Endocarditis: A Therapeutic Limbo?–Karan Kaushik Topiwala, Smit D. Patel, Martin D. Ollenschleger 2:17 p.m. S57.008 Potential eligibility for hyperacute treatment in childhood acute arterial ischemic stroke: findings from a single-center 12-year cohort study.–Melissa Hutchinson, Alexandra Kimmel, Caroline Granath, Lauren AA Beslow, Lori L. Billinghurst, Daniel J. Licht, Evelyn Kim Shih, Rebecca N. Ichord 2:28 p.m. S57.009 Comparative Outcome Analysis of Endovascular Acute Ischemic Stroke Treatment in Patients With and Without Pre-stroke Disability–Sanjana Salwi, Akshitkumar Mistry, Kiersten Espaillat, Matthew Fusco, Michael Froehler, Rohan Chitale, Eva Mistry 2:40 p.m. Q&A Panel with Authors

S58

Therapeutics in Neuromuscular Disorders

1:00 p.m.–3:00 p.m. CME

1:00 p.m. S58.001 Intravenous Immunoglobulin for Treatment of Demyelinating Polyneuropathy in Patients with Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial–Ari Breiner, Carolina Barnett Tapia, Leif Erik Lovblom, Bruce A. Perkins, Hans D. Katzberg, Vera Bril 1:11 p.m. S58.002 Prevalence and Associations of Peripheral Neuropathy at Disease Onset in ANCA-Associated Vasculitides: Insights from the DCVAS Study–Antje Bischof, Veronika Jaeger, Robert D. Hadden, Raashid Luqmani, Peter Merkel, Ravi Suppiah, Anthea Craven, Michael P. Collins, Thomas Daikeler 1:22 p.m. S58.003 Immune-mediated rippling muscle disease, associated neoplasia and response to therapy.– James Douglas Triplett, Teerin Liewluck, William J. Litchy, Margherita Milone 1:33 p.m. S58.004 Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X–Kleopas A. Kleopa, Christos Karaiskos, Jan Richter, Christina Tryfonos, Alexander Rossor, Mary Reilly, Irene Sargiannidou, Christina Christodoulou, Alexia Kagiava 1:44 p.m. S58.005 RNAi/gene therapy combined approach as therapeutic strategy for Charcot-Marie-Tooth 2A–Federica Rizzo, Silvia Bono, Sabrina Salani, Andreina Bordoni, Valentina Melzi, Marc Ruepp, Serena Pagliarani, Kordelia Barbullushi, Elena Abati, Chiara Cordiglieri, Nereo Bresolin, Giacomo Comi, Monica Nizzardo, Stefania Corti 1:55 p.m. S58.006 Results of the Dose-Escalation Portion of a Phase 2 Study of ACE-083, a Local Muscle Therapeutic, in Patients with Charcot-Marie-Tooth (CMT) Disease–Florian P. Thomas, Michael E. Shy, David N. Herrmann, Jeffrey Statland, David Walk, Colin Quinn, Nicholas Elwood Johnson, S H. Subramony, Chafic Y. Karam, Tahseen Mozaffar, Chad E Glasser, Barry Miller, Ashley Leneus, Robert Zeldin, Kenneth M. Attie 2:06 p.m. S58.007 Nusinersen Efficacy in Adults with Spinal Muscular Atrophy–John W. Day, Connie Wolford, Chelsea MacPherson, William Martens, Michael McDermott, Basil T. Darras, Darryl C. De Vivo, Zarazuela ZolkipliCunningham, Richard S. Finkel, Michael Zeineh, Jacinda B. Sampson, Katharine Hagerman, Tina Duong

2:28 p.m. S58.009 Kinase Inhibitors Improve Neurofilament Distribution in CMT2E Human Motor Neuron Axons–Mario A. Saporta, Renata Maciel, Anthony Cutrupi, Adriana Rebelo, Stephan Zuchner

S59

Migraine: Impact, Treatment Patterns and Resource Utilization

CME

1:00 p.m. S59.001 Short-term Outcomes in Patients with Migraine and Substance Abuse: A 5-year Review Utilizing the Nationwide Readmission Database 2010-14–Charles W. Brock, Varun Kumar, Chirag Narshibhai Savani, Luiz De Souza, Matthew Chung, James Ray Ghattas, Jose R. Rodriguez, Grace Kim, Tigran Kesayan, Martin Anthony Myers 1:11 p.m. S59.002 Life With Migraine, Effect on Relationships, Career and Finances, and Overall Health and Well-Being: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study–Dawn C. Buse, Sharron Murray, Paula Dumas, Aubrey Manack Adams, Michael L. Reed, Kristina Fanning, Richard B. Lipton 1:22 p.m. S59.003 Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a US Commercially Insured Population–Steven C. Marcus, Anand R. Shewale, Stephen D. Silberstein, Richard B. Lipton, William B. Young, Hema Viswanathan, Jalpa Doshi 1:33 p.m. S59.004 Women with migraine vary in time to peak headache pain intensity, functional impairment and pain interference based on menstrual migraine status: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study–Jelena Pavlovic, Dawn C. Buse, Michael L. Reed, Kristina Fanning, Sagar Munjal, Todd J. Schwedt, David W. Dodick, Richard B. Lipton 1:44 p.m. S59.005 Familial Transmission of Migraine and Mood Disorders- Evidence from a High Risk Study– Tarannum Lateef, lihong cui, Kailyn Witonsky, Kathleen Merikangas 1:55 p.m. S59.006 Demographics, Headache Characteristics, and Other Factors Associated With Opioid Use in People With Migraine: Results From the CaMEO Study–Richard B. Lipton, Todd J. Schwedt, Benjamin Friedman, Kristina Fanning, Michael L. Reed, Aubrey Manack Adams, Dawn C. Buse 2:06 p.m. S59.007 Opioid Use, Rebound Headache, and Resource Utilization Among Migraine Patients With Insufficient Response to Triptans Based on Real-World Data–Stephen D. Silberstein, Anand R. Shewale, Sarah Baradaran, Richard B. Lipton, Sarah Cotton, James Jackson, Hema Viswanathan 2:17 p.m. S59.008 Patterns and Characterization of Acute Prescription Migraine Medication Use: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study–Susan Hutchinson, Richard B. Lipton, Jessica Ailani, Michael L. Reed, Kristina Fanning, Aubrey Manack Adams, Dawn C. Buse

Friday

2:17 p.m. S58.008 The Transplantation of a Specific iPSC-Derived Neural Stem Cells Subpopulation Improves the Pathological Hallmarks of Spinal Muscular Atrophy with Respiratory Distress Type 1 in Mice.–Giulia Forotti, Monica Nizzardo, Michela Taiana, Monica Bucchia, Agnese Ramirez, Nereo Bresolin, Giacomo Comi, Stefania Corti

2:40 p.m. Q&A Panel with Authors

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

2:28 p.m. S59.009 Predictors of 30-Day Readmission and Prolonged Length of Stay After Hospitalization for Status Migrainosus: A Review of 5-Year National Data–James Ray Ghattas, Chirag Narshibhai Savani, Varun Kumar, Jose R. Rodriguez, Luiz De Souza, Tigran Kesayan, Matthew Chung, Grace Kim, Martin Anthony Myers, Charles W. Brock 2:40 p.m. Q&A Panel with Authors

= Abstract of Distinction

AAN.com/view/AM19Sci 121

RUN/WALK FOR BRAIN RESEARCH On your mark, get setâ&#x20AC;¦ help cure BRAIN DISEASE!

Join your colleagues on Tuesday, May 7, 2019, at 6:30 a.m., for a friendly run/walk. Winners will receive prizes and all proceeds will help support brain research. Sign up at AAN.com/view/RunWalk19 Sponsored by*:

*As of January 31, 2019

POSTER SESSIONS series of thematic abstract presentations in poster format presented Sunday through A Thursday with 5:30 p.m.–6:30 p.m. stand-by times for authors. Posters on related topics are grouped together in “neighborhoods” (noted by the numbers in the below map) for easy navigation, and e-posters provide an interactive, touchscreen experience. And, be sure not to miss the Friday Grand Finale, which will feature an innovation lunch when the poster hall will transform to highlight abstracts and talks as they relate to the neuroimaging community. 001 006 007 012 013 018 019 024 025 030 031 036

Sunday, May 5

Monday, May 6 11:30 a.m.–6:30 p.m. P2 Poster Session 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . 142

Tuesday, May 7

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4 Poster Session 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . 178

Thursday, May 9

003 004 009 010 015 016 021 022 027 028 033 034

001 016 017 032 033 048 049 064 065 080 081 096 097 112

002 015 018 031 034 047 050 063 066 079 082 095 098 111

003 014 019 030 035 046 051 062 067 078 083 094 099 110

004 013 020 029 036 045 052 061 068 077 084 093 100 109

005 012 021 028 037 044 053 060 069 076 085 092 101 108

006 011 022 027 038 043 054 059 070 075 086 091 102 107

007 010 023 026 039 042 055 058 071 074 087 090 103 106

008 009 024 025 040 041 056 057 072 073 088 089 104 105

001 002 003 004 005 006 012 011 010 009 008 007

1 2 3

11:30 a.m.–6:30 p.m. P1 Poster Session 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . 124

11:30 a.m.–6:30 p.m. P3 Poster Session 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . 160

002 005 008 011 014 017 020 023 026 029 032 035

001 006 007 012 013 018 019 024 025 030 031 036

002 005 008 011 014 017 020 023 026 029 032 035

003 004 009 010 015 016 021 022 027 028 033 034

013 014 015 016 017 018 024 023 022 021 020 019 025 026 027 028 029 030 036 035 034 033 032 031 037 038 039 040 041 042 048 047 046 045 044 043 049 050 051 052 053 054 060 059 058 057 056 055 061 062 063 064 065 066 072 071 070 069 068 067

4 5 6

001 002 003 004 005 006 012 011 010 009 008 007 013 014 015 016 017 018 024 023 022 021 020 019 025 026 027 028 029 030 036 035 034 033 032 031 037 038 039 040 041 046 045 044 043 042

001 002 003 004 005 006 007 008 016 015 014 013 012 011 010 009 017 018 019 020 021 022 023 024 032 031 030 029 028 027 026 025 033 034 035 036 037 038 039 040 048 047 046 045 044 043 042 041 049 050 051 052 053 054 055 056 064 063 062 061 060 059 058 057 065 066 067 068 069 070 071 072 080 079 078 077 076 075 074 073

11:30 a.m.–6:30 p.m. P5 Poster Session 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

001 010

002 009

003 008

004

007

005 006

ePosters

8 9 10

001 002 003 004 005 006 007 014 013 012 011 010 009 008

001 016 017 032

008 009 024 025

001 002 003 004 008 007 006 005

015 016 017 018 019 020 021 028 027 026 025 024 023 022

033 034 035 036 037 038 039 040 048 047 046 045 044 043 042 041

009 010 011 012 016 015 014 013

029 030 031 032 033 034 035 042 041 040 039 038 037 036

049 050 051 052 053 054 055 056 064 063 062 061 060 059 058 057

017 018 019 022 021 020

043 044 045 046 047 048 049 056 055 054 053 052 051 050

065 080 081 086

002 015 018 031

066 079 082 085

003 014 019 030

004 013 020 029

005 012 021 028

006 011 022 027

007 010 023 026

067 068 069 070 071 072 078 077 076 075 074 073 083 084

023 024 025 028 027 026

AAN.com/view/AM19Sci 123

POSTER SESSIONS

POSTER SESSION 1

AGING AND DEMENTIA: ANIMAL AND CELL MODELS

P1.1-001 Pathological

Changes To the Visual System in Alzheimer’s Disease–Sohi Mistry

P1.1-002 iPSC Model of

CHRFAM7A Effect on a7 Nicotinic Acetylcholine Receptor Function in the Human Context–Ivanna Ihnatovych, Tapan Nayak, Aya Ouf, Norbert Sule, Barbara Birkaya, Trinithas Boyi, Lee Chaves, Anthony Auerbach, Kinga Szigeti

P1.1-003 Neuroprotection

of HP-beta-CD in the adult transgenic mice of Alzheimer disease–Jiaqi Yao, Noel Calingasan, Paisith Piriyawat, M. Flint Beal, Salvador Cruz-Flores

P1.1-004 Inflammasome-

derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer’s prone mice–Amy Cheung, Douglas Golenbock, Kensuke Futai

P1.1-005 Procognitive and

neuroprotective effect of 5-HT7 agonist in an animal model by ICV amyloid-b injection–Alejandro Quintero Villegas, Hector Salvador Alvarez Manzo, Maria Oa Valenzuela Almada, Carlos Bernal Modragon, Rosalinda Guevara Guzman

Sunday

P1.1-006 Structure and

Pro-toxic Mechanism of the Human Hsp90/PPIase/Tau Complex–Javier Oroz, Bliss J. Chang, Piotr Wysoczanski, Chungtien Lee, Angel Perez Lara, Pijush Chakraborty, Romina Hofele, Jeremy Baker, Laura Blair, Jacek Biernat, Henning Urlaub, Eckhard Mandelkow, Chad Dickey, Markus Zweckstetter

P1.1-007 Reciprocal regulation

of filamin A and amyloid precursor protein expression in astrocytes– Victor Ekuta, Timothy Wong, Gewei Lian, Jatin Goyal, Volney L. Sheen

P1.1-008 Impaired Brain Cells Response in Obesity–Zara Latif

P1.1-009 Novel Insights

into Intersectin1 Mechanistic Contributions to Brain Disorders– Jessica O’Neil Wilson

124 2019 AAN Annual Meeting

Sunday, May 5

Poster Session 1 1. Aging, Dementia, Cognitive, and Behavioral Neurology: 1-001 to 1-031 2. Autoimmune Neurology; MS and CNS Inflammatory Disease: 2-001 to 2-107 3. Cerebrovascular Disease and Interventional Neurology: 3-001 to 3-066 4. Neuromuscular Disease and Clinical Neurophysiology (EMG): 4-001 to 4-039 5. Epilepsy/Clinical Neurophysiology (EEG): 5-001 to 5-035 6. Neuro-oncology; Child Neurology and Developmental Neurology: 6-001 to 6-070 7. Autoimmune Neurology/MS and CNS Inflammatory Disease ePosters: 7-001 to 7-010 8. Movement Disorders: 8-001 to 8-053 9. Neuro-ophthalmology/Neuro-otology; General Neurology; Research Methodology, Education, and History; Neuroscience Research Prize Recipients: 9-001 to 9-084 10. Headache: 10-001 to 10-026 AGING AND DEMENTIA: GENETICS AND NEUROPATHOLOGY

P1.1-010 Age of onset in

genetic prion disease and the design of preventive clinical trials–Eric Minikel, Sonia Vallabh, Margaret Orseth, Jean-Philippe Brandel, Stephane Haik, JeanLouis Laplanche, Inga Zerr, Piero Parchi, Sabina Capellari, Jiri G. Safar, Janna Kenny, Jamie Fong, Leonel Takada, Claudia Ponto, Peter Hermann, Tobias Knipper, Christiane Stehmann, Tetsuyuki Kitamoto, Ryusuke Ae, Tsuyoshi Hamaguchi, Nobuo Sanjo, Tadashi Tsukamoto, Hidehiro Mizusawa, Steven J. Collins, Roberto Chiesa, Ignazio Roiter, Jesus de PedroCuesta, Miguel Calero, Michael D. Geschwind, Masahito Yamada, Yoshikazu Nakamura, Simon Mead

P1.1-011 Tau and

neurodegeneration mismatch is a signature of polypathology in AD continuum–David A. Wolk, John Q. Trojanowski, David Irwin, Murray Grossman, Leslie Michael Shaw, Jeffrey Scott Phillips, Edward Lee, Sandhitsu Das, Corey McMillan

P1.1-012 Interactions Between

Brain Structures and Genetic Variants in Neurotransmitter Systems as Potential Biomarkers for Hallucinations and Delusions in Alzheimer’s Disease–Juweiriya Ahmed, Andrew D. Robertson, Sejal Patel, Jo Knight, Derek Beaton, Lena Palaniyappan, Stephen H. Pasternak, Mario Masellis, Elizabeth Finger

11:30 a.m.–6:30 p.m.

1 2 3

1-001-1-031

2-001-2-107

3-001-3-066

4 5 6

4-001-4-039

5-001-5-035

6-001-6-070

7-001-7-010

ePosters

8 9 10

8-001-8-053

9-001-9-081

10-001-10-026

P1.1-016 RS4548513

(CTNNA3): A Genetic Risk Factor for Visual Construction Deficiency in Parkinson’s disease–Damian Murezzan, Antonia Meyer, Ute Gschwandtner, Inga Liepelt, Kathrin Brockmann, Claudia Schulte, Peter Fuhr, Volker Roth

P1.1-017 Genetic

in Lexical Retrieval is Related to AD Pathologic Burden in Middle Frontal, Superior and Temporal Regions in Progressive Aphasia–Jessica Bove, Katheryn Cousins, Katya Rascovsky, Murray Grossman, David Irwin

Polymorphisms Associate with Frontotemporal Cortical Thickness in Sporadic Amyotrophic Lateral Sclerosis–Katerina Placek, Laura Hennessy, Pilar M. Ferraro, Jeffrey Duda, James Michael Gee, Shi D Gu, Lauren B. Elman, Leo McCluskey, Vivianna Van Deerlin, Murray Grossman, Corey McMillan

P1.1-014 Hippocampal tau

P1.1-018 Exome sequencing

P1.1-013 Longitudinal Decline

pathology burden in Lewy body disorders–Ranjit Ittyerah, David Gerhard Coughlin, Jeffrey Scott Phillips, Simon Miller, Edward Lee, John Q. Trojanowski, Daniel Weintraub, Andrew D. Siderowf, John E. Duda, Howard I. Hurtig, David A. Wolk, Paul Yushkevich, Murray Grossman, David Irwin

P1.1-015 Neuropathological

findings in Parkinson’s disease with mild cognitive impairment– Molly Knox, Charles H. Adler, Holly A. Shill, Erika Driver-Dunckley, Shyamal Mehta, Christine Belden, Edward Y. Zamrini, Geidy Serrano, Marwan N. Sabbagh, John N. Caviness, Lucia Sue, Kathryn Davis, Brittany Dugger, Thomas Beach

in carriers of the C9orf72 repeat mutation to identify pathogenic variants in other neurodegenerative genes–Alice Tran, Mary Kay Floeter

P1.1-019 TDP-43 cytoplasmic

inclusion formation in C9orf72associated FTLD/ALS–Ming Hin Lee, Seneshaw Asress, Chad Hales, Juan Vizcarra, David Gutman, Marla Gearing, Lih-Shen Chin, Lian Li, Jonathan D. Glass

P1.1-020 Small Vessel

Characteristics of Autopsied Patients with CADASIL and Those Heterozygous for HTRA1 Mutations: 3D Analysis Using the CUBIC Tissue Clearing Technique– Rie Saito, Kazuki Tainaka, Akiyoshi Kakita

BEHAVIORAL AND COGNITIVE NEUROLOGY: OTHER

P1.1-021 The Use of Standing

Desks to Address Self-Regulating Behavior in Elementary Students– David Wachob

P1.1-022 Model-Based

Truncation of Cognitive Test Batteries to Minimize Assessment Time and Information Loss–Stefan Vermeent, Ron Dotsch, Laura Klaming, Justin B. Miller, Ben Schmand

P1.1-023 Impact of Educational Inequality on the Incidence of Post-stroke Vascular Mild Cognitive Impairment Application of the Previous Study on Stratified Education-adjusted MoCA Assessment–Kulrithra Pisanuwongrak, Parunyou Julayanont, Tasanee Tantirittisak, Kenneth M. Heilman

P1.1-024 Using the Montreal

Cognitive Assessment (MoCA): to Predict Three Month Recovery Following a Stroke–Parunyou Julayanont, Kulrithra Pisanuwongrak, Tasanee Tantirittisak, Kenneth M. Heilman

P1.1-025 Concordance Between

Structural and Functional Connectivity Reflects Available Cognitive Reserve in Multiple Sclerosis During Cognitive Rehabilitation–Tom Fuchs, Stefano Ziccardi, Ralph H. B. Benedict, Alexander Bartnik, Devon Oship, Leigh Elkins Charvet, Michael Shaw, Curtis Wojcik, Jeta Pol, Faizan Yasin, Bianca WeinstockGuttman, Robert Zivadinov, Michael G. Dwyer Treatment, Care After Hospital Discharge, and Recovery Following Autoimmune and Infectious Encephalitis–Sylviah Nyamu, Raia Blum, Amanda Robyn Ramwell Tomlinson, Kendall Psaila, Nathalie Jette, Anusha Yeshokumar

P1.1-027 The Contribution

of Cognitive Impairment to Perceived Motor Disability in Amyotrophic Lateral Sclerosis– Ghazaleh Ahmadi Jazi, Negar Haghighimehmandari, Veena Mathew, Patrick Tierney, Namita Goyal, Ali Habib, Tahseen Mozaffar, S. Ahmad Sajjadi

Activity Related to Both How and Why Movements are Performed– Kevin Andrew Mazurek, David Paul Richardson, Nicholas Abraham, Edward Freedman, John Foxe

P1.1-029 Polyphenolic

compounds ameliorate stress– induced depression by preventing NLRP3 inflammasome priming–Tal Frolinger, Giulio Maria Pasinetti

P1.1-030 Scopolamine

Enhances Low Frequency Cortical Rhythms and Impairs Temporal Processing in the Medial Prefrontal Cortex during an Interval Timing Task–Qiang Johnson Zhang, Dennis Jung, Benjamin De Corte, YoungCho Kim, Joel C. Geerling, Nandakumar Narayanan

P1.1-031 Opioid Withdrawal

Shifts Amygdalar Transcriptome and is Correlated with Gut Dysbiosis–Sean S. O’Sullivan, James Park, Jonathan Gorky, Beverly Reyes, Elisabeth Van Bockstaele, James Schwaber

AUTOIMMUNE (AQP4/MOG) GLIOPATHIES AND NMOSDS

P1.2-001 Cerebellar Atrophies

in Neuromyelitis Optica Spectrum Disease (NMOSD) patients–Rodrigo Souza, Marilise Katsurayama, Leticia Franceschet Ribeiro, Fernando Cendes, Leonilda M. B. Santos, Felipe Von Glehn Silva, Clarissa L. Yasuda

P1.2-002 Degree of Retinal

Nerve Fiber Layer Thinning in Pediatric MOG-associated Optic Neuritis Appears Similar to Pediatric NMO–Nikita Shukla, Veeral Shah, Timothy E. Lotze

P1.2-003 Systematic Review

Investigating Relationship Between Neuromyelitis Optica Spectrum Disorder (NMOSD) and Vaccination–Aimen Vanood, Dean M. Wingerchuk

P1.2-004 Neuromyelitis Optica

Spectrum Disorders- Comparison as per Serostatus and Application of International Consensus Criteria–Prerna Bali, Rohit Bhatia, Nishita Singh, Padma Vasantha Hadakasira, Sreenivas Vishnubhatla

P1.2-005 The Efficacy and

Tolerability of Azathioprine for Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review–Adrian Espiritu, Paul Matthew Dimagniva Pasco

P1.2-006 Autonomic

Dysfunction in People with Neuromyelitis Optica Spectrum Disorders–Luka Crnosija, Magdalena Krbot Skoric, Marko Andabaka, Anamari Junakovic, Vanja Martinovic, Jovana Ivanovic, Sarlota Mesaros, Tatjana Pekmezovic, Jelena Drulovic, Mario Habek

P1.2-007 The Effect of Pain on Quality of Life and Co-occurring Symptoms in Patients with Neuromyelitis Optica Spectrum Disorder–Maureen A. Mealy, Lawrence Cook, Lauren Totonis, Ruth Andrea Salazar Camelo, Thomas Smith, Sharon Kozachik, Michael Levy

P1.2-008 Development of

Resistance to B-Cell Depletion Following Ten Years of Effective Rituximab Treatment in a Patient with Neuromyelitis Optica–Asaff Harel, Vishaan Nursey, Joel Stern, Souhel Najjar

P1.2-009 A Case of

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy(GFAP) Meningoencephalomyelitis Responsive to Infliximab–Justin Rodriguez, Rebecca Romero

P1.2-010 Neuromyelitis Optica

Spectrum Disorder in a Tertiary Hospital in the Philippines: A Case Series–Adrian Espiritu, Bryan Vincent Mesina, Athena Angellie Puerto, Nikolai Gil Reyes, Ludwig F. Damian, Jose Leonard R Pascual

P1.2-011 Area Postrema

syndrome: A Short Case Series Highlighting Diagnostic dilemmas, Clinical features and Outcome– Raghunandan Nadig, Thomas Mathew, GRK Sarma, Thomas Mani Kurian, Sagar Badachi

P1.2-012 An Atypical NMO

Presentation with Locked-In Syndrome–Mahnoor Rehman, Lara Basovic

P1.2-013 Clinical

characteristics, diagnostic and outcome differences in patients with optic neuritis–Dana Siegel, Meredith Van Harn, Rudy Wenner, Poonam Bansal, Mirela Cerghet, Anza Memon

P1.2-014 Spectral-Domain

Optical Coherence Tomography in Autoimmune Disorders with Optic Neuropathy: A Retrospective Analysis of Distinctive Features.– Shitiz K. Sriwastava, Sara Razmjou, Samuel Lichtman-Mikol, Maziar Eslami, Melody Gilroy, Evanthia Bernitsas

P1.2-015 Utilizing T-Cell

Suppression In Recurrent GFAP Antibody Encephalitis–Alexandra Nicholson, Michael Vincent Robers, Allison Stradiotto, Joseph Thanh-Phu Duong

P1.2-016 A Case of an

Aggressive Demyelinating NMO Spectrum Disorder-like Event in a Rheumatoid Arthritis Patient Treated with Tofacitinib–Svetlana Eckert, Bianca WeinstockGuttman, David Hojnacki

P1.2-017 Anti-APQ4-negative

NMO Spectrum Disorders with and without anti-MOG: A Retrospective Case Series–Alex Mirzoev, Tracy J. Eicher

P1.2-018 Paraneoplastic

Neuromyelitis Optica Spectrum Disorder in a Patient with Endometrial Adenocarcinoma– Andre Granger, Elina Zakin

P1.2-019 The Essence and

Boundaries of anti-Myelin Oligodendrocyte Glycoprotein Syndromes–Lei Liu, Jiawei Wang

P1.2-020 A Phase 1/2a Open-

Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) into Subjects with Transverse Myelitis (TM)– Jan Cameron Watts, Benjamin M. Greenberg INFLAMMATORY NEUROLOGICAL COMPLICATIONS OF SYSTEMIC DISEASE

P1.2-021 The Structural Basis of Susac’s Syndrome–David G. Munoz, Maryam Abdollahi

P1.2-022 Progressive Brain

Atrophy and Leptomeningeal Enhancement in Susac Syndrome–Ramsha Malik, Stephanie Garcia-Tarodo, Rohini D. Samudralwar, John A. Lincoln

P1.2-023 Pachymeningitis

in Rheumatic Disease–Rachel Kneeland, J. Thomas Berry, Monika Starosta, Sydney Brandwein

AAN.com/view/AM19Sci 125

Sunday

P1.1-026 Perceptions of

P1.1-028 Identifying Neural

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.2-024 Clinical spectrum of

patients with Primary central nervous system vasculitis–Deepa Dash, Manjari Tripathi, Rohit Bhatia, Rajesh Kumar Singh, Ajay Garg

P1.2-025 Case of hypertrophic

pachymeningitis with positive MPO-ANCA antibodies–Rhaisa Castrodad- Molina, Ernesto Borrero-Quintana, Maria E. Garcia Ayala, David Blas-Boria

P1.2-026 Wet, Wacky, and

Wobbly Without Hydrocephalus– Peter Hung, Thomas Fandel, Kunal V. Desai

P1.2-027 Adult acute

hemorrhagic leukoencephalitis: role of susceptibility-weighted imaging in diagnosis and importance of aggressive early immunotherapy.–Dana Alyse Sugar, Jonathan Ross Galli, Stacey Clardy, John E. Greenlee

P1.2-028 Rheumatoid

Meningitis with Elevated Cyclic Citrullinated Peptide Antibodies and No Evidence of Arthritic Disease–Deja Rose, Jonathan Li, Matthew Aaron Berk

P1.2-029 Progressive Multifocal Leukoencephalopathy in a Patient with Relapsed Multiple Myeloma: A Case Report and Literature Review–Sarah Woodson, Cory Manly, Mary Kwok, Jonathan K. Smith

P1.2-030 Systemic Autoimmune Diseases and Idiopathic Epilepsy– Keith Groshans, Yitao Ma

Sunday

P1.2-031 A Case of CNS

Vasculitic Changes in DRESS Syndrome–Kendra Roseann Cagniart, Virginia Baker

P1.2-032 Brain mass dilemma-

Rare presentation of ANCA negative Granulomatosis with polyangiitis–Sergio RamirezSalazar, Courtney Iser, Swathy Chandrashekhar, Mausaminben Y. Hathidara, Nidhiben A. Anadani

P1.2-033 BDNF as a surrogate

biomarker for systemic chronic damage in lupus.–Helena Alessi, Livia Almeida Dutra Antonio, Lília Maria, Paula Coube, Karina Hoshino, Fabiano Ferreira Abrantes, Fernanda Lopes, Alexandre Souza, Cristiane Kayser, Orlando Graziani Povoas Barsottini

126 2019 AAN Annual Meeting

P1.2-034 Infliximab-induced

Demyelinating Polyneuropathy in Neurosarcoidosis–Christina Lineback, Shailee Samir Shah, Jinny O. Tavee

P1.2-035 Movement Disorders associated with Systemic Autoimmunity: A Case Series– Jamie C. McDonald, Paolo M. Moretti, Stacey Clardy

P1.2-036 Skin, Gut and Nervous system – Think Degos Disease– Avirag Goswami, Sonia Lal, Kapil Singhal, Sahil Lal, Meenakshi Batrani

P1.2-037 Post-Malaria

Neurological Syndrome–Furqan Waseem, Gobind Singh, Deborah Young Bradshaw

P1.2-038 Acute Disseminated

Encephalomyelitis In An Adult Associated With Staphylococcus Aureus Bacteremia And Infective Endocarditis–Syeda Dania Shujaat, Sarah R. Durica

P1.2-039 Optic Neuritis and

Spinal Nerve Root MassesAn Unusual Presentation of Neurosarcoidosis–Saman Zafar, Aparna M. Prabhu, Anishee Undavia

P1.2-040 An adolescent female with angiography-negative childhood primary angiitis of the central nervous system–Celine Leung, Syndi Seinfeld

P1.2-041 Neurologic

Involvement in Seronegative Sjögren’s Syndrome with Positive Lip Biopsy: A Single Center Experience–Ka-Ho Wong, Jonathan Ross Galli, Rae E. Bacharach, Julia Klein, Lawanda Esquibel, Laura Pace, Dorota Lebiedz-Odrobina, John W. Rose, Bryan Trump, Christopher Hull, John E. Greenlee, Stacey Clardy

P1.2-042 Recurrent Occipital

Lobe Ischemic Strokes in COPA Syndrome–Juliet B. Morgan, Karl M. Meisel, Matthew Amans

P1.2-043 Optic Perineuritis and

Central Nervous System Vasculitis Induced after Dengue Infection– Fernando Jose Costa Baratela, Thales Skaff Da Matta, Juliana Oliveira, Nilo Olimpio Masocatto, Ivan Vieira, Pedro Leite Mendes, Ana Claudia Piccolo

Sunday, May 5 P1.2-044 Atypical

Epilepsy in Common Variable Immunodeficiency: A Single Institution Case Series–Jonathan Ross Galli, Jacob Kresser, Julia Klein, Adi Gundlapalli, Jonathan Graff-Radford, John E. Greenlee, Stacey Clardy

P1.2-045 Symptomatic

Cerebrovascular Manifestations as presenting symptom for Neurosarcoidosis–Anju Abu, Neel Naresh Patel, Laura J. Wu

P1.2-046 Neurosarcoidosis:

Longitudinal Experience in a Single-Center, Academic Health Care System–Jennifer Lord, Rae E. Bacharach, Jonathan Ross Galli, Jacob Kresser, Julia Klein, L Dana DeWitt, M. Mateo Paz Soldan, John W. Rose, John E. Greenlee, Stacey Clardy

P1.2-047 Acute Motor-

Sensory Axonal Neuropathy Associated with Systemic Lupus Erythematosus: A Challenge in Treatment–Smathorn Thakolwiboon, Amputch Karukote

P1.2-048 Neurobehçet

presenting with sympathetic ophthalmia and pseudotumoral brainstem lesion in afro-american patient.–Thiago Santos Carneiro, Melissa Betts Pergakis, Charles Mackel, Shuhan Zhu

P1.2-049 Progressive Multifocal Leukoencephalopathy Mimicking Acute Ischemic Stroke In A Patient With Idiopathic CD4 Lymphocytopenia–Murali K. Kolikonda, Rajashekar Reddy Yeruva, Srividya Sriramula, Saurav Das, Jignesh J. Shah, Wei Liu, Kerri S. Remmel

P1.2-050 A Case of Multiple

Cocaine-Induced Toxicities: Rash, Neuroleptic Malignant Syndrome, and Levamisole-Induced Leukoencephalopathy–Brigitte Furth Hurtubise, Adam MacLellan

P1.2-051 Unusual presentations for Lupus: From Occular Oddities to Cauda Equina Nerve Root Enhancement–Muhammad O. Salim Khan, Anza Memon

P1.2-052 Acute transverse

myelitis revealing primary biliary cirrhosis–Fida Oukhai Chtourou, Ines Ben Abdelaziz, Sabra Riahi, zakaria saied, Samir Belal, Jihene Ben Sassi, Faycal Hentati

11:30 a.m.–6:30 p.m. P1.2-053 Neurologic

Involvement in Progressive Hemifacial Atrophy: A Case Report Focused Review–Owen Tyler Owens, Alexis Alvarado Arias, Lauren Victoria Hatcher

P1.2-054 Longitudinally

Extensive Dorsal Column Lesion in a Patient with Longstanding Anti-Hu and Anti-Amphphysin Autoimmunity–Salman Aljarallah, Scott Douglas Newsome NEUROINFLAMMATORY COMPLICATIONS OF SYSTEMIC DISEASE: SARCOID, BEHCET, & CLIPPERS

P1.2-055 MRI Analysis in 54

Cases of Sarcoidosis-associated Myelitis Identifies Characteristic Imaging Features and Clues to Pathogenesis–Olwen Murphy, Jorge Andres Jimenez-Arango, Paula Barreras, Luisa Diaz-Arias, Maria A. Garcia-Dominguez, Ruth Andrea Salazar Camelo, Maria I. Reyes-Mantilla, Carlos A. PardoVillamizar

P1.2-056 Diagnosis and

Management of Pachymeningitis– Derek Wood, Rae E. Bacharach, Chu-Yueh Guo, Lana Zhovtis Ryerson, Michael John Bradshaw, Bret Mobley, Yunxia Wang, Jeffrey Marc Gelfand, Eoin P. Flanagan, Allen J. Aksamit, Stacey Clardy, Siddharama Pawate, Ilya Kister

P1.2-057 Rare Case

of Autoimmune GFAP Astrocytopathy-Associated LETM–Anvi Gadani, Subhendu Rath, Ashmanie Mahatoo, Amre Nouh

P1.2-058 CSF Cytokine Profile In definite Neuro-behcet Disease– Mariem Kchaou, meriam belghith, Khadija Bahrini, Mohamed Fredj, Ridha Barbouche

P1.2-059 Stroke Diagnosis and Treatment Patterns in Patients with Multiple Sclerosis–Elina Melamed, Ava L. Liberman, Matthew S. Robbins, Daniel L. Labovitz

P1.2-060 Differential Diagnosis in Late Onset Multiple Sclerosis– Florencia Yorio, Mariano Marrodan, Mauricio Franco Farez, Jorge D. Correale

P1.2-061 When Occam’s

Razor Fails: A McArdle Disease Diagnosis Following Idiopathic Transverse Myelitis–Wendy Chen, Steven Richard Dunham, Lydia Sharp

P1.2-062 Case Series of

Sarcoid Myelitis Masquerading as Disc-Related Compression Myelopathy–Lauren Gluck, Sarah Flanagan Wesley

P1.2-063 Hypertrophic Cervical Spine Pachymeningitis due to Sarcoidosis: A Case Report–Dev Mehta, Mark Li, Dmitry Khaitov, Hussam A. Yacoub

P1.2-064 Vanishing “Trident

Sign” in Recurrent Sarcoid Myelitis Treated with Rituximab– Xiaoyan Li, Silva Markovic Plese, Irena Dujmovic Basuroski

P1.2-065 CLIPPERS Syndrome: Case Report in a patient from Southern Colombia.–Christian Herrera-Céspedes, Andres Trujillo-Cardoso, Freddy EscobarMontealegre

P1.2-066 A travelling

salesman’s long journey toward a diagnosis of neurosarcoidosis– Sahar Hamidy Osman, Xiao-Tang Kong

P1.2-067 Adult-Onset Fulminant Necrotizing Encephalitis: A Rare Variant of Neurosarcoidosis– Amanda Thuringer, Yasir Nihad Jassam

P1.2-068 Brucellosis Presenting as a Longitudinally Extensive Transverse Myelitis–Bassem I. Yamout, Georges Elias Saab

P1.2-069 Co-ocurrence of

and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder–Amy Kunchok, Charles Malpas, Petra Nytrova, Eva Havrdova, Raed Alroughani, Murat Terzi, Bassem I. Yamout, Jyh Yung Hor, Rana Karabudak, Cavit Boz, Serkan Ozakbas, Francisco Javier Olascoaga Urtaza, Magdolna Simo, Franco Granella, Francesco Patti, Pamela Ann McCombe, Tunde Csepany, Bhim S. Singhal, Roberto Bergamaschi, Yara D. Fragoso, Talal Muteb Al-Harbi, Recai Turkoglu, Jeannette Lechner-Scott, Guy Laureys, Celia Oreja-Guevara, Eugenio Pucci, Patrizia Sola, Diana Ferraro, Ayse Altintas, Aysun Soysal, Ostoja (Steve) Vucic, Francois GrandMaison, Sara Eichau Madueno, Guillermo Izquierdo Ayuso, Alessandra Lugaresi, Marco Onofrj, Maria Trojano, Mark Marriott, Helmut Butzkueven, Ilya Kister, Tomas Kalincik

P1.2-073 Global and Regional

Hippocampal Volumes Are Preserved in Neuromyelitis Optica and Do not Seem to Be Related to Cognitive Impairment–Laura Cacciaguerra, Gianna Carla Riccitelli, Marta Radaelli, Elisabetta Pagani, Maria Assunta Rocca, Massimo Filippi

P1.2-074 A Global Atlas of

NMO Diagnosis and Treatment Practices–Kathryn Holroyd, Andre Vogel, Kat Lynch, Brittany Gazdag, Matthew Voghel, Nicholas Alakel, Horacio Chiong-Rivero, Farrah J. Mateen

P1.2-075 Neuromyelitis

NMOSDS AND AUTOIMMUNE (AQP4/MOG) GLIOPATHIES

optica spectrum disorders: The evaluation of 66 patients followed by Istanbul Bilim University, Department of Neurology–Burcu Altunrende, Mecbure Nalbantoglu, Umut Yücel, Gulsen Akman Demir

P1.2-070 Transverse myelitis

P1.2-076 A Curious Case of

presentation and outcomes at the Kansas University Health System–Mark-Victor Siwoski, Yasir Nihad Jassam

Bilateral Optic Neuropathy!– Khaled Abdalla, Aparna M. Prabhu, Madhura Tamhankar

P1.2-071 Spinal Cord Atrophy

Myelitis: Observations from 60 Consecutive Cases at UAB– Vanessa Sui, Malik Seals, Brandon Jay Pope, William R. Meador

in Neuromyelitis Optica Is Associated to Spinal Cord Lesions and Clinical Disability–Laura Cacciaguerra, Paola Valsasina, Sarlota Mesaros, Jelena Drulovic, Alessandro Meani, Massimo Filippi, Maria Assunta Rocca

P1.2-077 Idiopathic Transverse

P1.2-078 A case of primary

CNS lymphoma associated with neuromyelitis optica spectrum disorder: Is there a paraneoplastic link?–Emilio Rafael Garrido Sanabria, Ryan Kyle Jones, Alexander C. Ou, Olga Syritsyna, Kristin Sticco, Yupo Ma, Agnes Kowalska, Robert Peyster, Patricia K. Coyle

P1.2-079 Myelitis Associated

P1.2-086 Thalamic subregions

and visual function changes in NMOSD and RRMS patients using 7T MRI–Claudia Chien, Kunio Nakamura, Joseph Kuchling, Hanna Zimmermann, Bhaskar Thoomukuntla, Klemens Ruprecht, Thoralf Niendorf, Tim Sinnecker, Jens Wuerfel, Alexander U. Brandt, Daniel Ontaneda, Friedemann Paul

with Systemic Lupus Erythematous: Is it Lupus Myelitis, Neuromyelitis Optica, or Multiple Sclerosis?–AnneKatrin Proebstel, Jessica N. Williams, Cameron Speyer, Dorlan J. Kimbrough, Christoph J. Schankin, Carlo Chizzolini, Marten Trendelenburg, Tobias Derfuss, Karen Costenbader, Shamik Bhattacharyya

AUTOIMMUNE NEUROLOGY: BASIC SCIENCE: NEW DIRECTIONS

P1.2-080 Transverse Myelitis:

the establishment of transgenic T-cell-receptor experimental autoimmune neuritis in mice– Melissa Sgodzai, Hussein Bachir, Rafael M. Klimas, Jeremias Motte, Thomas Grüter, Xiomara Pedr, Ralf Gold, Kalliopi Pitarokoili

Lyme Disease or MOG-Antibody Associated Demyelination?–Neda Zarghami Esfahani, Ann Van De Walle Jones, Frank Bittner

P1.2-081 Clinically Isolated

Demyelinating Syndrome Associated with Anti-MOG Antibody–William F. Schmalstieg

P1.2-082 Neuromyelitis Optica

Spectrum Disorder : is it different in Morocco ?–Anas Bennis, Hicham El Otmani, Bouchra El Moutawakil, Mohammed Abdoh Rafai, Ilham Slassi Sennou

P1.2-083 Epidemiology

of NeuromyelitisOptica Spectrum DisordersPatients in Kuwait.–Samar Farouk Ahmed, Jasem Yousef Al-Hashel, Raed Behbehani, Raed Alroughani

P1.2-084 Beneficial Effects

of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy–Stéphane Fourcade, Janani Parameswaran, Leire Goicoechea, Nathalie Launay, Montserrat Ruiz, Frederic Sedel, Aurora Pujol

P1.2-085 SARM1 Loss of

Function in Chronic and Acute CNS Axonopathies–Raul Krauss, Robert Hughes, Todd Bosanac, Rajesh Devraj, Thomas Engber

P1.2-087 Regulatory T cells

in the CNS Impact Microglia Instead of Lymphocytes–Stefan Bittner, Julia Loos, Dirk Luchtman, Julian Loeffel, Beatrice Wasser, Katharina Birkner, Frauke Zipp

P1.2-088 Novel approaches for

P1.2-089 Alpha-Tocopherol Ameliorates Experimental Autoimmune Neuritis–Hideo Kihara, Shingo Konno, Toshiki Fujioka

P1.2-090 Immunomodulatory

Effects of Bortezomib in Experimental Autoimmune Neuritis in Lewis rats–Rafael M. Klimas, Melissa Sgodzai, Xiomara Pedreiturria, Hussein Bachir, Min-Suk Yoon, Ralf Gold, Kalliopi Pitarokoili

P1.2-091 IL-4 Receptor

Signaling is Relevant for Brain Homeostasis–Frauke Zipp, Carine Thalman, Dev Sams, Nikita Vlassenko, Jonathan Kipnis, Christina Vogelaar

P1.2-092 Oxidized Albumin

in Acute Ischemic Stroke is Associated With Better Outcomes–Kristin Salottolo, Leonard Rael, Jan Leonard, Russell E. Bartt, Jeffrey C. Wagner, David Bar-Or

P1.2-093 In vitro Microglia Cell Line and Human Mesenchymal Stem Cells Viability IS Inhibited by Hydrogen Gas–Hongxin Chen, Nizar Souayah

AAN.com/view/AM19Sci 127

Sunday

Neurosarcoidosis and Intrathecal Reactivation of Epstein-Barr Virus–Richard Salazar, Tiara Hypolite, Eric Bixby, Alex Nguyen

P1.2-072 Clinical determinants

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.2-094 May visual neglect

hide an autoimmune process?– Valentina Poretto, Alessandra Gaiani, Raffaella Tanel, Maria Pellegrini, Sabrina Marangoni, Costanza Papagno, Bruno Giometto MS CLINICAL PRACTICE AND DECISION MAKING

P1.2-095 Emotional Expressions associated with Therapeutic Inertia in Multiple Sclerosis care–Gustavo Saposnik, Jiwon Oh, Fabien S. Bakdache, Alonso Montoya, Pawel Kostyrko, Maria Terzaghi, Rosane Nisenbaum, Blessing Jaja, Christian Ruff, Philippe Tobler

P1.2-096 The Traffic Light

System reduces Therapeutic Inertia in MS Care: results from a RCT–Gustavo Saposnik, Muhammad Mamdani, Berenice Silva, Maria Saladino, Maria Terzaghi, Xavier Montalban, Philippe Tobler, Fernando Caceres

P1.2-097 A Descriptive

Nation-wide Survey of Laboratory Monitoring Practices of Multiple Sclerosis Clinicians in Canada– Aman Atwal, Alice Jane Schabas, Carolyn L. Taylor, Alex Jamie Head, Anthony Traboulsee, Krista Barclay, Robert L. Carruthers

P1.2-098 Influence of Live-

Online Education on Multiple Sclerosis Disease Management: Trends in Medical Knowledge and Practice Behaviors from Novice to Expert Clinicians–Anne C. Roc, Wendy Turell, Jerry S. Wolinsky, June Halper

Sunday

P1.2-099 Design and

Implementation of a PharmacistRun Multiple Sclerosis Optimization Clinic–Van Hellerslia, Edward J. Gettings

P1.2-100 Online Medical

Education Improves Knowledge of Immune Mechanisms in the Treatment of MS Among Neurologists–John Maeglin, Thomas Finnegan, Cate Murray, Gavin Giovannoni

P1.2-101 Therapeutic Inertia

Correlates with the Level of Agreement on the Landscape of MS Treatments–Jiwon Oh, Fabien S. Bakdache, Fernando Caceres, Alonso Montoya, Gustavo Saposnik

128 2019 AAN Annual Meeting

P1.2-102 Influence of Gender

and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists–Robert T. Naismith, Patricia K. Coyle, Shiv Saidha, Jennifer Robinson, Virginia Schobel

P1.2-103 Trends for Healthcare Cost among Commercially Insured Individuals with Multiple Sclerosis–Youngran Kim, Trudy Krause, Philip S. Blum, Leorah Aude Emmanuelle Freeman

P1.2-104 Facilitating

Collaboration in MS Care through Point-of- care Tools and Innovation in CME–Brooke Hefele, Matthew Frese, Lauren Welch, Andrew Grzybowski, Christina Gallo

P1.2-105 Telemedicine in

Multiple Sclerosis Care: A National Utilization Assessment and Systematic Review–Mitchell T. Wallin, Sarah L. Minden, Helene Machado, Lorene M. Nelson, Barbara Topol, William J. Culpepper, Shan Jin, Heidi Wynn Maloni, Samuel Yeroushalmi

P1.2-106 Cost effectiveness

of Fingolimod Compared to Interferon-ß1a in the Management of Pediatric-Onset Multiple Sclerosis (POMS) in Canada–Hamid Reza Nakhaipour, Umakanth Vudumula, Nagasuman Toram, Vivek Khurana, Robyn Schecter, Daniela Pohl, Nicholas Adlard

P1.2-107 A multiple sclerosis nurse practitioner fellowship: meeting the comprehensive needs of the multiple sclerosis community–Lynsey Lakin, Elizabeth H Morrison

ANTITHROMBOTIC TREATMENT IN ISCHEMIC STROKE

P1.3-001 A Stroke of Bad Luck

: Breakthrough Ischaemic Strokes on DOAC Therapy–Fiona Chan, William Curtis, Helen Gaenor Brown, Cullen Mark O’Gorman

P1.3-002 Triglycerides,

Creatinine and Body Mass Index are Independent Predictors of Occurrence of Stroke in Patients Adherent with Direct Oral Anticoagulant–Charles Zhang, Ye Rin Koh, Thomas N. Leahy, Harshit Shah, Haris Kamal, Marilou I. Ching

Sunday, May 5 P1.3-003 Timing of Anti-

Coagulation after Acute Ischemic Stroke and its relationship to risk of Intracranial Hemorrhage– Usman Shehzad, Kamil Stefanowski, Ryan Kyle Jones, Alex Gauger, Lindsay Stemke, Lev Bangiyev, David Fiorella, Michael Guido

P1.3-004 Treatment of floating thrombus with apixaban: report of a case.–Carlos Alberto Soto-Rincon, Alejandro Gonzalez Aquines, Sergio Andrés CastilloTorres, Emmanuel EscobarValdivia, Erik A García-Valadez, Juan Fernando Gongora Rivera

P1.3-005 Newer Anticoagulants in Patients with Atrial Fibrillation and Ischemic Stroke - a Two Year Experience–Pratik Bhattacharya, Karan Philip, Ramesh Madhavan

P1.3-006 Aspirin Resistance

And Ischemic Stroke: A Prospective Study In Indian Population.–Pranjal Sisodia, Rohit Bhatia, Renu Saxena, Padma Vasantha Hadakasira, Kameshwar Prasad, V Sreenivas, Gautam Sharma, Mamta Bhushan Singh

P1.3-007 Smoking and

Clopidogrel resistance in ischemic stroke–Hyuin Goo Kang, Yu Yong Shin, Sung Hyuk Heo, Dae-Il Chang, Bum Joon Kim

P1.3-008 The Effect of New

P2Y12 Receptor Antagonist, Ticagrelor, On Platelet Reactivity in Patients With Clopidogrel Resistance Undergoing Neuroendovascular Procedures.– Muhammad Umair Jahngir, Adnan I. Qureshi, Yasemin Akinci, Baljinder Singh

P1.3-009 Retrospective

Comparison of Medication Therapy Management and Stroke/TIA Outcomes in Patients Who Have Undergone Testing for Antiplatelet Responsiveness and Pharmacist Intervention and versus Those Who Have Not–Erica Westphal, Jessica Greger, Rachael Wojcik, Michelle Rainka, Francis Michael Gengo

P1.3-010 Fourteen-day Delay

of Cerebral Ischemia due to Vasospasm after Traumatic Subarachnoid Hemorrhage in Mild Head Injury–Ilavarasy Maran, Anvi Gadani, Isaac E. Silverman

11:30 a.m.–6:30 p.m. ENDOVASCULAR THERAPY IN ACUTE ISCHEMIC STROKE

P1.3-011 The Role of

Intravenous Thrombolysis in the Prediction of Functional Outcome in Patients who undergo Endovascular Thrombolysis with Newer Generation Stent Retrievers–n aijb

P1.3-012 Does Use of

Adjunctive Therapy to Mechanical Thrombectomy Improve Outcomes Without Significant Risk in LVOs.–Amrinder Singh, Haralabos Zacharatos, Ashish Kulhari, Hemal Patel, Audrey Arango, Keshav Holani, Avani Bhatnagar, Siddhart Kumar Mehta, Jawad F. Kirmani

P1.3-013 Prior Intravenous

Thrombolytics Administration is Associated with Increased Hospital Bills & Intracranial Hemorrhage Rates Without Improved Outcomes in Mechanical Thrombectomy Patients–Ameer Hassan, Hari Kotta, Laurie Preston, Leeroy Garza, Wondwossen G. Tekle, Amrou Sarraj, Adnan I. Qureshi

P1.3-014 Outcome of

mechanical thrombectomy in patients with acute ischemic stroke on anticoagulation therapy–Nurose Karim, Alicia Clara Castonguay, Ehad Afreen, Hisham Raza Alim Salahuddin, Syed F. Zaidi, Mouhammad A. Jumaa, Julie Shawver

P1.3-015 Monitored anesthesia

care by sedation-trained providers in acute stroke thrombectomy.– Diana Elizabeth Slawski, Hisham Raza Alim Salahuddin, Linda Saju, Syed F. Zaidi, Mouhammad A. Jumaa

P1.3-016 General Anesthesia

for Thrombectomy in Ischemic Stroke Leads to Poor Outcomes as Compared to Conscious Sedation–Chantal Bhan, Muhib Khan, Lee Elisevich, Tracy J Koehler, Justin Singer, Paul Mazaris, Rajeev Kumar Deveshwar, Bassel Raad, Joseph Zachariah, Elysia James, Raymond Scurek, Jeremy VandenBerg, Tricia Tubergen, Laurel Packard, Jiangyong Min, Tamer Abdelhak

P1.3-017 The first objective

predictor of the hemorrhagic events after endovascular treatment of acute ischemic stroke using 2D parametric parenchymal blood flow–Nada Abdelhameed Elsaid A Elsaid, Ahmed Saied, Krishna Joshi, Jessica Nelson, John Baumgart, Demetrius K. Lopes

P1.3-018 The Processing

Time for Recanalization and Size of Ischemic Lesions on DWI Is Related with Complete Reperfusion After Mechanical Thrombectomy–Dong Jin Shin, Jae Kwan Cha

P1.3-019 Inter-facility transfer

P1.3-024 First Pass Rates Differ

Between Anterior Circulation And Vertebrobasilar Occlusions During Mechanical Thrombectomy For Emergent Large Vessel Occlusions–David Daniel, Muhammad Zeeshan Memon, Manjot Grewal, Wayne Olan, Dimitri Sigounas, Christopher Putman, Edward Greenberg

P1.3-025 No Association

Between Number of Stent Retriever Passes and Hemorrhagic Transformation for Mechanical Thrombectomy Patients.–Ameer Hassan, Hari Kotta, Umar Shariff, Laurie Preston, Wondwossen G. Tekle, Adnan I. Qureshi

workflow for thrombectomy in a rural stroke network: Longer DoorIn-Door-Out (DIDO) time delays thrombectomy–Tamer Abdelhak, Muhib Khan, Laurel Packard, Hattie LaCroix, Tricia Tubergen, Cuyler Huffman, Justin Singer, Raymond Scureck

P1.3-026 Did Evolution

P1.3-020 RAPIDTM Based

P1.3-027 Evidence Improves

Treatment Algorithms Lead to Faster Activation of Neurointervention Team and Reduce Recanalization Times–Siddhart Kumar Mehta, Spozhmy Panezai, Sara Strauss, Briana DeCarvalho, Ashish Kulhari, Amrinder Singh, Jawad F. Kirmani

P1.3-021 To Stay or To

Go? Utilization of a Mobile Interventional Stroke Team Shortens Time to Treatment in Large Vessel Occlusion–Lili Velickovic Ostojic, Maryna Skliut, Johanna Therese Fifi

P1.3-022 Initial symptoms and

P1.3-023 Posterior Circulation

Large Vessel Occlusions are Associated with Longer Door?to-Groin Time–Eyad Almallouhi, Mohammad Anadani, Ali Alawieh, Christine Holmstedt, Alejandro Spiotta

Outcomes Beyond ‘Belief’: Comparison of Patient Outcomes in Pre- and Post- DAWN era.–Ashish Kulhari, Haralabos Zacharatos, Sanket Meghpara, Hemal Patel, Siddhart Kumar Mehta, Jawad F. Kirmani

P1.3-028 Impact of Race on

Mechanical Thrombectomy Safety Outcomes–Nicholas Liaw, Vasu Saini, Dileep R. Yavagal

P1.3-029 Patterns and

Outcomes of Endovascular Therapy in Mild Stroke: A FloridaPuerto Rico Collaboration–Negar Asdaghi, Dileep R. Yavagal, Kefeng Wang, Nils Hendrik Mueller, Nirav R. Bhatt, Hannah Gardener, Carolina M. Gutierrez, Erika Tatiana Marulanda-Londono, Sebastian Koch, Chuanhui Dong, Sofia Oluwole, Ricardo Hanel, Brijesh Prakash Mehta, Mary Robichaux, Ulises L. Nobo, Juan Carlos Zevallos, Tatjana Rundek, Ralph L. Sacco, Jose Gabriel Romano

P1.3-030 Mechanical

Thrombectomy in patients with low NIHSS: A retrospective chart review–Roohi Katyal, Claire Emmanuelle Delpirou Nouh, Chao Xu, Lance Ford, David Lee Gordon

Endovascular Therapy in Acute Ischemic Stroke Patients Presenting with Low National Institute of Health Stroke Scale Scores–Nicholas D. Osteraas, Daniel M. Schachter, James Conners, Sarah Song, Laurel Jean Cherian, Alejandro Vargas, Rima Dafer

P1.3-032 Less benefits of

Mechanical Thrombectomy on Acute Large Vessel Occlusion Stroke Patients Who were Transferred to a Comprehensive Stroke Center–Marwa A. Elnazeir, Michael Haboubi, Ruolan Liu, Elizabeth Hillery Wise, Tracy Ander, Jignesh J. Shah, Ozan Akca, Kerri S. Remmel, Wei Liu

P1.3-033 Predictors of Poor

Outcome after Mechanical Thrombectomy with Successful Recanalization–Mohammad Anadani, Mohamad Orabi, Ali Alawieh, Nitin Goyal, Fnu Abhi Pandhi, Hunter Mitchell, Andrei V. Alexandrov, Ilko Maier, Marios-Nikos Psychogios, Ovais Inamullah, Shareena A. Rahman, Christa Brittany Swisher, Salah G. Keyrouz, James Anthony Giles, Michelle Allen, Akash Kansagra, Stacey Wolfe, Peter Kan, Fabio Nascimento, Benjamin Gory, Pierre De Marini, Alejandro Spiotta

P1.3-034 Hemorrhagic

transformation after Mechanical Thrombectomy Revascularization in Large Vessel Occlusion Ischemic Stroke–Vasu Saini, Joshua Lukas, Sushanth Rao Aroor, Priyank Khandelwal, Nida Akram, Marie Christine Brunet, Dileep R. Yavagal, Jose Gabriel Romano

P1.3-035 Diabetes Mellitus

Predicts Symptomatic Intracerebral Hemorrhage Following Thrombectomy in Acute Ischemic Stroke–Mayra Montalvo Perero, Aleksandra Yakhkind, Mahesh Jayaraman, Ryan McTaggart, Andrew D. Chang, Ronald Akiki, Brian Mac Grory, Shawna M. Cutting, Tina Mariko Burton, Michael E. Reznik, Bradford B. Thompson, Linda C. Wendell, Shyam Sudarshan Rao, Nicholas S. Potter, Ali Mahta, Kevin N. Sheth, Joshua Z. Willey, Pooja Khatri, Karen L. Furie, Shadi Yaghi

P1.3-036 Higher Baseline LDL

levels and Increased Hemorrhagic Risk in Ischemic Stroke Patients Undergoing Mechanical Thrombectomy–Yoram Roman Casul, Dinesh V. Jillella, Fares Qeadan, Christopher Calder, Alexis Alvarado Arias, Huy Tran

P1.3-037 Improved Outcomes

after Mechanical Thrombectomy for In-hospital Strokes–Jasmina Ehab, Abdelrahman Beltagy, Nicholas Hilker, Nicole Slye, Henian Chen, David Z. Rose, William Scott Burgin, Swetha Renati

P1.3-038 A Comparison of

Outcomes Associated With Mechanical Thrombectomy in Acute Ischemic Stroke Patients Performed Within and Outside Clinical Trials In The United States–Adnan I. Qureshi, Baljinder Singh, Wei Huang, Ahmed Arshad Malik

P1.3-039 The Impact of “July

Phenomenon” on Door-to-Groin Time and Long-term ?Outcome of Stroke Patients Treated with Mechanical Thrombectomy–Eyad Almallouhi, Mohammad Anadani, Ali Alawieh, Christine Holmstedt, Alejandro Spiotta

P1.3-040 Mechanical

Thrombectomy In Acute Ischemic Stroke: Etiology And Trends Of Readmissions In A National Population-based Cohort Study (2010-2014)–Weizhe Li, Xiyan Yi, Chirag Narshibhai Savani, Tejinder Singh, Sukriye Damla Kara, Varun Kumar, William Scott Burgin, Swetha Renati

P1.3-041 Endovascular

Thrombectomy in Acute-Onset Ischemic Stroke – Beyond the Standard Time Windows: A Case Report and a Review of the Literature–Conan So, Naveed Chaudhry, John Cole, Dheeraj Gandhi, Melissa Motta

P1.3-042 Role of CT Perfusion

Parameters and Collateral Score in Predicting Outcomes in Large Vessel Occlusion Strokes Who Received Both Intravenous Alteplase and Endovascular Thrombectomy–Saurav Das, Connor J. Elliott, Michael Dahle, Riwaj Bhagat, Ashish Rameshrao Gandhe, Wei Liu, Kerri S. Remmel, Ozan Akca

AAN.com/view/AM19Sci 129

Sunday

delay in treatment of patients with posterior circulation strokes undergoing endovascular therapy–Juliana Gomez, Dongkwan Jin, Mohamed ShehabEldin

of Evidence Based Stroke Thrombectomy Treatment Change Efficiency Across Stroke Systems of Care?–Ashish Kulhari, Spozhmy Panezai, Sara Strauss, Audrey Arango, Hemal Patel, Siddhart Kumar Mehta, Jawad F. Kirmani

P1.3-031 Experience with

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.3-043 Femoral Neuropathy

Following Transfemoral Neuroendovascular Procedures. An Analysis of a Prospective Registry–Sehar Babar, Muhammad Fawad Ishfaq, Danish Kherani, Adnan I. Qureshi, Laura Qi

P1.3-044 Hemorrhagic

Transformation Following Mechanical Thrombectomy in Acute Ischemic Stroke and Risk of Seizures.–Ahmad El Alayli, Jay Kinariwala, Kushak Suchdev, Rohit Ajay Marawar LARGE VESSEL OCCLUSIONS: DETECTION, EPIDEMIOLOGY, AND OUTCOMES

P1.3-045 Withdrawn P1.3-046 A Clinical Paradigm for Classifying Neurologic Symptoms to Screen for Emergent Large Vessel Occlusions–Rebecca Pollard, Michelle H. Leppert, Charles Rawson, Mitchell Boehnke, Justin Honce, Lidia Nagae, Sharon Poisson, Eric Nyberg

P1.3-047 Gaze Deviation on

Initial CT as Predictor of Large Vessel Occlusion–Jeremy Kulacz, Alejandro Vargas, Laurel Jean Cherian, James Conners, Rima Dafer, Nicholas D. Osteraas, Sarah Song

Sunday

P1.3-048 Risk factors for

acute ischemic stroke caused by anterior large vessel occlusion– Matthew Daniel Adams, Philipp Hendrix, Nelson Sofoluke, Saran Kunaprayoon, Ramin Zand, Amy N. Kolinovsky, Thomas N. Person, Mudit Gupta, Oded Goren, Clemens M. Schirmer, Natalia Sana Rost, James E. Faber, Christoph J. Griessenauer

P1.3-049 How Much Does

Atrial Fibrillation Contribute to Large Vessel Occlusions?–Eric J. Seachrist, Sneha Jacob, Chris Ferari, Tamra Ishan Jayendra Ranasinghe, Ashley Petrone, Amelia Karen Adcock

P1.3-050 A Case Series of

Seven Patients with Recurrent Large-Vessel Strokes within 72 Hours of the Initial Event.–Kamil Stefanowski, Usman Shehzad, Elzbieta J. Wirkowski, David Fiorella

130 2019 AAN Annual Meeting

P1.3-051 Hyperviscosity in

Acute Ischemic Stroke with Large Vessel Steno-occlusive Lesion–Si Baek Lee, Sung-Hoon Kim, Hye-Eun Shin, Dong-Woo Ryu, Jung-Wook Park

P1.3-052 Time-Domain Near

Infrared Spectroscopy in Acute Ischemic Stroke Patients with Different Sites of Large Vessel Occlusion.–Giacomo Giacalone, Marta Zanoletti, Rebecca Re, Davide Contini, Lorenzo Spinelli, Alessandro Torricelli, Luisa Roveri

P1.3-053 Frequency of

Guideline-Ineligible Large Vessel Occlusion Strokes–Shashvat Desai, Bradley Molyneaux, Marcelo Rocha, Matthew T. Starr, Tudor G. Jovin, Ashutosh P. Jadhav CAROTID DISEASE

P1.3-054 One Year Follow-Up

after Elective Carotid Artery Stenting in 720 Patients: A Single Centre Experience–Vijaya Pamidimukkala, Murali Babu Rao Rachaputi, Michael Noronha, Srinivasa Rao Chinta, Veera Prasada Rao Ravela, Maruthi Prasad Immadisetty, Lakshmi Sudha Prasanna, Anurag Polavarapu, Sravanthi Byrapaneni, Naren Polavarapu, Sirichandana Gangasani, Ramesh Nakuru, Meghana Chilukuri, Deepthi Gali, Raghava Sarma Polavarapu

P1.3-055 Difference in

Outcomes in Patients with Carotid Stenting With and Without Balloon Angioplasty–Aakash N. Bodhit, Randall Edgell

P1.3-056 Baseline Physical

Activity Profiles in CREST-2 Trial Participants–Seemant Chaturvedi, Tanya N. Turan, Neil Gordon, Jenifer Voeks, Marc I. Chimowitz, Virginia J. Howard, George Howard, Kevin M. Barrett, Robert D. Brown, Ronald M. Lazar, Wesley Moore, Claudia Moy, Gary Roubin, Bart M. Demaerschalk, Malcolm Foster, Lawrence R. Wechsler, Brajesh K. Lal, James F. Meschia, Thomas G. Brott

Sunday, May 5 P1.3-057 Carotid Plaque

Characteristics Correlated to Baseline Vascular Risk Factors in a Large Randomized Trial: Results from CREST-2–Brajesh K. Lal, Matthew Chrencik, Amir Khan, Michael Jones, John Huston, Charles Sternbergh III, Joseph Rapp, Dipankar Mukherjee, Peter Henke, John Yokemick, Wesley Moore, Siddhartha Sikdar, Jenifer Voeks, George Howard, James F. Meschia, Thomas G. Brott

P1.3-058 Control of Blood

Pressure Following Carotid Artery Stenting: Is it Baroreceptor Resetting?–Vijaya Pamidimukkala, Murali Babu Rao Rachaputi, Michael Noronha, Srinivasa Rao Chinta, Veera Prasada Rao Ravela, Maruthi Prasad Immadisetty, Lakshmi Sudha Prasanna, Anurag Polavarapu, Sravanthi Byrapaneni, Naren Polavarapu, Laura Freedman, Ramesh Nakuru, Meghana Chilukuri, Deepthi Gali, Raghava Sarma Polavarapu

P1.3-059 No Association

Between Carotid Artery Atherosclerosis and Hyoid Proximity: Results from a Cross-sectional and Longitudinal Cohort Study–James E. Siegler, Glenn Leonel Konsky, Christopher Renner, Andres Moreno-De-Luca, David Gutman, Brett L. Cucchiara, Steven R. Messe

P1.3-060 Carotid

Revascularization and Medical Management for Asymptomatic Carotid Stenosis: CREST-2 Update–James F. Meschia, Brajesh K. Lal, George Howard, Tanya N. Turan, Gary Roubin, Robert D. Brown, Kevin M. Barrett, Seemant Chaturvedi, Marc I. Chimowitz, Bart M. Demaerschalk, Virginia J. Howard, John Huston, Ronald M. Lazar, Wesley Moore, Claudia Moy, Jenifer Voeks, Thomas G. Brott

P1.3-061 Cognitive Profile in Patients with Hemodynamic Failure due to Severe Carotid Stenosis–Mathias Palmer, Randolph S. Marshall, Qixuan Chen, Kevin Slane, Ronald M. Lazar, MaryKay A. Pavol

P1.3-062 Carotid Web in

patients with Carotid Stenosis and Stroke of Undetermined Etiology–Surya Sharma, Prakash Rameshchandra Paliwal, Hock Luen Teoh, Bernard PL Chan, Arvind Sinha, Vijay K. Sharma

11:30 a.m.–6:30 p.m. P1.3-063 Platelet YES1,

PIK3CB, and GNA14 Expression Correlates with Coated-Platelet Levels in Asymptomatic Internal Carotid Stenosis–Angelia Kirkpatrick, Eleanor Mathews, Lori Garman, Kaity White, Courtney Montgomery, George Dale

P1.3-064 Characterization and

Validation of Somatosensory Evoked Potential Morphology during Carotid Endarterectomy to Detect Stroke–Ahmed Jorge, Donald Crammond, Jeffery R. Balzer, Katherine Melonakos Anetakis, Parthasarathy Thirumala

P1.3-065 Slowly Progressive,

Acquired Hemicerebral Atrophy Secondary to Chronic Internal Carotid Vascular Disease Mimicking Neurodegenerative Disease–Jeffrey R. Vitt, Ali G. Hamedani, Sarah Horn, Kimberly Gannon, Raymond Price, Maxwell Andrew Greene

P1.3-066 ‘On-treatment platelet

reactivity’ under both high and low shear stress conditions and relationship with cerebral microembolic signals in asymptomatic and symptomatic carotid stenosis: Results from the HaEmostasis In carotid STenosis(HEIST) study.–Stephen Murphy, Soon Tjin Lim, Justin Kinsella, Sean Tierney, Bridget Egan, T. Martin Feeley, Sinead M. Murphy, Richard Walsh, Ronan Collins, Tara Coughlan, Desmond O’Neill, Sean O’Neill, Joseph Harbison, Prakash Madhavan, Mary Paula Colgan, Dermot Cox, Niamh Moran, George Hamilton, Dominick Mccabe

AMYOTROPHIC LATERAL SCLEROSIS

P1.4-001 Investigating

Directionality of Neurodegeneration in vivo in ALS using Multimodal MRI–Charmaine Toh, Andrew Keslake, Joseph Harding, Kathleen Baster, Nigel Hoggard, Julia Bigley, Christopher McDermott, Pamela Jean Shaw, Iain Wilkinson, Thomas M Jenkins

P1.4-002 The Vitamin D

Activator, CYP27B1, is a Novel Muscle Biomarker of ALS Disease Progression–Ying Si, Yuri Kwan, Siyu Zhou, Mohamed Kazamel, Ikjae Lee, Tina Anderson, Peter H. King

P1.4-003 Deconstructing

progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.–Nimish J. Thakore, Brittany Lapin, Erik P. J. Pioro

P1.4-004 The anatomical

substrate of bulbar impairment in ALS: insights from multiparametric brainstem imaging, corticobulbar connectivity and somatotopic motor cortex measures–Peter Bede, Rangariroyashe Chipika, Eoin Finegan, Stacey Li Hi Shing, Orla Hardiman

P1.4-005 Neurophysiological

Correlates of Excitability in ALS: Pretreatment Findings from the Retigabine and Mexiletine-2 Studies–Michael D. Weiss, Eric A. Macklin, Courtney E. McIlduff, Ostoja (Steve) Vucic, Leo Hong-Li Wang, Maxwell T. Ma, Sabrina Paganoni, Nicholas J. Maragakis, Richard S. Bedlack, Namita Goyal, Seward B. Rutkove, Dale J. Lange, Michael H. Rivner, Stephen Goutman, Shafeeq Ladha, Bjorn E. Oskarsson, Elizabeth Ann Mauricio, Robert H. Baloh, Zachary Simmons, Amy E. Chen, William Devries, Matthew Harms, Thomas H. Brannagan, Sasha Zivkovic, David Lacomis, Jeremy M. Shefner, Nazem Atassi, Merit E. Cudkowicz, Brian Wainger

P1.4-006 Neuroelectric

P1.4-007 Do Sleep Scales

Correlate with Pulmonary Function in ALS? Results From the ALS Nutrition/NIPPV Study Group–Ossama Khazaal, Terry D. Heiman-Patterson, Michael Sherman, Carlayne E. Jackson, Yvonne Rollins, Ashok Verma, Jeremy M. Shefner, Stephen N. Scelsa, Daniel S. Newman, Marta Mendiondo, Edward J. Kasarskis, Edward J. Kasarskis

revised classification of cognitive and behavioral impairment in ALS–Rosario Vasta, Debora Pain, Laura Peotta, Andrea Calvo, Cristina Moglia, Antonio Canosa, Umberto Manera, Antonio Ilardi, Alessandro Bombaci, Jean Pierre Zucchetti, Gabriele Mora, Barbara Iazzolino, Adriano Chio

P1.4-009 Withdrawn P1.4-010 The Canadian ALS

Neuroimaging Consortium (CALSNIC)–Sanjay Kalra, Christian Beaulieu, Michael G. Benatar, Hannah R. Briemberg, Annie Dionne, Nicolas Dupre, Dean Eurich, Richard Frayne, Angela L. Genge, Simon Graham, Christopher Hanstock, Julia Keith, Lawrence Korngut, Christen L. Shoesmith, Alan Wilman, Yee Hong Yang, Yana Yunusova, Lorne H. Zinman

P1.4-011 Relationship between Forced Vital Capacity and Slow Vital Capacity in individuals with Amyotrophic Lateral Sclerosis Patients–Jerold E. Reynolds

P1.4-012 MRI Alterations in the Brachial Plexus of ALS Patients– Pietro Giuseppe Scamarcia, Federica Agosta, Simonetta Gerevini, Edoardo G. Spinelli, Nilo Riva, Elisabetta Pagani, Angelo Quattrini, Andrea Falini, Massimo Filippi

P1.4-013 Intrathecal delivery of

ALS cerebrospinal fluid induces motor deficits and motor neuron death in mice–Jamie Wong, Anna Roselle, Serena Jane Elizabeth Shimshak, Saud A. Sadiq

P1.4-014 Radicava®

(edaravone) for Amyotrophic Lateral Sclerosis: New Formulation and Its Development Plan–Koji Takei, Tomoyuki Omura, Yoshinobu Nakamaru, Masae Kakubari, Tomoko Natori, Youichi Shiide, Yukiko Nishimura, Makoto Akimoto, Manabu Hirai, Joseph Palumbo

P1.4-015 BRIDGE: Dynamic

Imagery and Art Therapy in ALSA Clinical Study to Improve Patient Expression and Wellness–Juliet King, Greg Hull, Gwen Spehn, Kaitlin Knapp, Sandra Guingrich, Robert M. Pascuzzi

P1.4-016 Predicting benign

brachial monomelic amyotrophy: factors at presentation that differentiate from amyotrophic lateral sclerosis–Sona Mistry, Joseph Hosty, Abhijit Patil, Christopher McDermott, Pamela Jean Shaw, Thomas M Jenkins

P1.4-017 Radicava®

(edaravone) for Amyotrophic Lateral Sclerosis: US Experience at 1 Year After Launch–Tatyana Baranovsky, Glenn McAnanama, Wendy Agnese, Mike Martin

P1.4-018 An Update of Study

of ALS Reversals: LifeTime Exposures (StARLiTE)–Jesse Crayle, Jaime Raymond MPH, Paul Mehta, Richard S. Bedlack

P1.4-024 McGill University

Single Item Quality-of-Life ( QoL ) Scale Compared with ALS Health-Related Quality-of-Life Likert Scales Including Breathing QoL Measurement–Benjamin R. Brooks, Elena Bravver, William Bockenek, Scott C Lindblom, Navid Jalali, William B. Dawson, Urvi G. Desai, Any Linville, Tiffany Williamson, Fawn Paling, Nicole Lucas, Velma L. Langford, Scott Holsten, Mohammed S. Sanjak, Amber L. Ward, Rachel Hillberry, Shivangee Thorne, Kathryn Wright, Jennifer Mabry, Allison NewellSturdivant, Nicol Brandon

P1.4-025 Safety and Efficacy of

with advancing Fine’til 9 stage of ALS–Nimish J. Thakore, Brittany Lapin, Erik P. J. Pioro

Edaravone in Delaying Functional Decline in Amyotrophic Lateral Sclerosis: A Meta-Analysis– Marjorie Anne Dela Cruz Bagnas, Nikolai Gil Reyes, Jose Leonard R Pascual

P1.4-020 Biomarker Supervised

P1.4-026 Pitfalls in the

P1.4-019 Health utility declines

G-CSF (Filgrastim) Response in ALS Patients–Siw Johannesen, Bettina Budeus, Sebastian Peters, Sabine Iberl, Anne-Louise Meyer, Eva Zitzelsperger, Tim-Henrik Bruun, Wilhelm Schulte-Mattler, Armin Schneider, Ulrich Bogdahn

P1.4-021 Increasing the

Efficiency of ALS Clinical Trials Using Machine Learning–David L. Ennist, Albert Taylor, Danielle Beaulieu, Jonavelle Cuerdo, Andrew Conklin, Mike Keymer

P1.4-022 How the National

Amyotrophic Lateral Sclerosis (ALS) Registry Can Help with Your Research–Wendy Eileen Kaye, Laurie Wagner, Jaime Raymond MPH, Paul Mehta, Theodore Larson

P1.4-023 Characteristics

of respiratory dysfunction in amyotrophic lateral sclerosis: a retrospective cohort study in 236 cases–Hanhui Fu, Dongchao Shen, Kang Zhang, Shuangwu Liu, Hongfei Tai, Liying Cui

Diagnosis of Amyotrophic Lateral Sclerosis in a Hispanic Cohort– Bhavesh Trikamji, Margaret Adler

P1.4-027 Clinical and

Electrophysiological Profile and Study of Plasma Levels of Neurotoxic Metals in Amyotrophic Lateral Sclerosis–Butchi Raju Garuda, Aditya Mgv, Gopi Seepana, Sateesh T, Aruna Kumari Uppaturi

P1.4-028 Lifetime Sport

Practice and Brain Metabolism in Amyotrophic Lateral Sclerosis: a 18F-FDG-PET study–Cristina Moglia, Antonio Canosa, Andrea Calvo, Federico Casale, Fabrizio D’Ovidio, Marco Pagani, Adriano Chio

P1.4-029 Case Report: Familial Amyotrophic Lateral Sclerosis SOD1 c.122A>G (p.Glu41Gly) Mutation with Slow Disease Progression–Minh-Thuy Thi Nguyen, Shuhan Zhu

P1.4-030 ALS/FTD-linked

UBQLN2-P497H Increases K63linked Polyubiquitinated Protein Levels–Y. Taylan Esengul, Thomas Lukas, Yong Shi, Hong Zhai, HanXiang Deng, Teepu Siddique

P1.4-031 The

Posttranscriptional Regulation of Ubiquilin2 by HuR in ALS Pathogenesis–Liang Lu, Yan Zhang, Han-Cheon Kim

AAN.com/view/AM19Sci 131

Sunday

Biomarkers of Network Dysfunction in Amyotrophic Lateral Sclerosis–Bahman Nasseroleslami, Stefan Dukic, Roisin Mc Mackin, Amina Coffey, Antonio Fasano, Rangariroyashe Chipika, Marta Pinto Grau, Tom MJ Burke, Emmet Costello, Parameswaran Mahadeva Iyer, Mark Heverin, Niall Pender, Peter Bede, Orla Hardiman

P1.4-008 Validation of the

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 NEUROPHYSIOLOGY IN NEUROMUSCULAR DISORDERS I

P1.4-032 An improved

methodology for eliciting the somatosensory evoked potential of the Saphenous Nerve during the intraoperative monitoring in spine surgery–M. Angeles Sanchez-Roldan, Francisco Mora Granizo, Maria Tellez, Sedat Ulkatan

P1.4-033 Carpal Tunnel

Syndrome in Children from a Pediatric Neuromuscular Center–Obehioya T. Irumudomon, Partha S. Ghosh

P1.4-034 Kinetics And Fiber

Distribution Of The Three Muscle Heads Of Triceps For a Better C7 Myotomal EMG Study–James Noto, Cheran Elangovan, Sankar Bandyopadhyay

P1.4-035 Continuous Vagus

Nerve Monitoring using the Laryngeal Adductor Reflex–M. Angeles Sanchez-Roldan, Francisco Mora Granizo, Maria Tellez, Catherine Sinclair, Sedat Ulkatan

P1.4-036 Utility of Bumps

Test in The Diagnosis of Carpal Tunnel Syndrome Compared to Nerve Conduction Study–Mehdi Ghasemi, Christyn Marie Edmundson, Reza Seyed Sadjadi, William S. David

P1.4-037 Hematoma Risk

Sunday

After Needle Electromyography (EMG) In Patients on Newer Anticoagulants–Elanagan Nagarajan, Nolan Dyer, Emily Bailey, Anudeep yelam, Raghav Govindarajan

P1.4-038 Ratio of Distal to

Proximal Epidermal Nerve Fiber Density as Predictor of Small Fiber Neuropathy–Mark Farrenburg, Mazen M. Dimachkie, Duaa Jabari, Constantine Farmakidis, Omar Jawdat, Richard J. Barohn, Mamatha Pasnoor

P1.4-039 Neuromuscular

ultrasound for the non-invasive assessment of breast cancer patients with peripheral neuropathy from taxanes–Roy E. Strowd, Thomas Lycan, Alexandra Thomas, Fang-Chi Hsu, Christine Ahn, Omar Sangueza, Yusuke Shiozawa, Sun Hee Park, Chris Peters, Edgar Alfonso RomeroSandoval, Susan Melin, Steven Sorscher, Glenn Lesser, Francis O. Walker, Michael Cartwright

EPILEPSY: COMORBIDITIES AND SUDEP

P1.5-001 Factors Contributing

to Quality Of Life in Patients With Epilepsy.–Alexander G. Doyle, Caroline Abe, David Denney, Munro Cullum, David Montemayor, Jessica Adams, Denise Castillo, Hina N. Dave, Kan Ding

P1.5-002 Characterizing Peri-

Ictal Mood Changes in Patients with Epilepsy–Autusa Pahlavan, Scott Thompson, Jennifer L. Hopp

P1.5-003 Cross-sensitivity of

Sunday, May 5 P1.5-007 Anxiety and

Depression Symptoms in the Epilepsy Clinic: Examining Psychiatric Treatment Characteristics in a Learning Health System Model–Victor Jones, Jonathan Allan, Rachel Croxton, Kelly Conner, Pamela W. Duncan, Gretchen Brenes, Matthew H. Wong, Cormac A. O’Donovan, James Kimball, Beverly M. Snively, Heidi Munger Clary

P1.5-008 A survey of

neurologists screening and management of depression in patients with epilepsy–Giancarlo Riotto, Iman Ali, Rehan Aziz, Jasdeep Hundal, Ram Mani

P1.5-009 Symptoms and

Impacts in Epilepsy: Findings from Qualitative Patient Interviews– Jacqueline French, Betsy N. Williams, Jiyoon Choi, Chad Gwaltney, Rachel Bruce, Jean Paty, Daniel Friedman

P1.5-010 Impact of Autism

Psychiatric and Behavioral Side Effects with Antiepileptic Drug Use–Baibing Chen

Spectrum Disorder Diagnosis on Epilepsy in Patients with Tuberous Sclerosis Complex–Jillian Drogin, Michael Gelfand

P1.5-004 Psychiatric Effects

P1.5-011 Employment and

of Ketogenic Diet Therapies on Adults with Chronic Epilepsy– Abigail Shegelman, Mackenzie Cervenka, Tanya J.W. McDonald, Bobbie Henry-Barron

P1.5-005 Anxiety in

Patients Admitted for Epilepsy Monitoring–Prateek Kumar Panda, Stacy Schantz Wilkins, Boulenouar Mesraoua, Gonzalo Alarcon Palomo, Hassan Jassim Al Hail, Lubna Ebn Omer El Sheikh, Musab Ali, Abdul Raheem Al Rabi

P1.5-006 A severe bone loss

in pharmacoresistant epilepsy associates with enzyme-inducing antiepileptic drug–Amanda Rigotti, Leticia Franceschet Ribeiro, Marcia E. Morita, Marina Koutsodontis Alvim, Job Monteiro, Carlos A M Guerreiro, Fernando Cendes, Clarissa L. Yasuda

socioeconomic status after epilepsy surgery: A study in a Mexican cohort.–Adib Jorge De Sarachaga, Gerardo Arellano-Flores, José Antonio Villar-Gallegos, Lyda Osorio, Mario Arturo Alonso Vanegas, Iris Martinez, Laura HernándezVanegas

P1.5-012 Quality Of Life And

Disease Progress In Patients With Drug Resistant Epilepsy–Jaime Olivas, Marco Antonio Diaz Torres, Sergio Andres Castillo Torres, Aime Carolina Rodriguez Martinez, James Park

P1.5-013 Factors Associated

with Quality of Life in a Low-income Population with Epilepsy.–Camilo Espinosa Jovel, Sergio Ramirez-Salazar, Carlos Rincon Rodriguez, Fidel E. Sobrino Mejia

P1.5-014 Effect of Seizure

Auras on Mood in Epilepsy: the ESAME Survey–Kristin Bumsch, Subhendu Rath, Jose Antonio Montes-Rivera, Marie C. Eugene, Dorothy Wakefield, L John Greenfield

132 2019 AAN Annual Meeting

11:30 a.m.–6:30 p.m. P1.5-015 Self-Reported

Depression and Anxiety Scores Similar in Patients with Temporal and Extra-Temporal Lobe Epilepsy–Caroline Abe, Alexander G. Doyle, David Denney, Munro Cullum, David Montemayor, Jessica Adams, Denise Castillo, Hina N. Dave, Kan Ding

P1.5-016 Seizure-induced

demargination predicts peri-ictal respiratory decompensation–Jose L. Vega, Prabhu D. Emmady, Christina Roels, John Conforti, Mehmet Dorak, Catalina Ramirez

P1.5-017 Quantitative Pupil

Measurements In Epileptic Seizures And Non-Epileptic Events – A Step Towards SUDEP Pathophysiologic Mechanisms.– Sushma Reddy Yerram, Lynn Liu, David V. Lardizabal, Shawn M. Whitton, Sharmila Suri Mohanram EPILEPSY: ANTISEIZURE MEDICATIONS I

P1.5-018 Utilizing Optical

Coherence Tomography to Assess the Effect of Phenytoin on Retinal Structures in Epilepsy Patients– Melody Gilroy, Kalyan Yarraguntla, Samuel Lichtman-Mikol, Rohit Ajay Marawar, Deepti Zutshi

P1.5-019 Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Multicenter, Open-Label Study–Michael R. Sperling, Pavel Klein, Marc Kamin

P1.5-020 Analysis of Psychiatric Adverse Events and Suicidality in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures–Jay Salpekar, Mark Mintz, Pnina Mintz, Todd Grinnell, David Cantu, Yan Li, Mariana Vieira, Ana C. Pereira, David E. Blum

P1.5-021 Safety and Efficacy of

Adjunctive Perampanel in Younger (aged 4 to <7 years) and Older (7 to <12 years) Pediatric Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study–Andras Fogarasi, Robert Flamini, Matieu T. Milh, Steven M. Phillips, Shinsaku Yoshitomi, Anna Patten, Takao Takase, Leock Y. Ngo

P1.5-022 Analysis of Allergic

P1.5-029 Pharmacokinetic

P1.5-023 A Two-Part, Double-

P1.5-030 Population

Reactions in Clinical Trials of Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures–Trevor J. Resnick, Todd Grinnell, David Cantu, Yan Li, Joana Graça, Helena Gama, David E. Blum Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Patients with Epilepsy with a Predictable Seizure Pattern: Results from the Initial Open-Label Feasibility Part–Jacqueline French, Kore K. Liow, Blanca R. Vazquez, Pavel Klein, Daniel C. Tarquinio, Brittany Reich, Robert Small, Jouko Ilkka Isojarvi

P1.5-024 A Post-Marketing

Observational Study to Evaluate the Safety and Tolerability of Perampanel as Add-On Therapy in Patients with Epilepsy Aged =12 Years–Melissa Maguire, Elinor Ben-Menachem, Louis Maillard, Anna Patten, Stella Leock Ngo

P1.5-025 Analysis of Hepatic

and Hypothyroidism-related Events in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 years) with Focal Seizures–James W. Wheless, Sanjeev V. Kothare, Todd Grinnell, David Cantu, Yan Li, Raquel Costa, Luis Magalhaes, David E. Blum

P1.5-026 Selective T-type

P1.5-027 Cosyntropin is poorly

effective in treatment of infantile spasms–Kapil Arya, Genevieve C. Gabriel, Gregory B. Sharp, Debopam Samanta, Virginia Erin Willis, Sarah Cobb, Christopher P. Manbeck, Jacqueline Edens, Todd Outlaw, Meg Cash, Kara Christensen, Rachelle Stanley, Adrianne Phillips, Julish Selvy

P1.5-028 A 12-month, open-

label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report–Michael R. Sperling, Robert E. Hogan, Victor Biton, Daniel C. Tarquinio, Enrique J. Carrazana, Gary D. Novack

Pharmacokinetics Of Lamotrigine In Adults Patients With Epilepsy.– Cinthya Chavez, Ildefonso Rodriguez-Leyva, Rosa del Carmen Milan Segovia, Susanna E. Medellin Garibay, Silvia Romano Moreno

P1.5-031 Clobazam Retention

Rate in Pediatric Epilepsy–Ernesto Gonzalez-Giraldo, Natali Baner, Ashley Nutt, Eric H. Kossoff, Sudha Kessler

P1.5-032 Time to Onset of

Efficacy in Seizure Reduction With Cenobamate (YKP3089) in Patients With Uncontrolled Partial Seizures From 2 Randomized Clinical Trials–Marc Kamin, Louis Ferrari

P1.5-033 Effects of

Cenobamate on GABA-A Receptor Modulation–Ramesh C. Sharma, Woo Seok Song, Michiko Nakamura, Chiranjivi Neupane, Hyewon Shin, Susan Melnick, Kelli Glenn, Il-Sung Jang, MyoungHwan Kim, Jin Bong Park

P1.5-034 The Pharmacokinetics of Cenobamate in Special Populations–Stephen Greene, Laurie Orlinski, Caroline Streicher, Laurent Vernillet

P1.5-035 Efficacy and

Tolerability of Clobazam in Adult Drug-Refractory Epilepsy–Noah Levinson, Alisha Jamil, Pouya Khankhanian, Chloe Electra Hill, Kathryn A. Davis

CLINICAL ADVANCES IN CNS CANCER CARE

P1.6-001 Tumors in the cauda

equina: a SEER analysis of tumor types and predictors of outcome– Saurav Das, Alex Urevick, Beatrice Ugiliweneza, Eric Christopher Burton

P1.6-002 A Meta-Analysis

Determining the Prevalence of Treatment-Associated Neurotoxicity in CancerDirected Immunotherapy with Antibodies–Erika Santos Horta, Connie Bongiorno, Mustapha A. Ezzeddine, Elizabeth C. Neil

P1.6-003 MRI changes in

patients with newly diagnosed glioblastoma treated as part of a Phase II trial with bavituximab, radiation, and temozolomide–Ina Ly, Jonathan Cardona, Andrew Beers, Ken Chang, James Brown, David Reardon, Isabel ArrillagaRomany, Jorg Dietrich, Deborah A. Forst, Eudocia Q. Lee, Justin T. Jordan, Lakshmi Nayak, Patrick Y. Wen, Tracy T. Batchelor, William T Curry, Jayashree Kalpathy-Cramer, Elizabeth R. Gerstner

P1.6-004 EEG Findings in

Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome–Sammita Satyanarayan, Matthew Scott Markert, Dominic Anthony Hovsepian, David Post, Lori Muffly, David Miklos, Reena Parada Thomas, Brian Scott

P1.6-005 Gliomatosis cerebri:

Management and survival in the United States–Catherine Garcia, Stacey Slone, John L. Villano

P1.6-006 Incidence of Distant

Recurrence in Adult Gliomas– Peter C. Pan, Tony Wang, Fabio Massaiti Iwamoto, Teri Kreisl, Mary Welch, Aya Mohamed Haggiagi, Angela Lignelli, Andrew Bruce Lassman

P1.6-007 CAR-T-cell-Related

Encephalopathy Syndrome: High Rates of Neurotoxicity in Clinical Practice–Carlen Amy Yuen, Shasha Wu, Anthony Reder, Kourosh Rezania, Betty C. Soliven, James A. Mastrianni, Tao Xie, Andrew Artz, Satyajit Kosuri, Peter Riedell, Deric M. Park, Michael Bishop

P1.6-008 A case series of

metastatic glioblastoma at Memorial Sloan Kettering Cancer Center–Evan Noch, Sameer Farouk Sait, Alexandra M. Miller

P1.6-009 Primary brain tumors

admitted to the neurological intensive care unit: a single institution observational study– Jennifer Kang, Christa Brittany Swisher, John Kirkpatrick, James E Herndon II, Eric Lipp, Leslie Thomas, Margaret O. Johnson, David Ashley, Annick DesJardins, Dina Randazzo, Henry Friedman, Katherine B. Peters

P1.6-010 Patterns of Death

and Palliative Care in Glioma Patients–Marissa Ann Barbaro, Craig Blinderman, Fabio Massaiti Iwamoto, Teri Kreisl, Mary Welch, Yazmin Odia, Katharine Evans, Andrew Bruce Lassman

P1.6-011 Psychiatric

Disturbance As a Presenting Symptom in Central Nervous System Lymphoma–Akanksha Sharma, Natalie Ertz-Archambault, Luke Mountjoy, Alyx B. Porter, Maciej M. Mrugala

P1.6-012 Characterization

of Seizures (ILAE 1981 and 2017 Classifications) and their Response to Treatment in a Cohort of Patients with Glial Tumors.–Ignacio F. Casas-Parera, Alejandra Roffo, Alejandra Báez, Fernando Quintans, Paola Castellanos Oropeza, Cecilia Sanchez Retamar

P1.6-013 Prognostic Factors

and Survival in Primary CNS Lymphoma Patients at Yale–Isabel Prado, Frank J. Barbiero, Joachim M. Baehring, Kevin P. Becker, Zachary A. Corbin

P1.6-014 Feasibility of a

Structured Tumor-related Epilepsy Education Intervention in Adult Gliomas–Andrea C. Wasilewski, Jennifer N. Serventi, Chinazom Uchenna Ibegbu, Joy Ellen Burke, Thomas Wychowski, Nimish A. Mohile

P1.6-015 Primary CNS

posttransplant lymphoproliferative disease (PCNS-PTLD): Diagnosis, minimal treatment toxicity, and surveillance in renal transplant patients–Jeffrey Summers, Gino Mongelluzzo, Erika Leese, Anand Mahadevan, Maria Bermudez, Joseph Vadakara, Na Tosha N. Gatson

P1.6-016 Telehealth for

Specialty Neurofibromatosis (NF) Care–Justin T. Jordan, Marlon Seijo, Vanessa Merker, Shivkumar Bhadola, Raquel D. Thalheimer, Scott R. Plotkin

P1.6-017 Pineal parenchymal

tumors of intermediate differentiation treated with ventricular radiation and temozolomide–Justin Thomas Low, John Kirkpatrick, Katherine B. Peters

AAN.com/view/AM19Sci 133

Sunday

Calcium Channel Modulator CX8998 Fully Suppresses Seizures in the GAERS Genetic Model of Epilepsy at Human Achievable Concentrations–Margaret S. Lee, Evan Newbold, Spiridon Papapetropoulos

(PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration–Larisa Reyderman, Jim Ferry, Leock Y. Ngo, Min-Kun Chang, Jagadeesh Aluri, Peter Boyd, Ziad Hussein

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.6-018 A Feasibility Trial

of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma–Lisa R. Rogers, David M. Peereboom, Sarah Rolfe, Karen Devine, Kathy Smolenski, Andrew Sloan, Mohamed Hamza

Abnormalities in CNS Germ Cell Tumors–Sasmit Sarangi, Marc Albert Bouffard, Eric Tai-Lee Wong

P1.6-028 Standardized

Chemoradiation (CRT) in Newly Diagnosed Glioblastoma (GBM) Treated With Stupp Protocol– Assad Ali, Konrad Knusel, Addison Barnett, Anas Ahmed Moahmmed Saeed Bamashmos, Soumya Sagar, Manmeet Ahluwalia

Intrathecal (IT) Treatment and Surveillance in Leptomeningeal Carcinomatosis (LMC) Improves Patient Outcomes: developing Ommaya IT chemotherapy clinics–Erika Leese, Tierney McGee, Anand Mahadevan, Gino Mongelluzzo, Michel Lacroix, Joseph Vadakara, Andrew Conger, Na Tosha N. Gatson

P1.6-020 Neurological Adverse

P1.6-029 Treatment of Cerebral

P1.6-019 Impact of Delay of

Effects Due to Programmed Death (PD-1) Inhibitors–Siyu Shi, Ruhi Kanwar, Vamsi Varanasi, Ella Eisinger, Reena Parada Thomas, Justin Moore

P1.6-021 The Financial Burden

Cysts with Ommaya Reservoir – A Review of 4 Cases–Michellee Mayers, Nicholas Blondin CHILD NEUROLOGY: NEUROGENETICS

of Central Nervous System Cancers in the United States– Miren Pena, Chelsea Mendonca, Mehdi Siddiqui, Sheetal Hegde, Ali Seifi

P1.6-030 A kinome-wide

P1.6-022 Facial palsy induced

Mutations in TUBB4A: A New Spectrum of Disease–Brittany A. Charsar, Eline M.C. Hamilton, Zachary Cross, Omar Sherbini, Julia Kramer-Golinkoff, Cas Simons, Marjo Van Der Knaap, Adeline Vanderver

by cancer immunotherapy: a single center retrospective study–Carlen Amy Yuen, Pankti Reid, Zuoli Zhang, Betty C. Soliven, Jason Luke, Kourosh Rezania

P1.6-023 Planning a Glioma

Partial Resection with DTI Tractography and Virtual Reality– Henry Sanicola, Caleb Stewart, Stephen Fletcher, Morgan Brooks, Marcus Ware, Korak Sarkar

P1.6-024 iPROMPT: Integrated

Sunday

P1.6-027 Eye Movement

Predictive Radiographic biOMarkers of Progressed high grade astrocytic Tumors–Na Tosha N. Gatson, Erika Leese, Joseph Vadakara, Tierney McGee, Michel Lacroix, Gino Mongelluzzo

P1.6-025 NeMeRe, a Multi-

Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults–Shilpa Ghatnekar, Hilal Hachem, Amandeep Godara, Rima Patel, Suriya A. Jeyapalan

P1.6-026 Neurological

Complications in an ALS Patient with Metastatic Melanoma after Immunotherapy–Muhammad Hasanayn Jaffer, Neha Verma, Edwin N. Peguero, Sepideh Mokhtari, Asha Ramsakal

134 2019 AAN Annual Meeting

RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability–Jimmy Holder, Li Wang

P1.6-031 Classification of

P1.6-032 Spherical Nucleic

Acids Show Increased Distribution and Longer Persistence than Linear Oligonucleotides in Rat Brain Following Intrathecal Administration–Ekambar Kandimalla, Weston Daniel, Scott Mix, SubbaRao Nallagatla, Dustin Kentala, Ken Zasadny, Andrew Schook, Lena Cedrone, Paul Marks

P1.6-033 Phenotypic

Characterization of Individuals with SYNGAP1 Pathogenic Variants Reveals Correlation Between Posterior Dominant Rhythm and Developmental Progression–Andres Jimenez Gomez, Sizhe Niu, Fabiola AndujarPerez, Elizabeth McQuade, Alfred Balasa, David Huss, Rohini Coorg, Michael Quach, Sherry Vinson, Sarah R. Risen, Jimmy Holder

Sunday, May 5 P1.6-034 Establishing

Clinical Trial Readiness of the Rett Syndrome Hand Function Measure–Helen Leonard, Timothy A. Benke, Pamela Diener, Douglas Feltner, Petra Kaufmann, David N. Lieberman, Amie LoCicero, Thomas Macek, Bryan McGill, Julie Miner, Lynlee Muehring, Jeffrey L. Neul, Joan O’Keefe, Haojun Ouyang, Alan K. Percy, Daniel C. Tarquinio, Jenny Downs

P1.6-035 Resting-State

EEG Abnormalities in Children with Rett Syndrome–Samuel Tomlinson, Joni Saby, Clare CutriFrench, Dallas Armstrong, Eric D. Marsh

P1.6-036 JASPER Early

Intervention in TSC (JETS): Methods to enhance study participation and scalability in rare disorders–Shafali Jeste, Nicole McDonald, Charles A. Nelson, Connie Kasari

P1.6-037 Recurrent mosaic

MTOR c.5930C>T (p.Thr1977Ile) Variant Causing Megalencephaly, Asymmetric Polymicrogyria, and Cutaneous Pigmentary Mosaicism–Maureen Handoko, Lisa T. Emrick, Jill Rosenfeld, Xia Wang, Alyssa Tran, Alicia Turner, John Belmont, Brendan Lee, Carlos Bacino, Hsiao-Tuan Chao

P1.6-038 Iron deficiency and

response to treatment with regard to sleep difficulties in Angelman Syndrome–Conor Ryan, Ralitza H. Gavrilova, Suresh Kotagal

P1.6-039 A Expanded Cohort

Study of the X-linked HNRNPH2related Neurodevelopmental Disorder–Jennifer M. Bain, Olivia Thornburg, Rachel Salazar, Nicole Holuba LaMarca, Wendy Chung

P1.6-040 Case Series:

Expansion of MT-ATP6 Pathogenic Variant Phenotype–Reega Purohit, Linda Laux, Tracy Gertler

P1.6-041 Developmental and

behavioral characteristics of children with Dup15q syndrome– Charlotte Distefano, Rujuta Bhatt Wilson, Shafali Jeste

P1.6-042 Children with

Neurogenetic Disorders Hospitalized with Communityacquired Pneumonia are at Increased Risk for Poor Outcomes–Murali K. Kolikonda, Rajashekar Reddy Yeruva, Connor Glick, Julio Ramirez

11:30 a.m.–6:30 p.m. P1.6-043 Neurobehavioral

Issues in the Phenotypic Spectrum of Variations in OTX2–Himadri Patel, Harmanpreet Tiwana, Mayur Chalia, Melissa Yelton, Gayatra Mainali, Gerald Raymond, Ashutosh Kumar

P1.6-044 Novel autosomal

recessive variants in GEMIN5 gene lead to developmental delay motor dysfunction, and cerebellar atrophy.–Deepa Soundara Rajan, Stacie Oliver, Rogan Grant, Udai Pandey

P1.6-045 FOXG1 syndrome: A

rare disorder often misdiagnosed as cerebral palsy–Nerea Lia, Syed Daniyal Asad, Shashank Sama, Louisa Kalsner

P1.6-046 Diversity of

Epilepsy and Movement Disorder Phenotypes in STXBP1 Mutations–Darrah Haffner, Kimberly Goodspeed

P1.6-047 “Peer-to-Peer”: A

program to Connect a Clinical Genomicist and the Treating Neurologist to Correlate Genotype with Phenotype–Mark Mintz, Daphna Varadi, Pnina Mintz, Richard Boles

P1.6-048 Periodic Paralysis

in the Phenotypic Spectrum of CLCN1 Gene Mutation–Himadri Patel, Harmanpreet Tiwana, Gayatra Mainali, Matthew P. Wicklund, Ashutosh Kumar

P1.6-049 Neurodegeneration

and muscular involvement in intermediate autosomal recessive CLCN7-related Osteopetrosis: an atypical presentation–Joao Luís Oliveira Durães, Patricia Rodrigues Marques, Diana Duro, Sergio Bernardo Sousa, Maria Macário

P1.6-050 CEDNIK syndrome, a rare neuro-cutaneous disorder– Harmanpreet Tiwana, Gerald Raymond, Ashutosh Kumar

CHILD NEUROLOGY: NEUROMUSCULAR DISEASE TRIALS: DMD AND SMA

P1.6-051 Symptoms and

Complications Over Three Years among Later Childhood, Adolescent and Adult Spinal Muscular Atrophy Patients: A Natural History Study within U.S. Hospitals–Angela Paradis, Christina Wassel, Jill Dreyfus, Sandra P. Reyna, Nicole Johnson, Mehul Jhaveri

CHILD NEUROLOGY: NEUROMUSCULAR DISEASE TRIALS: DMD AND SMA

P1.6-052 Treatment Algorithm

for Infants Diagnosed with Spinal Muscular Atrophy Through Newborn Screening–Jacqueline Glascock, Jacinda B. Sampson, Amanda M. Haidet-Phillips, Anne M. Connolly, Basil T. Darras, John W. Day, Richard S. Finkel, Rodney Howell, Katherine Klinger, Nancy L. Kuntz, Thomas Prior, Perry Shieh, Thomas O. Crawford, Douglas A. Kerr, Jill Jarecki

P1.6-053 Motor Outcomes

after Clinical Treatment with Nusinersen: A Single-center Experience–Elizabeth Anne Kichula, Priya Devanarayan, Allan M. Glanzman, Timothy Estilow, Sabrina Yum, John Brandsema

P1.6-054 The Economic Burden of Spinal Muscular Atrophy Patients in a CommerciallyInsured Population in the United States–Joseph Goble, Dong Dai, Fernanda Boulos, Anni Weng, Kristen Johnson

P1.6-055 Effect of Aggressive

Therapies on Spinal Muscular Atrophy Type 1 Patients Receiving Nusinersen–Emmanuelle R. Tiongson, Melissa Cowell, Anna Kitabjian, Emily Gillett, Cheryl Lew, Leigh Ramos-Platt

P1.6-056 Number Needed to

Treat (NNT) in Spinal Muscular Atrophy Type 1 (SMA1) with AVXS-101 Relative to Nusinersen–Marcus Droege, Omar Dabbous, Martin Cloutier, Annie Guerin, Irina Pivneva, Eric Q. Wu, Douglas M. Sproule Replacement Therapy (GRT) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update–Meredith Schultz, Kathryn J. Swoboda, Michelle Farrar, Hugh John McMillan, Julie Anne Parsons, Courtney Wells, Francis Ogrinc, Bryan McGill, Douglas Feltner, James L’Italian, Douglas M. Sproule, Kevin Strauss

Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update–John W. Day, Claudia A. Chiriboga, Thomas O. Crawford, Basil T. Darras, Richard S. Finkel, Anne M. Connolly, Susan T. Iannaccone, Nancy L. Kuntz, Loren DM Pena, Meredith Schultz, Perry Shieh, Edward Clinton Smith, Douglas Feltner, Francis Ogrinc, Thomas Macek, Courtney Wells, Lynlee Muehring, James L’Italien, Douglas M. Sproule, Brian Kaspar, Jerry R. Mendell

P1.6-059 Phase 1 Study of

Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG)–Richard S. Finkel, John W. Day, Basil T. Darras, Nancy L. Kuntz, Anne M. Connolly, Thomas O. Crawford, Russell Butterfield, Perry Shieh, Gihan Tennekoon, Susan T. Iannaccone, Matthew N. Meriggioli, Sidney A. Spector, Francis Ogrinc, James L’Italien, Courtney Wells, Brian Kaspar, Douglas M. Sproule, Douglas Feltner, Jerry R. Mendell

P1.6-060 The Value of AVXS-

101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1: Improved Survival, Pulmonary and Nutritional Support, and Motor Function with Decreased Hospitalization–Omar Dabbous, Douglas M. Sproule, Douglas Feltner, Marcus Droege, Khan Farid, Ramesh Arjunji

P1.6-061 Ambulation Status,

Role Participation and Caregiver Assistance among Individuals with Spinal Muscular Atrophy Type III: Results from the 2018 Cure SMA Membership Survey–Lisa Belter, Jill Jarecki, Rosangel Esperanza Cruz, Colleen McCarthy O’Toole, Karen O’Brien, Sandra P. Reyna, Susan A. Hall, Angela Paradis

P1.6-062 A Phase 1b/2 Study

of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update–Kathryn Rae Wagner, Brenda L Y Wong, Barry Byrne, Cuixia Tian, Leslie Jacobsen, Giridhar Tirucherai, Michael Rabbia, Heidemarie Kletzl, Juergen Dukart, Rose Ong, Karl Yen, Gautam Sajeev, James Signorovitch, Susan J. Ward, Cliff Bechtold, Michelle Krishnan

P1.6-063 Interim Report

on the Safety and Efficacy of Longer-term Treatment With Nusinersen in Later-onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study–Basil T. Darras, Michelle Farrar, Eugenio Mercuri, Claudia A. Chiriboga, Jan Kirschner, Nancy L. Kuntz, Perry Shieh, Mar Tulinius, Jacqueline Montes, Giulia Gambino, Richard Foster, Ishir Bhan, Wildon Farwell, Sandra P. Reyna

P1.6-064 Clinical and

Electrophysiological outcomes of Spinal Muscular Atrophy type 1 patients treated with Nusinersen.–Emily Kern-Smith, Sumit Verma

P1.6-065 Case Series: Spinal

Muscular Atrophy Patients’ Response to Nusinersen in a Caribbean Cohort–Alexandra Montalvo, Mayela Marie Diaz Diaz, Janice Rodriguez Hernandez, Marisel Vazquez, Jessica Gonzalez Montes, Jocelyn Montalvo, Mireya M. Bolo-Diaz

P1.6-066 Deflazacort or

Prednisone Treatment for Duchenne Muscular Dystrophy: A Meta-Analysis of Disease Progression Rates in Recent Multicenter Clinical Trials–James Signorovitch, Traci Schilling, Gautam Sajeev, Zhiwen Yao, Erin McDonnell, G. L. Elfring, Marcio Nattan Portes Souza, Stuart Peltz, Basil T. Darras, Perry Shieh, Craig McDonald

P1.6-067 Effect of Ataluren

on Age at Loss of Ambulation in Nonsense Mutation Duchenne Muscular Dystrophy: Observational Data from the STRIDE Registry–Abdallah Delage, Filippo Bucella, Isabelle Desguerre, Francesco Muntoni, Andres Nascimento Osorio, Mar Tulinius, Salvatore Colucci, Allan Kristensen, Claudio Santos, Traci Schilling, Panayiota Trifillis, Olivia Zhang, Eugenio Mercuri

P1.6-068 Early signs of gross

motor delay in very young boys with Duchenne muscular dystrophy–Natalie Fae Miller, Lindsay N. Alfano, Megan Iammarino, Margaret Dugan, Melissa Moore-Clingenpeel, Chang-Yong Tsao, Megan A. Waldrop, Kevin M. Flanigan, Jerry R. Mendell, Linda Pax Lowes

P1.6-069 Developing Tools to

Assess Changes Associated with Aerobic Exercise in Boys with Duchenne Muscular Dystrophy– Aaron Simon Zelikovich, Theresa Oswald, Mattia Quattrocelli, Elizabeth McNally, Vamshi Rao, Nancy L. Kuntz

P1.6-070 Travel Burden of

Spinal Muscular Atrophy Patients in the United States–Joseph Goble, Dong Dai, Xue Song, Nianwen Shi, Fernanda Boulos, Lu Zhang, Kristen Johnson AUTOIMMUNE NEUROLOGY/MS AND CNS INFLAMMATORY DISEASE EPOSTER SESSION

P1.7-001 Optic Nerve Pathology and Visual Functioning in Pediatric Patients with antiMOG Antibodies–Benjamin M. Greenberg, Leslie A. Benson, Jennifer Graves, Darrel Conger, Amy T. Waldman

P1.7-002 Neuronal

Autoantibodies and Clinical Significance in Stiff-Person Spectrum Disorder–Juntaro Kaneko, Takahiro Iizuka, Yuko Kondo, Yuki Abe, Atsushi Kaneko, Kasumi Hattori, Shunsuke Kobayashi, Yoshikazu Ugawa, Kenji Sekiguchi, Kengo Maeda, Yushi Matsumoto, Naomi Kanazawa, Eiji Kitamura, Josep O. Dalmau, Kazutoshi Nishiyama

P1.7-003 Improving Patient

Experience, Clinical Practice, and Provider Knowledge and Competence of Chronic Inflammatory Demyelinating Polyneuropathy with Online Continuing Medical Education– Anne C. Roc, Wendy Turell, Richard J. Barohn

P1.7-004 Severe Cerebellar

Syndrome Improved with Plasma Exchanges in Patient with Lung Adenocarcinoma Treated with Durvalumab–Connie Gwendolyn Tang, Rita Axelrod, Goran Rakocevic

P1.7-005 Progressive

Neurodegeneration in X-Linked Agammaglobulinaemia–Timothy Richard Gall, Jason S. Hawley, Yitao Ma

P1.7-006 Safety of Checkpoint

Inhibitors for Cancer Treatment in Patients with Multiple Sclerosis: A Case Report–Cigdem Isitan, Sarah Flanagan Wesley

AAN.com/view/AM19Sci 135

Sunday

P1.6-057 AVXS-101 Gene-

P1.6-058 AVXS-101 Gene-

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.7-007 Progressive

Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)–Mahsa Khayatkhoei, Jaskaren Kaur Randhawa, Shivika Chandra, Rohini D. Samudralwar

P1.7-008 The potential of

Teriflunomide for regional and global brain volume protection in single subject MS patients–Alaleh Raji, Gerhard Winkler

P1.7-009 Acute disseminated

encephalomyelitis following Mycoplasma pneumoniae infection in a young adult collegiate athlete–Christina Rose Kyrtsos, Ronald Seese, Janet F. Waters

P1.7-010 Acute and Lasting

Benefits of a Virtual Reality in Multiple Sclerosis–Michael Shaw, Maria Palmeri, Lauren B. Krupp, Leigh Elkins Charvet

ATAXIA

P1.8-001 Results from the

Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia–Melissa Beiner, Victoria Wirtz, Vlad Coric, Robert Berman, Gilbert J. L’Italien

Sunday

P1.8-002 The impact of

ethnicity on the phenotype of a monogenetic disorder: spinocerebellar ataxias type 3–Shi-Rui Gan, Karla Patricia Figueroa, Susan L. Perlman, George R. Wilmot, Christopher Gomez, Jeremy D. Schmahmann, Henry L. Paulson, Vikram Shakkottai, Sarah H. Ying, Theresa A. Zesiewicz, Khalaf Bushara, Michael D. Geschwind, Guangbin Xia, S H. Subramony, Tetsuo Ashizawa, Stefan M. Pulst, Ning Wang, Sheng-Han Kuo

P1.8-003 Comparative Profiling

of Peripheral Blood Mononuclear Cells Proteome in Patients With Friedreich’s Ataxia–Deepti Pathak

136 2019 AAN Annual Meeting

P1.8-004 Overwhelming genetic heterogeneity and exhausting molecular diagnostic process in chronic and progressive ataxias: Facing up with an algorithm, a gene, a panel at the same time.– Lucia Jimena Zavala, Josefina Perez Maturo, Sergio Rodriguez Quirofa, PATRICIA VEGA, Dolores Gonzalez Moron, Nancy Medina, Nelida Garreto, Tomoko Arakaki, Marcelo Andres Kauffman

P1.8-005 Preclinical

Assessment of TAK-831, a Selective D-Amino Acid Oxidase Inhibitor, in a Genetic Model of Friedreich’s Ataxia (YG8sR)–Rosa Fradley, David Miller, Mark Pook, Jordi Serrats

P1.8-006 Ultrastructural

Changes in Brain Stem Pathways in a Patient with Ataxia Associated with SPG7 Mutations–John Matthew Ringman, Yuchuan Qiao, Yonggang Shi

P1.8-007 Updates to the

National Institute of Neurological Disorders and Stroke (NINDS) Friedreich’s Ataxia (FA) Common Data Element (CDE) Recommendations: 2018 FA Working Group Review–Katelyn Elizabeth Gay, Ilar Edun, Muniza Sheikh, Joy R. Esterlitz, David R. Lynch, Massimo Pandolfo, Amelie Gubitz, Codrin I. Lungu, Carolina Mendoza-Puccini

P1.8-008 Frataxin deficiency

causes excessive mitochondrial fragmentation associated with mitochondrial fission core components–Joseph Johnson, Elisia Clark, Elizabeth MercadoAyon, David R. Lynch, Hong Lin

P1.8-009 Structural Magnetic

Resonance Imaging Correlates of Neurodegeneration in a Spinocerebellar Ataxia Type 7 Cohort–Jacob Parker, Silvina Horovitz, Sanaz Attaripour, Shabbir Hussain I. Merchant, Patrick Mcgurrin, Mark Hallett

P1.8-010 Inpatient Verses

Outpatient Workup of Patients with Ataxia and Suspected Paraneoplastic Cerebellar Degeneration: Does Workup Location Matter?–Natalie P. Witek, Mitra Afshari, Yuanqing Liu, Bichum Ouyang, Deborah Hall

Sunday, May 5 P1.8-011 Cerebellar

endoplasmic reticulummitochondria calcium signal pathways are impaired in the KIKO mouse model of Friedreich ataxia–Hong Lin, Elisia Clark, Nathan Warren, Yi-Na Dong, Jordi Magrane, David R. Lynch

P1.8-012 Ataxia with

Transglutaminase 6 Mutation (SCA35) Responding to GlutenFree Diet: A Case Report–ChihChun Lin, Shi-Rui Gan, Deepak Kumar Gupta, Armin Alaedini, Peter Green, Sheng-Han Kuo

P1.8-013 Diagnostic Value of

Next Generation Sequencing Ataxia Panel as a Part of Multistep Investigation Approach in Sporadic and Autosomal Recessive Cerebellar Ataxias in Russia–Yury Seliverstov, Evgenii Nuzhnyi, Sergey A. Klyushnikov, Natalia Abramycheva, Anna Vetchinova, Sergei N. Illarioshkin

P1.8-014 Autosomal Recessive Spastic Ataxia of CharlovoixSaguenay. A new pathogenic mutation.–Moira Flanigan, Yasaman Safarpour, Wojciech Wiszniewski, Nizar Chahin, Delaram Safarpour

P1.8-015 Opsoclonus

Myoclonus Ataxia Related to West Nile Virus–Houda Boucekkine, Adys Mendizabal, Elias Impens, Sharon Lewis, Nabila Dahodwala PARKINSON’S DISEASE SURGICAL, STEM CELL, AND GENE THERAPIES

P1.8-016 Results of an Open

11:30 a.m.–6:30 p.m. P1.8-018 “Dual Frequency”

Deep Brain Stimulation Programming Paradigm for Gait and Balance Impairment in Parkinson’s Disease–Jessica A. Karl, Bichum Ouyang, Leonard Verhagen Metman

P1.8-019 National Trends

in Utilization of Deep Brain Stimulation In Primary Movement Disorders: National Inpatient Sample Study 2006-2014–Anantha Vellipuram, Mohammad Rauf Afzal, Mohtashim Arbaab Qureshi, Ihtesham A. Qureshi, Harathi Bandaru, Mohammad Ghatali, Alberto Maud, Rakesh Khatri, Darine Kassar, Paisith Piriyawat, Gustavo J. Rodriguez, Salvador Cruz-Flores

P1.8-020 Correlation of

Electrode Location and Outcomes of Gait and Axial Function in Parkinson’s Disease Patients managed with Subthalamic Deep Brain Stimulation–Yonglu Huang, Andres Felipe Deik Acosta Madiedo, Meredith Spindler, Adolfo Ramirez Zamora

P1.8-021 The Use of Omni

vs. Directional Programming in Parkinson Disease and Essential Tremor DBS Patients–Vibhash D. Sharma, Kelly E. Lyons, Jules Nazzaro, Rajesh Pahwa

P1.8-022 APOE E4 Carrier

Status Modulates Cognitive Outcome after Deep Brain Stimulation in Parkinson’s Disease Patients–Esther Yoon, Sarah Ahmed, Irene Dustin, Debra J. Ehrlich

Label, Dose Escalating, Phase 1 Clinical Trial Evaluating the Safety of a Human Neural Stem Cell Based Therapy in Parkinson’s Disease–Russell A. Kern, Ibon Garitaonandia, Rodolfo Gonzalez, Glenn Sherman, Andrey Semechkin, Emma Braine, Girish C. Nair, Andrew Howard Evans

P1.8-023 Using a quality

P1.8-017 PD-1102: A Phase

P1.8-024 CLOVER-DBS: A

1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and Motor Fluctuations–Amber D. Van Laar, Mark Richardson, Chadwick W. Christine, Stewart A. Factor, Robert Gross, Sandra K. Kostyk, Russell Lonser, Marc de Somer, Alexander Sedkov, Bernard M. Ravina, Adrian Kells, Krzysztoffs Bankiewicz, Paul Larson

improvement framework to examine deep brain stimulation in Parkinson’s disease: the RAD-PD initiative–Joohi Jimenez Shahed, Pierre-Francois d’Haese, James Kirk, Michele K. York, Arthur Berg, Ludy Chen Shih, Jason Schwalb, James McInerney Prospective, Multicenter Clinical Study with Blinding to Evaluate a Closed Loop Programming Algorithm for Directional Leads Based on External Feedback– Gregor Wenzel, Christof Br√ºcke, Leon Juarez Paz, Kenny Wynants, Heleen Scholtes, David Blum, Andrea Kuehn

P1.8-025 Monitoring Safety

and Effectiveness of Deep Brain Stimulation Systems in a RealWorld Population: The Product Surveillance Registry–Fernando L. Pagan, Mya C. Schiess, Leonard Verhagen Metman, George M. Plotkin, Kenneth P. Martinez

P1.8-026 Two Year Outcomes:

A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease (INTREPID)– Jerrold L. Vitek, Roshini Jain, INTREPID Study Group, Philip Starr

P1.8-027 The STN Sweet Spot for Tremor Control in Parkinson’s Disease.–Tamara Stiep, Anthony Diaz, Iahn Cajigas, Jonathan Jagid, Corneliu C. Luca

P1.8-028 Characteristics of

oscillatory activity in the globus pallidus internus in patients with Parkinson’s disease–Ping Zhuang, Mark Hallett, Detao Meng, Yuqing Zhang, Yongjie Li

P1.8-029 Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison– Katherine Emily Leaver, Joan Miravite, Calla Dilli, Brianna Sa, Roberto P. Ortega, Eileen Moran, Brian Kopell, Michael S. Okun, Kelly D. Foote, Vicki Shanker, Susan B. Bressman, Rachel J. Saunders-Pullman

P1.8-030 DIRECT-DBS: A

P1.8-031 Deep Brain stimulation in Parkinson: Use of kinematics to study impact of DBS on gait–Richa Tripathi, Garrett E. Alexander, Stewart A. Factor

on axial and non-motor symptoms in patients with Parkinson’s disease: a prospective study– Yasmine Miguel, Maya Mouallem, Bouchra Tannir, Maria Fraraccio, Christiane Lepage, Abbas Sadikot, Michel Panisset

P1.8-033 Long-term Effects

of Bilateral Subthalamic Deep Brain Stimulation on Postural Instability and Gait Disturbance in Parkinson’s Disease–Hae-Won Shin, Ho-Sung Ryu, Sun J. Chung

P1.8-034 Early Experiences

with Multiple Independent Current Control DBS in Parkinson’s Disease–Daniel Ramon Lorido, Jonathan Jagid, Corneliu C. Luca

P1.8-035 Men Are More

Likely to Have DBS for Tremor in Parkinson’s Disease–William Alexander Dalrymple, Scott A. Sperling, Joseph Flanigan, Madaline B. Harrison, Binit Shah, Matthew J. Barrett

P1.8-036 Refractory Gait

Freezing Following GPi Stimulation for Parkinson’s Disease–Benjamin Sketchler, Joohi Jimenez Shahed

P1.8-037 Dorsal GPi/GPe DBS

Induced Dyskinesia–Ahmad El Kouzi, Shannon Chiu, Matthew Robert Burns, Robert Stephen Eisinger, Leonardo B. Almeida, Adolfo Ramirez Zamora, Kelly D. Foote, Michael S. Okun, Wissam Georges Deeb

P1.8-038 Outcomes of Deep

Brain Stimulation Surgery in Parkinson’s Disease: Real Life Experience from a Tertiary Care Center–Ryan T. Brennan, David M. Whitney, Amy Hellman, John M. Bertoni, Diego Torres-Russotto, Danish Bhatti

P1.8-039 Outcomes of a

Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson’s Disease–Guenther Deuschl, Roshini Jain, Alex Wang, Heleen Scholtes, Roshini Jain, Jan Vesper

P1.8-040 Tradeoffs in current

steering technologies for deep brain stimulation–Simeng Zhang, Andrea Kuhn, Nader Pouratian, Binith Cheeran, Lalit Venkatesan, Alexander Kent, Alfons Schnitzler

HUNTINGTON’S DISEASE AND OTHER CHOREAS

P1.8-041 Salivary Biomarkers

in Huntington’s Disease–Jody Corey-Bloom, Chase Snell, Ameera Haque, Aeri Kim, Jordan Castleton, Haileigh Smith, Douglas Granger, Steven Granger, Elizabeth Thomas

P1.8-042 Preliminary

Reliability and Validity of a Novel Digital Biomarker Smartphone Application to Assess Cognitive and Motor Symptoms in Huntington’s Disease (HD)–Florian Lipsmeier, Cedric Simillion, Atieh Bamdadian, Anne Smith, Scott Schobel, Christian Czech, Christian Gossens, Patrick Weydt, Edward J. Wild, Michael Lindemann

P1.8-043 Defining Clinically

Meaningful Change on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS)– Dylan Trundell, Giuseppe Palermo, Scott Schobel, Jeffrey Long, Blair Leavitt, Sarah J. Tabrizi

P1.8-044 Decreased cerebral

blood flow in the striatum is an early event in Huntington’s disease pathology–Erin FurrStimming, Natalia Pessoa Rocha, Leigh Latham, Odelin Charron, George Papadimitropoulos, Gabriela D. Colpo, Leorah Aude Emmanuelle Freeman, Antonio Teixeira

P1.8-045 Electroconvulsive

Therapy (ECT) for the Treatment of Refractory Depression in Huntington’s Disease Patients: A Case Series–Jennifer Smith, Neil A. Nadkarni, Eric Gausche, Danny Bega

P1.8-046 Feasibility of Using

a Smartphone Application to Evaluate Huntington Disease– Jamie Lynn Adams, Emma Waddell, Karthik Dinesh, Kelsey Spear, Christopher Tarolli, Molly Elson, Alistair Glidden, Michael Curtis, David Mitten, Gaurav Sharma, E. Ray Dorsey

P1.8-047 Ancillary Service

Utilization and Impact in Huntington’s Disease–Jacob Esper Yomtoob, Chen Yeh, Danny Bega

P1.8-048 MRI Volumetric

Analysis of 20 Early Manifest Huntington Disease Patients to Determine the Safety of Delivering Gene Therapy to the Striatum–Steven S. Gill, Raymund Roos, Melvin Evers, Pavlina Konstantinova, Joseph J. Higgins

P1.8-049 The Visual System

in Huntington’s Disease–Ali G. Hamedani, Tanya Bardakjian, Pedro Gonzalez-Alegre

P1.8-050 White matter

microstructural alterations in Huntington Disease: when neurodegeneration starts?–Paula Christina Azevedo, Luiza Gonzaga Piovesana, Mateus Nogueira, Rachel Guimarães, Augusto Amato-Filho, Fernando Cendes, Iscia Lopes-Cendes, Clarissa L. Yasuda

P1.8-051 Allele Selective

Antisense Oligonucleotides for Reducing Mutant Huntingtin– Jeffrey Brown, Maria FrankKamenetsky, Kidist Aklilu, Jean-Cosme Dodart, Shaunna Berkovitch, Kristin Taborn, Michael Byrne, Naoki Iwamoto, Zhong Zhong, Chandra Vargeese

P1.8-052 Generalized Chorea

and JAK2V617F Mutation-Positive Myeloproliferative Disorders: A Case Report and Literature Review–Sagari R. Bette, Carlos Singer, Henry Paul Moore

P1.8-053 Chorea after West

Nile Virus Encephalitis: A Case Report–Alana E. Kirby, Mitra Afshari

NEURO-OPHTHALMOLOGY/ NEURO-OTOLOGY

P1.9-001 Development

of Portable Pupillometer for Assessment of Neurological Disease–Heather Moss, Megha Prasad Bindiganavale

P1.9-002 Macular Pigment In

Multiple Sclerosis–Alba Xhepa, Elisa Cozzi, Chiara Mancinelli, Silvia Rosa, Cinzia Cordioli, Leonardo Pantoni, Mario Cigada, Ruggero Capra, Giovanni Staurenghi

AAN.com/view/AM19Sci 137

Sunday

Prospective, Multi-center Clinical Study of a Directional DBS Lead – Therapeutic Windows with Directional Stimulation–Frank Steigerwald, P.R. Schuurman, Cordula Matthies, Anna Dalal Kirsch, Stephan Chabardes, Robertus Maria Alfonsius De Bie, Timo R. Ten Brinke, Elena Moro, Valérie Fraix, Sara Meoni, Leon Juarez Paz, David Blum, Kenny Wynants, Heleen Scholtes, Nic Van Dyck, Jens Volkmann

P1.8-032 Effects of STN-DBS

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 P1.9-003 Anti-glutamic acid

decarboxylase associated neurologic disorders referred from Neuro-ophthalmology and Neurotology: A case series with characterization of vestibuloocular function–Yujie Wang, Roksolyana Romana Tourkevich, Daniel R. Gold, Scott Douglas Newsome

P1.9-004 The Effects of Alcohol Consumption on Cognitive Performance Using the KingDevick Rapid Number Naming Test and the Mobile Universal Lexicon Evaluation System–Ali Shah Tejani, Bert B. Vargas, Emily Middleton, Craig Crandall, Mu Huang

P1.9-005 Investigating the

Structure and Function of the Retinohypothalamic Tract in Neuromyelitis Optica by Optical Coherence Tomography (OCT) and Pupillometry–Ethan Isaac Meltzer, Peter Sguigna, Teresa Frohman, Randy Kardon, Elliot M. Frohman

Sunday

P1.9-006 Angio-OCT micro

vascular markers and central auditory disorder as indipendent predictors of cognitive impairment in the Great Age Study population–Rodolfo Sardone, Giancarlo Sborgia, Marco Piccininni, Petronilla Battista, Alfredo Niro, Gianluigi Giuliani, Pasquale Puzo, Angelo Pascale, Alessandra Sborgia, Chiara Griseta, Maria Rosaria Barulli, Cristina Didio, Alessandra Grasso, Fabio Castellana, Francesco Coppola, Tiziana Lozupone, Roberta Rucco, Madia Lozupone, Francesco Panza, Giovanni Alessio, Nicola Quaranta, Giancarlo Logroscino

P1.9-007 Non-chiasmal

bitemporal pseudo-hemianopia: case series–Arina Bingeliene, Arun Sundaram

P1.9-008 Prognostic Factors

of Poor Outcome in Idiopathic Intracranial Hypertension–Nouha Farhat, Ferdaous Kharrat, Mouna Loukil, Ibrahim Kamoun, Olfa Hdiji, Salma Sakka, Mariem Damak, Chokri Abdellaziz Mhiri

P1.9-009 The standard

swinging flashlight test: reliable or not–Thierry Boucher, Élizabeth Fortin, Francois Evoy

138 2019 AAN Annual Meeting

P1.9-010 Acute Optic Neuritis:

looking for an accurate and early assessment–Victoria Fernandez, Luciana Melamud, Andres M. Villa

P1.9-011 Transcriptional control of optic nerve injury associated retinal ganglion cell death– Stephanie B. Syc, Hongtian Yang, Gareth Howell, Richard Libby

P1.9-012 Dwarf gecko as

a model for studying retinal neurogenesis–Adriana Mendez, Andrew Wegerski, Zhiyu Li, Temesgen Fufa, Robert Hufnagel

P1.9-013 Inferior colliculus

neurons that express the neuropeptide VIP project to auditory nuclei in the brainstem and thalamus.–Ryan Matthew Edelbrock, Nichole Beebe, David Goyer, Marina Silveira, Michael Roberts, Brett Schofield

P1.9-014 Delayed Development

Sunday, May 5 P1.9-020 A Case of Heidenhain

P1.9-028 Molecular background

P1.9-021 Posterior Ischemic

P1.9-029 Expanding the

Variant Creutzfeldt-Jakob Disease Presenting with Isolated Homonymous Quadrantanopia and Corresponding Nuclear Imaging Findings–Shivkumar Bhadola, Brittany Elyce Bolduc, Jonathan Dashkoff, Clotilde Hainline Optic Neuropathy, a previously unknown complication of lung transplantation–Brian Keller, Yasmeen Rauf, Archana Hinduja

P1.9-022 Wernicke

Encephalopathy Mimicking Idiopathic Intracranial Hypertension–Janice Leon, Olimpia Carbunar

P1.9-023 Acute Bilateral

Ophthalmoparesis due to Bacterial Meningitis in the Setting of Sphenoid Sinusitis–Austin Pereira, Felix J. Tyndel

of a Dural AV Fistula and PTEN Hamartoma Syndrome in Pseudo-Idiopathic Intracranial Hypertension–Doria Gold, Steven Galetta, Laura J. Balcer, Janet C. Rucker

P1.9-024 Optic Neuritis and

P1.9-015 Vancomycin

Defects in a Child with Acute Necrotizing Encephalopathy–Yin Allison Liu, Hisham Dahmoush, Shannon M. Beres

Ototoxicity May Lead to Bilateral Vestibular Hypofunction– Samantha Zak, Jennifer L. Cox, Lixin Zhang

P1.9-016 Observation of

Angular Deformity of a Straight Line–Bradley Jack Tishman, Levi Harris

P1.9-017 Herpes Simplex Virus

(HSV)-2 Meningoencephalitisassociated Bilateral Optic Neuritis Successfully Treated with Steroids and Intravenous Immunoglobulin–Faten El Ammar, William L. Conte, Asadolah Movahedan, Hassan Shah, Jeffrey Nichols, Adil Javed

P1.9-018 A Chronic Progressive

Optic Neuropathy in a Patient with Anti-Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies– Doria Gold, Laura J. Balcer, Steven Galetta

P1.9-019 Saturday Night

Retinopathy – A Rare Case of Acute Onset Vision Loss and Ophthalmoplegia–Maria Kristina Casanova Dorotan, Yongwoo Kim, Justin Y. Kwan

11:30 a.m.–6:30 p.m.

Intracranial Hypertension Caused by Chronic Lymphocytic Leukemia, Case Report–Sarah Madani, Poonam Bansal

P1.9-025 Binasal Visual Field

GENERAL NEUROLOGY: RESEARCH ADVANCES IN DIAGNOSIS, PATHOGENESIS, AND BIOMARKERS

P1.9-026 A Common Data

Language for Clinical Research Studies: Overview and Update on the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element (CDE) Recommendations–Muniza Sheikh, Ilar Edun, Robin Sadja Feldman, Katelyn Elizabeth Gay, Rebecca Johnson, Kristen R. Joseph, Joy R. Esterlitz, Carolina Mendoza-Puccini

P1.9-027 Evaluation of

microRNAs in patients with sporadic amyotrophic lateral sclerosis by liquid biopsy as a disease biomarker–Ikuko Takahashi, Ichiro Yabe, Yuka Hama, Hisashi Uwatoko, Shinichi Shirai, Masaaki Matsushima, Jun Utsumi, Hidenao Sasaki

of ALS based on whole exome sequencing analysis–Yuka Hama, Hidetoshi Date, Hiroyuki Ishiura, Jun Mitsui, Jun Yoshimura, Koichiro Doi, Shinichi Morishita, Shoji Tsuji, Miho Murata, Hidehiro Mizusawa, Yuji Takahashi NeuroChip: A low-cost and efficient diagnostic tool to detect neurological disease-related mutations–Aneesh Patankar, Christopher Grunseich, Sonja Waltraud Scholz, Kenneth H. Fischbeck

P1.9-030 Validation of an

Axonal Injury Model by Scanning Electron Microscopy Imaging– AnnaLisa Wilson, Victorio Pozo Devoto

P1.9-031 Decreased PI3,5P2

and PI5P in Fibroblasts from Patients with FIG4 Deficiency– Assia Shisheva, Diego Sbrissa, Bo Hu, Jun Li

P1.9-032 Neurofilament

Light Chain (NfL) Levels in CSF, Serum, and Plasma of Healthy Donors Using the Quanterix NfL Advantage Kit™–Christopher Harp, Robert Hendricks, Sally K. Fischer, Jochen Brumm, Ann Herman

P1.9-033 The Isoniazid

Metabolites Pyridoxal Isonicotinoyl Hydrazone and Hydrazine Regulate Heme Biosynthesis–Christopher Trent Brewer

P1.9-034 Evaluation of

apolipoprotein E and a-synuclein as potential biomarkers in CSF to monitor pharmaco-therapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia– Gururao Hariprasad, Ashish Gupta, Ruchika Pokhriyal, Imran Khan, Vinay Goyal, Rakesh Chadda, Rashmi Ramachandran

P1.9-035 Understand the

disease emergence in hereditary transthyretin amyloidosis (hATTR): a longitudinal study of asymptomatic carriers to inaugural disease manifestations.–Violaine PlanteBordeneuve, Farida Gorram, Bérénice Hébrard, Thibaud Damy, Samar Ayache, Tarik Nordine, Jean-Pascal Lefaucheur

P1.9-036 Association

between LDL-C/HDL-C ratio and Hemorrhagic Transformation in Acute Ischemic Stroke Patients– Yanan Wang, Quhong Song, Yajun Cheng, Chenchen Wei, Qian Wu, Liu Ming GENERAL NEUROLOGY: RARE AND UNUSUAL PRESENTATIONS OF NEUROLOGIC DISEASE

P1.9-037 Oromandibular

dystonia in a patient with herpes simplex virus encephalitis (HSVE)–Sylvia Josephy, Thomas W. Smith, Sepideh Madahian, Anas Hannoun, Dalia Abou Zeki, Raphael A. Carandang

P1.9-038 Plateau waves of

intracranial pressure mimicking seizure in a patient with fungal meningitis–Teresa Wu, Zahra Sadat-Hossieny, Carl Aaron Gold

P1.9-039 Case Report of

Transient Acute Parkinsonism in the setting of West Nile Virus Encephalitis–Husitha Reddy Vanguru, Carlos Ynigo Dy Lopez, Aashrai Sai Venkat Gudlavalleti, Amy E. Sanders

P1.9-040 A Rare Case of

Peripheral Neurolymphomatosis in Cutaneous T-cell Lymphoma– Pritikanta Paul, JaNean Engelstad, Robert Spinner, Gregory T. Pupillo, P. James B. Dyck

P1.9-041 Neurological

symptoms in a patient diagnosed with adrenal oncocytic cortical carcinoma.–Idaira Aguilar Tejedor, Kamil Detyniecki

P1.9-042 Apparent Germline

P1.9-043 A Rare Case of an

Blind: A Rare Presentation of Wernicke Encephalopathy–Waqas Israr Gilani, Shahab Khazanehdari, Emad Roshdy Noor

P1.9-047 A Representative

Case of Spinocerebellar Ataxia Type 7–Jason H. Margolesky, Olimpia Carbunar

P1.9-048 Extending The Clinical

Spectrum of Dejerine Sottas Syndrome: A new Family With Cognitive Impairment And Hearing Loss Carrying Trembler Mutation– Soumya Bouchachi, Nizar Souayah

P1.9-049 Syringomyelia with

Cystic Fibrosis: A Case Report and Literature Review–Charlotte Zhong, Benjamin Emanuel

P1.9-050 Creutzfeldt Jakob

(CJD) Disease presenting with Opthalmoplegia and Peripheral Neuropathy–Hesham Abdelazz Allam, Faisal Abdelaziz Ibrahim, Arooj Kohli, Hisham Gibriel Bakhiet Elkhider, Fazeel Mukhtar Siddiqui

P1.9-059 Unusual Respiratory

Manifestation in a Patient with Stiff Person Syndrome (SPS)– Andrew Lin, Alexis Alvarado Arias, Yoram Roman Casul, Animesh Gupta, Christopher Calder

P1.9-060 Intravascular

Lymphoma: A Rare Cause of Rapidly Progressive Myelopathy– Monica Ann Krause, Stephen W. English, Nicholas L. Zalewski

P1.9-066 Neurofilament light

test results vary substantially across different assay platforms and assay reagents–Florian Deisenhammer, Martina Podlesnic, Jens Kuhle, David Leppert, Zuzanna Michalak, Julian Deisenhammer, Kathrin Schanda, Rainer Ehling, Markus Reindl

P1.9-067 Development of a

Conceptual Model to Inform a Clinical Outcome Assessment Strategy in Adolescents and Young Adults with Fragile X Syndrome–Anna Fong Lee, Lisa Cordeiro, Chris Marshall, Emma Wilson, Jeannie Visootsak

P1.9-068 mHealth Interventions:

P1.9-051 A Case of a Cervical

P1.9-052 Cerebral Angiolipoma

RESEARCH METHODOLOGY, CLINICAL OUTCOME AND QUALITY IMPROVEMENT

P1.9-069 The Mayo Clinic

Pannus Without Rheumatoid Arthritis or Trauma–Rafail Beshai, Carl Hoegerl of the Parietal Region Presenting as Olfactory Hallucinations– Madhureeta Achari, Cesar Escamilla Ocanas, Taylor Gist, Nazaneen Amjadi

P1.9-053 Diabetic striatopathy;

An uncommon cause of stroke-like symptoms–Sharmeen Hussaini, Rashid Ali Ahmed, Gobind Singh, Hesham Masoud

P1.9-054 Paraplegia on

vacation: Surfer’s myelopathy variant–Majed Alzahrany, Sonja McVeigh, Natalie Elizabeth Parks

P1.9-055 Myasthenia Gravis

P1.9-056 Sensory Neuropathy

Erythromelalgia Presenting with Small Fiber Neuropathy–Pavan Patel, Christopher Reed Edwards, Yan Zhang

Consult Service Quality Improvement Project at a large Children’s Hospital–Surabhi Kaul, Carlos Alberto Perez, Jeremy Lankford

tongue! Prolonged paresthesia of the tongue after dental procedure–Muhammad O. Salim Khan, Iram Zaman

P1.9-044 Eyes make Brain go

amnesia and takotsubo cardiomyopathy: report of two cases and literature review– Cristina Valencia Sanchez, William Taylor Jackson, Amaal J. Starling, Erika Driver-Dunckley

P1.9-058 A Case of Sporadic

P1.9-065 Child Neurology

Lots on the Market but are they Studied? An Analysis of mHealth Interventions for Neuropsychiatric Conditions–Julia Frederica Reichel, Pallavi Pemmireddy, John Torous, Mia T. Minen

Presenting as Recurrent Falls in a Young Man–Daryl C. McHugh, Aleksandr Isakov, Rohit Reddy, Steven Xian, Fabreena Napier, Lenore C. Ocava

P1.9-045 Transient global

Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) with Hyperreflexia in North America–Xiao Weng, Uzma Usman, Phuongthao Quan, Yazan Al-Hasan, Justin Hoskin, Suraj Muley

P1.9-061 It’s on the tip of my

Acute Confusional Migraine in an Adult–Atif Zafar, Eric Noel, Mudassir Farooqui, Sajid Suriya, Lauren Victoria Hatcher Crazy–Pauline Hwang, Mayur Chalia

P1.9-057 A Rare Case of Acute

with Orthostatic Fainting: Transthyretin-related Amyloid Polyneuropathy–Wolfgang Heide, Leila Langfeldt

P1.9-062 Literature Bias in

Alzheimer’s Disease Research: An Exploration of Factors Influencing Treatment Outcomes–Travis Spear, Kate Yzquierdo, Anna Ivashchenko, Zung Vu Tran

P1.9-063 Improving Hospital

Discharge Time of Patients Admitted to Pediatric Neurology– Padmavati Rajdatta Eksambe, Yash Shah, Joy Stennett, Joshua J. Kim, Emma C. M. Laureta, Rose Marie Sy-Kho, Shefali Karkare, Sanjeev V. Kothare

P1.9-064 Precision Medicine

of Subarachnoid Hemorrhage Management for Early-HospitalDischarge: Safety, Feasibility, and Secondary Value-Based Health Economic Outcomes–Tasneem Fatema Hasan, Christina Collins, Lesia Mooney, Jessica Talbot, Amanda Fouraker, Katherine Nelson, Maryann Ohanian, Stephanie Bonnett, Robert Kaplan, David O. Hodge, Rabih G. Tawk, William David Freeman

Center for MS and Autoimmune Neurology Biorepository (CMSAN): Infrastructure Development–Jessica Ann Sagen, Charles L. Howe, Sean J. Pittock

P1.9-070 Work Productivity

Activity Impairment Results from the Cure SMA 2018 Community Update Survey–Lisa Belter, Rosangel Esperanza Cruz, Jill Jarecki

P1.9-071 The Successful Use

of Internal Research Funding as a Catalyst to Achieve External Grant Support–Lei Wang, James L. Bernat, Jeffrey A. Cohen

P1.9-072 Strategizing Clinical Trial Recruitment in the Digital Age–Pinky Agarwal, Sudeshna Ray, Daniel J. Burdick

P1.9-073 Methodology for

Development of IndicationSpecific Outcome Measures in Rare Disease Trials: An innovative research approach–Pamela Ventola, Anna Fong Lee, Jeannie Visootsak

AAN.com/view/AM19Sci 139

Sunday

IDH1 Mutation in a Patient with Ollier Disease and Glioblastomas: A Case Report–Sarah Kendroud, Daniel Groepper, Yoon Jae Choi

P1.9-046 Deaf, Confused and

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 1 RESEARCH METHODOLOGY AND EDUCATION: PATIENT AND CONTINUING MEDICAL EDUCATION

P1.9-074 Cannabinoid-Based

Therapeutics in Epilepsy: An Assessment of Knowledge and Attitudes of Neurologists, Pediatricians, and PCPs–Thomas Finnegan, Stacey L. Hughes, Barry E. Gidal

P1.9-075 Neurophobia, a

Worldwide Concern for Neurology Training: A Systematic Review.– Daniel Moreno-Zambrano, Joyce Meza, Maria Angelina Freire, David Fabricio Santana, Rocio Carolina Garcia Santibanez, Rocío Santibáñez-Vasquez

P1.9-076 CME-Certified Timed, Rapid Fire Debate of Hot Topics in MS Improves Awareness of Diagnostic and Therapeutic Data Among Neurologists and Primary Care Physicians–Thomas Finnegan, Cate Murray, Stephen Krieger, Patricia K. Coyle

P1.9-077 The development

of an evidence- and consensusbased approach to the neurologic examination–James Michael Hillis, Michael P.H. Stanley, Tracey Cho, Tracey A. Milligan

P1.9-078 Addressing Gaps in

MS Patient Care Via Personalized Continuing Education–Katie Robinson, Patricia K. Coyle, Robert Esgro

P1.9-079 Bed Side to Web

Sunday

Side Neurological Care–William Kurtis Jens, Balaji Krishnaiah, Papul Chalia, Samyuktha Ravi, Khoi Le, Natalie Aucutt-Walter, Thyagarajan Subramanian

P1.9-080 Social Media’s Impact on Stroke Education–Vaibhav Goswami, Scott Woolf, Fawaz AlMufti, Chirag Gandhi, Ramandeep Sahni

P1.9-081 Neurological

and neuroscience education: mitigating neurophobia to mentor health care providers–Stefano Sandrone, Jimmy V. Berthaud, Miguel Chuquilin Arista, Jacquelyne Cios, Pritha Ghosh, Rachel J. Gottlieb-Smith, Hani Kushlaf, Sneha Mantri, Neil Masangkay, Daniel L. Menkes, Kathryn S. Nevel, Harini Sarva, Logan D. Schneider

140 2019 AAN Annual Meeting

NEUROSCIENCE RESEARCH PRIZE RECIPIENTS

P1.9-082 Quantitative Analysis of Mechanical Impact using a Cellular Vibrational Model of Differentiated Neuroblastoma Cells–Caleb Shi

P1.9-083 Characterizing the

source of microglia proliferation after ischemic preconditioning– Rachel Chernoff

P1.9-084 A Novel Mechanism by which 4-Nonylphenol Accelerates Alzheimer&rsquo;s Pathogenesis and Induces both Tau-amyloid Mediated Toxicity and Neuroinflammation–Kevin Zhong

HEADACHE CLINICAL TRIALS I

P1.10-001 Galcanezumab

Significantly Reduced Health Care Resource Utilization and Acute Medication Use in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, DoubleBlind, Placebo-Controlled and Open-Label Extension–Shivang Joshi, Joshua Tobin, Janet Ford, Russell Nichols, Shonda Foster, Dustin Ruff, Holland Detke, Sheena K. Aurora

P1.10-002 Assessment of the

Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study–Uwe Reuter, Peter Goadsby, Michel LanteriMinet, Peggy Hours-Zesiger, Chrystel Fernandes, Michel D. Ferrari, Jan Klatt

P1.10-003 Patient Gains in Daily

Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine–Dustin Ruff, Janet Ford, Amaal J. Starling, Holland Detke, Russell Nichols, Martha Port, Sheena K. Aurora

P1.10-004 Impact of

Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication–Stephen D. Silberstein, Jessica Ailani, Joshua T. Cohen, Ronghua Yang, Paul P. Yeung, CD Gargano

Sunday, May 5 P1.10-005 Long-Term Impact

of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Episodic Migraine: Results of a 1-Year Study–Jan Lewis Brandes, Michael J. Marmura, Paul P. Yeung, Joshua T. Cohen, Sanjay Gandhi, Ronghua Yang

P1.10-006 The Impact of

Fremanezumab on MigraineSpecific Health-Related Quality of Life in Chronic Migraine Patients Who Previously Used Topiramate– Sanjay Gandhi, Richard B. Lipton, Joshua T. Cohen

11:30 a.m.–6:30 p.m. P1.10-012 The Impact of

Fremanezumab on MigraineSpecific Health-Related Quality of Life in Chronic Migraine Patients With Concomitant Preventive Medication Use–Sanjay Gandhi, Richard B. Lipton, Joshua T. Cohen

P1.10-013 Improvement in

Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification– Rashmi B. Halker, Michael J. Marmura, Joshua M. Cohen, Paul P. Yeung, Ronghua Yang

P1.10-014 Single and Multiple

Blind, Pilot Study Comparing 3 Mg Subcutaneous Sumatriptan With 6 Mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector for the Acute Treatment Of RapidlyEscalating Migraine Attacks– Roger Cady, Sagar Munjal, Ryan John Cady, Heather Manley, Elimor Brand-Schieber

Doses of Ubrogepant Are Not Associated With a Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males–Phung Bondiskey, Wendy Ankrom, Wen Liu, Chi-chung Li, Catherine Matthews, John Palcza, Deborah L. Panebianco, Tom Reynders, Sofie Mesens, John A. Wagner, Abhijeet Jakate, Eugene E. Marcantonio

P1.10-008 Long-Term Efficacy

P1.10-015 Long-Term Safety

P1.10-007 Randomized, Double-

of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use–Paul P. Yeung, Peter Goadsby, Adelene E. Jann, Joshua T. Cohen, Ronghua Yang, Xiaoping Ning

P1.10-009 Safety Findings from

the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine–John H. Krege, Emily Liffick, Erin G. Doty, Sherie A. Dowsett, Jia Ning Wang, Andy Buchanan

P1.10-010 Evaluation of

of Fremanezumab: Results of a 1-Year Study–Xiaoping Ning, Joshua T. Cohen, Nathan L. Bennett, Paul P. Yeung, Ronghua Yang

P1.10-016 Assessment of the

Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine–Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Dolezil, Stephen D. Silberstein, Paul Winner, Feng Zhang, Sunfa Cheng, Daniel D. Mikol

Cardiovascular Risks in Adult Patients with Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies–Tina Oakes, Richard Kovacs, Noah Rosen, Erin G. Doty, Phebe Kemmer, Sheena K. Aurora, Angelo Camporeale

P1.10-017 Immunogenicity

P1.10-011 Efficacy of

Significant Drug Interactions With Coadministration of Ubrogepant and an Ethinyl Estradiol/ Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis–Chi-chung Li, John Palcza, Jialin Xu, Bob Thornton, Wendy Ankrom, Abhijeet Jakate, Eugene E. Marcantonio

Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication–Peter J. McAllister, David W. Dodick, Joshua T. Cohen, Ronghua Yang, Paul P. Yeung, CD Gargano

Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine–James Martinez, Nada A. Hindiyeh, Greg Anglin, Kavita Kalidas, Michael Hodsdon, William Kielbasa, Brian Moser, Eric M. Pearlman, Sandra Garces

P1.10-018 Absence of Clinically

P1.10-019 Absence of Clinically

Significant Drug Interactions With Coadministration of Atogepant and an Ethinyl Estradiol/ Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis–Wendy Ankrom, Jialin Xu, Marie-Helene Vallee, Marissa F. Dockendorf, Danielle Armas, Ramesh Boinpally, Kwan-hong Chris Min

P1.10-026 The Impact of

Fremanezumab on Medication Overuse in Patients With Chronic Migraine–Stephen D. Silberstein, Sait Ashina, Zaza Katsarava, Kristen Bibeau, Michael Seminerio, Danielle E. Harlow, Joshua M. Cohen

P1.10-020 Long-term Efficacy

of Erenumab in Patients With Episodic Migraine Who Have Failed Prior Preventive Migraine Therapies–Uwe Reuter, Todd J. Schwedt, David B. Kudrow, Koen Paemeleire, Feng Zhang, Jan Klatt, Hernan Picard, Denise Elaine Chou, Daniel D. Mikol

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P1.10-021 Long-term Safety and

Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)–Jan Lewis Brandes, David B. Kudrow, Suzanne Klise, John H. Krege, Michael Case, Joel Raskin, Rashna Khanna, Raghavendra Vasudeva

P1.10-022 Long-Term Impact of

Fremanezumab on HeadacheRelated Disability and Quality of Life in Patients Who Reverted From a Chronic to an Episodic Migraine Classification–Jessica Ailani, Joshua M. Cohen, Marianna Shnayderman Yugrakh, Paul P. Yeung, Xiaoping Ning

P1.10-023 Eptinezumab Reduces

Sunday

Migraine Frequency Within the First Month After Treatment in Patients with Episodic or Chronic Migraine–Paul Winner, Peter J. McAllister, Eric Kassel, Roger Cady, Joe Hirman, David M. Biondi

P1.10-024 Long-Term Efficacy of

Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Severe Depression– Richard B. Lipton, Joshua M. Cohen, Paul P. Yeung, Ronghua Yang, Xiaoping Ning, Dawn C. Buse

P1.10-025 Early Impact of

Eptinezumab on the HealthRelated Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine–Merle Diamond, Richard B. Lipton, Ruslan Horblyuk, Joe Hirman, Roger Cady, Eric Kassel

AAN.com/view/AM19Sci 141

POSTER SESSIONS

POSTER SESSION 2

BEHAVIORAL ISSUES

P2.1-001 Incidence and

trends of Frontotemporal Disorders in Olmsted County: a population based study (1995-2010).–Pierpaolo Turcano, Cole Stang, Michelle M. Mielke, Alexandra Wennberg, Keith A. Josephs, J. Eric Ahlskog, Bradley F. Boeve, David S. Knopman, Ronald C. Petersen, Rodolfo Savica

P2.1-002 Absence of

Embarrassability Distinguishes Frontotemporal Dementia from Alzheimer’s Disease and Healthy Controls–Oleg Yerokhin, Sylvia Fong, Elvira Jimenez, Megan Laffey, Mario F. Mendez

P2.1-003 Hemispheric

Asymmetry Contributing to Socioemotional Behavior in Frontotemporal Dementia–Leila Parand, Andrew C. Carr, Elvira Jimenez, Paul Thomuson, Mario F. Mendez

P2.1-004 The Cognitive Aspects of Sexual Intimacy in Dementia Patients: A Neurophysiological Review and Insights for Diagnosis and Treatment–Anna Starikovsky Nordvig, Daniel Goldberg, Edward D. Huey

Monday

P2.1-005 Intrinsic amygdala

Poster Session 2 1. Aging, Dementia, Cognitive, and Behavioral Neurology: 1-001 to 1-035 2. Autoimmune Neurology; MS and CNS Inflammatory Disease: 2-001 to 2-110 3. Cerebrovascular Disease and Interventional Neurology: 3-001 to 3-069 4. Neuromuscular Disease and Clinical Neurophysiology (EMG): 4-001 to 4-045 5. Epilepsy/Clinical Neurophysiology (EEG): 5-001 to 5-036 6. Neuro-oncology; Global Health; Pain and Palliative Care; TRANSCENDS Scholarship Recipients: 6-001 to 6-079 7. Cerebrovascular Disease ePosters: 7-001 to 7-010 8. Movement Disorders: 8-001 to 8-054 9. Research Methodology, Education, and History; Neuro Trauma and Sports Neurology; Neurocritical Care; Medical Student Essay Award Recipients: 9-001 to 9-085 10. Headache: 10-001 to 10-025 P2.1-009 Allopregnanolone

improves neuropsychiatric symptoms in elderly men with Fragile X-associated tremor/ataxia syndrome (FXTAS): Results from an open label study–Aditi Trivedi, Jun Yi Wang, Nika Carrillo, Randi Hagerman

P2.1-010 Altered Brain

connectivity as an endophenotype for social behavior: A novel SNP affecting CSMD1 increases amygdala connectivity and prosocial behavior in a GWAS meta-analysis.–Kevin Bickart, Valerio Napolioni, Raiyan Khan, Jonas Richiardi, Michael Greicius

Metabolism Associated With Functional Motor Disorder: Preliminary Results Of The HYCORE Study.–Ismael Conejero, Laurent Collombier, Sandrine Alonso, Emilie Olié, Caroline Arquizan, Charlotte Boulet, Jorge Lopez-Castroman, Philippe Courtet, Mocrane Abbar, Eric Thouvenot

P2.1-006 Phenotypic Complexity

P2.1-011 Corticolimbic Fast-

and the Likelihood of a Diagnostic Result in a Sequencing Test of 2,300+ Genes Associated with Autism Spectrum Disorders and/ or Intellectual Disability–Tracy Brandt, Anita Shanmugham, Julie Scuffins, Jane Juusola, Dianalee McKnight

P2.1-007 Exploring functional

connectivity correlates of problem solving under stress–David Q. Beversdorf, Neetu Nair, John Hegarty, Bradley Ferguson, Patrick Hecht, Michael Tilley, Shawn Christ

P2.1-008 Delirium Assessment

for Acute Ischemic Stroke Patients at UNMC–Hae Young Baang, T. Scott Diesing, Daniel L. Murman

142 2019 AAN Annual Meeting

Monday, May 6

Tracking: Enhanced Multimodal Integration in Functional Neurological Disorder–Ibai Diez Palacio, Laura Ortiz-Teran, Benjamin Williams, Rozita Jalilianhasanpour, Juan Pablo Ospina, Bradford Dickerson, Matcheri Keshavan, W. Curt LaFrance, Jorge Sepulcre, David L. Perez

P2.1-012 Do Anxiety and

Depression Levels Interfere with Cognitive Performance in Ecuadorian Multiple Sclerosis Patients? – a Case-Control Study–Narcisa Barzola-Castro, Rosa Cepeda-Escalante, Joyce Antonella Jimenez-Zambrano, Alexander Burgos-Campuzano, Gabriela Acuna

P2.1-013 Reflexia Alternans in the Setting of Electroconvulsive Therapy–Shayan Amir Gates

P2.1-014 Impact of

Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, And Major Depressive Disorder– Benjamin Carroll, Rajeev Ayyagari, Darren Thomason, Fan Mu, Michael Philbin

P2.1-015 Safety,

Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831, a Selective D-amino Acid Oxidase Inhibitor, in Healthy Volunteers–Lin Xu, Nicholas DeMartinis, Jingtao Wu, Mahnaz Asgharnejad, Maria Quinton, Jens Wendland, Patricio O’Donnell

P2.1-016 Individual Differences

in Social Network Size Linked to Nucleus Accumbens and Hippocampal Volumes in Motor Functional Neurological Disorders–Juan Pablo Ospina, Rozita Jalilianhasanpour, Benjamin Williams, Ibai Diez Palacio, David L. Perez COGNITIVE DISORDERS

P2.1-017 Event Related

Potentials as a possible Traumatic Brain Injury (TBI) biomarker in older patients at risk of neurodegenerative disorders– Katherine Turk, Anna Marin, August Price, Rocco Palumbo, Andrew E. Budson

11:30 a.m.–6:30 p.m.

1 2 3

1-001-1-035

2-001-2-110

3-001-3-069

4 5 6

4-001-4-045

5-001-5-036

6-001-6-079

7-001-7-010

ePosters

8 9 10

8-001-8-054

9-001-9-085

10-001-10-025

P2.1-018 “Paroxysmal

Symptoms and Correlated EEG findings in Dementia with Lewy Bodies”–Deepmala Nandanwar, Edwin B. George, Rohit Ajay Marawar

P2.1-019 The Role of

Neuroimaging in a Fragile X Carrier with only Dementia and Perypheral Neuropathy–André Luiz Guimarães de Queiroz, Karlla Danielle Ferreira Lima, Hennan Salzedas Teixeira, Victor Mantelatto Bonsi, Leonardo Furtado Freitas, Marcio EscorcioBezerra, Alex Baeta

P2.1-020 Primary Familial Brain Calcification–Yazan Radaideh, Oluwatosin Akintola, Paul J. Maccabee

P2.1-021 The Cognitive

Phenotyping of McCune-Albright Syndrome: A Case Series–Lillian Ham, Laura Segala, Gina Norato, Michael D. Gregory, Alison Boyce, Maryland Pao, Michael Collins, Joseph Snow

P2.1-022 Compound

heterozygous C9ORF72 hexanucleotide repeat expansions causing FTD–Daniel Anderson, Hyungsub Shim, Christopher S. Nance, Khemissa Bejaoui, Shawna Feely

P2.1-023 A Novel PRNP-G131R

Mutation Associated with Familial Prion Disease–Jumana Tariq A Alshaikh, Kefeng Qin, Lili Zhao, James A. Mastrianni

P2.1-024 CSF1R Mutation-

negative Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): Genotypic Heterogeneity in an Important Cause of Earlyonset Dementia–Benjamin Peter Trewin, Jonathan Baskin, Stanley Levy, Joanne Sy, Stephen H. Tisch

P2.1-025 Distinctive Clinical

Features of Cerebral Amyloid Angiopathy Related Inflammation: the Vanderbilt University Medical Center Experience–James Everett Eaton, Matthew Schrag, Siddharama Pawate

P2.1-026 Morphometric

correlation of parkinsonian signs in different primary progressive aphasia syndromes–Blas Couto, Carla Florencia Bolano Diaz, Guido Vazquez, Franco Appiani, Carlos Santiago Claverie, Jesica Ferrari, Indira Garcia Cordero, Geraldine Borovinsky, Noelia Pontello, Facundo Manes, María Macarena Martínez Cuitiño

P2.1-027 Saccadic Eye

Movements: A Glimpse into Cognitive Impairment–Morganne Manuel, Brian Joseph Copeland, Abigail Olinde, Hannah Zachary, Jesus F. Lovera, Deidre J. Devier

P2.1-028 Early in vivo

signatures of neurodegeneration at individual level in isolated REM behaviour disorder–Giulia Carli, Silvia Paola Caminiti, Andrea Galbiati, Sara Marelli, Francesca Casoni, Luigi Ferini-Strambi, Daniela Perani AGING AND DEMENTIA: NEUROPSYCHOLOGY AND CLINICAL STUDIES I and Aging Center: Early Developmental History Screening Questionnaire–Wendy Shwe, Isabel Allen, Ariane E Welch, Dong Hwa Chung, Mikhail Pakvasa, Julie Pham, Michelle You, Howie Rosen, Gil Dan Rabinovici, Joel Kramer, Bruce L. Miller, Maria Gorno Tempini, Zachary Miller

P2.1-030 Cognitive Profiles in

Amyloid-Positive Mild Cognitive Impairment and Alzheimer’s Disease with and without Tau–Lauren McCollum, Laura Wisse, Sandhitsu Das, Robin de Flores, Paul Yushkevich, David A. Wolk

18 Months in Patients With Mild Cognitive Impairment or Dementia due to Alzheimer’s Disease–Yen Ying Lim, Ellen Huang, Jessica Kong, Paul Maruff, Judith Jaeger, Elena Ratti

P2.1-032 Prosodic Impairment

as a Marker of apoE4 Status in logopenic variant Primary Progressive Aphasia with AD Pathology–Naomi Nevler, Sharon Ash, David Irwin, Mark Liberman, Murray Grossman

P2.1-033 Creutzfeldt-Jakob

Disease Masquerading as Autoimmune Encephalitis– Sushma Kola, Eoin P. Flanagan, David T. Jones

P2.1-034 Elevation of 14-3-3

and Unique MRI findings in a Case of Logopenic Variant Primary Progressive Aphasia–Yazan AlHasan, Justin Hoskin, Xiao Weng, Suraj Muley, Marwan N. Sabbagh

P2.1-035 An Atypical

Presentation of Prion Disease with Alien Limb, Apraxia, and Intact Cognition–Saima Chaudhry, Matthew J. Wodziak

AUTOIMMUNE AND PARANEOPLASTIC ENCEPHALITIS

P2.2-001 Quantifying CSF

Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis–Gregory S. Day, Fatima Amtashar, Melanie Yarbrough, Peter Körtvelyessy, Harald Pruss, Bob Bucelli, Marvin Fritzler, Warren P. Mason, David F. Tang-Wai, Claude Steriade, Julien Hebert, Elizabeth Herries, Jack Ladenson, John C. Morris, Anne Fagan

P2.2-002 Sensitivity of Cell

Count and Protein in Cerebrospinal Fluid for the Diagnosis of Autoimmune Encephalitis–Julien Hebert, Priti Gros, Sarah Lapointe, Claude Steriade, Gregory S. Day, Catherine Maurice, Richard Wennberg, David F. Tang-Wai

P2.2-003 Autoimmune

encephalitis in children: A case series from a tertiary care center–Alice Rutatangwa, Nikita Mittal, Carla Marina Francisco, Emmanuelle Waubant

P2.2-004 Determining the

Prevalence of Sleep Disturbances in Autoimmune Encephalitis– Margaret Blattner, Gabriella DeBruin, Bob Bucelli, Gregory S. Day

P2.2-005 Autoimmune

Encephalitis in the Neurologic Intensive Care Unit: Clinical Characteristics, Complications, and Outcomes.–Shailee Samir Shah, Stephen A. VanHaerents

P2.2-006 Clinical, radiological

P2.2-012 Cerebral FDG-PET

Findings in a Patient with Limbic Encephalitis: an Important Aid to Localize the Affected Region and Support the Diagnosis of Autoimmune Encephalitis.–Dhara Murray-Frank, Maria Vera Silva, Samer Riaz, Camilo Garcia

P2.2-013 Coexisting Anti-Ma

and Anti-NMDA-R Antibody Syndromes in a Case of Brainstem and Limbic Encephalitis–Ryan Kammeyer, Amanda Lee Piquet

and laboratory comparison between autoantibody-negative and autoantibody-positive Autoimmune Encephalitis patients.–Antonino Giordano, Raffaella Fazio, Stefano Gelibter, Maria Volonté, Giuseppe Magnani, Giancarlo Comi, Vittorio Martinelli

P2.2-014 An unusual late

P2.2-007 Imaging and

P2.2-015 Anti-N-Methyl-D-

Pathologic Findings in an Adult and Pediatric Case of AntiGABA-A Receptor Encephalitis– Neena Cherayil, Ana G. Cristancho, Aivi Nguyen, Erin Caitlin Conrad, MacLean Nasrallah, Sona Narula, Eric Lancaster

P2.2-008 NMDAR encephalitis

presentation of anti-NMDA Receptor (NMDA-R) Autoimmune Encephalitis following Herpes Simplex Virus (HSV) Encephalitis–Amr Hassan Ewida, Kimberly Laxton, Anqi Lou, Neil Suryadevara, Amy E. Sanders Aspartate (NMDA) Encephalitis Associated with Tall-cell Variant Papillary Thyroid Carcinoma– Ahmad Mahadeen, Naresh Mullaguri, Christopher R. Newey, Pravin George

P2.2-016 When Autoimmune

associated with HIV “CNS escape”–Patrick Brian Moloney, Joseph Heskin, Yvonne Langan, Niall Conlon, Fiona Mulcahy, Siobhan Hutchinson

Encephalitis masquerades as an Eating Disorder, two case reports on unique presentation of anti - NMDAR Encephalitis.–Akash Virupakshaiah, Deborah Consolini, Charles Bean, Josephine Elia

P2.2-009 Improving Utilization

P2.2-017 A case of CSF

of Neurological Autoantibody Testing at a Public Hospital: A Quality Improvement Project–Kyle Matthew Blackburn, Rati Chkheidze, Ibrahim Hashim, Steven Vernino

P2.2-010 Need for ICD Code

for Suspected Autoimmune Encephalitis as Demonstrated by Retrospective Ten Year Analysis of Unspecified Autoimmune Encephalitis Treated with Immunoglobulin or Plasma Exchange–Paola Mendez Gomez, Rachel Walker, John Lacci, Ricardo Salinas, Ali Seifi

P2.2-011 What Does a

Positive Neuronal Antibody Titer Mean?–Fajun Wang, Konrad Knusel, Naveen George, Nataliya Pyatka, Hesham Ahmed Abboud

NMDA antibody negative NMDA encephalitis!–Khaled Abdalla, Aparna M. Prabhu, Pavan Patel, Maryamnaz Hosseinzadeh Zaribaf

P2.2-018 Diffuse White Matter

Disease and Rapidly Progressive Dementia Secondary to NonParaneoplastic Voltage-Gated Calcium Channels Antibody– Jonathan Landman, Daniel Garbin Di Luca, Melissa R. Ortega, Sakir H. Gultekin, Xiaoyan Sun

P2.2-019 A challenging case

of intractable seizures in a pediatric patient with antiGAD65 encephalitis–Supriya Kairamkonda, Kapil Arya, Genevieve C. Gabriel, Aravindhan Veerapandiyan

P2.2-020 Anti-GAD Antibody

Associated Encephalitis: A Child with Epilepsia Partialis Continua and Ataxia–Isaac Molinero, Vishal Mandge, Susan Erin Duberstein Coad

AAN.com/view/AM19Sci 143

Monday

P2.1-029 The UCSF Memory

P2.1-031 Cognitive Decline Over

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.2-021 Anti-GAD65 Antibody: a Possible Link to Encephalopathy, Aphasia, Seizures and Lateralized Weakness–Gabriela Tantillo, Rory Abrams, Nishant Kumar Mishra, Elizabeth Pedowitz, Stephen Krieger, Anusha Yeshokumar

P2.2-022 Drug-Resistant

Status Epilepticus Associated with GAD-65 Autoimmune Limbic Encephalitis–Rafia Shafqat, Vaibhav Goswami, Sydney Moseley, Stephen J. Marks

P2.2-023 GAD 65 Antibody

Encephalitis Presenting as New Onset Refractory Status Epilepticus (NORSE)–Amin Sanei Moghaddam, Ajaz Sheikh, Noor A. Pirzada

P2.2-024 Evaluation of the

Malignancy Risk Associated With Paraneoplastic Antibodies–Robert J. Marquardt, Moein Amin, Thomas Daly, Yuebing Li MD

P2.2-025 An Atypical

Presentation of Anti-Hu Receptor Meningoencephalitis–Brittany Lynn Heckel, Ellen Michelle Gibson, Omar Syed Shah, Joseph Caleb McCall

P2.2-026 Post-Herpes

Autoimmune Encephalitis–Luay Mrad, Waqar Waheed, Argirios Moustakas, Robert Fuino

P2.2-027 Voltage-Gated

Potassium Channel AntibodyMediated Encephalitis in Siblings–Kiel Woodward, Alexandria Valdrighi, Geetanjali Singg Rathore, Mary C. Rickard

Monday

P2.2-028 A Report on LGI1

Encephalitis in association with Squamous Cell Carcinoma of the Lung–Akash Virupakshaiah, Marinos C. Dalakas, Neeja Vivek Desai, Scott Mintzer, Jeffrey B. Ratliff

P2.2-029 Refractory LGI-1

Limbic Encephalitis and Secondary Mesial Temporal Lobe Epilepsy: A Case Report–Tahsin Tazwar Khan, Emilio Rafael Garrido Sanabria, Hanna Czarkowska, Rebecca Spiegel

144 2019 AAN Annual Meeting

Monday, May 6

11:30 a.m.–6:30 p.m.

AUTOIMMUNE OR PARANEOPLASTIC MOVEMENT DISORDERS: STIFF PERSON SYNDROME AND ATAXIA

P2.2-037 Bortezomib for the

P2.2-030 Presence of Systemic

P2.2-038 Isolated Dysarthria

due to Immune-mediated Brainstem Encephalitis Associated with Anti-Glutamate Acid Decarboxylase 65 antibodies– Sara Dawit, Erin M. Okazaki, Marie Francisca Grill

Inflammation with Pontine Perivascular Enhancement not Responsive to Steroids – Management Decisions in a Situation of Diagnostic Uncertainty–Buse Sengul, Tirisham Gyang, Aaron M. Carlson

P2.2-031 F/M Wave Area And

P2.2-039 Anti- Tr antibodies in

P2.2-048 The Hand that

Autoantibodies and Associated Comorbid Conditions in a Large Cohort of Stiff Person Syndrome– Michael Comisac, Yujie Wang, Salman Aljarallah, Nick Lukish, Scott Douglas Newsome F-Wave Duration Quantify Spinal Hyperexcitability in Glutamic Acid Decarboxylase (GAD) Antibody Positive Patients with Stiff Person Syndrome.–Mahmood Shbeb, Shitiz K. Sriwastava, Kalyan Yarraguntla, Abbas Jowkar, Edwin B. George

P2.2-032 Coexistence of

neuromyelitis optica and stiff person syndrome in a single patient: a case report–Amanda Thuringer, Yasir Nihad Jassam

P2.2-033 Long-term Rituximab Use Benefits Patients with Stiff Person Syndrome–Salman Aljarallah, Yujie Wang, Thomas Jack Shoemaker, Scott Douglas Newsome

P2.2-034 Anti Glutamic

Acid Decarboxylase Antibody Syndromes Occur At An Earlier Age In African Americans.–Shitiz K. Sriwastava, Meghana Srinivas, Kalyan Yarraguntla, Abbas Jowkar, Edwin B. George

P2.2-035 Double Hit and

Excellent Treatment Response: AMPA and GAD-65 Receptor Antibodies in a Young Woman with Stiff Person Plus Syndrome Misdiagnosed as Acute Scoliosis and Bipolar Disorder–Natalie P. Witek, Anjali Gera, Jennifer Denike, Christopher Goetz, Meagan O. Bailey

P2.2-036 GAD65 and Glycine

Receptor-Associated Neurologic Autoimmunity and Stiff-Person Syndrome within the University of Utah Health Care System– Jonathan Ross Galli, Amanda Lee Piquet, Jacob Kresser, Julia Klein, Judith E A Warner, Kathleen B. Digre, Lisa Kay Peterson, Anne Tebo, Thomas Haven, M. Mateo Paz Soldan, John W. Rose, John E. Greenlee, Stacey Clardy

Treatment of Refractory Stiff Person Spectrum Disorder–Khalil Husari, Lauren Tardo, Benjamin M. Greenberg

autoimmune cerebellar ataxia: Serial antibody testing and response to immunotherapy– Chrysanthi Barba, Harry Alexopoulos, Maria Dimitriadou, Sofia Akrivou, Popianna Tsiortou, Androniki Plomaritoglou, Marinos C. Dalakas

P2.2-040 Steroid therapy

in probable cerebellar-type Hashimoto’s encephalopathy– Masako Kinoshita, Naoko Uehara, Sayaka Mukai, Ai Demura, Tomoo Ogino, Makoto Yoneda

P2.2-041 A Previously

Undescribed Case of an Autoimmune Cerebellar Ataxia (ACA) Associated with a Novel Antibody Against Mouse Cerebellum.–Sabeena Iqbal Malik, Shitiz K. Sriwastava, Meghana Srinivas, Navid Seraji-Bozorgzad, Edwin B. George

P2.2-042 Bilateral Horizontal Gaze Paralysis - Case Series– Poonam Bansal

P2.2-043 Anti-GAD 65 Antibody Mediated Cerebellar hemiataxia– Abdul Rahman Alchaki, Nidhiben A. Anadani, Peter Edward Morrison, Lawrence M. Samkoff

P2.2-044 A Rare Case of

Non-Neoplastic Anti-GAD Positive Cerebellar Ataxia and Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM), Responsive to IVIG Therapy–Noushin Jazebi, Shashika Rodrigo, Diaa Hamouda, Ahmad A. Shawagfeh

P2.2-045 Paraneoplastic

cerebellar degeneration in a woman with gastric adenocarcinoma–Jonathan Lauritsen, Niyatee Samudra, Lauren Tardo, Edward Pan, Lauren Phillips, Meredith Anne Bryarly

P2.2-046 Autoimmune dystonia – a group of patients responsive to immunotherapy–Firas Sioufi, Kareem Sioufi

P2.2-047 Chronic Lymphocytic

Danced: A Case of Seronegative NMO presenting with Pseudoathetosis–Aditya Vikram Boddu, Joel Isaac Shenker

P2.2-049 Paraneoplastic

Syndrome with a Progressive Supranuclear Palsy phenotype– Abdallah Omar Amireh, Chaitanya V. Amrutkar, Erik Von Burton

P2.2-050 A Young Woman

with Palatal Myoclonus, Memory loss and Seizures–Shawn Allen, Mohammad A. Kabir, Thanujaa Subramaniam, Aaron F. Struck MS IMMUNOLOGY AND BASIC SCIENCE

P2.2-051 Discovering Context-

dependent Whole Blood Gene Expression Quantitative Trait Loci (eQTL) In Relapsing Remitting Multiple Sclerosis–Raghavendran Partha, Paola G. Bronson, Dipen P. Sangurdekar

P2.2-052 Distribution and

Efficacy of Ofatumumab and Ocrelizumab in Humanized-CD20 Mice following Subcutaneous or Intravenous Administration–Julia Baguña Torres, Megan Sealey, Rainer Kneuer, David Leppert, Jay Roodselaar, Gisbert Weckbecker, Bart Cornelissen, Daniel Anthony

P2.2-053 IL-11 Induces

Encephalitogenic Th17 cells in Experimental Autoimmune Encephalomyelitis–Nazanin Kiapour, Sahil Kapoor, Silva Markovic-Plese

P2.2-054 Effect of Fumarates

on Human iPSC Derived Neural Progenitor Cells and Human Primary Neurons–Maryam Nakhaei-Nejad, Chieh-Hsin Lee, David Barilla, Fabrizio Giuliani

P2.2-055 Cladribine modulates

the expression of ICAM-1 and VCAM-1 on human brain endothelium; relevance to multiple sclerosis (MS)–Simon Hawke, Pierre Julliard, Georges Grau

P2.2-056 Evaluating the Effect

of Cladribine on Marmoset B- and T-Cell Proliferation and Survival– Yolanda Kap, Ursula Boschert, Bert A. Hart

P2.2-057 High Dose Biotin,

MD1003, Protects Axons in a Mouse Model of Chronic Spinal Cord Demyelination–Arthur Warrington, Morgane Perdomini, Delphine Bernard, Moses Rodriguez

P2.2-058 The Role of Cyclophilin A in Immune-mediated CNS Inflammation–Unsong Oh, Vahnee Garimella, Julie McVoy

P2.2-059 Paracrine Modulation of Microglial Activation and Oligodendroglial Differentiation as Potential Therapeutic Mechanisms of Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs) Cellular Therapy in MS–Gillian Carling, Jacelyn Greenwald, Saud A. Sadiq, Violaine K. Harris

P2.2-060 Serum Exosomes

from Multiple Sclerosis subjects express EBV-derived proteins and activate Monocyte-Derived Macrophages–Samia J. Khoury, May Mrad, Layane Nakib

P2.2-061 Thalamic

P2.2-062 Serum Intestinal

Fatty Acid Binding Protein in Multiple Sclerosis as a Marker of Intestinal Barrier Integrity–Carlos Rodrigo Camara-Lemarroy, Jamie Greenfield, Claudia Silva, Luanne Metz, V. Wee Yong

Tyrosine Kinase Selectively Prevents Antigen-Activation of B cells and Ameliorates B-Cell-Mediated Experimental Autoimmune Encephalomyelitis– Sebastian Torke, Roland Grenningloh, Wolfgang Brueck, Ursula Boschert Shafaatian, Martin Weber

P2.2-064 Novel Mouse Model

to Study Cerebellar Dysfunction in Multiple Sclerosis–Natalie Favret, Clara Arndtsen, Jamie Wong, Anna Iacoangeli, Saud A. Sadiq

P2.2-065 Characterization of

Myelin-reactive CD8+ T cells in Multiple Sclerosis–Joseph J. Sabatino, Michael R. Wilson, Peter A. Calabresi, Stephen L. Hauser, Jonathan Schneck, Scott S. Zamvil

P2.2-066 Pharmacokinetic/

Pharmacodynamic Characterization of Siponimod (BAF312) in Blood versus Brain in Experimental Autoimmune Encephalomyelitis Mice–Marc Bigaud, Julien Perdoux, Pamela Ramseier, Sarah Tisserand, Beatrice Urban, Christian Beerli

P2.2-067 Oligodendroglial

FGFR1 gene targeting protects against cerebellar demyelination and axonal degeneration in MOG35-55 induced chronic EAE–Ranjithkumar Rajendran, Vinothkumar Rajendran, Christine Stadelmann-Nessler, Martin Berghoff

P2.2-068 Single Cell

Analysis of Acute Inflammatory Demyelinating Syndromes Identify Cell States Enriched for MS Susceptibility–Claudiu Iulian Diaconu, Vilas Menon, Philip De Jager

P2.2-069 Dimethyl Fumarate

Exerts Selective Effects on Key B Cell Subsets and IgG Levels Which May Contribute to its Therapeutic Benefit in MS While Maintaining Protective Humoral Immunity– Amit Bar-Or, Fabrizio Giuliani, Yang Mao-Draayer, Scott S. Zamvil, Becky J. Parks, Chongshu Chen, Devangi S. Mehta, Sami Fam

P2.2-070 Single-Cell Genomics

Reveals Spatial and StageAssociated Diversity in Multiple Sclerosis–Lucas Schirmer, Dmitry Velmeshev, Diane Jung, Stephanie Vistnes, Staffan Holmqvist, Brian Tung, Nitasha Goyal, Aparna Bhaduri, Simone Mayer, Maximilian Haeussler, Dorothy Schafer, Richard Reynolds, Lawrence Shiow, Arnold R. Kriegstein, David Rowitch

P2.2-071 Dimethyl Fumarate (DF) Suppresses GMCSFproducing Th1 cells in EAE and human CD4 T cells.–Farinaz Safavi, Zichen Li, Guang-Xian Zhang, Mohamad Rostami

P2.2-072 Flotillin-1/2

autoantibodies in patients with inflammatory disorders of the CNS–Sara Mariotto, Alberto Gajofatto, Daniela Alberti, Sabine Lederer, Salvatore Monaco, Sergio Ferrari, Romana Hoeftberger

P2.2-073 Intrathecal Injections

of Primary Progressive Multiple Sclerosis Derived Antibodies Result in Motor Deficits and CNS Pathology in Mice Suggesting Leading Role of Antibodies in CSF Effects–Francesca Cali, Alexandra Leigh Tse, Jamie Wong, Jerry Lin, Saud A. Sadiq

P2.2-074 Establishment of

Neurofilament Light Chain (NfL) SIMOA assay as well as a conversion factor to enable comparison to historical results using Bovine calibrators.–Robert Hendricks, teresa davancaze, Christopher Harp, Ann Herman, Dana Baker, Jochen Brumm, H. Christian Von Budingen, Michael Townsend, Erica Eggers, Sally K. Fischer

P2.2-075 The Role of Pericytes

in the Pathophysiology of Multiple Sclerosis–Erdem Tuzun, Emine Sekerdag, Dila Atak, Ayse Yilmaz, Canan Ulusoy, Müjdat Zeybel, Özgür Öztop-Çakmak, Atay Vural, Cem Ismail Kucukali, Yasemin Gursoy-Ozdemir

P2.2-076 Regulatory T cells Modulate B-cell Calcium Fluctuation–Juergen Haas, Cornelia Wuerthwein, Mirjam Korporal-Kuhnke, Sven Oliver Jarius, Brigitte Wildemann

P2.2-077 Inhibition of Bruton’s

Tyrosine Kinase Prevents Inflammatory Macrophage Differentiation: A Potential Role in Multiple Sclerosis–Yasemin Beguem Alankus, Roland Grenningloh, Philipp Haselmayer, Andrew Bender, Julia Bruttger

P2.2-078 Microarray Analysis

Indicates Altered Expression Levels of B Cell Genes in Benign Multiple Sclerosis–Recai Turkoglu, Ece Akbayir, Melis Sen, Vuslat Yilmaz, Cem Ismail Kucukali, Erdem Tuzun

P2.2-079 A Study of Long

Noncoding RNAs Expression Levels in the CSF of Multiple Sclerosis Patients–Anna Iacoangeli, Natalie Favret, Clara Arndtsen, Saud A. Sadiq

P2.2-080 Analyzing Normal

and Multiple Sclerosis Brain Cells Using Single-Nucleus RNA Sequencing: Transcriptome Analyses of Normal and Diseased Cells Expressing S1P Receptors and Related Enzymatic Genes– Benjamin Siddoway, Yasuyuki Kihara, Deepa Jonnalagadda, Christine Liu, Victoria Blaho, Jerold Chun

P2.2-081 Effect of Route

of Administration on the Biodistribution of a Novel AntiCD20 Antibody in Experimental Autoimmune EncephalomyelitisVariant Mice–Mary-anne Migotto, Rajiv Bhalla, Karine Mardon, Jacqueline Orian, Gisbert Weckbecker, Rainer Kneuer, David C. Reutens

P2.2-082 NfL Levels in

CSF, Serum, and Plasma of RRMS and PPMS Patients in a Cross-sectional UCSF Cohort– Christopher Harp, Xiaoye Ma, Robert Hendricks, Sally K. Fischer, Erica Eggers, H. Christian Von Budingen, Michael Townsend, Ann Herman

P2.2-083 Cross-talk between

Multiple Sclerosis (MS)-relevant B cell subsets and myeloid cells: potential contribution to the CNScompartmentalized inflammation associated with disease progression–Hanane Touil, Rui Li, Leah Zuroff, Craig S. Moore, Luke M. Healy, Francesca Cignarella, Laura M. Piccio, Samuel Ludwin, Jennifer L. Gommerman, Alexandre Prat, Jack P. Antel, Amit Bar-Or

AAN.com/view/AM19Sci 145

Monday

Energy Dysregulation Drives Microstructural Changes Of Thalamo-Cortical Projections In Multiple Sclerosis–Vito Ricigliano, Matteo Tonietto, Raffaele Palladino, Emilie Poirion, Francesca Branzoli, Geraldine Bera, Elisabeth Maillart, Bruno Stankoff, Benedetta Bodini

P2.2-063 Inhibition of Bruton’s

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.2-084 CD39/CD73

Implication In Neuroimmunological Inflammatory Disorders–Mariem Kchaou, khadija Bahrini, meriam belghith, Samir Belal, Ridha Barbouche

P2.2-085 Melanoma cell

adhesion molecule-expressing memory helper T cells in CNSdemyelinating diseases–Ryotaro Ikeguchi, Yuko Shimizu, Wakiro Sato, Takashi Yamamura, Kazuo Kitagawa

P2.2-108 Serological and

P2.2-093 Nilotinib-associated

P2.2-101 Calcineurin Inhibitors

P2.2-109 Miller-Fisher

Demyelinating Disease–Casey James Judge, Negar Moheb, Christopher Melinosky

P2.2-094 Longitudinal Changes

P2.2-087 Longitudinal

P2.2-095 Neuroblastoma Cell

P2.2-088 Effect of

Line and Lymphocytes Talk for Cladribine Influenced Apoptosis and Inflammation Pathways in Multiple Sclerosis (MS): An “In Vitro” Study–Maddalena Ruggieri, CD Gargano, M Mastrapasqua, C Palazzo, Antonio Frigeri, Andrea Visconti, Damiano Paolicelli, Maria Trojano

Subcutaneous Treatment With Anti-CD20 Antibody on B-cell Depletion in a LipopolysaccharideInduced Inflammatory Mouse Model–Janet Dawson, Ismahane Touil, Anja Scheidegger, Melanie Vogelsanger, David Leppert, Gisbert Weckbecker

P2.2-096 Gene Expression

P2.2-089 Human MAIT Cell

P2.2-097 A novel mouse model

Response Shows Subset Diversity in Multiple Sclerosis–Jorge D. Correale, Edgar Carnero Contentti, Mauricio Franco Farez

P2.2-090 Transcriptional

Monday

P2.2-100 Prevalence of Axonal

Primary Progressive MS Patients Impairs Remyelination in an Experimental Model of Multiple Sclerosis–Anna Roselle, Serena Jane Elizabeth Shimshak, Jamie Wong, Saud A. Sadiq

an Inflammatory Stimulus are Vulnerable to Damage by CD8+ Cytotoxic T Cells Implicated in Axon Injury–William F. Schmalstieg Expression of Gluco- and Mineralocorticoid Receptors and their Targets in Multiple Sclerosis–Clemens Goedel, Franziska Kuestermann, Muriel Stoppe, Sarah Haars, Johannes Orthgiess, Astrid Unterlauft, Florian Then Bergh

Profiling of Autologous Bone Marrow Mesenchymal Stem CellDerived Neural Progenitors (MSCNPs) from Patients with Multiple Sclerosis–Jacelyn Greenwald, Tamara Vyshkina, Saud A. Sadiq, Violaine K. Harris

P2.2-091 Co-existence of

Multiple Sclerosis and AntiNMDA Receptor Encephalitis: What We Can Learn From It?–Bade Gulec, Hatice Kurucu, Suha Bozbay, Yalim Dikmen, Haluk Sayman, Erdem Tuzun, Melih Tutuncu, Ugur Uygunoglu, Cengiz Yalcinkaya, Sabahattin Saip, Aksel Siva

146 2019 AAN Annual Meeting

11:30 a.m.–6:30 p.m.

P2.2-092 Cerebrospinal Fluid of

in the Expression of IL-33 in Relapsing Remitting Multiple Sclerosis–Subramaniam Sriram, John Tossberg, Chandramohan Natarajan, Guzel Shaginurova, Chase Floyd Spurlock, Thomas Martin Aune

P2.2-086 Axons Exposed to

Monday, May 6

Profiles of Proteins Involved in Cladribine Metabolism and their Possible Correlation with EpsteinBarr Virus Variants–R Mechelli, G Manfre, G Pellicciari, R Renie, C Romano, Giovanni Ristori, Andrea Visconti, Marco Salvetti of demyelinated lysolecithin lesions at different stages of remyelination–Jonpaul Bonsignore, Robert Zivadinov, Michael G. Dwyer, Marilena Preda, Michelle Sveinsson, Ferdinand Schweser, Suyog U. Pol

P2.2-098 From Mouse to Man

– Translational Aspects of Serum Neurofilament Light Chain in Multiple Sclerosis–Frauke Zipp, Falk Steffen, Johannes Piepgras, Vinzenz Fleischer, Felix Luessi, Sergiu Groppa, Stefan Bittner AUTOIMMUNE NEUROMUSCULAR DISORDERS

P2.2-099 Peripheral Nerve

Hyperexcitability Syndromes: a Single Center Experience.– Gregorio Spagni, Raffaele Iorio, Valentina Damato, Amelia Evoli

sensory neuropathy with IgM binding to Trisulfated heparin disaccharide (TS-HDS) in patients with Fibromyalgia–Asma Malik, Ghazala Hayat, Glenn Lopate, Jacqueline Jones, Alan Pestronk Can Be Safely Reduced in Most Patients with Well-controlled Myasthenia Gravis.–Yuko Takahashi, Yoichiro Nishida, Yurie Nose, Satoru Ishibashi, Nobuo Sanjo, Tetsuya Kanai, Akiyuki Uzawa, Fumiko Oda, Yukiko Ozawa, Satoshi Kuwabara, Takanori Yokota

P2.2-102 Comparison of the

Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in the MGTX Randomized Trial–Tarrant McPherson, Immaculada Aban, Petra W. Duda, Ramin Farzaneh-Far, Gil I. Wolfe, Henry J. Kaminski, Gary Raymond Cutter

P2.2-103 Bilateral sixth nerve

Clinical Profile of Antibody Positive Autoimmune Gastrointestinal Dysmotility Patients Receiving IVIg–Chen Yan, Greg Owendoff, Ryan Matthew Edelbrock, Robert Wilson DO Syndrome Presenting in an Air Force Recruit with Extensive Maxillary Sinus Disease as Unilateral Ophthalmoplegia– Morgan Christina Jordan, Brian Stephens, Jason Albert Friedman

P2.2-110 Novel Findings

in Hereditary Sensory and Autonomic Neuropathy Type IV–Aditi Vian Varma-Doyle, Lori Mcbride, Michael Marble, Ann H. Tilton

STROKE IN THE YOUNG AND ELDERLY

P2.3-001 The Oldest Strokes in the Oldest State: Experience of Acute Stroke at Maine Medical Center–Michael P.H. Stanley, John Dziodzio, David Seder

cranial palsy: Should we think of Myasthenia Gravis?–Lithey Poveda, Emilio Herrera, Guillermo Gonzalez-Manrique, Freddy Escobar-Montealegre

P2.3-002 Differences in

P2.2-104 CIDP Disease Burden:

P2.3-003 Do Older stroke

Results of a US Nationwide Patient Survey–Jeffrey Aaron Allen, Lisa Butler, Todd D. Levine, Ann L. Bullinger, Carol L. Koski

P2.2-105 Does CIDP Increase

The Risk of Acquiring Other Autoimmune Disorders? A New York State Planning and Research Cooperation System Database Analysis (1998-2014)–Sanjila Islam, Yu Zhang, Kevin Nolasco, Jaideep Vaidya, Vijay Atluri, Basit Shafiq, Nizar Souayah

P2.2-106 First Report of

Confirmed CIDP in a Patient with Neuromyelitis Optica Spectrum Disorder (NMOSD)–Maitreyi Murthy, Machteld E. Hillen

P2.2-107 Refractory

Contactin-1-seropositive chronic inflammatory demyelinating polyneuropathy with involvement of cranial nerves: A case report.– Emilio Rafael Garrido Sanabria, Iakov N. Rudenko, Michael Todinca, Dwayne O’Brian Brown, Ryan Kyle Jones, Christopher Bellber, Roberta J. Seidman, Saima Siddiqui, Christopher Bellber

Presenting Symptoms of Acute Stroke Among Young and Older Adults–Haley Huggins, Lester Y. Leung patients with higher NIHSS scores have increased DTN time?–Nidhi Kasatwar, Lee Birnbaum

P2.3-004 The relationship

between individual risk factors and likelihood to list modifiable stroke risk factors amongst racial/ethnic minority seniors in Los Angeles–Demelio Alejandro Urbano, Josephine Menkin, Carmen Carrillo, Catherine Sarkisian

P2.3-005 Mechanical

Thrombectomy is effective and safe on elderly stroke patients– Marwa A. Elnazeir, Michael Haboubi, Ruolan Liu, Elizabeth Hillery Wise, Tracy Ander, Jignesh J. Shah, Kerri S. Remmel, Wei Liu

P2.3-006 Characteristics

and Outcomes of Mechanical Thrombectomy in Nonagenarians– Sishir Mannava, Vasu Saini, Nida Akram, Marie Christine Brunet, Dileep R. Yavagal, Amer Malik

P2.3-007 Clinical Outcomes

following Endovascular Therapy and/or Thrombolysis in Elderly with Large Vessel Occlusion Strokes: A “Real World” Experience–Tamra Ishan Jayendra Ranasinghe, Ashley Petrone, Amelia Karen Adcock

P2.3-008 Not all Strokes in

the Young are Vasculitis: A Challenging Case of Thrombotic Thrombocytopenic Purpura– Steven C. Swavely, Sridhara Sashy Yaddanapudi, Amandeep Dolla

P2.3-009 Hypercoagulable

States in Young Adults with Ischemic Stroke in a Stroke Belt State–Sarah R. Durica, Joshua Santucci, Sama Astani, Chad J. Stuckey, Claire Emmanuelle Delpirou Nouh, Chao Xu, David Lee Gordon

P2.3-010 Focal Cerebral

Arteriopathy in Young Adult Stroke Patients–Mary Clare McKenna, Noel Fanning, Simon Cronin

P2.3-011 Angiomatosis

Cerebri–Meghan Purohit, Dinesh V. Jillella, Jayashree Sundararajan

P2.3-015 Outcomes in

Transferred Stroke Patients with Large Vessel Occlusion (LVO) after IV rt-PA–Nikil Swamy, Nobl Barazangi, Warren Kim, Charlene Chen, Michael Ke, Christine S. Wong, Billy Gao, Jessica Choe, Ilana Spokoyny, Nicholas Telischak, Joey English, Alan H. Yee, Ann Bedenk, Julia Fernandes, David Grosvenor, Sulila Patel, David C. Tong

P2.3-016 Interfacility Transfer for Mechanical Thrombectomy – Direct to Neuroangiography or CT Angiography First?–Kelley Humbert, Michele Sellers, Elizabeth Neuhaus-Booth, B Pukenas, Brett L. Cucchiara

P2.3-017 Transfer to Nearest

Primary Stroke Center Portends Significant Delays and Poorer Outcomes in LVOs.–Audrey Arango, Laura Suhan, Jordan Yakoby, Briana DeCarvalho, Maya Inman, Avani Bhatnagar, Ashish Kulhari, Siddhart Kumar Mehta, Spozhmy Panezai, Jawad F. Kirmani

P2.3-018 Gender Disparities

Between Risk Factors and Stroke Mechanisms in Young Adult Stroke–Elena Michaels, Lester Y. Leung

in Misdiagnosis of Ischemic Stroke or TIA During Telestroke Consultation–Tara Danielle Von Kleist, Alaa Mohammed, Himanshu Chokhawala, Gabriel Vidal, Richard Zweifler

P2.3-013 Impact of race in

P2.3-019 Complicated

P2.3-012 Associations

ischemic stroke affecting young adults–Haitham Hussein, Bhavani Kashyap, Carol Droegemueller, Lauren Erickson, Sally I. Othman, Sarah Jamal, Leah R. Hanson, Morgan M. Brown TELESTROKE AND TRANSFER PROCESS for Triage of Primary Intracerebral Hemorrhage Patients: Optimizing ICH Care Across Health Care Systems–Katie Alex, Jennifer Meeks, Arvind Bambhoroliya, Sunil Sheth, Sean I. Savitz, Farhaan S. Vahidy

P2.3-020 Telestroke Technology Decreases Time to Neurologist Evaluation for Emergent Stroke Treatment During After Hours–Andrew Jiahao Zhang, Mohammed Hamad Alkuwaiti, Sarah A. Engkjer, Christopher Streib

P2.3-021 Telestroke Sub-events and their Contribution to Doorto-Needle Time in a Telestroke Network–Rahul Haridas Rahangdale, Chris Hackett, David G. Wright, Sandeep S. Rana, Robert Fishman, Ashis H. Tayal

P2.3-028 Neuroprotection by

P2.3-023 Differences in Door-

P2.3-029 Glutamate Induces

of Secure Messaging System Reduces Response to Page in Telestroke Network–Chris Hackett, Rahul Haridas Rahangdale, Sandeep S. Rana, Robert Fishman, David G. Wright, Patty Noah, Ashis H. Tayal to-Needle Times and Functional Outcomes between Primary Stroke Centers and Non-Primary Stroke Centers in a Telestroke Network Among Patients Receiving Intravenous Tissue Plasminogen Activator–Shaun Ajinkya, Deepak N. Reddy, Christine Holmstedt

P2.3-024 Extending Telestroke

Call Window to 24 Hours Increases Call Volume and Acute Stroke Treatments–Chris Hackett, Rebekah Heintz, Rahul Haridas Rahangdale, David G. Wright, Robert Fishman, Sandeep S. Rana, Ashis H. Tayal

P2.3-025 C3FIT (Coordinated,

Collaborative, Comprehensive, Family-Based, Integrated, and Technology-Enabled Care): A Randomized Controlled Comparative Effectiveness Trial on Stroke Health Care Delivery.– Neethu Gopal, Lisa Nordan, Patricia Commiskey, Courtney Graddy, William David Freeman CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY: PRECLINICAL WORK AND BIOMARKERS

P2.3-026 Intra-arterial

mesenchymal stem cell therapy modulates inflammasome to confer neuroprotection in animal model of ischemic stroke–Pallab Bhattacharya, Deepaneeta Sarmah, Harpreet Kaur, Kanchan Vats, Jackson Saraf, Kiran Kalia, Dileep R. Yavagal

P2.3-027 Utilizing Single Cell

Immune Profiling to Identify Serum-based Biomarkers for Transient Ischemic Attacks–Kate Elizabeth Therkelsen, Amy Tsai, Michael Mlynash, Byeongtaek Oh, Irina Eyngorn, Brice Gaudilliere, Paul M. George

Non Steroidal Anti-Inflammatory Drugs Against an In Vivo & In Vitro Ischemic Stroke via Downregulating Intrinsic Apoptosis Pathways.–Dinesh Tripathi, Sunita Tiwari, Chetna Mishra Synthesis of Thrombogenic Peptides and Extracellular Vesicle Release from Human Platelets– Deepa Gautam, Rameshwar Nath Chaurasia, Debabrata Dash

P2.3-030 Serum Troponin Level

In Acute Ischemic Stroke Identifies Patients with Concomitant Visceral Infarcts–Idrees Azher, Ashutosh Kaushal, Andrew D. Chang, Shawna M. Cutting, Brian Mac Grory, Tina Mariko Burton, Katarina B. Dakay, Bradford B. Thompson, Michael E. Reznik, Linda C. Wendell, Nicholas S. Potter, Ali Mahta, Alexander Merkler, Hooman Kamel, Mitchell S. V. Elkind, Mahesh Jayaraman, Michael Atalay, Karen L. Furie, Shadi Yaghi

P2.3-031 Low

Holotrancobalamin- A Risk Factor And Better Marker Than Cobalamin And Homocysteine In Acute Stroke.–Yatin Sagvekar, Ish Anand, Prahlad Kumar Sethi, Anuradha Batra, Seema Bhargava, Mamta Kankra, Anshu Rohatgi, Virti Shah, Neha Pandita, Rahul Sharma

P2.3-032 The Relationship

Between Serum Highly Sensitive C-Reactive Protein, Severity And Short-Term Outcome In Acute Stroke At The Lagos University Teaching Hospital, Lagos, Nigeria.–Oguntunde Funke Olapeju, Mustapha A. Danesi, Oluwadamilola Omolara Ojo, Njide Okubadejo

P2.3-033 Utility of D-dimer

for oncologic disease suspicion in patients with cryptogenic ischemic stroke.–Maria Bullrich, Victoria Aldinio, Gustavo Da Prat de Magahlaes, Santiago Isa, Gabriel Martino, Maria Pilar Sanchez de Paz, Emilia M. Gatto, Gabriel Persi

AAN.com/view/AM19Sci 147

Monday

P2.3-014 Establishing Criteria

Migraines treated with Thrombolysis as an Ischemic Stroke mimic via Telestroke– Ravyn Cash, Randheer Yadav, Sushil Sham Lakhani, Smeer Salam, karen wiles, Vivien H. Lee

P2.3-022 Implementation

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.3-034 Thromboelastography

with Platelet Mapping(TEGPM) is a Sensitive Indicator of Radiographically Confirmed Ischemic Stroke: A Retrospective Analysis.–Niraj Ashok Arora, Kelly Bowers, Richard Hammer, Ahmer Asif

P2.3-035 Differences

in Admission Electrolyte Concentrations among Stroke Etiologies–Rachel Forman, Laurel Jean Cherian, James Conners, Rima Dafer, Nicholas D. Osteraas, Sarah Song, Alejandro Vargas CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY: PREHOSPITAL AND IN-PATIENT EVALUATION AND TREATMENT

P2.3-036 Design of a Phase

III Study of Intravenous Glibenclamide (BIIB093) for Large Hemispheric Infarction: the CHARM Study–Kevin N. Sheth, W. Taylor Kimberley, Gregory W. Albers, Holly E. Hinson, Bradley Molyneaux, Raul G. Nogueira, Jeffrey L. Saver, Thorsten Steiner, Kazunori Toyoda, Max Wintermark, Jacob S. Elkins, Aaron Deykin, Michael Wald, Jaren Landen

P2.3-037 Prediction of

Malignant Edema in Anterior Circulation Stroke: Validation of the EDEMA Score and Added Value of Stroke Severity–Yajun Cheng, Simiao Wu, Yanan Wang, Ruozhen Yuan, Liu Ming

Monday

P2.3-038 Neuro-Checks and the

National Institute of Health Stroke Scale in Acute Stroke–Andres De Leon Benedetti, Iszet CampoBustillo, Jose Gabriel Romano, Sebastian Koch

P2.3-039 Early mobilization

after 12 hours post thrombolysis is feasible and safe in minor stroke patients–Muhib Khan, Tricia Tubergen, Hattie LaCroix, Laurel Packard, Cuyler Huffman, Alana Garcia, Nicholas Ames, Dawn Newell, Donald Packard, Bassel Raad, Joseph Zachariah, Elysia James, Andrea Goosen, Angela Frye, Tamer Abdelhak, Brian Silver

148 2019 AAN Annual Meeting

P2.3-040 Fast-track versus

Long-term Hospitalizations for Patients with Non-disabling Acute Ischaemic Stroke–Joachim Fladt, Laurine Hofmann, Michael Coslovsky, Anna Imhof, David Seiffge, Alexandros Polymeris, Sebastian Thilemann, Christopher Traenka, Raoul Sutter, Beat Schaer, Beat Kaufmann, Nils Peters, Leo Bonati, Stefan T. Engelter, Philippe A. Lyrer, Gian Marco De Marchis

P2.3-041 Understanding

the Environment of Care for Hospitalized Stroke Patients– Alyssa Chao, Nozomi Tahara, Mona Bahouth

P2.3-042 Disparities in the

effect of atrial fibrillation on discharge destination and length of stay in patients hospitalized for ischemic stroke: the Florida Puerto Rico Atrial Fibrillation Stroke Study–Nicole Beaton Sur, Chuanhui Dong, Kefeng Wang, Marco Di Tuillo, Carolina M. Gutierrez, Sebastian Koch, Enid Garcia, Juan Carlos Zevallos, William Scott Burgin, David Z. Rose, Jose Gabriel Romano, Jeffrey Goldberger, Ralph L. Sacco, Tatjana Rundek

P2.3-043 Practice Alert:

Generalized Tonic-Clonic Seizures Associated with Intra-arterial Administration of High Doses of Verapamil in Treatment of Cerebral Vasospasm–Mr. Endrit Ziu, Adnan I. Qureshi, Muhammad Umair Jahngir, Laura Qi, Micheal Ortiz Torres

P2.3-044 Triage of Acute

Strokes Using an EMS-driven Rapid Arterial Occlusion Evaluation (RACE) Protocol: a Longitudinal Study.–Ehad Afreen, Alicia Clara Castonguay, Syed F. Zaidi, Mouhammad A. Jumaa, Nurose Karim, Giana Dawod, Nicholas Daniel Henkel, Hisham Raza Alim Salahuddin, Julie Shawver, Andrea Korsnack

P2.3-045 Improving field

Identification of Large vessel occlusion: A retrospective review analysis–Parneet Kaur Grewal, Sourabh Lahoti, Sushanth Rao Aroor, Kaitlin Michelle Snyder, Kristin McQuerry, L Creed Pettigrew, Larry B. Goldstein

Monday, May 6 P2.3-046 A Prehospital Los

Angeles motor scale (LAMS) score of 4 or more predicts intervention for acute stroke.–Tej Stead, Paul Banerjee, Latha Ganti

P2.3-047 Improvement in Stroke Survey Scores for Rural EMS Providers–Eric J. Seachrist, Sneha Jacob, Ashley Petrone, Amelia Karen Adcock

P2.3-048 Reasons for

Prehospital Delay in Acute Ischemic Stroke: a Prospective Cohort Study–Joachim Fladt, Nicole Meier, David Seiffge, Christopher Traenka, Alexandros Polymeris, Sebastian Thilemann, Raoul Sutter, Henrik Gensicke, Nils Peters, Leo Bonati, Stefan T. Engelter, Philippe A. Lyrer, Gian Marco De Marchis

11:30 a.m.–6:30 p.m. P2.3-054 Endovascular

Reconstruction of Intracranial Aneurysms with Pipeline in Pediatric Patients–Peyman Shirani, Eytan Raz, Ashkan Mowla, Matthew Gusler, Maksim Shapiro

P2.3-055 Utility of Routine Neck

MRA in a Pediatric MRI Stroke Protocol–Austin Baltensperger, David Mirsky, John Maloney, Llana Neuberger, Laura Fenton, Timothy Bernard, Nicholas Stence

P2.3-056 Screening Tool to

Provide Early Stroke Detection after Cardiac Catheterization in Children–Catherine Salussolia, Patrick Vittner, Loren Brown, Louisa G. Keith, Sonali Tanya Sen, Miya Bernson-Leung, Agnieszka Kielian, Michael J. Rivkin, Dana B. Harrar

P2.3-049 RAcial Disparities

P2.3-057 Monogenic Causes

P2.3-050 Cerebral Oximetry in

DISSECTION AND VASCULOPATHY

in Ich After iv-tpA and Neurointerventional Treatment (RADIANT)–Chia-Chun Chiang, Dawn Meyer, Brett C. Meyer, Kunal Agrawal, Royya F. Modir Acute Ischemic Stroke Patients According to Brain Area and Recanalization Status–Giacomo Giacalone, Marta Zanoletti, Rebecca Re, Davide Contini, Lorenzo Spinelli, Alessandro Torricelli, Luisa Roveri PEDIATRIC STROKE

P2.3-051 A Life Saving

Treatment in an Adolescent Girl Presenting with Headache and Stupor–Vishal Mandge, Isaac Molinero, Susan Erin Duberstein Coad

P2.3-052 Clinical Presentation,

Neuroimaging Characteristics and Long-term Outcome in Pediatric Cerebral Venous Sinus Thrombosis: A Retrospective Study–Cemal Karakas, Danielle Takacs, Ethan Edmondson, Kristen Fisher, Nikita Shukla, Gary D. Clark, Davut Pehlivan

P2.3-053 Retrospective Cohort

Analysis in Neonatal Cerebral Sinus Venous Thrombosis–Cemal Karakas, Danielle Takacs, Ethan Edmondson, Kristen Fisher, Nikita Shukla, Gary D. Clark, Davut Pehlivan

of Cerebrovascular Disease in Childhood–Bridget LaMonica Ostrem, Paul Caruso, Eric Grabowski, Patricia Musolino

P2.3-058 Spontaneous

Consecutive Four Vessel Cervicocephalic Dissections and Flow-Limiting Ischemic Stroke– Anvi Gadani, Ilavarasy Maran, Amre Nouh

P2.3-059 Gene Expression

Profile of Cervical Artery Dissection by Time of Event–Ilana Green, Timothy McMurry, Stephen R. Williams, Keith Keene, Debra Owens, Fang-Chi Hsu, Stefan Bekiranov, Michèle Sale, Bradford B. Worrall, Andrew Mebane Southerland

P2.3-060 Recurrent

Cervicocephalic Dissections are Associated with Variants in Connective Tissue Disease Genes–Mohammad Ridha, Jessica Mintz, Barbara Voetsch

P2.3-061 IV Thrombolysis for

Stroke Due to Cervicocephalic Arterial Dissection: What Is The Right Practice?–Owais Khadem Alsrouji, Muhammad Affan, Panayiotis Mitsias

P2.3-062 VZV-Induced Central Nervous System Vasculopathy: Clinical, Imaging and Biological Features–Jean Khoury, Adarsh Bhimraj, Tracey Huijun Fan, Ken Uchino, Sung Min Cho

P2.3-063 Treatment and

Follow-up of VZV-Induced Central Nervous System Vasculopathy– Jean Khoury, Adarsh Bhimraj, Tracey Huijun Fan, Sung Min Cho, Ken Uchino

P2.3-064 Two Cases of

Transient Global Amnesia in Marfan Syndrome–Kenneth Allen Morris, Alejandro A. Rabinstein, Nathan P. Young

P2.3-065 A unique case

of Turner syndrome with spontaneous intracranial artery dissection–Aman Deep, Balaji Krishnaiah, Anvita Potluri, Talal Aboud, Nitin Goyal, Rena Sukhdeo, Adam Arthur, Andrei V. Alexandrov

P2.3-066 Clinicoradiographic

Course of Focal Intracranial Arteriopathy in Young Adults– Adam MacLellan, Lironn Kraler, Neil E. Schwartz, Sarah Lee

P2.3-067 Racial disparities in

moyamoya disease in a North American cohort–Khadija Irshad, Shaneela Malik, Lonni Schultz

P2.3-068 Is there a distinct

phenotype for non-Asian moyamoya patients?–Hajere Gatollari, Eliza Cushman Miller, Amelia Katharine Boehme, E. Sander Connolly, Mitchell S. V. Elkind, Joshua Z. Willey

P2.3-069 Moyamoya Disease

and Associated Risk Factors: Analysis of a National Database– Animesh Gupta, Fares Qeadan, Sajid Suriya, Mudassir Farooqui, Andrew Lin, Alexis Alvarado Arias, Atif Zafar, Michel T. Torbey

P2.4-001 A Prospective

Study of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Identifying Ultrasonographic Features for Diagnosis and Prognosis–Nicholas Crump, Michael Cartwright, Richard A L Macdonell

P2.4-002 Serum Cytokines

and Chemokines in Chronic Inflammatory Demyelinating Polyneuropathy Compared to Diabetic Neuropathy, Idiopathic Neuropathy and Other Inflammatory Neuropathies– Jeffrey Z. Shije, Joy Ukaigwe, Xiaoyu Che, Thomas H. Brannagan, Mady Hornig

Syndrome following Influenza Vaccination in the United States: A CDC/FDA Vaccine Adverse Event Reporting System Study, 1990-2016–Kevin Nolasco, Nizar Souayah

P2.4-004 Trends In Outpatient

And Hospitalization Charges Relevant To the Management of Chronic Inflammatory Demyelinating Polyneuropathy: A Statewide Planning and Research Cooperative System (SPARCS) Study 2002-2014–Yu Zhang, Kevin Nolasco, Sanjila Islam, Jaideep Vaidya, Vijay Atluri, Basit Shafiq, Nizar Souayah

P2.4-005 A Case Series of

Patients with Neurofascin Associated Peripheral Neuropathies–Angela AzizDonnelly, Richard A. Monti, Rocio Carolina Garcia Santibanez

P2.4-006 Clinical and

P2.4-010 Rituximab for

the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: A retrospective chart review– Matthew Varon, Mamatha Pasnoor, Duaa Jabari, Constantine Farmakidis, Omar Jawdat, Melanie Glenn, Jeffrey Statland, Richard J. Barohn, Mazen M. Dimachkie

P2.4-011 Acute Immune

Sensory Polyradiculopathy (AISP): A Challenging Diagnosis–Rocio Vazquez Do Campo, Andrea Boon, P. James B. Dyck, Jennifer Anne Tracy

P2.4-012 The prevalence,

severity and risk factors for chemotherapy induced peripheral neuropathy at 0 and 2 years after the completion of paclitaxel therapy–Noah A. Kolb, Summer Karafiath, Felix Vivanco, J. Robinson Singleton, A. Gordon Smith

P2.4-018 Guillain Barre

Syndrome Variant with Facial Diplegia and Paresthesias presenting with Bulbar Weakness–Bhavesh Trikamji, Margaret Adler

P2.4-019 Clinical and

Epidemiological Profile of a Brazilian’s cohort of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy–Viviane Tavares Carvalho, Caroline Lourenço Medeiros, Vanessa Lessa, Luis F. Maia, Arthur Ramalho Monfredinho, Thiago Rodrigues, Ivan Abreu, Eduardo Rodrigues Davidovich, Camila Pupe, Osvaldo J M Nascimento

P2.4-020 Severe Subacute

Motor Neuronopathy Associated with Non-Hodgkin B Cell Lymphoma–Nucike Khezri, Svetlana Eckert, Gil I. Wolfe, Nicholas Joseph Silvestri

Electrophysiological Features of Chronic Inflammatory Demyelinating Polyneuropathy in Chile.–Jose Gabriel Cea Munoz, Juan Francisco Idiaquez, Jose Manuel Matamala, Rodrigo Salinas, Roque Villagra, Andres Stuardo

P2.4-013 Proximal Median

P2.4-021 Miller Fischer

P2.4-007 Long Term Differential

P2.4-014 Inflammatory

P2.4-022 Different Effects of

Outcomes of CIDP Patients After Using IVIG, Plasmapheresis, Or Corticosteroids: A Statewide Planning and Research Cooperative System (SPARCS) Study 2002-2014–Yu Zhang, Kevin Nolasco, Sanjila Islam, Jaideep Vaidya, Vijay Atluri, Basit Shafiq, Nizar Souayah

P2.4-008 Vasculitic Peripheral

Neuropathy, differences between Systemic and Non-Systemic etiologies.–Juan Castiglione, Mariano Marrodan, Ana Lia Taratuto, Lucas Alessandro, Patricio Brand, Fabio Adrian Barroso

P2.4-009 Acute Inflammatory Demyelinating Polyneuropathy following Pembrolizumab infusion–Anand Venkatraman, Jeffrey Gluckstein, Salvatore Anthony D’Amato, Jorge Torres, Galen V. Henderson

Neuropathy with Brachial Plexitis After PICC Placement; a Case Study and Review of Neurologic Complications Associated with Central Venous Catheter Placement–Christa Seligman, Karin Woodman Ischemic Nerve Injury Can Cause CIDP-like Neuropathy–Pariwat Thaisetthawatkul, P. James B. Dyck

P2.4-015 Acute Motor And

Sensory Axonal Neuropathy following Diarrheal Illness with Concomitant Dry Beri Beri following Bariatric Surgery– Hesham T. Ghonim, Sherif Elwan, Ahmed El Dokla

P2.4-016 Nivolumab induced

neurological syndrome mimicking acute inflammatory demyelinating polyneuroradiculopathy responding to infliximab–Supriya Kairamkonda, Betul Gundogdu, Aravindhan Veerapandiyan, Natasha Hameed, Nidhi Kapoor

P2.4-017 Multifocal motor

neuropathy: a rare and complex disease - an university center’s experience.–Caroline Lourenço Medeiros, Viviane Tavares Carvalho, Arthur Ramalho Monfredinho, Thiago Rodrigues, Luis F. Maia, Vanessa Lessa, Ivan Abreu, Eduardo Rodrigues Davidovich, Camila Pupe, Osvaldo J M Nascimento

Syndrome after Vaccination in the United States: A CDC/FDA Vaccine Adverse Event Reporting System Study, 1999-2017–Kazi Md Asif Hilmi, Nizer Souayah, Kevin Nolasco, Kazi Nusrat Tamanna Selective Phosphodiesterase Inhibitors on Experimental Autoimmune Neuritis.–Toshiki Fujioka, Wataru Hagiwara, Hideo Kihara, Masashi Inoue, Takafumi Uchi, Tsukasa Kudeken, Shingo Konno, Hideki Sugimoto

P2.4-023 Acute Motor-Sensory Axonal Variant of GBS with Cranial Nerve Involvement (Dysphagia) in a Patient with Acute Cervical Myelopathy Masking Upper Motor Neuron Signs–Jenny Argudo Luzuriaga, Max R. Lowden

P2.4-024 Is Alcoholic

Neuropathy Selective ?–Natarajan Visvanathan, Rahul Nimmakayala

P2.4-025 2 cases of

hypertrophic CIDP associated to other autoimmune neurological disorders: Myasthenia Gravis and Multiple Sclerosis.–Victor Mantelatto Bonsi, André Luiz Guimarães de Queiroz, Karlla Danielle Ferreira Lima, Marcio Luiz Escorcio Bezerra, Liliane Dutra Batist Nascentes, Alex Baeta

AAN.com/view/AM19Sci 149

Monday

ACQUIRED NEUROPATHIES I

P2.4-003 Guillain- Barré

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.4-026 Safety of Therapeutic

P2.4-034 Chilaiditi syndrome

P2.4-027 Readmissions

P2.4-035 Aliskiren and

Plasma Exchange for the Treatment of Guillain-Barré Syndrome in Polycythemia Vera–Rory Abrams, Gregory A. Elder

after Guillain-Barré Syndrome: Nationally Representative Data– Mallory Roberts, Peter Jin, Susan Shin, Mandip Singh Dhamoon

P2.4-028 Prospective, Open-

Label Study Evaluating the Safety and Tolerability of Higher Infusion Rates of Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. Interim analyses.–Yue Jiang, Vera Bril, Christine Heung, Shabber Mannan, Eduardo Ng, Evelyn Sarpong, Jafar Shabanpour, Carolina Barnett Tapia

P2.4-029 The Recovery of

Severe Foot Drop in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in relation to Electrodiagnostic Findings of the Affected Tibialis Anterior (TA) Muscle–Dinushi Weerasinghe, Aravindhan Veerapandiyan, Michael Stanton, David N. Herrmann, Eric L. Logigian

P2.4-030 A 65 year old man

with MADSAM associated with neurosarcoidosis–Yohei Harada, Hisham Gibriel Bakhiet Elkhider, Neil Masangkay, Mitesh P. Lotia

P2.4-031 Role of Cerebrospinal

Monday

Fluid Protein and Laboratory Testing in Guillain Barre Syndrome–Kasser Saba, Zahra Sadat-Hossieny, William D. Arnold, Bakri Elsheikh, David Kline, Amro Stino GENETIC MUSCLE DISORDERS I

P2.4-032 The effect of

L-Arginine on mitochondrial function, nitric oxide synthesis and nitrative stress–Celia H. Tengan, Camila Barros, Carlos T. Moraes, Jomenica De Bortoli Livramento

P2.4-033 A novel Biological

(FOX-115) improves endurance of motor performances in old mice–Ruggero G. Fariello, Roberta Schellino, Marina Boido, Jan Willem Vrijbloed, Alessandro Vercelli

150 2019 AAN Annual Meeting

and radiological sign in myotonic dystrophy type 1–Shinei Kato, Yuichi Hayashi, Nobuaki Yoshikura, Megumi Yamada, Akio Kimura, Takayoshi Shimohata cytokine’s expression in mdx mice–David Feder, Thaina Marin, Bruno Bertassoli, Giuliana Petri, Jose Ramos, Fernando Fonseca, Alzira A S Carvalho

P2.4-036 New Insights About

Myofibrillar Myopathies: The Role Of Metalloproteinases 2 And 9 In The Pathogenesis–Alzira A S Carvalho, Emmanuelle Lacene, Vinicius Gomes, Roseli Corazzini, Norma Romero

P2.4-037 Axial Weakness as

the Presenting Manifestation of Myopathy–Andrea Parks, Jason Karamchandani, Yves Troyanov, Rami Massie, Erin K. O’Ferrall

P2.4-038 Paraspinal Atrophy

Suggesting Underlying Genetic Etiology–Daniel Schwartz, Jamie Fong, Dena Matalon, Janice Chun Yee Wong, Maxwell Andrew Greene

P2.4-039 Nitrative Stress In

Skeletal Muscle Of Patients With Mitochondrial DNA Mutation– Jomenica De Bortoli Livramento, Thiago Araujo, Gabriela Rodrigues, Camila Barros, Beatriz H. Kiyomoto, Beny Schmidt, Acary S. B. Oliveira, Celia H. Tengan

P2.4-040 A patient with Late

onset Pompe Disease presenting with prominent muscle cramps, proximal lower extremities muscle weakness, and widespread myotonic discharges seen in electromyography.–Amr Hassan Ewida, Richardson Timothy, Irine Siraj, Ahmed Eldokla

P2.4-041 Exome sequencing

reveals novel candidate genes and potential oligogenic inheritance in patients with the complex trait arthrogryposis–Davut Pehlivan, Yavuz Bayram, Zeynep Coban Akdemir, Jawid Fatih, Richard Gibbs, Jennifer Posey, Nursel Elcioglu, Beyhan Tuysuz, James R. Lupski

P2.4-042 A unique myopathic

phenotype of novel SPTAN1 mutation without encephalopathy in siblings–Arayamparambil Anilkumar, Ibrahim Makki Binalsheikh, Douglas Miller

Monday, May 6 P2.4-043 Molecular link

between insulin resistance and skeletal muscle atrophy in myotonic dystrophies–Giovanni Meola, Laura Valentina Renna, Francesca Bosè, Elisa Brigonzi, Barbara Fossati, Rosanna Cardani

P2.4-044 Low Dose Dantrolene

Treatment Reduced Pain in Patients with Strongman Syndrome.–Ludivine Chamard Witkowski, Richard Dumais, Sandra Magalhaes, Bernard Brais

P2.4-045 Novel missense

mutation in CAPN3 gene detected in a tunisian family with limb girdle muscular dystrophy type 2–Sabrine Rekik, Stacy Schantz Wilkins, Nouha Farhat, Hanen Haj Kacem, Frederic Costes, François Jérôme Authier, Chokri Abdellaziz Mhiri

EPILEPSY: WOMEN’S ISSUES

P2.5-001 Discontinuation Rates for Hormonal Contraception on Enzyme Inducing versus Other Antiepileptic Drug Categories: Interim Analysis of the Epilepsy Birth Control Registry–Andrew G. Herzog, Isabelle Dost, Devon MacEachern

P2.5-002 Catamenial epilepsy:

prevalence in a heterogenous cohort of women with epilepsy–McKenna Kelly, Page B. Pennell, Jacqueline French, Cynthia L. Harden, Anne R. Davis, Ms. Connie Lau, Alexa Ehlert, Stephanie Allien, Sarah Barnard

P2.5-003 Trends In The Anti-

Epileptic Drug Usage During Pregnancy And Malformation Outcomes Over Two Decades In Kerala Registry Of Epilepsy And Pregnancy–Ravish Keni, Manna Jose, Sankara Sarma, Sanjeev V. Thomas

P2.5-004 Is Pre-conceptional

counselling for Women with Epilepsy (WWE) beneficial: Experience from Kerala Registry of Pregnancy and Epilepsy, India–Jitupam Baishya, Manna Jose, Prabhakaran Sarma, Sanjeev V. Thomas

P2.5-005 Increased Lamotrigine Clearance and Decreased Levels with Non-oral Hormonal Contraceptive Use–Alexa Moriah King, Elizabeth Gerard

11:30 a.m.–6:30 p.m. P2.5-006 Adherence of Saudi

women with epilepsy to folic acid intake in pre-conceptional period in Riyadh, Saudi Arabia.–Ahmed Alqahtani, Ali Basher Saud Alanazi, Saleh Alduhayan, Abdulaziz Alfadhel, Mohammad alfahadi, Waleed Alharbi, Raghad Alharthi, Majed Alhameed, Ahmad Abulaban, Emad Masuadi

P2.5-007 Malformation Risk

Of Newer AEDs In Women With Epilepsy–Sanjeev V. Thomas, Manna Jose, RESHMA A.S., VEENA P EPILEPSY: GENETICS

P2.5-008 STXBP1 is associated

with bruxism in awake patients–Arezoo Rezazadeh, Victor Souza Torres De Lira, Alexandra Silberberg, Shelly K. Weiss, Elizabeth Donner, Maria M. Zak, Laura Bradbury, Muhammed Uddin, Stephen Scherer, O. Carter Snead, Alfonso Fasano, Danielle M. Andrade

P2.5-009 Outcome of Genetic

Testing for Patients with Epilepsy is Associated with Age of Seizure Onset, Presence of Other Neurological Features and Concurrent Testing of Parents– Dianalee McKnight, Julie Scuffins, Elizabeth Butler

P2.5-010 FRRS1L gene

Homozygous Mutation (p.Gly246del) in Puerto Rican Families With Epileptic Encephalopathy and Dyskinetic Movements–Imane Abdelmoumen, Sandra Liliana Jimenez, Ignacio Valencia, Joseph J. Melvin, Michael Schneider

P2.5-011 Genetic

Characterization and Prognosis of Adult Patients with LennoxGastaut Syndrome: A Prospective Case-Series Study–Robert De Santis, Tara Sadoway, Danielle M. Andrade

P2.5-012 Will You Get

Stuck? Predicting Trafficking Deficient SCN1B Mutations from Localization and Amino Acid Change–Rachel Joy Saban, Salma Aljamal, Meaghan Berns, Gustavo A. Patino

P2.5-013 Seizures, dystonia

and progressive cerebellar degeneration in homozygous DNAJC19 mutation without dilated cardiomyopathy or 3-methylglutaconic aciduria– Marta Ruiz Lopez, Fadi Hamdan, Arezoo Rezazadeh, Isabel Aznarez, Berge A. Minassian, Patrick Cossette, Jacques Michaud, Elizabeth Slow, Danielle M. Andrade

P2.5-014 Progressive

Myoclonus Epilepsy of Lafora First Diagnosed in El Salvador–René Silva, Reyna M. Duron, Walter Flores, Yanez Siriani, Viet-Huong Nguyen, Miyabi Tanaka, Antonio V. Delgado-Escueta

P2.5-015 Differential

Methylation Profiles of BDNF Promoters I and IV in Patients with Temporal Lobe Epilepsy–Thais Secchi, Isabel C Bandeira, Lucas Giombelli, Ágata de Carvalho, Mariana Fitarelli-Kiehl, Eduardo Amorim, Talissa Bianchini, Isabel Werlang, Ana Abujamra, Sandra Leistner-Segal, Marino Bianchin

P2.5-016 Adenosine Deaminase (ADA1) Gene Variants are Associated with Mood Disorders in Patients with Temporal Lobe Epilepsy–Thais Secchi, Luiza de Castro, Isabel C Bandeira, Eduardo Amorim, Suelen Mota, Talissa Bianchini, Maria Luiza Saraiva Pereira, Marino Bianchin EPILEPSY: STATUS EPILEPTICUS

P2.5-017 The Risk of Seizure

P2.5-018 Outcomes of Status

Epilepticus in Elderly: a systematic review.–Mahsa Sadeghi, Mehdi Eshraghi, Katherine Akers, Shahram Hadidchi, Mihir Kakara, Morad Nasseri, Advait Mahulikar, Rohit Ajay Marawar

P2.5-019 Clinical Features

and Outcomes of Patients with Status Epilepticus Caused by Neuroinflammation–Makoto Hara, Hideto Nakajima, Tomotaka Mizoguchi, Takayoshi Akimoto, Yuki Yokota, Momoko Ebashi, Masaki Ishihara, Akihiko Morita, Satoshi Kamei

Burst Suppression Ratio and Patient Outcome in Refractory Status Epilepticus–Neil Mehdiratta, Shenghua Zhu, Marcus Ng

P2.5-021 Benefits of

Extended Targeted Temperature Management (TTM) in the Management of Super-Refractory Status Epilepticus Secondary to anti-NMDAR encephalitis–Ausaf Ahmed, Sharjeel Panjwani, Nicholas Capaldo, Hongyan Li

P2.5-022 Cefepime-induced

Non-convulsive Status Epilepticus–Chris Hollen, Syeda Maria Muzammil, Tammam Dayyoub

P2.5-023 Implementation of

Seizure and Status Epilepticus Protocols in the Emergency Department of a large Academic Hospital–Kyna Schreiber

P2.5-024 Increased Risk

of Status Epilepticus in Poststroke Epilepsy Patients on Coumadin–Magdalena Stepien, Jacob Manske, Michael C. Smith, Rebecca O’Dwyer

P2.5-025 Pharmacological

treatment of status epilepticus at UNMC: assessment of seizure outcomes–Hae Young Baang, Nicholas Swingle, Kalyan C. Sajja, Deepak Madhavan, Olha D. Taraschenko

P2.5-026 Cessation of

Intrathecal Tranexamic Acid Induced Status Epilepticus with Pentobarbital–Devin Elizabeth Prior, Kevin Robert Chysna, Vijay Renga EPILEPSY: DIAGNOSIS AND CLINICAL CARE I

P2.5-027 Using Data Mining

Tools, Microservices Architecture And Artificial Intelligence Modules For The “Juvenile Myoclonic Epilepsy JME-1000 Project”–David Discua, Reyna M. Duron, Carlos Arias, Christopher Patterson, Viet-Huong Nguyen, Iris Martinez, Julia N. Bailey, Miyabi Tanaka, Adriana Ochoa, Aurelio Jara-Prado, Marco T. Medina, Evelyn Alvarez, Laura Guilhoto, Elza M. Targas Yacubian, René Silva, Antonio V. Delgado-Escueta

P2.5-028 Improving Lennox-

P2.5-036 Implementation of the

P2.5-029 Predictors of 30-

THE POWER OF CASE REPORTING IN NEUROONCOLOGY I

Gastaut Syndrome from Diagnosis to Management through Online Continuing Education: Changes in Patient Experience, Clinical Practice, and Provider Knowledge and Competence–Wendy Turell, Anne C. Roc, Juliann M. Paolicchi, Georgia D. Montouris day readmission after index hospitalization for epilepsy: a 5-year national estimate using the Nationwide Readmission (NRD) database–Chirag Narshibhai Savani, Varun Kumar, Colby Allen Richardson, Sheyar Amin, Stephanie Elizabeth MacIver, Alfred T. Frontera, Selim R. Benbadis

P2.5-030 How Common Are

Idiopathic Seizures in the Elderly? A Retrospective Review.–Louis Beers, Yuxiang Zhang, Rani A. Sarkis

P2.5-031 Differential

diagnosis of epileptic seizure and syncope using machine learning algorithms–Hayom Kim, Jung Bin Kim

P2.5-032 Long-term Follow

up of Epilepsy Patients After a Single Neurologist Visit–Chintan Prajapati, Mamta Bhushan Singh, Padma Vasantha Hadakasira, Vinay Goyal, Garima Shukla, Venugopalan Y. Vishnu, V Sreenivas, Victor H. Patterson, Roop Gursahani

P2.5-033 Differentiation

Liverpool Adverse Events Profile in Patients with Epilepsy at the University of Puerto Rico Epilepsy Clinics–Hector Alonso-Quinones, Sonia M. Caraballo-Cartagena, Ignacio Luis Pita Garcia

P2.6-001 Central Meningioma

Necrosis after CAR T-Cell Therapy–Seth Nathatn Levin, Claudiu Iulian Diaconu, Rebecca Gabrielle Straus Farber, Philip De Jager, Ran Reshef, Claire Riley

P2.6-002 A Case of Extracranial

Metastatic Spread of a PTCH1and TP53-mutated, Cerebellar Desmoplastic/Nodular Medulloblastoma in a Patient with Li-Fraumeni Syndrome–Mary Jane Lim Fat, Ugonma Nnenna Chukwueke, Helen Shih, Keith Ligon, Annie Chan, David Meredith, Lisa Doherty, Patrick Y. Wen

P2.6-003 Presentation of

High Grade Glioma Resembling Like Acute Disseminated Encephalomyelitis–Yash Shah, Padmavati Rajdatta Eksambe, Shefali Karkare, Sanjeev V. Kothare

P2.6-004 Leptomeningeal

Carcinomatosis in a patient with Waldenstrom Macroglobulinemia.–Sania Atta, Adil Iqbal, Brij M. Ahluwalia-Singh

of Epileptic Seizures from Dissociative Attacks, an Ongoing Dilemma.–Fiona Chan, Sasha Aleksander Filipe Korotaj Dionisio, Alexander C. Lehn, Lisa Gillinder

P2.6-005 A Rare Case of

P2.5-034 A Survey of Health

neurolymphomatosis–David Valentine, Andreas N. Neophytides, Alexander Allen, Ian Lustbader, Arielle Marisa Kurzweil

Care Professionals’ Perceptions of Convulsive Seizure Freedom and Antiepileptic Drug Adherence– Elizabeth Rappa, Frank Kung, Imad M. Najm, Tobias Loddenkemper, Betsy N. Williams, Jani Hegarty

P2.5-035 Pediatric Focal

Epilepsy: Patient Characteristics, Treatment Choices, Healthcare Resource Use and Costs by Developmental Delay and Behavioral Disorders Comorbidity Subgroups: A US Claims Database Analysis–Solene Thieffry, Simon Borghs, Li Wang, Sulena Shrestha, Nadia Foskett

Primary Neurolymphomatosis in Natural Killer T-Cell Lymphoma– Mallory Roberts, Amy Chan

P2.6-006 A protean case of

P2.6-007 A rare case of Isolated Neurolymphomatosis of Multiple Cranial Nerves Palsy–Marjorie Ho, Sen Sheng, Poornachand Veerapaneni, Nidhi Kapoor

P2.6-008 Superficial Siderosis

Associated with Central Neurocytoma–Mina Lobbous, Paula Province Warren, Mohamed Kazamel

AAN.com/view/AM19Sci 151

Monday

Recurrence in Patients with Status Epilepticus Requiring Anesthetic Treatment–Angela Parsons, Amy Z. Crepeau

P2.5-020 Quantitative EEG

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.6-009 Successful Treatment of CNS Involvement in Cutaneous T-Cell Lymphoma Mycosis Fungoides–Shreya Nayak, Jan Drappatz

P2.6-010 Intraventricular

lipids: A clue to early diagnosis of asymptomatic spinal dural teratoma rupture–Aparna Vaddiparti, Annie S. Daniel

P2.6-011 Multifocal Cerebral

Infarction and Status Epilepticus as a Result of 3-bromopyruvate Toxicity for Treatment of Ocular Melanoma–Abigail M. Taylor, Marie Francisca Grill, Michael Christiansen, Alyx B. Porter

P2.6-012 An Uncommon Cause

of Subcortical Low Intensity T2 Lesion–Sonia M. CaraballoCartagena, Laura Bimbela-Nieves, David Blas-Boria, Luis GarciaIrizarry

P2.6-013 Glioblastoma

multiforme that present with radiographic dural tails. Questioning the prognosis paradigm with case-based evidence of greater than average length of survival–Nara Michaelson

P2.6-014 Isolated CNS Blastic

Plasmacytoid Dendritic Cell Neoplasm in a Patient with AML– Nicholas R. Metrus, Rebecca Anne Harrison, Sherise D. Ferguson, Shiao-Pei Weathers

P2.6-015 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) manifesting in the Course of Treatment of Hodgkin’s Lymphoma with Brentuximab– Jessica Frey, Divisha Raheja

Monday

P2.6-016 Pilocytic Astrocytoma

in an Elderly Patient with Eleven Years of Follow-up: A Case Report and Commentary on Management of PA in An Elderly Patient–Lucas Cofer, Jonathan Howard

P2.6-017 Glioblastoma and

Disseminated Intravascular Coagulation: Literature Review and Illustrative Case–Oluwaseun O. Akinduro, Rana Hanna ALShaikh, Tasneem Fatema Hasan, Ernesto Ayala, Alfredo QuinonesHinojosa, Kristin Cushenbery, Julie E. Hammack, Mark Jentoft, Jangwon Yoon, Zbigniew K. Wszolek, William David Freeman

152 2019 AAN Annual Meeting

P2.6-018 To Biopsy or Not

to Biopsy? A case of primary intramedullary spinal cord lymphoma presenting as longitudinally extensive transverse myelitis within cervical cord–Sammita Satyanarayan, Adam Rizvi, Seema Nagpal

P2.6-019 Unusual case of

recurrent SMART (stroke-like migraine attacks after radiation therapy) syndrome–Smit D. Patel, Ashmanie Mahatoo, Avinash Prasad

P2.6-020 An Unusual Cause of

Longitudinal Extensive Transverse Myelitis (LETM) in an AntiAquaporin-4 Antibody Positive Case–Steven Yang, Annie Lee Hsieh, Maria Virginia Diaz Rojas, Rabia Choudry, Patrick B Cooper, Aparna M. Prabhu

P2.6-021 Atypical radiographic

appearance of anaplastic ependymoma that mimics arteriovenous malformation: a case report–Annie Lee Hsieh, Maria Virginia Diaz Rojas, Steven Yang, Patrick B Cooper, Alessandro Bombonati, Jeet Patel, Yan Zhang BASIC SCIENCE AND TRANSLATIONAL DISCOVERIES IN NEUROONCOLOGY

P2.6-022 Small RNA Deep

Sequencing Identifies Unique Extracellular-derived Bioactive Noncoding RNA Cargos in Pediatric Brain Tumors–Setty Magana, Timothy Peterson, Jared Evans, Ian Parney

P2.6-023 Combined

Pharmacologic Inhibition of MEKERK and PI3K/mTOR Signaling in Glioblastoma Models Enhances Therapeutic Antitumor Activity– Karisa C. Schreck, Amy Allen, Jiawen Wang, Christine Pratilas

P2.6-024 Inflammatory signaling supports cancer cell growth within the leptomeninges– Adrienne Boire, Yudan Chi, Jan Remsik, Camille Derderian, Elena Pentsova, Linas Mazutis, Dana Pe’er

P2.6-025 Selective Activation of PIK3CB in Glioblastoma Multiforme–Abigail Winn, Zhi Sheng

Monday, May 6

11:30 a.m.–6:30 p.m.

P2.6-026 Stearoyl CoA

P2.6-035 Efficacy of Extended

P2.6-027 Genomic Signatures

P2.6-036 Clinical presentation,

Desaturase is an essential regulator of fatty-acid-induced ER stress and a therapeutic target in gliomablastoma–Arsalan Hashemiaghdam, Kelsey Pinkham, Isam Adam, David Park, Mohammad El-Abtah, Kamila Rosiak, Aleksander Kirov, Christian Badr From Bench to Bedside - a Protocol for Translation: sigQC– Andrew Dhawan, Jacob Scott, Adrian Harris, Francesca Buffa

P2.6-028 Using PIK3CB

and Connexin-43 Inhibition to Sensitize Glioblastoma Cells to Temozolomide–Farah Shah, Zhi Sheng

P2.6-029 Comparative Analysis

of Tumor Treating Fields Using Conventional versus Alternative Transducer Array Placement for Posterior Fossa Glioblastoma–Eric Tai-Lee Wong, Pyay San, Victoria White, Edwin Lok

P2.6-030 Impact of EGFR

Amplification in Newly Diagnosed Glioblastoma Treated with Adjuvant Temozolomide: Four-year experience of a single major tertiary care institution–Addison Barnett, Konrad Knusel, Anas Ahmed Moahmmed Saeed Bamashmos, Soumya Sagar, Manmeet Ahluwalia

P2.6-031 Factors Associated

with Tumour Recurrence in WHO Grade II Meningiomas–Ding Fang Chuang, Guan Rong Lee, David Chia, Chee Kian Tham, Wee Yao Koh, Xuling Lin

P2.6-032 Radiographic

Appearance of Leptomeningeal Disease in Patients with EGFR Mutated Non-Small Cell Lung Carcinoma Treated with Tyrosine Kinase Inhibitors – A Case Series–Ugur Sener, Andrew L. Lin, Jonathan Yang, Rachna Malani

P2.6-033 Neuropsychological

and resting state fMRI changes with Spiritual Practice–Santosh Gupta, Urvashi Shah, Rose Dawn Bharath, Aishani Desai, Arvind Prajapati, Mangesh Ghodke, Cecilia Fernandes

P2.6-034 3-D Brain Tumor

Modeling for Improved Patient Health Literacy and Trainee Education–Na Tosha N. Gatson, Sara Flora

Adjuvant Temozolomide Cycle Duration in Newly Diagnosed Glioblastoma: Four-year experience of a single major tertiary care institution–Addison Barnett, Konrad Knusel, Assad Ali, Anas Ahmed Moahmmed Saeed Bamashmos, Soumya Sagar, Manmeet Ahluwalia management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells–Philipp Karschnia, Justin T. Jordan, Deborah A. Forst, Isabel Arrillaga-Romany, Tracy T. Batchelor, Joachim M. Baehring, Nathan Floyd Clement, Luis Nicolas Gonzalez Castro, Aline Herlopian, Marcela Maus, Michaela H. Schwaiblmair, Jacob Soumerai, Ronald Takvorian, Ephraim Hochberg, Jeffrey Barnes, Jeremy Abramson, Matthew Frigault, Jorg Dietrich GLOBAL NEUROLOGY: CLINICAL RESEARCH AND CASE REPORTS

P2.6-037 Developing an

Inpatient Neurology Registry To Understand Neurological Disease Burden in Zambia–Aparna Nutakki, Lorraine Chishimba, Mashina Chomba, Stanley Zimba, Deanna Saylor

P2.6-038 Neurocysticercosis

and HIV Among Zambian Youth: A Geographic Approach–Alexandra Buda, Owen Dean, Heather Adams, Sylvia Mwanza-Kabaghe, Gretchen L. Birbeck, Michael Potchen, Esau G. Mbewe, Pelekelo Kabundula, David Bearden

P2.6-039 GBS after the

Zika-outbreak in Colombia: The newcomer is gone but the problem continues!–Carlos A. Pardo-Villamizar, Guillermo Gonzalez-Manrique, Jorge Andres Jimenez-Arango, Jairo Lizarazo, Jose Vargas, Reydmar Lopez, Andres Felipe Zea-Vera, Jorge Angarita, Martha Moyano, Paula Barreras, Laura S. MunozArcos, Jaime Quintero, Susana Dominguez, Gustavo Eduardo Ramos, Cindy L. Beltran, Maria A. Garcia-Dominguez, Julie Benavides, David R. Cornblath, Beatriz Parra, Lyda Osorio

P2.6-040 A Comparison of the

Full Outline of Unresponsiveness (FOUR) and Glasgow Coma Scale (GCS) Scores in Predicting Mortality Among Patients with Altered Level of Consciousness in Uganda.–Amir Abdallah, Bart M. Demaerschalk, Abdirahman Aden, Davis Kimweri, Richard Butterfield, Nan Zhang, Cumara Barahona O’Carroll

P2.6-041 Jellyfish

Envenomation causing Irukandji Syndrome Presenting as Generalized Muscle Spasms in a Young Adult Male in Laiya, Batangas, Philippines- A Case Report.–Alexandria Matic, Carissa C. Dioquino, Gia Mandigma, Maritoni Rosales

P2.6-042 Diagnosis and

Treatment of Neuromyelitis Optica in Ethiopia–Katherine Elizabeth Delaney, Mohamed Tawfik Shabana, Mehari Gebreyohanns GLOBAL NEUROLOGY: EDUCATION AND HEALTH SYSTEMS RESEARCH

P2.6-043 Neurology

International Residents Videoconference and Exchange (NIRVE)–Sanskriti Sasikumar, Priti Gros, Morris Freedman, Dalia Rotstein

P2.6-044 Global Health

Education in Child Neurology and Neurodevelopmental Disabilities Training Programs: A National Survey–Andres Jimenez Gomez, Robert Clinton Stowe, Alfred Balasa, Jonathan Castillo, Timothy E. Lotze

P2.6-045 Global Teleneurology

P2.6-046 Task-shifting to

Optimize Outpatient Neurological Care in Zambia–Ana Claudia Villegas, Michelle Powell Kvalsund, Deanne Saylor, Omar Siddiqi

and Establishment of Acute Stroke Care Pathway in Rural Northwest India using Community Health Workers: data from Ludhiana rural population-based stroke registry–Jeyaraj Durai Pandian, Shavinder Singh, Kate Mahesh, Clarence Samuel, Deepshikha Kamra

P2.6-048 Challenges Faced in

Semi Urban & Rural Rehabilitation Center: A single Center Prospective Study from India– Devashish Devrao Ruikar, Sachin Kokane, Devashish Devrao Ruikar

P2.6-049 Electronic Fetal

Monitoring as a Remedy for Cerebral Palsy in Africa: First Do No Harm–James C. Johnston, Thomas Sartwelle, Berna Arda, Mehila Zebenigus OPTIMIZING END OF LIFE CARE AND UNDERSTANDING COMPREHENSIVE PAIN MANAGEMENT IN THE MIDST OF AN OPIOID CRISIS

P2.6-050 A Palliative Care

Education Needs Assessment Survey of Neurology Residents– Tara Cook, Robert Arnold, Julie Childers

P2.6-051 Modes of death

of hospitalized patients with Parkinson’s disease: a 12-year retrospective analysis–Manon Auffret, Vincent Morel, Guillaume Robert, Marc Verin

P2.6-052 Psychological

Attachment Styles of Surrogate Decision Makers and Neuro ICU Goals-of-Care Decisions–Prerak Juthani, Andrea Knies, Aida Martinez, Jolanta Pach, Tara Ashley Kimbrough, Stephanie Tu, David Y. Hwang

P2.6-053 Advance directives

of treatment in ALS patients: The Piedmont and Valle d’Aosta register experience in the 20082013 period.–Cristina Moglia, Antonio Ilardi, Antonio Canosa, Alessandro Bombaci, Umberto Manera, Rosario Vasta, Adriano Chio, Andrea Calvo

P2.6-054 Outcomes of Patients

with Cancer Related Pain Who Use Cannabis: Trends and Data from the Nationwide Inpatient Sample Database–Martin Anthony Myers, Chirag Narshibhai Savani, Varun Kumar, Charles W. Brock

P2.6-055 Hospitalizations

for Opioid Overdoses in the United states from 2003-2014. Trends from the Nationwide Inpatient Sample and Predictors of Mortality.–Sahil Gupta, Salim Ghazi

P2.6-056 Multivariate Pattern

Analysis of Emotion Regulation in Opioid-Dependent and OpioidNaïve Chronic Pain Patients– Behnaz Jarrahi, Sean Mackey

P2.6-057 Diffusion Tensor

Tractography of Brainstem Fibers and Application to CombatRelated Pain–Yu Zhang, Andrei A. Vakhtin, Jennifer Jennings, J. Wesson Ashford, David Clark, Ansgar Furst

P2.6-058 Subjective Mental

and Physical Wellbeing Correlates with Pain in Military Personnel with Trans-tibial Amputations– Igal Mirman, William Haywood Mays, Jeffrey Metter, Laura Talbot

P2.6-059 Pain Compounding

Pain: Fibromyalgia and Migraine Comorbidity–Erin Bettendorf, Silvie Belaskova, Daniel Krashin, Natalia Murinova THE EXTREMES OF EXTREMITY AND BACK PAIN

P2.6-060 Nerve-Specific Local

and Systemic Analgesic Effects of Acupuncture in Healthy Adults, Measured by Quantitative Sensory Testing (QST)–Alexandra Dimitrova, Dana Colgan, Barry S. Oken

P2.6-061 Predictors of 30-day

Readmissions and Prolonged Length of Stay Following Hospitalization for Complex Regional Pain Syndrome Type 1 - A 5-year National Estimate– Charles W. Brock, Chirag Narshibhai Savani, Varun Kumar, James Ray Ghattas, Luiz De Souza, Jose R. Rodriguez, Matthew Chung, Grace Kim, Tigran Kesayan, Martin Anthony Myers

P2.6-062 “Burning Foot

Syndrome” due to Acute Copper Deficiency Myeloneuropathy after Bariatric Surgery–Paul Martin Elsbernd, Laura Baugh

P2.6-064 Retrospective

Diagnosis of Painful Diabetic Polyneuropathy from Electronic Abstraction of Medical Records– Brittany Lapin, Alex Milinovich, Matthew Karafa, Andrew Schuster, Kristen Johnson, Fernanda Boulos, Nimish J. Thakore

P2.6-065 A Prospective Clinical Trial to Assess High Frequency Spinal Cord Stimulation (HF-SCS) at 10 kHz in the Treatment of Chronic Intractable Pain from Peripheral Polyneuropathy– Vincent Galan, Paul CM Chang, James Scowcroft, Sean Li, Peter Saats, Jeyakumar Subbaroyan

P2.6-066 High Frequency

Spinal Cord Stimulation (HF-SCS) at 10 kHz for the Treatment of Neuropathic Limb Pain from Painful Diabetic Neuropathy– Charles E. Argoff, Nagy Mekhail, Christian Nasr, Rod Taylor, David Caraway, Brad Gliner, Jeyakumar Subbaroyan, Lisa Brooks

P2.6-067 Dorsal Root Ganglion Stimulation: A Potentially Effective Treatment for Painful Hereditary and Idiopathic Axonal Polyneuropathy–Kwo Wei David Ho, Torge Rempe, Nividia Jerath, Ajay Antony

P2.6-068 CONVEY, A Phase

2 Placebo-Controlled, DoubleBlind, Enriched Enrollment Randomized Withdrawal Study Design of Vixotrigine for the Treatment of Pain in Participants With Confirmed Small Fiber Neuropathy–Leslie Shinobu, Michael J. Polydefkis, Giuseppe Lauria, Catharina Faber, Roy L. Freeman, Deborah Steiner, Himanshu Naik, Fiona Forrestal, Nikki Bolsover, Katherine T. Dawson

P2.6-069 Electrical Impedance

Myography for Assessing Patients with Low Back Pain–Seward B. Rutkove, Yung Wang, Laura Freedman, Anna Lyczmanenko, John Keel

P2.6-063 Comparison of the

firing pattern of superficial dorsal horn neurons evoked by robotic and human manual brushing.– Dongchul Lee, Dongchul Lee, Kwan Yeop Lee, Zachary Kagan, Kerry Bradley

AAN.com/view/AM19Sci 153

Monday

Service: First Insights–Riley Bove, Jalayne Arias, Andrew Barnecut, Linda Branagan, Felicia Chow, Jeffrey Marc Gelfand, S. Andrew Josephson, Maya Katz, Catherine Lomen-Hoerth, Erica Schleimer, Nilika Shah Singhal, Michael R. Wilson, Theodore Niyongabo, Aliza Norwood, Claudia Kaneza, Elizabeth Kohnen, Cathryn Christensen, Jon Van Leeuwen

P2.6-047 Stroke surveillance

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY EPOSTER SESSION

P2.7-010 ‘At a Loss for Words’:

P2.7-001 Metformin Use and

PARKINSON’S DISEASE: CLINICAL TRIALS, WEARABLES, AND NONPHARMACOLOGIC THERAPY

Stroke Risk in Hispanic and NonHispanic Diabetic Male Veterans– Eliana Vasquez, Daniel MacCarthy, Mini Jacob, Helen Hazuda, Sudha Seshadri, Claudia L. Satizabal, Chen-Pin Wang

P2.7-002 Intra-arterial tPA

administration during Mechanical Thrombectomy is Associated with Increased Risk of Subarachnoid Hemorrhage–Vasu Saini, Priyank Khandelwal, Joshua Lukas, Kunakorn Atchaneeyasakul, Robert M Starke, Eric Peterson, Dileep R. Yavagal

P2.7-003 “Sacral Vein Sign”

on MRI with Typical Findings of Spinal Arteriovenous Fistula Suggests a Pelvic Arteriovenous Fistula with Retrograde Spinal Venous Drainage–Rohit Swarnkar, Eufrosina I. Young, Amar Swarnkar, Sudha Thota

P2.7-004 Atypical presentation of Neurologic complications of Osler-Weber-Rendu Syndrome: A case series–Faddi Ghassan M. Saleh Velez, Laura Castillo Saavedra, Jorge Guy Ortiz-Garcia

P2.7-005 Cocaine- induced

Vasospasm During Mechanical Thrombectomy in Acute Ischemic Stroke Patients: A Report of Two Cases–Marina Kushnirsky, Muhammad Zeeshan Memon, Robert M Starke, Marie Christine Brunet, Dileep R. Yavagal

Monday

P2.7-006 Artificial Intelligence in Acute Stroke Diagnostics: Application in Large Vessel Occlusions–Nick Murray

P2.7-007 Moyamoya Disease Associated with Autoimmune Hemolytic Anemia: A Case Report–Shreya Agarwal, Dasul Jin, Siddharth Gupta, Xue Ming

POEMS syndrome complicated by Acute Ischemic Stroke–Sneha Jacob, Molly Knox, Kara A. Sands

P2.8-001 Automatic Scoring

of Parkinson’s Disease Motor Symptoms Using a Smartwatch– Nicholas Shawen, Julianne Knott, Joseph Lee, Tanya Simuni, Margaret Daeschler, Arun Jayaraman

P2.8-002 Continuous

Monitoring of Orthostatic Hypotension and Instability Events in Parkinson Disease–Aaron Hadley, Luca Marsili, Andrea Sturchio, Alberto J. Espay, Dustin A. Heldman, Aristide Merola

P2.8-003 Continuous Objective

Monitoring in Parkinson’s Disease: A description of over 25,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) wearable monitoring device–Peter Lynch, Rajesh Pahwa, Filip Bergquist, Malcolm Horne

P2.8-004 Activity-independent

detection of mediation states in individuals with Parkinson’s disease using wearable sensors– Murtadha Hssayeni, Michelle Burack, Joohi Jimenez Shahed, Behnaz Ghoraani

P2.8-005 An Investigation

of Tracking Technology in the Setting of an Established Exercise Program for Individuals with Parkinson’s Disease: A 10-Month Program–Sarah Ingersoll, Kenneth Hayashida, Daniel M. Togasaki, Jenny Lee, Niquelle Brown, Tenzin Babu, Kris Mendenhall, Rushabh Modi

P2.8-006 Wearable sensor

Treatment of Steroid Responsive Cerebral Amyloid Angiopathy Related Inflammation without Brain Biopsy–Kavneet Kaur, Vaibhav Goswami, Rafia Shafqat, Kristina Maselli, Anila Thomas

(Parkinson’s Kinetigraph) and dopamine transporter imaging as potential biosignature for constipation in Parkinson’s–Daniel van Wamelen, Valentina Leta, Aleksandra Podlewska, Dhaval Trivedi, Yi Min Wan, Vinod Metta, Per Odin, Heinz Reichmann, K Ray Chaudhuri

P2.7-009 A case of

P2.8-007 The Feasibility of

P2.7-008 Diagnosis and

prosopagnosia with the retained ability to recognize caricatures– Melissa Cook, Jeanna Del Vecchio West-Miles, Wendy Chao

154 2019 AAN Annual Meeting

Using Smart Gloves to Quantify Hand Movements in Parkinson’s Disease–Mohammadreza Abtahi, Nicholas Constant, Gozde Cay, Umer Akbar, Kunal Mankodiya

Monday, May 6 P2.8-008 Patient-Centered

Clinical Trial Design: A Case Study in Parkinson’s Disease–Katrina A. Gwinn, Shomesh Chaudhuri, A. Hauber, Brennan Mange, Heather Benz, Brittany Caldwell, Anindita Saha, Martin Ho, Stephanie Christopher, Margaret Sheehan, Anne Donnelly, Lauren McLaughlin, Murray Sheldon, Andrew Lo

11:30 a.m.–6:30 p.m. P2.8-016 Medical Cannabis

in the Treatment of Parkinson’s Disease–Bennett H. Myers, Tanya Geist, Paul B. Hart, Traci Aladeen, Alexandra Begley, Erica Westphal, Stefania Floarea, Michelle Rainka, Laszlo Mechtler

P2.8-017 KICK-OUT PD:

Objective Monitoring of Physical Activity in Parkinson Disease– Sneha Mantri, Stephanie Wood, John E. Duda, James F. Morley

Qualitative Analysis of Expectations and Outcomes in a Pilot Study of a Parkinson’s Disease Karate Intervention–Jori Fleisher, Claire Niemet, Brianna Jean Sennott, Monica Lee, Courtney Whitelock, Deborah Hall, Cynthia L. Comella

P2.8-010 Withdrawn

P2.8-018 The effect of

P2.8-009 Self-Reported and

P2.8-011 Assessing Tele-Health

Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (ATHOME PD): Initiation of a LongTerm Observational Study–Ruth Schneider, Shalini Anthwal, Elise Paulin Kayson, Larsson Omberg, Christopher Tarolli, Eric A. Macklin, Lauren Bataille, E. Ray Dorsey, Lara Mangravite, Michael Schwarzschild, Tanya Simuni

P2.8-012 A Virtual Cohort

Study of LRRK2 G2019S Carriers: A Novel Model for Long-Term Observation–Ruth Schneider, Taylor Myers, E. Ray Dorsey, Robert G. Holloway

P2.8-013 Can Art Therapy

improve signs and symptoms of Parkinson’s Disease? Preliminary Results from the “ExplorArtPD Study”–Alberto Cucca, Kush Sharma, Ikuko Acosta, Mahya Beheshti, Marygrace Berberian, Hilary C Bertish, Andrew S. Feigin, Jiyoon Jung, Todd Hudson, Daniella Mania, John Ross Rizzo, Milton Biagioni

P2.8-014 Effect of Balanced

Based Torso Weighting on Gait in Parkinsonism.–Delaram Safarpour, Martina Mancini, Charles Murchison, Stephanie Woods, Andrew Lesher, John E. Duda, James F. Morley

P2.8-015 KICK-OUT PD:

Mobility, Quality of Life, and Feasibility Outcomes in a Pilot Study of a PD-Specific Karate Intervention–Brianna Jean Sennott, Claire Niemet, Monica Lee, Courtney Whitelock, Deborah Hall, Cynthia L. Comella, Jori Fleisher

metronome and music on gait variability in people with Parkinson’s disease–Amy Hellman, Vivien Marmelat, Austin Duncan, Shane Meltz, Ryan Meidinger

P2.8-019 Determining the

Efficacy of a Vibration Induced Intervention on Improving Arm Swing and Subsequent Gait Stability in Parkinsonian Patients–William Forrester Taber, Richard Wu, Shane Sterling, Beau Billings, Shani Peter, Sonia Koul, Karina Pique, Roei Golan, Melissa Ma, Sabrina Cajuste, Morgan Bradley, Brooke Hartenstein, Charles Maitland PARKINSON’S DISEASE NONMOTOR SYMPTOMS

P2.8-020 Clinical Experience in Over 100 Using Pimavanserin for Parkinson’s Disease Psychosis– Gupta Vardhan Harsh, Kelly E. Lyons, Rajesh Pahwa

P2.8-021 Physical Activity and

Rates of Cognitive Decline in Early Parkinson Disease–Sneha Mantri, Thomas F. Tropea, James F. Morley

P2.8-022 The Effect of High-

Intensity Exercise on Objective Sleep Outcomes in Parkinson’s Disease–Amy W. Amara, Allen Joop, Raima A. Memon, Jennifer Pilkington, Kimberly Wood, Marcas Bamman

P2.8-023 Transcranial Direct

Current Stimulation for LimbKinetic Apraxia in Parkinson’s Disease – a Randomized, Double-blinded, Sham-controlled Trial–Jung E. Park, Hyung-Ryeol Jang, Lee-Uhn Kim, Geun-Jin Park, Seo-Kyung Kim, Jeong-Eun Bae, Jiyi Hong, Mark Hallett

P2.8-024 How Parkinson’s

Disease Affects Value-Based Decisions–Leila MontaserKhousari, Akram Bakkour, Raphael Gerraty, Daphna Shohamy

P2.8-025 Suicidal Behavior

in Parkinson Disease–Brian Koo, Nada Ahmed, Amritha Alapati, Rucha Bahekar, Priyanka Chilakamarri, Mohamed Elfil, Keerthana Nalamada, Pooja SirDeshpande, Elan D. Louis

P2.8-026 Alzheimer’s Disease

Genetic Risk Variants Predict Cognitive Decline in Parkinson’s Disease–Laura Baratta, Thomas F. Tropea, Krisna Maddy, Michael Guo, Jacqueline Rick, John Q. Trojanowski, Daniel Weintraub, Vivianna Van Deerlin, Alice ChenPlotkin

P2.8-027 Determinants of

Weight Change in Parkinson’s Disease–John Hall Herndon, Erik Barr, Ann L. Gruber-Baldini, Joseph M. Savitt, F. Rainer Von Coelln, Stephen G. Reich, Lisa M. Shulman

P2.8-028 Mild Cognitive

Impairment changes Natural Reading in Parkinson‘s Disease– Josefine Waldthaler, Lena Stock, Charlotte Krüger-Zechlin, Lars Timmermann

P2.8-029 Impulse Control

Disorders in Parkinson’s disease – a cross-sectional and longitudinal study of severity–Fahd Baig, Mark Kelly, Michael Lawton, Yoav BenShlomo, David Okai, Michele Hu

P2.8-030 Neural Correlates of

P2.8-031 Anxiety and

depression are associated with levodopa-responsive, but not levodopa-unresponsive, freezing of gait in Parkinson’s disease– Johnathan Lucas McKay, Felicia Goldstein, Stewart A. Factor

P2.8-032 Heart Rate Variability

And Sympathetic Skin Response In Idiopathic And Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease–Amira Nasri, Nouha Farhat, Imen Kacem, Sabrina Zidi, Saloua Mrabet, Salma Sakka, Amina Gargouri, Mariem Damak, Mouna Ben Djebara, Chokri Abdellaziz Mhiri, Riadh Gouider

in Parkinson’s Disease Using the Mobile Universal Lexicon Evaluation System (MULES) Test–Jenna Conway, Caroline Gonzalez, Samuel Fallon, John Martone, Lisena Hasanaj, Abbey Lepor, Liliana Serrano, Janet C. Rucker, Steven Galetta, Steven Frucht, Laura J. Balcer

P2.8-034 Genomic variants

associated with cognitive impairment in Parkinson’s disease: Ethnicity-specific genome-wide association study–Sun J. Chung, Nari Choi, Juyeon Kim, Kiju Kim, Mi-Jung Kim, Young Jin Kim, HoSung Ryu, Kye Won Park

P2.8-035 Cognitive

Improvement After Six-Week Action Observation and Motor Imagery Training in Patients with Parkinson’s Disease–Elisa Canu, Federica Agosta, Michela Leocadi, Elisabetta Sarasso, Francesca imperiale, Sebastiano Galantucci, Andrea Tettamanti, Maria Volonté, Massimo Filippi

P2.8-036 Non-motor

phenotypes in Parkinson’s disease patients with metabolic syndrome.–Jesús D. MeléndezFlores, Sergio Andrés CastilloTorres, Christopher CerdaContreras, Beatriz Chávez, Ingrid Estrada-Bellman

P2.8-037 Pimavanserin versus

quetiapine for the treatment of psychosis in Parkinson’s disease and dementia with Lewy bodies– Sarah Horn, Nabila Dahodwala

P2.8-038 Diminished fMRI

global signal differences between eyes closed and eyes open resting state in REM behavior disorder (RBD) and Parkinson’s disease–Jessika Suescun, Mya C. Schiess, Luca Giancardo, Richard Castriotta, Timothy M. Ellmore

P2.8-039 Olfactory

Hallucinations as a Non-motor sign of Parkinson’s disease – A Single Center Experience–Shivika Chandra, Mya C. Schiess, Raja Mehanna

P2.8-040 Kickboxing and

Cognition in Parkinson’s Disease– Colin McLeod, Amy Delambo, Ali Delambo, Travis Turner, Vanessa K. Hinson

P2.8-041 Usefulness of

the Stroke Drivers Screening Assessment (SDSA) in patients with Parkinson’s syndrome– Nobutoshi Morimoto

P2.8-042 “Incomplete Design”

Errors Distinguish Design Fluency Performance in Parkinson’s Disease Patients with Left Motor Onset Symptoms–Daymond Wagner, Paul J. Eslinger, EunYoung Lee, Mechelle Lewis, Xumei Huang

P2.8-043 Comparison of

EEG Connectivity measures and Frequency analysis for identification of patients with Mild Cognitive Impairment in Parkinson´s disease – a Random Forest Analysis–Menorca Chaturvedi, Jan Guy Bogaarts, Florian Hatz, Vitalii Cozac, Antonia Meyer, Ute Gschwandtner, Peter Fuhr, Volker Roth

P2.8-044 Longitudinal Cortical

Changes Associated With Apathy in Parkinson’s Disease–Francesca imperiale, Elisa Canu, Tanya Stojkovic, Iva Stankovic, Silvia Basaia, Andrea Fontana, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi, Federica Agosta

P2.8-045 Profile of Non-motor

Symptoms and Impact on Quality of Life of Parkinson Disease Patients in a Neurology Clinic in Lagos Nigeria–Babawale Arabambi, Yomi A. Ogun, Olajumoke Oshinaike

P2.8-046 Cholinesterase

Inhibitor Taper Worsens Symptoms in Patients with Parkinson’s Disease–Lauren R. Moo, Erica Martinez, Megan Dunay, Stephen Thielke PARKINSON’S DISEASE THERAPEUTICS I

P2.8-047 Results of a Phase 1

Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease.–Andrew M. Goldfine, Robert Faulkner, Vasu Sadashivam, Omid Omidvar, John Hill, Singaravelu Jagadeesan, Anil Sharma, Siu-Long Yao

P2.8-048 Efficacy results of

a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease–Eric S. Farbman, Mark F. Lew, Cheryl H. Waters, Robert A. Hauser, Michael Klingler, Charles Oh

P2.8-049 Preclinical

Development of a Novel Precision Olfactory Delivery (POD®) L-dopa Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease– Kelsey Satterly, Greg Davies, Bhavin Gajera, Jennifer Wright, Hong Lin, Shweta Muppaneni, Khang To, Inna Dashevsky, Stephen Bevan Shrewsbury, John Hoekman

P2.8-050 Gastric Retention of

the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers–Nadav Navon, R. Michael Gendreau

P2.8-051 ITI-214, A Novel

Phosphodiesterase I Inhibitor for the Treatment of Parkinson’s Disease: Results from A Phase I/ II Clinical Study–Robert Davis, Robert Riesenberg, Daniel T. Laskowitz, Jeff Guptill, Laurie Sanders, Jeffrey W. Cooney, Andrew Satlin, Jennifer O’Brien, Sophie Duthiel, Stephanie Cruz, Joseph Hendrick, Peng Li, Lawrence Wennogle, Steven Glass, Maria Pinho, Eve Taylor, Susan Kozauer, Michal Weingart, Sharon Mates, Gretchen Snyder, Kimberly Vanover

P2.8-052 Efficacy of ND0612

for nocturnal problems and early morning OFF: A blinded rater study of 2 dosing regimens–Alberto J. Espay, Aaron Ellenbogen, Sheila Oren, Ryan Case, Karl D. Kieburtz, C. Warren Olanow

P2.8-053 Efficacy and Safety

of Apomorphine Sublingual Film for The Treatment of &ldquo;OFF&rdquo; Episodes in Patients With Parkinson&rsquo;s Disease: Phase 3, Double-Blind, Placebo-Controlled Trial–Stewart A. Factor, Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, Kenneth Sciarappa, Parul Bhargava, Gazal Vakili, David E. Blum, Bradford A. Navia, C. Warren Olanow

AAN.com/view/AM19Sci 155

Monday

Impaired Motivation in Parkinson’s Disease–Lauren M. Massimo, Chinwe Nwadiogbu, Corey McMillan, Nabila Dahodwala

P2.8-033 Rapid Picture Naming

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2

RESEARCH METHODOLOGY AND EDUCATION: GRADUATE EDUCATION

P2.9-001 Enhancing Skills in

Serious Illness Communication in Neurology Residents Using Simulation- A Pilot Study–Marcey L. Osgood, Brian Silver, Vandana Nagpal, Jennifer Reidy

P2.9-002 The Implementation

and Assessment of a Comprehensive Simulation-Based Curriculum in Treating Acute Neurological Emergencies at UC San Diego: Preliminary Results and Findings–Victoria Lily Wu, Cynthia Gonzalez

P2.9-003 Application of Non-

Mydriatic Retinal Photography in the Outpatient Neurology Setting–Nataliya Pyatka, Matthew Kyle Banks, Neel Fotedar, Michael L. Morgan, David C. Preston

P2.9-004 Judgements of

Competence: Negotiated Meaning Making in Resident Evaluations– Douglas P. Larsen, Roxann Lawrence, Lara Varpio

P2.9-005 Using Smartphone

Mindfulness Apps to Increase Trainee Resilience and Reduce Burnout–Crystal Jing Jing Yeo, Andreia Barbieri, Gustavo C. Roman, Janice F. Wiesman, Suzanne Powell

P2.9-006 Making Well

and Breaking the News; Simulation Based training for Neurology Residents; a need for Standardization–Muhammad Niazi, Harmanpreet Tiwana, Nadia Bowling, Hector Lopez, Jody Wood, Theresa Brosche, Max R. Lowden

P2.9-020 Effect on the Clinical

Standardized Patients versus Mannequin-Simulation for Training in Neurologic Emergencies – How “Real” is Real Enough? A Pilot Study–Catherine S.W. Albin, James Gordon, Emil Petrusa, Sahar Fatima Zafar

P2.9-013 A Medical Legal

Curriculum for Residents to Increase Physician Comfort in Patient Interactions–Kate Elizabeth Therkelsen, Laurice T. Yang

P2.9-014 The Impact of a

Dedicated Emergency Department Neurology Resident on the Inpatient Neurology Service– Shuja Sheikh, Rajanigandhi Hanumanthu, Machteld E. Hillen

P2.9-015 Enhancing Neurology

P2.9-016 Advocacy education in

P2.9-009 Brain Death

Determination Skills Workshop for Neurology Residents–Roshni A. Patel, Lisa Brown, Mindi Driehorst, Brian Cummings, Michael LefflerMcCabe, Ezgi Tiryaki

156 2019 AAN Annual Meeting

P2.9-019 Burnout Rate Among

P2.9-012 The Use of

P2.9-008 Childbearing and

parenthood during residency and fellowship.–Khadija Irshad, Devanshi Dharaiya, Iram Zaman

Video-Based, Online Curriculum in Movement Disorders for Neurology Housestaff: A Pilot Study–Lina Vadlamani, Prerak Juthani, Jeremy Moeller, Sara Maguire Schaefer

as a Learning Tool for Neurology Noon Conference Curriculum– Kristie Bauman, Joshua Makepeace, Sarah Zubkov, Ching Tsao, Mercedes P. Jacobson

Assessment of Residents’ Perceptions of Inappropriate Neurology Consults–Caroline Gentile, Emma Loebel, Charles Sanky, Stephen Krieger

P2.9-007 Real-Time

P2.9-018 An Interactive,

Iraqi Neurology Residents–Omar Muhsin Ali Al-Janabi, Justin Barber, Bailee Boggess, Kevin F. O’Connor, Zabeen Mahuwala, Timothy Ainger, Allison CabanHolt, Gregory A. Jicha, Richard Ronan Murphy

P2.9-011 Flipped Classrooms

Resident Education Utilizing Prehospital Stroke Telemedicine to Shorten Time to Acute Stroke Intervention–Philip W. Tipton, Caitlin D’Souza, Jeffrey Brent Peel, Kevin M. Barrett, Benjamin H. Eidelman, James F. Meschia, Elizabeth Ann Mauricio, Wendy Hattery, David Strauss, Rochelle Putzier, Jason Lawrence Siegel, Troy Delaney, Amy Lannen, Leslie Simon, Ronald Ferreira, Dale Gamble, Elliot Dimberg, Josephine F. Huang, Sarvam TerKonda, William David Freeman

Neurologists: A Multifaceted Program for Neurology Trainee and Faculty Wellbeing–Rebecca Kate Miller-Kuhlmann, Nicholas Michael Murray, Shefali Dujari, Amanda Sandoval Karamian, Maryam Hamidi, Elaine Su, Nina Bozinov, Tresa McGranahan

Monday

P2.9-010 Brain Death Exam

Monday, May 6

neurology residency: A survey of U.S. neurology residency program directors–Kara Stavros, Jonathan Cahill

P2.9-017 Outcomes of a “Boot

Camp” for incoming neurology residents–David Valentine, Alexander Allen, Raymond Vincent Mirasol, Arielle Marisa Kurzweil

11:30 a.m.–6:30 p.m. RESEARCH METHODOLOGY AND EDUCATION: UNDERGRADUATE EDUCATION

P2.9-028 Osler Apprenticeship

Program: Impact of peer advising on medical student preparedness and experience in the Neurology Clerkship–Christine Shrock, Leah Mische, Charlene Gamaldo, Roy E. Strowd, Christopher Oakley, Rachel Marie E. Salas

P2.9-029 The Effects of

Learning Environment after Expansion of the Thrombectomy Time Window–Elizabeth M. Aradine, Scott Vota

Residents’ teaching on Medical Students’ Neurology Experience and Interest–Zafer Keser, Yvo Andres Rodriguez-Linares, Jennifer Tremont, George N. Ansoanuur, Masumeh Hatami, Peggy Hsieh, Erin Furr-Stimming

P2.9-021 The?Impact of?a

P2.9-030 Empowering residents

24-hour?Thrombectomy?Window on Resident Education–Rachel Aubert, Elizabeth M. Aradine, Juan Pablo Pauta Martinez, Prachi Mehndiratta, Scott Vota

P2.9-022 Improving Neurology Resident Well-Being Through Appreciative Inquiry: Results of a Pilot Session–Jeffrey Dewey, Jason J. Sico, Jeremy Moeller

P2.9-023 Medicolegal

Considerations Influence Neurology Residents’ Perception of Inappropriate Consults–Emma Loebel, Caroline Gentile, Charles Sanky, Stephen Krieger

P2.9-024 Resident Tele-

education using the Zeriscope Device–Nicholas Milano, Eyad Almallouhi, Jimmy Suh, Mohammad Anadani

P2.9-025 Assessment of

Resident Opinions and Knowledge of Neurology Subspecialty Fellowship Application–Sarah R. Ahmad, Babak Razavi

P2.9-026 The Past, Present,

and Future of the Clinical Neurophysiology Fellowship: A Survey of Program Directors– Kalea Lynn Colletta, Dorthea Juul, Larry R. Faulkner

P2.9-027 Surveying the Clinical Learning Environment in Terms of Wellness, Burnout, Psychological Safety, and Mistreatment in a Neurology Residency Program at an Academic Medical Centre– Jeffrey Barrett Joseph Schachter, Celine Leung, Nital Appelbaum, Sally Santern, Scott Vota

to enhance Medical Students’ Education during their Neurology Clerkship–Yvo Andres RodriguezLinares, Zafer Keser, George N. Ansoanuur, Masumeh Hatami, Peggy Hsieh, Erin Furr-Stimming

P2.9-031 Can students help

bridge the great divide? Student perceptions of neurology and psychiatry clerkship integration– Justin Mowchun, Julia Frew, Glenda Hostetter Shoop

P2.9-032 Student Satisfaction

and NBME Outcomes with Team Based Learning on the Neurology Clerkship, a Pilot Study–Steven Richard Dunham, Zulfi Haneef, Doris Kung

P2.9-033 Validity of Neurology Core Clinical Experience Score–Tafline Kao, Lan Qin

P2.9-034 Assessment of

Medical Student Clinical Skills during Neurology Clerkship: A Quality Improvement Study–Erin Barnes, Thiago Santos Carneiro, Elie Sader, Okeanis Vaou

P2.9-035 How am I really doing in Neuro Small Group? Student Perceptions of Feedback in Neurology Case-Based Learning Sessions–Claire Patricia Hogue, Justin Mowchun

P2.9-036 Development of

the Summer NeuroImaging Research Program (SNIRP) for Undergraduates: Novel Research to Engage Students and Enhance the Academic Mission–John R. Absher, Morgan Fretwell, Tatsuhiro Kato, Wes Wimpey, Enrique Urrea-Mendoza, Fanny Guillerminet

P2.9-037 Top 5 Reasons Not to Choose Neurology as a Career– Okeanis Vaou, Elie Sader

P2.9-038 Effect of a faculty-

led comprehensive mentorship program on medical student recruitment and research productivity in neurology–Shuhan Zhu, Elie Sader, Natalie Thom, Okeanis Vaou, Anna D. Hohler

P2.9-039 Assessment of a

Movement Disorders Video Curriculum for Neurology Clerkships–Sagari R. Bette, Danielle Spengler Shpiner, Jason H. Margolesky, Corneliu C. Luca, Henry Paul Moore, Carlos Singer, Yolanda Reyes-Iglesias

P2.9-040 Can Interactive CaseBased Modules Improve Medical Student Shelf Examination Performance?–Leighton Mohl, Samuel J. Maiser

P2.9-041 Medical Student

Assessment Across Multiple Clinical Campuses: Are We Consistent?–Sherri A. Braksick, Gary S. Gronseth, Suzanne Hunt, William Cathcart-Rake, Jon Schrage, Yunxia Wang

P2.9-042 You Never Forget

Your First? Impact of Interview Timing on Final Rank Order–Fallon Schloemer, Ann Helms, Chad Carlson

P2.9-043 Disclosure of Medical

P2.9-046 Exosomal and Plasma

P2.9-053 MULES on the

P2.9-047 Highly Sensitive

P2.9-054 Increased Optic

Protein Biomarkers of Neuronal Injury and Inflammation in Chronic Mild TBI: A Chronic Effects of Neurotrauma Consortium (CENC) Biomarker Discovery Project– Kimbra L. Kenney, Pashtun-Poh Shahim, Chen Lai, Bao-Xi Qu, Christina Devoto, William Walker, Ramon R. Diaz-Arrastia, Jessica Gill Single Molecular Array Immunoassay Measurement of t-Tau, NF-L, GFAP, and UCH-L1 Biomarkers in Acute Concussion/ Mild Traumatic Brain Injury (mTBI) Patient Serum and Saliva Samples–Ahmed Chenna, Christos John Petropoulos, John Winslow

P2.9-048 CTE Pathology Absent in Former Military Services Members: A Preliminary Study Demonstrating No Increase in Neurodegenerative Proteinopathy Following TBI–Arushi Tripathy, Ashley Shade, Brittany Erskine, Kristi Bailey, George Perry, Rudolph Castellani

P2.9-049 Chronic

Neurobehavioral Symptoms in Retired Athletes and Military Veterans with a History of Head Trauma–Adam J. Darby, Christopher Giza

P2.9-050 Ice Hockey Head

Errors in Stroke Patients: A Randomized Controlled Trial in a Simulation Curriculum–Diana M. Barratt, Maryam Shakir, Yinghui Li, Rodolfo Bonnin

Impact Kinematics Are Not Associated with Changes in Clinical Concussion Measures– Thomas A. Buckley, Katherine Breedlove, Melissa Suzanne DiFabio, Jessie Oldham

P2.9-044 The Addition of

P2.9-051 Use of a Novel

NEURO TRAUMA AND SPORTS NEUROLOGY I

P2.9-045 Patterns of Brain

Volume Loss in Traumatic Brain Injury–Somayeh Meysami, Cyrus Raji, David Merrill, Li-Jung Liang, Mario F. Mendez

Clinically Relevant Symptom Scale for Acute Concussion–Matthew T. McCarthy, Sarah Janse, Natalie Pizzimenti, Anthony Khoury Savino, Jeffrey S. Kutcher, Brian Crosser, Sean C. Rose

P2.9-052 Abnormal Levels of

Expired End-Tidal Carbon Dioxide (ETCO2) are Associated with Severity of Injury in Adults with Mild to Moderate Traumatic Brain Injury at a Level I Trauma Center–Yasmeen Elsawaf, Linda Papa

Nerve Sheath Diameter after Mild Traumatic Brain Injury in a High-Risk Population–Chloe E. Super, Lauren East, Parth Pradeep Agrawal, Mary Dement, Ian M. Heger, Robert W. Gibson, Matthew Lyon

P2.9-055 Discordance of

Cardiovascular Autonomic Discharge after Concussion is related to ChrM2 Gene Receptor Subtypes–Michael F. La Fountaine, Asante Hohn, Caroline Leahy, Anthony Testa, Joseph Weir

P2.9-056 Astroglial activation

and altered amyloid metabolism in human repetitive concussion– Pashtun Shahim, Kaj Blennow, Henrik Zetterberg

P2.9-057 Plasma NF-L, tau,

GFAP and advanced MRI imaging in the evaluation of mild Traumatic Brain Injury in a prospective cohort of active rugby players– Etienne Laverse, Karl Zimmerman, Tong Guo, Ravjeet Samra, John A. Hardy, Henrik Zetterberg, David James Sharp, Huw R. Morris

P2.9-058 The Effect of

Repetitive Head Impact Exposure on Response Inhibition in Contact Sport Athletes–Kelsey Bryk, Alexander Wright, Jonathan Smirl, Michael Jakovac, Paul Van Donkelaar

P2.9-059 The National Institute

of Neurological Disorders and Stroke (NINDS) Updates to the Spinal Cord Injury (SCI) Common Data Element Recommendations– Robin Sadja Feldman, Kristen R. Joseph, Muniza Sheikh, Joy R. Esterlitz, Vanessa Noonan, Lyn Jakeman, Carolina MendozaPuccini

P2.9-060 The Life time risk after NFL, A Retrospective study– Suresh Kumar, Milan Jaiswal

P2.9-061 ENIGMA Military

Brain Injury: Altered Subcortical Volume in Chronic TBI Revealed by Mega-Analysis–Emily Dennis, Elisabeth Wilde, Artemis Zavaliangos-Petropulu, Mary Newsome, Randall Scheibel, Maya Troyanskaya, Carmen Velez, Benjamin Wade, Ann Marie Drennon, Gerald York, Erin D. Bigler, Tracy Abildskov, Brian Taylor, Carlos Jaramillo, Blessen Eapen, Heather Belanger, Rajendra Morey, Courtney Haswell, Heather Bouchard, Maheen Adamson, Xiaojian Kang, Inga Koerte, Martha Shenton, Harvey S. Levin, Sidney Hinds, William Walker, Paul M Thompson, David Tate

P2.9-062 Exosome Proteins

as Prognostic and Diagnostic Biomarkers for Mild Traumatic Brain Injury–Miranda Flamholz, Kryshawna Beard, Margalit Haber, Zijian Yang, Jina Ko, Erika Silverman, Tawny MeredithDuliba, Nimay Kulkarni, Danielle Sandsmark, Dave Meaney, David Issadore, Ramon R. Diaz-Arrastia

P2.9-063 Relationship between

Rapid Number and Picture Naming Tests of a Concussion Assessment Battery–Melissa Suzanne DiFabio, Jessie Oldham, Thomas Kaminski, Thomas A. Buckley

P2.9-064 The Impact of

Traumatic Brain Injury on Arterial Compliance and Cerebral Blood Flow–Tran Viet Le, Tsubasa Tomoto, Marcel Turner, Sami Horani, Takashi Tarumi, Rong Zhang, Kan Ding NEUROCRITICAL CARE: CARDIAC ARREST

P2.9-065 Neurological

Outcomes in Cardiac Arrest Patients with Non-shockable vs. Shockable Rhythm Treated With Targeted Temperature Management–Gopika Hari, Matthew Pavlovec, Larissa Stanberry, Pezhman Roohani, Maximilian Mulder, Lee Wolfinbarger, Peter Lee, James Robert White

P2.9-066 Evidence of Late

Cognitive Recovery after Cardiac Arrest with Anoxia and Extended Coma–Ryka Sehgal, Henning Voss, Nicholas D. Schiff, Peter B. Forgacs

AAN.com/view/AM19Sci 157

Monday

Virtual Reality into the Neurology Curriculum–John Patrick HoltonBurke, Scott Vota, Diana OyoungOliver

Sidelines: A Vision-Based Assessment Tool for SportsRelated Concussion–Samuel Fallon, Lisena Hasanaj, Darlina Liu, Omar Akhand, John Martone, Julie Giles, Nikki Webb, Julia Drattell, Liliana Serrano, JohnRoss Rizzo, Janet C. Rucker, Dennis Cardone, Steven Galetta, Laura J. Balcer

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 2 P2.9-067 Efficacy of Early

Neurological Examination in Determining Survival in Post Cardiac Arrest Patients who Underwent Hypothermia Protocol–Rajanigandhi Hanumanthu, Julian Paul Agin-Liebes, Machteld E. Hillen, Annapoorna Bhat, Weredes M. Olango

P2.9-068 NeuroCardiac

Comprehensive Care Clinic Seeks to Define and Detect Neurological, Psychiatric, and Functional Sequelae in Cardiac Arrest Survivors–Danish Ghazali, Alex Presciutti, Evie Sobczak, Julia Kelly, Deepti Anbarasan, Linda Golding, MaryKay A. Pavol, Sachin Agarwal

P2.9-069 Is Therapeutic

Hypothermia For Cardiac Arrest Changing Outcomes: A National Inpatient Sample Analysis 2008-2014–Mohammad Rauf Afzal, Ihtesham A. Qureshi, Mohtashim Arbaab Qureshi, Michael Alexander Castellano, Harathi Bandaru, Anantha Vellipuram, Paisith Piriyawat, Alberto Maud, Gustavo J. Rodriguez, Rakesh Khatri, Salvador Cruz-Flores

P2.9-070 National Trends

Monday

in Utilization of Therapeutic Hypothermia for Cardiac Arrest: National Inpatient Sample Study 2008-2014–Mohtashim Arbaab Qureshi, Mohammad Rauf Afzal, Ihtesham A. Qureshi, Harathi Bandaru, Shayan Ul Haque, Michael Alexander Castellano, Anantha Vellipuram, Paisith Piriyawat, Rakesh Khatri, Alberto Maud, Darine Kassar, Gustavo J. Rodriguez, Salvador Cruz-Flores

P2.9-071 Ischemic stroke

after targeted temperature management for out-of-hospital cardiac arrest: A MRI findings– Minyoul Baik, Kyung Min Kim, Sung Soo Ahn, Ji Hoe Heo, Kyoo Ho Cho

P2.9-072 High Motor Glascow

Coma Scale score is associated with Survival to Discharge in Cardiac Arrest Patients: Retrospective Data from the MOCHA Study–Jonathan Duskin, Brandon Finn, Katie Dam, Helena W. Lau, Sonya Zhou, Cora Ormseth, Emily Jean Gilmore, Rachel Beekman, Melissa Mercado, David M. Greer

158 2019 AAN Annual Meeting

Monday, May 6

P2.9-073 Variability in post-

P2.9-081 Association of

P2.9-074 Racial Differences

MEDICAL STUDENT ESSAY AWARD RECIPIENTS

arrest prognosis knowledge by healthcare providers–Adarsh Menon, Sugeet Jagpal, Kiwon Lee, Jonathan McCoy, Jasdeep Hundal, Ram Mani In Hospital Utilization Of Therapeutic Hypothermia Among Cardiac Arrest Patients In United States–Mohammad Rauf Afzal, Mohtashim Arbaab Qureshi, Ihtesham A. Qureshi, Harathi Bandaru, Shayan Ul Haque, Michael Alexander Castellano, Anantha Vellipuram, Rakesh Khatri, Alberto Maud, Gustavo J. Rodriguez, Salvador Cruz-Flores NEUROCRITICAL CARE: EPILEPSY AND STATUS EPILEPTICUS

P2.9-075 Withdrawn P2.9-076 Impact of Early

Treatment on Duration and Outcomes in Status Epilepticus– Christine Elizabeth Chuck, Tammy L. Smith, Ivan Da Silva, Sayona John

P2.9-077 Treatment Comparison of Critically Ill Patients with Non-Convulsive Seizures or Non-Convulsive Status Epilepticus Receiving Levetiracetam Prophylaxis–Safa Kaleem, Rana Moosavi, Musa Kiyani, Christa Brittany Swisher

P2.9-078 Racial Disparity in

the Development of Seizure as a Delayed Complication of Subdural Hematoma–Stacy C. Brown, Zachary King, Lindsey Kuohn, Hooman Kamel, Emily Jean Gilmore, Jennifer A. Frontera, Guido Jose Falcone, Kevin N. Sheth

P2.9-079 Incidence of Seizures

with Fat Embolism Syndrome and Impact on Outcome: An Analysis of National Inpatient Sample Database–Ephrem Teklemariam, Ankur Bhargava, John Gaughan, Christa Schorr, Tapan R. Kavi

P2.9-080 Ketamine does not

affect Intracranial Pressure in patients with brain injury but effectively suppresses Cortical Spreading Depolarization– Mohammad Abbas, Alexis Alvarado Arias, Andrew Carlson

rhythmic and periodic EEG patterns in ICU patients and in-hospital mortality–Carlos F. Muniz, Mohammad K. Ali, Andrea S. Synowiec, Kevin M. Kelly

P2.9-082 Synaptic Organization of the Reciprocal Circuit Linking the Prefrontal Cortex and the Basolateral Amygdala–Laura McGarry

P2.9-083 Intensive Blood

Pressure Treatment in Deep Intracerebral Hemorrhage–Audrey Leasure

P2.9-084 The Civil War Soldier as the Model for Treating Hysterical Women in the 19th Century–Stephanie Margaux Roses

P2.9-085 Predicting benign

brachial monomelic amyotrophy: factors at presentation that differentiate from amyotrophic lateral sclerosis–Sohi Mistry

HEADACHE CLINICAL TRIALS II

P2.10-001 Impact of

Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication–Paul Winner, Rashmi B. Halker, Joshua T. Cohen, Ronghua Yang, Paul P. Yeung, CD Gargano

P2.10-002 Reduction in the

Severity of Headache in Patients With Chronic and Episodic Migraine With Fremanezumab Treatment–Messoud Ashina, Joshua T. Cohen, Sanjay Gandhi, Ronghua Yang

P2.10-003 Single Therapeutic

and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults–Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Kaifeng Lu, Danielle McGeeney, Antonia Periclou

11:30 a.m.–6:30 p.m. P2.10-004 ACT for Migraine:

Effect of Acceptance and Commitment Therapy (ACT) for High Frequency Episodic Migraine without Aura: A phaseII, multicentric, randomized, open-label study–Licia Grazzi, Carolyn Bernstein, Alberto Raggi, Emanuela Sansone, Eleonora Grignani, Meghan Searl, Paul B. Rizzoli

P2.10-005 Pharmacokinetics,

safety, and tolerability of DFN02, an intranasal sumatriptan spray containing a permeation enhancer, compared with intranasal sumatriptan in healthy adults–Anirudh Gautam, Soumya Gupta, Pradeep Singh Rawat, Sagar Munjal

P2.10-006 Eptinezumab for

Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy?2) Trial–David B. Kudrow, Richard B. Lipton, Stephen D. Silberstein, Roger Cady, Barbara Schaeffler, David M. Biondi, Jeff Smith

P2.10-007 Eptinezumab

Meaningfully Improves Quality of Life (QoL) in Patients with Episodic or Chronic Migraine Within 1 Month After Treatment–Egilius L H Spierings, A Jim Nagy, Roger Cady, Joe Hirman, Eric Kassel, David M. Biondi, Ruslan Horblyuk

P2.10-008 Reduction in the

Number of Headache Hours in Chronic and Episodic Migraine With Fremanezumab–Joshua T. Cohen, Sanjay Gandhi, Ronghua Yang

P2.10-009 Long-Term Safety

Evaluation of Ubrogepant for the Acute Treatment of Migraine– Jessica Ailani, Susan Hutchinson, Richard B. Lipton, Kerry Louise Knievel, Sung Y. Yu, Michelle Finnegan, Lawrence Severt, Armin Szegedi, Joel M. Trugman

P2.10-010 One-Year Treatment

with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study–Holland Detke, Patricia Pozo-Rosich, Uwe Reuter, David Dolezil, Lily Li, Shufang Wang, Sheena K. Aurora

P2.10-011 How Adverse Events

P2.10-018 Early and Sustained

P2.10-012 Improved

P2.10-019 A Multi-Center,

Are Collected and Reported: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan–David B. Kudrow, John H. Krege, Rashna Khanna, Hans Hundemer, Paul Berg, Michael Ossipov, Patricia Pozo-Rosich Functionality, Pain Relief, and Satisfaction in Patients Treated With Ubrogepant vs Placebo: Results from 2 Single-Attack Phase 3 Studies, ACHIEVE I and II–Hema Viswanathan, Richard B. Lipton, Jessica Ailani, Rashmi B. Halker, Anand R. Shewale, Sihui Zhao, Joel M. Trugman, Sung Y. Yu, David W. Dodick

P2.10-013 Quarterly

Administration of Fremanezumab Does Not Show “Wearing Off” Effect During Third Month After Injection–Cory Blaiss, Darko Stevanovic, Joshua T. Cohen, Ronghua Yang, Bo Jiang, Nicholas Gross

P2.10-014 Safety from Phase

3 Clinical Studies Comparing Galcanezumab and Placebo in Patients with Episodic and Chronic Migraine–Mark Bangs, David B. Kudrow, Shufang Wang, Tina Oakes, Jeffrey Carter, G.M. Terwindt, Delphine Magis, Virginia L. Stauffer

Effect of OnabotulinumtoxinA for Chronic Migraine Treatment: Pooled Analysis of PREEMPT Data–Aubrey Manack Adams, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Ronald DeGryse, H. Christoph Diener Randomized, Placebo-Controlled, Double-Blind, Crossover Study Evaluating DFN-15, a Liquid Celecoxib Formulation, for the Acute Treatment of Migraine with or without Aura in Adults–Alex Bennett, Sagar Munjal

P2.10-020 Early Migraine

Response by Month 1 and Clinically Meaningful Improvements in Health-Related Quality of Life (HRQoL) in Patients with Migraine in Phase 3 Trials of Eptinezumab–Stewart J. Tepper, David B. Kudrow, Ruslan Horblyuk, Roger Cady, Eric Kassel, Joe Hirman

P2.10-021 Effect of Age

on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine–Virginia L. Stauffer, Ira M. Turner, Phebe Kemmer, Martha Port, Kathleen Day, Angelo Camporeale

P2.10-025 Efficacy of Erenumab

in Chronic Migraine Patients With and Without Allodynia–Denise Chou, Dawn C. Buse, David W. Dodick, Sharon Richards, Jan Klatt, Daniel D. Mikol, Sunfa Cheng, Richard B. Lipton

NEW! Don’t miss out on the Guided Diversity Efforts – Poster Walk – Poster Session 2! More details to come.

P2.10-016 OnabotulinumtoxinA

P2.10-023 Long-Term Impact of

Monday

of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Chronic Migraine: Results of a 1-Year Study–Peter J. McAllister, Paul P. Yeung, Joshua T. Cohen, Sanjay Gandhi, Ronghua Yang Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study–John F. Rothrock, Richard B. Lipton, William B. Young, Esther Jo, Aubrey Manack Adams, Andrew M. Blumenfeld

Daily, Oral Doses of 150 mg Ubrogepant Administered for 28 Days Are Generally Well Tolerated, With No Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males–Wendy Ankrom, Phung Bondiskey, Wen Liu, John Palcza, Deborah L. Panebianco, Marissa F. Dockendorf, Catherine Matthews, Walter Kraft, John A. Wagner, Abhijeet Jakate, Eugene E. Marcantonio

P2.10-022 Precision Olfactory

Delivery (POD®) of Drugs for Neurological Disease: A Safety, Tolerability and Comparative Bioavailability Study of POD Dihydroergotamine Mesylate (INP104) to Approved IV D.H.E. 45® and Migranal® Nasal Spray.–Stephen Bevan Shrewsbury, Maria Jeleva, Jason Lickliter, Kelsey Satterly, John Hoekman

P2.10-015 Long-Term Impact

P2.10-024 Multiple, Once-

Fremanezumab on HeadacheRelated Disability, Quality of Life, and Patient Satisfaction in Episodic Migraine and Chronic Migraine–Joshua T. Cohen, Nicolas Saikali, Paul P. Yeung, Ronghua Yang, Xiaoping Ning

P2.10-017 Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD® Device Compared to D.H.E. 45® for Injection from the INP104-101 Clinical Trial–Karen Craig, John Hoekman, Maria Jeleva, Kelsey Satterly, Jason Lickliter, Stephen Bevan Shrewsbury

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

AAN.com/view/AM19Sci 159

POSTER SESSIONS

POSTER SESSION 3

FRONTOTEMPORAL DEMENTIA I

P3.1-001 Utility of the

FTLD-CDR in the mild FTLD: Data from the ARTFL/LEFFTDS Consortium–Toji Miyagawa, Danielle Brushaber, Reilly Dever, Julie Fields, Leah Forsberg, Ralitza H. Gavrilova, Hilary Heuer, David S. Knopman, John Kornak, Joel Kramer, Walter Kremers, Kelsey Rankin, Katya Rascovsky, Jeremy Syrjanen, Bradley F. Boeve, Adam L. Boxer, Howard J. Rosen

P3.1-002 Characterization of

language features of subtypes of primary progressive aphasia based on clustering analysis of brain metabolism–Jordi A. Matias-Guiu, Maria Nieves Cabrera-Martín, José Luis Ayala, Vanesa Pytel, Teresa MorenoRamos, Jose Luis Carreras, Jorge Matias Guiu Guia

P3.1-003 Neuropsychiatric

Symptoms and the Ultimate Game in Frontotemporal Dementia Compared to Alzheimer’s Disease–Oleg Yerokhin, Andrew C. Carr, Elvira Jimenez, Megan Laffey, Mario F. Mendez

P3.1-004 Getting Granular with Progranulin: Abnormal Eating in FTLD+GRN–Lauren McCollum, Vivianna Van Deerlin, Michael Baer, Edward Lee, David A. Wolk, John Q. Trojanowski, Murray Grossman, David Irwin

Tuesday

P3.1-005 Clinical Swallowing

Profile of Patients with Frontotemporal Dementia–Carlo Iacolucci, Petronilla Battista, Roberta Barone, Alessandra Vitulli, Milena Longo, Martina Castrovillari, Rosa Capozzo, Rosanna Tortelli, Giancarlo Logroscino

P3.1-006 Prominent Auditory

Hallucinations in Behavioral Variant Frontotemporal Dementia Associated with a MAPT Mutation–Mary J. Widmeyer, Maria Lapid, Ralitza H. Gavrilova, Julie Fields, Leah Forsberg, Kejal Kantarci, Val John Lowe, Bradley F. Boeve

160 2019 AAN Annual Meeting

Tuesday, May 7 11:30 a.m.–6:30 p.m.

Poster Session 3 1. Aging, Dementia, Cognitive, and Behavioral Neurology: 1-001 to 1-031 2. MS and CNS Inflammatory Disease: 2-001 to 2-103 3. Cerebrovascular Disease and Interventional Neurology: 3-001 to 3-071 4. Neuromuscular Disease and Clinical Neurophysiology (EMG): 4-001 to 4-046 5. Epilepsy/Clinical Neurophysiology (EEG): 5-001 to 5-033 6. Neuro-oncology; Sleep; Autonomic Disorders; Child Neurology and Developmental Neurology: 6-001 to 6-070 7. Neuromuscular Disease and Clinical Neurophysiology (EMG) ePosters: 7-001 to 7-010 8. Movement Disorders: 8-001 to 8-052 9. Neurocritical Care; Neuro Trauma and Sports Neurology; General Neurology: 9-001 to 9-079 10. Headache: 10-001 to 10-026

1 2 3

1-001-1-031

In Familial Frontotemporal Dementia due to MAPT, GRN or C9orf72 mutations–Angela B. Deutschlander, Rodolfo Savica, Michael Heckman, Danielle Brushaber, Jeremy Syrjanen, Howard J. Rosen, Adam L. Boxer, Bradley F. Boeve, Zbigniew K. Wszolek

P3.1-008 Characterization

of Sequence Variants in Downstream Flanking Region of C9orf72 Hexanucleotide Repeat in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis– Kaitlyn Grando, Eunran Suh, Donald Neal, Hayley Richardson, Laura Hennessy, Corey McMillan, David Irwin, Edward Lee, Murray Grossman, Leo McCluskey, Lauren B. Elman, Sharon Xie, John Q. Trojanowski, Vivianna Van Deerlin

P3.1-009 Frontotemporal Lobar

Degeneration in the Differential Diagnosis of the OldestOld–Lindsay Embree, Joshua A. Sonnen, John M. Hoffman, Yoshimi Anzai, Dustin Hammers, Amanda Kucera, Norman L. Foster

P3.1-010 Regionally Specific

Variation in Brain Structure in Behavioral Variant Frontotemporal Dementia Compared to Alzheimer’s Dementia–Somayeh Meysami, Cyrus Raji, David Merrill, Mario F. Mendez

BEHAVIORAL AND COGNITIVE NEUROLOGY: LANGUAGE, MEMORY, AND VISUOPERCEPTION I

P3.1-011 Pilot study

investigating the use of high frequency transcranial magnetic stimulation for primary progressive apraxia of speech– Danielle Spengler Shpiner, Katalina F. McInerney, Justine Allen, Jordyn Rice, Corneliu C. Luca, David J. Adams, Joyce Gomes-Osman

P3.1-012 Prosodic Stress:

Acoustic Changes in Spoken English in Patients with Left and Right Hemisphere Lesions–Chris Hollen, Elliott D. Ross, Bappaditya Ray

P3.1-013 Neuropsychological Similarities and Differences between Typical Amnestic Alzheimer’s Disease and Its Non-Amnestic Variants–Mario F. Mendez, Li-Jung Liang, Diana Chavez, Elvira Jimenez, Leila Parand, Lorena Monserratt

P3.1-014 Mapping the Neural

Basis of Declarative Verbal Memory: Evidence from Mesial Temporal Lobe Lesions–Ezequiel Gleichgerrcht, Leonardo F. G. Bonilha, Deqiang Qiu, Christopher Leatherday, Natalie Voets, Nigel P. Pedersen, David W. Loring, Jon T. Willie, Robert Gross, Daniel L. Drane

3-001-3-071

4 5 6

4-001-4-046

5-001-5-033

6-001-6-070

7-001-7-010

ePosters

8 9 10

8-001-8-052

P3.1-007 Motor Features

2-001-2-103

9-001-9-079

10-001-10-026

P3.1-015 Incidental learning

throughout life–Paula Carolina Torres, Agostina Galiani, Maria Goldfeder, Fatima Pagani Cassara, Vladimiro Sinay, Maria Roca, Diana Bruno

P3.1-016 Accelerated

Forgetting in Patients with Epileptic and Psychogenic Seizures–Rebecca L. Tom, Barbara C. Jobst

P3.1-017 A Case of Reversible

Bilateral Hippocampal Injury Secondary to Benzodiazepine Abuse–Chun Chu, Keithan Sivakumar, Christopher Melinosky

P3.1-018 Serial-position effect as a biomarker in the diferential diagnosis of mild cognitive impairment. A multimodal biomarkers aproach.–Ismael Luis Calandri, Maria Martin, Patricio Chrem Méndez, Belén Helou, Maria Florencia Clarens, Lucia Crivelli, Ricardo F. Allegri

P3.1-019 Glutamate-weighted

CEST (GluCEST) MRI contrast at the site of transcranial magnetic stimulation is related to changes in motor evoked potentials–John Dominic Medaglia, Abigail Cember, Ravi Nanga, Hari Hariharan, Brian Erickson, Apoorva Kelkar, Eric M. McConathey, Olu Faseyitan, Roy H. Hamilton, H. Branch Coslett, Mark Elliott, Geereddy Ravinder Reddy

P3.1-020 A Visual World

After Losing All Vision: The Preservation of Visual Imagery Following Complete Loss of Light Perception–Connor Dietz, Manuela Malaspina, Jason Barton

P3.1-021 The Mental Rotation

Test (MRT) Used as a Clinical Tool to Monitor Disease Progression in EOPD–Thyagarajan Subramanian, Bryan Mullen, Paul J. Eslinger, Daymond Wagner, Samyuktha Ravi, Kala Venkiteswaran, Megha Subramanian

P3.1-022 Pareidolia as a

Manifestation of Folie á Deux– monica khokhar, Alan R. Hirsch

P3.1-023 Left hemispatial

neglect with a splenial lesion– Tigran Kesayan, Hamlet Gasoyan, Kenneth M. Heilman

P3.1-024 Frontal Cortical

Networks in Hemineglect–Daniel Antoniello, Shayan Khazaei NOVEL BIOMARKERS

P3.1-025 An inflammatory

marker panel provides insight into immune pathways involved in cognition: the Northern Manhattan Study–Mitchell S. V. Elkind, Yeseon Moon, Janet T. DeRosa, Chensy Marquez, Tatjana Rundek, Clinton B. Wright, Ralph L. Sacco, Mady Hornig, Ken Cheung

P3.1-026 Plasma lipocalin-2

levels in the preclinical stage of Alzheimer’s disease–Emily Rose Eruysal, Costantino Iadecola, Makoto Ishii

P3.1-027 A Highly Sensitive

P3.1-028 Soluble TREM2 CSF

concentration in Alzheimer’s disease track VCAM1, known to regulate leukocyte migration into the brain–Jagan Pillai, Sean Maxwell, Lynn Bekris, James B. Leverenz

Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-risk Individuals: A Retrospective Cohort Analysis–M Florencia Iulita, Aravind Ganesh, Rowan Pentz, Lisi Flores Aguilar, Palma Gubert, Adriana Ducatenzeiler, Sharon Christie, Gordon Wilcock, A. Claudio Cuello

P3.1-030 Age-Related

Differences in Electrophysiological Activity in Response to Increasing Sensory Degradation and Visual Task Demands–Kirk R. Daffner, Adam Billig, Hura Behforuzi, Nicole Feng

P3.1-031 Novel method

utilizing Arterial Spin Labeling single acquisition 3D Echo Planar Imaging for determining CNS Glymphatic Clearance–Charles R. Joseph, Christopher Benhatzel, Olivia Hopper, Michael Lockwood

MS CLINICAL ASSESSMENTS AND OUTCOME MEASURES

P3.2-001 Predictors of

Processing Speed Test Performance in a Large Multiple Sclerosis Population–Devon Conway, Robert A. Bermel, Sarah Pope Planchon

P3.2-002 A Natural Language

Algorithm Identifies Multiple Sclerosis Relapses from Clinical Notes With High Sensitivity– Tanya Krishnakumar, Chelsea Chen, Vincent Damotte, Erica Schleimer, Adam Santaniello, Jeffrey Marc Gelfand, Antoine Lizee, Pierre-Antoine Gourraud, Jill Hollenbach, Riley Bove

P3.2-003 myMS; A

Comprehensive Patient-Centered Mobile App to Monitor MS at Home–Daniel Pelletier, Tony Rennert, Martha Chang, Santi Decunto, Steven Cen

P3.2-004 Automated gait

analysis using wearable sensors can detect objective and reliable quantification of disability in people with Multiple Sclerosis–Lorenza AngelinI, William Hodgkinson, Craig Smith, Jessie Moorman Dodd, Jaydip Ray, F Storm, Claudia Mazzà, Basil Sharrack, David J. Paling

P3.2-005 Identifying SPMS:

Are U.S. Neurologists Aligned on the Most Influential Disease and Patient Metrics?–Robert T. Naismith, Shiv Saidha, Patricia K. Coyle, Jennifer Robinson, Virginia Schobel

P3.2-006 Constructing a

Molecular Model of Disease Severity in Multiple Sclerosis– Christopher Barbour, Peter Kosa, Mark Greenwood, Bibiana Bielekova

P3.2-007 Manual Dexterity Test is a Better Predictor of Disability than Walking Speed in Multiple Sclerosis: A Large Outpatient Analysis–Nabil Khan, Michael Shaw, Kathleen Sherman, Erik Charlson, Jonathan Howard, Lana Zhovtis Ryerson, Lauren B. Krupp, Leigh Elkins Charvet

P3.2-008 Mobilizing a Digital

Research Ecosystem for Multiple Sclerosis Research and Care– Fletcher Lee Hartsell, Katherine Ann Heller

P3.2-009 LIFEware Life

Satisfaction and Pessimism are Correlated with the Beck Depression Inventory-Fast Screen and with Disability Progression in Individuals with Multiple Sclerosis–Bianca WeinstockGuttman, Katelyn S. Kavak, Dejan Jakimovski, Osman Ozel, Ralph H. B. Benedict, Robert Zivadinov, Caila B. Vaughn

P3.2-010 Screening for

Cognitive Impairment in People with Multiple Sclerosis: Is A Unidimensional Measure Really Sufficient to Detect the Cognitive Elephant in the Room?–Mark Gudesblatt, Jared Srinivasan, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Lori Fafard, Daniel Golan, Cynthia L. Sullivan, Jeffrey A. Wilken, Glen Doniger

P3.2-011 Validation of

the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening Tool–Tjalf Ziemssen, Daniela Piani Meier, Bryan Bennett, Chloe Johnson, Katie Tinsley, Andrew Trigg, Frank Dahlke, Davorka Tomic, Chloe Tolley, Mark S. Freedman

P3.2-012 Clinical Evaluation of

a Software Medical Device for the Self-Assessment of Patients Living with Multiple Sclerosis: Results of the MSCopilot Study–Elisabeth Maillart, Pierre Labauge, Mikael Cohen, Adil Maarouf, Sandra Vukusic, Cécile Donzé, Philippe Gallien, Jérôme De Sèze, Bertrand Bourre, Thibault Moreau, Séverine Bieuvelet, Morgane Vallée, Fabien Bertillot, Anne-Laure Argoud, Saad Zinai, Ayman Tourbah

P3.2-013 Deep Neural Net

Forecasting of Multiple Sclerosis Disease Severity–Benjamin Insley, Syed Rizvi, Jonathan Cahill, Joshua Stone, Carsten Eickhoff

P3.2-014 Importance of

Optical Coherence Tomography Angiography in Differential Diagnosis of NMOSD and RRMS– B. Irem Tiftikcioglu, Sinan Emre, Fethi Idiman, Egemen Idiman

P3.2-015 Longitudinal study

of retinal layer thinning and brain atrophy in clinically isolated syndrome and multiple sclerosis–Yumin Huang Link, Max Borgström, Anders Tisell, Elisabeth Wilhelm, Peter Lundberg, Hans Link

P3.2-016 Validity and Potential

Added Value of Multi-Domain Computerized Cognitive Assessment for Patients with Multiple Sclerosis–Daniel Golan, Jeffrey A. Wilken, Timothy Fratto, Robert Kane, Jared Srinivasan, Myassar Zarif, Barbara Bumstead, Lori Fafard, Marijean Buhse, Mark Gudesblatt

P3.2-017 A Novel Clinically-

Feasible Balance Task Predicts Future Falls and Fall-Related Injuries Better Than Traditional Metrics in Early Multiple Sclerosis Patients–Rachel Brandstadter, Michelle Fabian, Ilana B. Katz Sand, Sylvia Klineova, Stephen Krieger, Fred D. Lublin, Aaron E. Miller, Claire Riley, James F. Sumowski

P3.2-018 The Impact of

Cognitive Testing on Disability Measurement during the Followup of People with Multiple Sclerosis–Francesco Sacca, Teresa Costabile, Christian Basile, Sara Ferraro, Anna Maria Barbarulo, Elisabetta Signoriello, Giacomo Lus, Vincenzo Brescia Morra

AAN.com/view/AM19Sci 161

Tuesday

Electrochemiluminescence (ECL) Immunoassay for Measurement of Amyloid Beta1-42 peptide in Human Plasma–Pankaj D. Mehta, David L. Miller, Bruce A. Patrick, Thomas M. Wisniewski

P3.1-029 Identification and

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.2-019 Wearable sensors for evaluation gait disorder in MS estimated by Learning Entropy– Ondrej Dostal, Oldrich Vysata, Ladislav Pazdera, Martin Valis

P3.2-020 Retinal Damage

in Multiple Sclerosis Disease Subtypes quantified by optical coherence tomography–Nouha hamza, Olfa Hdiji, Imen Abid, Salma Sakka, Hanen Hajkacem, Nouha Farhat, Mariem Damak, Jamel Feki, Chokri Abdellaziz Mhiri

P3.2-021 Multiple Sclerosis

Apps: The dawn of a new era: A comprehensive review–Sharon Stoll, Tess Litchman, Sarah Flanagan Wesley, Charisse D. Litchman

P3.2-022 Withdrawn P3.2-023 EDSS and Timed 25

Foot Walk Correlate with Spinal Cord Areas: Baseline Results from the SPI2 Clinical Trial of MD-1003 (high-dose biotin) in Progressive Multiple Sclerosis–Valerie A J Block, Amber M. Alexander, Nico Papinutto, Anand Rajesh, Tristan Gundel, Douglas L. Arnold, Frederic Sedel, Bruce A. C. Cree, Roland G. Henry

Tuesday

P3.2-024 FLOODLIGHT:

Smartphone-Based SelfMonitoring Is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures–Xavier Montalban, Patricia Mulero, Luciana Soledad Midaglia Fernandez, Jennifer Graves, Stephen L. Hauser, Laura J. Julian, Mike Baker, Jan Schadrack, Christian Gossens, Alf Scotland, Florian Lipsmeier, Corrado Bernasconi, Shibeshih Belachew, Michael Lindemann

P3.2-025 Visualization of the

Topographic Thickness Alterations in the Intra-retinal Layers of Multiple Sclerosis Patients with History of Optic Neuritis–Hong Jiang, Giovana Rosa Gameiro, Huiling Hu, Jeffrey Hernandez, Sylvia R. Delgado, Jianhua Wang

P3.2-026 Upper limbs

impairment in patients with multiple sclerosis: a relevant and currently undervalued measure.– Ricardo Alonso, Barbara Eizaguirre, SIlva Berenice, Cecilia Pita, Leila Cohen, Sandra Vanotti, Domingo Orlando Garcea

162 2019 AAN Annual Meeting

P3.2-027 Peripheral nervous system electrodiagnostic abnormalities in Multiple Sclerosis–Alexis A. Lizarraga, Kottil W. Rammohan, Bianca Weinstock-Guttman, Khema R. Sharma

P3.2-028 Disability or Disease:

What Stands at the Basis of Connectivity Patterns within the Visual Network following Damage to the Optic Nerve?–Yael Backner, Friedemann Paul, Netta Levin

P3.2-029 Transcranial Direct

Current Stimulation (tDCS) can Enhance Physical Training Outcomes in Multiple Sclerosis (MS)–Giuseppina Pilloni, Claire Choi, Michael Shaw, Kathleen Sherman, Massimiliano Pau, Lauren B. Krupp, Leigh Elkins Charvet

P3.2-030 Understanding Motor

Performance in People with Multiple Sclerosis Using Virtual Reality–Khalid I. El-Salem, Alham Alsharman, Hanan Khalil, Alia Alghwiri MS CLINICAL TRIALS AND THERAPEUTIC RESEARCH

P3.2-031 Reduction in 48-Week

Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis–Jerry S. Wolinsky, Ludwig Kappos, Xavier Montalban, Fabian Model, Lahar R. Mehta, Stanislas Hubeaux, Gavin Giovannoni

P3.2-032 Long-term Effect of

Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple Sclerosis–Jeffrey Alan Cohen, Ludwig Kappos, Nadia Tenenbaum, Andre Couturier, Harald Kropshofer, Davorka Tomic, Jens Kuhle

P3.2-033 Effect of Ibudilast

on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial–Robert J. Fox, Matthew Karafa, Victoria Konig, Sneha Natarajan, Christian Barro, Robert A. Bermel, Christopher Coffey, Andrew D. Goodman, Eric Klawiter, Kazuko Matsuda, Robert T. Naismith, Jens Kuhle, On behalf of NN102 SPRINT MS Investigators

Tuesday, May 7 11:30 a.m.–6:30 p.m. P3.2-034 Evaluation of shorter

P3.2-039 Serum Neurofilament

P3.2-035 Optimal Response to

P3.2-040 Multiple Sclerosis

infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis–Timothy L. Vollmer, Enrique Alvarez, Kavita Nair, Jeffrey Alan Cohen, Aaron L. Boster, Donna L. Masterman, Ashish Pradhan, Bruno C. Musch, Xiaoye Ma, Jinglan Pei, Brandon P. Moss, Bianca Weinstock-Guttman, Robert A. Bermel Dimethyl Fumarate is Mediated by a Reduction of Th17.1 cells after 3 Months of Treatment–Maria José Mansilla, Juan Navarro-Barriuso, Silvia Presas, Aina Teniente-Serra, Bibiana Quirant-Sanchez, Cristina M. Ramo, Eva M Martínez-Cáceres

P3.2-036 Ozanimod Efficacy

Light Chain in a Phase 1/2 Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis–Laura Elizabeth Baldassari, Sarah Marie Planchon Pope, Peter Imrey, Robert A. Bermel, Kunio Nakamura, Elizabeth Fisher, Jenny J. Feng, Ken Sakaie, Daniel Ontaneda, Jeffrey Alan Cohen (MS) Relapse Rates and Healthcare Costs with Generic Glatiramer Acetate: a Retrospective Claims Analysis of US Health Plan Data–Steven B. Hall, Sanjeev Balu, Michael Grabner, Xian Zhang, Daniel Kantor

in Relapsing Multiple Sclerosis Supported by Open-Label LongTerm Extension of Two Phase 3 Trials–Lawrence Steinman, Giancarlo Comi, Bruce A. C. Cree, Amit Bar-Or, Krzysztof Selmaj, Douglas L. Arnold, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, James K. Sheffield, Vivian Huang, Diego Silva, Ludwig Kappos, Jeffrey Alan Cohen

P3.2-041 Meta-analysis of real-

P3.2-037 Improved Clinical and

Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up–Douglas L. Arnold, Gavin Giovannoni, Hans-Peter Hartung, Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Jerry S. Wolinsky, Karine Coutant, Kalpesh Prajapati, Fabian Model, Lahar R. Mehta, Anthony Traboulsee

MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in AlemtuzumabTreated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)–Daniel Pelletier, Douglas L. Arnold, Alexey Boyko, Giancarlo Comi, Hans-Peter Hartung, Eva Havrdova, Jihad Said Inshasi, Pamela Ann McCombe, Kunio Nakamura, Celia Oreja-Guevara, Carlo Pozzilli, Krzysztof Selmaj, Thomas F. Scott, Luke Chung, Nadia Daizadeh, Salman Afsar, Bart Van Wijmeersch

P3.2-038 Incidence of Relapses in Patients with Biotin-Treated Progressive Multiple Sclerosis (IPBio-SeP Study): Intermediate Analysis of a French, Multicenter Study–Sophie Mathais, Xavier Moisset, Frederic Taithe, Pierre Labauge, Jean Pelletier, Giovanni Castelnovo, Eric Berger, Christine Lebrun Frenay, Jean-Phillippe Camdessanche, Sandra Vukusic, Pierre Clavelou

world adherence and persistence of maintenance once- or twicedaily oral disease-modifying drugs (dimethyl fumarate, fingolimod, and teriflunomide) in multiple sclerosis–Amy L. Phillips, Jacqueline Ann Nicholas, Natalie Edwards, Roger Edwards, Anna Dellarole, Megan Grosso

P3.2-042 Reduced Rate of Brain

P3.2-043 Effect of MD1003

(high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Long-term Safety Data at 48 Months of Followup–Jerome De Seze, Gilles Edan, Thibault Moreau, Bruno Brochet, Frederic Sedel, Ayman Tourbah

P3.2-044 Modified Ketogenic

Diet Therapy for Relapsing Multiple Sclerosis: PatientReported Outcomes–James Nick Brenton, Brenda Banwell, A. G. Christina Bergqvist, Diana LehnerGulotta, Lauren Gampper, Emily Leytham, Myla D. Goldman

P3.2-045 Effect of Alemtuzumab

P3.2-049 Effect of ibudilast on

P3.2-046 Investigating the

P3.2-050 Alemtuzumab

on Serum Neurofilament Light Chain Levels: Comparison to SC IFNB-1a and Assessment Over 7 Years (CARE-MS I)–Jens Kuhle, Nadia Daizadeh, Christian Barro, Zuzanna Michalak, David Leppert, Jean Godin, Srinivas Shankara, Tarek Samad, Alan K. Jacobs, Luke Chung, Nora Roesch, Carina Kaiser, Ludwig Kappos, Evis Havari Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study–Till Sprenger, Christine Lebrun-Frenay, Patrick Vermersch, Min Park, Dennis Chinchilla, Pamela Ann McCombe, John A. Lincoln, Ludwig Kappos, Niels Bergsland, Michael G. Dwyer, Steven J. Cavalier, Nora Roesch, Kathleen C. Somera-Molina, Elizabeth Poole, Robert Zivadinov

P3.2-047 Tolerogenic dendritic

cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials.–Silvia Presas, Barbara Willekens, M José Mansilla, Judith Derdelinckx, Wai Ping Lee, Juan Navarro-Barriuso, Aina Teniente-Serra, Bibiana Quirant-Sanchez, Griet Nijs, Maxime De Laere, Inez Wens, Patrick Cras, Paul Parizel, Wim Van Hecke, Annemie Ribbens, Geert Adams, Marie Madeleine Couttenye, Herman Verheij, Anke Kip, Ascensión López-Díaz de Cerio, Susana Inoges, Felipe F Prosper, Catharina Groß, Heinz Wiendl, Marieke van Ham, Anja Ten Brinke, Ana Maria Barriocanal-Barriocanal, Anna Massuet-Vilamajo, Niel Hens, Zwi Berneman, Eva M MartínezCáceres, Nathalie Cools, Cristina M. Ramo (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)–Edward J. Fox, Sibyl E. Wray, Richard A. Shubin, Jenna Bosco, Michael Weiss, Sean Power, Koby Mok, James Eubanks

Outcomes After Switching From Fingolimod In Real-Life Clinical Practice–Ines Gonzalez, Joaquin Pena Martinez, Agustin Oterino Duran, Eva Costa Arpin, Ana García-Pelayo, A. Regal, Dulce M. Solar Sanchez, Jose Ramon Lorenzo González, Maria Rodriguez Rodriguez, Leticia Alvarez, Jose Maria Prieto Gonzalez, Ana Lopez Real

P3.2-051 Effect of Siponimod

on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis–Ralph H. B. Benedict, Robert J. Fox, Davorka Tomic, Bruce A. C. Cree, Patrick Vermersch, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Shannon Ritter, Goeril Karlsson, Christian Wolf, Ludwig Kappos

P3.2-052 Glatiramer Acetate

Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis–Shlomo Flechter, Ariel L. Miller, Laura Popper, Nadav Bleich Kimelman, Shai Rubnov, Uri Danon, Ehud Marom, Ron E. Milo, Joab Chapman, Alla Shifrin, Ronit Gilad, Chen Hoffmann, Dimitrios Karussis, Arnon Karni

P3.2-053 Ocrelizumab Safety

and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies–Sahar Alimohamadi, Brandi L. Vollmer, Kavita Nair, Stefan Sillau, John Corboy, Timothy L. Vollmer, Enrique Alvarez

P3.2-054 Long-Term Reduction

in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis–Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Amit Bar-Or, Gavin Giovannoni, Fabian Model, Stanislas Hubeaux, Lahar R. Mehta, Jerry S. Wolinsky

P3.2-055 Treatment

With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received =4 Courses–Regina Berkovich, Ann D. Bass, Aaron L. Boster, Giancarlo Comi, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Nils Lycke, Richard A L Macdonell, Sven Schippling, Barry A. Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Claudio Rodriguez, Anthony Traboulsee

P3.2-056 Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)–Kyle Smoot, Chiayi Chen, Tiffany Gervasi, Lindsay Lucas, Kiren Kresa-Reahl, Pavle Repovic, Jessica R. Craddock, Stanley L. Cohan

P3.2-057 Real-World

Effectiveness of Alemtuzumab in Relapsing-Remitting MS Patients in Germany: Interim Results of the TREAT-MS Study–Katja Akgün, Robin White, Raimar Kern, Ulrich Engelmann, Rocco Haase, Benjamin Guikema, Tjalf Ziemssen

P3.2-058 Improved Clinical and

MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS II (TOPAZ Study)– Barry A. Singer, Raed Alroughani, Simon Broadley, Sara Eichau Madueno, Hans-Peter Hartung, Eva Havrdova, Ho Jin Kim, Kunio Nakamura, Carlos Alberto Navas, Carlo Pozzilli, Alex Rovira, Patrick Vermersch, Sibyl E. Wray, Luke Chung, Nadia Daizadeh, Salman Afsar, Krzysztof Selmaj

P3.2-059 Real-World

Experience with Ocrelizumab– Brandon P. Moss, Erica Hailey Parrotta, Laura Elizabeth Baldassari, Jeffrey Alan Cohen, Daniel Ontaneda

P3.2-060 Diroximel Fumarate

(DRF) in Patients With RelapsingRemitting Multiple Sclerosis: Interim Efficacy Results From the Phase 3 EVOLVE-MS-1 Study–Douglas L. Arnold, Christopher C. LaGanke, Dragana Obradovic, Mark Gudesblatt, Lili Yang, Catherine Miller, Richard Leigh-Pemberton, Maria V. LopezBresnahan, Boris Kandinov, Jerry S. Wolinsky

P3.2-061 Cladribine tablets

were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial–Susan L. Scarberry, Doris Damian, Yann Hyvert, Fernando Dangond, Lori Lebson, Thomas Leist

P3.2-062 Lymphopenia rates

in CLARITY/CLARITY Extension are consistent in patients with or without high disease activity at baseline–Stuart D. Cook, Gavin Giovannoni, Patrick Vermersch, Per Soelberg Sorensen, Birgit Keller, Dominic Jack

P3.2-063 Effect of MD1003

(high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months–Jerome De Seze, Gilles Edan, Thibault Moreau, Bruno Brochet, Frederic Sedel, Ayman Tourbah

P3.2-064 Effects of Dimethyl

Fumarate on Brain Volume Change in Relapsing-remitting Multiple Sclerosis: a Pooled Analysis of the Phase 3 DEFINE and CONFIRM Studies–Kunio Nakamura, Oksana Mokliatchouk, Douglas L. Arnold, Tarek Yousry, Ludwig Kappos, Nancy D. Richert, Elizabeth Fisher, Sarah Gheuens

P3.2-065 Discontinuation

and Comparative Effectiveness of Dimethyl Fumarate and Fingolimod in Two Large Academic Medical Centers at 36-month Follow-Up–Carrie Michelle Hersh, Brandi L. Vollmer, Haleigh Harris, Kavita Nair, Robert A. Bermel, John Corboy, Robert J. Fox, Timothy L. Vollmer, Jeffrey Alan Cohen, Daniel Ontaneda, Enrique Alvarez

P3.2-066 A Novel Small

Molecule Promotor of Remyelination–Chandramohan Natarajan, Asa Rose, Subramaniam Sriram

AAN.com/view/AM19Sci 163

Tuesday

P3.2-048 Open Label Extension

macular measures in progressive MS: OCT analysis from a phase II trial–Robert A. Bermel, Janel Barnes, Jon Yankey, Elizabeth Klinger, Sneha Natarajan, Christopher Coffey, Andrew D. Goodman, Eric Klawiter, Kazuko Matsuda, Robert T. Naismith, Robert J. Fox, On behalf of NN102 SPRINT MS Investigators

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.2-067 7-Year Outcomes in

MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study)–Mitzi Joi Williams, Lilyana M. Amezcua, Regina Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Annette Okai

P3.2-068 Peginterferon beta-1a

every 2 weeks demonstrated better outcomes than glatiramer acetate (GA) once daily in patients with relapsing-remitting multiple sclerosis (RRMS): propensity score matching (PSM) of phase 3 data from ADVANCE and CONFIRM–Thomas F. Scott, Oksana Mokliatchouk, Carmen Castrillo-Viguera, Adrian Harrington, Maria Naylor

P3.2-069 Analysis of disease

activity return after natalizumab withdrawal in multiple sclerosis– Luna Fuentes Rumi, Jose Maria Cabrera Maqueda, Ester Carreon Guarnizo, Rocio Hernandez Clares, Maria Teresa Alba Isasi, Julián Vázquez Lorenzo, Gabriel Valero López, Ana Ester Baidez Guerrero, Moises Morales de la Prida, Maria Canovas Iniesta, Judith Jimenez Veiga, Adelaida León Hernández, Francisca Velaquez Marin, Joaquín Zamarro Parra, Francisca IniestaMartínez, Ana M. Morales Ortiz, Jose Meca Lallana

P3.2-070 Efficacy of Short

Washout Periods After Switching from Natalizumab to an Alternative DMT.–Le Hua, Haleigh Harris, Devon Conway, Carrie Michelle Hersh

Tuesday

P3.2-071 Long-Term Effect

of Teriflunomide in Subgroups Defined by Prior Treatment: Pooled Analysis of the Phase 2 Study and Phase 3 TEMSO, TOWER, and TENERE Core and Extension Studies–Giancarlo Comi, Mark S. Freedman, Jose Meca Lallana, Patrick Vermesch, Byoung Joon Kim, Alexander Parajeles, Keith R. Edwards, Ralf Gold, James Overell, Houari Korideck, Jeffrey Chavin, Elizabeth Poole, Patricia K. Coyle

164 2019 AAN Annual Meeting

P3.2-072 Phase 2 AFFINITY

Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics–Bing Zhu, Peter A. Calabresi, Gavin Giovannoni, Raju Kapoor, Robert T. Naismith, Hans-Peter Hartung, Douglas L. Arnold, Paul Wolstencroft, Kristina Johnson, Shifang Liu, Ih Chang, Wenting Cheng, Aaron Deykin

P3.2-073 Peg-Interferon beta

1a induces a sustained and long lasting overexpression of interferon related genes.–Antonio Bertolotto, Marzia Caldano, Maddalena Arigoni, Martina Olivero, Federica Brescia, Jessica Bertolo, Fabiana Marnetto, Simona Malucchi, Raffaele Calogero

P3.2-074 Number Needed to

Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine–Aaron L. Boster, Regina Berkovich, Daniel Kantor, Elizabeth Poole, Nora Roesch, Jeffrey Chavin, Maxneil Guce, Aaron E. Miller

P3.2-075 Effectiveness and

Safety of Fingolimod in Patients Switching from Dimethy Fumarate, Teriflunomide, and Daclizumab in Daily Clinical Routine: Interim Results from PANGAEA 2.0–Tjalf Ziemssen, Ulf Schulze Topphoff

P3.2-076 Serum Anti-JCV

Antibody Status in Western Australian Patients With Multiple Sclerosis–Marzena Pedrini, Shaila Jeereddy, William Carroll, Allan G. Kermode

P3.2-077 High frequency

repetitive transcranial magnetic stimulation can improve balance and white matter integrity in patients with RRMS. A long term follow up study–Hatem Samir Mohammed Shehata, Sherif M. Hamdy, Maged Mohamed AbdelNaseer, Iman Yassine, Mona Sherbiny, Talaat Hassan, Nevin Shalaby

Tuesday, May 7 11:30 a.m.–6:30 p.m. P3.2-078 Antidrug Antibodies

Have Minimal Impact on the Pharmacodynamic Profile and Clinical Efficacy of Alemtuzumab in RRMS Patients From the CARE-MS Studies–Tjalf Ziemssen, Antonio Bertolotto, Samuel F. Hunter, Jan Nils Lycke, Alan K. Jacobs, Luke Chung, Qifeng Yu, Isabel Firmino, Christopher C. LaGanke

P3.2-079 Corticosteroids

affect the dynamics of multiple sclerosis lesions formation–Maria Gaitan, Gabriela De Pino, Maria C. Ysrraelit, Gabriela Michelin, Paulina Yañez, Jorge D. Correale

P3.2-080 Long-term Clinical

Outcomes in Patients with CIS Treated with Interferon Beta-1b: Clinical and MRI Results from BENEFIT 15–Ludwig Kappos, Mark S. Freedman, Gilles Edan, HansPeter Hartung, Xavier Montalban, Frederik Barkhof, Ralf Koelbach, Eva-Maria Wicklein

P3.2-081 Real-world Efficacy

of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM–Kathryn Giles, Konstantin E. Balashov, Cynthia C. Jones, Richard A L Macdonell, Catherine Miller, Joerg Windsheimer, Fan Wu, Nicholas J. Everage

P3.2-082 Sustained

improvement in clinical and MRI outcomes in Newly Diagnosed relapsing-remitting multiple sclerosis (RRMS) patients treated for up to 4 years with peginterferon beta-1a: subgroup analysis of ADVANCE/ATTAIN– Scott Douglas Newsome, Thomas F. Scott, Douglas L. Arnold, Oksana Mokliatchouk, Matthias Meergans, Maria Naylor

P3.2-083 Biotin in Progressive

Multipe Sclerosis in reallife–Thibault Moreau, Ayman Tourbah, Jerome De Seze, Marc Debouverie, Eric Berger, Guillaume Mathey, Nicolas Collongues, Agnes Fromont, gaelle romain

P3.2-084 Delayed-release

Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis–Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Amit Bar-Or, Robert J. Fox, Chongshu Chen, Catherine Miller

P3.2-085 Real life efficacy

and tolerability of Teriflunomide: multicentre study in Galicia (TERIGAL 2018).–Antonio Pato, Elena Alvarez Rodriguez, Daniel García Estévez, Ana García-Pelayo, María Rodríguez Rodríguez, Eva Costa Arpín, Ana Rodriguez Regal, Miguel Angel Llaneza Gonzalez, Agustín Martínez, Laura Ramos, Ines Gonzalez, María del Campo Amigo Jorrín, Jose Ramon Lorenzo Gonzalez, Jose Maria Prieto Gonzalez

P3.2-086 PANGAEA:

Effectiveness and safety of fingolimod over 5 years in daily clinical practice–Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt, Holger Albrecht, Judith Haas, Luisa Hildegard Klotz, Chrstoph Lassek, Christian Cornelissen, Ulf Schulze Topphoff

P3.2-087 Clinical Characteristics and Outcomes Among NARCOMS Registry Participants Treated With Alemtuzumab–Amber Salter, Tuula Tyry, Robert J. Fox, Lobat Hashemi, Kathryn Munoz, Thomas Carattini, Alden Smith, Gary Raymond Cutter

P3.2-088 Teriflunomide Use

in Participants With RelapsingRemitting MS Enrolled in the NARCOMS Registry–Lobat Hashemi, Amber Salter, Tuula Tyry, Samantha Lancia, Robert J. Fox, Kathryn Munoz, Thomas Carattini, Alden Smith, Gary Raymond Cutter

P3.2-089 Identifying

Physiological Predictors of the Solumedrol-Resistant Multiple Sclerosis Relapse and its Clinical Repercussions–Dolly B. Roy, Kaibin Shi, Fu-Dong Shi

P3.2-090 Autologous

Haematopoetic Stem Cell Transplantation – an Irish Tertiary Referral Centre Experience–Maria Gaughan, Christopher McGuigan

P3.2-091 Ocrelizumab

Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design–Gavin Giovannoni, Laura Airas, Riley Bove, Alexey Boyko, Gary Raymond Cutter, Jeremy C. Hobart, Jens Kuhle, Jiwon Oh, Carmen Tur, Monika Garas, Fabian Model, Marianna Manfrini, Jerry S. Wolinsky

P3.2-092 Cannabis use by

Patients with Multiple Sclerosis in Colorado–Christopher Domen, Laura J Weinkle, Ian Shelton, Stefan Sillau, Kavita Nair, Enrique Alvarez

P3.2-093 The Effects of Disease Modifying Therapy on Retinal Structures in Relapsing Remitting Multiple Sclerosis Patients– Melody Gilroy, Samuel LichtmanMikol, Rachel Darling, Carla E. Santiago-Martinez, Evanthia Bernitsas

P3.2-094 Real-World Fingolimod efficacy and safety in Emirati patients with multiple sclerosis– Antonia Ceccarelli, Victoria Mifsud, Rawan Yasser Gaber Elhennawy, Beatrice Benedetti, Syed Irteza Hussain, Stephen D. Samples

P3.2-095 Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, raterblinded phase 3b study–Nolan Campbell, Jeffrey Alan Cohen, Heinz Wiendl, John F. Foley, Helmut Butzkueven, Lana Zhovtis Ryerson, Gavin Giovannoni, Douglas L. Arnold, Gilles Defer, Joep Killestein, Gary Raymond Cutter, Zheng Ren, Rachna Kasliwal, Giuseppina Stifano, Ih Chang, Pei-Ran Ho

P3.2-096 Baseline

P3.2-097 Treatment

Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study–Sibyl E. Wray, Francois H. Jacques, Tamara Miller, Jacqueline Ann Nicholas, Susan Mozzicato, Mary-Jean Fanelli, Houari Korideck, Martin Kappler, Nadia Daizadeh, Colin Mitchell, Samuel F. Hunter

Clinically Meaningful HealthRelated Quality of Life Improvements With Alemtuzumab in RRMS Patients in Clinical Practice: Interim Results From a Prospective, Non-Interventional, Real-World Study (PROMiS)– Bhupendra O. Khatri, Julia Morawski, Luke Chung, Elizabeth Poole, Lobat Hashemi, Denise Bury

P3.2-099 Real-world switching patterns among US generic glatiramer acetate multiple sclerosis patients–Jessica K. Alexander, Jyotsna Kasturi, Sigal Melamed-Gal, Rinat Ariely, Michaela Vardi, Zhaohui Su, Thomas Brecht, Allison Bryant

P3.2-100 Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY Extension–Gavin Giovannoni, Birgit Keller, Dominic Jack

P3.2-101 The effect of

cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLEMS study–James D. Bowen, Doris Damian, Yann Hyvert, Fernando Dangond, Daniel Jones, Megan Grosso, Thomas Leist

P3.2-102 Gaps in treatment and treatment discontinuation among patients with multiple sclerosis newly-initiating once- or twicedaily oral disease-modifying drugs–Jacqueline Ann Nicholas, Natalie Edwards, Danielle E. Harlow, Amy L. Phillips

P3.2-103 Characteristics of

Patients Switching from AntiCD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis.–Brandi L. Vollmer, Kavita Nair, John Corboy, Timothy L. Vollmer, Enrique Alvarez STROKE CONTINUUM OF CARE I: STROKE PREVENTION, RISK FACTORS AND QUALITY METRICS

P3.3-001 Design and

Implementation of a Multidisciplinary Integrated Stroke Prevention Clinic–Seung Yun Kim, Yongwoo Kim, Jennifer Andres, Van Hellerslia, S Ausim Azizi, Anjail Sharrief, Imama Ali Naqvi

P3.3-002 Sleep Disordered

Breathing (SDB) - An Overlooked Modifiable Risk Factor in Acute Stroke Care–Aashrai Sai Venkat Gudlavalleti, Julius Latorre, Vishal Shah

P3.3-003 Pharmacological

Smoking Cessation Therapies for Patients with Cerebrovascular Disease: a Systematic Review– Neal S. Parikh, Setareh Salehi Omran, Mitchell S. V. Elkind, Joshua Z. Willey

P3.3-004 Improving Stroke

Education in Spanish-Speaking Patients–Minh-Thuy Thi Nguyen, Heping Sheng, Shuhan Zhu

P3.3-005 Motivation for

Behavioral Change for Weight Loss in Obese Patients with Acute Stroke or TIA–Hailey Amanda Orgass, Emily Daigle, Zachary King, Cora Ormseth, Sara Jasak, Emily Jean Gilmore, Lauren Hachmann Sansing, Hardik Amin, Walter N. Kernan, Guido Jose Falcone, Kevin N. Sheth, Jennifer L. Dearborn

P3.3-006 Geographic

Proximity to Healthy Food is Not Independently Associated with Ischemic Stroke Risk Factors–Alan Dale Howard, Chigozirim Izeogu, Adeniyi Idigo, Michael J. Lyerly

P3.3-007 Abdominal Obesity is a Risk Factor for Ischaemic Stroke–Touhidar Rahman

P3.3-008 Association between

albuminuria and the risk of stroke: a secondary analysis of the SPRINT trial–Ricardo Jorge Soares Dos Reis, Lia Leitão, João Sérgio Neves, Rute Baeta Baptista, Miguel Bigotte Vieira, Finnian Mc Causland

P3.3-009 Correlation of

Different Sleep Apnea Scores with Polysomnographic Study in Patients with Acute Stroke and Transient Ischemic Attack–Samir Patel, Dave Nikhil, Samhita Panda, Chandrashekhar Agrawal

P3.3-010 A hospital’s

perspective: economic evaluation of hospitalization vs rapid outpatient evaluation for TIA and minor strokes.–Steven David Shapiro, Jorge M. Luna, Rachel Pauline Mehendale, Babak Navi, Benjamin R. Kummer, Sara Kate Rostanski, Claudia Rosen, David Vawdrey, Bernard S. Chang, Eliza Cushman Miller, Mitchell S. V. Elkind, Joshua Z. Willey

P3.3-011 Alcohol-Related

Hospital Encounters Trigger Stroke Events–Caroline Gentile, Laura Stein, Mandip Singh Dhamoon

P3.3-012 Association Between Recent Cannabis Use and Acute Ischemic Stroke–Carmela San Luis, Shashank Shekhar, Rebecca L. Sugg, Christa O’hana San Luis Nobleza, Shreyas Gangadhara

P3.3-013 Clinical Characteristics of Methamphetamine Associated Acute Ischemic Stroke–Sandeep Songh Walia, Kwan L. Ng

P3.3-014 Cerebral Small Vessel Disease and Cervicocerebral Large Artery Stenosis Independently Increase Ischemic Stroke Risk in the General Population–Fei Han, Fei-Fei Zhai, Shuang Yan, Ding-Ding Zhang, Jiang-Tao Zhang, Lixin Zhou, Jun Ni, Ming Yao, Liying Cui, Ming-Li Li, Zheng-Yu Jin, Yi-Cheng Zhu

P3.3-015 Trans Esophageal

Echo in Transient Ischemic Attack–Digvijaya D. Navalkele, Dominique Monlezun, Daniel Bouchette, Sheryl Martin-Schild

P3.3-016 Stroke Code Quality

Metrics and Functional outcomes: Advanced Practice Providers versus Neurology Residents– Muhib Khan, Laurel Packard, Hattie LaCroix, Tricia Tubergen, Cuyler Huffman, Bassel Raad, Joseph Zachariah, Jordan Andrew Combs, Michelle Del Castillo DeJesus Brazitis, Ashok Sriram, Justin Singer, Raymond Scureck, Tamer Abdelhak

P3.3-017 Stroke Version 2.0

Common Data Element (CDE) Review: Updates to the National Institute of Neurological Disorders and Stroke (NINDS) CDEs for Stroke–Robin Sadja Feldman, Damon Collie, Katelyn Elizabeth Gay, Muniza Sheikh, Joy R. Esterlitz, Jeffrey L. Saver, Steven Warach, Carolina MendozaPuccini

P3.3-018 Impact of Residency

Training Programs on Outcomes of Acute Ischemic Stroke–Smit D. Patel, Karan Kaushik Topiwala, Neel Patel, Tapan Mehta, Gracia Chu-wai Mui

P3.3-019 Nutritional knowledge and counseling of stroke patients by neurology residents–Karima Benameur

AAN.com/view/AM19Sci 165

Tuesday

Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide–Ludwig Kappos, Amit Bar-Or, Jeffrey Alan Cohen, Giancarlo Comi, Jorge D. Correale, Patricia K. Coyle, Anne H. Cross, Jerome De Seze, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, David Leppert, Cecile Kerloeguen, Roman Willi, Dieter Haering, Davorka Tomic, Alexandra L. Goodyear, Martin Merschhemke, Stephen L. Hauser

P3.2-098 Significant and

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 STROKE CONTINUUM OF CARE II: POST-STROKE COMPLICATIONS, RECOVERY AND OUTCOMES

P3.3-020 Care giver burden

among carers of young stroke survivors–Rajeswari Aghoram, Indira Priya Done, Sunil K. Narayan

P3.3-021 In-hospital Delirium

and Long-Term Cognitive Outcomes among Patients with Ischemic Stroke: A populationbased cohort analysis–Arvind Bambhoroliya, Jennifer Meeks, Jon Tyson, Charles Miller, Babar Khan, Sunil Sheth, Louise D. McCullough, James C. Grotta, Jaroslaw Aronowski, Sean I. Savitz, Farhaan S. Vahidy

P3.3-022 Review of Current

Pharmacotherapy for Post-Stroke Depression–Fasiha Syed, Nabeel Herial

P3.3-023 Dysphagia

Severity and Medullary Lesion Localization–Davit Eliauri, Aleko Turiashvili

P3.3-024 Early Detection

Factors of Post-Stroke Dysphagia–Valney Oliveira Oliveira Santos, Rodrigo Sobral de At Rocha, Felipe Oliveira Costa

P3.3-025 Stroke associated

pneumonia: Usefulness of a practical and straightforward scale.–Victoria Aldinio, Maria Bullrich, Maria Pilar Sanchez de Paz, Emilia M. Gatto, Gabriel Persi

P3.3-026 Delirium is Associated

Tuesday

with Increased Readmissions and Mortality in Patients with Acute Ischemic Stroke–Xiyan Yi, Varun Kumar, Chirag Narshibhai Savani, Tejinder Singh, Swetha Renati

P3.3-027 Higher In-Hospital

Mortality, Length of Stay, and 30-day Readmission Rates among Stroke Patients with Delirium: A Population based Analysis–Farhaan S. Vahidy, Arvind Bambhoroliya, Jennifer Meeks, Omar Rahman, Alicia Zha, Babar Khan

P3.3-028 Pseudobulbar affect in patients with stroke–Maria Constanza Segamarchi, Matias Alet, Carlos Santiago Claverie, Sandra Lepera, Leonardo Adrian Gonzalez, Raul Carlos Rey

P3.3-029 Impact of Anemia on

Stroke Morbidity and Mortality– Sara Shapouran, Taha Nisar

166 2019 AAN Annual Meeting

Tuesday, May 7 11:30 a.m.–6:30 p.m.

P3.3-030 Socio-Demographic

P3.3-038 Disease, Institutional

P3.3-031 The Obesity Paradox

P3.3-039 Proportional Recovery

and Clinical Study of Post Stroke Cognitive Decline: A Hospital Based Study–Rameshwar Nath Chaurasia Characterizes Outcome from Acute Ischemic Stroke: Evidence from 1033 Patients–Zuolu Liu, Nerses Sanossian, Sidney Starkman, Scott Hamilton, Gilda Avila-Rinek, David S. Liebeskind, Latisha Sharma, Marc Eckstein, Samuel Stratton, Robin A. Conwit, Jeffrey L. Saver

P3.3-032 Patients with

Dementia or Stroke Hospitalized with Community-acquired pneumonia are at Higher Risk of Long-term Mortality–Rajashekar Reddy Yeruva, Murali K. Kolikonda, Thomas Chandler, Julio Ramirez

P3.3-033 Factors Affecting

Readmission Rates for Patients with Ischemic Stroke Hospitalized in an Integrated Health System of Stroke Care–Scott Mayhugh Le, Julie Fussner, Cathy A. Sila

P3.3-034 Hemorrhagic

Complications after Acute Stroke Therapies Are Not Elevated in Patients with Chronic Kidney Disease, with or without Hemodialysis–Daniel M. Schachter, Micaela Schachter, Bichum Ouyang, Alejandro Vargas, Nicholas D. Osteraas, Sarah Song, Rima Dafer, James Conners, Lauren Koffman, Laurel Jean Cherian

P3.3-035 High Dietary Glycemic

Load is Associated with Poor Functional Outcome in Patients with Acute Cerebral Infarction– Chan Young Lee, Min Young Chun, Yoonkyung Chang, Tae-Jin Song, A-ram Kim, Yuri Kim, Yong-Jae Kim

P3.3-036 Factors Associated

and Community Factors Influencing Compliance in Stroke Patient Follow-up–Yue Ran Sun, Chizoba Ezepue, Randall Edgell in Post-Stroke Aphasia–Melissa Bailey, Peter Turkeltaub

P3.3-040 A protocol for acute neurofunctional rehabilitative therapy following ischemic stroke–Gizely Andrade, Ana Fatima Ximenes Meireles, Erika Batista Lopes, Fabricio Oliveira Lima, Fernanda Martins Maia

P3.3-041 Limbic Atrophy in

Post-Stroke Epilepsy: a Voxel Based Morphometry Study– Marilise Katsurayama, Marina Koutsodontis Alvim, Alessandro Viana Sousa, Leticia Franceschet Ribeiro, Wagner Mauad Avelar, Iscia Lopes-Cendes, Fernando Cendes, Clarissa L. Yasuda

P3.3-042 Botulinum toxin

A modulates parietal cortex activity in post-stroke upper limb spasticity–Petr Hlustik, Tomas Veverka, Pavel Hok, Pavel Otruba, Alois Krobot, Petr Kanovsky

P3.3-043 Patient Perception

Confounds True Recovery After Stroke–Elisabeth B. Marsh, Courtney Whilden, Sheena Khan, Dania Mallck

P3.3-044 Implementing a

Sustainable Plan for the COAST Stroke Advance Directive–ChiaChun Chiang, Alyssa Bautista, Julian C. Duda, Brett C. Meyer, Kunal Agrawal

P3.3-045 Non-high-density

lipoprotein cholesterol is associated with hemorrhagic transformation after acute ischemic stroke–Yanan Wang, Yajun Cheng, Simiao Wu, Quhong Song, Liu Ming

With Outpatient Neurology Clinic Follow-Up After Acute Stroke Hospitalization at a Large Public City Hospital–Jonathan Bryan Tiu, Alexander Allen, Jon Marc M. Finamore, Dixon Yang, Sara Kate Rostanski

P3.3-046 Females Have Worse

P3.3-037 Screening and

P3.3-047 Effect of Anti-

Treatment for Osteoporosis after Stroke: Results from the Ontario Stroke Registry–Eshita Kapoor, Peter Austin, Shabbir Alibhai, Angela Cheung, Peter Cram, Leanne Casaubon, Jimming Fang, Joan Porter, Marla Prager, Moira Kapral

In-hospital Outcomes After Reperfusion Therapy in Ischemic Stroke–Dinesh V. Jillella, Fares Qeadan, Ken Uchino, Yoram Roman Casul, Asad Ikram, Christopher Calder, Huy Tran Hypertensive Medications on Hemorrhagic Transformation in Ischemic Stroke–Yoram Roman Casul, Dinesh V. Jillella, Fares Qeadan, Christopher Calder, Danielle Sorte, Huy Tran

P3.3-048 A Task-Based

Approach to Quantifying Movement Deficits Due to Stroke–Bradley Cahn, Jill Shah, Sandra Saldana-Ortega, Cora Ormseth, Hitten Zaveri, Kevin N. Sheth

P3.3-049 External validation

of SICH predicting scores–Taha Nisar, Rajanigandhi Hanumanthu, Sara Shapouran, Shuja Sheikh, Priyank Khandelwal EMERGENCY EVALUATION AND THROMBOLYSIS

P3.3-050 Artery of Percheron

Infarct: A difficult diagnosis in the emergency room. Report of 7 cases in Argentina–Lucrecia Bandeo, Maria Agustina Rubio Bonnet, Alberto Rodriguez, Daniele Barrio Löwer, Pablo Shubaroff, Claudia Paola Veasquez Carretero, Maria Emilia Tajan, Maria Graciela Cersosimo, Maria Carolina Gonzalez Perez, Marta Bala, Miguel Saucedo, Javier Halfon, Luciana Vanesa Leon Cejas, Maria Sol Pacha, Marcela Uribe Roca, Pablo Bonardo, Manuel Fernandez Pardal, Ricardo C. Reisin

P3.3-051 Door to stroke alert timing quality improvement project–Joshua Luster, Dhanalakshmi Thiyagarajan, Daniel Joseph Ackerman

P3.3-052 Resident stroke

simulation improves decisionmaking and door to needle time in Community Hospital.–Niranjan N. Singh, Lauren Polezogopoulos, Vikas Kumar, Yara Nazzal

P3.3-053 Better Systems,

Better Patient Care–Joseph Michael Rios, Latha Ganti

P3.3-054 Evaluation of A Rapid Outpatient Stroke Clinic for TIA and Minor Stroke Patients in the Emergency Department–Rachel Pauline Mehendale, Steven David Shapiro, Bernard S. Chang, Eliza Cushman Miller, Sara Kate Rostanski, Benjamin R. Kummer, Joshua Z. Willey, Mitchell S. V. Elkind

P3.3-055 A Comparison of

the Evaluation and Treatment of Transient Ischemic Attack in a Comprehensive Stroke Center and Four Acute Stroke Ready Hospitals–Jessica Jarnot, Andrew Jiahao Zhang, Apameh Salari, Leah Stinson, Mohammed Hamad Alkuwaiti, Sarah A. Engkjer, Angela Heyer, Amy Reichert, David C. Anderson, Christopher Streib

P3.3-056 Acute Bacterial

Parotitis: A Rare Complication of Orolingual Angioedema Associated with IV Alteplase– Matthew W. Rondeau, Sean Hashemi, Samuel Rubin, Barbara Voetsch

P3.3-057 The Existential

Problem of Thrombolysis Aborted Stroke: A Case Presentation and Systematic Review–Chad Kendall Bush, Daniel Vela-Duarte

P3.3-058 Safety and Efficacy

of Thrombectomy Beyond Traditional Time Window: ‘Real World’ Applicability of DAWN trial.–Hemal Patel, Ashish Kulhari, Briana DeCarvalho, Sanket Meghpara, Avani Bhatnagar, Amrinder Singh, Siddhart Kumar Mehta, Jawad F. Kirmani

P3.3-059 Thrombolysis in

patients with Down Syndrome and Ischemic Stroke–Xiyan Yi, Varun Kumar, Chirag Narshibhai Savani, Tejinder Singh, Weizhe Li, Sukriye Damla Kara, William Scott Burgin, Swetha Renati

P3.3-060 “No Touch” Period

24 hours Post TPA Infusion–Zara Fatima, James M. Gilchrist

P3.3-061 Predictors of

P3.3-062 Prevalence of Multiple Territory Stroke Pattern after Thrombolysis in Patients with or without known Atrial Fibrillation.– Muhammad Azeem, Mehdi Ghasemi, Muhammad Nagy, Malgrozata Miller, Majaz Moonis, Brian Silver, Nils Henninger

Get with the Guidelines (GWTG) target of less than 45 minutes for intravenous thrombolysis improves 90 day outcome– Abdallah Mahmoud Hamdallah, Muhib Khan, Tracy J Koehler, Daniel Sacchetti, Tricia Tubergen, Stephanie Mullennix, Jeff Skinner, Raymond Scureck, Justin Singer, Tamer Abdelhak, Brian Silver

P3.3-064 No Difference in

Door-to-Needle Times by Choice of Antihypertensive Agent Prior to Thrombolysis: A Single Center Experience–Joseph F. Carrera, Brian J. Sorace, Uzoamaka Ugochukwu

P3.3-065 IMITA Score:

distinguishing between ischemic stroke and stroke mimics–Julieta Rosales, Mario Emiliano Ricciardi, Julian Nicolás Acosta, Mauricio Franco Farez, Sebastian F. Ameriso

P3.3-066 Predictors of

TC-Perfusion alterations in Stroke-Mimics attended as stroke-code–Alicia GonzalezMartinez, Santiago Trillo-Senin, Carmen Benavides-Bernaldo de Quiros, Laura Casado Fernandez, Ines Muro Garcia, Maria de Toledo Heras, Ana Beatriz Gago Veiga, Antonio Barbosa Del Olmo, Rafael Manzanares Soler, Jose A. Vivancos Mora

P3.3-067 Louisiana’s Stroke

System of Care – Progress in Recanalization Therapy–Sheryl Martin-Schild, Digvijaya D. Navalkele, Ramy El Khoury, Oleg Y. Chernyshev, Ted Colligan, Yvette Legendre, Deborah Spann, Paige Hargrove

P3.3-068 Louisiana’s Level

III Stroke Center Performance Improvement Progress–Sheryl Martin-Schild, Digvijaya D. Navalkele, Ramy El Khoury, Oleg Y. Chernyshev, Ted Colligan, Yvette Legendre, Deborah Spann, Paige Hargrove

P3.3-071 The Emerging Role of

Recombinant Tissue Plasminogen Activator in Improving Neuroplasticity in Patients With Acute Ischemic Stroke–Rasha Soliman, Hend Mamdoh, Mona Hussein, Laila Rashed

ACQUIRED DISEASES OF MUSCLE

P3.4-001 Application of

electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study–Bhaskar Roy, Seward B. Rutkove, Richard J. Nowak

P3.4-002 Serologic and

Pathologic Correlation in Idiopathic Inflammatory Myopathies: A Retrospective Chart Review–Gloria OrtizGuerrero, Mazen M. Dimachkie, Mamatha Pasnoor, Richard J. Barohn, Omar Jawdat, Constantine Farmakidis, Jeffrey Statland, Melanie Glenn, Duaa Jabari

P3.4-003 Willingness to

Participate in Natural History Studies amongst Patients with Sporadic Inclusion Body Myositis (sIBM): A Comparison Between the United States and Australia– Veena Mathew, Ali Habib, Namita Goyal, Robert Goldberg, Merrilee Needham, Tahseen Mozaffar

P3.4-004 A Case of

Pembrolizumab-Induced Autoimmune Necrotizing Myopathy–Nita Chen, Sarita Said-Said, Mari Perez-Rosendahl, Tahseen Mozaffar

P3.4-005 Prevalence and

Characterization of Pain as a Symptom Amongst Sporadic Inclusion Body Myositis (sIBM) Patients–Sarita Said-Said, Veena Mathew, Shalini Shah, Namita Goyal, Manisha Kak, Ali Habib, Tahseen Mozaffar

P3.4-006 Necrotizing

Version Of NIHSS Scale–Apratim Chatterjee, Biman Kanti Ray

Autoimmune Myopathy Associated with Tubular Aggregates–Nicolas N. Madigan, Teerin Liewluck, Margherita Milone, Elie Naddaf

P3.3-070 Not Making a List:

P3.4-007 HIV-associated

P3.3-069 Validation Of Bengali

The Agraphic Santa Claus and the Limitations of NIHSS–Micah Etter, Preeth Manu, Mohammad Hassan El-Ghanem

Myositis and Response to Immune Therapy–Niyatee Samudra, Jordan Scott Loeb, Shaida Khan

P3.4-008 Pembrolizumab

Induced Myositis–Hisham Gibriel Bakhiet Elkhider, Hillary Ann Williams, Faisal Abdelaziz Ibrahim, Rohit Dhall

P3.4-009 Genetic Testing -

Muddying the Water for Diagnosis of Inflammatory Myopathies– Marc Jeffrey Van De Rijn, Karra Jones, Erik K. Henricson, Nanette Joyce

P3.4-010 A Mixed Picture:

Dermatomyositis with features of Necrotizing Myopathy–Aqsa Ullah, Michelle Serpa Nunes, Abdul R. Mamsa, Enrique A. Serrano

P3.4-011 A Cross-Sectional

Study of Inclusion Body Myositis: Novel Exam Findings for Early Screening and Detection, Correlation with Items in the Current Functional Rating Scale–Ava Yun Lin, Maggie Clapp, Elizabeth Karanja, Kevin Dooley, Benjamin J. Koo, Conrad Weihl, Leo Hong-Li Wang

P3.4-012 A Case Series of

Immune Checkpoint InhibitorAssociated Peripheral Nervous System Complications–Alexandra Muccilli, Maulik Shah, Elan Guterman

P3.4-013 Ocular symptoms

after immune checkpoint inhibitors.–Neel Fotedar, Hemani Ticku, Vishakhadatta Mathur Kumaraswamy, Daniel W. Miller, Mark Cohen, Michael L. Morgan, Komal Sawlani

P3.4-014 Dermatomyositis after Intralesional Immunotherapy for Warts–Daniel Anderson, Andrea Jean Swenson, Steven A. Moore, Ludwig Gutmann

P3.4-015 The Checkpoint

Inhibitor Imperative: Differentiating neuromuscular complications–Devin Elizabeth Prior, Henry F. Martin-Yeboah, Nathaniel Michael Robbins, Victoria Lawson

P3.4-016 Familial Inclusion

Body Myositis with Negative Anti-cytosolic 5’-nucleotidase 1A (cN1A) Antibody Test.–Shaweta Khosa, Samra Vazirian, Shrikant Mishra, Negar Khanlou, Emil Heinze, Sandeep Singh, Natasha Zohuri, Robert Freundlich

AAN.com/view/AM19Sci 167

Tuesday

Symptomatic Intracerebral Hemorrhage After rtPA–Taha Nisar, Rajanigandhi Hanumanthu, Shuja Sheikh, Sara Shapouran, Priyank Khandelwal

P3.3-063 Treatment within the

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.4-017 Amyloid Myopathy as

an initial manifestation of Primary AL associated amyloidosis: A Case Report and review of literature.–Kunal Bhatia, Pradeep Chakravarthy Bollu, Premkumar Nattanmai Chandrasekaran, Douglas Miller ACQUIRED NEUROPATHIES II

P3.4-018 A Randomized

Lifestyle Intervention Study Improves Mobility and Neuropathy in Diabetes–Lindsay A. Zilliox, Neda Ilieva, Min Zhan, James W. Russell

P3.4-019 Driving Ability

Correlated with Severity of Polyneuropathy–Jaime R. Lopez, Alastair Cho, Viet Nguyen, Leslie H. Lee, Scheherazade Le, Sungho K. Cho

P3.4-020 Determinants of

HIV-Associated Neuropathic Pain Using a Novel Instrument– Alagoma Murtala Iyagba, Mayowa Owolabi, Adesola Ogunniyi

P3.4-021 Elevated Creatine

Kinase in Patients with Peripheral Neuropathy–Allison Macke, Arun Krishna Nagaraj, Chad Hoyle, William D. Arnold, Bakri Elsheikh

P3.4-022 Unexpected Diagnosis of Acute Hemiparesis–Rhaisa Castrodad- Molina, Karina Rodriguez-Juan

P3.4-023 Complex C1-2

Osteophyte Presenting with Severe Dysphagia and Ptosis– Ushtar Amin, Sheyar Amin, Yazan M. Suradi, Puya Alikhani

P3.4-024 Case series on Nitrous

Tuesday

Oxide Toxicity–Haoming Pang, Bhavesh Trikamji, Luis A. Chui, Margaret Adler

P3.4-025 Severe Central and

Peripheral Nervous System Toxicity Associated with Vinblastine in the Treatment of Hodgkins Lymphoma–Jeffrey Barrett Joseph Schachter, Mejgan Mukhtarzada, XinLi Du

168 2019 AAN Annual Meeting

P3.4-026 Cyclic Sciatica:

Presentation of a Case With Intra and Extrapelvic Endometriosis Affecting the Sciatic Nerve and Utility of MR Neurography– Marcela Uribe Roca, Lucrecia Bandeo, Miguel A. Saucedo, Marta Bala, Daniela Binaghi, Anibal Chertcoff, Daniela Binaghi, Marta Bala, Cintia Marchesoni, Luciana Vanesa Leon Cejas, Maria Sol Pacha, Pablo Bonardo, Manuel Fernandez Pardal, Ricardo C. Reisin

P3.4-027 Hyperbaric

Oxygen Therapy: A Treatment for Radiation Induced Plexopathy–Geeta Verma, Carolyn Goldschmidt, Susan Vaughan

P3.4-028 Bilateral

Diaphragmatic Paralysis As A Complication Of Chiropractic Cervical Manipulation–James Noto, William Kurtis Jens, Zachary Simmons

P3.4-029 A Retrospective Chart

Review of 49 Patients referred for Skin Punch Biopsy for Small Fiber Neuropathy Symptoms–Samar Bajwa, Leila Darki, Said R. Beydoun

P3.4-030 A 69-year-old woman

with diplopia and lower extremity weakness: A case of Bing-Neel Syndrome–Ibrahim Migdady, Maryann Mays, Kerry H. Levin

P3.4-031 Evaluating IVIG

Dosing Strategies in Neurologic Indications & Outcomes–Thy Nguyen, Doha Ayish, Hammad A. Bokhari

P3.4-032 A retrospective chart review to assess the efficacy and tolerability of switching from an alternative brand of IVIG to Panzyga® in patients with autoimmune neuromuscular disorders–Natasha Campbell, Sylvia DeMelo, Rami Massie GENETIC NEUROPATHIES

P3.4-033 Familial Amyloid

Polyneuropathy: Impact of Biopsies and Mutations on Diagnostic Considerations– Christopher H. Gibbons, Alejandra Gonzalez-Duarte, Alejandra Gonzalez-Duarte, Fabio Adrian Barroso, Marta Campagnolo, Sharika Rajan, Roy L. Freeman

Tuesday, May 7 11:30 a.m.–6:30 p.m. P3.4-034 Autosomal Recessive Charcot-Marie-Tooth Disease in Turkey–Arman Cakar, Ayse Candayan, Halil Ibrahim Akcay, Gulshan Yunisova, Cagri Ulukan, Hacer Durmus, Esra Battaloglu, Fatma Yesim Parman

P3.4-035 Hereditary Sensory

Autonomic Neuropathy Type-1C (HSAN1c) by a Novel Mutation of Asn177Asp in SPTELCS2 Gene–Taylor R. Anderson, Karen Krajewski, Jun Li

P3.4-036 A Triad of CMT1A

P3.4-044 Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: Two Siblings with A Novel Mutation in The DARS2 Gene.–Anudeep yelam, Elanagan Nagarajan, Miguel Chuquilin Arista, Raghav Govindarajan

P3.4-045 GDAP1-Related

Charcot-Marie-Tooth Disease: Additional Evidence for the c.692C>T Variant as a Pathogenic Mutation–Carolina Vivar, David Avila

Hereditary Neuropathy, Antineurofascin-155 IgG Antibodies and Relapsing Remitting Multiple Sclerosis–Elena I. Grebenciucova, Jinny O. Tavee

P3.4-046 A Case of Recurrent

P3.4-037 A Giant Axonal

EPILEPSY: ANTISEIZURE MEDICATIONS II

Neuropathy (GAN)-like syndrome due to a mutation in Microtubule Associated Protein 1B (MAP1B): a new syndrome.–Edward J. Cupler, Faisal Rifai, Youssef Al Said

P3.4-038 A Novel Myelin

Protein Zero variant in CharcotMarie-Tooth Disease Type 2I–Hani Kushlaf

P3.4-039 Variant of Uncertain Significance in Charcot Marie Tooth Disease: GDAP1 Protein Modeling and Phenotype Correlation–Laura Cline, Jacob Andring, Robert McKenna, S H. Subramony

P3.4-040 Early Onset Ataxia in a Patient with CMT2A2–Ricardo E. Madrid

P3.4-041 Prospective 16-year

Longitudinal Study of Dominant Intermediate CMT Type C Neuropathy–Yi Pan, Jafar Kafaie, Florian P. Thomas

P3.4-042 The Yield of

Targeted Gene Panels in Axonal Neuropathies–Diana Lee, Lois Dankwa, Steven Scherer

P3.4-043 Assessing the

immediate effect of ground reaction ankle foot orthoses on balance in individuals with inherited neuropathies–Katherine Burke, Keneth Cornell, Amy Swartz, Natalie Grant, Sabrina Paganoni, Reza Seyed Sadjadi

Fever, Encephalopathy, and Unilateral Weakness–Marwah Elsehety, Suur Biliciler, Nassim Naderi, Hope Northrup

P3.5-001 Safety and Efficacy

of Adjunctive Perampanel in Pediatric Patients (Aged 4 to ?12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study–J R Flamini, Andras Fogarasi, Matieu T. Milh, Steven M. Phillips, Shinsaku Yoshitomi, Leock Y. Ngo, Anna Patten, Takao Takase, Antonio Laurenza

P3.5-002 Risk of Hospitalization in Patients With Uncontrolled Epilepsy Treated with a Long Versus Short Half-Life Adjunctive Antiepileptic Medication–Joyce A. Cramer, Jessie Yan, Ryan Tieu, Russell Knoth, Contessa Fincher, Manoj Malhotra, Jiyoon Choi

P3.5-003 Cross-sensitivity of

behavioral adverse effects of perampanel and levetiracetam.– Hatem Tolba, Lawrence J. Hirsch, Kamil Detyniecki, Jennifer Bonito, Hamada Hamid Altalib

P3.5-004 Characteristics of

Interventional Epilepsy Clinical Trials During the Last Decade– Vahid Eslami, Lola C. Morgan, Sahra Emamzadehfard, Aizaz R. Hundal, Iffat Ara Suchita, Charles Akos Szabo

P3.5-005 Perampanel Use

in Established, Refractory, and Super-Refractory Status Epilepticus (SE): a Summary of Cases from Austria, Finland, Germany, and Spain–Adam Strzelczyk, Susanne Knake, Reetta Kälviäinen, Estevo Santamarina, Manuel Toledo, Sophia Willig, Alexandra Rohracher, Eugen Trinka, Felix Rosenow

P3.5-006 Expert Opinion: A New Treatment Algorithm for LennoxGastaut Syndrome (LGS) in Adult Patients–Sanjeev V. Kothare, Sami M. Aboumatar, David E. Burdette, Ruben I. Kuzniecky, Georgia D. Montouris, William E. Rosenfeld, Steve S. Chung

P3.5-007 Effect of Concomitant

Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Safety and Efficacy of Adjunctive Perampanel in Patients Aged 4 to ?12 years with Partial-Onset Seizures (POS): Final Results from the 311 Core Study–Matieu T. Milh, J R Flamini, Andras Fogarasi, Steven M. Phillips, Shinsaku Yoshitomi, Anna Patten, Takao Takase, Leock Y. Ngo

P3.5-008 Pharmaceutical

Evaluation And Therapeutic Drug Monitoring Of Levetiracetam In Patients With Epilepsy–Maria Patricia Hernandez Mitre, Ildefonso Rodriguez-Leyva, Herlinda Castillo Ibarra, Susanna E. Medellin Garibay, Silvia Romano Moreno, Sergio Zarazua Guzman, Helgi Helene Jung Cook, Rosa del Carmen Milan Segovia

P3.5-009 Pharmacokinetic

P3.5-010 Analysis of

Hematological and Serum Chemistry Abnormalities in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures–Prakash Kotagal, Tobias Loddenkemper, Todd Grinnell, David Cantu, Yan Li, Raquel Costa, Joana Moreira, David E. Blum

Analyses of Extended-Release Oxcarbazepine (Oxtellar XR®) as Once-Daily Monotherapy in Adults and Children with PartialOnset Seizures–Shannon Wayne Mendes, Welton O’Neal, Ronald N. Marcus, Azmi Nasser

P3.5-012 Dexamethasone is

effective in treatment of infantile spasms (IS)–Genevieve C. Gabriel, Kapil Arya, Gregory B. Sharp, Debopam Samanta, Virginia Erin Willis, Sarah Cobb, Christopher P. Manbeck, Adrianne Phillips, Julish Selvy, Todd Outlaw, Meg Cash, Kara Christensen, Rachelle Stanley, Jacqueline Edens

P3.5-013 Relationship Between Adverse Event Incidence and Eslicarbazepine Acetate (ESL) Dose Across Weight Groups in Clinical Trials of Adjunctive ESL in Children (Aged 4–17 Years) with Focal Seizures–Jesus Eric PinaGarza, Steven M. Wolf, Patricia E. McGoldrick, Todd Grinnell, David Cantu, Yan Li, Mariana Vieira, Fabio Ikedo, David E. Blum

P3.5-014 First Canadian

experience of brivaracetam in a highly difficult to treat epilepsy population: a two-center clinical study–Jeanne Lafortune, Charles Deacon, Jean-Francois Clement, Joanna Wai Ling Ma

P3.5-015 Medical Marijuana

and Its Use in TreatmentRefractory Seizures: The Pittsburgh Experience–Bahareh Sianati, Carol Schramke, James P. Valeriano

P3.5-016 Eslicarbazepine

Acetate in Post-Stroke Epilepsy: A post-hoc Analysis from the Clinical Practice Study EuroEsli–Francisco Sales, João Chaves, Vicente Villanueva, Rob McMurray, Rui Loureiro, Hélder Fernandes

P3.5-017 Phase II, Open-Label

Pharmacokinetic (PK) Study of Perampanel Oral Suspension as Adjunctive Therapy in Pediatric Patients (Aged =1 to <24 months) with Epilepsy: Study 238 Design and Preliminary Safety Data–J Ben Renfroe, Guntis Rozentals, Jagadeesh Aluri, Yuko Umetsu, Yimin Ma, Antonio Laurenza, Leock Y. Ngo

P3.5-018 Inpatient

P3.5-026 Determining Utility of

P3.5-019 Study 410 Enrollment

P3.5-027 Elevated Healthcare

Hospitalization Rates in Patients Diagnosed with Epilepsy and Treated with Perampanel or Lacosamide–R Edward Faught, Xuan Li, Jiyoon Choi, Manoj Malhotra, Russell Knoth Update: Multicenter, Open-Label, Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients with PartialOnset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS)–Pavel Klein, Betsy N. Williams, Antonio Laurenza, Anna Patten, Manoj Malhotra

P3.5-020 Efficacy and

Tolerability of Perampanel as Adjunctive Therapy in Refractory Epilepsy–Donald Campbell Barr, Francisco Pascual Gomez, Richard Castillo, Batool Kirmani

P3.5-021 Tolerability and

Effectiveness of Adjunctive Lacosamide in Patients with Cerebrovascular Epilepsy Etiology: Exploratory Post-hoc Analysis of A Non-interventional Trial–Christian Brandt, Ali Bozorg, Svetlana Dimova, Ying Zhang, Bjorn Steiniger Brach, Bruno Ferro

P3.5-022 Inpatient

Hospitalization Risk In Patients With Epilepsy Before And After Perampanel Treatment–R Edward Faught, Xuan Li, Jiyoon Choi, Manoj Malhotra, Russell Knoth EPILEPSY: DIAGNOSIS AND CLINICAL CARE II

P3.5-023 Consequences of

diagnostic delay in patients with new onset focal epilepsy characterized by subtle seizures– Jacob Pellinen, Erica Tafuro, Jacqueline French

P3.5-024 Assessing Factors

Influencing Seizure Self-Prediction in a Prospective Randomized Trial–Jonathan Andrew Hartshorn, Sheryl R. Haut, Timothy J. Fries, Michael D. Privitera

Additional Days in the Epilepsy Monitoring Unit (EMU) for Patients without Events in First 5 Days of Admission–Neena Cherayil, Pouya Khankhanian, Michael Gelfand

Burden Among Patients with Active Generalized Tonic-Clonic (GTC) Convulsions–Shehryar Sheikh, Nicholas Thompson, Jiyoon Choi, Manoj Malhotra, Lara Jehi

P3.5-028 A new definition

of seizure clusters based on temporal clustering patterns in seizure diaries–Sharon Chiang, Sheryl R. Haut, Victor Ferastraoaru, Vikram Rao, Maxime Baud, William H. Theodore, Robert Moss, Daniel Goldenholz

P3.5-029 Quality of Epilepsy

Care in Medicaid-only Neurology Resident Clinic–Genna Waldman, Michelle Bell

P3.5-030 The Clinical Outcome of Non-Diagnostic Epilepsy Monitoring Unit (EMU) Studies– Nessim Amin, Jacquelyne Cios, Preeta Gupta, Marilly Palettas, Juan Peng

P3.5-031 Telemedicine for

epilepsy patients – an emergence of the 21st century clinic–Melissa Reider-Demer, Dawn Eliashiv, John M. Stern, Inna Keselman, Marc R. Nuwer

P3.5-032 Seizure Comorbidity

Increases Odds Of 30-Day Readmission After an Index Hospitalization for Sepsis–Jonah Fox, Alain Zingraff Lekoubou Looti, Kinfe Bishu, Bruce I. Ovbiagele

P3.5-033 The Effect of

Completing a Neurology Clerkship on Diagnostic Accuracy of Paroxysmal Spells–Brian James Hanrahan, Arun Raj Antony, Peter Woodward Jones, Jonathan Berken, Desiree Markantone, Alexandra Urban, Anto Bagic

P3.5-025 Risk factors for

readmission in a nationally representative sample of children with epilepsy–Sudha Kessler, Shavonne Massey, Nicholas Scott Abend, Allison Wright Willis

AAN.com/view/AM19Sci 169

Tuesday

Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients with Epilepsy Under Ictal and Inter-ictal Conditions – Interim Report–Robert E. Hogan, Michael R. Sperling, Pavel Klein, Eric Segal, Enrique J. Carrazana, Gary D. Novack

P3.5-011 Efficacy Extrapolation

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3

THE POWER OF CASE REPORTING IN NEUROONCOLOGY II

P3.6-001 Radiation-Induced

Neuropathy - a Late Effect of Cancer Therapy–Anna Grisold, Wolfgang Grisold

P3.6-002 Sequelae of Cranial

Irradiation: Stroke-like Migraine Attacks After Radiation Therapy (SMART) Syndrome–Diaa Hamouda, Noushin Jazebi, ShiaoPei Weathers

P3.6-003 Atypical Non-

Enhancing Primary Central Nervous System Lymphoma–Erik Valenti, Xiao-Tang Kong

P3.6-004 Primary Diffuse

Leptomeningeal Gliomatosis, a Rare Mimic of Tuberculous Meningitis–Mina Lobbous, Paula Province Warren

P3.6-005 Rare Presentation

Paraneoplastic Myasthenia Gravis as the Initial Presentation in a Patient with Non-Hodgkin’s Lymphoma–Justine E. Cormier, Sara Maguire Schaefer

P3.6-012 Co-occurrence of

Follicular Lymphoma and CNS Intravascular Lymphoma in a patient with HIV/AIDS: A Case report–Ana Luisa de Carvalho Cardozo Hernández, Randall Reidler, Tiffany Statler, Zanetta Lamar, Mercedes Porosnicu, Michael Beatty, Justin W. Beuthin, Roy E. Strowd

P3.6-013 Use of Temozolamide in a Rare Case of Diffuse Leptomeningeal Glioneuronal Tumor–Mayra Montalvo Perero, Sasmit Sarangi, Alexander C. Mohler

P3.6-014 Chemotherapy in

of CLL as Expansile Spinal Cord Lesions: ?A Radiographic Chronicle of Treatment Response– Helen Cheung, Amy Chan

Hemangioblastomatosis: A Case Report with Mutational Profiling and Literature Review–Yuxiang Zhang, Kareem Makkawi, Ahmad Daher

P3.6-006 Latent Radiation-

P3.6-015 Cardiac Arrest due

Induced Cerebral Vasculopathy– Niall O’Mara, Eoghan Patrick Deasy, Mairead Crowley, Bernadette Monaghan, Jessica Stack, Noel Fanning, Daniel Costello

P3.6-007 Multinodular and

Vacuolating Neuronal Tumor - Are We Only Seeing the Tip of the Iceberg?–Hao Huang, Leah Croll, Howard W. Sander, Neil Bansal, Elcin Zan, Arielle Marisa Kurzweil

P3.6-008 WHO grade I

Tuesday

P3.6-011 A Case of

meningioma with simultaneous pulmonary metastasis: a rare presentation–Adeel Chaudhry, Akshita Patel, Jose Bonnin, Mohammed Salhab, Kathryn S. Nevel

P3.6-009 Ischemic Stroke

After CAR-T Cell Therapy–Varun Bipinchandra Shah, Noushin Jazebi, Merry Chen

P3.6-010 A case of Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR): a distinct genetic locus with an excellent outcome–Dipali P. Nemade, Paul Knowles, Mary Payne, Niru Nahar

170 2019 AAN Annual Meeting

to Autonomic Dysfunction in a Patient with Primary Spinal Cord Glioblastoma–Tracey Huijun Fan, Naresh Mullaguri, Christopher R. Newey

P3.6-016 CNS non-

germinomatous germ cell tumor causing obstructive hydrocephalus, Parinaud’s syndrome, and secondary Parkinsonism–Sydni Cole, Sasmit Sarangi, David Einstein, Eric TaiLee Wong

P3.6-017 A 43 year-old woman

with primary central nervous system angiosarcoma with CICLEUTX gene rearrangement–Evan Noch, Benjamin Nacev, Jason Chan, Suzanne Wolden, William Tap, Cristina Antonescu, Yasmin Khakoo

P3.6-018 Optic Neuropathy

Related to Esophageal Carcinoma–Sasmit Sarangi, Marc Albert Bouffard, Eric Tai-Lee Wong

P3.6-019 Glioblastoma with

bilateral extraocular muscle infiltration–Michael Wren Ruff, Sani Kizilbash

Tuesday, May 7 11:30 a.m.–6:30 p.m. P3.6-020 Primary peripheral

P3.6-027 Alteration of resting-

INTERFACE OF SLEEP AND NEUROLOGY

P3.6-028 Stroke In Population

neurolymphomatosis of the brachial plexus: a case report.–Meenakshi Sundaram Salvadeeswaran, Somalinga Nagendra Karthik, Pandi Suresh, Devanand Janardhanan, Bharathi Sundar, Usharani Sabhesan, Anita Mahadevan

P3.6-021 Witnessed Apneas

During Sleep are Associated with Elevated Tau-PET Signal in the Entorhinal Cortex in Cognitively Unimpaired Elderly–Diego Z. Carvalho, Erik Kent St. Louis, Bradley F. Boeve, Christopher Schwarz, Scott Przybelski, David S. Knopman, Val John Lowe, Michelle M. Mielke, Ashritha Reddy, Ronald C. Petersen, Clifford R. Jack, Prashanthi Vemuri

P3.6-022 Clinical

Polysomnography Trial of Suvorexant for Treating Insomnia in Alzheimer’s Disease–William J. Herring, Paulette Ceesay, Ellen Snyder, Donald Biwise, Kerry Budd, Jill Hutzelmann, Joanne Stevens, David Michelson

P3.6-023 Mindfulness Based

Stress Reduction as a treatment for Chronic Insomnia in Traumatic Brain Injury Patients–John Kent Werner

P3.6-024 Pitolisant Treatment

Improves Multiple Clinical Symptoms of Prader-Willi Syndrome (PWS) in Children–Lara Pullen, Maria Picone, Litjen Tan, Charles Johnston, Holger Stark

P3.6-025 Sleep Disorders

and Polysomnographic Findings in Patients with Alternating Hemiplegia of Childhood–Linh Tran, Sujay M. Kansagra, Ryan Ghusayni, Bassil Kherallah, Talha Gunduz, Melissa McLean, Lyndsey Prange, Richard L. Kravitz, Mohamad A. Mikati

P3.6-026 Insomnia in Epilepsy:

Association Between Insomnia Symptom Severity and DiseaseRelated Characteristics–Thapanee Somboon, Maeve Pascoe, Madelyn Eippert, Monica Bruton, Lu Wang, James Bena, Nancy R. Foldvary-Schaefer

state functional connectivity in patients with REM sleep behavior disorder (RBD): a cross-sectional study from the J-PPMI cohort– Noritaka Wakasugi, Hiroki Togo, Youhei Mukai, Noriko Nishikawa, Miho Murata, Yuji Takahashi, Takashi Hanakawa With Sleep Disturbance In Russia/Siberia: Gender Features. WHO Epidemiological Program MONICA-Psychosocial–Dmitriy Panov, Valery Gafarov, Igor Gagulin, Almira Gafarova, Eldar Krymov, Elena Gromova

P3.6-029 Sleep Quality

Correlates with the Carotid intima-media Thickness in Stroke-free community-dwelling adults–Pablo R. Castillo, Oscar H. Del Brutto

P3.6-030 Severity of

Obstructive Sleep Apnea and Burden of Cerebral Microbleeds in Patients with Atrial Fibrillation–George Koshy Vilanilam, Mohammed Badi, Eric Goldstein, Vivek Gupta, Kevin M. Barrett, Thomas G. Brott, James F. Meschia, Brynn K. Dredla

P3.6-031 Upper Airway

Stimulation Therapy Predictors for Treatment of Obstructive Sleep Apnea–Tina Elizabeth Waters

P3.6-032 Impact of Upper

Airway Stimulation Treatment for Obstructive Sleep Apnea on Comorbid Insomnia, Depression and Sleepiness Patient Reported Outcome Measures–Tina Elizabeth Waters, Alan Kominsky, Lu Wang, Harneet Walia, Nancy R. Foldvary-Schaefer, Joan Aylor, Maeve Pascoe, Reena Mehra NARCOLEPSY AND HYPERSOMNOLENCE

P3.6-033 Defining Disrupted

Nighttime Sleep (DNS) in Pediatric Narcolepsy–Kiran Prasad Maski, Erin Steinhart, Elaina Little, Cecilia Diniz Behn, Alicia Colclasure, Thomas E. Scammell

P3.6-034 Efficacy and Safety

of Pitolisant in Patients With Narcolepsy: A Review of Clinical Trials–Yves Dauvilliers, JeanCharles Schwartz, Craig Davis, Jeffrey M. Dayno

P3.6-035 Hormonal

Contraceptive and Pitolisant CYP3A4 Induction–Philippe Robert, Jean-Charles Schwartz

P3.6-036 Burden of Narcolepsy: A Survey of Patients and Physicians–Michael J. Thorpy, Joseph Hopper, Albena Ilieva Patroneva

P3.6-037 Misdiagnoses and

Comorbidities among Participants in the Nexus Narcolepsy Registry–Maurice Ohayon, Michael J. Thorpy, Jed Black, Michael J. Williams, David Pasta, Danielle Hyman, Kathleen Villa

P3.6-038 Healthcare Cost

and Utilization Before and After Diagnosis in Pediatric Patients With Newly Diagnosed Narcolepsy: A Claims-based Analysis–Sheila Reiss Reddy, Michael Broder, Ryan Tieu, Ginger Carls, Kathleen F. Villa, Judi Profant, Ann Halbower

P3.6-039 A Longitudinal Study of Hypersomnolence in the US General Population and its Chronicity–Maurice Ohayon

P3.6-040 The Cumulative

Effect of Partial Chronic Sleep Restriction on Objective Daytime Sleepiness in Neurologically Healthy Individuals–John Feemster BA, Paul Timm, David James Sandness, Ashley Enke, Stuart McCarter, Luke Teigen, Thomas Gossard, Naima Covassin, Virend Somers, Erik Kent St. Louis

P3.6-041 A D1 receptor positive allosteric modulator (LY3154207) enhances wakefulness in sleep deprived healthy volunteers– Kevin M. Biglan, Paul Ardayfio, William Kielbasa, Kjell Svensson

available wearable provides valid estimate of sleep stages–Suzanne Stevens, Catherine Siengsukon AUTONOMIC DISORDERS: ORTHOSTATIC HYPOTENSION AND SYNUCLEINOPATHIES

P3.6-043 Differentiation

of Autonomic Dysfunction in Multiple System Atrophy Sub types and Idiopathic Parkinson’s Disease–Divyani Garg, Achal K. Srivastava, Ashok Jaryal, Ravindra Pandey, Raj Rajagovindan, Awadh K. Pandit, Deepti Vibha, Garima Shukla, Kameshwar Prasad

Spectrum of Cardiovascular Autonomic Dysfunction and 24hour Blood Pressure Variability in Early Idiopathic Parkinson’s Disease–Ivy Sebastian, Kate Mahesh, Himani Khatter, Bharat Singh, Jeyaraj Durai Pandian

P3.6-045 Diagnosis and

Treatment of Neurogenic Orthostatic Hypotension: Online, Case-based Education Successfully Improved Knowledge and Competence of Cardiologists and Neurologists–John Maeglin, Thomas Finnegan, Cate Murray, Satish R Raj

P3.6-046 The Relationship

Between Changes in Orthostatic Blood Pressure and Symptoms in Patients with Orthostatic Hypotension–Roy L. Freeman, Christopher H. Gibbons, Razvan Lapusca, Ben M. Illigens, Marta Campagnolo, Ahmad R. Abuzinadah, Dong in Sinn

P3.6-047 Droxidopa and

Midodrine Treatment Persistence in Patients With Orthostatic Hypotension–Lawrence Hewitt, Steven Kymes, Kenneth Jackson, Michelle Widolff, Christine Sullivan, Satish R Raj

P3.6-048 Effects of Droxidopa

Treatment for Neurogenic Orthostatic Hypotension in Patients Concomitantly on Dopa Decarboxylase Inhibitors–Steven Kymes, Clement Francois, Christine Sullivan, Kim McLeod, Amy M. Duhig, Augustina Ogbonnaya, Apryl Quillen, Joan Cannon, Italo Biaggioni, Cyndya Shibao, Binglin Yue, Robert A. Hauser

P3.6-049 Postprandial

Hypotension in Parkinson’s Disease and Multiple System Atrophy–Amanda C. Peltier, Jordan Kimmet, Emily Garland, Bonnie Black, Andre Diedrich, Cyndya Shibao, Italo Biaggioni

P3.6-050 MRI Morphometry in

Early Multiple System Atrophy: Correlations with Indices of Disease Burden & Tracking Progression–Prashanthi Vemuri, Anna Castillo, Kaely Thostenson, Chadwick Ward, Ashritha Reddy, Tonette Gehrking, Jade Gehrking, Anita Zeller, Clifford R. Jack, Phillip A. Low, Wolfgang Singer

AUTONOMIC DYSFUNCTION: POTS AND PERIPHERAL NERVE

P3.6-051 Insurance Denial

for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility–Ryan Matthew Edelbrock, Greg Owendoff, Chen Yan, Robert Wilson DO

P3.6-052 Thermoregulatory

Sweat Testing in Sensory Neuronopathies–Jacqui-Lyn Saw, Anthony J. Windebank, Sarah E. Berini

P3.6-053 Postural Tachycardia

Syndrome might be a Cause of Cerebrospinal Fluid Hypovolemia– Nobuo Araki, Takashi Mitsufuji, Hitoshi Kawasaki, Kei Ikeda, Naotoshi Tamaura, Toshimasa Yamamoto

P3.6-054 Autonomic

manifestations after initiating TTR stabilizer in ATTR amyloidosis.– Maria Alejandra Gonzalez Duarte, Karla Cardenas-Soto, Claudia Mendoza-Tejeda, Karla García-García, Maria del Carmen Rivera-Garcia, Brenda Yazmin Rubio-Navarro

P3.6-055 Multi-sensory

gain abnormalities in postural tachycardia syndrome exceed those of migraine–Leah Millsap, K.C. Brennan, Melissa M. Cortez

P3.6-056 Sweat Gland Nerve

Fiber Density: Development of a Novel, Unbiased 3D Reconstruction Methodology– Karla Minota, Ann M. Schmeichel, James Schmelzer, Jayawant Narayan Mandrekar, Phillip A. Low, Wolfgang Singer

P3.6-057 Correlating Pathologic and Physiologic Measures in Ross Syndrome–Adam Loavenbruck, Rishi Sharma, William R. Kennedy AUTONOMIC MANIFESTATIONS OF DISEASE

P3.6-058 Fingolimod does

not seem to alter autonomic modulation of bladder in patients with relapsing-remitting multiple sclerosis–Max Josef Hilz, Klemens Winder, Ralf Linker, De-Hyung Lee, Ruihao Wang

P3.6-059 Autonomic

Dysfunction in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Plasma Cellproliferative Disorder, Skin Changes (POEMS) Syndrome– Kamal Shouman, Michelle L. Mauermann

P3.6-060 German Validation

of the Composite Autonomic Symptom Score 31–Ruihao Wang, Francesca Canavese, Tassanai Intravooth, Wolfgang Singer, Max Josef Hilz

P3.6-061 Frequency of

Seizures and Epilepsy in Familial Dysautonomia–Bhumika Balgobin, Jose-Alberto Palma, Miguel Perez, Horacio C. Kaufmann

P3.6-062 Neurogenic bladder

dysfunction in patients with familial dysautonomia: a cross-sectional study–Bhumika Balgobin, Erin Barnes, Benoit Peyronnet, Jose-Alberto Palma, Christy Spalink, Benjamin Brucker, Horacio C. Kaufmann

P3.6-063 Autonomic Related

Gastrointestinal Manifestations of Alternating Hemiplegia of Childhood–Milton Pratt, Lyndsey Prange, Melissa McLean, Mohamad A. Mikati

P3.6-064 Autonomic

manifestations before and after renal denervation.–Maria Alejandra Gonzalez Duarte, Brenda Poled JImenez-Lopez, Moises Alejandro Soto-Limon, Karla Cardenas-Soto, Claudia MendozaTejeda, Patricia Marin, Alejandro Ricalde CHILD NEUROLOGY: NEUROMUSCULAR DISEASE: BIRTH TO ADULTHOOD I

P3.6-065 Evidence of

Decreased Epidermal Neurite Density in Juvenile Fibromyalgia Patients–Alexis Boneparth, Shan Chen, Daniel Horton, L. Nandini Moorthy, Heather Downs, Hang Lee, Anne Louise Oaklander

P3.6-066 Characterization of

Genetic Neuropathy in Childhood: Single Center Experience.–Rachel Logan, Rebecca Luke, Elise McClanahan, Sumit Verma

P3.6-067 Utility of

Electromyography in Neonatal Hypotonia: A Tertiary Center 10year Experience.–Daniel Guillen, Matthew Ginsberg, Anthony Hanna, Hoda Abdel-Hamid

AAN.com/view/AM19Sci 171

Tuesday

P3.6-042 Commercially-

P3.6-044 Withering Hearts:

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.6-068 White matter lesions

detected by MRI in neonates and children with Congenital Myotonic Dystrophy–Lindsay Peglar, Usha Nagaraj, Cuixia Tian, Charulata Venkatesan

P3.6-069 Age of Onset,

Functional Status, and Quality of Life Outcomes in Patients with Congenital and ChildhoodOnset Myotonic Dystrophy Type 1–Alyssa Kelder, Paul Horn, Jean Bange, Irina Rybalsky, Cuixia Tian

P3.6-070 Hypotonic Neonate

Diagnosed with Congenital Myasthenic Syndrome with Novel Pathogenic Variants in the CHAT Gene–Neal Sankhla, Salman Rashid, Amitha Ananth, Michael Alonzo Lopez NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG) EPOSTER SESSION

P3.7-001 Unusual Quivering Muscle–Zabeend Kaizar Mahuwala, Laura Okonokhua

P3.7-002 Nerve Action Potential Analysis Versus Biopsies in Small Fiber Polyneuropathy–Matthew J. Parry, Alan R. Larsen

P3.7-003 A pilot trial of

alternate day deflazacort in Becker muscular dystrophy– Roberta Marozzo, Valentina Pegoraro, Corrado Angelini

P3.7-004 Cognitive

Abnormalities In DM1: A Five Years Longitudinal Study–Corrado Angelini, Elena Pinzan, Francesca Bevilacqua, Gabriele Siciliano, Paola Cudia

Tuesday

P3.7-005 Non-coding

repeats in the ATXN8OS gene are expanded in Japanese patients with amyotrophic lateral sclerosis–Makito Hirano, Makoto Samukawa, Chiharu Isono, Kazumasa Saigoh, Yusaku Nakamura, Susumu Kusunoki

P3.7-006 Electrodiagnostic

elucidation of a novel variant in the acetylcholine receptor gene identified by rapid trio exome sequencing, leading to the diagnosis and treatment of congenital myasthenia syndrome in an infant presenting with fetal akinesia deformation sequence.– Anisha Chandra Schwarz, Amanda Freed, Brianna Brei, Sarah Clowes Candadai, Shilpi Chabra, Leo Hong-Li Wang, James P. Bennett

P3.7-007 Reinnervation in

Face Transplantation: The Role of Electromyography–Hunaid Hasan, Elie Ramly, Rami Kantar, Etoile Leblanc, Eduardo Rodriguez, FarngYang Foo

P3.7-008 Concentric Needle

Voluntary Jitter Assessment in Patients with Mitochondrial Myopathy.–Vitor Marques Caldas, Eduardo Estephan, Andre Macedo Serafim Da Silva, Rodrigo de Holanda Mendonça, Mary Souza de Carvalho, Carlos Otto Heise, Edmar Zanotelli

P3.7-009 EMG, MEP, and

SSEP in the Intraoperative Neurophysiologic Monitoring of Lumbar Surgeries–Viet Nguyen, Noah Atikilt, S. Charles Cho, Leslie H. Lee, Scheherazade Le, Jaime R. Lopez

P3.7-010 Patient Reported

Quality of Life Measures in Limb-Girdle Muscular Dystrophy: Correlation with Clinical Outcomes–Tina Duong, Heather Gordish-Dressman, Carolina Tesi Rocha, Robert T. Leshner, Susan Sparks

P3.8-003 Incidence and trends

of Progressive Supranuclear Palsy and Corticobasal Syndrome in Olmsted County: a population based study (1995-2005).–Cole Stang, Pierpaolo Turcano, Alexandra Wennberg, Keith A. Josephs, James H. Bower, J. Eric Ahlskog, Bradley F. Boeve, David S. Knopman, Rodolfo Savica

P3.8-004 Impact of Supine

Hypertension in Target Organ Damage and Mortality in Patients with Neurodegenerative Synucleinopathies–Jose-Alberto Palma, Angelo Porciuncula, Gabriel Redel-Traub, Daniela Samanieg-Toro, Yvonne W. Lui, Lucy Norcliffe-Kaufmann, Horacio C. Kaufmann

P3.8-005 Prevalence estimates

and clinical characterization for tremor and dystonia in Progressive Supranuclear Palsy–Aparna Wagle-Shukla, Anand Rajan, Zakia Jabarkheel, Nikolaus McFarland

P3.8-006 Video research

visits for atypical parkinsonian syndromes among Fox Trial Finder participants–Christopher Tarolli, Grace A. Zimmerman, Steven Goldenthal, Blake Feldman, Sarah Berk, Bernadette Siddiqi, Catherine Kopil, Sohini Chowdhury, Kevin M. Biglan, E. Ray Dorsey, Jamie Lynn Adams

P3.8-007 The Diagnostic

ATYPICAL PARKINSONISM

Journey of Patients with Progressive Supranuclear Palsy (PSP) in US Electronic Health Record Data–Emma Viscidi, Nasha Wang, Susan A. Eaton, Susan A. Hall, Joseph Kupferman, Yuval Zabar, Angela Paradis, Tien Dam

P3.8-001 Repetitive transcranial

P3.8-008 Symptoms of

magnetic stimulation with H coil in Progressive Supranuclear Palsy: a double-blind, placebo-controlled, crossover study–Mario Fichera, Maria Volonté, Giancarlo Comi, Letizia M. Leocani

P3.8-002 Evaluation and

Management of Sleep-related Disorders in a Multidisciplinary Multiple System Atrophy Clinic–Michelle Devine, Won Yong Lee, Pravin Khemani, Gregory S. Carter

172 2019 AAN Annual Meeting

Tuesday, May 7 11:30 a.m.–6:30 p.m.

Levodopa Intolerance During Acute Levodopa Challenge Test: Predictor of MSA in Early Years of Parkinsonism–Mrinal Kumar Acharya, Gautam Gangully, Atanu Biswas, Shyamal Das

P3.8-009 A Clinical Staging

System and Convenient Prognostic Tool for Progressive Supranuclear Palsy–Lawrence I. Golbe, Emily Beisser, Francesca Elghoul, Pamela Ohman-Strickland

P3.8-010 Wide distribution

of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation–Hiroaki Sekiya, Hisatomo Kowa, Hinako Koga, Mariko Takata, Wataru Satake, Naonobu Futamura, Itaru Funakawa, Kenji Jinnai, Motonori Takahashi, Takeshi Kondo, Yasuhiro Ueno, Motoi Kanagawa, Kazuhiro Kobayashi, Tatsushi Toda

P3.8-011 Levodopa-

induced dyskinesia in Atypical Parkinsonism: A population-based cohort study–Pierpaolo Turcano, Cole Stang, James H. Bower, Alexandra Wennberg, J. Eric Ahlskog, Michelle M. Mielke, Rodolfo Savica

P3.8-012 Distinct clinical

features of predominant presynaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy–Sun J. Chung, Ho-Sung Ryu, Jungsu S Oh, Kye Won Park, Chaewon Lee, Sooyeoun You, Mi-Jung Kim, Young Jin Kim, Juyeon Kim, Kiju Kim, Jae Seung Kim

P3.8-013 Unique findings of

susceptibility-weighted magnetic resonance (MR) imaging in multiple system atrophy (MSA): The differentiation of MSA from Parkinson’s disease (PD)–Aki Arai

P3.8-014 Bradykinesia,

Mitochondrial Myopathy and Progressive Ophthalmoplegia Associated with a Novel DNM1L Mutation–Mered Parnes, Hassaan H. Bashir, Joseph Jankovic

P3.8-015 Expression change

of plasma microRNAs in multiple system atrophy and Parkinson’s disease.–Hisashi Uwatoko, Yuka Hama, Shinichi Shirai, Ikuko Takahashi, Masaaki Matsushima, Hideki Houzen, Kazufumi Tsuzaka, Ichiro Yabe, Hidenao Sasaki

P3.8-016 Pseudobulbar Affect in Parkinsonian Syndromes–Mazen Elkurd, Cameron Mohammadi, Yasar Alejandro Torres-Yaghi, Laxman Bhaqwan Bahroo, Elizabeth E. Mundel, Nadia Yusuf, Fernando L. Pagan

P3.8-017 Impact of REM Sleep Behavior Disorder on Orthostatic Hypotension in Multiple System Atrophy–Yuji Saitoh, Masayuki Miyazaki, Miho Murata, Yuji Takahashi

P3.8-018 RT001 to treat

neurodegeneration—Case Study: Improvement in a single patient with Late Onset Tay-Sachs Disease (LOTS)–Peter Milner, Robert James Molinari, Harry Saal, Mikhail S. Shchepinov

P3.8-019 A Futility Trial of

Sirolimus in Multiple System Atrophy: Protocol, Recruitment and Preliminary Adverse Event Profile–Jose-Alberto Palma, Jose Martinez, Erin Barnes, Sharon Sanz Simon, Lucy NorcliffeKaufmann, Horacio C. Kaufmann

P3.8-020 An Unusual Case of

Parkinsonism in a Young Woman, What Can It Be?–Sonia M. Caraballo-Cartagena, Carmen Serrano

P3.8-021 Role of uric acid and

Apo A1 as biomarkers in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in North Indian population–Tanish Modi, Ritu Shree, Jasbinder Kaur, Missamma Mulagala, Manoj Goyal, Sahil Mehta

P3.8-022 Autistic Parkinsonism: NBIA with Mosaic WDR45 Mutation and DaTscan positive dopa-Responsiveness–Lin Zhang, Norika Malhado-Chang, Suma Shankar, Randi Hagerman

P3.8-023 Secondary

Parkinsonism due to Large Anterior Cranial Fossa Meningioma–Nikita Khetarpal, Wissam Al-Janabi, Anza Memon

P3.8-024 Analysis of a Large

P3.8-025 Is the Latency from

Progressive Supranuclear Palsy Onset to Diagnosis Improving?– Mansoureh Mamarabadi, Hadie Razjouyan, Lawrence I. Golbe

P3.8-026 Stiff Person Syndrome as a Mimic of Parkinsonism– Maria Virginia Diaz Rojas, Jeffrey B. Ratliff

P3.8-027 Hospital Utilization

Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders–Benjamin Carroll, Fan Mu, Rajeev Ayyagari, Sanjay Gandhi

pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene.–Diana Angelika Olszewska, Christopher McGuigan, Henry Houlden, James Polke, Rohan De Silva, Brian Lawlor, Michael Hutchinson, Michael Hutton, Alan Beausang, Isabelle Delon, Francesca Brett, Ioanna Sevastou, Timothy Lynch PARKINSON’S DISEASE THERAPEUTICS II

P3.8-029 Prevalence,

Benefits, and Adverse Effects of Cannabis Use in Parkinson’s Patients–Amelia Carwin, Hubert H. Fernandez

P3.8-030 A Pooled Analysis for

Eight Randomized Controlled Trials of Istradefylline, an Adenosine A2A Receptor Antagonist: Efficacy as Adjunct to Levodopa in Parkinson’s Disease (PD)–Stuart H. Isaacson, Nobutaka Hattori, Marco Onofrj, Akihisa Mori, Keizo Toyama, Phyllis M. Salzman, Marc Cantillon, Eri Ohta, Peter A. LeWitt

P3.8-031 In silico drug

screening by using genome-wide association study (GWAS)-data repurposed dabrafenib, an antimelanoma drug, for Parkinson’s disease–Takeshi Uenaka, Wataru Satake, Pei-Chieng Cha, Hideki Hayakawa, Kousuke Baba, Shiying Jiang, Kazuhiro Kobayashi, Motoi Kanagawa, Yukinori Okada, Hideki Mochizuki, Tatsushi Toda

P3.8-032 APOmorphine infusion

and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data–Daniel van Wamelen, Marios Politis, Dag Aarsland, Per Odin, Teus Van Laar, Tove Henriksen, Ben Corcoran, Gillian Vivian, Miriam Parry, Nicola Mulholland, K Ray Chaudhuri

P3.8-033 Impact of carbidopa-

levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson’s Disease: Results from a pooled metaanalysis–David G. Standaert, Vardhaman Patel, Sonya Snedecor, Sandeep Thakkar, Yash Jalundhwala, Pavnit Kukreja, David Kratochvil, Yanjun Bao, Rajesh Pahwa

P3.8-034 Population

Pharmacokinetics Model of Apomorphine/ApomorphineSulphate Administered as a Sublingual Film or Subcutaneously in Healthy Subjects and Patients With Parkinson’s Disease–Felix Agbo, Howard Bockbrader, Yu-Yuan Chiu, S. Chapel, Gerald Galluppi, Bradford A. Navia, David Blum

P3.8-035 NILO-PD: A Phase 2A

Study of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Study Design and Status Update–Tanya Simuni, Brian Fiske, Kalpana Merchant, Christopher Coffey, Helen Matthews, Richard Wyse, Patrik Brundin, David K. Simon, Michael Schwarzschild, David Weiner, Jamie Lynn Adams, Charles Stanley Venuto, Laura Trusso, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff

P3.8-036 Safety and Efficacy

of Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease in a FourWeek Double-blind, Placebocontrolled Randomized Crossover Study–Aleksandar Videnovic, Amy W. Amara, Cynthia L. Comella, Paula Schweitzer, Helene A. Emsellem, Kris Liu, Amanda Sterkel, Mildred D. Gottwald, Joshua Steinerman, Philip Jochelson, Robert A. Hauser

P3.8-037 A Novel Levodopa/

Carbidopa Prodrug (ABBV-951) 24Hour Continuous Subcutaneous Infusion Treatment for Parkinson’s Disease–Matthew Rosebraugh, Philip Kym, Wei Liu, Maurizio F. Facheris, Janet Benesh PARKINSON’S DISEASE CLINICAL FEATURES AND CLINICAL CARE I

P3.8-038 Reducing

Complications in Hospitalized Parkinson’s Patients–Sana Aslam, Edith Simpson, Matthew Baugh, Holly A. Shill

P3.8-040 Estimating an

Individual’s Risk of Parkinson’s Disease based on Comprehensive Family History–Paolo M. Moretti, Stefan M. Pulst, Lisa A. CannonAlbright

P3.8-041 Rab GTPase

Expression Changes in a-Synucleinopathy and Tauopathy Disorders–Mayur Parmar, Gina Bae, Nathaniel Ma, Shivang Jadvani, Nikolaus McFarland

P3.8-042 The effect of race on accuracy of coding with ICD-10 code G20–Margi Bharatbhai Patel, Katherine Barnes, David G. Standaert, Marissa Nicol Dean

P3.8-043 Characteristics

of Homebound Medicare Beneficiaries with Parkinson Disease–Adys Mendizabal, Michelle Fullard, Allison Wright Willis

P3.8-044 Association of Motor

and Non Motor Symptoms Severity with Motor Laterality Asymmetry in Parkinson´s Disease–Esther Cubo Delgado, E Casas-Peña, S Arnaiz Senderos, Maria S. Escalante Arroyo, F Carrillo-Padilla, Mercedes Pueyo Morleaans, Juan Carlos MartinezCastrillo, Pilar Sanchez Alonso, Marta Blazquez Estrada, N Lopez Ariztegui, I Gaston Zumibendi, P Alonso Losada, M Menendez Gonzalez, Araceli Alonso Canovas, JC Segundo Rodriguez, Pablo Martinez Martin, Diego Santos Garcia

P3.8-045 Outcomes of Elective

Orthopedic Surgery in Parkinson’s disease – a Nationwide Study–Michelle Fullard, Dylan S Thibault, Hanan Zisling, James Crispo, Allison Wright Willis

P3.8-046 Trajectories of

cognitive and functional decline in Parkinson’s disease–Jennifer G. Goldman, Douglas Merkitch, Bryan A. Bernard, Alice Negron, Glenn Thurston Stebbins

P3.8-039 The Association of

Gut Microbiome Composition and Parkinson’s Disease in Patient Cohort of Central California– Hsiang-Chin Lori Chou, Venu Lagishetty, Jeff M. Bronstein, Jonathan Jacobs, Beate Ritz

AAN.com/view/AM19Sci 173

Tuesday

Progressive Supranuclear Palsy Cohort Reporting to a Single Clinical Center–Rana Hanna AL-Shaikh, Maryam Ossi, Micheal Heckman, Audrey Strongosky, Owen A. Ross, Jay A. Van Gerpen, Neill R. Graff-Radford, Ryan J. Uitti, Zbigniew K. Wszolek

P3.8-028 The second clinical-

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.8-047 Infection and

Parkinson’s Disease: a Systematic Review and Metaanalysis–Muhammed Khaled Elfaituri, Sherief Ghozy, Eman El-Sayed Sakr, Salma Said Elkolaly, Mohamed Magdy Khattab, Mariam Abdelmageed Mahmoud, Mariam Abdelmageed Mahmoud, Samar Muhammad Mehyar, Mansour Alhattab, Ahmed Mahmoud Ahmed Ismail, Mohamed Abdelmongy, Mostafa Mahmoud Fahmy, Esraa Mamdouh Gharib, Asma Hallab, Mostafa Ebraheem Morra, Kenji Hirayama, Nguyen Tien Huy

P3.8-048 Intensity-based

exercise groupings in Parkinson’s Disease: Analysis from the Parkinson’s Foundation Quality Improvement Initiative (PFQII)–Danielle Larson, Margaret Yu, Adam J. Margolius, Hanzi Gao, Miriam R. Rafferty, Angela Roberts, Sam Wu, Tanya Simuni

P3.8-049 Infections leading

to hospitalization or sepsis preceding clinically diagnosed a-synucleinopathies: a casecontrol study in Olmsted County, MN (1991-2010).–Shemonti Hasan, Michelle M. Mielke, J. Eric Ahlskog, James H. Bower, Pierpaolo Turcano, Rodolfo Savica

P3.8-050 Comparison of

a Standardized Treadmill Perturbation to the Pull Test to Assess Postural Instability in Parkinson’s Disease–Amber Marie Stutz, Kenneth Louie, Chiahao Lu, Scott E. Cooper

Tuesday

P3.8-051 Medication adherence and discontinuation in a national cohort of Medicare beneficiaries with Advanced Parkinson’s Disease–Nabila Dahodwala, Jordan Jahnke, Pengxiang Li, Vrushabh Ladage, Prasanna Lakshmi Kandukuri, Yanjun Bao, Yash Jalundhwala, Jalpa Doshi

P3.8-052 Dysautonomia

Predicts Progression to Functional Dependence in Early Parkinson’s Disease–Cameron MillerPatterson, Lana Chahine

174 2019 AAN Annual Meeting

NEUROCRITICAL CARE: INTRACEREBRAL HEMORRHAGE AND BRAIN ARTERIOVENOUS MALFORMATIONS

P3.9-001 Performance and

Yield of MRI in Patients with Deep Intracerebral Hemorrhage–Luke Moretti, Jennifer A. Frontera, Aaron S. Lord, Jose L. Torres, Koto Ishida, Barry M. Czeisler, Ariane Lewis

P3.9-002 Prevalence and

Impact of Systemic Inflammatory Response in Acute Intracerebral Hemorrhage–Lauren Kaplan, Aisha Saand, Fang Yu, Sherry Chou

P3.9-003 The Use and Yield of

Vascular Imaging in Patients with Deep Intracerebral Hemorrhage– Luke Moretti, Jennifer A. Frontera, Aaron S. Lord, Jose L. Torres, Koto Ishida, Barry M. Czeisler, Ariane Lewis

P3.9-004 Use and Complications of Pharmacologic VTE Prophylaxis in Intracerebral Hemorrhage Patients–John Zurasky, Tamela Stuchiner, Katherine Lin Berry, Elizabeth A. Baraban

P3.9-005 Outcomes with

Reversal of Vitamin K AntagonistAssociated Intracerebral Hemorrhage–Hannah Breit, Christopher Ryan Green, Fiona Lynch, Ivan Da Silva, Sayona John

P3.9-006 Cerebral Small

Vessel Disease Markers and Their Relation to Hematoma Volume, Expansion and Functional Outcome–Anand Warrier, Rohit Bhatia, Ajay Garg, Vishwajeet Singh, Manjari Tripathi, Deepa Dash, Padma Vasantha Hadakasira, Kameshwar Prasad, Sreenivas Vishnubhatla

P3.9-007 Treatment Outcomes of Primary Endovascular Embolization in Patients Randomized in Unruptured Arteriovenous Malformations with a Subgroup Analysis of ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)–Sindhu Sahito, Omar Saeed, Adnan I. Qureshi

Tuesday, May 7 11:30 a.m.–6:30 p.m. P3.9-008 A Tertiary Care

P3.9-014 The Role of Induced

P3.9-009 Comparison of

P3.9-015 Pupillometry as

Center’s Experience with Andexanet Alfa for Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage– Matthew S. Smith, Julia Beatty, Shaun Keegan, David Robinson, kyle walsh, paige garber Intervention with Medical Treatment if Young Patients with Unruptured Brain Arteriovenous Malformation–Omar Saeed, Sindhu Sahito, Mushtaq H. Qureshi, Muhammad Fareed Suri, Adnan I. Qureshi NEUROCRITICAL CARE: ISCHEMIC STROKE AND COMPLICATIONS OF CARDIOCIRCULATORY SUPPORT

P3.9-010 Early Prediction of

Malignant Brain Edema After Ischemic Stroke: a Systematic Review and Meta-Analysis– Simiao Wu, Ruozhen Yuan, Yanan Wang, Chenchen Wei, Shihong Zhang, Xiaoyan Yang, Bo Wu, Liu Ming

P3.9-011 Ischemic and

Hemorrhagic Stroke in Native Americans–Zachary King, Rachel Beekman, Stacy C. Brown, Audrey Leasure, Hailey Amanda Orgass, Emily Jean Gilmore, Lauren Hachmann Sansing, Charles Matouk, Kevin N. Sheth, Guido Jose Falcone

P3.9-012 Reversible Cerebral

Vasoconstriction Syndrome resulting from Tyramine-Rich diet while on Antidepressants– Keithan Sivakumar, Hussam A. Yacoub, Preet M. Varade

P3.9-013 Impact Of Doing

Echocardiogram (ECHO) And Brain Magnetic Resonance Imaging (MRI) On Length Of Stay And Hospital Charges In Sschemic Stroke Patients In United States: Analysis of Nationwide Inpatient Sample (NIS) 2006-2014–Huy Q. Nguyen, Mohammad Rauf Afzal, Harathi Bandaru, Mohtashim Arbaab Qureshi, Mohammad Ghatali, Anantha Vellipuram, Paisith Piriyawat, Rakesh Khatri, Darine Kassar, Alberto Maud, Gustavo J. Rodriguez, Salvador Cruz-Flores

Hypertension and Hyperbaric Oxygen Therapy in Moyamoya Disease: A Case Report–Lisa M. Pabst, Smeer Salam, Sushil Sham Lakhani, Tamara Strohm, Deepak Gulati, Shraddha Mainali, Diana Greene-Chandos, Archana Hinduja a predictor of outcome after hemicraniectomy–Anand Mamdani, Venkatesh Aiyagari, DaiWai Olson

P3.9-016 Transcranial Doppler

Emboli Monitoring in Patient with Left Ventricular Assistant Device: A Systematic Review of the Literature–Tracey Huijun Fan, Catherine Hassett, Ken Uchino, Sung Min Cho

P3.9-017 Neurological

Complications of Left Ventricular Assist Device–Harathi Bandaru, Mohammad Rauf Afzal, Alberto Maud, Darine Kassar, Rakesh Khatri, Gustavo Rodriquez, Paisith Piriyawat, Salvador Cruz-Flores, Anantha Vellipuram

P3.9-018 Neurologic

Complications Associated with Veno-Venous ECMO: A Systematic Review–Cory J. Rice, Ibrahim Migdady, Sung Min Cho

P3.9-019 Neurologic

Complications of HeartWare and HeartMate II–Lucy Zhang, Meghan Purohit, Catherine Hassett, Sung Min Cho, Andrew Blake Buletko NEUROCRITICAL CARE: CASE REPORTS

P3.9-020 A Unique Case

of Malignant Edema due to Cerebellar Diaschisis Necessitating Decompressive Craniectomy–Brigitte Furth Hurtubise, Lironn Kraler

P3.9-021 A Case of Spinal Cord

Edema with Cord Compression Due to Systemic Lupus Erythematosus and Osmotic Shifts, Treated with Hypertonic Saline.–Joshua Cahan, Edward M. Manno, Eric M. Liotta

P3.9-022 Successful monitoring

and treatment of neurotoxicity in a patient treated with CAR-Tcell therapy enhanced by ocular ultrasound–Cristina Valencia Sanchez, Molly Knox, Bhavesh Patel, Marie Francisca Grill, Januario Castro, Allison Rosenthal, Maciej M. Mrugala, Brent P. Goodman

P3.9-023 Delayed Symptoms:

An Unusual Case of Hypoxicischemic Encephalopathy–Aaron Rothstein, Arielle Marisa Kurzweil, Jon Marc M. Finamore

P3.9-024 Cerebellar

Meningioangiomatosis Presenting as Chronic Headache and Vertigo with Traumatic Subarachnoid Hemorrhage–Victoria Lily Wu, Patrick M. Chen, Jamie LaBuzetta

P3.9-025 Relapsing course of

refractory neuroleptic malignant syndrome eventually leading to a full recovery–Ava Giugliano, Sudhir V. Datar, Kyle Hobbs

P3.9-026 Case Report: B mode

ultrasound images of the thoracic spine–Jonathan Gomez, Mark Frenkel, Samuel Carmichael, Aarti Sarwal NEURO TRAUMA AND SPORTS NEUROLOGY II

P3.9-027 Medical Cannabis in

the Treatment of Post-Traumatic Concussion–Jennifer McVige, Dilpreet Kaur, Paul B. Hart, Michael Lillis, Laszlo Mechtler, Vincent Harry Bargnes, Said Shukri

P3.9-028 Rapidly

P3.9-029 Longitudinal Change

in Diffusion Kurtosis Imaging Metrics as a Biomarker of Mild Traumatic Brain Injury.–Teena Shetty, Joseph T Nguyen, Esther Kim, Matthew Garvey, Taylor Cogsil, Apostolos Tsiouris, Sumit Niogi, Aashka Dalal, Kristin Halvorsen, Tianhao Zhang, Joseph C. Masdeu, Pratik Mukherjee, Luca Marinelli

P3.9-030 Does a Post-

Concussion Change in King-Devick Score Predict Return to Play in Collegiate Athletes?–Katie Hunzinger, Kelsey Bryk, Thomas Kaminski, Thomas A. Buckley

P3.9-040 Axonal

P3.9-032 Twinning with

P3.9-041 Acute visual

Treatment: Occupational Therapy’s Role in Identifying Impacted Occupational Domains–Madison Brooke Harris, Christopher Giza, Samia Rafeedie, David McArthur, Talin Babikian, Douglas R. Polster, Aliyah Ryan Snyder Concussions–Stephanie AlessiLaRosa, Richard Hanley, Jeffrey S. Kutcher

P3.9-033 Ground Reaction

Force Patterns in the Golf SwingRole in Injury Prevention and Performance–Robert J. Giombetti, Nicholas Moreno, Alex Galvan

P3.9-034 Indirect Gunshot

Spinal Cord Injury: A Case Report and Review of Literature–Tarek Joseph Chedid, Maria Khoueiry, Tarek El Halabi, Samir F. Atweh

P3.9-035 Relationships

Between Self-reported Anger, Aggression, and Concussion History in Hockey Players– Melissa Suzanne DiFabio, Thomas A. Buckley

P3.9-036 Blast Traumatic Brain Injury: Developing Personalized 3D Computational Models for use in High-Fidelity Blast Physics Simulations using Human MRI Scans–Paul Martin Elsbernd, Adam M. Willis, Candice Cooper GENERAL NEUROLOGY: NEUROLOGIC DISEASE DUE TO OVERDOSE, INTOXICATION, OR DEFICIENCY

P3.9-037 Transient Paralysis in

the Setting of Thyrotoxicosis and Concurrent Stimulant Overdose– Jacob Sambursky, Michelle Serpa Nunes, Enrique A. Serrano

P3.9-038 Botulinum toxin type

A overdoses: analysis of the FDA adverse event reporting system database–Rashid Kazerooni

P3.9-039 Myelopathy in the

setting of fentanyl abuse–Olivia Tong, Alina Masters-Israilov, Lenore C. Ocava, Jillian Rosengard, Peter C. Mabie

Neuropathy, Myelopathy and Hypercoagulable State Secondary to Chronic Nitrous Oxide Abuse Despite Combined B12 Supplementation–Amanda Olney, Geetha Kanakeswaran, Mangala Venkatesh, Praveen Venkatachalam disturbance associated with hydrogen peroxide ingestion–Jiae Lee, Olivia Tong

P3.9-042 Acute reversible

cerebral vasoconstrictive syndrome after treatment with Ketamine and Dihydroergotamine–Hsiangkuo Yuan, Stephanie J. Nahas, Matthew Aaron Berk

P3.9-043 Neurotoxicity

from Intrathecal Gadolinium Administration (IT-Gad)–Nicholas Calvo, Marium Jamil, Scott Feldman, Aashit K. Shah, Feryal Nauman, Joseph M. Ferrara

P3.9-044 Headache, visual

loss, and encephalopathy associated with intravenous ozone administration–Olivia Tong, Matthew S. Robbins

P3.9-045 PPI Induced

Hypomagnesemic Hypoparathyroidism Leading to PRES Syndrome–Negar Moheb, Anam Malik, Casey James Judge, Tarick Sheikh

P3.9-046 Hypercalcemic

Encephalopathy As An Initial Manifestation Of Hyperthyroidism Due To Endemic Goiter In Mexican Highlands, And Simultaneous Primary Hyperparathyroidism, A Case Report.–Marlene Arbeu Reyes

P3.9-047 Myoclonus – A Rare Presentation of Myxedema Coma–Ramsha Malik, Allison Marie Boyle

P3.9-048 Olfactory

Hallucinations as a Unique Presentation of Anti-depressant Discontinuation Syndrome– Shweta Varade, Casey James Judge, Megan Caroll Leary, Preet M. Varade

P3.9-049 Revisit: Clinical,

Laboratory And Electrodiagnositc Features Of Zinc DeficiencyInduced Peripheral Neuropathy– David Rahimian, Narsis Aminian, Favio Bumanlag, Shivani Maddigunta, Jin Jun Luo

P3.9-050 Clinical

Manifestations Of Peripheral Neuropathy In Patients With Erectile Dysfunction And Testosterone Deficiency–David Rahimian, Favio Bumanlag, Anita Khanna Mehta, Xiaohong Si, Jin Jun Luo

P3.9-051 Vitamin B12 deficiency presenting with acute psychosis– Stanley Zimba, Deanna Saylor

GENERAL NEUROLOGY: NEUROTHERAPEUTICS, TREATMENTS, AND CLINICAL TRIALS

P3.9-052 Ropinirole

Hydrochloride Remedy for Amyotrophic Lateral Sclerosis– Shinichi Takahashi, Satoru Morimoto, Hideyuki Saya, Hideyuki Okano, Masashi Aoki, Norihiro Suzuki, Jin Nakahara

P3.9-053 Cyclical Vomiting

Associated with a Focal Lesion of the Area Postrema Successfully Managed with Medical Marijuana–Eric Hirsch, Jack Gierlich, Erica Glants, Tahir Sheikh, Daryl Duran, Ranga C. Krishna

P3.9-054 Rebound Pain in a

Patient Taking Medical Marijuana for Phantom Limb Syndrome–Eric Hirsch, Jack Gierlich, Erica Glants, Tahir Sheikh, Daryl Duran, Ranga C. Krishna

P3.9-055 Does Lamotrigine

Work for Migraine-Associated Vertigo Better than Topiramate?– Mubasher Jaffri, Samantha Zak, Jamie So, Jennifer L. Cox, Lixin Zhang

P3.9-056 Pilot cross-sectional trial of localized transcutaneous magnetic stimulation shows improvement in foot pain secondary to plantar fasciitis (PF), diabetic neuropathy (DN), and chemotherapy neuropathy (CM)–Ejaz Shamim, Loraine Yarngo, Abigail Rapp, Leslie Greenberg, Robert Fischell

P3.9-057 Effect of

L-methylfolate on Depressive Symptoms in Patients with MTHFR Mutations–Michelle Rainka, Jacqueline Meaney, Erica Westphal, Traci Aladeen, Kaitlin Landolf, Sarah Stanford, Patrick Galdun, Natalie Asbach, Francis Michael Gengo, Horacio Capote

AAN.com/view/AM19Sci 175

Tuesday

Progressive Myelopathy due to Fibrocartilaginous Embolism of the Spinal Cord–Omama Siddiqui, Shyam S. Moudgil, Elizabeth Bankstahl, Safa Maki

P3.9-031 Pediatric Concussion

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 3 P3.9-058 Efficacy of Tissue

Plasminogen Activator (tPA) vs. Aspirin in Patients with a National Institute of Health Stroke Scale (NIHSS) Score Under 5–Sara Hameed, Iftekhar Ahmed, Adrian Moritz, Graham Lee

P3.9-059 Decrease in

therapeutic effect among botulinum toxin type A agents: analysis of the FDA adverse event reporting system database– Rashid Kazerooni

P3.9-060 Responsiveness of

Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy–P. James B. Dyck, Teresa Coelho, Marcia Waddington Cruz, Thomas H. Brannagan, Sami L. Khella, Chafic Y. Karam, John L. Berk, Michael J. Polydefkis, John C. Kincaid, Janice F. Wiesman, William J. Litchy, Michelle L. Mauermann, Elizabeth Ackermann, Brenda F. Baker, Shiangtung W. Jung, Spenser Guthrie, Michael Pollock, Peter J. Dyck GENERAL NEUROLOGY: ADVANCES IN QUALITY OF CARE AND WELLNESS

P3.9-061 The Impact of

Hereditary Transthyretin Amyloidosis (hATTR) on Work: The Patients’ Perspectives–Kimberly Raymond, Michelle White, Spenser Guthrie, Michael Pollock

Tuesday

P3.9-062 Quality of Life (QOL)

in Patients with Transthyretin Amyloidosis Accompanied by Peripheral Neuropathy (PN)–Asia Sikora Kessler, Aaron Yarlas, Andrew Lovley, Kristen McCausland, Spenser Guthrie, Michael Pollock, Michelle White

P3.9-063 Providing Quality

Teleneurology Consults to a State Prison System–Barbara K. O’Connell, Chris Hackett, Jack Protetch, Lauren Richards, Joseph Spataro, Prarthana Prakash, Kevin M. Kelly

P3.9-064 The Functionality,

Evidence and Privacy Issues around Smartphone Apps for the Top Neuropsychiatric Conditions: A Comprehensive Study–Ariana Gopal, Gabriella Sahyoun, Eric Stieglitz, John Torous, Mia T. Minen

176 2019 AAN Annual Meeting

Tuesday, May 7 11:30 a.m.–6:30 p.m.

P3.9-065 Arts Intervention

P3.9-074 Prevalence and

P3.9-066 Residential Medical

P3.9-075 Nonalcoholic

for Inpatients with Refractory Epilepsy or Migraine: Pilot Feasibility Study–Lara K. Ronan, Lindsay Schommer, Angeline S. Andrew Intervention Improves Fitness of Patients with Major Depression– Francisco Eduardo Ramirez, Neil Nedley

P3.9-067 Comorbidity Burden of Patients with Cluster Headache– Natalia Murinova, Anusha Mannava, Jenna R. Kanter, Jennifer Wax, Daniel Krashin

P3.9-068 Tale of Caution:

Identifying Migrainous Infarction Using Database–Anusha Mannava, Daniel Krashin, Jennifer Wax, Jenna R. Kanter, Silvie Belaskova, Natalia Murinova

P3.9-069 Influence Of Early

Neurological Complications On Clinical Outcome Following Heart Transplantation.–Agustin Pappolla, Pedro Colla, Natalia Balian, Clarisa Cea, Ricardo Marenchino, Cesar Belziti, Maria Zurru

P3.9-070 The Patient Odyssey

to Confirmed Acute Hepatic Porphyria Diagnosis: Neurological Symptoms and Use of Drugs Known to Provoke Porphyria Attacks Prior to Diagnosis–Hélio Pedro, Sean Rudnick, Madeline Merkel, John Ko, Barbara H. Johnson, Virginia Noxon, Ashley Cole, Sonalee Agarwal

P3.9-071 Recent trends in

Guillain-Barré Syndrome related hospitalizations, mortality and resource utilization in United States (2006-2014)–Varun Kumar, Chirag Narshibhai Savani, Charles DeMello Schutt, Sheyar Amin, Tejinder Singh, Rossitza I Chichkova, Yazan M. Suradi

P3.9-072 Characteristics

of Patients Intubated for Psychogenic Non-epileptic Seizures–Stephan A. Mayer, Tanuwong Viarasilpa, Nicha Panyavachiraporn, Gamaleldin M. Osman, Panayiotis N. Varelas, Noel Akioyamen

P3.9-073 Positive Signs in

Organic Neurological Diseases.– Orwa Aboud, Ayman A. AlSalaimeh, Archana Hinduja

Factors Associated with Diabetic Peripheral Neuropathy in Ilorin, North-Central Nigeria.–Abiodun Hamzat Bello, Kolawole W. Wahab, Emmanuel O. Sanya Wernicke’s Encephalopathy: A Retrospective Study of a Reemerging Neurological Disorder in Kashmir Region of Northern India.–Irfan Ahmad Shah, Yuman Kawoos, Ravouf Parvez Asimi, Bashir Ahmad Sanaie, Mushtaq Ahmad Wani, Maqbool Wani

P3.9-076 Demographic and

Hemodynamic Characteristics of a large Cohort of Patients with Transient Global Amnesia (TGA)–Ralph Werner, Alexandra Ekstrom, Johannes C. Wohrle

P3.9-077 Quantifying

the burden of unfilled clinic appointment slots created by late-notice cancellations–Hilary Hanbing Wang, Nicole Batino, Laurice T. Yang

P3.9-078 Burnout among

Japanese Female Neurologists: a Preliminary Investigation–Ikuko Aiba, Takayoshi Shimohata, Nobutaka Hattori, Yoshiko Unnno, Kazuto Yoshida, Atsushi Takeda, Ryosuke Takahashi, Tatsushi Toda

P3.9-079 Art Therapy in the

Management of Neurology Wellness and Burnout- A Pilot Study–Juliet King, Brooke F. Walls, Sarah Elizabeth Zauber, Ashely Hildebrandt, Saurabh Singhal, Robert M. Pascuzzi

10 MIGRAINE I

P3.10-001 Impact of Migraine

Headache Day Frequency on Associated Health : Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study–Todd J. Schwedt, Richard B. Lipton, Aftab Alam, David W. Dodick, Sagar Munjal, Kristina Fanning, Michael L. Reed, Dawn C. Buse

P3.10-002 Feasibility and

Acceptability of Smartphone Based Migraine Behavioral Therapy in the Neurology Clinic: A Single Arm Study–Mia T. Minen, Jane Padikkala, Sumaiya Tasneem, Samrachana Adhikari, Ashley Bagheri, Thomas Berk, Sarah Jinich, Scott Powers, Elizabeth Seng, Mary Ann Sevick, Richard B. Lipton

P3.10-003 Assessing Unmet

Treatment Needs and Associated Disability in Persons With Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study– Michael L. Reed, Richard B. Lipton, Sagar Munjal, Aftab Alam, Dawn C. Buse, Kristina Fanning, Todd J. Schwedt, David W. Dodick

P3.10-004 The Italian chROnic

migraiNe (IRON) Registry: a report from the first 340 patients–Piero Barbanti, Luisa Fofi, Licia Grazzi, Paola Torelli, Fabrizio Vernieri, Sabina Cevoli, Nicola Vanacore, Piero Barbanti

P3.10-005 Development and

Validation of the Migraine Knowledge Assessment Tool— MigKAT-12©–David Lee Gordon, Claire Emmanuelle Delpirou Nouh, Michael Roy Bellew, Joshua Santucci, Chao Xu

P3.10-006 Provider Preference for Acute Migraine Treatment in the Emergency Room: A Professional Practice Gap–Hao Huang, Thomas Berk

P3.10-007 Investigating

the Role of Artmaking as a Therapeutic Tool in the Treatment of Chronic Migraine–Amanda Elizabeth Simon, Asha Shajahan, Christopher Gottschalk

P3.10-008 Incidence of

Pregnancy Related Migraine Headache During Pregnancy and Post-Partum and Associated Comorbidities: An Update from a Nationwide Inpatient Sample Database–Martin Anthony Myers, Charles W. Brock, Chirag Narshibhai Savani, Varun Kumar

P3.10-009 Cognitive Dysfunction in Chronic Migraine–Faiza Waheed Butt, Melissa Schorn, Daniel Krashin, Natalia Murinova

P3.10-010 High Prevalence of

Rape and Sexual Abuse among Chronic and Refractory Migraine Patients–Agustin Oterino Duran, Maria Toriello, Fernando Iglesias, Fernando Hoyuela, Sara Perez-pereda, Vicente GonzálezQuintanilla, Olga Umaran, JavierGonzalo Ocejo

Chronic Migraine Epidemiology and Outcomes (CaMEO) Study Demonstrate a High Level of Unmet Need for Migraine Treatment in People Who Discontinue Acute Prescription Migraine Medication–Aubrey Manack Adams, Susan Hutchinson, Jessica Ailani, Michael L. Reed, Kristina Fanning, Richard B. Lipton, Dawn C. Buse

P3.10-012 How Often Do ED

Patients Receive Opioids for the Treatment of Migraine?–Raima M. Amin, Daniel Krashin, Natalia Murinova

P3.10-013 The Impact of

Offering Monthly and Quarterly Dosing Options for a New Class of Migraine Preventive Therapy on Likelihood of Acceptance and Adherence in Adults With Migraine–Robert Cowan, Joshua T. Cohen, Erik Rosenman, Ravi Iyer

P3.10-014 Serum Phosphate

Levels in Patients with Migraine– Young Ik Jung, Byung-Su Kim

P3.10-015 Medical Cannabis for

Chronic Migraine: A Retrospective Review–Laszlo Mechtler, Vincent Harry Bargnes, Paul B. Hart, Jennifer McVige, Nicolas Saikali

P3.10-016 Enhancing outpatient

infusion with interdisciplinary care to manage refractory pediatric migraine: Preliminary outcomes from “CAMP” (the Comprehensive Aggressive Migraine Protocol)– Jennifer Bickel, Subhjit Sekhon, Dane Stephens, Madeline Boorigie, Mark Connelly

P3.10-017 Most Bothersome

P3.10-018 Obesity is

Associated with Increased Odds of Hospitalization Following Emergent Care for Pediatric Migraine–Christina Lynch Szperka, Jennifer Glusman, Dylan S Thibault, Sudha Kessler, Shavonne Massey, Nicholas Scott Abend, Payal B. Patel, Ana RecoberMontilla, Allison Wright Willis

in migraine is evoked by both melanopsin and cone directed stimulation–Eric Kaiser, Harrison McAdams, Aleksandra “Sasha” Igdalova, David H. Brainard, Geoffrey Karl Aguirre

P3.10-020 Trends in the

Incidence of Migraine in Patients Hospitalized for Acute Ischemic Stroke in the United States Using the Nationwide Inpatient Sample Database–Luiz De Souza, Chirag Narshibhai Savani, Varun Kumar, Tigran Kesayan, Jose R. Rodriguez, Matthew Chung, James Ray Ghattas, Grace Kim, Martin Anthony Myers, Charles W. Brock

P3.10-021 Change in

Catastrophizing After Onabotulinumtoxin A Treatment in Chronic Migraine with Medication Overuse: Preliminary Findings– Frank Andrasik, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Matilde Leonardi, Domenico D’Amico, Licia Grazzi

P3.10-022 Association of

Conversion Disorder and Migraine–Daniel Krashin, Natalia Murinova

P3.10-023 The Effect of

Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Healthcare Academic Institute–Heidi Yuan, Ka-Ho Wong, Rob Davis, Seniha N. Ozudogru

Alternate Viewing Area Catch live streams of select plenary sessions, education programs, and other unique and encore programming. Located in the Neuro Center.

P3.10-024 Ubrogepant is

Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans–Andrew M. Blumenfeld, Peter Goadsby, David W. Dodick, Susan Hutchinson, Chengcheng Liu, Michelle Finnegan, Joel M. Trugman, Armin Szegedi

P3.10-025 Early Detection

of Persons at Risk for Incident CM–Charles Iaconangelo, Richard B. Lipton, Daniel Serrano

P3.10-026 Altered Permeability

of Blood-CSF Barriers in Migraine–Robert Cowan, Melanie Sweeney, Abhay Sagare, Elizabeth Imma Iziegbe Ekpo, Bharati Sanjanwala, Noah Gross, Xianghong Arakaki, Alfred Fonteh, Berislav V. Zlokovic, Michael G. Harrington

NEW This Year!

Tuesday

Associated Migraine Symptom: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study–Sagar Munjal, Aftab Alam, Michael L. Reed, Kristina Fanning, David W. Dodick, Todd J. Schwedt, Dawn C. Buse, Richard B. Lipton

P3.10-019 Visual discomfort

POSTER SESSIONS

P3.10-011 Results From the

Experience the Annual Meeting Your Way

Now available through the AAN Conferences App, you can live stream select programs and courses on your mobile device wherever is convenient for you. Download the AAN Conferences App today!

AAN.com/view/AM19Sci 177

POSTER SESSIONS

POSTER SESSION 4

AGING AND DEMENTIA: CLINICAL TRIALS

P4.1-001 Baseline

Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease–Christian Von Hehn, Philipp Von Rosenstiel, Ying Tian, Shuang Wu, Tianle Chen, LeAnne Skordos, Katie Harrison, Claudia Prada, Spyridon Chalkias, Raj Rajagovindan, Paul S. Aisen, Stephen P. Salloway, Samantha Budd Haeberlein, Alfred W. Sandrock

P4.1-002 Baseline

Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD)–Kaycee Sink, Susanne Ostrowitzki, Laurie Millar, Francis Warren, Helen C. Lin, Jillian Smith, Andres Schneider, Reina Fuji, Angelica Quartino, Howard Mackey, Michael Rabbia, Susan Yule, Paulo Pacheco Fontoura, Rachelle Doody

P4.1-003 Concordance

of Florbetapir (18F) PET and Elecsys® ß-Amyloid(1–42) Cerebrospinal Fluid Immunoassay in the Phase III CREAD (BN29552) Study of Crenezumab in Early (Prodromal-to-Mild) AD–Christina Rabe, Timo Grimmer, Mercidita Navarro, David Clayton, Ekaterina Manuilova, Udo Eichenlaub, Jillian Smith, Susanne Ostrowitzki, Lee Honigberg, Tobias Bittner

Wednesday

P4.1-004 GeneMatch: A Novel Recruitment Registry using APOE Genotyping to Accelerate Referrals to Alzheimer’s Prevention Studies–Jessica Langbaum, Pierre Tariot, David Gordon, Hayley Graf, Jason H T Karlawish, J. Scott Roberts, Elisabeth M. Wood, Angela Bradbury, Trisha Walsh, Nellie High, Eric M. Reiman

P4.1-005 The Alzheimer

Prevention Initiative Generation Program: Evaluation of CNP520 in Preclinical Alzheimer’s Disease– Beth Borowsky, Cristina Lopez Lopez, Pierre Tariot, Angelika Caputo, Fonda Liu, MarieEmmanuelle Riviere, Marie-Laure Rouzade-Dominguez, Ronald Thomas, Jessica Langbaum, Vissia Viglietta, Eric M. Reiman, Ana Graf

178 2019 AAN Annual Meeting

Wednesday, May 8 11:30 a.m.–6:30 p.m.

Poster Session 4 1. Aging, Dementia, Cognitive, and Behavioral Neurology: 1-001 to 1-029 2. MS and CNS Inflammatory Disease: 2-001 to 2-106 3. Cerebrovascular Disease and Interventional Neurology: 3-001 to 3-071 4. Neuromuscular Disease and Clinical Neurophysiology (EMG): 4-001 to 4-041 5. Epilepsy/Clinical Neurophysiology (EEG): 5-001 to 5-036 6. Neuroepidemiology; Child Neurology and Developmental Neurology: 6-001 to 6-072 7. Movement Disorders ePosters: 7-001 to 7-010 8. Movement Disorders: 8-001 to 8-052 9. Infectious Disease; Research Methodology, Education, and History; Practice, Policy, and Ethics: 9-001 to 9-081 10. Headache: 10-001 to 10-025

1 2 3

1-001-1-029

Precision Medicine Intervention in Patients at Risk for Dementia due to Alzheimer’s disease–Richard S. Isaacson, Hollie Hristov, Katherine Hackett, Nabeel Saif, Suzanne Hendrix, Joseph E. Safdieh, Matthew E. Fink, Juan Melendez, Aneela Rahman, Sonia Bellara, Paige Lee, Emily Caesar, Randy Cohen, Josefina Meléndez-Cabrero, Mu Ji Hwang, Cara Berkowitz, Olivia Scheyer, Lisa Mosconi, Alon Seifan, Robert Krikorian

P4.1-007 Efficacy of Memantine

Added to Cholinesterase Inhibitors on SIB Higher-Order Cognitive Domains: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD–Frederick A. Schmitt, George Grossberg, Pierre Tariot, Suzanne Hendrix, Noel Ellison, Majid Kerolous

P4.1-008 SIB Maintenance of

Response With Memantine Added to Cholinesterase Inhibitors: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD–Frederick A. Schmitt, Pierre Tariot, George Grossberg, Suzanne Hendrix, Noel Ellison, Majid Kerolous

P4.1-009 Sildenafil Alters

Hippocampal Fractional Amplitude of Low Frequency Fluctuations (fALFF) in Patients with Alzheimer’s Disease–Niyatee Samudra, Michael Motes, Hanzhang Lu, Ramon R. DiazArrastia, John Hart, Kyle B. Womack

P4.1-010 Metformin and Newer Oral Hypoglycemic Agents are Associated with Better Cognitive Test Performance Over Ten Years in Older Diabetic Men–Siena Duarte, Eric Vittinghoff, Elizabeth Barrett-Connor, Kristine Yaffe

P4.1-011 Long-Term Efficacy

for Parkinsonism and Safety of Zonisamide in Patients with Dementia with Lewy Bodies: A Phase III Trial–Shunji Toya, Miho Murata, Toshinari Odawara, Kazuko Hasegawa, Ritsuko Kajiwara, Hisao Takeuchi, Kentaro Takai, Kenji Kosaka

P4.1-012 Long-term Efficacy

of Zonisamide on Parkinsonism in Dementia with Lewy Bodies: A Post-hoc Analysis of Phase 3 Trial–Kentaro Takai, Miho Murata, Toshinari Odawara, Kazuko Hasegawa, Kenji Kochi, Shunji Toya, Kenji Kosaka

P4.1-013 Transcranial Direct

Current Stimulation Improves Verbal Fluency in Patients with Primary Progressive Aphasia–Mahdieh Hosseini, Eric M. McConathey, Molly Ungrady, Murray Grossman, H. Branch Coslett, Roy H. Hamilton

3-001-3-071

4 5 6

4-001-4-041

5-001-5-036

6-001-6-072

7-001-7-010

ePosters

8 9 10

8-001-8-052

P4.1-006 A Multidomain

2-001-2-106

9-001-9-081

10-001-10-025

P4.1-014 Safety and Efficacy

of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting.–Vincent Harry Bargnes, Paul B. Hart, Sheila Gupta, Laszlo Mechtler

P4.1-015 Intranasal Glulisine in Down Syndrome: A Pilot Safety and Tolerability Trial–Michael Rosenbloom, Maria Pyle, Lauren Erickson, Justin Schlichting, Terry R. Barclay, Leah R. Hanson AGING AND DEMENTIA: NEUROPSYCHOLOGY AND CLINICAL STUDIES II

P4.1-016 Structured delirium

care pathway is associated with reductions in length of stay, cost and readmissions in hospitalized adults–Sara LaHue, Judy Maselli, Stephanie Rogers, Jennifer Canlas, Julie Carpenter, Rhiannon Croci, Yintai Fong, Ralph Gonzales, Brian Holt, S. Andrew Josephson, Sudha Lama, Charles McCulloch, Jan Yeager, Vanja C. Douglas

P4.1-017 Snow laughing matter:

Delirium severity increases in winter months compared with summer months–Vanja C. Douglas, Judy Maselli, Sara LaHue

P4.1-018 Identifying Common

Themes in ICU Deaths of Patients with a Diagnosis of Alzheimer Disease–Ian Michael Grant, Borna Bonakdarpour

P4.1-019 Caregiver Depression

and Emergency Department Utilization in Dementia–Elan Guterman, Isabel Allen, S. Andrew Josephson, Katherine L. Possin

P4.1-020 The Lived Experience

of Lay Caregivers Caring for Persons with Dementia–Ann Marie Mayo, Kathleen Siegle, Eileen Savell, Bonnie Bullock, Gloria Preston, Guerry Marie Peavy

P4.1-021 Real World Treatment of Parkinson’s Disease Dementia (PDD) in the United States (U.S.)–Krista Schroeder, Leanne Munsie, Paul Ardayfio, Susan Warner, Kevin M. Biglan

P4.1-022 MCI and OSA–

Sanskruti Patel, Christina Maxwell, G. Peter Gliebus

P4.1-023 Vascular dementia in elderly .Population-based study in Matanzas.–Rodny Munoz Perez, Alejandro Mayol Cabrera, Camelia Valhuerdi Porto, Adolfo Juan Valhuerdi Cepero, Juan J Llibre Rodriguez, Milena Munoz Rodriguez, Yesenia Hoyos, Allen Machado, Rudbeckia Porto Alvarez, Bibiana Valhuerdi Porto

P4.1-024 Characteristics of

Young-onset and Late-onset Dementia Patients at a Rural and Remote Memory Clinic–Jennifer Wong, Andrew Kirk, Landon Perlett, Chandima Karunanayake, Debra Morgan, Megan O’Connell

P4.1-025 Subjective Cognitive

P4.1-026 The Free and Cued

Selective Reminding Test Predicts Alzheimer’s Disease Neuropathology–Ellen H. Grober, Richard B. Lipton, Cuiling Wang

P4.1-027 Color Vision

Impairment in Prodromal and Dementia Stages of Lewy Body Disease versus Alzheimer’s Disease–Robert Unger, Patrick Flanigan, Mitra Khosravi, Babak Tousi

Receptive Fields’ Size in Understanding Complex Visual Dysfunctions: Posterior Cortical Atrophy Model–Pieter Boudewijn De Best, Noa Raz, Nitzan Guy, Tamir S. Ben-Hur, Serge Dumoulin, Yoni Pertzov, Netta Levin

P4.1-029 Quantification of

Real-World Life Space from Instrumented Vehicles in Drivers with Cognitive Aging–Jennifer Merickel, Emily L. Frankel, Matthew Rizzo

CHECK POINT INHIBITORS AND PARANEOPLASTIC NEUROLOGICAL DISORDERS

P4.2-001 Neurologic Adverse

Events associated with Immune Checkpoint Inhibitor Therapy– Sophie Lan-Linh Duong, Frank J. Barbiero, Anita J Huttner, Richard J. Nowak, Joachim M. Baehring

P4.2-002 Pembrolizumab-

Associated Paraneoplastic Disorders: A Case Series– Alexander J. Gill, Michael Angel Perez, Christopher Perrone, Charles Joonghie Bae, Amy A. Pruitt, Eric Lancaster

P4.2-003 Immune checkpoint

inhibitor induced anti-GAD limbic encephalitis–Matthew Chung, Sepideh Mokhtari

P4.2-004 Characterization of

Encephalopathy Associated with Immune Checkpoint Inhibitor Therapy–Danmeng Wei, Olha D. Taraschenko

P4.2-005 Nivolumab-induced

myasthenia gravis with myositis in patients with genitourinary cancer–Ruiqing Sun, Varun Bipinchandra Shah, Sudhakar Tummala, Merry Chen

P4.2-006 Hunting the real

culprit: a complex case of nivolumab-related myelitis.– Valentina Poretto, Manuela Buganza, Stefania Filipponi, Sabrina Marangoni, Silvio Piffer, Franco Chioffi, Bruno Giometto

P4.2-007 Pembrolizumab-

Induced Myasthenia Gravis– Mohanad ALGaeed, Loulwah Mukharesh, Morgan Michelle Heinzelmann, Henry J. Kaminski

MS THERAPEUTICS: MOA AND SAFETY

P4.2-008 NFL pattern in

progressive Multiple Sclerosis cohort under MD1003 treatment–Beatrice Pignolet, Francesca Ammoscato, Jonathan Ciron, Florence Bucciarelli, Lise Scandella, Damien Biotti, Fleur Lerebours, Guillaume Dorcet, Céline Rabadeux, Noellie Freitas, Fabrice Bonneville, Sharmilee Gnananpavan, David Brassat

P4.2-009 Longitudinal stability

of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study–Louise Mason, Thomas Berger, Raju Kapoor, Hans-Peter Hartung, Ih Chang, Zheng Ren, Nolan Campbell, Pei-Ran Ho

P4.2-010 Two Cases of

Meningitis Associated with Ocrelizumab Therapy–Michael E. Theriault, Andrew Solomon

P4.2-011 Fingolimod related

cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis– Fernando Xavier Cuascut Lassus, Steven Richard Dunham, George J. Hutton

P4.2-012 Leprosy in two

patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod–Alfred Balasa, George J. Hutton

P4.2-013 Dimethyl Fumarate

Dose Reduction in Lymphopenic Relapsing Remitting Multiple Sclerosis Patients: Clinical and MRI Outcomes–Ka-Ho Wong, Rae E. Bacharach, Erica Marini, Tram Nguyen, Stacey Clardy, Melissa M. Cortez, L Dana DeWitt, John E. Greenlee, Julia Klein, M. Mateo Paz Soldan, John D. Steffens, John W. Rose

P4.2-014 Infectious Risk

Stratification in Multiple Sclerosis Patients Receiving Immunotherapy – An Update–Jonas Graf, Verena Leussink, Thomas Dehmel, Marius Ringelstein, Norbert Goebels, Ortwin Adams, Colin MacKenzie, Clemens Warnke, Torsten Feldt, Anna Lammerskitten, Luisa Hildegard Klotz, Sven G. Meuth, Heinz Wiendl, Hans-Peter Hartung, Orhan Aktas, Philipp Albrecht

P4.2-015 Evaluating the

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis–Enrique Alvarez, Kavita Nair, Ian Shelton, Sean Selva, Natalie Voge, Nassim Zanganeh, Stefan Sillau, Timothy L. Vollmer

P4.2-016 A Rare Complication

of Fingolimod: Case Report of Posterior Reversible Encephalopathy Syndrome– Carrie Downey Allison, Derrick Robertson, Lise Casady, Janice Y. Maldonado

P4.2-017 Among Real-world

Multiple Sclerosis Patients That Experience Delayed-release Dimethyl Fumarate-associated Lymphopenia, Meaningful Lymphocyte Reconstitution Occurs Approximately 3 Months After Discontinuation of Delayedrelease Dimethyl Fumarate–John W. Rose, Enrique Alvarez, Darin T. Okuda, Mark Gudesblatt, Emily S. Riser, Timothy Spelman, Helmut Butzkueven, Sami Fam, Katherine A. Riester, Fan Wu, Catherine Miller

P4.2-018 No significant risk

of malignant melanoma growth under cladribine treatment: in vitro studies–Ilona Berestjuk, Sophie Tartare-Deckerc, Christine Lebrun Frenay

P4.2-019 Serious Adverse

Events in Rituximab-Treated Patients with Multiple Sclerosis and Related Disorders–Asya Izraelit Wallach, Brandi L. Vollmer, John Corboy, Karolina Dubovskaya, Ilya Kister, Enrique Alvarez

P4.2-020 Central Nervous

System T Cell Lymphoproliferative Disease Following Treatment with Alemtuzumab–Lindsay A. Horton, Murtaza Khan, Douglas Ney, Bette DeMasters, Enrique Alvarez, Amanda Lee Piquet

P4.2-021 Risk factors for

Development of Lymphopenia in Dimethyl Fumarate-treated Patients with Multiple Sclerosis– Caroline Holst Bloch, Tobias Sejbaek, Matthias Kant, Morten Blaabjerg, Henrik Boye Jensen, Preben B. Andersen, Annett Petersen, Monika Gora

AAN.com/view/AM19Sci 179

Wednesday

Impairment: A Clinical and neuropsychological Entity, sustained by a specific Topography of Lesions. The Cingulum Cohort of Marseille, France.–Nathalie Sambuchi, Nadine Girard, Olivier Coulon, Henri D. Becker, Yonas E. Geda, Bernard Francois Michel

P4.1-028 The Role of Population

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.2-022 Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis–Maria MateoCasas, Saul Reyes, Stefania De Trane, Ozlem Yildiz, Benjamin Turner, Joela Mathews, Gavin Giovannoni, Edel O’toole, Klaus Schmierer

P4.2-023 Delayed-release

Dimethyl Fumarate-associated Lymphopenia: On-treatment and Post-treatment Implications– Andrew Chan, Robert J. Fox, Amit Bar-Or, Chongshu Chen, Sami Fam, Ralf Gold, Jerome Hanna, Devangi S. Mehta, J. Theodore Phillips, Lili Yang, Catherine Miller

P4.2-024 Immunization

and Multiple Sclerosis: Recommendations from the French Multiple Sclerosis Society–Christine Lebrun Frenay, Sandra Vukusic

P4.2-025 Safety of Ocrelizumab

in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis–Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Richard W. Hughes, John McNamara, Ashish Pradhan, David Wormser, Harold Koendgen, Jerry S. Wolinsky

P4.2-026 Influence of

Clinical and Cerebrospinal Fluid Parameters on the Effect of Therapeutic Plasma Exchange in Patients with Multiple Sclerosis– Christian Eienbröker, Maria Seipelt, Michael Pütz, Kerstin Schlegel, Tanja Maier-Giebing, Björn Tackenberg

Wednesday

P4.2-027 Cytomegalovirus

(CMV) Primoinfection in a patient with Multiple Sclerosis treated with Alemtuzumab–Clara Aguirre Hernandez, Virginia Meca Lallana, Pedro Sanchez, Beatriz del Río Muñoz, Fabiola García Vaz, Jose Vivancos Mora

P4.2-028 Changes in

the immune cell profile in fingolimod-treated patients with relapsing multiple sclerosis: primary analysis of the FLUENT study–Yang Mao-Draayer, Jeffrey Alan Cohen, Amit Bar-Or, Bruce A. C. Cree, May Han, Barry A. Singer, Scott Kolodny, Xiangyi Meng, Lesley Schofield, Marina Ollervides Ziehn

180 2019 AAN Annual Meeting

P4.2-029 Multiple sclerosis

treatment strategy after natalizumab-associated progressive multifocal leukoencephalopathy–Rasha Waheed, Fabian Sierra Morales, Igor J. Koralnik, Dusan Stefoski, Michael Ko, Bichum Ouyang, Lakshmi Warrior

P4.2-030 Increased Multiple

Sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate– Sylvia R. Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil W. Rammohan

P4.2-031 The Marburg Multiple Sclerosis - Cohort — Loss of MEDA under two standard treatment sequences–Jan Philip Jurs, Maria Seipelt, Kerstin Schlegel, Christian Eienbröker, Björn Tackenberg

P4.2-032 Immunosuppresion

following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated with fingolimod–Jose Maria Cabrera Maqueda, Luna Fuentes Rumi, Gabriel Valero López, Teresa Alba Isasi, Rocio Hernandez Clares, Ester Carreon Guarnizo, Judith Jimenez Veiga, Francisca Iniesta-Martínez, Aida León-Hernández, Joaquín Zamarro Parra, Ana M. Morales Ortiz, Jose Meca Lallana

P4.2-033 PML Risk Perception

in Patients Initiating Natalizumab for Multiple Sclerosis–Regina Berkovich, Aida Yakupova, Evan Riddle

P4.2-034 Temporal profile of

lymphocytes following treatment with cladribine tablets in patients switching from lymphocyte depleting or sequestering disease modifying drugs (DMDs)–Suzanne J. Hodgkinson, Meena Sharma

P4.2-035 Predicting

Natalizumab Discontinuation due to Breakthrough Disease in Multiple Sclerosis Patients–Devon Conway, Haleigh Harris, Carrie Michelle Hersh, Le Hua

P4.2-036 Skin Warts during

Fingolimod Treatment in Patients with Multiple Sclerosis–Bassem I. Yamout, Nesreen Jaafar, Maya Zeineddine

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.2-037 Limited Effects

P4.2-045 Dissection of

P4.2-038 Autoimmune

P4.2-046 Updated safety

of Interferon ß-1a in an IgGdriven Model of Multiple Sclerosis Pathology–Jeffrey L. Bennett, Timothy Fellin, Adeline Matschulat, Andre Navarro, Gregory Owens Hemolytic Anemia after Treatment with Fingolimod: A Case Report–Arif Husain, Nada Ghanime Abou Fayssal

P4.2-039 Longitudinal analysis

of Peripheral Blood Mononuclear Cells in Lymphopenic and Nonlymphopenic Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Dimethyl Fumarate–Maryam NakhaeiNejad, Chieh-Hsin Lee, David Barilla, Gregg G. Blevins, Fabrizio Giuliani

P4.2-040 Stability of JC Virus Index over Time – a Five Year Retrospective Study.–Maria Gaughan, Michael Gilligan, Christopher McGuigan

P4.2-041 Characterization of the Peripheral Blood Transcriptome in Alemtuzumab-Treated RelapsingRemitting Multiple Sclerosis Patients From the CARE-MS I and II Studies–Mindy Zhang, Yi-Chien Chang, Srinivas Shankara, Alan K. Jacobs, Jean Godin, Katherine Klinger, Stephen Madden

P4.2-042 The Effect of

Ocrelizumab Therapy on Immunoglobulin Levels in Patients with Multiple Sclerosis–Vincent Tran, Paul M. Miller, Jill Marie Olson, Tamara Miller, Augusto A. Miravalle

P4.2-043 VERISMO: A

Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab–David Wormser, Joanna Evershed, Germano Ferreira, Daniela Stokmaier, Qing Wang, Tjalf Ziemssen

P4.2-044 ADA Genetic Variants

Influence Central Inflammation and Clinical Characteristics in MS: Implications for Cladribine Treatment–Mario Stampanoni Bassi, Fabio Buttari, Ilaria Simonelli, Francesco Sica, Roberto Furlan, Gerolama Marfia, Marco Salvetti, Antonio Uccelli, Giuseppe Matarese, Andrea Visconti, Diego Centonze

the Distinct Susceptibility of Hematopoietic Precursors and Immune Cells to Cladribine–F Carlini, F Ivaldi, N Kerlero De Rosbo, Ursula Boschert, Andrea Visconti, Antonio Uccelli analysis of cladribine tablets in the treatment of patients with multiple sclerosis–Stuart D. Cook, Gavin Giovannoni, Thomas Leist, Sana Syed, Axel Nolting, Doris Damian, Regina Schick

P4.2-047 Efficacy and Safety

of Teriflunomide in Patients of Differing Ages: Analysis of Pooled Clinical Trials–Jiwon Oh, Sandra Vukusic, Klaus Tiel-Wilck, Mauro Zaffaroni, Stanley L. Cohan, Jihad Said Inshasi, David Rog, Darren Phillip Baker, Kathleen C. Somera-Molina, Yelena Gorfinkel Pyatkevich, Elizabeth Poole, Keith R. Edwards

P4.2-048 Effects of Fingolimod

on Cytokine and Chemokine Levels in Patients with Multiple Sclerosis–Murat Kurtuncu, Vuslat Yilmaz, Halil Ibrahim Akcay, Recai Turkoglu, Burcu Altunrende, Canan Ulusoy, Suzan Adin Cinar, Sema Icoz, Mithat Kasap, Zeynep Caliskan, Gokturk Otunc, Mefkure Eraksoy, Erdem Tuzun

P4.2-049 Effects of Ocrelizumab

on Immune Parameters in a Cohort of MS Patients–Ye Hu, Lakshman Narain Arcot Jayagopal, Michael J. Persenaire, Annette Wundes, Gloria Von Geldern

P4.2-050 Intrathecal MSC-

NP Treatment in Patients with Progressive Multiple Sclerosis is Associated with Modulation of Cerebrospinal Fluid Biomarkers– Shayna Zanker, Violaine K. Harris, Tamara Vyshkina, Saud A. Sadiq

P4.2-051 Immunological

phenotyping identifies a subgroup of MS patients experiencing a pro-inflammatory immune cell activation upon therapeutic B cell removal–Silke H√§usser-Kinzel, Nitzan Nissimov, Zivar Hajiyeva, Wolfgang Brueck, Martin Weber

P4.2-052 Turning mechanistic

immunomodulatory insights into personalized treatment strategies for multiple sclerosis–Achilles Ntranos, Ilana B. Katz Sand, Patrizia Casaccia

P4.2-053 Delayed-release

Dimethyl Fumarate Treatment Shifts the Immune Repertoire in Patients With RelapsingRemitting Multiple Sclerosis: Results of PROCLAIM, an Open-label Phase 3 Study–Derrick Robertson, Tomasz Zielinski, Mark C. Cascione, Becky J. Parks, Chongshu Chen, Devanghi Mehta, Sami Fam MS EPIDEMIOLOGY, CO-MORBIDITIES, AND MODIFIABLE RISK FACTORS

P4.2-054 Clinical and

Radiological Correlates of Multiple Sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.–Estelle Seyman, Ashley Jones, Melanie Guenette, Jiwon Oh

P4.2-055 The Frequency

of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study–Solmaz Asnafi, Padraig Morris, Sean J. Pittock, Brian G. Weinshenker, Jacqueline Palace, Silvia Messina, Elia Sechi, Eoin P. Flanagan

P4.2-056 Integrative analysis

of risk burden, microbiome and metabolome in people at risk for multiple sclerosis–Zongqi Xia, Charles White, Yian Gu, Aleksandar Kostic, Philip De Jager

P4.2-057 Variation in

P4.2-058 Increased Risk of

Comorbidities in Patients Before and After Multiple Sclerosis Diagnosis and Initiation of Treatment: A Study Using the US Department of Defense Database–Rebecca Persson, Marianne Ulcickas Yood, Michael R. Wagner, Amber Evans, Sally Lee, Neil Minton, Steve Niemcryk, Anders Lindholm, Susan Jick

Co-morbidities in patients with Multiple Sclerosis in a Racially Diverse and Low Socioeconomic Status Population–Van Hellerslia, Edward J. Gettings, Mark Weiner, Huaqing Zhao

P4.2-060 Untreated Patients

with Multiple Sclerosis: Prevalence and Characteristics in Denmark and in the United States–Mette Nørgaard, Caroline Foch, Melinda Magyari, Emmanuelle Boutmy, Katalin Veres, Finn Sellebjerg, Per Soelberg Sorensen, Meritxell Sabidó Espin

P4.2-061 Diet during

adolescence and association with Multiple Sclerosis in Colombian patients–Jaime Toro, Daniel Noriega, Jorge Patiño, Maria I. Reyes-Mantilla, Lisseth Estefania Burbano, Saul Reyes, David Felipe Cuellar Giraldo, Fabián Cortés, Camilo Torres, Jorge Ríos, Alejandra Duque Ramirez

P4.2-062 Multiple Sclerosis

P4.2-065 The Economic

Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (On behalf of the NARCRMS Health Economics Outcomes Research [HEOR] Advisory Group)–Terrie Livingston, Yang Mao-Draayer, Kottil W. Rammohan, David K.B. Li, June Halper, Sara McCurdy Murphy, Lisa Patton

P4.2-066 A Modified

Mediterranean Dietary Intervention for Multiple Sclerosis: Results of a Pilot Study–Ilana B. Katz Sand, Elise Digga, Emma Benn, Richa Desphande, Samantha Gallo, Michelle Fabian, Aaron E. Miller, Lenore Arab

P4.2-067 The North American

Registry for Care and Research in Multiple Sclerosis (NARCRMS) (On behalf of the NARCRMS Site PIs)–Kottil W. Rammohan, David K.B. Li, June Halper, Sara McCurdy Murphy, Lisa Patton

Prevalence Rates Within a Healthcare Delivery System in Northern California: A Retrospective, Electronic Health Records-Based Study From 2010 to 2016–Robert Romanelli, Qiwen Huang, Joseph R. Lacy, Alana T. Wong, Lobat Hashemi, Alden Smith

P4.2-068 Food Allergies Are

P4.2-063 Dietary Intake and the

P4.2-069 The Impact of Social

Effect on Disease Progression in People with Multiple Sclerosis– Elisa Meier-Gerdingh, Kathryn Fitzgerald, Ralf Gold, Kerstin Hellwig

P4.2-064 Multiple Sclerosis

(MS) and Neuromyelitis optica (NMO): Admission trends, In-hospital Events, Outcomes, Treatment and Regional Differences In Distribution: A study of the National Inpatient Sample 2006-2014–Mohammad Rauf Afzal, Jiaqi Yao, Harathi Bandaru, Mushtaq H. Qureshi, Mohammad Ghatali, Anantha Vellipuram, Rakesh Khatri, Darine Kassar, Alberto Maud, Gustavo J. Rodriguez, Salvador Cruz-Flores

Associated With Increased Disease Activity In Multiple Sclerosis–Rami Fakih, Camilo Diaz-Cruz, Alicia S Chua, Cindy Gonzalez, Brian Curran Healy, Neda Sattarnezhad Oskouei, Bonnie Glanz, Howard L. Weiner, Tanuja Chitnis Capital on Patients with Multiple Sclerosis–Saul Reyes, Sebastian Suarez, Kimberley Allen-Philbey, Alison Thomson, Gavin Giovannoni

P4.2-070 The Natural History

of Primary Progressive Multiple Sclerosis in Buenos Aires, Argentina–Catalina Bensi, Mariano Marrodan, Jorge D. Correale, Mauricio Franco Farez

P4.2-071 National estimate

of incidence and predictors of 30-day readmission associated with multiple sclerosis using nationwide readmission database–Varun Kumar, Natalie Moreo, Chirag Narshibhai Savani, Chetan P. Gandhy, Derrick Robertson

P4.2-073 Oxysterols and

Apolipoproteins in Multiple Sclerosis: A 5-year Follow-up Study–Murali Ramanathan, Kelly Fellows, Sonia Bhattacharya, Mary Lou Bodziak, Dejan Jakimovski, Jesper Hagemeier, Richard Browne, Bianca WeinstockGuttman, Robert Zivadinov

P4.2-074 Generalizability of

the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS-PATHS) Data: Experience from a Single Site–Gabrielle Macaron, Hong Li, Malory Weber, Marisa P. McGinley, Jeffrey Alan Cohen, Robert A. Bermel

P4.2-075 Late Onset

Multiple Sclerosis: Clinical and Radiographic Characteristics– Smathorn Thakolwiboon, Amputch Karukote, Mirla L. Avila

P4.2-076 Sociodemographic

Factors Associated with Clinical Outcomes in CNS Inflammatory and Infectious Diseases: A Retrospective Cohort Study–Dan Tong Jia, Alexandra Boubour, Sarah Torres, Kathryn Rimmer, Gen Li, Yifei Sun, Kiran Thakur

P4.2-077 Driving Continuous

Improvement of MS Care Quality –Year One Experience and Findings from the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Research Collaborative–Brant Oliver, Amy Hall, Randy Messier, Michelle Patel, Caroline Geremakis

P4.2-078 Cognitive and clinical predictors of employment status among patients with Multiple Sclerosis in Argentina–Sandra Vanotti, Natalia Ciufia, Barbara Eizaguirre, Nadia Cabral, Cecilia Yastremiz, Aldana Marinangeli, Maria Laura Saladino, Orlando Garcea, Fernando Caceres

P4.2-079 Worsening of MS

Associated With Relapse Contributes to Disability Over the First 15 years–Daniel Diehl, Wisam Elmalik, Edward J. Gettings, Chris Hackett, Carol Schramke, Thomas F. Scott

P4.2-072 Lack of Low-

Frequency Complete-Penetrance Coding Variants Responsible from Familial Multiple Sclerosis–Aksel Siva, Elif Everest, Ugur Uygunoglu, Melih Tutuncu, Sabahattin Saip, Taskin Duman, Eda T. Turanli

AAN.com/view/AM19Sci 181

Wednesday

Employment Status among People with MS in the United States, United Kingdom and Germany– Amber Salter, Alexander Stahmann, Jeff Rodgers, Janina Schrader, Richard St. John Nicholas, Ruth-Ann Marrie, Rod Middleton

P4.2-059 Prevalence of Vascular

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.2-080 Personality traits

and perception of health-related quality of life in people with multiple sclerosis: An analysis of the NEO-FFI-3 and MSIS-29 questionnaires–Virginia Meca Lallana, Yolanda Higueras, María Brañas, Pedro Carrascal, Ofir Rodríguez-De la Fuente, Jorge Maurino, Javier Ballesteros

P4.2-081 Characteristics

of Multiple Sclerosis Patients Treated With Disease-Modifying Therapies in Puerto Rico–Joanne Chia, Manuel Nunez, Hector Hernandez, Gustavo Jimenez, Sibin Stephen, Lobat Hashemi

P4.2-082 Disability Level and

Headache: A Further Examination of these Comorbid Conditions in Patients Receiving Care in a Multiple Sclerosis Center: A Cross-Sectional Study–Kathryn Schaubhut, Kaitlyn Morio, Laura J. Balcer, Leigh Elkins Charvet, Richard B. Lipton, Mia T. Minen

P4.2-089 Economic Burden of

Multiple Sclerosis in Egypt – A Societal Perspective–Magd Fouad Zakaria, Mai Sharawy, Mohamed Raed, Islam Anan MS SPECIAL POPULATIONS: PREGNANCY AND PEDIATRICS

Comorbidity Burden among Multiple Sclerosis (MS) Patients in the US–Lauren Bartolome, Regina Berkovich, M. Janelle CambronMellott, Jeffrey Bramlett, Wendy Su, Patricia Russo

P4.2-090 No Evidence of

P4.2-083 MS race: How does

Pregnancy-Related Issues in Multiple Sclerosis Patients: the Patient’s Voice.–Casey Engel, Myla D. Goldman

speed affect our patients–Ricardo Alonso, Barbara Eizaguirre, SIlva Berenice, Cecilia Pita, Sandra Vanotti, Domingo Orlando Garcea

P4.2-084 Modifiable Risk

Factors and Risk of Disability Progression after a First Demyelinating Event: a Long Term Follow-Up Study–Gloria Dalla Costa, Mario Risi, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Giancarlo Comi, Vittorio Martinelli

P4.2-085 Benign Multiple

Sclerosis - Recognition as a Defined Clinical Subtype–Sophia Yang, Madison Clague, Saud A. Sadiq

P4.2-086 Multiple sclerosis

Wednesday

P4.2-088 Multiple Sclerosis and

mortality in patients from an Argentine cohort–Franco Appiani, Carla Florencia Bolaño Diaz, Guido Vazquez, Maria Celeste Curbelo, Judith Diana Steinberg, Blas Couto, Adriana Carra

P4.2-087 Updates to the

National Institute of Neurological Disorders and Stroke (NINDS) Multiple Sclerosis (MS) Common Data Element (CDE) Recommendations: 2018 MS Oversight Committee (OC) Review–Katelyn Elizabeth Gay, Ilar Edun, Muniza Sheikh, Joy R. Esterlitz, Fred D. Lublin, Ursula Utz, Codrin I. Lungu, Carolina Mendoza-Puccini

182 2019 AAN Annual Meeting

Disease Activity in Pediatriconset Multiple Sclerosis Patients Receiving Rituximab–Nikita Shukla, Timothy E. Lotze

P4.2-091 A Survey Study of

P4.2-092 Neurofilament Light

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.2-094 Anti CD20

Therapies and Pregnancy in Neuroimmunological Disorders – A Case Series from Germany–Tania Kuempfel, Sandra Thiel, Ingrid Meinl, Antonios Bayas, Andrea Ines Ciplea, Frank Hoffmann, Ulrich Hofstadt-van Oy, Muna-Miriam Hoshi, Antje Neubert, Marius Ringelstein, Orhan Aktas, Muriel Stoppe, Florian Then Bergh, Björn Tackenberg, Annette Walter, Martin Weber, Ralf Gold, Kerstin Hellwig

P4.2-095 Pregnancy Outcomes

From an International Registry of Patients Treated With Delayedrelease Dimethyl Fumarate– Nicholas J. Everage, Cynthia C. Jones, Kerstin Hellwig, David Rog, Shifang Liu, Jiani Mou, Claudia Prada, Jerome Hanna

P4.2-096 Pregnancy outcomes

in patients with multiple sclerosis and exposure to branded glatiramer acetate–Shahd Qassem, Sigal Melamed-Gal, Peleg Baruch

Chain Levels In Pregnant Multiple Sclerosis Patients–Juan Pablo Cuello, Maria Luisa Martinez Ginés, Jens Kuhle, Jose Manuel Garcia Dominguez, Alberto Lozano Ros, Fernando Romero Delgado, Yolanda Higueras, Ariana Meldaña Rivera, Haydee Goicochea Briceño, Santiago Garcia Tizon, Huan De-Leon Ruiz, Roberto Alvarez Lafuente, Maria Inmaculada Domínguez-Mozo, Silvia Perez Perez, silvia Medina Heras, jose ignacio Fernández Velasco, Amalia Tejeda-Velarde, Clara De Andres, Luisa Maria Villar

P4.2-097 Minimal

P4.2-093 The use natalizumab

Continuous vs. Cyclic Oral Contraceptives in Women with Multiple Sclerosis–Chelsea Chen, Tanya Krishnakumar, William Rowles, Annika Anderson, Lynn Do, Riley Bove

in multiple sclerosis patients during pregnancy is safe and prevents disease reactivation– Raed Alroughani, Samar Farouk Ahmed, Doaa Elsherbeny, Jasem Yousef Al-Hashel

concentrations of rituximab in the breastmilk of women treated for multiple sclerosis–Sara LaHue, Kristen M. Krysko, Alice Rutatangwa, Annika Anderson, William Rowles, Lynn Do, Riley Bove

P4.2-098 Obstructive

Sleep Apnea in Pediatric Neuroinflammatory Conditions–Michelle Jasmin Jaeggi, Stephanie Grover, Tara Berenbaum, Samantha Stephens, Shelly K. Weiss, E. Ann Yeh

P4.2-099 Comparison Of

P4.2-100 Pregnancy Outcome in Multiple SclerosisPatients Exposed to Disease ModifyingTherapies.–Samar Farouk Ahmed, Manal Almuteri, Jasem Yousef Al-Hashel, Raed Alroughani

P4.2-101 Pregnancy

Outcomes from the Global Pharmacovigilance Database on Interferon Beta-1b Exposure– Kerstin Hellwig, Fernando Duarte Caron, Eva-Maria Wicklein, Aasia Bhatti, Alessandra Adamo

P4.2-102 Effects of Pregnancy

on Specific Domains of Multiple Sclerosis Symptoms: A Quality Improvement Project at UPMC– Shreya Nayak, Sandra Alhaj, Rock A. Heyman, Janet F. Waters

P4.2-103 Rituximab for

Treatment of Aggressive Multiple Sclerosis During Pregnancy: A Case Series–Jessica Rice

P4.2-104 Diagnostic value of

oligoclonal bands in children: A nationwide populationbased cohort study–Magnus Spangsberg Boesen, Alfred Peter Born, Poul Erik Hyldgaard Jensen, Finn Sellebjerg, Morten Bjorn Blinkenberg, Magnus Christian Lydolph, Mikala Klok Jørgensen, Lene Rosenberg, Jesper Qvist Thomassen, Malene Landbo Børresen

P4.2-105 Plasma Exchange

and Natalizumab Rescue Therapy for Severe Intrapartum Multiple Sclerosis Relapses–Eoghan Patrick Deasy, Niall O’Mara, Orna O’Toole

P4.2-106 Grip Fatigability

but not Strength Discriminates those with Pediatric Onset Multiple Sclerosis from Controls– Giuseppina Pilloni, Michael Shaw, Raghav Malik, Lauren B. Krupp, Leigh Elkins Charvet UNUSUAL STROKE ETIOLOGIES, PRESENTATIONS AND TREATMENTS

P4.3-001 Mid-Atlantic Region State Ratios of Emergency Hyperbaric Chambers (EHC) to Comprehensive Stroke Centers (CSC) for Symptomatic Cerebral Air Embolus (SCAE)–Reid D. Taylor, Bill Owens, Cathy Grindstaff, Katherine Shulman

P4.3-002 Unusual Cause of

Acute Ischemic Stroke: A Case of Cerebral Air Embolism Post Transthoracic Lung Biopsy– Golshan Fahimi, Hamid Rajebi

P4.3-003 A Rare Case of Air

Embolus During Administration of tPA for Acute Ischemic Stroke– Kristopher Southard, Tracey Huijun Fan, Lucy Zhang, Dhimant Dani, Jayashree Sundararajan

P4.3-004 A case of accidental

ingestion of Hydrogen Peroxide causing massive cerebral gas embolic strokes–Panna Lal Bhattacharyya, Supriya Kairamkonda, Sanjeeva Reddy Onteddu, Krishna Nalleballe, KellyAnn Patrice

P4.3-005 Cerebral Fat Embolus

(CFE): A Rare Cause of Multifocal Infarctions with Potential for Full Recovery–Reid D. Taylor, Katherine Shulman, Jackie Gosnell, Terrie Smith, Melissa Hoffman, Thomas Large

P4.3-006 Tip-of-the-

Basilar Stroke secondary to Fat Embolization after Hip Arthroplasty–Mangala Gopal, Gaurav Thakur, Sushil Sham Lakhani, Archana Hinduja

P4.3-007 Erythrocytapheresis: An emerging treatment option for cerebral fat embolism from hemoglobinopathy related bone marrow necrosis.–Areena Siddiqui, Aparna Vaddiparti, Sanjay Mittal

P4.3-008 Delayed Diagnosis

of Fibrocartilaginous Embolism: Assessing the Vertebral Body on MRI–Estevana Isaac, Steven C. Swavely, Kiran Talekar, Joseph Caleb McCall

P4.3-009 CNS Manifestations

of Hemophagocytic Lymphohistiocytosis (HLH)–Hunter Edwards, Katherine Shulman, Reid D. Taylor Polycythemia as an Uncommon Cause of Large Vessel Occlusion Resulting in Acute Ischemic Stroke–Bhageeradh Mulpur, Lacy Samuel Handshoe, Andrew Blake Buletko

P4.3-011 Multiterritorial

ischemic strokes in idiopathic hypereosinophilic syndrome– Kyung Jung “Paula” Lee, Matthew W. Rondeau, Furha Cossor, Michal Vytopil, Barbara Voetsch

P4.3-021 Isolated Cervical

P4.3-030 Outcomes of Acute

P4.3-013 Prudent testing

P4.3-022 Intravascular

P4.3-031 Thermoregulatory

in Cancer Patients. A CaseControl Study–Agustin Pappolla, Pedro Colla, Claudia Alonzo, Laura Brescacin, Alejandra Heriz, Andrea Horsch, Idaira Payares Utria, Federico Anrriquez, Federico Nicolas Sosa Albacete, Maria Justich, Maria Zurru

of factor V Leiden in Ischemic stroke–Shivakrishna Kovi, Anthony Noto

P4.3-014 An Uncommon

Lymphoma Presenting with Spinal Cord Infarct and Recurrent Ischemic Strokes–Stephanie Lyden, Rima Dafer

Cause of Multifocal Intracerebral Hemorrhages: Adult-Onset Leukoencephalopathy with Calcifications and Cysts–Nataliya Pyatka, Julia Ting Bu, Mark Cohen, Cathy A. Sila

P4.3-023 Simultaneous Epidural

P4.3-015 Lacunar Strokes in

Due to Anterior Disco-osteoarterial Conflict Mimicking Stiff Person Syndrome–Olwen Murphy, Philippe Gailloud, Scott Douglas Newsome

Cryptococcal Meningitis: Clinical and Radiographic Features in a U.S. Cohort–Daniel Vela-Duarte, Eric Nyberg, Stefan Sillau, Paula Castellanos, Daniel Chastain, Carlos Franco-Paredes, Andrés Henao-Martínez

P4.3-016 Hypertension

Increases Risk of Ischemic Stroke in Multiple Sclerosis: Retrospective Analysis of a National Database–Asad Ikram, Fares Qeadan, Mudassir Farooqui, Sajid Suriya, Maryam Zulfiqar, Dinesh V. Jillella, Ashley Wegele, Corey C. Ford, Michel T. Torbey, Atif Zafar

P4.3-017 Fabry disease and

Stroke: Effectiveness of Enzyme Replacement Therapy (ERT) in Stroke Prevention, a Review with Meta-Analysis–Sen Sheng, Leihong Wu, Yohei Harada, Hisham Gibriel Bakhiet Elkhider, Nidhi Kapoor, Onteddu Reddy, Krishna Nalleballe

P4.3-018 Sickle Cell Trait and

Risk for Early-Onset Ischemic Stroke–Rebecca Zhang, Kathleen Ryan, Haley Lopez, Zachary Flair, John Cole, Marcella A. Wozniak, Michael Phipps, Jose G. Merino, Carolyn Cronin, Steven J. Kittner

P4.3-019 Degos’ disease: the

hint is in the skin–Daniel Calame, William Lapin, Monica Marcus, Lisa M. Nassif

P4.3-020 Diagnostic Challenges in Vascular Myelopathies– Michlene Passeri, Ram Narendra Narayan

Anterior Spinal Artery Aneurysms (CASAAs): A Case Series and The Comprehensive Outcome Analysis of surgical vs nonsurgical interventions–Pooja SirDeshpande, Lakshmi Leishangthem, Robert W. Hurst, Sudhakar R. Satti

and Intramedullary Hemorrhage: A Case Report.–Shailee Samir Shah, Christina Lineback, Richard A. Bernstein

P4.3-024 Spinal Claudication

P4.3-025 Spinal Cord Infarction:

A Diagnostic Challenge–Michlene Passeri, Ram Narendra Narayan

P4.3-026 CADASIL in a

Patient with Bilateral Internal Carotid Artery Agenesis–Allycia MacDonald, Tony Alvaro

P4.3-027 Rapidly progressive

dementia with seizures due to venous hypertension from arteriovenous hemodialysis graft–Maria Antonietta Mazzola, Anil Ramineni, Joseph D. Burns, David P. Lerner

P4.3-028 Recurrent Stroke

in Giant Cell Arteritis Despite Immunotherapy–Benjamin Cox, Jimmy R. Fulgham, James P. Klaas

Basilar Occlusion Ischemic Strokes with Advent of Modern Thrombectomy Devices, a New York State Experience–Husitha Reddy Vanguru, Rayan Mamoon, Carlos Ynigo Dy Lopez, Hesham Masoud, Karen C. Albright, Amelia Katharine Boehme Dysfunction in a Patient with Locked-in Syndrome Due to Bilateral Ventral Pontine Infarction–Morgan Christina Jordan, Paul Martin Elsbernd, John H. Sladky

P4.3-032 Outcome in Acute

Basilar Artery Occlusion Based on Time and Severity at Presentation: A Retrospective Review–Sajid Suriya, Piotr Bzdyra, Mudassir Farooqui, Asad Ikram, Saif A. Bushnaq, Saji Bushnaq, Christine Meadows, Michel T. Torbey, Atif Zafar

P4.3-033 Association of

Functional Outcome in Basilar Artery Occlusion in Relation to Baseline Comorbidities: A Retrospective Review–Piotr Bzdyra, Sajid Suriya, Asad Ikram, Saji Bushnaq, Christine Meadows, Mudassir Farooqui, Saif A. Bushnaq, Atif Zafar, Michel T. Torbey

P4.3-034 Interrater Agreement for Measurements of Vertebral Artery Origin Stenosis–Caitlin Bell, Shailesh Male, Laura Bell, Hussain Tore, Christopher Streib

P4.3-035 Comparison

CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY: VERTEBRAL AND BASILAR ARTERY DISEASE

Between Medical Therapy And Endovascular Treatment Of Extracranial Atherosclerotic Vertebral Artery Disease: A Systematic Review–David Daniel, Muhammad Zeeshan Memon, Shahram Majidi, Haydee Del Calvo, Chen Chen, Yan Ma, Adnan I. Qureshi

P4.3-029 Outcomes of

P4.3-036 Prevalence of

Mechanical Retrieval Therapy in Basilar Artery Occlusions: A Single Center Study–Angela M. Hawkins, Harold H. Morris, Coleman Martin

Atherosclerotic Vertebrobasilar Disease in patients with Ischemic Stroke in an Argentinian cohort of patients–Lucrecia Bandeo, Miguel A. Saucedo, Marta Bala, Luciana Vanesa Leon Cejas, Maria Sol Pacha, Marcela Uribe Roca, Pablo Bonardo, Manuel Fernandez Pardal, Ricardo C. Reisin

AAN.com/view/AM19Sci 183

Wednesday

P4.3-010 Secondary

P4.3-012 Acute Ischemic Stroke

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.3-037 Second Generation

Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single-Center Experience–Aldo Mendez Ruiz, Gloria Lopez Cardenas, Jorge Roa, Cynthia Zevallos, Andrea Holcombe, Biyue Dai, Sudeepta Dandapat, Edgar A. Samaniego, Santiago OrtegaGutierrez

P4.3-038 : Vertebral artery

origin stenosis: systematic review of randomized clinical trials– Chizoba Ezepue, Randall Edgell, Andre Guthrie STROKE GENETICS AND EPIDEMIOLOGY

P4.3-039 Concerning Temporal

Trends in Transient Ischemic Attack Hospitalization–Jonathan William Sahawneh, Melissa Gazi, Michael J. Lyerly

P4.3-040 Healthcare Utilization

Prior to Fatal Stroke Admission: Nationally Representative Data–Sarah Alexandra Levy, Laura Stein, Mandip Singh Dhamoon

P4.3-041 A Comparative Case

Series of Haitian and non-Haitian Acute Stroke Patients at a Single Center in Miami, Florida–Kristen Taylor Ashourian, Thomas Weppelmann, Juan Lopez, Benjamin Sirutis, Chistopher Brown, Amy Starosciak, Juan Lozano, Diana M. Barratt

P4.3-042 Stroke in Himalayan Region of Nepal: Knowledge and Awareness of Early Management–Rajeev Ojha, Krishna Kumar Oli

Wednesday

P4.3-043 Acute Stroke

Management: A Plight of Nepal–Avinash Chandra, Basant Pant

P4.3-044 Hospital-based Stroke Register Studies and Clinical Features and Outcomes of Stroke Patients in China and other Asian Countries: A Systematic Review–Chen Ye, Wendan Tao, Yao Xiong, Liu Ming

P4.3-045 Effect of

Documentation Patterns on Prevalence of Comorbid Conditions in Ischemic Stroke– Dinesh V. Jillella, Moein Amin, Shumei Man, Ken Uchino

184 2019 AAN Annual Meeting

P4.3-046 Genome-wide DNA

methylation profiling in peripheral blood from different TOASTsubtypes stroke patients.–Juan Marta-Enguita, Idoia RubioBaines, Amaya Urdanoz-Casado, Idoia Blanco-Luquin, Aiora Ostolaza, Miren Roldan, Alberto Labarga, Jaime G. Gallego, Roberto Muñoz, Maite Mendioroz

P4.3-047 Serious Misdiagnosis-

Related Harms Due to Missed Vascular Events in the United States—Incidence, Settings, and Causes–Ali Shabahang Saber Tehrani, Najlla Nassery, Adam Schaffer, Chihwen Yu-Moe, Gwendolyn Clemens, Zheyu Wang, Mehdi Fanai, Dana Siegal, David E. Newman-Toker HEART BRAIN CONNECTIONS

P4.3-048 Prevalence and

Prognosis of Atrial Fibrillation Among Hospitalized Ischemic Stroke Patients with Comorbid Seizures in the United States– Alain Zingraff Lekoubou Looti, Kinfe Bishu, Bruce I. Ovbiagele

P4.3-049 Factors associated

with atrial fibrillation detection on longterm cardiac monitoring in Stroke–Jane Khalife, Shyam Majmundar, Diana Tzeng, Robin N. Dharia, Shaista Alam, Fred Rincon, Pascal Jabbour, Dan Frisch, Reginald Ho, Arnold Greenspon, Rodney D. Bell, Nabeel Herial

P4.3-050 N-Terminal Probrain

Natriuretic Peptide as a marker for diagnosis of Cardioembolic Stroke–Virti Shah, Anshu Rohatgi, Chandrashekhar Agrawal, Rajeeev Ranjan, Seema Bhargava, Yatin Sagvekar

P4.3-051 Recurrent Ischemic Stroke secondary to Left Ventricular Non-compaction– Keithan Sivakumar, Hussam A. Yacoub

P4.3-052 Advanced Cardiac

Imaging In Patients With Ischemic Stroke. When To Scan?–Mohamad Orabi, Shaun Ajinkya, Jimmy Suh, Tarun Girotra, Chirantan Banerjee

P4.3-053 Neurologic

Complications during Short-term Cardiac Support with Impella Devices–Catherine Hassett, Sung Min Cho, Ibrahim Migdady, Cory J. Rice, Ken Uchino

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.3-054 Rate of ischemic

stroke and intracranial hemorrhage following left ventricular assist device placement: a systematic review–Mohammed Alhaidar, Hamidreza Saber, Ali Ebrahim, Kumar Rajamani

P4.3-055 Therapeutic

Anticoagulation after Ischemic Stroke in Patients with LVADs does not cause Hemorrhagic Conversion: A Single Center Retrospective Study–Jeffrey Ruta, Ivan Cuesta Isabel, David Rahimian, Arslan Mirza, Mitchell Silver, Yoshiya Toyoda, Eman Hamad, Imama Ali Naqvi

P4.3-056 Simultaneous

cardio-cerebral infarction: A rare phenomenon–Parul Goyal, Shreyas Gangadhara

P4.3-057 A Retrospective

Analysis of Anticoagulation Reinstitution in Patients with Left Ventricular Assist Device who Developed Intracerebral Hemorrhage at Mayo Clinic Arizona–Sara Dawit, Christan Santos, Nikki Matos, William David Freeman, Cumara Barahona O’Carroll

P4.3-058 Comparison of Point of Care Ultrasound to Standard Transthoracic Echocardiography for Acute Stroke and TIA–n aijb

P4.3-059 Neurological

outcomes of patients with mycotic aneurysms in infective endocarditis–Hang Shi, Harsh Shah, Ives Valenzuela, Neal S. Parikh, Jose Gutierrez, Joshua Z. Willey

P4.3-060 Outcome of

Thrombectomy in Stroke Due to Infective Endocarditis: A Case Series–Elie Sader, Natalie Thom, Sandra McDonald, Mohamad Abdalkader, Thanh Ngoc Nguyen, David M. Greer, Anna Marisa Cervantes-Arslanian

P4.3-061 Utility Of Retrieved

Thromboembolism Tissue Culture In A Patient With Suspected Infective Endocarditis–Anand Vilaschandra Patel, Jeffrey M. Katz, Richard Libman

P4.3-062 Prior Antithrombotic

Therapy is Associated with Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease–Yajun Cheng, Junfeng Liu, Shuting Zhang, Jie Li, Chenchen Wei, Yanan Wang, Liu Ming

P4.3-063 Trends of patent

foramen ovale (PFO) closure from 2008 to 2014 at National level: US experience–Rakesh Khatri, Mohammad Rauf Afzal, Ihtesham A. Qureshi, Shayan Ul Haque, Harathi Bandaru, Anantha Vellipuram, Paisith Piriyawat, Alberto Maud, Salvador CruzFlores, Gustavo J. Rodriguez

P4.3-064 Identifying Patients

with Cryptogenic Stroke Eligible for PFO Closure–Mona Al Banna, Apameh Salari, Kamakshi Lakshminarayan, Gregg D. Meekins, Christopher Streib

P4.3-065 Does Risk of

Paradoxical Embolism (ROPE) score correlate with PFO closure criteria?–Apameh Salari, Mona Al Banna, Kamakshi Lakshminarayan, Gregg D. Meekins, Christopher Streib SYSTEMIC DISEASE AND STROKE

P4.3-066 The Impact of

Chronic Kidney Disease Stage on Intracranial Vascular Resistance– Shivani Ghoshal, Jonathan Gomez, Barry Freedman, Aarti Sarwal, Charles H. Tegeler

P4.3-067 Impact of renal failure on acute stroke–Franco Appiani, Carla Florencia Bolaño Diaz, Blas Couto, Guido Vazquez, Carlos Santiago Claverie, Francisco Klein

P4.3-068 Stroke and Retinal

Microvascular Abnormalities– Claudia Paola Veasquez Carretero, Maria Agustina Rubio Bonnet, Maria Graciela Cersosimo, Maria Carolina Gonzalez Perez, Maria Emilia Tajan, Florencia Judith Cardillo, Mario Javier Halfon, Adriana Kohn, Pablo Shubaroff

P4.3-069 The Black Sheep

of Stroke Etiologies: Visual Abnormalities and Cerebral Infarction in Association with Lambl’s Excrescences–Micah Etter, Preeth Manu, Chelsea S. Kidwell

P4.3-070 Exploring the

Relationship Between Chronic Obstructive Pulmonary Disease and Posterior Reversible Encephalopathy Syndrome—a possibly under-recognized cause of an uncommon syndrome– Nneka Stacy Amadife, Jessica Doyle Lee

P4.3-071 Predictors of favorable response to the placement of the ventriculoperitoneal shunt in patients with idiopathic normal pressure hydrocephalus–Mario Ricciardi, Lucas Alessandro, Ismael Luis Calandri, Mauricio Franco Farez, Juan Villalonga, Martin Fausti, Frida Herrmann, Ricardo F. Allegri

MOTOR NEURON DISEASE

P4.4-001 A case of aggressive motor neuron disease without profound loss of motor neuron cells–Yin Allison Liu, Yan Chen Wongworawat, Ravi Raghavan, Jeffrey Rosenfeld

P4.4-002 Correlation between

P4.4-007 Observational

Quantitative Data in Adult Patients with SMA Dosed with Nusinersen–Cosette M. Burian, Ashley Bozeman, Teepu Siddique, Robert L. Sufit, John-Michael Li, Jinny O. Tavee, Lisa Wolfe, John R. Coleman, Senda Ajroud-Driss

P4.4-008 Feasibility and

Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis–Namita Goyal, Marie Wencel, Nadia Araujo, Lishi Zhang, Eileen Medina, Isela Hernandez, Tahseen Mozaffar

P4.4-009 Monitoring and

promoting effectiveness and adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring: a pilot and feasibility, randomised controlled trial.–Treesa James, Esther Hobson, Natasha Mupambo, Christopher McDermott

P4.4-010 Accelerated Pathology

Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis–Lisa Meng, Stacy A. Rudnicki, Noah Lechtzin, Bettina Cockroft, Fady I. Malik, Andrew A. Wolff, Jeremy M. Shefner

in Chlorovirus (ATCV-1) Infected SOD1G93A Transgenic ALS Mice and Association of Increased Serum Anti-ATCV-1 IgG1 Subclass with ALS–Gary L. Pattee, Tom Petro, James Van Etten, David Dunigan, Irina Agarkova, Zack Guinn

P4.4-003 Survival prediction

P4.4-011 Brain White Matter

models in motor neuron disease– Edoardo G. Spinelli, Federica Agosta, Nilo Riva, Andrea Fontana, Silvia Basaia, Elisa Canu, Veronica Castelnovo, Yuri Falzone, Paola Carrera, Giancarlo Comi, Massimo Filippi

P4.4-004 Meta-analysis of

P4.4-005 Two Cases of

Spinal Muscular Atrophy due to Mutations in the VRK1 Gene– Angela R. Sung, Paolo M. Moretti, Aziz I. Shaibani

P4.4-006 Oculomotor

Dysfunction in Motor Neuron Disease–Christine Lu, Clover Youn, Sergei Yakushin, Jonathan Cauchi, Daniel J. MacGowan, Stephen N. Scelsa

P4.4-012 Nusinersen for spinal

muscular atrophy - results of an expanded access programme– Maria Mazurkiewicz Beldzin, Katarzyna Kotulska-Józwiak, Ilona Kopyta, Sandra Modrzejewska, Ewa Emich-Widera, Katarzyna Tomaszek, Justyna Paprocka, Olga Judith Hernandez Fustes, Jacek Pilch, Jerzy Pietruszewski, Anna Lemska

P4.4-013 Fat mass loss

correlates with survival in amyotrophic lateral sclerosis patients: prospective cohort study–Ikjae Lee, Mohamed Kazamel, Peter H. King

system in ALS: Comparison of the US and European Populations– Justin Y. Kwan, Diana Zhenmei Li, Brooke Lubinski, Anahita F. Deboo, Monserrat Diaz-Abad, Ammar Al-Chalabi, Terry D. HeimanPatterson

P4.4-015 Nusinersen in Adults

with Spinal Muscular Atrophy, A Single Center Experience–Orly Moshe-Lilie, Nizar Chahin, Amy C. Visser, Diana Dimitrova, Chafic Y. Karam

P4.4-016 Spinal Muscular

Atrophy: A Review of Epidemiology, Burden and Unmet Needs–Aoife Callan, Thej Kumar Nallagangula, Shantanu Jawla, Herve Jullien De Pommerol, Valery Risson

P4.4-017 Determinants of

Mortality Among Hospitalized Patients with Amyotrophic Lateral Sclerosis – Results from the 2016 National Inpatient Sample–Gilbert J. L’Italien, Irfan Qureshi, Brendan Clark, Zachary Simmons

P4.4-018 Analysis of nutritional

status as a predictor of survival in patients with bulbar amyotrophic lateral sclerosis (ALS)–Mariela Bettini, Gisella Gargiulo Monachelli, Maria Florencia Teves Echazu, Carolina Azcona, Marcelo Francisco Rugiero

P4.4-019 Dextromethorphan-

Quinidine (Nuedexta) Improves Swallowing in Bulbar Onset ALS Patients with Pseudobulbar Affect - Pre-Post Observational Study in 86 ALS Patients–Nathasha Saurin Shah, Kathryn Wright, Elena Bravver, Urvi G. Desai, Velma L. Langford, William Bockenek, Scott C Lindblom, Any Linville, Fawn Paling, Tiffany Williamson, Benjamin R. Brooks

P4.4-020 Structural and

Functional Organization of the Brain Connectome in Patients with Different Motor Neuron Diseases: A Multicenter Study– Federica Agosta, Silvia Basaia, Francesca Trojsi, Nilo Riva, Camilla Cividini, Cinzia Femiano, Cristina Moglia, Maria Monsurrò, Yuri Falzone, Andrea Falini, Giancarlo Comi, Adriano Chiò, Gioacchino Tedeschi, Massimo Filippi

P4.4-021 CX3CL1 Disruption

Differentially Influences the Neuroprotective Effects of Mesenchymal Stromal Cells on ALS–Dongya Huang, Xiaoyan Zeng

P4.4-022 Adherence to

Riluzole Therapy Improves Time to and Frequency of All Cause Hospitalization in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis.–Gilbert J. L’Italien, Irfan Qureshi, Enrique Arvelo, Zachary Simmons

P4.4-023 Diffusion Tension

Imaging as the Biomarker for Amyotrophic Lateral Sclerosis– Seol-Hee Baek, JinSeok Park, Yoo Hwan Kim, Hung Youl Seok, Ki-Wook Oh, Heejin Kim, Ye-Ji Kwon, Youngbo Sim, Woo-Suk Tae, Seung Hyun Kim, Byung-Jo Kim

P4.4-024 Diminshed Muscle

Oxygenation During Exercise in Ambulatory Spinal Muscular Atrophy Patients–Jacqueline Montes, Ashley Goodwin, Michael McDermott, Feliz-Marie Hernandez, Kayla Coutts, Ashwini K. Rao, Carol Garber, Darryl C. De Vivo

P4.4-025 Population Based

Surveillance and Survival Characteristics of Amyotrophic Lateral Sclerosis (ALS) Cases in the Atlanta Metropolitan Area, 2009 – 2011–Reshma Punjani MPH, Wendy Eileen Kaye, Laurie Wagner, D. Kevin Horton

P4.4-026 Factors Associated

with Poor Compliance of Noninvasive Ventilator Support in Patients with ALS–Anem Kohli, Carol Schramke, Sandeep S. Rana

P4.4-027 Clinical Factors

Predicting Cognitive Errors in The Misdiagnosis of Amyotrophic Lateral Sclerosis (ALS)–Rohit Gummi, Catherine Rodriguez, Emily Bailey, Anudeep yelam, Elanagan Nagarajan, Raghav Govindarajan

P4.4-028 Facial Onset SensoryMotor Neuronopathy: A Series of Two Cases Illustrating a Disease Spectrum–Rabia Yasin, Amro Stino, Adam Quick, Chad Hoyle, William D. Arnold, Samantha Jo LoRusso, Stephen J. Kolb

AAN.com/view/AM19Sci 185

Wednesday

Genetic Expression Profiles in Amyotrophic Lateral Sclerosis– Samuel A. Frank, Jihad Aljabban, Clara Castillejo Becerra, Dexter Hadley, Adam Quick

MRI Differentiates Kennedy’s Disease from Other Motor Neuron Disease Clinical Phenotypes– Edoardo G. Spinelli, Pilar M. Ferraro, Giorgia Querin, Nilo Riva, Cinzia Bertolin, Ilaria Martinelli, Christian Lunetta, Andrea Fontana, Gianni Soraru, Massimo Filippi, Federica Agosta

P4.4-014 Validation of a staging

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.4-029 Frequency,

Symptomology, and Course of HIV-Associated ALS: Case Series and Review–Zachary Satin, Elham Bayat

P4.4-030 Primary Lateral

Sclerosis (PLS) vs. Hereditary Spastic Paraperesis (HSP) in Presenilin-1 (PSEN1) related Dominant Dementia–Ghazaleh Ahmadi Jazi, Jonathan Cauchi, Ali Habib, Namita Goyal, Tahseen Mozaffar

P4.4-031 Multielectrode array

analysis of human iPSC-motor neuron maturation following co-culture with iPSC- spinal cord astrocytes–Arens Taga, Raha Dastgheyb, Jessica Joseph, Christa Habela, Jean-Philippe Richard, Norman Haughey, Nicholas J. Maragakis

P4.4-032 Patient-Reported

Outcomes Measures in Children with Spinal Muscular Atrophy– Valery Risson, Thej Kumar Nallagangula, Vivek Khurana, Herve Jullien De Pommerol, Aoife Callan

P4.4-033 Co-existing riboflavin transporter deficiency (RTD) type 2 and muscle AMP deaminase deficiency in two long-term RTD survivors: report of a family–Lin Zhang, Dominic Thyagarajan

P4.4-034 Effect of Radicava

on Uric Acid Levels: Preliminary Results–Terry D. HeimanPatterson, John Furey, Isabelle Kaminer, Anahita F. Deboo, Justin Y. Kwan, Sabrina Paganoni NEUROPHYSIOLOGY IN NEUROMUSCULAR DISORDERS II

Wednesday

P4.4-035 Hybrid Recording

System of Electromyography and Ultrasound in Neuromuscular Disorder–Kenji Sekiguchi, Nobuo Kohara, Shunsuke Watanabe, Yoshikatsu Noda

P4.4-036 Safety of Needle

Electromyography in Critically Ill Intensive Care Unit (ICU) Patients–Elanagan Nagarajan, Keerthivas Premkumar, Anudeep yelam, Raghav Govindarajan

P4.4-037 Scrubber’s Radial

Palsy - Proximal Compression of the Radial Nerve at the Origin of the Brachioradialis–Crystal Jing Jing Yeo, Amanda C. Guidon, Suma Babu

186 2019 AAN Annual Meeting

P4.4-038 The Neurophysiology

of Oxaliplatin Effects on Peripheral Nerve–Mark M. Stecker

P4.4-039 Increased Incidence

of Martin Gruber Anastomosis in Individuals with Ulnar Neuropathy–Shreya Gandhy, Mary Russo, Faranak Najibi, Elham Bayat

P4.4-040 The Sensitivites of

Median Mixed Palmar Distal Latencies in the Diagnosis of Carpal Tunnel Syndrome (Onset, Peak, Either Onset or Peak, or Onset and Peak)–Elie Sader, Alexandre Mason Sharma, Michelle Kaku, Peter Siao Tick Chong

P4.4-041 The effect of

botulinum toxin injections on EMG–Robin Petrizzo, Dawn Dieke

EPILEPSY: EEG AND NEUROPHYSIOLOGY

P4.5-001 Lack of

Standardization of the Level of Encephalopathy on EEG: a Barrier to the Widespread Use of EEG for Brain Monitoring–Carolina B. Maciel, Eliezer Sternberg, Raj Desai, Jacqueline Baron-Lee, Nishi Rampal, Lawrence J. Hirsch, Emily Jean Gilmore

P4.5-002 The Sounds of

Seizures: Audio-Triggered Detection by Convolutional Neural Network (CNN)–Maysaa Merhi Basha, Alon Albalak, Hani Alhourani, Aashit K. Shah, Ming Dong

P4.5-003 Long-term Stability

of Interictal Spike Trajectories in Pediatric Invasive EEG Recordings–Samuel Tomlinson, Jeremy Wong, Erin Caitlin Conrad, Eric D. Marsh

P4.5-004 EEG source

localization comparing lowdensity EEG including subtemporal coverage with high density EEG–Omar A. Danoun, Benjamin Cox, Benjamin Henry Brinkmann, Lily Wong-Kisiel

P4.5-005 Age Norms of EEG

during Sleep from 0 to 100 years old–Luis Paixao, Haoqi Sun, Robert J. Thomas, Leila Kheirandish-Gozal, David Gozal, Sydney Cash, M. Brandon Westover

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.5-006 EEG Source Imaging from Standard Long-term Video EEG Recording in Patients with Medically-refractory Focal Epilepsy–Benjamin Cox, Omar A. Danoun, Lily Wong-Kisiel, Benjamin Henry Brinkmann

P4.5-007 Longitudinal Analysis

of Interictal EEGs in Patients with TLE and Hippocampal Sclerosis– Mariana Rabelo De Brito, Thiago Prado, Marina Koutsodontis Alvim, Lucas Santos, Clarissa L. Yasuda, Marcia E. Morita, Fernando Cendes

P4.5-008 Quantitative EEG

of Intracranial Recordings for Detection of Seizure Onset and Localization Compared to Standard Intracranial Tracing– Steven Gangloff, Alexandra Urban, Anto Bagic, Naoir Zaher

P4.5-009 Validation of a

dry-electrode EEG recording system: Results of a multi-reader blinded comparison to standard EEG–Katherine A. Zarroli, Halley Alexander, Derek Bauer, Seiji Tanabe, Christina Hucek, Mark S. Quigg

P4.5-010 Surface-

Electromyography (sEMG) Patterns of Clonic Bursts during Generalized Tonic-Clonic (GTC) Seizures–Damon Philip Cardenas, Shannon Voyles, Luke Whitmire, Jose E. Cavazos

P4.5-011 In the kingdom of

triphasic waves, white matter is the eminence grise–Ivan Kotchetkov, Brin Freund, Peter W. Kaplan

P4.5-012 Diagnostic Utility of

Continuous sEMG Monitoring in a Home Setting - Real-world use of the SPEAC® System–Luke Whitmire, Shannon Voyles, Damon Philip Cardenas, Jose E. Cavazos

P4.5-013 Is There a Role for

Magnetoencephalography in Pre-surgical RNS Implantation in Drug-Resistant Temporal Lobe Epilepsy?–Abdullah Alshammaa, Ryan Austin Keating, Nour Baki, Abhimanyu Mahajan, Gregory L. Barkley, Andrew J. Zillgitt, Susan M. Bowyer

P4.5-014 Glossokinetic

Potentials: Insights from intracranial EEG–Ayse Kacar Bayram, Dennis Spencer, Rafeed Alkawadri

P4.5-015 Ictal urinary

urgency localized by Stereoelectroencephalogram.–Dhara Murray-Frank, Huan Gia Huynh, Juan C. Bulacio, Imad M. Najm, Camilo Garcia

P4.5-016 The Prognostic

Value of Quantitative EEG in Patients Undergoing Mechanical Thrombectomy for Acute Ischemic Stroke–Adam Dickey, Weredeselam Olango, Matthew Charles Agan, William P. Roche, Panayiotis Mitsias, Michael R. Frankel, Jonathan Ratcliff, Gabriel M. Rodrigues, Raul G. Nogueira, Diogo Casarin Haussen, Ioannis Karakis

P4.5-017 Wearable Sensors

for the Detection of Convulsive Seizures–Ryan James McGinn, Mini Thomas, Esteve Hassan, Kugsang Jeong, Joseph C. Perumpillichira

P4.5-018 The Use of Collodion versus Traditional Paste for Reducing Artifact in Ambulatory Electroencephalography Studies in the Pediatric Population– Danielle Rachelle Brigham, Yash Shah, Ivan M. Pavkovic, Shefali Karkare, Sanjeev V. Kothare

P4.5-019 An Effective Tool for

Teaching EEG Interpretation to Residents and Medical Students– Meghan Hubert, Jacquelyne Cios, Maureen Cavalcanti, Anand Khurma

P4.5-020 Case Report: Change

in Electrocorticogram Detection of RNS with Initiation of Ketogenic Diet–Janet Greenwood, George Nune, Brain Lee, Charles Liu, Christi Heck

P4.5-021 Correlation of

Indicators of P300 Cognitive Potentials with Epilepsy Forms–Maruf Salokhiddinov, Rano Azizova

P4.5-022 Assessing Retinal

Cytoarchitecture between Temporal Onset Focal and Primary Generalized Seizure Types Utilizing Optical Coherence Tomography–Samuel LichtmanMikol, Melody Gilroy, Rachel Darling, Kalyan Yarraguntla, Rohit Ajay Marawar, Deepti Zutshi

P4.5-023 Normalized transfer

entropy used as an informational transfer measure of ictal pathophysiology in patients undergoing stereo-EEG for epilepsy surgery–Angelica M. Lee, Brian Litt, Jay Pathmanathan EPILEPSY: GENERAL MEDICAL ISSUES, PNES, AND OTHER

P4.5-024 The Relationship

between Seizures, Ictal-Interictal EEG Activity, Clinical Outcome, and Dynamic Neurologic Changes following Traumatic Brain Injury– Muhammad Muzzammil Edhi, Brigid Angelini, Maryum Shoukat, Solomon Kassa, Hassan Osama Mostafa Aboul Nour, Farrukh Javed, Elahe Bordbar, Mohammad Tabaeizadeh Fesharaki, Justin Gallagher, Sophie Stekhoven, Valdery Moura, Jin Jjing, Manohar Ghanta, M. Brandon Westover, Sahar Fatima Zafar, Eric Rosenthal

P4.5-025 Seizures after

Cardiovascular Surgery: An unexpected complication–Carla Florencia Bolaño Diaz, Franco Appiani, Ricardo Daniel Bernater, Pamela Bobadilla, Analia Calle, Veronica Campanille, Blas Couto, Carlos Santiago Claverie, Maria Elena Fontela, Alejandro Thomson, Guido Vazquez, Roberto Favaloro, Alfredo Thomson

P4.5-026 Prognosis and

Clinical Factors to Predict Seizure Recurrence in Patients with Alcohol-Related Seizures–Min Young Chun, Hyeon Jin Kim, Eunjin Kwon, Jee-Eun Lee, Chan Young Lee, Sol-Ah Kim, Yun seo Choi, Hyang Woon Lee

P4.5-030 Two Cases of

Provoked Seizure Associated With Kratom Ingestion–Devin John Burke, Annika Shearer, Anne C. Van Cott

P4.5-031 Medically Refractory

Epilepsy Associated with Celiac Disease–Amy Postelnik, Madeline Cara Fields

P4.5-032 Profile and Outcome

of Psychogenic Nonepileptic Seizures Patients undergoing Video-EEG Monitoring–Madison Wolfe, Sanjay P. Singh, Ram Mohan R. Sankaraneni

P4.5-033 An Institutional

Experience on Semiology of Psychogenic Nonepileptic Seizures–Golshan Fahimi, Shahram Izadyar

P4.5-034 Serum Levels of

Inflammasome Complex Factors are Suppressed in Focal Epilepsy Patients–Ebru Nur Yavuz, Erdem Tuzun, Canan Ulusoy, Cem Ismail Kucukali, Nerses Bebek, Betul Baykan

P4.5-035 Toll-like Receptor

3 Inhibition and its effect on epileptogenesis–Oded Shor, Felix Benninger

P4.5-036 Spanish Epilepsy

Education Available on the Web–Reyna M. Duron, Joana Carcamo, Victoria González, David Discua, Lupe Martinez, Susan Pietsch-Escueta NEUROEPIDEMIOLOGY: ALS, MS, PARKINSON’S DISEASE AND EPILEPSY

Incidence in Ischemic Stroke Patients Treated with Mechanical retrieval therapy: A Single Center Study–Harold H. Morris, Angela M. Hawkins, Coleman Martin

of a Large Cohort of US Patients Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015–Jaime Raymond MPH, Bjorn E. Oskarsson, Paul Mehta, Theodore Larson, D Kevin Horton DrPH

P4.5-028 Postencephalitic

P4.6-002 A comparison of the

P4.5-027 Acute Seizure

Epilepsy and Acute Symptomatic Seizures, in Infectious, Undetermined Etiology and Autoimmune Encephalitis–Abril Marone, Lucas Alessandro, Gabriela Ugarnes, Mauricio Franco Farez

P4.5-029 Epilepsia Partialis

Continua Secondary to Diabetic Ketoacidosis–Jacob Lee Van Orman, Tyler Koehn, Thomas Duginski

clinical and genetic features of Amyotrophic Lateral Sclerosis across Latin American and European populations–Orla Hardiman, Marie Ryan, Russel McLaughlin, Mark A Doherty, Tatiana Zaldivar Vaillant, Joachen hackembruch, Abayuba Perna, Maria Cristina Vazquez, Giancarlo Logroscino, Carlos N. Ketzoian, Joel Gutierrez, Gloria LaraFerandez

Thromboembolic Events Among Amyotrophic Lateral Sclerosis Patients in a US Health Insurance Claims Database–Varant Kupelian, Emma Viscidi, Sue T. Hall, Li Li, Susan A. Eaton, Anne Dilley, Nicolas Currier, Toby A. Ferguson, Laura Fanning

P4.6-004 Progression of

Symptoms in relation to the Site of Onset in Amyotrophic Lateral Sclerosis: new Evidence supporting the Prion-like Hypothesis–Adriano Chio, Andrea Calvo, Cristina Moglia, Antonio Canosa, Rosario Vasta, Sara Cabras, Letizia Mazzini, Enrica Bersano, Fabrizio D’Ovidio, Umberto Manera

P4.6-005 An Analysis of Freetext Responses by Individuals Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry–Heather Jordan, Jaime Raymond MPH, Wendy Eileen Kaye

P4.6-006 PRO-ACE: Global

Collaborative Ecosystem in a Post-PRO-ACT Era–Alexander Sherman, James D. Berry, Marc Gotkine, Jonathan D. Glass, Christian Lunetta, Mary Kay Floeter, Bryan Traynor, Igor Katsovskiy, Olga Kharakozova, Alex Korin, Amanda Podesta, Ervin Sinani, Natalia Tarasenko, Merit E. Cudkowicz

P4.6-007 Forecasting Multiple

Sclerosis Hospitalization and Healthcare Burden in the United States from 2017 to 2040–Kanika Sharma, Frank Bittner, Tracey Cho

P4.6-008 Effects of cigarette

smoking and smoking cessation on Multiple Sclerosis severity: a cross-sectional study–Andrei Ivashynka, Sandra D’Alfonso, Massimiliano Copetti, Paola Naldi, Andrea Fontana, Aliona Cucovici, Maurizio Leone

P4.6-009 An increase in the

prevalence of Multiple Sclerosis has moved Kuwait to a high-risk zone–Raed Alroughani, Fajer AlHamdan, Sameera Shuaibi, Samar Farouk Ahmed, Raed Behbehani, Shashishekha Janardan Lamdhade, Jasem Yousef Al-Hashel

P4.6-010 Interferon Beta

1b Treatment in Patients with Multiple Sclerosis, Trigger for Tuberculosis?–Carmen Adella Sirbu, Ionut Caloianu, Alexandru Nistor, Octavian Mihai Sirbu

P4.6-011 Lewy body

dementia (LBD) prevalence and cholinesterase inhibitor use in Florida–Bhavana U. Patel, Melissa Armstrong, Erin Hastings

P4.6-012 Vision loss in

Parkinson’s disease: prevalence and association with outcomes among Medicare beneficiaries–Ali G. Hamedani, Allison Wright Willis

P4.6-013 Risk of readmission

for injury in patients with epilepsy in the US–Yoni Goldstein, Churl-Su Kwon, Parul Agarwal, Mandip Singh Dhamoon, Madhu Mazumdar, Nathalie Jette

P4.6-014 Characteristics

of periventricular nodules in patients with 22q11. 2 deletion syndrome–Arezoo Rezazadeh, Eduard Bercovici, Eva Chow, rasmus Kiehl, Timo Krings, Anne Bassett, Danielle M. Andrade NEUROEPIDEMIOLOGY: STROKE, CRITICAL CARE, HEADACHE AND GLOBAL HEALTH

P4.6-015 Cognitive decline after a mild or moderate stroke and TIA: evidence from the SWIFT Trial–Bernadette Boden-Albala, Eric Roberts, Noa Appleton

P4.6-016 Seasonal Variation in Stroke Incidence in Black versus White Medicare Beneficiaries– Tehniyat Baig, Monica Lin Chen, Ananya Sahu, Julien Valverde Twiggs, Hooman Kamel

P4.6-017 Disparities,

Predictors and Trends of Left Atrial Appendage Closure Among Hospitalized Patients with Atrial Fibrillation in the United States–Mohammed Badi, George Koshy Vilanilam, Daniela Markovic, Thomas G. Brott, James F. Meschia, Kevin M. Barrett, Josephine F. Huang, Peter Pollak, Michelle P. Lin

AAN.com/view/AM19Sci 187

Wednesday

P4.6-001 Clinical Characteristics

P4.6-003 Incidence of Venous

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.6-018 Comparing the

Outcomes of Patients with Idiopathic Subarachnoid Hemorrhage by Three Distinct Perimesencephalic Bleed Patterns–Jeffrey C. Wagner, Constance McGraw, Russell E. Bartt, Kathryn L McCarthy, Rebecca van Vliet, Madison Price, Alicia Erin Bennett, Alessandro Orlando, Benjamin Atchie

P4.6-019 Time Trends, Race

Disparities, and Administration of Intravenous Thrombolysis for Acute Ischemic Stroke: A Statewide Study–Jolanta Marszalek, Krishna Nalleballe, Aliza Brown, Lindsay Malatesta, Onteddu Reddy

P4.6-020 For Men Only, High

Hematocrit Values Are Associated With Stroke In The Young–Russell E. Bartt, Kristin Salottolo, Kathryn L McCarthy, David Bar-Or

P4.6-021 Systematic

Characterization of Large Vessel Occlusion Strokes at a CSC– Shashvat Desai, Marcelo Rocha, Bradley Molyneaux, Matthew T. Starr, Tudor G. Jovin, Ashutosh P. Jadhav

P4.6-022 Is Altitude Associated With Ischemic Stroke In The Young?–Kristin Salottolo, Kathryn L McCarthy, Rebecca van Vliet, Russell E. Bartt, David Bar-Or

P4.6-023 Acute neurological

complications after adult single and double lung transplant– Yasmeen Rauf, Rabia Yasin, Brian Keller, Bryan Whitson, Archana Hinduja

Wednesday

P4.6-024 Association between

neurological syndromes and Arbovirus in Buenos Aires Relationship between Guillain Barre Syndrome, Encephalitis and Myelitis with Zika, Dengue and Chikungunya–Alejandro Kohler, Mauricio Franco Farez, Evelyn Heck, Fabio Adrian Barroso, Veronica A. Bruno

188 2019 AAN Annual Meeting

P4.6-025 Long-Term Outcomes

of Guillain-Barre Syndrome Associated with Zika Virus Infection–Diana Walteros, Jesus Soares, Ashley Styczynski, Joseph Abrams, Jose Galindo, Jorge Acosta-Reyes, Elsa Bravo, Zuleima Arteta, Alma Solano, Franklyn Prieto, Maritza Gonzales, Edgar Lechuga, Jorge Salinas, Ermias Belay, Lawrence Schonberger, Inger Damon, Martha Ospina, James J. Sejvar

P4.6-026 The Pattern of

Neurologic Disease in Tanzanian Tribal Populations–Whitley Warfield Aamodt, Michael Rubenstein, Allison Wright Willis

P4.6-027 Migraine and

the Prevalence of Metabolic Syndrome among Women– Pamela M. Rist, Julie E. Buring, Daniel Chasman, Tobias Kurth CHILD NEUROLOGY: MOVEMENT DISORDERS

P4.6-028 Genetic testing of

>1300 patients with cerebral palsy reveals an etiology in onethird of cases, underscoring the need for broad genetic testing and a significant recurrence risk for families.–Francisca Millan Zamora, Houda Elloumi, Claire Teigen, Julie Scuffins, Rebecca Torene, Dianalee McKnight

P4.6-029 Evalualuation

of Tremor in Childhood Electrophysiologically Influences Prognosis and Outcome–Bennett L. Lavenstein, Mark Hallett, emananuel akano, Panyakaew Oh

P4.6-030 Alice in Wonderland

Syndrome: Case Series and Analysis–Edward J. Fine, Osman Farooq, Sarah G. Finnegan, Maria Daniela Zambrano, Mohamed Nasser

P4.6-031 Neuropsychological

Assessment In Patients With Alternating Hemiplegia Of Childhood (AHC)–Cecilia Fernandes, Melanie Bonner, Lyndsey Prange, Melissa McLean, Monisha Sachdev, Julie Christina Uchitel, Philip Smith, Richard D’Alli, Jennifer Ricano, Joan Jasien, Mohamad A. Mikati

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.6-032 Insights into

Alternating Hemiplegia of Childhood from EEG Monitoring during an Episode, and Successful Prophylaxis with Levetiracetam– Alex Mirzoev, Tyler Vanderhoof, Jordan Stefko, Marvin Miller, Cassandra J. Milling

P4.6-033 A Very Rare Cause of a Common Tremor–Yasser Kabbani, Ann Murray

P4.6-034 KMT2B early

childhood onset dystonia presenting as failure to thrive– Andrew Ng, Serena Galosi, Lisa Salz, Terence Wong, Shimul Chowdhury, Shimul Chowdhury, Jennifer R L Friedman

P4.6-039 Unilateral Primary

CNS Vasculitis in a Child Associated with Increased ICP and Treated with Maximal Medical Therapy and Decompressive Hemicraniectomy–Cynthia X. Wang, Darryl Miles, Veena Rajaram, Brett Whittemore, Benjamin M. Greenberg

P4.6-040 Disability Scores After Idiopathic Pediatric Transverse Myelitis are Associated with Clinical Features at Onset of Illness–Jordan Cole, Alyssa Lui, Hongjie Gu, Rachel Butler, Soe Soe Mar

P4.6-041 Limbic Encephalitis

CHILD NEUROLOGY: NEUROINFLAMMATORY DISEASE

as Presentation of Hodgkin Lymphoma in a Pediatric Patient: The Ophelia Syndrome–Gabriela Tuttrup, Daniella Miller, Valerie Cruz Flores, Pinki Prasad, Lolie Yu

P4.6-035 Cortical Abnormalities

P4.6-042 Prospective

and Cognitive Impairment in Pediatric MS Patients–Ermelinda De Meo, Lucia Moiola, Maria Pia Amato, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Massimo Filippi, Maria Assunta Rocca

P4.6-036 Imaging analysis

differentiates vascular versus inflammatory myelopathies in children–Maria A. GarciaDominguez, Laura Muñoz-Arcos, Eliza M. Gordon-Lipkin, Paula Barreras, Olwen Murphy, Izlem Izbudak, Andres Villabona, Luisa Diaz-Arias, Carlos A. PardoVillamizar

P4.6-037 Autoimmune

encephalitis associated with N-type voltage-gated calcium channels in children: a case series–Jeffrey M. Kornitzer, James Huynh, Firas A. Taha, Eric Segal

P4.6-038 Autoimmune Glial

Fibrillary Acidic Protein (GFAP) Astrocytopathy Following Herpes Simplex Encephalitis (HSE) in a pediatric patient–Maureen Handoko, William Ilhwan Hong, Danielle Takacs, Edward J. Espineli, Kirti Saxena, Eyal Muscal, Sarah R. Risen

characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria–Giulia Fadda, Patrick Waters, Mark Woodhall, Sarosh Irani, Robert Allan Brown, Julia O’Mahony, Denise Castro, Giulia Longoni, E. Ann Yeh, RuthAnn Marrie, Douglas L. Arnold, Brenda Banwell, Amit Bar-Or CHILD NEUROLOGY: LEUKODYSTROPHIES

P4.6-043 Natural History of

Neurological and Neuroimaging Progression in Childhood Cerebral X-Linked Adrenoleukodystrophy (CCALD).–Mohammed A. Almuqbil, Masoud Mokhtarani, Lena Bezman, Miriam Kaufman, John Henderson, Gerald Raymond, Seyed Ali Fatemi

P4.6-044 Developmental

outcomes of Aicardi Goutières Syndrome–Laura Ann Adang, Francesco Gavazzi, Valentina De Giorgis, Micaela De Simone, Elisa Fazzi, Jessica Galli, Jamie Koh, Julia Kramer-Golinkoff, Simona Orcesi, Kyle Peer, Nicole Ulrick, Sarah Woidill, Justine Shults, Adeline Vanderver

P4.6-045 Autoimmune

hepatitis in Aicardi-Goutières Syndrome–Zachary Cross, Alyssa Kriegermeier, Joseph McMann, Elizabeth Rand, Asako Takanohashi, Nicole Ulrick, Adeline Vanderver, Laura Ann Adang

P4.6-046 Cross-analysis of

Interferon Signature in a cohort of Aicardi-Goutières Syndrome subjects–Francesco Gavazzi, Asako Takanohashi, Constance Besnier, Jamie Koh, Julia KramerGolinkoff, Kyle Peer, Sarah Woidill, Adeline Vanderver

P4.6-047 Consensus

Guidelines: MRI Surveillance of Children with Presymptomatic Adrenoleukodystrophy–Bela Turk, Eric James Mallack, Laura Ann Adang, Catherine Becker, Florian Eichler, Keith Van Haren, Kim Hollandsworth, Joanne Kurtzberg, Jennifer M. Kwon, Troy Lund, Gustavo Maegawa, Ann Moser, Paul Orchard, Joseph Orsini, Bob Rauner, Gerald Raymond, Molly Regelman, Maura R.Z. Ruzhnikov, Amber Salzman, Adeline Vanderver, Elisa Seeger, Seyed Ali Fatemi

P4.6-048 Metachromatic

Leukodystrophy: An Approach to Treatment–Christian Krarup, Christine I. Dali, Ingeborg Kr[auml] geloh-Mann, David Whiteman, Norman W. Barton

P4.6-049 Expanded Phenotype

of GFPT1-related Disorder is a Mimicker of Mitochondrial Leukoencephalopathy–Guy Theodore Helman, Suvasini Sharma, Joanna Crawford, Bijoy Patra, Puneet Jain, Stephen Bent, J. Andoni Urtizberea, R. K. Saran, Ryan J Taft, Marjo Van Der Knaap, Cas Simons

P4.6-050 Language Skills

in Children with Alexander Disease–Debra Levin, Hannah Cooper, Geraldine Liu, Jack Sollee, Jennifer Burstein, Joseph Donaher, Amy T. Waldman Evaluation of Disability Inventory Computer Adaptive Test Captures Impairments in Alexander Disease–Hannah Cooper, Stacy Cusack, Kimberly Kopin, Jennifer Halterman, Tracy Kornafel, Jack Sollee, Geraldine Liu, Amy T. Waldman

P4.6-052 Utilization of

Wearable Technology to Characterize the Natural History of Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation–Amena Smith, Miriam Kaufman, Connor Murray, Jennifer Keller, Christopher Joseph, Leena Mohapatra, Amy Bastian, Seyed Ali Fatemi

Hospital of Philadelphia Pediatric Dysphagia Instrument (CHOP PDI): a Novel Tool for Swallow Dysfunction–Christina Minkoff, Jennifer Burstein, Sarah Greer, Jack Sollee, Hannah Cooper, Geraldine Liu, Joseph Donaher, Amy T. Waldman

P4.6-054 A Comprehensive

and Dynamic Approach for Genetic Testing for Patient with Leukodystrophy Demonstrates a Genetic Etiology in 33% of Cases–Fanggeng Zou, Taylor Zuck, Courtney Downtain Pickersgill, Francisca Millan Zamora, Kyle Retterer, Julie Scuffins, Dianalee McKnight

P4.6-055 Novel Classifications

of Alexander Disease Based on MRI Phenotypes–Amy T. Waldman, Jack Sollee, Geraldine Liu, Hannah Cooper, Arastoo Vossough

P4.6-056 Clinical

Outcome Assessments in TUBB4A-associated Leukoencephalopathies–Adeline Vanderver, Julia Kramer-Golinkoff, Brittany A. Charsar, Omar Sherbini, Zachary Cross, Ann Harrington, Kimberly Kopin, Elizabeth Cross

P4.6-057 Diagnostic tips from a case series of patients with Late Onset Tay Sachs disease– Giulietta Riboldi, Kara Anstett, Heather Lau CHILD NEUROLOGY: METABOLIC DISEASE

P4.6-058 AGIL-AADC Gene

Therapy Results in Sustained Improvements in Motor and Developmental Milestones Over 5 Years in Children With AADC Deficiency–Yin-Hsiu Chien, NiChung Lee, Sheng-Hong Tseng, Chun-Hwei Tai, Anne Marie Conway, Mark Pykett, Wuh-Liang Hwu

P4.6-059 Patients with

Inherited Metabolic Disorders (IMD) transplanted with MGTA456, a CD34+ Expanded Cell Therapy Product, Show Rapid Engraftment in Preliminary Phase 2 Trial Results–Paul Orchard, Glen Raffel, Carolyn H. Condon, Catherine Monaghan, Jennifer Braun, Ryan Shanley, Troy Lund, Ashish Gupta, Anthony E. Boitano, Michael P. Cooke, John Davis, John E. Wagner

P4.6-060 Exploring mTOR

Inhibition as Treatment for Mitochondrial Disease–Abigail Nancy Sage, Rachel Salazar, Kristin Engelstad, Angela M. Curcio, Alexander G. Khandji, James Garvin, Darryl C. De Vivo

P4.6-061 Exploring Triheptanoin as Treatment for Short Chain Enoyl CoA Hydratase Deficiency– Kristin Engelstad, Rachael Salazar, Dorcas Koenigsberger, Susan Brodlie, Nicole La Marca, Erin Stackowitz, Darryl C. De Vivo

P4.6-062 Mitochondrial

Dysfunction: Consider SPATA5 mutations–Saranya Khurana, Lauren D’Angela Weaver, Chandrabhaga Miskin, Joseph J. Melvin, Michael Goldenthal

P4.6-063 Can pathology help

in functional interpretation of genetic variants – A case report of Novel variants in NARS2 gene with mitochondrial dysfunction presenting as early infantile epileptic encephalopathy with cardiac and skeletal muscle involvement–Wilson Heredia, Uta Lichter-konecki, Leslie Walsh, John Ozolek, Geoffrey Murdoch, Deepa Soundara Rajan

P4.6-064 Aberrant Mitophagy In

P4.6-068 Expanded newborn

screening (NBS) leads to early diagnosis and treatment in children with Cobalamin C disease (CblC) and aids in identifying and treating presymptomatic affected family members–Isabella Herman, Maureen Handoko, Lisa T. Emrick CHILD NEUROLOGY: EPILEPSY I

P4.6-069 Epilepsy in Alternating Hemiplegia of Childhood: Characteristics, Neuroimaging, and Response to Therapy–Julie Christina Uchitel, Ashley Helseth, Lyndsey Prange, Melissa McLean, Ryan Ghusayni, Monisha Sachdev, Arsen S. Hunanyan, Mohamad A. Mikati

P4.6-070 Loss of Function

Variants in the CSTB Gene Cause Microcephaly, Developmental Delay, Hyperkinetic Movements, and Early Onset Epilepsy–Amanda Rogers, Marwan Shinawi, Toni Pearson

P4.6-071 Episodic status

epilepticus with hemiplegia and involuntary movements associated with novel ATP1A2 mutation–Daniel Calame, Mered Parnes

The Pediatric Neurodegenerative Syndrome TBCKE–Jesus Tintos-Hernandez, Kierstin Keller, Douglas C. Wallace, Xilma R. OrtizGonzalez

P4.6-072 Behavioral alterations

P4.6-065 Mitochondrial

MOVEMENT DISORDERS EPOSTER SESSION

Encephalomyopathy, Lactic acidosis, And Stroke-like episodes(MELAS) manifesting with Intermittent Cortical Blindness secondary to Occipital Lobe Seizures–Rashid Ali Ahmed, Anqi Lou, Ekenedilichukwu Chidinma Nwoye, Amr Hassan Ewida, Guojun NMN Zhang

P4.6-066 Late-onset multiple

acyl-CoA dehydrogenase deficiency with a complex genetic finding–Joao Luís Oliveira Durães, Maria Macário

P4.6-067 Undiagnosed Late-

onset Ornithine transcarbamylase (OTC) Deficiency Presenting With Psychiatric Symptoms–Syeda Maria Muzammil, Deepti Chrusciel, Roohi Katyal

associated with the use of levetiracetam in pediatric patients with epilepsy–Carla Manterola, Camila Cortes

P4.7-001 Substantia Nigra

(SN) Hyperechogenicity is a Reliable Biomarker for Disease Progression From Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD)–Samyuktha Ravi, Vikram Shivkumar, Duc Dang, Timothy Gilmour, Nitish Harid, Jian-Li Wang, Balaji Krishnaiah, Kala Venkiteswaran, Thyagarajan Subramanian

P4.7-002 The Pseudodystonia:

Important Pitfalls in the Diagnosis of Dystonia–Ling Pan, Steven Frucht

P4.7-003 Disruption of

spermatogenesis and infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2)–Brent L. Fogel, Olivier Becherel, Scott Zeitlin, Hemamali Samaratunga, Jessica Greaney, Hayden Homer, Martin Lavin

AAN.com/view/AM19Sci 189

Wednesday

P4.6-051 The Pediatric

P4.6-053 The Children’s

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.7-004 A single ascending

dose (SAD) study of a D1 receptor positive allosteric modulator (LY3154207) in healthy volunteers–Kjell Svensson, Paul Ardayfio, William Kielbasa, Kevin M. Biglan

P4.7-005 Preliminary validation

of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients–Florian Lipsmeier, Kirsten I. Taylor, Ronald Postuma, Timothy Kilchenmann, Detlef Wolf, Yan-Ping Zhang, Wei-Yi Cheng, Ekaterina Volkova-Volkmar, Alf Scotland, Jens Schjodt-Eriksen, Frank Boess, Daniel Ness, Christian Gossens, Anke Post, Michael Lindemann

P4.7-006 STN LFP and SUA

characterization of dyskinesia in PD using microelectrode recordings–Joohi Jimenez Shahed, Musa Ozturk, Heet Kaku, Ashwin Viswanathan, Nuri Ince

P4.7-007 Gender disparities in

deep brain stimulation surgery for Parkinson’s disease–Daniel Garbin Di Luca, Danielle Spengler Shpiner, Iahn Cajigas, Juan Sebastian Diaz, Jason H. Margolesky, Henry Paul Moore, Bonnie E. Levin, Carlos Singer, Jonathan Jagid, Corneliu C. Luca

P4.7-008 Hyperglycemic

Induced Chorea-Ballismus Responsive to Valbenazine: a Video Case Report and Review of the Literature.–Victor Saunders, Doris Chen, Kwan L. Ng, Lin Zhang

Wednesday

P4.7-009 Gait Analysis of

GBA Mutation Carriers with Parkinson’s Disease–Anjali Gera, Joan O’Keefe, Bichum Ouyang, Gian D. Pal

P4.7-010 Changes to Levodopa

Daily Dose in Parkinson&rsquo;s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis–Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner, Reed Johnson, Dustin Chernick, Larissa Felt, Rajiv Patni

190 2019 AAN Annual Meeting

DYSTONIA AND BOTULINUM TOXIN THERAPY

P4.8-001 Muscle pattern

changes in patients with cervical dystonia (CD) receiving botulinum toxin (BTX)–Eric Gutflais, Rachel J. Saunders-Pullman, Susan B. Bressman, Matthew Swan, Erin Deegan, Rivka Sachdev, David Lucido, Vicki Shanker

P4.8-002 Long-term outcomes

of late deep brain stimulation in DYT1 dystonia–Hwai Yin Ooi, Joan Miravite, Deborah Raymond, Robert Ortega, Harini Sarva, Fedor Panov, Michele Tagliati, Ronald Alterman, Brian Kopell, Susan B. Bressman, Rachel J. SaundersPullman

P4.8-003 Pilot feasibility study

of a semi-automated threedimensional scoring system for cervical dystonia–Genko Oyama, Takuto Nakamura, Satoko Sekimoto, Yasushi Shimo, Nobutaka Hattori, Hiroyuki Kajimoto

P4.8-004 The Dystonia Coalition Natural History Project: Nine Years of Progress–Scott Norris, Joel S. Perlmutter, Laura Jo Wright, Janet Hieshetter, Kimberly Kuman, H. A. Jinnah

P4.8-005 Neural Responses

Are Abnormal During Reflexive Blinking in Blepharospasm: An Event-Related fMRI Study– Phuong Nguyen, Diane Kelly, Erika Shelton, Brian D. Berman

P4.8-006 Wireless,

Wearable, Soft Electronics for Blepharospasm Assessment– Laura M. Scorr, Woon-Hong Yeo, Shinjae Kwon, Yun-Soung Kim, Gamze Kilic Berkmen, Adam Cotton, H. A. Jinnah

P4.8-007 Golfer’s Cramp: Effect of Propranolol and Looking at the Hole–Charles H. Adler, Debra Crews, Troy McDaniel, Jennifer Tucker, Christian Marquardt, Nan Zhang, John N. Caviness

P4.8-008 Hand Motor Control in Patients with Cervical Dystonia: an fMRI Study–Pavel Hok, Dominika Lachmanova, Martin Nevrly, Lenka Hvizdosova, Pavel Otruba, Petr Kanovsky, Petr Hlustik

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.8-009 Cervical dystonia

patient’s satisfaction level after 3 years of botulinum toxin treatment–Vivay Peter Misra, David Charles, Tae Mo Chung, Carlo Colosimo, Savary Om, Pascal Maisonobe

P4.8-010 Basal Ganglia and

Cerebellar Circuits Have Distinct Roles in Blepharospasm–Amanda Glickman, Erika Shelton, Brian D. Berman

P4.8-011 Cultural adaptation

and validation of the Hiligaynon Montreal Cognitive Assessment Tool (MoCA-Hil) among X-linked dystonia parkinsonism patients:The first phase in the XDP Cognitive Assessment Initiative– Nicole Aliling, Adovich Rivera, Nikolai Gil Reyes, Roland Dominic Jamora

P4.8-012 Immunogenicity of

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study–Allison Brashear, Daniel D. Truong, Cynthia L. Comella, Joseph Jankovic, Atul T. Patel, Greg Prawdzik, Roman Rubio, Mahan Chehrenama

P4.8-017 Jaw Opening

Oromandibular Dystonia following Acute Stroke: Analysis and Review–Jeenendra Prakash Singhvi, Amit Shankar Singh, Syed Junaid

P4.8-018 ATP1A3 Gene

Mutations Associated with RapidOnset Dystonia-Parkinsonism (RDP) Presenting with Functional Neurologic Disorder: A Report of Two Cases–Tara Michelle Biller, Rosalind Shengi Chuang, Susie I. Ro

P4.8-019 Pilot trial of botulinum

toxin and occupational therapy for Writer’s Cramp–Jung E. Park, Ejaz Shamim, Pattamon Panyakaew, Camilo Toro, Jonathan James Sackett, Pawan Mathew, Barbara P. Karp, Codrin I. Lungu, Katharine Alter, Monica Anne Faye Villegas, Tianxia Wu, Omar Ahmad, Sungyoung Auh, Mark Hallett

P4.8-020 Identifying Reliable

Measures of Impairment in Focal Hand Dystonia Patients–Noreen Bukhari-Parlakturk, Joyce En-Hua Wang, Nicole Calakos

P4.8-021 Indications, Outcomes

the current dystonia classification from 2013 to 2017–Alberto Albanese, Sanskriti Sasikumar, Joachim Krauss, Alfonso Fasano

and Cost of pediatric Deep Brain Stimulation Surgeries in the United States: An Analysis of the Kids’ Inpatient Sample–Emmanuel Oladele Akano, Fadar Oliver Otite, Bennett L. Lavenstein, Debra J. Ehrlich

P4.8-014 A dopa-responsive

P4.8-022 Kufor-Rakeb

P4.8-013 Implementation of

dystonia-Parkinsonism-cerebellar syndrome associated with GCH1 gene mutation.–Andrew Robert Garrett, Shayan Amir Gates, Jason S. Hawley

P4.8-015 Assessment of

Syndrome with Prominent Dystonia and New Mutations in ATP13A2 Gene in Two Siblings– Tritia Reina Yamasaki, Riham El Khouli, Melanie Bunch, R. Steven Amato, John T. Slevin

standing balance by force plate posturography in X-linked Dystonia Parkinsonism (XDP)– Christopher D. Stephen, David Balkwill, Patrick Acuna, Susan King, Richard F. Lewis, Nutan Sharma

P4.8-023 The Trend in

P4.8-016 Botulinum toxin

(MYOBLOC) in the treatment of adult sialorrhea–William G. Ondo, Stuart H. Isaacson, Mark F. Lew, Khashayar Dashtipour, Dilip Chary, Thomas Clinch, Fernando L. Pagan

injection changes resting state cerebellar connectivity in cervical dystonia.–Martin Nevrly, Pavel Hok, Pavel Otruba, Michaela Kaiserova, Lenka Hvizdosova, Zbynek Tudos, Petr Hlustik, Petr Kanovsky

Botulinum Toxin Injection among Medicare Neurology Providers in the United States from 2012 to 2016–Shahnaz Miri, Laxman Bhaqwan Bahroo

P4.8-024 RimabotulinumtoxinB

P4.8-025 Individualized

OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study–Gerard Francisco, Ganesh Bavikatte, Wolfgang H. Jost, Daniel Bandari, Simon Fuk Tan Tang, Michael C Munin, Joan Largent, Aleksej Zuzek, Anand Patel, Alberto Esquenazi

P4.8-026 Individualized

OnabotulinumtoxinA Treatment for Lower Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study–Alberto Esquenazi, Ganesh Bavikatte, Wolfgang H. Jost, Daniel Bandari, Michael C Munin, Simon Fuk Tan Tang, Joan Largent, Aleksej Zuzek, Anand Patel, Gerard Francisco

P4.8-027 Botulinum Toxin

for the treatment of muscle spasms associated with Stiff Person Syndrome–Emile Sami Moukheiber, Michael Comisac, Scott Douglas Newsome OTHER HYPERKINETIC MOVEMENT DISORDERS AND TREMOR

P4.8-028 Tremor in the

Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor–ShengHan Kuo, Ruo-Yah Lai, Darya Tomishon, Karla Patricia Figueroa, Stefan M. Pulst, Susan L. Perlman, George R. Wilmot, Christopher Gomez, Jeremy D. Schmahmann, Henry L. Paulson, Vikram Shakkottai, Sarah H. Ying, Theresa A. Zesiewicz, Khalaf Bushara, Michael D. Geschwind, Guangbin Xia, S H. Subramony, Tetsuo Ashizawa Patients with Parkinson’s Disease and Essential Tremor–Alexander Michael Lopez, Daniel O. Claassen, Paula Trujillo Diaz

P4.8-030 The importance of

intra-operative assessment in VIM DBS for Tremor: Insights from 145 procedures–Abhimanyu Mahajan, Alexander Joseph Garcia Bader, Andrew P. Duker, Alberto J. Espay, Cara Jacob, Aristide Merola, George Mandybur

Extended Hospitalizations due to Altered Arousal and Speech Dysfunction Following Deep Brain Stimulation for Essential Tremor– Shannon Donovan Anderson, Antonia Gragg, Kim Burchiel

P4.8-032 Distinguishing tremor

components in Essential Tremor: a digital spirography study–Thomas Osterholt, Felipe Vial, Mark Hallett, Dietrich Haubenberger

P4.8-033 Cortical

P4.8-039 Physical activity, sleep and tic severity in children– Tamara M. Pringsheim, Elaheh Nosratmirshekarlou, Davide E. Martino

P4.8-040 The Impact of Tourette Syndrome and Tic Disorders on Education, Occupational, and Personal Life–Irene Malaty, Wissam Georges Deeb, Diana Shineman

P4.8-041 Assessing the social

hyperexcitability in sialidosis type 1–Felipe Vial, Sanaz Attaripour, Patrick Mcgurrin, Camilo Toro, Mark Hallett

determinants of health in Tourette Syndrome–Marisela E. Dy, Lisa Osiecki, Angela Essa, Carol Mathews, Nicte I. Mejia, Jeremiah M. Scharf

P4.8-034 Hyperkinetic

P4.8-042 Development of an

Movement Disorders Associated With Immunosuppressant And Cefepime Use In Inpatients–Blas Couto, Carla Florencia Bolaño Diaz, Mara Gonzalez Toledo, Macarena Gonzalez, Carlos Santiago Claverie, Guido Vazquez, Franco Appiani, Alejandro Thomson, Oscar S. Gershanik, Gonzalo Javier Gomez-Arevalo

P4.8-035 Effects of

Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials–Cynthia L. Comella, Carlos Singer, John M. Kane, Khodayar Farahmand, Joshua Burke, Scott Siegert

P4.8-036 RECLAIM-DCP:

A Randomized, Double-Blind, Placebo-Controlled Study of Deutetrabenazine for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents–Daniel O. Claassen, Jonathan W. Mink, Mered Parnes, Mark Forrest Gordon, Hadas Barkay, Maria Wieman, Juha M. Savola, Roberta Battini, Joseph Jankovic, Leon S. Dure

P4.8-037 Diagnosis and

Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers–Irene Malaty, Wissam Georges Deeb

P4.8-038 Self-Reported

Substance Use in a Real-World Sample of Subjects with Tourette Syndrome and Other Tic Disorder.–Wissam Georges Deeb, Ahmad El Kouzi, Irene Malaty

EMG Based Tic Detector–Wissam Georges Deeb, Stephanie Cernera, Aysegul Gunduz, Michael S. Okun

P4.8-043 Prescriptions

for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A National Pharmacoepidemiologic Study–Nicholas Cothros, Davide E. Martino, Carly McMorris, Dave Stewart, Ali Tehrani, Tamara M. Pringsheim

P4.8-044 Longitudinal follow-up

of dual-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor–Bhavana U. Patel, Ryan Peter Barmore, Ahmad El Kouzi, Pam Zeilman, Leonardo B. Almeida, Kelly D. Foote, Michael S. Okun

P4.8-045 Outcomes with VIM

deep brain stimulation in dystonic tremor versus essential tremor– Takashi Tsuboi, Zakia Jabarkheel, Kelly D. Foote, Michael S. Okun, Aparna Wagle-Shukla

P4.8-049 Hereditary Spastic

Paraplegia: The Relationships of Patient Perceived Functional Impact and Objective Quantified Multi-Dimensional Gait Analysis– Jared Srinivasan, Annina Giannuzzi, Abhilash Sharma, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Stacy Trebing, Christina Burke, Lori Fafard, John K. Fink, , Arnaud Gouelle, Mark Gudesblatt

P4.8-050 Autonomic Testing

Profiles in Scans Without Evidence of Dopaminergic Deficit (SWEDD)–Lauren Jackson, Pierpaolo Turcano, Derek William Stitt, Elizabeth A. Coon, Rodolfo Savica

P4.8-051 Novel Mutation of

NUS1 Gene Presenting With Developmental and Epileptic Encephalopathy and Movement Disorders–Neha Prakash, Cindy Zadikoff, Lisa Kinsley, Steven Lubbe, Niccolò Mencacci, Dimitri Krainc

P4.8-052 Hemi Masticatory

Spasm: Series of 8 Cases–Divya Madathiparambil, Vinay Goyal, Garima Shukla, Mamta Bhushan Singh

NEUROHIV AND OTHER RETROVIRUSES

P4.9-001 Cognitive Performance and Total and Regional Brain Volumes in Zambian Youth with HIV–Owen Dean, Alexandra Buda, Heather Adams, Sylvia MwanzaKabaghe, Michael Potchen, Esau G. Mbewe, Pelekelo Kabundula, Gretchen L. Birbeck, David Bearden

P4.9-002 Increased Caloric

Accelometry in Diagnosing Orthostatic Tremor–Nicholas Calvo, Joseph M. Ferrara

Intake is Associated with Lower Cognitive Scores in HIV-Positive Women–Lakshmi Warrior, Kathleen Weber, Elizabeth Daubert, Audrey French

P4.8-047 Psychiatric

P4.9-003 Rare Case of Human

P4.8-046 Smartphone

Comorbidities in United States Military Veterans with Movement Disorders in Tampa, Florida– Chetan P. Gandhy, Gabriela Alejandra Bou, Muhammad Hasanayn Jaffer, Kristen Lynn Zemina, Karl Albert Kasischke, Robert Myers, Yangxin Huang, Theresa A. Zesiewicz

T-lymphotropic Virus-1 (HTLV1) with Amyotrophic lateral sclerosis–Shaweta Khosa, Abel Wu, Shri Kant Mishra

P4.8-048 TANGO2 Mutation:

A Novel Cause of Movement Disorders–Matthew Robert Burns, Shannon Chiu, Ahmad El Kouzi, Irene Malaty

AAN.com/view/AM19Sci 191

Wednesday

P4.8-029 Cerebellar Structure in

P4.8-031 Risk Factors Causing

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.9-004 Teriflunomide Reduces Spontaneous Lymphoproliferation of Peripheral Blood Mononuclear Cells From Patients With Human T-Lymphotropic Virus (HTLV)-1– Associated Myelopathy/Tropical Spastic Paraparesis–Yoshimi Akahata, Nyater Ngouth, Joan M. Ohayon, Matthew J. Mandel, Jeffrey Chavin, Timothy Turner, Steven Jacobson

P4.9-005 Neurofilament

Light Chain Protein Levels in HIV Positive Subjects with Neuropathy–Anne M. Damian, Richard L. Skolasky, Henrik Zetterberg, Kaj Blennow, Corey Demsky, Magnus Gisslen, Justin C. McArthur, Ned C. Sacktor

P4.9-006 Inhibiting

Mononuclear Phagocyte Functions in a HIV Associated Neurocognitive Disorders Mouse Model–William R. Tyor, Woldeab Haile, Christina Gavegnano, Heather Bimonte-Nelson, Rajeth Koneru, Leonard Maroun, Raymond Schinazi

P4.9-007 Occurrence of

pneumocystis pneumonia in patients with neurological disease on immunosuppression: a singlecenter investigation–Yuebing Li MD, Mary Alissa Willis, Tiffany Lee, Sana Khan Syed

P4.9-008 Minimal Effect on

Cognitive Function Despite High Prevalence of Mental Health Disorders in Treated HIV–Elizabeth Horne, Lillian Ham, Chuen-Yen Lau, Stanley I. Rapoport, Joseph Snow, Avindra Nath, Bryan Smith

Wednesday

P4.9-009 Inflammatory HIV-

associated progressive multifocal leukoencephalopathy associated with high CD4 count–Joy Z. Ding, Ryan Gotfrit, Carlos Torres

P4.9-010 Thrombotic

thrombocytopenic purpura (TTP) presenting with severe neurological manifestations in a patient with well-controlled HIV-1–Tara Ashley Kimbrough, Paul Sanmartin, Bogdan Ioannis Patedakis Litvinov, Dhasakumar S. Navaratnam

P4.9-011 Immune

Reconstitution Inflammatory Syndrome in a newly diagnosed patient with HIV and Central Nervous System Tuberculosis (TB)–Osama Mahmoud Abuhadid, Rajanigandhi Hanumanthu, Machteld E. Hillen

192 2019 AAN Annual Meeting

P4.9-012 PML presenting as

an isolated vertigo: a diagnositic challange–Bayan Moustafa, Sushant Puri

P4.9-013 An Unusual Case of

Multiple-Ring-Enhancing Lesions on Brain MRI in Varicella Zoster Virus Encephalitis–Tasneem Fatema Hasan, Hunaid Hasan, Parker LaVigne, Sindhu Devarashetty, Meredith Wooster NEUROVIROLOGY

P4.9-014 Hepatitis E virus

infection and posterior reversible encephalopathy syndrome: a case report and review of the literature.–Andrea Loggini, Mary Christine Deato, Jeffrey Nathanson, Fulvio Roberto Gil

P4.9-015 Abulia: A case of

Powassan Encephalitis–Nilufer Yalcin, Mohammed Al-Dulaimi, Daniel McQuillen, Doreen Ho

P4.9-016 West Nile encephalitis in a patient with initially negative CSF serology.–Paul Sanmartin, Jeremy Moeller, Tara Ashley Kimbrough

P4.9-017 A Bird Whisperer’s

Tale: The unique occurrence of stroke as a precursor to diagnosing West Nile Meningoencephalitis.–Sneha Jacob, Abigail M. Taylor, Gyanendra Kumar, Roberto Patron, Marie Francisca Grill

P4.9-018 Case Series:

Congenital Zika Virus Infection associated with Epileptic Spasms–Mayela Marie Diaz Diaz, Alexandra Montalvo, Janice Rodriguez Hernandez, Jessica Gonzalez Montes, Marisel Vazquez, Mireya M. Bolo-Diaz, Jocelyn Montalvo

P4.9-019 The Diagnosis of

Pseudorabies Virus Encephalitis and Endophthalmitis by Next Generation Sequencing in Two Chinese Pork Retailers–Lei Liu, Jiawei Wang

P4.9-020 An unusual case

of feline-transmitted Rabies: A Diagnostic and Preventative Approach.–Freddy EscobarMontealegre, Christian HerreraCéspedes, Lithey Poveda-Conde, Jorge Méndez-Díaz

P4.9-021 An Uncommon Case of Treatment-Responsive SSPE–Kate Wills Hocquard, Stephen W. English, Cheolsu Shin

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.9-022 West Nile Virus

P4.9-029 West Nile Virus

P4.9-023 A Quality

P4.9-030 A Case of Presumed

Neuroinvasive Disease Associated with Rituximab Therapy–Micaela Rose Owens, Lisa Choe, Jose Rivera, David Avila Improvement Project Studying the Integration of a Proposed Diagnostic Algorithm on Inpatient Encephalitis into the Electronic Medical Record and its Impact on Length of Hospital Stay–Tyler Kaplan, Jacob Kresser, Jonathan Ross Galli, Tracey Cho, Stacey Clardy, Amanda Lee Piquet

P4.9-024 A simple

bioinformatics approach to disentangle the etiology and prognosis of CNS infections– Kevin Tan, Raphael Zellweger, Sophie Yacoub, Yvonne Chan, Derek TL Soon, Humaira Shafi, Say-Tat Ooi, Monica Chan, Sze Chien Ang, Leslie W. Jacobson, October Sessions, Angela Vincent, Jenny Low, Eng-Eong Ooi, Lin-fa Wang, Limin Wijaya

P4.9-025 Evaluation of

BioFire Film Array Meningitis/ Encephalitis (ME) panel in testing of CSF specimen of patients of meningoencephalitis in Indian scenario–Anshu Rohatgi, Chand Wattal, Neeraj Goel, Yatin Sagvekar, Neha Pandita, Virti Shah, Swarn Lata

Encephalitis Associated with Intraventricular Diffusion Restriction–Neil Kanta Shetty, Ayush Batra, Minjee Kim Post-Transplant West Nile Virus Encephalitis without CSF Pleocytosis or IgM Positivity–Neil Kanta Shetty

P4.9-031 Cerebrovascular

manifestations of herpes simplex virus infection of the central nervous system: a systematic review–Larissa Irene Sellner, Slaven Pikija, Eva Christina Schulte, Laszlo Sztriha, Raffaele Nardone, Johann Sellner

P4.9-032 Super Refractory

Status Epilepticus Secondary to La Crosse Virus Encephalitis: A Case Report–Leighton Mohl, Benjamin Robert Miller

P4.9-033 Unusual movement

disorders and atypical MRI findings in patients with West Nile Encephalitis: A case series of two patients with evidence of clinical and imaging resolution with IVIG–Ehad Afreen, Irfan Sahail Sheikh, Ajaz Sheikh

P4.9-034 Elsberg Syndrome,

The Often Missed Other Cauda Equina–Lalanthica Yogendran, Bianca Barcelo, Neal J. Baumbach

P4.9-026 Progressive Multifocal

P4.9-035 A 59-year-old

P4.9-027 A Case of Hepatitis

P4.9-036 Oculomeningoen-

Leukoencephalopathy in an Immunocompetent Patient: A Rare Case with Radiologic-Pathologic Correlation–Faisal Fecto, Jason Maljaars, Diego Oliveira, Karra Jones, Bruno Policeni, Tracey Cho, Andrea Jean Swenson E Transverse Myelitis–Michael Doyle, Thomas Sinon Monaghan

P4.9-028 Neuroinvasive West

Nile Virus: a Case Series in Nebraska–Matthew Purbaugh, Erin Smith, Sachin Kedar, Scott Diesing, Fuad-al Ali, Hae Young Baang, Krishna Mourya Galla, Brian Westerhuis, Kiel Woodward, Jamison Hofer, Danmeng Wei, Mohamed Taha, Kalyan Reddy Malgireddy, Praveen Hariharan, Navya Joseph, Daniel Alejandro Crespo, Brian Jose Villafuerte Trisolini, Navnika Gupta

Immunocompetent Man with Rapid Onset of Truncal Ataxia: A Case of Acute Cerebellitis Secondary to Varicella Zoster Virus.–Cassandra Paden Cross, Stephen W. English, Monica Ann Krause, Nicholas L. Zalewski cephalomyeloradiculitis: A case of fulminant varicella zoster infection in the setting of systemic lupus erythematosus–Christopher Perrone, Dina Jacobs

P4.9-037 A Novel Case of

Herpes Simplex Encephalitis Complicated by Cerebral Venous Thrombosis–Preston J. Eibling, Jenna Alys Decker, Mary S. Feldman

P4.9-038 Neuroinvasive

Spectrum of West Nile Virus.– Meghana Srinivas, Shitiz K. Sriwastava, Mihir Kakara, Maysaa Merhi Basha, Evanthia Bernitsas

P4.9-039 Post-operative HSV-2 Encephalitis Following Temporal Lobe Resection for Glioblastoma Multiforme–Prompan Mingbunjerdsuk, Kartavya Sharma, Kathrin R. Husmann, Sherri A. Braksick

P4.9-040 Acute Myositis in

Three Adult Men with Rapid Resolution–Laura Danielson, Tamra Ishan Jayendra Ranasinghe, Shumaila Sultan, Jack E. Riggs

P4.9-041 West Nile

Radiculomyelitis–Mariana Vinokur, George A. Small

P4.9-042 Measles encephalitis

without CSF pleocytosis and typical rash: a case report–Hyung Seok Ahn, Jung Hwa Lee, Hyunjo Lee, Sang-Beom Jeon

P4.9-051 Wenceslao López

Albo: the unsuspected influence of Cajal and Charcot on Monterrey, México–Sergio Andrés CastilloTorres, Héctor Ibarra-Sifuentes, Carlos Alberto Soto-Rincon, Diego Cautu-Garcia, Juanita CristernaRamírez, Verónica GallegosJiménez, José Olvera-Sandoval, Ingrid Estrada-Bellman

P4.9-052 Headaches in Ulysses Grant–Sweta Sengupta, Timothy Alan Collins, E. Wayne Massey

P4.9-053 Parallels to the

Modern Understanding of Speech Production in Indian Philosophical History–Anand Venkatraman, Puneet Opal, M.G Prasad

P4.9-054 Gender Disparity

HISTORY OF NEUROLOGY

Between Neurologists in Brazil: Is It Really Decreasing?–Vanessa Dias Veloso, Camila Pupe

P4.9-043 Potassium Bromide:

P4.9-055 An 8,000-year

The First Successful Treatment of Epilepsy–Teng Jiao Peng, Sumire Sato

P4.9-044 John Yerbury Dent

and Apomorphine: an unfinished history–Manon Auffret, Marc Verin

P4.9-045 Women in History:

Neuromuscular Medicine–Angela Aziz-Donnelly, Eleanor V. Thomas, Rocio Carolina Garcia Santibanez

P4.9-046 Marie-Foix Syndrome: A Classical Crossed Pontine Syndrome?–Guillermo Ruben Delgado-Garcia, Carolina Rodríguez-Návarez, Teresa V. Corona Vazquez, Bruno Estanol Vidal

P4.9-047 Conceptualizing

P4.9-048 Babinski’s sign from

the evolutional point of view “Why would you think that the big toe is related to your brain?”– Nada Abdelhameed Elsaid A Elsaid, Ahmed Saied

P4.9-049 The History of

Neurological Serendipities–Taha Nisar, Walter G. Husar

P4.9-050 Ophelia’s syndrome

revisited.–Carlos Alberto SotoRincon, Sergio Andrés CastilloTorres, Alejandro R. Marfil-Rivera, Ian Carr

P4.9-056 A History of

Dihydroergotamine in Migraine– Sutapa Ray, Stephen Bevan Shrewsbury

P4.9-057 Torres Homem and

the Book “Lessons about Nervous System Diseases” of 1878–Ylmar Correa Neto, Catarina Dantas Correa

P4.9-058 Sir Roger Bannister:

The Fastest and Famed Neurologist–Jordan Mayberry, E. Wayne Massey

P4.9-059 Charcot’s 1886

Preface to Sœur Jeanne des Anges : Autobiographie d’une hysterique possédée: An English Rendition–Guillermo DelgadoGarcía, Carolina RodríguezNávarez, Teresa V. Corona Vazquez, Bruno Estanol Vidal

P4.9-060 Hypogonadism,

alopecia and neurological manifestations: evolving syndromes from an old association.–Ali Hussain Abusrair, Saeed A. Bohlega

P4.9-061 S. Weir Mitchell,

Successes and Failures of the Father of American Neurology– Abraham Kalikstein, Noah Rosen

P4.9-062 Neurological Illness on the Supreme Court–Eric S. Farbman

P4.9-063 Reimbursement Does

Not Cover Inpatient Costs for tPAManaged Patients As tPA Cost Has Continued to Rise–Cathy A. Sila, Colin Beilman, Jason Makii

P4.9-070 A retrospective

descriptive study to evaluate physician education on driving practices of patients who develop a neurological condition–Emily Jernigan Elliott, Margaret M. Swanberg

P4.9-064 Implementation of

P4.9-071 Documentation of

P4.9-065 Collaborative

P4.9-072 Implementation

an electronic medical recordenhanced dashboard to optimize pre-rounding for residents on the Stroke Neurology service–Kevin F. O’Connor, Mauricio Fernando Villamar, Michael Dobbs Care in Stroke Centers: Role of Neurologists in Implanting Loop Recorders for Detection of Atrial Fibrillation–Nabeel Herial, Melissa Warren, Robin N. Dharia, Diana Tzeng, Shaista Alam, Fred Rincon, Pascal Jabbour, Rodney D. Bell, Robert H. Rosenwasser

P4.9-066 Transition

Preparedness: a Pilot Study in Texas Children’s Hospital Muscular Dystrophy Care Clinic– JaMis Monet Jackson, Timothy E. Lotze, Diane Murrell, Hannah Todd

P4.9-067 Epilepsy: Transition

from Pediatric to Adult Care. Recommendations of the Ontario Epilepsy Implementation Task Force–Danielle M. Andrade, Anne Bassett, Eduard Bercovici, Felippe Borlot, Esther Bui, Peter R. Camfield, Guida Quaglia Clozza, Eyal Cohen, Timothy Gofine, Lisa Graves, Jon Greenaway, Beverly Guttman, Maya Guttman-Slater, Ayman Emam H. Hassan, Megan Henze, Miriam Kaufman, Bernard Lawless, Hannah Lee, Lezlee Lindzon, Lysa Lomax, Mary Pat McAndrews, Dolly Menna-Dack, Berge A. Minassian, Janice Mulligan, Rima Nabbout, Tracy Nejm, Mary Secco, Laurene Sellers, Michelle Shapiro, Marie Slegr, Rosie Smith, Peter Szatmari, Leeping Tao, Anastasia Vogt, Sharon E. Whiting, O. Carter Snead

P4.9-068 Implementing

Cognitive Behavior Screening in a Hispanic Cohort with Amyotrophic Lateral Sclerosis–Bhavesh Trikamji, Margaret Adler

P4.9-069 The AAN Live Well,

Lead Well Program: Promoting Wellness through Leadership– Heidi B. Schwarz, Jennifer Rose Molano, Neil A. Busis

Code Status in Hospitalized Patients: A Pilot Quality Improvement Project–Parneet Kaur Grewal, Swati Pradeep, Benjamin Thomas Barnes, Jessica Doyle Lee, Jessica McFarlin of Standard Note Templates Captures True Level of Service (LOS) Coding–Kavit Shah, Abdullah Alshammaa, Meredith Van Harn, Muhammad Affan, Daniel S. Newman, Gregory L. Barkley, Amy Pappas, Daniel Miller

P4.9-073 Does CMS GMLOS

In the Neurological ICU Represent Reality in Academic Medical Centers?–Mohammad Hajighasemi-Ossareh, Ling Zheng, May A. Kim-Tenser, Benjamin Emanuel, Jeyson Flores, Steven Cen, Sebina Bulic

P4.9-074 The Handoff

Experience–Nicholas Samuel Streicher P4.9-075 Improving Hospital Discharge Time: An Indepth Analysis–Derek Yuan, Dharampreet Singh, Kelly L. Tisovic, Leena E. Youssefian, Alice Rutatangwa, Cara E. Harth P4.9-076 Comparing Patient Perceptions on Multiple Sclerosis Management and Care – A Sub-analysis of Geographic Differences–Mitzi Joi Williams, Dawn Wendy Langdon, Gavin Giovannoni, Maija Pontaga, Nektaria Alexandri P4.9-077 Resident Documentation Practices And Neurohospitalist Group Revenue– Brandon Scott Pope, Jennifer Simpson P4.9-078 Effects of Guideline on Prevalence of Cerebral Sinus Venous Thrombosis (CSVT) before and after 2011: Call to Action– Smit D. Patel, Neeta Garg, Gracia Chu-wai Mui P4.9-079 Burnout among practicing neurologists in Massachusetts–Connie Kang-Ling Wu, Sylvia Josephy, Anna D. Hohler, Anindita Deb

AAN.com/view/AM19Sci 193

Wednesday

Consciousness as Arousal+Awareness – Historical Parallels from Indian Philosophy– Anand Venkatraman, Sthaneshwar Timalsina, Puneet Opal

History of Use and Abuse of Opium and Opioids: How That Matters For A Successful Control Of The Epidemic ?–Sankar Bandyopadhyay

PRACTICE, POLICY, AND ETHICS I

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 4 P4.9-080 Impact of

Transthoracic Echocardiogram on Length of Stay and Hospital Charges in Ischemic Stroke and Transient Ischemic Attack Patients in United States: Analysis of Nationwide Inpatient Sample 2006-2014–Huy Q. Nguyen, Mohammad Rauf Afzal, Harathi Bandaru, Anantha Vellipuram, Alberto Maud, Darine Kassar, Rakesh Khatri, Gustavo Rodriquez, Paisith Piriyawat, Salvador CruzFlores P4.9-081 Lack of childcare restricts work related travel for physician moms–Yasmeen Rauf

10 MIGRAINE II

P4.10-001 A Randomized Trial of Telemedicine for Migraine Management–Deborah I. Friedman, Balaraman Rajan, Abraham Seidmann

Wednesday

P4.10-002 Predictors of Non-

Adherence with Acute Migraine Medications–Abigail Lofchie, Nicole Butler, Mathew Robbins, Elizabeth Seng P4.10-003 Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study– Dawn C. Buse, Aftab Alam, David W. Dodick, Todd J. Schwedt, Sagar Munjal, Kristina Fanning, Michael L. Reed, Richard B. Lipton P4.10-004 Undiagnosed Chronic Migraine Is Associated With Higher Economic Burden Compared With Diagnosed Chronic Migraine: Results From a Claims-Based Retrospective Study–Steven C. Marcus, Anand R. Shewale, William B. Young, Justin S. Yu, Jelena Pavlovic, Hema Viswanathan, Jalpa Doshi P4.10-005 Poor Acute Treatment Optimization and Frequent Nausea in Episodic Migraine (EM) are Associated with New Onset Chronic Migraine (CM): Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study–Todd J. Schwedt, Richard B. Lipton, Aftab Alam, Michael L. Reed, Kristina Fanning, Dawn C. Buse, Sagar Munjal, David W. Dodick P4.10-006 OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine– Alina Masters-Israilov, Matthew S. Robbins

194 2019 AAN Annual Meeting

P4.10-007 ‘Sleep Disturbance

and Environmental Reactivity as Potential Mechanisms for Comorbidity of Mood and Anxiety Disorders with Migraine– Tarannum Lateef, lihong cui, Vadim Zipunnikov, Kailyn Witonsky, MIke Xiao, Kathleen Merikangas P4.10-008 Methylation Analyses of Stress-Modified Genes in Migraine–Agustin Oterino Duran, Maria Toriello, Sara Perez-pereda, Fernando Hoyuela, Vicente González-Quintanilla, Fernando Iglesias, Olga Umaran, Jesus Castillo P4.10-009 Healthcare Expenditure in Migraine Compared to Other Leading Causes of Disability: Adequate or Not?–Leonhard Schaetz, Parth Joshi, Aoife Callan, Vivek Khurana, Jasper Huels P4.10-010 Message Framing to Determine Best Methods for Discussing Migraine Behavioral Treatments with Persons with Migraine.–Adama Jalloh, Olivia Begasse De Dhaem, Mia T. Minen P4.10-011 A Randomized Controlled Trial to Assess the Effect of Telephone Based Motivational Interviewing on the Initiation and Adherence to Behavioral Therapy for Migraine– Mia T. Minen, Gabriella Sahyoun, Ariana Gopal, Arwa Adib, Pallavi Pemmireddy, Valeriya Levitan, Audrey Halpern P4.10-012 Exploring Natural Cohorts of Chronic Migraine Phenotype–Yohannes W. Woldeamanuel, Bharati Sanjanwala, Addie M. Peretz, Robert Cowan P4.10-013 Risk of Worse Shortterm Outcomes Associated with hospitalization for migraine and co-morbid psychiatric illness: A Nationwide Population-Based Cohort Study–Chirag Narshibhai Savani, Varun Kumar, James Ray Ghattas, Luiz De Souza, Jose R. Rodriguez, Matthew Chung, Tigran Kesayan, Grace Kim, Martin Anthony Myers, Charles W. Brock P4.10-014 Angiotensin Receptor Blockers and ACE Inhibitors for Migraine Prophylaxis - A Systematic Review–Tara Dorosh, Krista Ryon, Christine Ganzer, Alon Seifan

Wednesday, May 8 11:30 a.m.–6:30 p.m. P4.10-015 Effect of

Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine–Kathleen Day, Michael A. Ament, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric M. Pearlman, Sheena K. Aurora P4.10-016 Migraine and Cluster Headache Classification Using a Supervised Machine Learning Approach: A Multimodal MRI Study–Roberta Messina, Robert Leech, Fernando Zelaya, Ottavia Dipasquale, Diana Wei, Massimo Filippi, Peter Goadsby P4.10-017 Acute Anti-Migraine Prescription Varies According to Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study–Hu Li, Maurice Borges Vincent, Xiang Zhang, Robert Goodloe, Sheena K. Aurora P4.10-018 Work Activities Associated with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study–Aftab Alam, Sagar Munjal, Michael L. Reed, Ryan Bostic, Dawn C. Buse, David W. Dodick, Todd J. Schwedt, Richard B. Lipton P4.10-019 Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study–Aftab Alam, Sagar Munjal, Michael L. Reed, Ryan Bostic, Dawn C. Buse, Todd J. Schwedt, David W. Dodick, Richard B. Lipton P4.10-020 Prophylactic Use of SNRIs to Treat Pediatric Migraine via Reduction of Comorbid Anxiety and Depression–Sarah Jean McAlister, Christopher Oakley P4.10-021 Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene?Related Peptide Receptor–Eric Moore, Christopher Burgey, Mark Fraley, Andrew Danziger, Chris Regan, Chi-chung Li, Rebecca White, Pradeep Banerjee, Christopher Salvatore P4.10-022 Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy–Kerry Louise Knievel, Louise Lombard, Andy Buchanan, Simin Baygani, Joel Raskin, Joshua Tobin

P4.10-023 Impact of

OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT)– Guy Boudreau, Werner J. Becker, Corrie Graboski, May Ong-Lam, Ian Finkelstein, Suzanne N. Christie, Meetu Bhogal, Goran Davidovic P4.10-024 Eptinezumab Increases Days Free from Canonical Migraine-Associated Symptoms Within 1 Month of Treatment in Patients with Chronic Migraine–Jack D. Schim, Peter Goadsby, Eric Kassel, David M. Biondi, Joe Hirman, Roger Cady P4.10-025 Does the presence of Cranial Autonomic Symptoms in Chronic Migraine Patients Predict Efficacy of Botox Injections?–Nina Yakovlevna Riggins, Annika Ehrlich, Laura Dapkus, Peter Goadsby

BEHAVIORIAL AND COGNITIVE NEUROLOGY: LANGUAGE, MEMORY, AND VISUOPERCEPTION II

P5.1-001 Effect of Leukoaraiosis on Decline in Naming in Primary Progressive Aphasia–Adam Odolil, Amy Wright, Lynsey Keator, Donna Tippett, Argye E. Hillis

P5.1-002 Anatomical Correlates of Verbal Fluency in Parkinson Disease–Federico J. RodriguezPorcel, Janina Wilmskoetter, Leonardo F. G. Bonilha

P5.1-003 Network-Based

Approach to the Role of the Inferior Frontal Gyrus in Word Retrieval and Selection–Joely Alyssa Mass, Denise Y. Harvey, Apoorva Kelkar, John Dominic Medaglia, Roy H. Hamilton

Thursday, May 9 11:30 a.m.–6:30 p.m.

Poster Session 5 1. Aging, Dementia, Cognitive, and Behavioral Neurology: 1-001 to 1-032 2. MS and CNS Inflammatory Disease: 2-001 to 2-111 3. Cerebrovascular Disease and Interventional Neurology: 3-001 to 3-069 4. Neuromuscular Disease and Clinical Neurophysiology (EMG): 4-001 to 4-041 5. Epilepsy/Clinical Neurophysiology (EEG): 5-001 to 5-034 6. Neuro-rehabilitation; General Neurology; Child Neurology and Developmental Neurology: 6-001 to 6-070 7. Aging, Dementia, Cognitive, and Behavioral Neurology ePosters: 7-001 to 7-010 8. Movement Disorders: 8-001 to 8-050 9. Infectious Disease; Neurocritical Care; Practice, Policy, and Ethics: 9-001 to 9-078 10. Headache: 10-001 to 10-028

1 2 3

1-001-1-032

2-001-2-111

3-001-3-069

4 5 6

4-001-4-041

5-001-5-034

6-001-6-070

7-001-7-010

ePosters

8 9 10

8-001-8-050

9-001-9-078

POSTER SESSIONS

POSTER SESSION 5

10-001-10-028

P5.1-004 The Contribution

of Residual Anatomical Brain Networks in Language Recovery in Post-Stroke Aphasia–Apoorva Kelkar, Peter Turkeltaub, Dorian Pustina, John Dominic Medaglia

P5.1-005 Impaired Global

Network Topology in Residual Connectomes in Stroke-induced Aphasia–John Dominic Medaglia, Apoorva Kelkar, Dorian Pustina, Peter Turkeltaub FRONTOTEMPORAL DEMENTIA II

P5.1-006 Greater Relative

White Matter Burden is a Distinct Feature of Tauopathies in Frontotemporal Degeneration Spectrum–Lucia Giannini, Corey McMillan, Sharon Xie, David A. Wolk, Edward Lee, John Q. Trojanowski, Murray Grossman, David Irwin

P5.1-007 Plasma neurofilament

Participant Characterization in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) Rare Disease Clinical Research Consortium–Adam L. Boxer, Howard J. Rosen, Bradley F. Boeve, Hilary Heuer, Giovanni Coppola, Brian Appleby, Yvette Bordelon, Danielle Brushaber, Bradford Dickerson, Kimiko Domoto-Reilly, Kelley Faber, Howard Feldman, Julie Fields, Jamie Fong, Leah Forsberg, Tatiana Foroud, Nupur Ghoshal, Murray Grossman, Neill R. Graff-Radford, Ging-Yuek R. Hsiung, Edward D. Huey, Kejal Kantarci, Daniel Kaufer, Diana Kerwin, David S. Knopman, John Kornak, Joel Kramer, Irene Litvan, Ian R.A. Mackenzie, Mario F. Mendez, Bruce L. Miller, Chiadi Uchendu Onyike, Alexander Pantelyat, Madeline Potter, Rosa Rademakers, Katya Rascovsky, Erik Roberson, Carmela Tartaglia, Arthur Toga, Sandra Weintraub

P5.1-009 Characteristics and

Progress on 369 Subjects in the Longitudinal Evaluation Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol–Leah Forsberg, Danielle Brushaber, Giovanni Coppola, Bradford Dickerson, Jamie Fong, Ralitza H. Gavrilova, Nupur Ghoshal, Jill S. Goldman, Neill R. Graff-Radford, Murray Grossman, Hilary Heuer, Ging-Yuek R. Hsiung, Edward D. Huey, David Irwin, Kejal Kantarci, Anna Karydas, David S. Knopman, John Kornak, Walter Kremers, Walter Kremers, Maria Lapid, Diane Lucente, Ian R.A. Mackenzie, Rosa Rademakers, Eliana Marisa Ramos, Joanne Taylor, Arthur Toga, Zbigniew K. Wszolek, Bradley F. Boeve, Adam L. Boxer, Howard J. Rosen

P5.1-010 The Multidomain

Impairment Rating (MIR) Scale: Initial Reliability Data on a Multidimensional Scale for FTLD–Bradley F. Boeve, Howard J. Rosen, Adam L. Boxer, John Kornak, Hilary Heuer, Julie Fields, Leah Forsberg, Danielle Brushaber, Mary M. Machulda, Virginia Sturm, Peter A. Ljubenkov, Reilly Dever, Jeremy Syrjanen, Walter Kremers

NEUROIMAGING: AGING, VASCULAR, AND OTHER

P5.1-011 Brain glucose

metabolism in Lewy Body Dementia: implications for diagnostic criteria–Silvia Paola Caminiti, Arianna Sala, Leonardo Iaccarino, Luca Beretta, Andrea Pilotto, Luigi Gianolli, Sandro Iannaccone, Giuseppe Magnani, Alessandro Padovani, Luigi FeriniStrambi

P5.1-012 18F-AV-1451 Tau

Tracer Uptake Correlates with Medial Temporal Lobe Subregional Atrophy in Amyloid Negative Individuals–Sandhitsu Das, Long Xie, Laura Wisse, Ranjit Ittyerah, Paul Yushkevich, David A. Wolk

P5.1-013 Abnormal

neuropsychological memory testing and hippocampal volume in a clinical population.–Robert Ruchinskas, Trung P. Nguyen

P5.1-014 Cholinergic-Related

White Matter Lesion Load is Associated with Alzheimer’s Disease-Signature Cortical Thickness: The Northern Manhattan Study–Michelle Rae Caunca, Ken Cheung, Noam Alperin, Sang L. Lee, Sandino Cespedes, Mitchell S. V. Elkind, Ralph L. Sacco, Tatjana Rundek, Clinton B. Wright

AAN.com/view/AM19Sci 195

Thursday

light chain predicts disease progression in asymptomatic genetic frontotemporal dementia– Julio C. Rojas -Martinez, Ping Wang, Adam Staffaroni, Yann Cobigo, Amy Wolf, Hilary Heuer, Jamie Fong, Joanne Taylor, Andreas Jeromin, Howard J. Rosen, Bradley F. Boeve, Adam L. Boxer

P5.1-008 Progress and

POSTER SESSIONS

POSTER SESSION 5 P5.1-015 Periventricular

Cerebral Blood Flow as a Biomarker for Cerebral Small Vessel Disease–Sudipto Dolui, Marta Vidorreta, Ilya Nasrallah, David A. Wolk, John A. Detre

P5.1-016 Associations Between Amyloid Burden, White Matter Hyperintensities and Cognition in Cognitively Normal Older Adults–Benjamin Chapin, Eric Vidoni, Amber Watts, Jeffrey M. Burns

P5.1-017 Assessment of Deep

Medullary Veins on 3T MRI in a Population-based Cohort–DongHui Ao, Ding-Ding Zhang, Fei-Fei Zhai, Jiang-Tao Zhang, Fei Han, Ming-Li Li, Jun Ni, Ming Yao, ShuYang Zhang, Liying Cui, Zheng-Yu Jin, Lixin Zhou, Yi-Cheng Zhu

P5.1-018 Optical Properties and Oximetry Parameters of Cerebral Atrophic and Normal Regions in Healthy Volunteers–Luisa Roveri, Marta Zanoletti, Rebecca Re, Davide Contini, Lorenzo Spinelli, Alessandro Torricelli, Giacomo Giacalone

P5.1-019 Cognition predicted by

brain biomarkers and demographic factors–Angeliki Tsapanou, Christian Habeck, Yaakov Stern

P5.1-020 Increased Activity in

PET Imaging Markers of Primary Progressive Aphasia due to Likely Alzheimer’s Disease Pathology– Emily Roll, Murray Grossman, Molly Ungrady, Prerana Vaddi, Sophia Dominguez-Perez, Katheryn Cousins, Corey McMillan, Ilya Nasrallah, David Irwin, Jeffrey Scott Phillips

P5.1-024 The Relationship of

Amyloid Beta in the Retina to that of the Brain is Burden-specific– David P. Bissig, Daniel Schwartz, Erin Boespflug, David Lahna, Lisa C. Silbert

P5.1-025 Diffusion Tensor

Imaging in pre-dementia risk states: white matter atrophy findings in Mild Behavioral Impairment–Sascha Gill, Meng Wang, Nils Forkert, Frank MacMaster, Eric E. Smith, Zahinoor Ismail

P5.1-026 Phenotypes and

Biomarkers in Posterior Cortical Atrophy: Application of Consensus Clinical Diagnostic Criteria and the AT(N) Framework–Scott McGinnis, Bonnie Wong, Deepti Putcha, Mark Eldaief, Megan Quimby, Jessica Collins, Michael Brickhouse, Bradford Dickerson

P5.1-027 Correlates between

Functional Brain Network among the Elderly with Youthful Memory in Superaging–Min Young Chun, Bori Kim, Sujung Yoon, In Kyoon Lyoo, Jee Hyang Jeong, Geon Ha Kim

functional connectivity and amyloid deposition in healthy controls–Ricardo Bruña, David López-Sanz, Theodore Huppert, Ann Cohen, Yue-Fang Chang, Yu Dennis Cheng, Fernando Maestu, James T. Becker

NEUROIMAGING: ALZHEIMER DISEASE

P5.1-028 Association of Cortical

P5.1-021 The Neural Substrate

Thursday

P5.1-023 Clinical and Molecular

of Memory Impairment in the Oldest old with Dementia; The 90+ Study–S. Ahmad Sajjadi, Nasim Sheikh-Bahaei, Davis Woodworth, Dana E. Greenia, Maria M. Corrada, Claudia Kawas

P5.1-022 Multimodal Magnetic Resonance Imaging versus 18F-FDG-PET to Identify Mild Cognitive Impairment–Sudipto Dolui, Zhengjun Li, Ilya Nasrallah, John A. Detre, David A. Wolk

196 2019 AAN Annual Meeting

and Subcortical Aß Deposition with Depressive and Anxiety Symptoms: A Population-based Cross-sectional Study–Janina Krell-Roesch, Maria Vassilaki, Jeremy Syrjanen, Nicole Curnutt, David Gritsch, Prashanthi Vemuri, Michelle M. Mielke, Val John Lowe, Clifford R. Jack, Walter Kremers, David S. Knopman, Gorazd B. Stokin, Ronald C. Petersen, Yonas E. Geda

P5.1-029 Functional brain

connectome organization associated with atrophy and hypometabolism in posterior cortical atrophy–Raffaella Migliaccio, Federica Agosta, Silvia Basaia, Camilla Cividini, Maxime Montembeault, Marie-Odile Habert, Aurelie Kas, Massimo Filippi

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.1-030 Tracking

P5.2-004 Adjusting

P5.1-031 WMH Progression

P5.2-005 A History of Migraine

Neurostructural Preclinical Predictors of Alzheimer’s Disease: Linking Clinical Markers to the Size of the Ventral Tegmental Area and Other Subcortical Nuclei–Matteo De Marco, Annalena Venneri but not Regression is Associated with a Higher CSF tau/Aß and Temporal Amyloid Concentration in The Amyloid PET Scan–Omar Muhsin Ali Al-Janabi, Christopher Bauer, Chintan K. Rupareliya, Ahmed Bahrani, Larry B. Goldstein, Richard Ronan Murphy, Charles D. Smith, Donna Wilcock, Gregory A. Jicha, Brian Gold

P5.1-032 Structural Brain

Organization Associated with Gait in Mild Cognitive Impairment Subtypes–Gilles Allali, Maxime Montembeault, Olivier Beauchet

MS METRICS OF PROGNOSIS AND DISEASE PROGRESSION

P5.2-001 Longitudinal

Measures of Radiographic Outcomes as Predictors of Clinical Disability in Multiple Sclerosis: A 12-Year Study–Jenny J. Feng, Kunio Nakamura, Richard A. Rudick, Jeffrey Alan Cohen, Elizabeth Fisher, Daniel Ontaneda

P5.2-002 Dietary and Lifestyle

Factors in Multiple Sclerosis Progression: Results from a 5-year Longitudinal MRI Study–Jesper Hagemeier, Dejan Jakimovski, Bianca Weinstock-Guttman, Sirin Gandhi, Yi Guan, Deepa Ramasamy, Tom Fuchs, Niels Bergsland, Michael G. Dwyer, Murali Ramanathan, Robert Zivadinov

P5.2-003 Vitamin D and

Tobacco Use and Long-Term Clinical and MRI Outcomes among CIS patients: 11-year Follow-up of BENEFIT.–Elena H. Martinez-Lapiscina, Kassandra L. Munger, Marianna Cortese, Frederik Barkhof, Gilles Edan, Mark Freedman, Hans-Peter Hartung, Xavier Montalban, Ludwig Kappos, Frederick W. Foley, Iris Katharina Penner, Bernhard Hemmer, Edward J. Fox, Sven Schippling, Eva-Maria Wicklein, Alberto Ascherio

neurofilament light levels using an MRI-based estimate of total axonal bulk improves its prediction of MS progression–Jonathan Phillips, Ruturaj Masvekar, Peter Kosa, Kayla Jackson, Ann Weideman, Bibiana Bielekova Headache is Associated with Worse Disability and Walking Speed in a Cohort of Patients with MS–Anne M. Damian, Kathryn Fitzgerald, Smith Erin, Ellen M. Mowry

P5.2-006 Serum Neurofilament

Light Chain and Glial Fibrillary Acid Protein in Patients With Multiple Sclerosis–Xavier Ayrignac, Aleksandra Maleska Maceski, Clarisse Carra-Dalliere, Mahmoud Charif, Cyndi Catteau, Nelly Ginestet, Pauline Prin, Lucas Corti, Frédéric Pinna, Sylvain Lehmann, Pierre Labauge

P5.2-007 The association

between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis–Eleonora Tavazzi, Murali Ramanathan, Christian Barro, Jesper Hagemeier, Dejan Jakimovski, Niels Bergsland, Davorka Tomic, Harald Kropshofer, David Leppert, Zuzanna Michalak, Michael G. Dwyer, Ralph H. B. Benedict, Bianca WeinstockGuttman, Jens Kuhle, Robert Zivadinov

P5.2-008 HLA genotype as

a marker of Multiple Sclerosis prognosis: results from a multicentric extension study– Andreas Lysandropoulos, Gaetano Perrotta, Thibo Billiet, Annemie Ribbens, Pietro Maggi, Marie Theaudin

P5.2-009 No Association

Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis–Sven G. Meuth, David W. Brandes, Matthew Carraro, Giancarlo Comi, Yang MaoDraayer, Guillermo Izquierdo Ayuso, Ho Jin Kim, Gabriel Pardo, Basil Sharrack, Carlo S. Tornatore, Bart Van Wijmeersch, Tjalf Ziemssen, Alan K. Jacobs, Luke Chung, Nadia Daizadeh, Heinz Wiendl

P5.2-010 Predicting EDSS in MS through Imaging Biomarkers Using Artificial Neural Networks–David Chaar, Mihir Kakara, Sara Razmjou, Evanthia Bernitsas

P5.2-011 Loss of Brain Iron is

Linked to Disability in Multiple Sclerosis - The Difference Between Concentration and Mass of Iron–Jesper Hagemeier, Michael G. Dwyer, Niels Bergsland, Bianca WeinstockGuttman, Robert Zivadinov, Ferdinand Schweser

P5.2-012 Unilateral Motor

Progression in Multiple Sclerosis: Association with a Single Critical Corticospinal Tract Lesion–Elia Sechi, Mark Keegan, Timothy Kaufmann, Orhun H. Kantarci, Brian G. Weinshenker, Eoin P. Flanagan

P5.2-013 The neutrophil-to-

lymphocyte and monocyteto-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis– Christopher Hemond, Bonnie Glanz, Rohit Bakshi, Tanuja Chitnis, Brian Curran Healy

P5.2-014 Oligoclonal band

number as a predictor of multiple sclerosis disease course– Christopher Perrone, Ritobrato Datta, Christine Farrell, Aditya Rao, Clyde E. Markowitz, Joseph R. Berger

P5.2-015 Cognition as a

Disability Progression Marker: Two-Years Follow-Up of People with Multiple Sclerosis–Jiri Motyl, Lucie Kadrnozkova, Jana Dusankova, Michaela Andelova, Tomas Uher, Manuela Vaneckova, Dana Horakova

P5.2-016 Baló Concentric

P5.2-017 Serum GFAP

Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis–Laura Airas, Heidi Hoegel, Eero Rissanen, Markus Matilainen, Marjo Nylund, Jens Kuhle

the Immunophenotype of Clinically Isolated Syndrome Patients Who Convert or Not To Multiple Sclerosis–Chieh-Hsin Lee, Maryam Nakhaei-Nejad, David Barilla, Carlos Rodrigo CamaraLemarroy, Luanne Metz, Claudia Silva, V. Wee Yong, Fabrizio Giuliani

P5.2-019 Late onset MS is

associated with more severe longitudinal development of central brain atrophy compared to adult onset MS–Dora Dujmic, Dejan Jakimovski, Jesper Hagemeier, Niels Bergsland, Deepa Ramasamy, David Hojnacki, Channa Kolb, Alexis A. Lizarraga, Bianca Weinstock-Guttman, Robert Zivadinov

P5.2-020 Clinical Profile and

functional outcomes of idiopathic inflammatory demyelinating disorders of CNS in adults.– Sankar Prasad Gorthi, Ranjit G, Vijay Chandran, Arvind Prabhu, Aparajita Chatterjee

P5.2-021 Real Life Evidence for

CSF Neurofilaments Light Chain in Clinical Practice.–Karina CarrilloLoza, Saúl Reyes, Lucia Bianchi, David Holden, Maria Espasandin, Francesca Ammoscato, Benjamin Turner, Klaus Schmierer, Monica Marta, Gavin Giovannoni, Sharmilee Gnananpavan

P5.2-022 Positive Predictive

Value of Elevated Unique Cerebrospinal Fluid Oligoclonal Bands–Casey Farin, Christopher Paul Eckstein, Mark B. Skeen MS NEUROIMAGING

P5.2-023 Sex-specific

Differences in Rim Appearance of Multiple Sclerosis Lesions on Quantitative Susceptibility Mapping–Besher Tolaymat, Wei Zheng, Huanwen Chen, Seongjin Choi, Xu Li, Daniel Harrison

P5.2-024 Demyelination,

Inflammation and Axonal Loss Explain Different Patterns of Fractional Anisotropy Abnormalities in MS Cortical Normal Appearing Gray Matter and Lesions–Paolo Preziosa, Svenja Kiljan, Martijn D Steenwijk, Alessandro Meani, Wilma van de Berg, Geert Schenk, Maria Assunta Rocca, Massimo Filippi, Jeroen JG Geurts, Laura Jonkman

P5.2-025 3D MR image

synthesis using unsupervised deep learning algorithm in MS patients–Amirhossein Jabarzedeh, Lokesh A. Rukmangadachar, Daniel Pelletier

P5.2-026 A comparison of FLAIR and T1 maps from MP2RAGE at 7T for quantifying lesion volume and its correlation to disability in multiple sclerosis–Margaret Spini, Seongjin Choi, Daniel Harrison

P5.2-027 New/Enlarging Lesion

Count: Man versus Machine–Wim Van Hecke, Annemie Ribbens, Thibo Billiet, Robert Zivadinov, Deepa Ramasamy, Michael G. Dwyer, Niels Bergsland, Ellen Carl, Chenyu Wang, Linda Ly, Yael Barnett, Lynette Masters, Michael Barnett, Heidi N. Beadnall

P5.2-028 Correlation

Between Neurologic Challenge Task Performance and Lesion Localization of Sub-Threshold Lesions in Multiple Sclerosis Patients with EDSS Score of 0–Ali Antoine, James F. Sumowski, Stephen Krieger

P5.2-029 Automatically

segmented medulla oblongata volume as a surrogate for spinal cord atrophy in multiple sclerosis–Niels Bergsland, Dejan Jakimovski, Bianca WeinstockGuttman, Robert Zivadinov

P5.2-030 Inflammatory activity

associated with increased rate of brain and retinal neuro-axonal injury in early MS The aim of this study is to address the effect of local inflammatory activity in brain and retinal neuro-axonal injury along MS course.–Irene Pulido Valdeolivas, Magi Andorra, David Gómez-Andrés, Kunio Nakamura, Salut Alba-Arbalat, Erika Lampert, Irati Zubizarreta, Sara Llufriu, Eloy Martinez-Heras, Elisabeth Solana, Nuria Sola-Valls, Maria Sepúlveda, Ana Tercer-Uribe, Yolanda Blanco Morgado, Albert Saiz, Anna Camos-Carreras, Bernardo Sanchez-Dalmau, Pablo Villoslada, Elena H. Martinez-Lapiscina

P5.2-031 Investigation into

the Relationship between Digital Brain Volume and Computerized Screening Assessment of Cognitive Function in People with Multiple Sclerosis: Objective Analytics to Quantify Disease Impact – Cross Sectional Relationship–Jared Srinivasan, Jeeyoon Kang, Lori Fafard, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Cynthia L. Sullivan, Jeffrey A. Wilken, Daniel Golan, Mark Gudesblatt

P5.2-032 Quantitative Spinal

Cord MRI in MS patients with Sexual Dysfunction: A Crosssectional Study.–Estelle Seyman, David Dongkyung Kim, Aditya Bharatha, Courtney S. Casserly, Paula Alcaide-Leon, Suradech Suthiphosuwan, Jiwon Oh

P5.2-033 Clinical and

Conventional MRI Predictors of Cognitive Rehabilitation Efficacy in Multiple Sclerosis–Tom Fuchs, Ralph H. B. Benedict, Stefano Ziccardi, Leigh Elkins Charvet, Michael Shaw, Alexander Bartnik, Devon Oship, Rebecca Campbell, Jose Escobar, Faizan Yasin, Jeta Pol, Curtis Wojcik, Robert Zivadinov, Michael G. Dwyer

P5.2-034 Integration and

Characterization of Brain MRI Data from the Italian Neuroimaging Network Initiative (INNI) for the Study of Multiple Sclerosis–Loredana Storelli, Maria Assunta Rocca, Elisabetta Pagani, Patrizia Pantano, Nicola De Stefano, Gioacchino Tedeschi, Paola Zaratin, Massimo Filippi

P5.2-035 Cognitive Impairment and Deep Grey Matter Lesions on 7T MRI in Multiple Sclerosis– Christine Tomkinson, Eric Habib, Alan Kuurstra, Manas Sharma, Heather Rosehart, Marcelo C. Kremenchutzky, Joe Gati, Ravi Sivasankara Menon, Sarah Anne Morrow

P5.2-036 Cerebellar Volume

Loss in Radiologically Isolated Syndrome–Ilena George, Mohamed-Mounir El Mendili, Christina Azevedo, Christine Lebrun Frenay, Orhun H. Kantarci, Aksel Siva, Darin T. Okuda, Daniel Pelletier, Matilde Inglese

AAN.com/view/AM19Sci 197

Thursday

Sclerosis: Benign Evolution in a Tunisian Population–Oussama Landolsi, Ines Ben Abdelaziz, Aymen Arous, Jihene Ben Sassi, Samir Belal, Faycal Hentati

P5.2-018 Characterization of

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.2-037 Lower Total Cerebral

Arterial Flow Contributes to Cognitive Performance in Multiple Sclerosis Patients–Dejan Jakimovski, Ralph H. B. Benedict, Karen Marr, Sirin Gandhi, Niels Bergsland, Bianca WeinstockGuttman, Robert Zivadinov

P5.2-038 Increased Iron

Accumulation in Red Nucleus, Spelium, Putamen and Thalamus in Multiple Sclerosis and CIS: A 7 Tesla MRI Study–Belgin Kocer, Alyssa Zhu, Anisha Keshavan, Bruce A. C. Cree, Roland G. Henry, Jeffrey Marc Gelfand

P5.2-039 Loss of intrathalamic

tissue integrity in pediatric-onset multiple sclerosis measured with DTI.–Ritobrato Datta, Christine Till, Elissa DeSomma, Emily Barlow-Krelina, Nadine Akbar, Sudipto Dolui, Sridar Narayanan, Douglas L. Arnold, E. Ann Yeh, Brenda Banwell

P5.2-040 Impact of Cervical

Stenosis on Multiple Sclerosis Lesion Distribution in the Spinal Cord–Daniel Gratch, David Do, Matthew K. Schindler, James Schmitt, Pouya Khankhanian, Joseph R. Berger

P5.2-041 MS patients with

low central vein sign frequency can be identified by FLAIR* MRi sequences–Federica Azzolini, Matteo Grammatico, Giovanna Carlucci, Lucia Goanta, Stefania Dallagiacoma, Anna Maria Rita Repice, Benedetta Forci, Francesca Dipasquale, Leonardo Marchi, Enrico Fainardi, Luca Massacesi

Thursday

P5.2-042 Instrumental,

Clinical, and Patient Reported Sensorimotor Correlates of Spinal Cord Grey and Total Cord Areas– Amber M. Alexander, Jennifer Arjona, Nico Papinutto, William Stern, Antje Bischof, Valerie A J Block, Jeffrey Marc Gelfand, Douglas S. Goodin, Xiaoming Jia, Andrew R. Romeo, Jennifer Graves, Bruce A. C. Cree, Stephen L. Hauser, Roland G. Henry

198 2019 AAN Annual Meeting

P5.2-043 Functional

Connectivity with the Default Mode Network Predicts Efficacy of Cognitive Rehabilitation in People with Multiple Sclerosis– Alexander Bartnik, Tom Fuchs, Ralph H. B. Benedict, Stefano Ziccardi, Devon Oship, Bianca Weinstock-Guttman, Leigh Elkins Charvet, Robert Zivadinov, Michael G. Dwyer

P5.2-044 Magnetization

Transfer Saturation Reveals Subclinical Optic Nerve Demyelination in Pediatric Multiple Sclerosis–Giulia Longoni, Robert Allan Brown, Kimberly Young, Tara Berenbaum, Dumitru Fetco, Stephanie Grover, Fiona Evann Costello, Arun Y. Reginald, Amit Bar-Or, Ruth-Ann Marrie, Douglas L. Arnold, Sridar Narayanan, Brenda Banwell, John Sled, Donald Mabbott, E. Ann Yeh

P5.2-045 Higher EBV response

is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: a case-controlled magnetization transfer ratio study–Michael G. Dwyer, Dejan Jakimovski, Murali Ramanathan, Bianca Weinstock-Guttman, Niels Bergsland, Deepa Ramasamy, Ellen Carl, Robert Zivadinov

P5.2-046 Correlation between

Magnetization Transfer Ratio and Functional Status in Multiple Sclerosis patients–Ali Ebrahim, Zainab Alalawi, Kalyan Yarraguntla, Fen Bao, Mohammed Alhaidar, Samuel Lichtman-Mikol, Sara Razmjou, Navid SerajiBozorgzad, Evanthia Bernitsas

P5.2-047 Dynamics of PseudoAtrophy in RRMS Patients Treated with Interferon beta-1a as Assessed by Monthly Brain MRI–Nicola De Stefano, Antonio Giorgio, G Gentile, Maria Laura Stromillo, Claudio Grasperini, Andrea Visconti, Maria Pia Sormani, Marco Battaglini

P5.2-048 Resting-state

functional correlates of Social Cognition in Multiple Sclerosis–Alvino Bisecco, Gabriella Santangelo, Federica Di Nardo, Renato Docimo, Manuela Altieri, Rocco Capuano, Simona Pappacena, Alessandro D’Ambrosio, Simona Bonavita, Mario Ciriillo, Fabrizio Esposito, Gioacchino Tedeschi, Ivan Rocha Ferreria Da Silva

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.2-049 Cortical Thickness,

Subcortical Volumes and Disability in Multiple Sclerosis: A Prospective Longitudinal Study– Mihir Kakara, Sara Razmjou, David Chaar, Kalyan Yarraguntla, Fen Bao, Carla E. Santiago-Martinez, Evanthia Bernitsas

P5.2-050 Nystagmus-

associated imaging signatures in Multiple Sclerosis: evaluation of subcortical and infratentorial structures–Peter Bede, Eoin Finegan, Rangariroyashe Chipika, Stacey Li Hi Shing, Jeffrey Lambe, Janice M. Redmond

P5.2-051 Spine atrophy and

sensory-motor disability in African Americans with Multiple Sclerosis–Mohamed-Mounir El Mendili, Maria Petracca, Amgad Droby, Giacomo Boffa, Swetha Paduri, Christopher Langston, Daniel Peter Kurz, Ilena George, Claire Riley, Jonathan Howard, Sylvia Klineova, Matilde Inglese

P5.2-052 Influence of

T2-Hyperintense Lesions on Cervical Spinal Cord Atrophy and Disability in Patients with Multiple Sclerosis–Maria Assunta Rocca, Paolo Preziosa, Emanuele Pravatà, Paola Valsasina, Claudio Gobbi, Chiara Zecca, Massimo Filippi

P5.2-053 Changes in Brain

Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients– Francisco Perez Miralles, Daniel Prefasi, Antonio García-Merino, Jose Ramon Ara, Guillermo Izquierdo Ayuso, Virginia Meca Lallana, Francisco Gascon, Maria Luisa Martinez Gines, Lluis Ramio Torrenta, Lucienne Costa Frossard Franc, Oscar Fernandez, Sara Moreno Garcia, Jorge Maurino, Bonaventura Casanova

P5.2-054 Is there a relationship between Incidental Learning and Self-temporal Projection in relapsing remitting multiple sclerosis patients?–Carmen Rodrigo, Maria Goldfeder, Agostina Galiani, Fatima Pagani Cassara, Vladimiro Sinay, Maria Roca, Diana Bruno

P5.2-055 Resting State

Network Functional Connectivity Abnormalities in Systemic Lupus Erythematosus: Correlations with Neuropsychological and Neuropsychiatric Variables– Raffaello Bonacchi, Maria Assunta Rocca, Paolo Preziosa, Giuseppe A. Ramirez, Enrica Bozzolo, Gianna Carla Riccitelli, Valentina Canti, Paola Valsasina, Patrizia Rovere-Querini, Angelo Manfredi, Massimo Filippi

P5.2-056 Gray Matter Volume

Loss Is Increased in Younger Patients With Relapsing Multiple Sclerosis but Minimized by Ozanimod: Experience From the Ozanimod Phase 3 Program–Sven Schippling, Bruce A. C. Cree, Xavier Montalban, Douglas L. Arnold, Ludwig Kappos, Giancarlo Comi, Karthik Bodhinathan, Yu Chen, James K. Sheffield, Diego Silva

P5.2-057 Deep learning enables thalamic atrophy measurement on clinical quality T2 FLAIR images–Michael G. Dwyer, Keith Carolus, Niels Bergsland, Dejan Jakimovski, Bianca WeinstockGuttman, Ferdinand Schweser, Ralph H. B. Benedict, Robert Zivadinov

P5.2-058 Brain Volume Loss and

Cognition in Teriflunomide-Treated Patients in TEMSO–Jens Wuerfel, Richard A L Macdonell, Maria Pia Sormani, Aaron E. Miller, Ludwig Kappos, Young-Min Lim, Deyanira Ramirez, Bassem I. Yamout, Kathleen C. Somera-Molina, Elizabeth Poole, Till Sprenger

P5.2-059 Effect of Treatment

Naiveté on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS–Samuel F. Hunter, Florian P. Thomas, Xiangyi Meng, Lesley Schofield, Nadia Tenenbaum, Bruce A. C. Cree

P5.2-060 Magnetic Resonance

Imaging Measures as Prognostic Parameters for Physical and Cognitive Outcomes up to 8 Years in Patients with Relapsing Forms of Multiple Sclerosis–Timothy L. Vollmer, Dieter Haering, Daniela Piani Meier, Davorka Tomic, Till Sprenger, Douglas R. Jeffery

P5.2-061 Regional Myelin-

Specific MRI Abnormalities in Susac Syndrome Suggests Demyelination is a Pathologic Feature–Poljanka Johnson, Jillian Chan, Irene Vavasour, Shawna Abel, Lisa Eunyoung Lee, Heather Yong, Vanessa Wiggermann, Cornelia Laule, Andrew Woolfenden, Anthony Traboulsee, David K.B. Li, Roger Tam, Shannon Kolind, Robert L. Carruthers

P5.2-062 Long-Term Monitoring

Of Brain Volume Loss In Multiple Sclerosis–Mikolaj Pawlak, Alicja Kalinowska-Lyszczarz, Ewa Kotecka-Sowinska, Jacek Wencel, Dorota Gulczynska, Radoslaw Kazmierski

P5.2-063 Atrophied T2 lesion

volume and cognitive outcomes in multiple sclerosis–Eleonora Tavazzi, Ralph H. B. Benedict, Jesper Hagemeier, Dejan Jakimovski, Niels Bergsland, Michael G. Dwyer, Bianca Weinstock-Guttman, Robert Zivadinov

P5.2-064 Global and regional brain atrophy in highly active MS-A biomarker for therapy switch–Alaleh Raji, Gerhard Winkler

P5.2-065 Myelinating Proteins in MS are Linked to Volumetric Brain MRI changes–Staley A. Brod, John A. Lincoln, Flavia Nelson

P5.2-066 Trigeminal

nerve root enhancement in multiple sclerosis–Lokesh A. Rukmangadachar, Steven Tversky, Margaret E. Burnett

P5.2-067 Short-term MRI-

P5.2-068 The Effect of

Glitiramer Acetate 40mg TIW on Multiple Brain MRI Parameters over One Year–Jacob Rube, Fen Bao, Samuel Lichtman-Mikol, Sara Razmjou, Kalyan Yarraguntla, Carla E. Santiago-Martinez, Navid Seraji-Bozorgzad, Evanthia Bernitsas

P5.2-076 Analysis of Relapse

P5.2-070 Volume Loss in Deep

P5.2-077 The effect of oral

volumes as markers of clinical disability and cognitive dysfunction in multiple sclerosis–Niels Bergsland, Ralph H. B. Benedict, Michael G. Dwyer, Tom Fuchs, Ferdinand Schweser, Bianca Weinstock-Guttman, Robert Zivadinov Gray Matter and Thalamic SubNuclei in Placebo-treated Patients with Multiple Sclerosis in the Phase 3 TEMSO Study–Stefano Magon, Laura Gaetano, Mallar Chakravarty, Ludwig Kappos, Till Sprenger, Steven J. Cavalier, Nora Roesch, Karthinathan Thangavelu, Jens Wuerfel

by MRC Sum Score in the PATH Study of Subcutaneous Immunoglobulin in CIDP–Vera Bril, Ingemar S.J. Merkies, Hans-Peter Hartung, Richard A. Lewis, Gen Sobue, John-Philip Lawo, Orell Mielke, Billie Durn, David R. Cornblath, Ivo N. Van Schaik Steriods in Chronic Demyelinating Polyneuropathy associated with Diabetes Mellitus–Thangjam Suraj Singh

P5.2-078 Treatment Satisfaction and Work Productivity in a Clinical Study of IgPro20 Maintenance Treatment of CIDP–Hans-Peter Hartung, Rajiv Mallick, Vera Bril, Nan van Geloven, Richard A. Lewis, Gen Sobue, John-Philip Lawo, Orell Mielke, Billie Durn, David R. Cornblath, Ingemar S.J. Merkies, Ivo N. Van Schaik

P5.2-083 Precision Therapy for

Neuromyelitis Optica Spectrum Disorder: A Retrospective Analysis of the Use of ClassSwitched Memory B-cells for Individualized Rituximab Dosing Schedules–Benjamin Peter Trewin, Stephen Adelstein, Judith M. Spies, Heidi N. Beadnall, Joshua Barton, Nicholas Ho, Michael Barnett

P5.2-084 New Sensorineural

Hearing Loss can be Associated with Disabling Autoimmune Disease–Kimia Ghavami, Mollie Carruthers, Robert L. Carruthers MS SYMPTOM ASSESSMENT AND MANAGEMENT

Reduction In IVIG By Specific Immunoaffinity Chromatography Reduces Spontaneous Reporting Rates Of Hemolytic Reactions– Amgad Shebl, Susie Gabriel, Kirsty Van Dinther, Alphonse Hubsch, Liane Hoefferer, Susan Welsh

Concomitant Immunosuppressive Therapy Use During a Phase 3 Open-label Study of Eculizumab in Adults with Generalized Myasthenia Gravis: an Interim Analysis–Richard J. Nowak, Srikanth Muppidi, Said R. Beydoun, Fanny O’Brien, Marcus Yountz, James F. Howard

P5.2-085 Long-term Effectiveness of 9-d-tetrahydrocannabinol:Cannabidiol Oromucosal Spray in Clinical Practice: results from a 18-months Multicenter Italian Study–Francesco Patti, Clara Chisari, Emanuele D’Amico, Claudio Solaro, Sebastiano Arena, Pasquale Annunziata, Maria Donata Benedetti, Eliana Berra, Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla, Raffaella Cerqua, Gianfranco Costantino, Federica Esposito, Claudio Gasperini, Angelica Guareschi, Matilde Inglese, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Jerzy Pietruszewski, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Edoardo Sessa, Francesco Sacca, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Litterio A. Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia

P5.2-074 Adrenal Insufficiency

P5.2-081 Molecular

P5.2-086 Feasibility of Using

IMMUNOTHERAPIES: NEW TARGETS AND SIDE EFFECTS

P5.2-071 Factors associated

with headache in intravenous immunoglobulin treatment for neurological diseases.–Jonas Graf, Jens Ingwersen, Klaudia Lepka, Philipp Albrecht, HansPeter Hartung, Marius Ringelstein, Orhan Aktas

P5.2-072 Naturally Occurring

Anti-Neuronal Antibodies within IVIg Preparations: Importance in Clinical Practice–Maria Dimitriadou, Harry Alexopoulos, Sofia Akrivou, Eleni Gola, Marinos C. Dalakas

P5.2-073 Isoagglutinin

and Multiorgan Failure in a Patient Receiving Alemtuzumab Therapy–Paul M. Miller, Vince Tran, Augusto A. Miravalle, Tamara Miller

P5.2-075 Long-term

efficacy of intravenous immunoglobulin treatment in 49 patients with chronic inflammatory demyelinating polyradiculoneuropathy–Julia Seybold, Pauline Terhoeven, Ralf Linker, De-Hyung Lee

P5.2-079 RVT-1401, A Novel

Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration–Jon William Collins, Lori Elizabeth Jones, Michele Snyder, Eric Sicard, Paul Griffin, Lindsey Webster, Regan Fong, Christine Morel Coquery, Stephen Piscitelli

P5.2-080 Changes in

Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS–Haggai Kaspi, Revital Aricha, Natalie Abramov, Yael Gothelf, Chaim Lebovits, Joseph Petroziello, Yossef Levy, Ralph Kern

P5.2-082 Saturation of alpha4

Wearable Technology with a Social Cognitive Theory-based Physical Activity Promotion Program in Youth with Multiple Sclerosis–Stephanie Grover, Samantha Stephens, Jane E Schneiderman, Jennifer Stinson, Marcia Finlayson, Robert W Motl, E. Ann Yeh

integrin (CD49d) in patients undergoing treatment with natalizumab in extended interval dose.–Nuole Zhu, Silvia Presas, Cristina M. Ramo, Eva MartinezCaceres, Joan Punet-Ortiz, Aina Teniente-Serra

AAN.com/view/AM19Sci 199

Thursday

based Prediction of Clinical MS Progression in a Real World Setting–Wim Van Hecke, Diana Sima, Thibo Billiet, Jeroen Van Schependom, Christine Ernon, Marie D’hooghe, Dominique Leon Dive, Guy Nagels, Dirk Smeets

P5.2-069 Thalamic nuclei

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.2-087 INROADS: A Phase 3

Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment– Michelle Cameron, Jeffrey Alan Cohen, Aaron E. Miller, Andrew D. Goodman, Myla D. Goldman, Robert Elfont, Cindy Souza-Prien, Larissa Felt, Rajiv Patni

P5.2-088 Which treatments

improve fatigue and quality of life in Multiple Sclerosis? Evidence appraisal and development of visual interactive evidence maps– Amy Tsou, Jonathan Treadwell, Eileen Erinoff, Karen Schoelles

P5.2-089 Sexual Dysfunction in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Prevalence–David Dongkyung Kim, Catherine Leurer, Bethany So, Courtney S. Casserly, Estelle Seyman, Stefan Baral, Jiwon Oh

P5.2-090 Interoception as

a neurocognitive mechanism underlying fatigue in Multiple Sclerosis–Cecilia Gonzalez Campo, Paula Salamone, Vladimiro Sinay, Diana Bruno, Fatima Pagani Cassara, Adolfo Garcia, Lucas Sedeño, Agustin Ibanez

P5.2-091 Origins of Fatigue

in an Early Multiple Sclerosis Cohort–Colleen Marino, James F. Sumowski

P5.2-092 A Survey of CannabisBased Product Use in Multiple Sclerosis Patients at the University of British Columbia Hospital–Alice Jane Schabas, Vlatka Vukojevic, Carolyn L. Taylor, Ana-Luiza Sayao, Virginia A. Devonshire, Anthony Traboulsee, Robert L. Carruthers

Thursday

P5.2-093 N-acetyl cysteine for

fatigue in progressive multiple sclerosis: A pilot randomized double-blind placebo-controlled trial–Kristen M. Krysko, Antje Bischof, Bardia Nourbakhsh, Roland G. Henry, Nisha Revirajan, Michael Manguinao, Yan Li, Emmanuelle Waubant

P5.2-094 Telerehabilitation

reduces travel cost and time: A survey of participants with multiple sclerosis in an urban treatment setting–Pamela Best, Ariana Michelle Frontario, Michael Shaw, Leigh Elkins Charvet

200 2019 AAN Annual Meeting

P5.2-095 Combined Triaxial

Accelerometeric Sensors and Ultrasonography-Guided Botulinum Toxin Type-A Injection Can Improve Outcome In Upper Extremities Tremor in Multiple Sclerosis–Hatem Samir Mohammed Shehata, Sherif M. Hamdy, Maged Mohamed Abdel-Naseer, Alaa Elmazny, Amr Mohammed, Mohammed Hegazy, Mye Basheer, Sarah Abdo, Nevin Shalaby

P5.2-096 The Extent of the

Relationship between Sleep Disturbances and walking ability in People with Multiple Sclerosis–Khalid I. El-Salem, Alham Alsharman, Hanan Khalil, Duha Mohammed Al-Shorafat, Patrick Esser, Helen Dawes

P5.2-097 A Novel Approach

to Treatment of Trigeminal Neuralgia in Multiple Sclerosis Patients Using Minimally Invasive Trigeminal Ablation (MITA)– Yasser Tajali, Boris Paskhover, Max Ward, Yehuda Herschman, Machteld E. Hillen

P5.2-098 Lacosamide Efficacy

in Trigeminal Neuralgia and Other Neuropathic Pain Syndromes: A Case Series–Scott M. Belliston

P5.2-099 Social anxiety among

patients with multiple sclerosis: a population-based case-control study in Ecuador–Joyce Antonella Jimenez-Zambrano, Roberto Rodríguez-Díaz, Gabriela Acuna

P5.2-100 Cannabis Use in

People with Multiple Sclerosis and Self-Reported Spasticity– Lucinda L. Hugos, Jessica Rice, Michelle Cameron

P5.2-101 Gait and

Balance Outcomes in Adrenomyeloneuropathy (AMN)–Reza Seyed Sadjadi, Neha Godbole, Richard F. Lewis, David Balkwill, Florian Eichler

P5.2-102 Processing speed

of information deficit induces a lack of functional impulsivity in Multiple Sclerosis–Heloise Joly, Nicolas Capet, Clement Suply, Saskia Bresch, Mikael Cohen, Christine Lebrun Frenay

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.2-103 Arabic Modified

Fatigue Impact Scale: Validity and Reliability in People with Multiple Sclerosis–Alham Alsharman, Hanan Khalil, Alia Alghwiri, Khalid I. El-Salem, Aseel Aburub, Duha Mohammed Al-Shorafat, Sarah Al-Shalabi

P5.2-104 Cognitive-motor

interaction in Multiple Sclerosis: how it impacts on patient’s Quality of Life.–Barbara Eizaguirre, Aldana Marinangeli, Ricardo Alonso, SIlva Berenice, Sandra Vanotti, Domingo Orlando Garcea

P5.2-105 Immunophenotyping

of Depression and Fatigue in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Dimethyl Fumarate–ChiehHsin Lee, Zoya Zaeem, David Barilla, Maryam Nakhaei-Nejad, Fabrizio Giuliani

P5.2-106 Multiple Sclerosis

and Use of Medical Cannabis: A Retrospective Review Evaluating Symptom Outcomes–Katelyn McCormack, Emily Lewandowski, Michelle Rainka, Traci Aladeen, Erica Westphal, Amir Mazhari, Laszlo Mechtler

P5.2-107 Evidence of early

Central Nervous System degeneration in Multiple Sclerosis patients with impulsivity–Nicolas Capet, Heloise Joly, Clement Suply, Lydiane Mondot, Saskia Bresch, Mikael Cohen, Christine Lebrun Frenay

P5.2-108 Prevalence and

Factors Associated with Anxiety in Argentinian Patients with Multiple Sclerosis–Anibal Chertcoff, Celeste Curbelo, Johana Bauer, Flavia Ferrandina, Santiago Blanco, Alejandra D. Martinez, Judith Diana Steinberg, Adriana Carra

P5.2-109 Demyelinating

Disease Associated with Parkinsonism: A Case Report– Zachary Britt Jordan, Barbara Kelly Changizi

P5.2-110 Long-Term Follow-

Up and Results of Patients with MRI Negative Demyelinating Diseases–Ozgu Kizek, Canan duman ilki, Tuncay Gunduz, Murat Kurtuncu, Mefkure Eraksoy

P5.2-111 The “MS Hug”:

Definition, Characteristics, Course, and Misattribution Risk–Dean M. Wingerchuk, Cristina Valencia Sanchez, Jonathan L. Carter

BLOOD PRESSURE AND STROKE

P5.3-001 Out with the Old and

In with the New - Understanding Barriers and Facilitators in Obtaining “New” Blood Pressure Goal for Patients with Ischemic Stroke–Jason J. Sico, Laura Burrone, Sharon Bottomley, Lisa Keefner, Teresa Damush, Paul W. Hurd, Brenda Fenton

P5.3-002 Blood Pressure

at Hospital Arrival Does Not Reliably Distinguish Hypertensive Intracerebral Hemorrhage–Nasir Fakhri, Scott Moody, Kayleigh Murray, Samantha Costa, Shadi Yaghi, Tina Mariko Burton, Shawna M. Cutting, Ali Mahta, Linda C. Wendell, Bradford B. Thompson, Shyam Sudarshan Rao, N. Stevenson Potter, Karen L. Furie, Brian Mac Grory, Michael E. Reznik

P5.3-003 Low and steady:

Evidence for target blood pressure 24 hrs post-thrombectomy– Cheran Elangovan, Muhammad Niazi, Nathan DeTurk, Cesar Velasco, Alicia Richardson, Kenneth Liu, David Matthew Ermak

P5.3-004 Sympathetic Nervous System Dysfunction Correlates with Increased Blood Pressure Variability after Acute Stroke– Adam De Havenon, Ka-Ho Wong, Michael Dela Cruz, Melissa M. Cortez, Gregory W. Hawryluk

P5.3-005 High In-Hospital

Systolic Blood Pressure Variability and Poor Functional Outcomes in Primary Intracerebral Hemorrhage Patients–Katie Alex, Jennifer Meeks, Arvind Bambhoroliya, Christopher Fraher, Sean I. Savitz, Farhaan S. Vahidy

P5.3-006 Blood Pressure

Variability Post Mechanical Thrombectomy And Outcomes– Phong Thanh Vu, Jessica Frey, Ashley Petrone, Yasser Kabbani, Swarna Rajagopalan

P5.3-007 Patients with

Parenchymal Hemorrhagic Transformation and Poor Functional Outcome Have Distinct Systolic Blood Pressure Trajectories 72 hours After Mechanical Thrombectomy– Sreeja Kodali, Sumita Strander, Andrew Silverman, Tijil Agarwal, Christoph Stretz, Anson Wang, Lauren Hachmann Sansing, Joseph Schindler, Kevin N. Sheth, Nils Petersen

P5.3-008 Examining the

Mortality Benefit of Various Post Ischemic Stroke/TIA Hypertension Goals – an VAbased Observational Study–Jason J. Sico, Xin Hu, Laura Myers, Greg Arling, Dawn M. Bravata

P5.3-009 Admission Blood

Pressure and Outcome after Successful Recanalization: a collaborative pooled analysis– Mohammad Anadani, Mohamad Orabi, Nitin Goyal, Fnu Abhi Pandhi, Hunter Mitchell, Andrie Alexandrov, Ilko Maier, MariosNikos Psychogios, Jan Liman, Ovais Inamullah, Shareena A. Rahman, Christa Brittany Swisher, Salah G. Keyrouz, James Anthony Giles, Michelle Allen, Akash Kansagra, Benjamin Gory, Pierre De Marini, Stacey Wolfe, Jasmeet Singh, Peter Kan, Fabio Nascimento, Luis Idrovo Freire

P5.3-012 Novel Oral

Anticoagulants (NOACs) vs. Warfarin in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A retrospective study of functional and radiographic outcomes among patients enrolled in BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis) at UVA.– Jeremy David Wells, Matthew E. Ehrlich, Michelle C. Johansen, Shareena A. Rahman, Sherita Chapman, Bradford B. Worrall, Nicole A. Chiota-McCollum

P5.3-013 Study of the factors

predicting clinical outcome in patients with Cerebral Venous Sinus Thrombosis–Salma Suhana, Veeranna Mohan Gadad

P5.3-014 Cerebral Venous

Thrombosis and Intracerebral Hemorrhage due to Pegaspargase Therapy for Acute Lymphoblastic Leukemia–Monica Scarsella, Peter Brown, Ibrahim Migdady, Ken Uchino

P5.3-015 Reactive

thrombocytosis related cerebral venous thrombosis: A rare complication of untreated iron deficiency anemia–Aparna Vaddiparti, Aarthi Kannan, Annie S. Daniel

P5.3-016 Clinical course of

CEREBRAL VENOUS SINUS THROMBOSIS (CVST)

seizures in patients with cerebral venous thrombosis–Ozge Uygun, Esme Ekizoglu, Nilufer BarlasYesilot, Betul Baykan

P5.3-010 Cerebral venous

P5.3-017 Safety and

thrombosis from thrombocytosis in a patient with thalassemia and splenectomy–Sahar Hamidy Osman, Wengui Yu

P5.3-011 Cerebral Venous

INTRACEREBRAL ANEURSYM AND OTHER NEUROVASCULAR MALFORMATIONS

P5.3-018 Congestive Heart

Failure is Strongly Associated with Hereditary Hemorrhagic Telangiectasia (HHT): Analysis of a Large National Database– Mudassir Farooqui, Fares Qeadan, Catherine Vigil, Sajid Suriya, Myranda Robinson, Syed Quadri, Ashley Wegele, Michel T. Torbey, Atif Zafar

Familial Cerebral Cavernous Malformation: An Analysis of Prospective Database–Nazeem Arsalan, Sajid Suriya, Mudassir Farooqui, Myranda Robinson, Ashley Wegele, Asad Ikram, Leslie A. Morrison, Atif Zafar

P5.3-020 Treatment of Type

B (Indirect) Carotid Cavernous Fistula with Flow Diverting Stents: Case report and Review of literature.–Kunal Bhatia, Ahmer Asif, Yasemin Akinci, Lakshmi Digala, Edgard Pereira, Adnan I. Qureshi

P5.3-021 A Case of Dural A-V Fistula with Bilateral Thalamic Hyper-intensity–R.N Komal Kumar, Anvita Potluri, Suresh Giragani

P5.3-022 Rapidly Progressive

Cognitive Decline from a Dural AV Fistula–Sarah Berth, Arjun Seth, Adam B. Cohen, Ferdinand Hui, Lucia Rivera Lara, Lisa Sun

P5.3-023 Clinical and

Radiographic Features of Multiple Intracranial Arteriovenous Malformations–Shannon Chiu, Deena Mohamed Nasr, Kelly D. Flemming, Waleed Brinjikji, Giuseppe Lanzino

P5.3-024 Is There Any Pivotal

Association Between Smoking and Alpha-1 Antitrypsin Level and Function in Aneurysmal Subarachnoid Hemorrhage?– Saeed Ansari, Alexander Houck, Sarah Ganji, Oleksandra Dryn, Reza Bavarsad Shahripour, Payam Moein, Yasser Khorchid, Balaji Krishnaiah, Ramin Zand, Andrei V. Alexandrov

P5.3-027 Early Elevation

of Plasma Lipocalin-2/NGAL is Associated with Poor Neurofunctional Outcome in Subarachnoid Hemorrhage Patients–Fang Yu, Aisha Rasool Saand, Jong Woo Lee, Liangge Hsu, MingMing Ning, Eng Lo, Sherry Chou

P5.3-028 Novel explanation

of angular remodeling in stent assisted coiling (SAC) of bifurcation aneurysms: Is it the stent or the coils?–Ahmed Saied, Nada Abdelhameed Elsaid A Elsaid, Krishna Joshi, Mohamed Gomaa, Talal Amer, Mohamed Shehab-Eldin, Demetrius K. Lopes

P5.3-029 Systematic Review

of the Angiographic Evoluation of Neck Residual (Class II) Aneurysms–Alberto Maud, Luis Carrete, Paisith Piriyawat, Mohammad Rauf Afzal, Mohtashim Arbaab Qureshi, Ihtesham A. Qureshi, Harathi Bandaru, Anantha Vellipuram, Salvador Cruz-Flores, Gustavo J. Rodriguez, Rakesh Khatri

P5.3-030 Impact of daughter

vessel selection for stent deployment on the recanalization rates of bifurcation aneurysms treated with single stent-assisted coiling (SAC)–Ahmed Saied, Nada Abdelhameed Elsaid A Elsaid, Krishna Joshi, Mohamed Gomaa, Talal Amer, Mohamed ShehabEldin, Demetrius K. Lopes INTRACEREBRAL HEMORRHAGE AND CEREBRAL AMYLOID ANGIOPATHY

P5.3-031 Location of

Autoregulation and Personalized Blood Pressure Monitoring in Patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)–Andrew Silverman, Anson Wang, Sreeja Kodali, Sumita Strander, Branden Cord, Ryan Hebert, Charles Matouk, Kevin N. Sheth, Emily Jean Gilmore, Nils Petersen

Intracerebral Hemorrhage and Cause of Death in the Longitudinal Follow-up of ICH Survivors in ERICH (ERICH-L) Study–Ian Bakk, Lee A. Gilkerson, Tyler Paul Behymer, Padmini Sekar, Charles Moomaw, Christina Kourkoulis, Elisheva Ruth Coleman, Russell Sawyer, Matthew L. Flaherty, Alessandro Biffi, Daniel Woo, Jonathan Rosand

P5.3-026 Endovascular Therapy

P5.3-032 Predictors and

P5.3-025 Dynamic Cerebral

Versus Clipping For Aneurysmal Subarachnoid Hemorrhage, 20042014 Trends–Anand Venkatraman, Ayaz M. Khawaja, Nilay Kumar, Maira Mirza

Associated Outcomes with Unanticipated Surgical Evacuation in Patients with Intracerebral Hemorrhage: Post Hoc Analysis of ATACH 2 Trial–Adnan I. Qureshi, Omar Saeed, Mushtaq H. Qureshi

AAN.com/view/AM19Sci 201

Thursday

Thrombosis In A Single Center Tertiary Hospital Of A South East Asian Country (CVSTS Study) – A Retrospective Study On The Clinical Profiles Of Patients with Cerebral Venous Thrombosis– Miguela Marie Alicante Senga, Jose Paciano Baltaza Reyes

Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) in Patients with Concurrent Migraine Headaches and Focal Neurological Deficits.– Baljinder Singh, Ahmer Asif, Adnan I. Qureshi, Sehar Babar, Danish Kherani

P5.3-019 Life Expectancy in

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.3-033 In-hospital Mortality,

Resource Utilization and 30-Day Readmission among Patients with Intracerebral Hemorrhage Transferred to Centers with Higher Level of Care–Arvind Bambhoroliya, Jennifer Meeks, Sunil Sheth, Opeolu Adeoye, Osman Mir, Louise D. McCullough, Sean I. Savitz, Farhaan S. Vahidy

P5.3-034 A cross sectional

analytical study of cognitive impairment in survivors of spontaneous intracranial hemorrhage (ICH).–Sankar Prasad Gorthi, Gautam Kumar, Vijay Chandran, Arvind Prabhu, Aparajita Chatterjee

P5.3-035 Hypervitaminosis

E and a-tocopherol levels in Intracranial Hemorrhagic Stroke–Nicole K. Le, Jane Chang, Tigran Kesayan, David Z. Rose

P5.3-036 Unusual intracerebral hemorrhagic (ICH) stroke presentation: Tumor to tumor metastasis.–Alexis Alvarado Arias, Sayid Suriya, Karen SantaCruz, Mohammad Abbas, Atif Zafar

P5.3-037 Simultaneous

Ischemic stroke and Intracerebral Hemorrhage due to Amyloid Angiopathy presenting as a Therapeutic Challenge–Moein Amin, Dinesh V. Jillella, Ken Uchino

P5.3-038 A Case of Cerebral

Amyloid Angiopathy Associated Primary Progressive Aphasia– Juan Pablo Pauta Martinez, Rachel Aubert, Prachi Mehndiratta

Thursday

P5.3-039 Similarities and

Differences in Intracerebral Hemorrhage Risk Factors by Race/Ethnicity–Steven J. Kittner, Padmini Sekar, Kevin N. Sheth, Mary Comeau, Matthew L. Flaherty, Fernando Testai, Michael R. Frankel, Michael Lucas James, Gene Y. Sung, Mitchell S. V. Elkind, Bradford B. Worrall, Chelsea S. Kidwell, Nicole Gonzales, Sebastian Koch, Christiana E. Hall, Lee Birnbaum, Douglas Joseph Mayson, Bruce M. Coull, Marc Malkoff, Ji Young Chong, Elisheva Ruth Coleman, Gunjan Parikh, Christopher D. Anderson, Jacob L. McCauley, Jennifer Osborne, Misty Wethington, Lee A. Gilkerson, Tyler Paul Behymer, Charles Moomaw, Jonathan Rosand, Carl D. Langefeld, Daniel Woo

202 2019 AAN Annual Meeting

P5.3-040 Mortality and Long

Term Outcome after Spontaneous Intracerebral Hemorrhage– Thouraya Mguidich, Abderrazek Hedhili, Salma Sakka, Nouha Farhat, Hanen Hajkacem, Mariem Damak, Chokri Abdellaziz Mhiri

P5.3-041 Primary Occipital

Lobar Hemorrhages Associated with Lower 1 Year Mortality– Rachel W. Pan, Ashley D. Blatsioris, Elizabeth A.S. Moser, Ravan J.L. Carter, Chandan Saha, Aaron Cohen-Gadol, Thomas J. Leipzig, Linda S. Williams, Jason S. Mackey

P5.3-042 Role of Anti-Platelets

& Anti-coagulants in Intracerebral hemorrhage: Analysis of a Large National Database–Sajid Suriya, Mudassir Farooqui, Daniel Devitt Barnett, Owen Tyler Owens, Asad Ikram, Mohammad Abbas, Corey C. Ford, Atif Zafar, Michel T. Torbey

P5.3-043 Hemoglobin A1c

in Intracerebral Hemorrhage: A Cross-sectional Analysis of a Large National Database.– Mudassir Farooqui, Asad Ikram, Owen Tyler Owens, Sajid Suriya, Alexis Alvarado Arias, Mohammad Abbas, Andrew Lin, Atif Zafar

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.3-047 The Absence of

P5.3-052 Computed

P5.3-048 To CTA or Not to CTA:

P5.3-053 Clinical and

Collaterals is Associated with Larger Infarct Volume and Worse Outcome–Eric Kimmel, Sami Alkasab, Girish Bathla, Jillian Harvey, Santiago Ortega Gutierrez, Kaustubh S. Limaye, Ann Van De Walle Jones, Enrique C. Leira, David Hasan, Edgar A. Samaniego Should We Continue to Order CT Angiography of Head and Neck in Patients with TIA?–Ivo Bach, Anusha Boyanpally, Sean Reilly, Machteld E. Hillen

P5.3-049 Tissue Based

Selection for Large Vessel Occlusion Thrombectomy Leads to Similar Functional Outcomes in Conventional (0-6 hours) and Extended (>6 hours) Window– Chantal Bhan, Muhib Khan, Lee Elisevich, Tracy J Koehler, Justin Singer, Paul Mazaris, Rajeev Kumar Deveshwar, Bassel Raad, Joseph Zachariah, Jordan Andrew Combs, Michelle Del Castillo DeJesus Brazitis, Raymond Scurek, Tricia Tubergen, Laurel Packard, Jiangyong Min, Todd Mulderink, Tamer Abdelhak

P5.3-050 Underestimation of

CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY: IMAGING AND LOCALIZATION

Ischemic Core on Perfusion CT in Patients with Acute Large Vessel Occlusion: Results from the BEST Prospective Cohort Study–James E. Siegler, Steven R. Messe, Heidi Sucharew, Tapan Mehta, Niraj Ashok Arora, Amy Starosciak, Felipe De Los Rios La Rosa, Natasha Barnhill, Akshitkumar Mistry, Kishan Patel, Salman Assad, Amjad Tarboosh, Katarina B. Dakay, Jeff Wagner, Alicia Erin Bennett, Bharathi Jagadeesan, Christopher Streib, Stewart A. Weber, Rohan Chitale, John J. Volpi, Stephan A. Mayer, Shadi Yaghi, Mahesh Jayaraman, Pooja Khatri, Eva Sanjam Amin

P5.3-046 Early Ischemic

P5.3-051 Computed

P5.3-044 A Unique Case

of Cavum Veli Interpositum Hemorrhage in an Adult–Kavneet Kaur, Vaibhav Goswami, Rafia Shafqat, Hussein Alshammari, Stephen J. Marks

P5.3-045 Validation of ICH

and ICH-GS scores in cohort of Indian patients with Intracerebral hemorrhage–Puneeth Malapur, Rohit Bhatia, Deepa Dash, Manjari Tripathi, Sreenivas Vishnubhatla

Changes on Serial CT Imaging in Acute Ischemic Stroke–Alexandra L. Czap, Jose-Miguel Yamal, Noopur Singh, Stephanie Parker, Suja Rajan, Ritvij Bowry, James C. Grotta

Tomography Perfusion Imaging in Evaluation of Patients With Acute Stroke is Not Associated With Increased Risk of Acute Kidney Injury–Kelsey Satkowiak, Joseph F. Carrera, Andrew Mebane Southerland

Tomography Perfusion provides clinically relevant core infarct for thrombectomy selection–Hussam Shaker, Muhib Khan, Todd Mulderink, Tracy J Koehler, Justin Singer, Paul Mazaris, Jiangyong Min, Nabil Wees, Nadeem I. Khan, Tamer Abdelhak imaging features of contrast induced neurotoxicity after cerebral angiography – Case series–Cynthia Zevallos, Sudeepta Dandapat, Gloria Lopez Cardenas, Andrea Holcombe, Khaled Asi, Edgar A. Samaniego, Sameer Ansari, Aldo Mendez Ruiz, Biyue Dai, Santiago Ortega-Gutierrez

P5.3-054 Ischemic Stroke

Subtyping, Based on Vascular Imaging: A University Hospital Based Study–Mohammad Shahidullah

P5.3-055 Focal Parietal Lobe

Atrophy in Antiphospholipid Syndrome: Retrospective Analysis–Ka-Ho Wong, Wayne Fang, Elaine J. Skalabrin, Allen Sawitzke, Edward Y. Zamrini, Karen Salzman, Greg Stoddard, Christian Davidson, Jeffrey Anderson, Jennifer J. Majersik

P5.3-056 Hazy DWI Restriction

in Pons on Hyperacute MRI: DWI ‘Smog Sign’–Asad Ikram, Mudassir Farooqui, Daniel VelaDuarte, Syed Quadri, Sajid Suriya, Dinesh V. Jillella, Michel T. Torbey, Atif Zafar

P5.3-057 Cardiovascular and

metabolic risk factors for the development of cerebral small vessel disease: Longitudinal FLAIR imaging in the Mayo Clinic Study of Aging–Eugene L. Scharf, Jonathan Graff-Radford, Scott Przybelski, David S. Knopman, Gregory Preboske, Christopher Schwarz, Matthew Senjem, Jeffery Gunter, Kejal Kantarci, Michelle M. Mielke, Ronald C. Petersen, Clifford R. Jack, Prashanthi Vemuri

P5.3-058 Imaging of

angiogenesis in white matter hyperintensities using simultaneous 68Ga-NOTA-PRGD2 PET/MRI–Lingling Ding, Bo Hou, Jie Zang, Tong Su, Feng Feng, Zhaohui Zhu, Bin Peng

P5.3-059 Case Report:

Sonographic demonstration of a perfusion dependent stroke with negative MRI and a flow limiting stenosis–Jonathan Gomez, Stacey Wolfe, Kyle Fargen, Jasmeet Singh, Charles H. Tegeler, Aarti Sarwal

P5.3-060 Transcranial Doppler-

detected Microembolic Signals as a Predictor of New Brain Ischemic Lesion after Elective Coronary Intervention–Roman Herzig, Dasa Viszlayova, David Skoloudik, Miroslav Brozman, Katerina Langova, Peter Kurray, Lukas Patrovic, Silvia Kiralova, Martin Valis

P5.3-061 Subclinical peripheral

arterial disease in patients with acute ischemic stroke; study with an ultrasonography–Sanghee Ha, Yu Yong Shin, Bum Joon Kim

P5.3-062 The Perplexing Texting of Dystextia – Whynn th Mesrage Indcates Thar Is A Probm–Taylor R. Anderson, Albert Gjeluci, Shyam S. Moudgil

P5.3-063 Acute anterior

thalamic infarcts affecting Memory and Cognition- an important but less well known lacunar syndrome–Deepmala Nandanwar, Kumar Rajamani

P5.3-064 Lesion Topography

and Its Correlation with Etiology in Medullary Infarction: Analysis from a Multi-Center Stroke Study in China–Yuehui Hong, Lixin Zhou, Ming Yao, Yi-Cheng Zhu, Liying Cui, Jun Ni, Bin Peng

P5.3-065 Bilateral Medial

Medullary Syndrome with Atypical Clinical Presentation and Brain MRI Findings–Ali Farooqui, Murali K. Kolikonda, Satheesh Kumar Bokka, Wei Liu An Occi-dental Discovery of Bálint Syndrome–Anirudha Swaminathan Rathnam, Muhammad Affan, Daniel Miller

P5.3-067 Novel Neuroimaging

Pattern In A Patient With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy–Rodica E. Petrea, Dharani Mudugal, Angel Mironov, Sanjay P. Singh

Blindness: An Unusual Cause of Vision Loss in the 21st Century– Matthew William Rondeau, Avinash Rao Sagi, Barbara Voetsch

P5.3-069 Non-invasive

Longitudinal Assessment of Cerebrovascular Reactivity after TBI using functional Near Infrared Spectroscopy–Michael Sangobowale, Justin Morrison, Franck G. Amyot, Hasan Ayaz, Yerram Reddy, Nimay Kulkarni, Erika Silverman, Tawny MeredithDuliba, Megan Moyer, Danielle Sandsmark, Ramon R. DiazArrastia

GENETIC MUSCLE DISORDERS II

P5.4-001 A novel TTN deletion

causes Autosomal Dominant Limb-Girdle Muscular Dystrophy with Dilated Cardiomyopathy– Kelly Rich, Jennifer A. Roggenbuck, Ana Morales, Christopher Tan, Douglas Eck, Wendy Marie King, Matteo Vatta, Thomas L. Winder, Bakri Elsheikh, Ray Hershberger, John T. Kissel

P5.4-002 Relationships

between DMD mutations and neurodevelopment in dystrophinopathy–Mathula Thangarajh, Jos Hendriksen, Michael McDermott, William Martens, Kimberly Hart, Robert C. Griggs

P5.4-003 NEO1 and NEO-EXT

Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease– Mazen M. Dimachkie, Richard J. Barohn, Priya Kishnani, Shafeeq Ladha, Eugen Mengel, Loren DM Pena, Sabrina Sacconi, Philip Van Damme, John Vissing, Kristina an Haack, Christopher Hug, Judith Johnson, Charlotte Sensinger, Benedikt Schoser

P5.4-004 GNE Myopathy

Biomarkers: Essential for Diagnosis and Response to Therapy–May Christine Malicdan, Petcharat Leoyklang, William Gahl, Nuria Carillo-Carrasco, Marjan Huizing

P5.4-005 The IPANEMA

Study: Top Line Results from an Investigator-Initiated Multi-site Late-onset Pompe Disease Prevalence Study–Marie Wencel, Namita Goyal, Aziz I. Shaibani, Mazen M. Dimachkie, Nicholas Elwood Johnson, Jaya Raghav Trivedi, Laurie Gutmann, Matthew P. Wicklund, Sankar Bandyopadhyay, Angela L. Genge, Miriam L. Freimer, Alan Pestronk, Julaine M. Florence, Chafic Y. Karam, Jeffrey Ralph, Ali Habib, Tahseen Mozaffar

P5.4-006 A Novel Homozygous

TNNT1 Missense Mutation in a French-Canadian Kindred Causing a Unique Clinical and Pathological Phenotype of Congenital Nemaline Myopathy with Rods, Cores and Lobulated Fibers–David Pellerin, Benjamin Ellezam, Jean Mathieu, Bernard Brais

P5.4-007 GNE Myopathy in

Turkey: Clinical Features and Novel Mutations–Hacer Durmus, Serdar Ceylaner, Fatma Yesim Parman, Feza Deymeer, Piraye Serdaroglu

P5.4-008 Long-Term Efficacy

of Dichlorphenamide for the Treatment of Primary Periodic Paralysis (PPP)–Nicholas Elwood Johnson, Jeffrey Statland, Fredric J. Cohen, Robert C. Griggs

P5.4-009 A Survey of Patient-

Identified Symptom Themes and Attitudes Toward Clinical Trials in Facioscapulohumeral Muscular Dystrophy (FSHD)–David A. Shirilla, Thienhuu Nguyen, June Kinoshita, Barry Miller, Mazen M. Dimachkie, Mamatha Pasnoor, Chad E Glasser, Kenneth M. Attie, Jeffrey Statland

P5.4-010 A novel frameshift

mutation in DNA2 causes early onset myopathy with velopharyngeal weakness and cardiac arrhythmias–Ariadna Gonzalez Del Angel, Francisca Fernandez-Valverde, Benoit Rucheton, Claude Jardel, Edoardo Malfatti

P5.4-011 Carotid Artery

Dissection in a Young Woman with Ullrich Congenital Muscular Dystrophy–Sarita Said-Said, Namita Goyal, Tahseen Mozaffar

P5.4-012 The Potential Role of

Estrogen in Moderating Symptom Severity in Women with RYR1Related Myopathy–Lydia Sharp, Milvia Y. Pleitez, Rachel Yee, Susan Hamilton

P5.4-013 TTR Knockdown

Therapy in Patients with hATTR Amyloidosis Who Have Disease Progression despite Liver Transplant–Orly Moshe-Lilie, Diana Dimitrova, Stephen B. Heitner, Chafic Y. Karam

P5.4-014 Lack of Genotype-

Phenotype Correlation in Individuals with DMPK Expansions–Amanda S. Lindy, Katelyn Beattie, Rhonda Brandon, Hui Yang, Dianalee McKnight

P5.4-015 mRna Expression

Genes Associated To Myofibrillar Myopathies – Preliminary Study–Alzira A S Carvalho, Emmanuelle Lacene, Matheus M. Perez, Beatriz Alves, David Feder, Fernando Fonseca, Norma Romero

P5.4-016 Transition to

Adulthood in Duchenne/Becker Muscular Dystrophy–Andrew Donaldson, Debra Guntrum, Emma Ciafaloni, Jeffrey Statland

P5.4-017 A Novel Case

of Overlapping of Myotonic Dystrophy Type 2 and Bethlem Congenital Muscular Dystrophy–Mayur Chalia, Sankar Bandyopadhyay

P5.4-018 X-Linked Myotubular

Myopathy and Fragile X Syndrome in a Female Patient–Dustin Jacob Paul, Susan T. Iannaccone

P5.4-019 PYGM mRNA

Expression In Patients With McArdle Disease: Demographic, Clinical, Genetic And Morphological Correlations.– David Feder, Matheus M. Perez, Beatriz Alves, Denise Cristofolini, Itatiana Rodart, Winter Figueiredo, Fernando Fonseca, Alzira A S Carvalho

P5.4-020 Thyrotoxic

Periodic Paralysis: An Unusual Presentation of Hyperthyroidism in a 20 year-old Male–Sean Smith, Muhammad Al-Lozi

P5.4-021 A Novel Compound

Heterozygous Mutation In Titin Leads To Core Myopathy With Heart Disease–Ryan Castoro, Jean Pierre Betancourt, Stacy Stark

AAN.com/view/AM19Sci 203

Thursday

P5.3-066 Floating Heads:

P5.3-068 Transient Smartphone

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.4-022 Diagnostic Challenges of Congenital Myopathies in the Adult Neuromuscular Clinic– Stefan Nicolau, Teerin Liewluck, Jennifer Anne Tracy, Ruple S. Laughlin, Margherita Milone NEUROMUSCULAR JUNCTION DISORDERS

P5.4-023 Incidence and

Predictors of readmission in patients with Myasthenia Gravis: A National population-based cohort study (2010-14).–Tejinder Singh, Chirag Narshibhai Savani, Varun Kumar, Charles DeMello Schutt, Sheyar Amin, Yazan M. Suradi, Rossitza Chichkova

P5.4-024 LEMS with Anti-VGCC Antibodies and Dermatomyositis with Anti-TIF1-Gamma Antibodies: A Unique Case Study of Concomitant Autoimmune Neuromuscular Conditions without Malignancy–Michael Isfort, Diana Mnatsakanova, Chet Oddis, David Lacomis

P5.4-025 Response Rates

in Placebo arm of MG Clinical Trials–Srikanth Muppidi, Verena Clarissa Samara, Kathie Lin, Neelam Goyal

P5.4-026 Congenital

Myasthenic Syndrome with A Novel Agrin Gene Mutation– Gema Estefania Giler, Anudeep yelam, Elanagan Nagarajan, Raghav Govindarajan

P5.4-027 The Diagnostic Yield

of Repetitive Nerve Stimulation in Seropositive vs. Seronegative– Tingting Hua, Emily Bailey, Raghav Govindarajan

Thursday

P5.4-028 Efficacy and

limitations of cyclophosphamide in refractory myasthenia gravis– Sofia Garcia Trejo, Enrique Gomez Figueroa, Steven Vargas Ca√±as

P5.4-029 Assessment of

disease severity in patients with Myasthenia Gravis – Clinical Phenotype and Immunological Correlation–Butchi Raju Garuda, Deepthi Vemuri, Gopi Seepana, Sateesh T, Aruna Kumari Uppaturi

204 2019 AAN Annual Meeting

P5.4-030 Are the choices

of Therapeutic options for the Management of Myasthenia Gravis Crisis with acute respiratory failure-Influenced by the patient’s Age. A New York State Planning and Research Cooperation System Database Analysis (1998-2014)–Shuja Sheikh, Kevin Nolasco, Taha Nisar, Abu Nasar, Nizar Souayah

P5.4-031 A case of

hepatocellular carcinoma presenting with myasthenia gravis–Steven Fussner, Tanu Garg, Lydia Sharp

P5.4-032 Myasthenia Gravis

Mimicking Stroke - Implications of Cognitive Errors and Clinical Factors–Natalie Anna Kukulka, Emily Bailey, Anudeep yelam, Elanagan Nagarajan, Raghav Govindarajan

P5.4-033 High Prevelance Of

Osteoporosis And Osteopenia In Adult Myasthenia Gravis Patients-A Pilot Study From An Academic Institution In Central Pennsylvania–Nadia Bowling, Sankar Bandyopadhyay

P5.4-034 Comparison of

Clinical and Laboratory Features of Myasthenia Gravis in Different Ethnic, Gender and Age groups.–Shabnam Pakneshan, Kamal Shouman, Sara Razmjou, Robert P. Lisak

P5.4-035 Successful Rituximab Desensitization In Two Patients With Myasthenia Gravis–Joome Suh, Amanda C. Guidon

P5.4-036 Volumetric Analysis and Densitiy of Extraocular Muscles in patients with Myasthenia Gravis–Alejandro Kohler, Mauricio Franco Farez, Alberto Daniel Rivero

P5.4-037 Burden of Disease

in Patients with Refractory Myasthenia Gravis–Aditi Sharma, Bhaskar Roy, Babar Khokhar, Richard J. Nowak

P5.4-038 Nocebo In Myasthenia Gravis: A Systematic Review And Meta-Analysis Of Randomized Placebo-Controlled Trials–Adithya Varma, Panagiotis Zis

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.4-039 Retrospective

longitudinal assessment of MG-ADL score with treatment of myasthenia gravis–Matthew Varon, Mamatha Pasnoor, Tamara Winden, Suzanne Hunt, Omar Jawdat, Constantine Farmakidis, Duaa Jabari, Melanie Glenn, Jeffrey Statland, Richard J. Barohn, Mazen M. Dimachkie

P5.4-040 Clinical and

demographic features of LRP4 positive myasthenia gravis patients–Siva Prasad Reddy Pesala, Mazen M. Dimachkie, Michael H Rivner, Lin Mei, Melanie Glenn, Constantine Farmakidis, Omar Jawdat, Duaa Jabari, Andrew Heim, Brandy Quarles, Richard J. Barohn, Mamatha Pasnoor

P5.4-041 Elevated

Antiganglioside Antibodies in a Case of Paraneoplastic Neuromuscular Junction Disorder–Noushin Jazebi, Ahmad Yusuf Solaiman, Xiang Fang

EPILEPSY: ANTISEIZURE MEDICATIONS III

P5.5-001 Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)–Anup D. Patel, Antonio Gil-Nagel, Richard Chin, Wendy G. Mitchell, M. Scott Perry, Leon A. Weinstock, Claire Roberts, Lauren Whyte, Kevan VanLandingham

P5.5-002 Evaluation of

Withdrawal Seizures During Conversion from Antiepileptic Drug Regimens Containing Carbamazepine to Eslicarbazepine Acetate Monotherapy–R Eugene Ramsay, Todd Grinnell, Uma Menon, David E. Blum, JungAh Jung

P5.5-003 Adherence to AED

treatment for patients with focal seizure receiving monotherapy with eslicarbazepine acetate or prior generation generics: Evidence from a large US commercial claims database– Darshan Mehta, Andrew Lee, Jason Simeone, Beth L. Nordstrom

P5.5-004 Adjunctive

Perampanel in Pediatric Patients with Epilepsy: Population Pharmacokinetic (PK) and Exposure-Response Analyses– Oneeb Majid, Larisa Reyderman, Jim Ferry, Ziad Hussein

P5.5-005 Long-Term Safety and

Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an OpenLabel Extension Trial–Jonathan J. Halford, Ingrid E. Scheffer, Rima Nabbout, Rocio SanchezCarpintero, Yael Shiloh-Malawsky, Matthew H. Wong, Daniel Checketts, Kevan VanLandingham

P5.5-006 Efficacy and

Tolerability of Adjunctive Brivaracetam in Adults With Focal Seizures by Antiepileptic Drug Treatment History: Post Hoc Analysis–Pavel Klein, Kathy Foris, Xavier Nondonfaz, Sami Elmoufti, Svetlana Dimova, Christian Brandt

P5.5-007 The proposed

multimodal mechanism of action of cannabidiol (CBD) in epilepsy: modulation of intracellular calcium and adenosine-mediated signaling–Kathryn Nichol, Colin Stott, Nicholas Alexander Jones, Royston A. Gray, Michael Bazelot, Benjamin Whalley

P5.5-008 Perampanel in Real-

World Clinical Care of Patients with Epilepsy: Retrospective Phase IV Study 506 – Second Interim Analysis–Robert T. Wechsler, James W. Wheless, Marcelo E. Lancman, Sami M. Aboumatar, Anna Patten, Betsy N. Williams, Manoj Malhotra

P5.5-009 Study 506 –

Second Interim Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Pediatric Subgroup (Aged <12 Years)–Katherine Moretz, James W. Wheless, Eric Segal, Marcelo E. Lancman, Anna Patten, Betsy N. Williams, Manoj Malhotra

P5.5-010 Comparative

Neuropsychological Effects of Carbamazepine and Eslicarbazepine Acetate–Kimford J. Meador, Jordan Seliger, Babak Razavi, Jessica Falco-Walter, Scheherazade Le, David W. Loring

P5.5-011 Time Course of

Efficacy and Tolerability Outcomes With Adjunctive Brivaracetam in Adults: A Post Hoc Analysis– Kimford J. Meador, Cedric Laloyaux, Sami Elmoufti, Teresa De Jesus Gasalla, Jesse Fishman, Melinda S. Martin, Pavel Klein

P5.5-012 Long-term Retention on Adjunctive Brivaracetam in Adults With Focal Seizures Previously Exposed to Carbamazepine, Lamotrigine, Levetiracetam, or Topiramate: A Post Hoc Analysis–Steve S. Chung, Melinda S. Martin, Svetlana Dimova, Sami Elmoufti, Cedric Laloyaux

P5.5-013 Experience with

Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center–Ahmet Tanritanir, Xiaofan Wang, Tobias Loddenkemper

P5.5-014 Inpatient

Hospitalization Risk in Medicaid Patients with Epilepsy Before and After Perampanel Treatment– Debanjana Chatterjee, Xuan Li, Manoj Malhotra, Jiyoon Choi

P5.5-015 Efficacy and

Tolerability of Switching from Traditional Sodium Channel Blockers to Lacosamide in Epilepsy Patients–Wonshik Kim, Dong Wook KIM

P5.5-016 Analysis of Patient

Characteristics and Outcomes by Prior AED use: Data from Pooled Observational Studies of Routine Perampanel use across Europe–Eugen Trinka, Katherine Carpenter, Alexandra Rohracher, Georg Zimmermann

P5.5-017 Study 506 –

EPILEPSY: SURGERY AND IMAGING

P5.5-018 Aura as a Predictor of

Outcome after Epilepsy Surgery– Scott Grossman, Patricia C. Dugan, Jacqueline French

in Patients with Intractable Mesial Temporal Lobe Epilepsy who Undergo Laser Ablation.–Akta Patel, Sara Dawit, George Mastorakos, Richard Zimmerman, Amy Z. Crepeau

P5.5-020 Level Four Epilepsy

Center Experience With Stereoelectroencephalography–Irina Podkorytova, Ghazala Perven, Kan Ding, Mark A. Agostini, Ryan Hays, Sasha Alick, Marisara Dieppa, Rohit Das, Hina N. Dave, J. H. Harvey, Rodrigo Zepeda Garcia, Bradley Lega

P5.5-021 Altered resting-state network topology in drug-naïve idiopathic generalized epilepsy– Jung Bin Kim, Hayom Kim

P5.5-022 Epilepsy MRI

Interpretations Outside Of Comprehensive Epilepsy Centers Often Miss Epileptogenic Lesions–Gloria Ortiz-Guerrero, Prompan Mingbunjerdsuk, John Leever, Utku Uysal, Patrick Landazuri, Carol M. Ulloa

P5.5-023 Epilepsy Surgery

Outcomes in the setting of Encephalitis: A Case Series– Elizabeth Spurgeon, Ruta Nandan Yardi, Stephen Hantus

P5.5-024 Hospital Readmissions After an Epilepsy Related Surgical Intervention in the Nationwide Readmissions Database–Varsha Subramaniam, Churl-Su Kwon, Parul Agarwal, Mandip Singh Dhamoon, Madhu Mazumdar, Nathalie Jette

P5.5-025 Epilepsy Surgery

Trends In the United States, 2009–2014–Anantha Vellipuram, Mohammad Rauf Afzal, Mohtashim Arbaab Qureshi, Ihtesham A. Qureshi, Harathi Bandaru, Mohammad Ghatali, Darine Kassar, Alberto Maud, Rakesh Khatri, Paisith Piriyawat, Gustavo J. Rodriguez, Salvador Cruz-Flores

P5.5-026 Contralateral

hippocampal atrophy after temporal lobe surgery: volumetric analysis of preoperative and longterm postoperative MRI–Bruna Silva, Leticia Franceschet Ribeiro, Helder Tedeschi, Enrico Ghizoni, Fernando Cendes, Clarissa L. Yasuda

P5.5-027 The Pathogenesis

and A Novel Surgical Approach to Treating Drug-Resistant Status Epilepticus Associated with Neurocysticercosis–Christina Law, Jayant N. Acharya, Krishnamoorthy Thamburaj, Michael Sather, Vinita J. Acharya

P5.5-028 VNS therapy vs.

discontinuation of VNS therapy: Long-term seizure outcome–Sonia Gill, Hsiangkuo Yuan, Michael R. Sperling, Scott Mintzer, Christopher Skidmore, Maromi Nei

P5.5-029 Patient selection

and outcomes of placement of the Neuropace Responsive Neurostimulator for the treatment of intractable epilepsy: a single center experience–Mark A. Agostini, Sasha Alick, Rohit Das, Hina N. Dave, Marisara Dieppa, Kan Ding, J. H. Harvey, Ryan Hays, Ghazala Perven, Bradley Lega, irina podkorytova, Rodrigo Zepeda Garcia, vijay ram, Joseph Flay

P5.5-030 Effects of Low-

Frequency Stimulation of Anterior Piriform Cortex on Memory in Epileptic Rats–Arezou Bayat, Sweta Joshi, Lalitha Kurada, Mohamad Koubeissi

P5.5-031 Evaluating an

Online Tool to Determine Appropriateness for Epilepsy Surgery Evaluation in Brazil– Marino Bianchin, Bianca Cecchele Madeira, Paulo Fagundes, Suelen Mota, Eduardo Amorim, Barbara Krammer, Ingrid Silveira, Eduardo Mazzocato, Talissa Bianchini, Thais Secchi, Suzana Schonwald

P5.5-032 Early Use of Vagal

Nerve Stimulation (VNS) in a Patient with New Onset Refractory Status Epilepticus (NORSE)–Bonnie Wong, Ji Yeoun Yoo, Madeline Cara Fields

P5.5-033 Combined Treatment

of Bilateral Periventricular Nodular Heterotopia with Laser Ablation and Neuropace Leads Placement after Stereo-EEG Evaluation–Irina Podkorytova, Mark A. Agostini, Bradley Lega, Rodrigo Zepeda Garcia, Ryan Hays, Ghazala Perven

P5.5-034

Stereoelectroencephalography following grids and strips: case series of six patients–Melissa Crowder, Krzysztof Bujarski

NEURO-REHABILITATION: STROKE RECOVERY

P5.6-001 Swallowing outcomes

and discharge destinations in acute-stroke tube-feedingdependent dysphagia patients treated with neuromuscularelectrical-stimulation during inpatient rehabilitation–David S. Kushner, Douglas JohnsonGreene, Maite Maguregui, Stacy A. Thomashaw, Jennifer Rodriguez

P5.6-002 Functional anomaly

mapping using BOLD timecourses reveals local and distant dysfunction caused by stroke–Andrew DeMarco, Peter Turkeltaub

P5.6-003 Causes of interruption

of acute rehabilitation and readmission after stroke–Amanda Herrmann, Sally I. Othman, Sarah Jamal, Haitham Hussein

P5.6-004 The Relationship

of Neurologic Impairments to Post-Stroke Fatigue in an Urban, Minority Population–Tracey Yee, Nadege Gilles, Yelena Ilyasova, Steven R. Levine

P5.6-005 Repetitive

Transcranial Magnetic Stimulation in Improving Lower Extremity Function and Gait Among Stroke Patients: A Meta-analysis– Alexandria Matic, Jeryl Ritzi Tan yu, Diana-lynn Que, Maria Cristina Macrohon-Valdez

P5.6-006 A Pilot Study of

Right Cerebellar tDCS as a Therapeutic Adjuvant in Chronic Aphasia after Left-Hemisphere Stroke–Elizabeth Dvorak, Andrew DeMarco, Catherine Stoodley, Peter Turkeltaub

P5.6-007 Effect of Training

Eye Hand Coordination Using Emerging Natural User Interface Technologies for Improving Hand Function in Stroke Survivors- A Randomized Controlled Study– Nikhil Choudhary NEURO-REHABILITATION: FROM MECHANISM TO TREATMENT

P5.6-008 Action Observation

Training Increases Dynamic Functional Connectivity in Patients with Multiple Sclerosis–Claudio Cordani, Paola Valsasina, Luca Gavazzeni, Alessandro Meani, Paolo Preziosa, Federica Esposito, Mauro Comola, Massimo Filippi, Maria Assunta Rocca

AAN.com/view/AM19Sci 205

Thursday

Second Interim Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years)–Eric Segal, James W. Wheless, Katherine Moretz, Patricia E. Penovich, Anna Patten, Betsy N. Williams, Manoj Malhotra

P5.5-019 Long-term Outcomes

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.6-009 Remotely Supervised Transcranial Direct Current Stimulation (RS-tDCS) Paired with a Hand Exercise Program to Improve Manual Dexterity in Progressive Multiple Sclerosis: A Randomized Sham Controlled Trial–Charles Feinberg, Michael Shaw, Maria Palmeri, Kathleen Sherman, Guadalupe Zunigaestrada, Jennifer Stone, Ashwin Raj Kumar, Lauren B. Krupp, Vikram Kapila, Preeti Raghavan, Leigh Elkins Charvet

P5.6-010 Clinical and fMRI

Effects of Action Observation and Motor Imagery Training on Dual-Task Performances in Parkinson’s Disease Patients With Postural Instability and Gait Disorders–Elisabetta Sarasso, Federica Agosta, Matteo Chiesi, Noemi Piramide, Elisa Canu, Ilaria Ravani, Sebastiano Galantucci, Andrea Tettamanti, Maria Volonte, Massimo Filippi

P5.6-011 Interventional First-

Person Video Game Training Reduces Fall Risk in Parkinson’s Disease by Improving Gait, Contrast Sensitivity, Visual Acuity and Cognition–Sonia Koul, Beau Billings, Shane Sterling, Karina Pique, Roei Golan, Brooke Hartenstein, Andres Yunis, Mirna Hanna, William Forrester Taber, Richard Wu, Shani Peter, Charles Maitland

P5.6-012 Motor Function of

Individuals with HNRNPH2-related Disorders.–Rachel Salazar, Sara Beenders, Nicole La Marca, Olivia Thornburg, Arielle Snow, Sylvie Goldman, Jennifer M. Bain

Thursday

P5.6-013 A Mixed-Methods

Evaluation of Neurorehabilitation Resources for Pediatric Cerebral Malaria Survivors in Blantyre, Malawi–Alexandra Boubour, Sebastian Mboma, Gretchen L. Birbeck, Carol Mitochi, Terrie Taylor, Karl Seydel, Macpherson Mallewa, Dorothy Chinguo, Melissa Gladstone, Suraya Mohamed, Kiran Thakur

P5.6-014 Restoration of

Barnes maze, Protein Kinase M? and MAP2 by Minocycline plus N-Acetylcysteine when first dosed 72 hours after experimental traumatic brain injury–Syed Rahman, Elena Nikulina, Michael Vaysblat, Kristen Whitney, Peter Bergold

206 2019 AAN Annual Meeting

P5.6-015 The cofilin/Limk1

pathway controls the rate of regenerating motor axons– Alexandra Lynn Da Silva, Michele Frendo, Keith Phan, Samantha Butler

Thursday, May 9 11:30 a.m.–6:30 p.m. GENERAL NEUROLOGY: NEUROIMAGING AND DISEASE

P5.6-022 One Hundred Years of

in neuromuscular disease: Successes, challenges, and a path forward–Linda Pax Lowes, Natalie Fae Miller, Megan Iammarino, Margaret Dugan, Lindsay N. Alfano

Innovation: Automatic Detection of Brain Ventricular Volume using Deep Learning in a Large-Scale Multi-Institutional Study– Michelle Han, Jennifer Quon, Lily Kim, Katie Shpanskaya, Ed Lee, John Kestle, Rob Lober, Michael Taylor, Vijay Ramaswamy, Michael Edwards, Kristen Yeom

P5.6-017 New treatments, now

P5.6-023 Abnormal DWI Signals

P5.6-016 Activity monitoring

what: A pilot study investigating the use of in-home body-weight support harness systems to maximize the therapeutic benefit of novel treatments for spinal muscular atrophy.–Megan Iammarino, Lindsay N. Alfano, Natalie Fae Miller, Madalynn Wendland, Linda Pax Lowes

P5.6-018 AbobotulinumtoxinA,

onabotulinumtoxinA and incobotulinumtoxinA neurotoxin content and activity: Potential implications for duration of efficacy in patients–Malgorzata Field, Andrew Splevins, Marcel van der Schans, Jan Langenberg, Daan Noort, Philippe Picaut, Keith Foster

P5.6-019 Burden of Spasticity

Among Patients and Caregivers: Results of a Multinational Survey–Atul T. Patel, Theodore Wein, Laxman Bhaqwan Bahroo, Ophelie Wilczynski, Carl Rios, Manuel Murie

P5.6-020 Economic evaluation of abobotulinumtoxinA vs onabotulinumtoxinA in reallife clinical management of post-stroke upper limb spasticity–Natalya Danchenko, Jonas Lundkvist, Andreas Lysandropoulos, Pascal Maisonobe

P5.6-021 A study on Affordable Rehabilitation Care in Developing Countries with Use of Low Cost Technologies–Sachin Kokane, Devashish Devrao Ruikar, Devashish Devrao Ruikar

of Spine in a Sporadic Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia caused by a novel c.1907T>A. Mutation in CSF1R–Shanglin Li, Ming Yao, Yi-Cheng Zhu, Bin Peng, Liying Cui

P5.6-030 Evolution of Magnetic Resonance Signal Characteristics in Inferior Olivary Nuclei in Patients Presenting with Palatal Myoclonus Syndrome – Cases– Neil Manering, Kolar N. Murthy

P5.6-031 Magnetic Resonance

Imaging-Based Evaluation of the Etiology of Non-traumatic Myelopathies in Bangladesh: A Hospital-based Observational Cross-sectional Study from Two Tertiary Care Centers of Dhaka.– Abul K. Shoab, Mohammad Aftab Haleem

P5.6-032 Diagnostic utility

of hypoglossal canal MRI in uncovering an unusual cause of Isolated hypoglossal nerve palsy.–Appaji Rayi, Yasmeen Rauf, Bakri Elsheikh

P5.6-024 Clinical and

P5.6-033 Chronic Vestibular

P5.6-025 Cocaine Use

P5.6-034 Cerebral Venous

Radiographic Characterization of Synthetic Cannabinoid-induced Toxic Leukoencephalopathy– Jordan Amar, Jeffrey Ruta, David Rahimian, Paul M. Katz Associated with Bilateral Globus Pallidus Changes; Similar to Carbon Monoxide intoxication.– Muhammad Azeem, Seydeh Nasim Cheraghi, Muhammad Nagy, Van Vu, Vinay Maliakal, Nils Henninger, Kate Daniello

P5.6-026 Capecitabine

Induced Leukoencephalopathy: Is there a correlation with liver metastases?–Faisal Abdelaziz Ibrahim, Shilpa Chaku, James Chris Tanner, Zara Fatima, Hisham Gibriel Bakhiet Elkhider, James M. Gilchrist

P5.6-027 Tacrolimus Induced

Osmotic Demyelination in Patient with Liver Transplantation–Juan Pablo Pauta Martinez, John Patrick Holton-Burke, Prachi Mehndiratta

P5.6-028 Is Acute

Immunodeficiency Syndrome (AIDS) a risk factor for Central Pontine Myelinolysis (CPM).–Muhammad Waleed Zeb, Muhammad Rizwan Husain, Sachin Kapur

P5.6-029 Post-Mortem

Neuroimaging in Amyotrophic Lateral Sclerosis–Abdullah Ishaque, Peter Seres, Alan Wilman, Christian Beaulieu, , Sanjay Kalra

Syndrome Associated with Anterior Inferior Cerebellar Artery loop into the Internal Acoustic Meatus–Temitope A. Lawal, Divya Singhal Sinus Thrombosis Associated with Electroconvulsive Therapy Resulting in Dural Arteriovenous Fistula–Mohammed Al-Dulaimi, Nilufer Yalcin, Lincoln Darla, Ritu Bagla

P5.6-035 Clinical and

radiographic mismatch in fat embolism syndrome in hemoglobin SC disease–Shahla Moghbel, Arathi Nandyala, Steven E. Lo

P5.6-036 Brainstem Posterior Reversible Encephalopathy Syndrome–Paul Sanmartin, Jeremy Moeller, Jens Witsch

P5.6-037 Creutzfeldt-Jakob

Disease Associated Longitudinally Extensive Transverse Myelitis; a Rare Presentation Accompanied By Rapid Disease Progression– Zachary Britt Jordan, Ahmed Abd Elazim, Stevon Hunter Boyett, Divyesh Mehta, Omar Mohammed Hussein, Amro Stino CHILD NEUROLOGY: AUTISM AND BEHAVIORAL NEUROLOGY

P5.6-038 Novel Mutation in

ACSL4 Gene Leading to X-linked Intellectual Disability, Autism and ADHD–Siddharth Gupta, Fatima Toor, Bei You, Jeffrey M. Kornitzer

P5.6-039 Evaluation of Dystonia and Dystonic Posturing in a cohort of patients with autism spectrum disorder (ASD)–Carly Ray, Jeffrey M. Kornitzer, Neil Chen, Xue Ming

P5.6-040 Genetic test results

for 523 patients with ASD/ID: The diagnostic yield of multigene analysis (Autism/ID Xpanded test) is higher than conventional first-tier tests, such as FMR1 repeat analysis and chromosomal microarray–Anita Shanmugham, Tracy Brandt, Julie Scuffins, Dianalee McKnight

P5.6-041 “Tell me with whom you walk, and I will tell you who you are”: A Social Network Analysis of Adolescents with ADHD–Renato Arruda, Antonio Ribeiro, Marco Antonio Arruda

P5.6-042

Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism status does not predict serum folate and B12 in children with Attention-Deficit/ Hyperactivity Disorder (ADHD)– Sarah Nessah Silverstein, Asher Junger, Keith Pecor, Jeffrey M. Kornitzer

P5.6-043

Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism and associated vitamin D levels in children with Attention-Deficit/Hyperactivity Disorder (ADHD)–Sarah Nessah Silverstein, Keith Pecor, Asher Junger, Jeffrey M. Kornitzer

P5.6-044 A Prospective

P5.6-045 Disparities in the

Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents - a Nationwide Study–Marco Antonio Arruda, Renato Arruda, Marcelo E. Bigal, Vincenzo Guidetti

Initiatives for Early Recognition and Comprehensive Management of Autism Spectrum Disorder to Empower Health Professionals and Health Care Providers: Two Decade Experience from a Tertiary Care Centre in India–Prateek Kumar Panda, Sheffali Gulati

P5.6-047 Health Care Transition and Longitudinal Care for Adolescents and Young Adults with Hydrocephalus–Michael A. Williams, Tessa van der Willigen, Patience White, Cathy Cartwright, David Wood, Mark Hamilton

P5.6-048 Assessing

Effectiveness of an Educational Intervention on Gaps in Child Neurology Knowledge for Pediatric Residents–Anisa Rahman, Meeryo Choe, Christopher Giza, David McArthur, Rujuta Bhatt Wilson CHILD NEUROLOGY: EPILEPSY II

P5.6-049 In Silico Predictions

P5.6-054 Late-onset Rasmussen encephalitis: Diagnosis Difficulty– Emna Sansa, Ines Ben Abdelaziz, Jihene Ben Sassi, Mourad Zouari, Samir Belal, Faycal Hentati INJURY IN DEVELOPING BRAIN: FETAL NEUROLOGY, TRAUMA AND STROKE

P5.6-055 Mesenchymal Stem/ Stromal Cell Therapy during Pediatric Cardiac Surgery on Neurogenesis in the Porcine Subventricular Zone–Nisha Kapani, Takuya Maeda, Kamil Sarkislali, Zaenab Dhari, Camille Leonetti, Robert Ulrey, Patrick Hanley, Richard Jonas, Nobuyuki Ishibashi

P5.6-056 Novel In Vivo Model

of Prenatal Hypoxic Injury and Genetic Mitochondrial Hyposufficiency–Ana G. Cristancho, Elyse Gadra, Tal Yardeni, Douglas C. Wallace, Stewart Anderson, Eric D. Marsh

P5.6-057 Estrogen receptor

of KCNQ Channel Variant Pathogenicity in Epilepsy–David Ritter, Paul Horn, Katherine Dana Holland

GPR30 is participated in the longterm adverse effect of neonatal dexamethasone treatment in female rats–Keiko Lo, Kowk-Tung Lu

P5.6-050 Correlations

P5.6-058 Sleep Disturbances

between genetic, biochemical, and clinical characteristics in glucose transporter 1 deficiency syndrome: a single-center study.–Shin Nabatame, Rie Nakai, Ryoko Hayashi, Junpei Tanigawa, Koji Tominaga, Kuriko KagitaniShimono, Keiichi Ozono

P5.6-051 Clinical Decision

Support to Promote SUDEP Discussions–Stephen Downs, Randall Grout, Jeffrey R. Buchhalter, Anup D. Patel, Amy Miller, Ann Clark, Mary J. Holmay, Tyler J. Story

P5.6-052 Evolution of Dietary

Therapies in Treatment of Childhood Drug Resistant Epilepsy: an overview of nine studies including six randomized controlled trials accomplished over last twelve years in a tertiary care teaching hospital in North India–Sheffali Gulati, Prateek Kumar Panda

P5.6-053 Safety Education by

Frontline Providers in Pediatric Patients with Suspected Seizures–Daniel Freedman, Dara V. Albert

in Pediatric Intracranial Hypertension–Alexandra Behar Kornbluh, Katherine Thompson, Gada Mcmahen, Shawn C. Aylward, Lenora Moore Lehwald

P5.6-059 Neurocognitive

outcomes and their Diffusion Tensor Imaging (DTI) correlates in children with Mild Traumatic Brain Injury (mTBI)–Priyanka Madaan, Deepak Kumar Gupta, Deepak Agrawal, Atin Kumar, Prashant Jauhari, Biswaroop Chakrabarty, Shobha Sharma, R M Pandey, Vinod K Paul, MC Misra, Sheffali Gulati

P5.6-060 Neurologic Sequelae

of Infective Endocarditis in Children–Emmanuelle Favilla, Kimberly Taing, Marin Jacobwitz, Amisha Patel, Therese Giglia, Daniel J. Licht, Jennifer McGuire, Lauren AA Beslow

P5.6-062 Fetal Pain: A Review

of Available Evidence–Meaghan Berns, Rachel Joy Saban

P5.6-063 Psychogenic Gait

Disorder Complicating Recovery after Concussion: A Case Series–Scott I. Otallah

P5.6-064 Kernicterus in the

21st Century: Bilirubin-Induced Brain Injury Due to Glucose6-Phosphate Dehydrogenase Deficiency–Denise Fay Chen, Sumit Verma

P5.6-065 Caffeine Augments

Anesthesia Neurotoxicity in the Fetal Macaque Brain–Kevin Noguchi, Stephen A. Johnson, Francesca Manzella, Kobe Masuoka, Sasha Williams, Lauren Martin, Gregory Dissen, Hrissanthi Ikonomidou, Katie Schenning, John Olney, Ansgar Brambrink CHILD NEUROLOGY: NEUROMUSCULAR DISEASE: BIRTH TO ADULTHOOD II

P5.6-066 Strengthening

knowledge when data are scarce: the role of social media after AFM.–Riley Bove, Mia Carleton, Parents of Children With AFM Moderator Group

P5.6-067 A Case of Rapidly

Progressive Juvenile-Onset Amyotrophic Lateral Sclerosis with a rare SOD1 genetic variant–Alejandro J. De La Torre Ribadeneira, Shailee Samir Shah, Vamshi Rao

P5.6-068 Stiff Person

Syndrome: An Elusive Diagnosis in a Pediatric Patient–Gabriela Tuttrup, Daniella Miller, Maria B. Weimer

P5.6-069 Early onset congenital

myopathies and LGMD phenotype investigated by muscle MRI in two trasportinopathy families–Roberta Marozzo, Valentina Pegoraro, Elena Pinzan, Corrado Angelini

P5.6-070 Juvenile Myasthenia

Gravis: Evaluation of presentation and treatment outcomes in a large cohort–Jason Singh Gill, Veeral Shah, Timothy E. Lotze

P5.6-061 Favorable Outcome

in Children and Adults with PRES despite Clinical and Radiological Differences–Richard S.K. Young, Subhendu Rath, Junaid Aslam, Marie C. Eugene, Gregory Wrubel, Robert Hynecek

AAN.com/view/AM19Sci 207

Thursday

Open-label Trial of Long-Acting Liquid Methylphenidate for the Treatment of Attention Deficit/ Hyperactivity Disorder in Intellectually Capable Adults with Autism Spectrum Disorder–Gagan Joshi, Maura DiSalvo, T. Atilla Ceranoglu, Janet Wozniak, Maribel Galdo, Barbora Hoskova, Nina Dallenbach, Rose Castle, Joseph Biederman

P5.6-046 Novel Research

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 AGING AND DEMENTIA/ BEHAVIORAL AND COGNITIVE NEUROLOGY EPOSTER SESSION

P5.7-001 Medial temporal

lobe subfield volumes are spared in non-amnestic Alzheimer’s disease–Jeffrey Scott Phillips, Laura Wisse, Paul Yushkevich, James Michael Gee, Murray Grossman, David Irwin

P5.7-002 Synergistic

Disease (CJD) Presenting as Epilepsia Partialis Continua: An Uncommon Presentation–Shadi Milani, Maryam Hosseini

P5.7-009 Young-onset

Creutzfeldt-Jakob disease with neuropsychiatric presentation and prolonged disease course–Roshan Dhanapalaratnam, Roy Gary Beran, Michael Buckland, Cecilia Cappelen-Smith

neuropathology resulting from co-expression of TDP-43 and tau protein in vivo–Alexander Joseph Moszczynski, Niveen Fulcher, Patrick McCunn, Kathryn Volkening, Cleusa DeOliveira, Susanne Schmid, Robert Bartha, Michael J. Strong, Madeline Harvey

P5.7-010 A case of

P5.7-003 Predicting Clinical

P5.8-001 Striatal Acetylcholine

Course in Persons with Mild Cognitive Impairment using structural MRI.–Ali Ezzati, Andrea R. Zammit, Danielle Harvey, Christian Habeck, Nima Mesgarani, Charles G. Hall, Richard B. Lipton

P5.7-004 Preliminary

neuropathological findings in porcine brains following hypobaric exposure–Melissa Cook, Paul Sherman, John H. Sladky

P5.7-005 Connectomics in Brain Aging and Dementia–Yue-Fang Chang, Yu Dennis Cheng, Ann Cohen, Theodore Huppert, Tae Kim, Fernando Maestu, Rebecca Roush, Beth Snitz, James T. Becker

P5.7-006 A Care Pathway for

Thursday

P5.7-008 Creutzfeldt-Jakob

Post-Stroke Spatial Neglect: Initial Analysis of a PracticeBased Rehabilitation Research Network–A. M. Barrett, Nicole Diaz-Segarra, Kena Patel, Robert Gillen, Emma Kaplan, M. Chris Gonzalez-Snyder, Jenny Masmela, A. M. Barrett

P5.7-007 Machine Learning

of Quantified Volumetric MR Imaging for Diagnostic Delineation of Alzheimer’s Dementia and Mild Cognitive Impairment in the Alzheimer’s Disease Neuroimaging Initiative–Cyrus Raji, Somayeh Meysami, Maxwell Wang, Jamila Ahdidan, David Merrill, Mario F. Mendez

208 2019 AAN Annual Meeting

Lymphomatosis Cerebri: a diagnostic challenge–Sen Sheng, Yu-Ting Chen, Mark A. Pippenger, Shirley Ong

PARKINSON’S DISEASE: ANIMAL MODELS AND IMAGING and Dopamine are Necessary for Motor Function in Parkinsonism– Nigel S. Bamford, Jonathan McKinley, Ziqing Shi

P5.8-002 L-Dopa-Induced

Dyskinesias are Reduced by Propranolol in Parkinsonian Mice– Nigel S. Bamford, Ziqing Shi, Ian Bamford, Jonathan McKinley

P5.8-003 Glial alpha-synuclein induces a unique transcriptional program in vivo–Abby Lauren Olsen, Mel Feany

P5.8-004 Over Expression

of PERK Suppresses the Neurodegenerative Phenotypes in PINK1 Mutant Flies by Enhancing Mitochondrial Function–Ying Cui, Guoliang Xiang, Yvyv Nan, Xueyi Wen, Zaiwa Wei, Qinghua Li

P5.8-005 A kinome-wide

Drosophila RNAi screen identifies glial adenylate kinases as modifiers of neuronal alphasynuclein toxicity–Abby Lauren Olsen, Mel Feany

P5.8-006 PBT434 Prevents

a-synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy–David T. Finkelstein, Nadia Stefanova, Paul Adlard, Margaret Bradbury, David A. Stamler

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.8-007 Dopaminergic Grafts

P5.8-014 Microstructure

P5.8-008 Study of Yerba

P5.8-015 Impaired midbrain

Prevent Risk Of Secondary Parkinsonism In Cocaine Self-administering Rats–Kala Venkiteswaran, Tara Cayton, Alex Kim, Megha Subramanian, Thyagarajan Subramanian, Patricia Sue Grigson-Kennedy Mate (Ilex Paraguariensis) as a Neuroprotective Agent of Dopaminergic Neurons in an Animal Model of Parkinson’s Disease–Lilana Tribbia, Gimena Gomez, Andrea Cura, Roy Rivero, Alejandra Bernardi, Juan Ferrario, Bertha Baldi-Coronel, Oscar S. Gershanik, Emilia M. Gatto, Irene Taravini

alterations in the midbrain of Parkinson’s patients: a multishell diffusion MRI study–Hairong Chen, Guangwei Du, Sica Christopher, Ernest Wang, Mechelle Lewis, Lan Kong, Xuemei Huang networks connectivity underlies freezing of gait in Parkinson’s disease–Amgad Droby, Laura Avanzino, Martina Putzolu, Giulia Bommarito, Elisa Pelosin, Matilde Inglese

P5.8-016 Tracking Cortical

the basal ganglia in the control and learning of motor sequences in mice–Tori Riccelli, Joshua Dudman

Changes Throughout Cognitive Decline in Parkinson’s Disease: A Longitudinal MRI Study–Elisa Canu, Federica Agosta, Tanya Stojkovic, Silvia Basaia, Iva Stankovic, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi

P5.8-010 Progression

P5.8-017 Relationships

P5.8-009 Exploring the role of

of Parkinson’s Disease: A Longitudinal MRI Study of Functional Brain Connectome in a Large Cohort of Patients– Massimo Filippi, Silvia Basaia, Homa Zahedmanesh, Tanya Stojkovic, Iva Stankovic, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Federica Agosta

P5.8-011 Different Patterns

of Brain Activity During Lower Limb Movements in Parkinson’s Disease Patients With and Without Freezing of Gait–Noemi Piramide, Elisabetta Sarasso, Maria Volonté, Elisa Canu, Sebastiano Galantucci, Giancarlo Comi, Andrea Tettamanti, Massimo Filippi, Federica Agosta

P5.8-012 Functional Network

Connectivity Predicts Spreading of Cortical Atrophy in Parkinson’s Disease–Federica Agosta, Silvia Basaia, Homa Zahedmanesh, Tanya Stojkovic, Iva Stankovic, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi

P5.8-013 Dual-Task in

Parkinson’s Disease: A Gait Analysis and Functional MRI Study–Elisabetta Sarasso, Federica Agosta, Andrea Gardoni, Sebastiano Galantucci, Andrea Tettamanti, Maria Volonté, Massimo Filippi

Between Substantia Nigra Resting State Functional Connectivity and Uric Acid in REM Sleep Behavior Disorder and Parkinson’s Disease–Timothy M. Ellmore, Jessika Suescun, Richard Castriotta, Mya C. Schiess

P5.8-018 Longitudinal Evolution

of White Matter Damage in Parkinson’s Disease–Pietro Giuseppe Scamarcia, Federica Agosta, Edoardo G. Spinelli, Tanya Stojkovic, Iva Stankovic, Vladana pica, Igor Petrovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi

P5.8-019 Gray Matter Atrophy in Parkinson’s Disease and Freezing of Gait Assessed Using Surface-Based Algorithm–Petr Kanovsky, Miroslav Vastik, Pavel Hok, Katerina Mensikova, Petr Hlustik

P5.8-020 EEG-fNIRS Combined

Neuroimaging Study on PD patients performing UPDRS Motor Tasks–Mohammadreza Abtahi, Yalda Shahriari, Manob Jyoti Saikia, Gozde Cay, Umer Akbar, Kunal Mankodiya

P5.8-021 Initial Long-term

Treatment with Rotigotine Maintains Striatal Dopamine Transporter Binding in De Novo Patients with Parkinson Disease– Ken Ikeda, Harumi Morioka, Maya Kyuzen, Junya Ebina, Masahiro Sawada, Sayori Hanashiro, Junpei Nagasawa, Masaru Yanagihashi, Kiyoko Murata, Takanori Takazawa, Osamu Kano, Kiyokazu Kawabe, Yasuo Iwasaki

P5.8-022 Quantifying iron

deposition within the substantia nigra of Parkinson’s disease by quantitative susceptibility mapping–Dongya Huang, Xiaoyan Zeng PARKINSON’S DISEASE CLINICAL FEATURES AND CLINICAL CARE II

P5.8-023 Barriers and

Characteristics of Caregiving Preparedness in Parkinson’s disease: a qualitative approach– Chinwe Nwadiogbu, Marcela Pavon, Sarah Horn, Nabila Dahodwala

P5.8-024 What Bothers

Parkinson Patients: Clinical Curation of their Verbatim Reports–Lakshmi Arbatti, Connie C. Marras, Caroline M. Tanner, David G. Standaert, Andrew Nguyen, Ira Shoulson

P5.8-025 A Closer Look at the

Unmet Needs, Research and Care Priorities for Women with Parkinson’s–Megan Feeney, Allison Wright Willis, Veronica Todaro, Sharon Krischer, Danielle Agpalo, Christiana Evers

P5.8-026 SNCA G51D Missense

P5.8-027 Levodopa

Responsiveness Subtypes of Freezing of Gait: Results Using a Levodopa Test–Stewart A. Factor, Garrett E. Alexander, Barbara Sommerfeld, Douglas Bernhard, Johnathan Lucas McKay, John Hanfelt, Samantha John, Felicia Goldstein

P5.8-036 Case-based Medical

P5.8-029 Incidence and

P5.8-037 Risk Factors in

Transmission in Peripheral Mononuclear Cells in Parkinson’s Disease–Leila Saadatpour, Adithya Gopinath, Phillip Mackie, Subhashie Wijemanne, Habibeh Khoshbouei Predictors of 30 days readmission associated with Parkinson’s disease: 5-year National estimate (2010-2014)–Tejinder Singh, Varun Kumar, Chirag Narshibhai Savani, Sheyar Amin, Charles DeMello Schutt, Rossitza Chichkova, Yazan M. Suradi

P5.8-030 G2019S mutation and motor complications of levodopa in Parkinson disease–Nouha Farhat, Sawssan Ben romdhan, Amira Nasri, Abderrazek Hedhili, Salma Sakka, Amina Gargouri, Mouna Ben Djebara, Mariem Damak, Riadh Gouider, Chokri Abdellaziz Mhiri

P5.8-031 Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson’s Disease by Expert Care Centers From 2010 to 2017: The Parkinson’s Foundation Quality Improvement Initiative (PF-QII)–Ornella Maria Dubaz, Samuel Wu, Guanhong Miao, Tanya Simuni

P5.8-032 Survival in Parkinson disease, the Trondheim cohort– Eldbjorg Hustad, Jan O. Aasly

P5.8-033 Levodopa doses and

improvement in LRRK2 G2019S carriers compared to noncarriers–Nouha Farhat, Sawssan Ben romdhan, Amira Nasri, Camila Ibagon, Mouna Ben Djebara, Stacy Schantz Wilkins, Amina Gargouri, Mariem Damak, Riadh Gouider, Chokri Abdellaziz Mhiri

P5.8-034 Trend in PEG

placement in Parkinson’s disease compared to Alzheimer dementia and ALS–Duk Soo Kim, Richard Jones, Anelyssa D’Abreu, Joseph H. Friedman, Umer Akbar

P5.8-035 Endemic parkinsonism associated with the rare haplotype of LRRK2 gene– Katerina Mensikova, Kristina Kolarikova, Radek Vodicka, Radek Vrtel, Tereza Bartonikova, Martin Prochazka, Petr Kanovsky

Education Improves Neurologists’ Competence in Diagnosing and Managing Levodopa-induced Dyskinesia–James Martorano, Thomas Finnegan, Cate Murray, Rajesh Pahwa Essential Tremors for the Development of Parkinson’s Disease vs Parkinsonism–Hsien Lee Lau, Sarah Marmol, Jason H. Margolesky

P5.8-038 Oral cavity disorders

in Parkinson’s disease: more than meets the eye–Manon Auffret, Vincent Meuric, Emile Boyer, Martine Bonnaure-Mallet, Marc Verin

P5.8-039 MANAGE-PD: A

clinician-reported tool to identify patients with Parkinson’s Disease inadequately controlled on oral medications – Results from vignette-based validation–Angelo Antonini, Per Odin, Yash Jalundhwala, Peter N. Schmidt, Anne Skalicky, Leah Kleinman, Jorge Zamudio, Koray Onuk, Pavnit Kukreja, Yanjun Bao, Fernando Cubillos, Hubert H. Fernandez

P5.8-040 Comorbidity and

Polypharmacy in Parkinson’s disease: comparative study with control group. Results from the COPPADIS Study Cohort.– Asuncion Avila-Rivera, S. Jesus Maestre, M. Aguilar, L. Planellas, J. Garcia Caldentey, N. Caballol Pons, I. Legarda, J. Hernandez Vara, Esther Cubo Delgado, Lydia Lopez-Manzanares, I. González Aramburu, Maria-Jose Catalan, L. López Díaz, J.M. García Moreno, C. Borrué, J.C. Martínez Castrillo, M. Alvarez Sauco, Lydia Vela, Pablo Martinez Martin, Diego Santos Garcia, Asuncion AvilaRivera

P5.8-041 Molecular and Genetic Characterization of Parkinson’s Disease: A Center-Wide Approach.–Thomas F. Tropea, Jacqueline Rick, Noah Han, Vivianna Van Deerlin, Andrew D. Siderowf, Alice Chen-Plotkin

P5.8-043 Parkinsonian

patients experiences operating the computer with their eyes: the MAMEM project.–Sevasti Bostantjopoulou-Kambouroglou, Zoe Katsarou, Meir Plotnik, Gabi Zeilig, Ioannis Daglis, George Liaros, Fotios Kalaganis, Konstantinos Georgiadis, Yiannis Kompatsiarisk, Spiros Nikolopoulos

P5.8-044 Jumping as a Strategy to Overcome Freezing of Gait while Turning in Parkinson’s Disease–Karlo J. Lizarraga, Bhairavei Gnanamanogaran, Alfonso Fasano, Anthony E. Lang

P5.8-045 Non-invasive

Assessment of Dysphagia in Degenerative Disorder (Parkinson’s Disease)–Sunita Gudwani, Prabhakar Upadhyay, Kamlesh Sharma, Senthil Kumaran, Rajesh Sagar, Rajinder Kumar Dhamija

P5.8-046 Vitamin D Assessment in Veterans with Parkinson’s Disease–Fariha Jamal, George Robert Jackson, Suzanne Moore, Aliya Sarwar

P5.8-047 Impact of Parkinson’s Disease on Faith and Spirituality - a Comparative Study–Dawit K. Worku, Seti Belay, Amha Weldehana

P5.8-048 Prevalence and

clinical correlates of metabolic syndrome in patients with Parkinson’s disease.–Jesús D. Meléndez-Flores, Sergio Andrés Castillo-Torres, Christopher CerdaContreras, Beatriz Chávez, Ingrid Estrada-Bellman

P5.8-049 Sporadic Parkinson’s

Disease and Amyotrophic Lateral Sclerosis: A New Syndrome?– Sushant Puri, Michael D. Carrithers

P5.8-050 Exploring the

Experience of Wearing Off in Parkinson’s Disease: A Qualitative Research Approach–Lana Chahine, Connie C. Marras, Margaret Daeschler, Steven Kahl, Robyn Rapoport, Arina Goyle, Chelle Precht, Catherine Kopil

P5.8-042 Novel Assistive Dress Shoe & Footwear Needs Analysis for Patients with Parkinson’s Disease–Lohrasb Sayadi, Jamasb Sayadi, Mustafa Chopan, Arman Fijany, Neal S. Hermanowicz

AAN.com/view/AM19Sci 209

Thursday

Mutation Causing Juvenile Onset Parkinson’s Disease–Christa Suzanne Cooper, Jennifer G. Goldman, Cyrus P. Zabetian, Ignacio Mata, James B. Leverenz

P5.8-028 Altered Dopamine

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5

BACTERIA, FUNGI, AND PRIONS

P5.9-001 Utility of whole body

18-FDG-PET in management of Tuberculous Meningitis: A preliminary study from a tertiary care institute of North India–Manish Modi, Anumiti Jain, Manoj Goyal, Bhagwant Rai Mittal, Kusum Sharma, Sameer Vyas, Apurva Sood, Navneet Sharma, Vivek Lal

P5.9-002 Prophylactic

Palmitoylethanolamide Prolongs Survival and Decreases detrimental Inflammation in Aged Mice with Bacterial Meningitis– Ev-Christin Heide, Laura Bindila, Julia Post, Dörthe Malzahn, Beat Lutz, Jana Seele, Roland Nau, Sandra Ribes

P5.9-003 Nontraumatic

Spontaneous Pneumocephalus in Clostridium Septicum Central Nervous System Infection – A Case Report–Amputch Karukote, Smathorn Thakolwiboon, GyeongMo Sohn

P5.9-004 Acute Disseminated

Streptococcus Anginosus Abscesses in a Young Immunocompetent Patient–Jane Khalife, Connie Gwendolyn Tang, Matthew Bokhari

P5.9-005 Listeria

meningoencephalitis in an immunocompetent child–Surabhi Kaul, Rajan Patel, Ian J. Butler

P5.9-006 Late-Onset Austrian

Syndrome in a Patient with Bacterial Meningitis–Sara Shapouran, Rastko Racocevic, Kathleen Pergament, Machteld E. Hillen

Thursday

P5.9-007 Read Between the

Lyme’s: Case Series of Bannwarth Syndrome–Phong Thanh Vu, Nishtha Modi, Jessica Frey, Tamra Ishan Jayendra Ranasinghe, Eric J. Seachrist

P5.9-008 Microvessel Cerebral

Vasculitis and Peripheral Neuropathy as Neurologic Manifestations in Rocky Mountain Spotted Fever–Laura Danielson, Quynh Vo, Muhammad M. Alvi

P5.9-009 Eisenmenger

Syndrome presenting as Focal Seizures–Stephen W. English, Cassandra Paden Cross, Carole Warnes, Elie Naddaf, Zelalem Temesgen

210 2019 AAN Annual Meeting

P5.9-010 A Rare Case

of Mucormycosis Clivus Osteomyelitis Presenting With Stroke-Like Symptoms–Jessie Jacobson, Haley Spotts, Jonathan Kim, Nathan Jansen, Heather Yun

P5.9-011 Cryptococcus

Strikes Again: Recurrent Cryptococcal Meningitis in an Immunocompetent Host– Catherine McDermott, David Hale

P5.9-012 Comparison of Lumbar

and Ventricular Cerebrospinal Fluid for Diagnosis and Monitoring of Meningitis–Bhavika Kakadia, Mazen Zaher, Clint Badger, Tapan R. Kavi

P5.9-013 Acute Chorea

associated with Group C Streptococcus Pharyngitis– Maryamnaz Hosseinzadeh Zaribaf, Pavan Patel, Khaled Abdalla, Aparna M. Prabhu

P5.9-014 A Case of

Neurobrucellosis in a nonendemic area–Yuri Bronstein, Marko Petrovic, Nazely Ashikian, Jose Dryjanski-Yanovsky

P5.9-015 Immunomodulating

Biologics and sCJD–Kyung Jung “Paula” Lee, Mohamed Ridha, Sophia Lin, Emily Anderson, Jayashri Srinivasan

P5.9-016 Lyme Neuroborreliosis

Initially Presenting as a Cavernous Sinus Syndrome: A Case Report–Hannah Nicole Rinehardt, Benjamin Jiang, Michael Luttrull, Chad Hoyle

P5.9-017 Bartonella Papillitis

Mimicking Anti-MOG Optic Neuritis–Peter Sguigna, Wilmot Bonnet, Andrew Yu, Deepa Sirsi, Benjamin M. Greenberg

P5.9-018 Diagnostic Challenge:

Sporadic Creutzfeldt-Jakob Disease (sCJD) Presenting with Isolated Visual Symptoms–Adeolu Oluwaseun Morawo, Pauline Hwang, Harmanpreet Tiwana

P5.9-019 Sarcoidosis to

Nocardiosis: An odyssey of doubt and agony–Amit Shankar Singh, Jeenendra Prakash Singhvi, Sudesh Prabhakar, Virender Kumar Khosla, Anita Sharma, Rahatdeep Singh Brar, Arshdeep Singh

Thursday, May 9 11:30 a.m.–6:30 p.m. P5.9-020 Carbon Monoxide

P5.9-030 Paradoxical reaction

P5.9-021 Aortic Fungus Ball –

NEUROCYSTICERCOSIS AND OTHER PARASITIC INFECTIONS

exposure, a red herring in a patient with rapidly progressive dementia, later diagnosed with Creutzfeldt-Jakob disease– Haoming Pang, Cina Sasannejad, Natalie Diaz An Unusual Cause of Paraplegia– Prashant Natteru, Carmela San Luis, Lakshmi Ramachandran Nair, Alexander P. Auchus

P5.9-022 Leprosy presenting

as orofacial pain: case report.– Philippe Joaquim Oliveira Men Macedo, Mariana Reis Prado, Marcelo de Oliveira Paixao, Yago Castro, Martha Débora Lira Tenório, Roberto Prado

P5.9-023 The Mysterious

Mold: A Case of Coccidioides Meningitis–Diana Elizabeth Slawski, Tyler Trahan, Ryan Eid, Patricia Greenstein, Margaret Hayes

P5.9-024 Unilateral Periorbital

and Facial Swelling with Multiple Unilateral Cranial Nerve Deficits in an Uncontrolled Diabetic–Frank Dicken, Tarek Emran Ali, Fred Odago, Ima M. Ebong

P5.9-025 Community-acquired

Klebsiella pneumoniae meningitis. Questioning the demographic paradigm with new recommendations for diagnosis and effective treatment–Nara Michaelson

P5.9-026 Pituitary Apoplexy

Mimicking Meningoencephalitis: A Case Report and Literature Review–Chun Chu, Casey James Judge

P5.9-027 Suboxone abuse

with shared needle as a cause of Botulism in an IV drug user– Shuvro Roy, Yasmeen Rauf, Chad Hoyle

P5.9-028 Lyme disease

presenting as multiple small cerebral infarcts of undetermined source.–Arthur Alcantara Lima, Rahul Haridas Rahangdale, Murat Sari, Ashis H. Tayal, Thomas F. Scott

P5.9-029 Sudden Death from

Rupture of Cerebral Abscess into Subarachnoid Space–Courtney Curran, Ambica Nakhasi, Gina Prochilo, Tapan R. Kavi

in non-HIV patients with CNS tuberculosis: what, when and how?–Rogelio DominguezMoreno, Carlos Cantu, Maria Alejandra Gonzalez Duarte

P5.9-031 Intramedullary

spinal neurocysticercosis–Jacob Manske, Courtney McVey, Harris Chengazi, Omar Siddiqi, Deanna Saylor

P5.9-032 Neurocysticercosis

in Qatar–Yanal Ramzi Shaheen, Fatima Al-Maadid, Mohamed Medhat Soliman, Gayane Robert Melikyan, Boulenouar Mesraoua, Dirk T. Deleu, Hassan Jassim Al Hail, Ahmed Own, Ahmed El Sotouhy, Ziyad Mahfoud, Naim I. Haddad

P5.9-033 Brain eating

Balamuthia amoebic infection – A Case Report–Varalakshmi Ballur Narayana Reddy, Meredith Wicklund, Christopher Paul Robinson

P5.9-034 Spinal

Schistosomiasis masquerading as an Intramedullary Astrocytoma– Alexandra Kvernland, Ericka Shin Wong, Arielle Marisa Kurzweil

P5.9-035 MRI findings and

evolution of active or calcified cysts in treated and untreated patients with neurocysticercosis– Job Monteiro, Fernando Cendes, Leticia Franceschet Ribeiro

P5.9-036 Neurotoxoplasmosis

in Immunocompetent Patients Mimicking Lymphoproliferative Disease–Karlla Danielle Ferreira Lima, André Luiz Guimarães de Queiroz, Hennan Salzedas Teixeira, Victor Mantelatto Bonsi, Bruno Shigueo Yonekura Inada, Marcio Escorcio-Bezerra, Carmen Lucia Penteado Lancellotti, Alex Baeta

P5.9-037 New Diagnosed

Active Neurocysticercosis: Serial Image Findings and Corresponding Clinical Manifestations–Asfi Rafiuddin, Amanda Michael, Hai Chen

P5.9-038 An Unusual

Radiographic Feature of Toxoplasma Encephalitis in Renal Transplant Recipient–Paulus Sugianto, Cindy Cecilia, Muhammad Hamdan

NEUROCRITICAL CARE: SUBARACHNOID HEMORRHAGE

P5.9-039 Validation of the

original FRESH score in patients with subarachnoid hemorrhage– Jens Witsch, Lindsey Kuohn, Charles Matouk, Ryan Hebert, Branden Cord, Lauren Hachmann Sansing, Guido Jose Falcone, Kevin N. Sheth

P5.9-040 Role of Systemic

Inflammatory Response Syndrome (SIRS) in Subarachnoid Hemorrhage (SAH) Outcome–Yash Pandya, Yazan Bittar, Aisha Rasool Saand, Fang Yu, Murat Kaynar, Sherry Chou

P5.9-041 Early uptrending white blood cell count can be a predictor of poor outcome in patients with aneurysmal subarachnoid hemorrhage–Idrees Azher, Robert Riggio, Ashutosh Kaushal, Kayla Murray, Scott Moody, Samantha Costa, Katarina B. Dakay, Bradford B. Thompson, Michael E. Reznik, Linda C. Wendell, Nicholas S. Potter, Shyam Sudarshan Rao, Shadi Yaghi, Brian Mac Grory, Tina Mariko Burton, Shawna M. Cutting, Ryan McTaggart, Mahesh Jayaraman, Karen L. Furie, Ali Mahta

P5.9-042 Variability In Reported Physician Practices For Brain Death Determination–Sherri A. Braksick, Christopher Paul Robinson, Gary S. Gronseth, Sara E. Hocker, Eelco F. M. Wijdicks, Alejandro A. Rabinstein

P5.9-043 Prediction of

P5.9-044 Radiological Severity

Determines Glycemic Burden In Aneurysmal Subarachnoid Hemorrhage And Patient Outcome–Syeda Dania Shujaat, Syeda Maria Muzammil, Claire Emmanuelle Delpirou Nouh, Chao Xu, Bappaditya Ray

readmissions and in-hospital mortality amongst patients admitted with aneurysmal subarachnoid hemorrhageInsights from National Database– Sukriye Damla Kara, Varun Kumar, Chirag Narshibhai Savani, Tejinder Singh, Xiyan Yi, Weizhe Li, William Scott Burgin, Swetha Renati

P5.9-046 Decreased Odds for

Vasospasm Treatment in Patients with Aneurysmal Subarachnoid Hemorrhage After Transitioning from Neurosurgery-Led Care to a Neurology-Led Multidisciplinary Approach–Russell E. Bartt, Stephanie Jarvis, Lauren Cittadino, Benjamin Atchie, Kathryn L McCarthy, Rebecca van Vliet, Madison Price, Alicia Erin Bennett, Jeffrey C. Wagner, Alessandro Orlando, David Bar-Or

P5.9-047 Role of Glycemic

Burden and Glycemic Burden Variability in Determination of Temporary and Permanent Cerebrospinal Fluid diversion after Aneurysmal Subarachnoid Hemorrhage–Syeda Maria Muzammil, Syeda Dania Shujaat, Bappaditya Ray, Chao Xu, Claire Emmanuelle Delpirou Nouh, Brad Bohnstedt

P5.9-048 Lactococcus garvieae endocarditis with an initial presentation of subarachnoid hemorrhage–Abinayaa Purushothaman Ravichandran, Nathan Paul Fenstermacher, Shweta Varade, Preet M. Varade NEUROCRITICAL CARE: BRAIN DEATH AND TRAUMATIC BRAIN INJURY

P5.9-049 Epidemiological

Factors Influencing Organ Donation Following Brain Death– Christopher Ryan Green, Yuanqing Liu, Bichum Ouyang, Torrey Boland Birch

P5.9-050 Two Cases of

Fulminant Acute Motor and Sensory Axonal Neuropathy Mimicking Brain Death–Shashika Rodrigo, Noushin Jazebi, Neel Naresh Patel, Alok Dabi

P5.9-051 Bobbing-Like Ocular

Movements in a Patient with Brain Death–Julie McDaniel, Enrique C. Leira, Deema A. Fattal

P5.9-052 End of Life

Preferences: Medical Students’ Attitudes Toward Life Support– Charlotte Zhong, Peggy Nguyen, Gene Y. Sung

P5.9-053 Outcomes in

Neurologically Critically Ill Patients with Fixed Dilated Pupils: A Retrospective Cohort Study– Alana Kornspun, Juhyun Kim, Joshua Bederson, Christopher Kellner, Neha Dangayach

P5.9-054 The Successful

Implementation of a TBI Brain Donation Pathway–Erika Silverman, Brian Edlow, Carol Moore, Daniel P. Perl, Kimbra L. Kenney, Margalit Haber, Danielle Sandsmark, Geoffrey Manley, Ramon R. Diaz-Arrastia, Megan Moyer

P5.9-055 Characterization

of acute traumatic cerebral venous sinus thrombosis–Daniel Schwartz, Jason Talbott, Judy Ch’ang, Vineeta Singh

P5.9-056 Implementation of

Attending-Supervised IPASS Handoffs in the Neuro-ICU–Laura Cifrese, Sonia Gill, Megan Margiotta, Amandeep Dolla PRACTICE, POLICY, AND ETHICS II

P5.9-057 Utility of Digital

Ophthalmoscope in Neurology Residency–Jennifer Chima, Tracey Huijun Fan, Robert J. Marquardt, Ken Uchino, Jayashree Sundararajan

P5.9-058 Does Non-automated

P5.9-061 Impact of doing

Echocardiogram and Brain Magnetic Resonance Imaging on Length of Stay and Hospital Charges in Transient Ischemic Attack Patients in United States: Analysis of Nationwide Inpatient Sample 2006-2014–Harathi Bandaru, Mohammad Rauf Afzal, Huy Q. Nguyen, Anantha Vellipuram, Darine Kassar, Rakesh Khatri, Alberto Maud, Gustavo Rodriquez, Paisith Piriyawat, Salvador Cruz-Flores

P5.9-062 Regional Variation in Medicare Part D Drug Spending Amongst Neurologists–Adam De Havenon, Ka-Ho Wong, Brian Callaghan, Gregory J. Esper

P5.9-063 AAN Axon Registry:

Limitation and Barriers to Optimal Participation and Performance at an Academic center–Neeta Garg, Victor Riquelme, Salim I. Dib, Jose Gabriel Romano

P5.9-064 A Survey of Attitudes Towards Genetic Testing in Amyotrophic Lateral Sclerosis (ALS)–Changrui Xiao, Fabiane Lima, Erin Zahradnik, Joumana Baroody, Mark Siegler, Betty C. Soliven, Kourosh Rezania, Raymond P. Roos

P5.9-065 Use of a Philadelphia Specific Spanish Toolkit in the neurology outpatient clinic in Temple University Hospital– Mercedes P. Jacobson, Imama Ali Naqvi, Ching Tsao, Theresa Webster, Kristine Cruz Arandela, Maria Kristina Casanova Dorotan

Phone Call Notification Improve No-Show Rates in Neurology Resident Clinic?–Abdullah Alshammaa, Kavit Shah, Sarah Madani, Muhammad Affan, Salman Zahoor, Nour Baki, Asad M. Yousuf, Lonni Schultz, Iram Zaman, Tobias Walbert

P5.9-066 Framing a Holistic

P5.9-059 Gender disparities

from Child to Adult Neurologists: Implementation and Financial Strategies for Child and Adult Neurologists–Bruce H. Cohen, Ann H. Tilton, Neil A. Busis, Lawrence W. Brown

in course speakers at the AAN Annual Meeting–Morgan Figurelle, Amy K. Guzik

P5.9-060 Perception of Futile

Provision of Care among Clinicians in the Neurointensive Care Unit–Julio A. Chalela, Shanna Amoroso

Approach to ALS Management: Eliciting a Stakeholder Perspective on the Need for Palliative Care–Klaudia Kukulka, Karla Washington, Raghav Govindarajan, David Mehr

P5.9-067 Transition of Care

P5.9-068 Challenges with the

use of Prehospital Stroke Scales for early identification of Large Vessel Occlusion Strokes.–Rahul Haridas Rahangdale, Kelly Szabo, Jonathan Daly, Krista Foster, Philip McCoy, David Poliner, Matthew Poremba, Philip Nawrocki, Benjamin Lawner

AAN.com/view/AM19Sci 211

Thursday

QTc interval prolongation using aneurysm location and bleeding pattern in aneurysmal subarachnoid hemorrhage.–Jay Kinariwala, Kushak Suchdev, Meghana Srinivas, Hamidreza Saber, Aaron Desai, Mohammad Ibrahim

P5.9-045 Predictors of 30-day

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

POSTER SESSIONS

POSTER SESSION 5 P5.9-069 Establishing a

resident-led lumbar puncture clinic to improve resident satisfaction and skills during neurology residency–Elie Sader, Jason L. Weller

P5.9-070 Contribution towards

Public Health Awareness Activities and Continuing Medical education for Empowering Health Care Professionals on Childhood Neurodevelopmental Disorders: Experience of a Tertiary Care Teaching Hospital in North India over the last decade-Going E-way–Prateek Kumar Panda, Sheffali Gulati

P5.9-071 Perceptions of

Preventive Stroke Care Received by Women in Different Primary Care Settings–Caroline Atlas, Nadege Gilles, Sarah Zelonis Weingast, Alla Akivis, Ovadia Abulafia, Ernest Garnier, Steven R. Levine

P5.9-072 Strategies to

Decrease Post Hospital Discharge Negative Outcomes for Patients with Neurological Diseases.–Erin Smith, Krishna Mourya Galla, Harrison Lang, Emily L. Frankel, Sachin Kedar, Matthew Rizzo, Scott Diesing, Matthew Garlinghouse, Nicholas Swingle, Fuad-al Ali, Hae Young Baang, Kiel Woodward, Brian Westerhuis, Danmeng Wei, Jamison Hofer, Kalyan Reddy Malgireddy, Mohamed Taha, Navya Joseph, Praveen Hariharan, Daniel Alejandro Crespo, Brian Jose Villafuerte Trisolini, Navnika Gupta, Matthew Purbaugh

Thursday

P5.9-073 Quality Improvement in Laboratory Analysis of Paraneoplastic Panels–Nikesh Bajaj, Rachael King, Neda Sattarnezhad Oskouei, Zaneta Ahuja, Martin Kelly Nicholas

P5.9-074 Improving Patient

Return to Residency Clinic using a Patient Portal: A Residency Quality Improvement Project– Christina Rose Kyrtsos, Ying Sun, Janet F. Waters

P5.9-075 Evaluation of the Duke Neurology Advanced Practice Provider Training Program–Joel C. Morgenlander, Bryan D. Walker

P5.9-076 Effects of a novel

practice model on medical team burnout in an academic neurology practice–Drew S. Kern, Enrique Alvarez, Kathy A. Deanda, Herbert Sudfeld, Peter Smith, Laura Palmer, Jennifer Simpson, Lauren C. Frey

P5.9-077 Improving

neurologists’ adherence to guidelines on prevention of possible complications of systemic corticosteroid therapy–Verena Clarissa Samara, Srikanth Muppidi

P5.9-078 First Year Experience at SAC Health System, the First Federally Qualified Health Center (FQHC) Based Neurology Clinics–Nancy Baker, Travis Erik Losey

P5.10-008 Syndrome of Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL): A Case Report with Newly Described Electroencephalography (EEG) findings, Symptomatic Treatment Strategies, and Literature Review–Sam Hooshmand, Andrew Scrima, Fallon Schloemer

P5.10-009 Quality of life in

patients with cluster headache during the active periods–SooKyoung Kim, Cho Soo-Jin, Jeong Jin Yi, Minwon Park, Heeyoung Kang, Young-Soo Kim

P5.10-010 A Tale of two

HEADACHE

headaches – Use of Dynamic CT Myelogram to Localize Cerebrospinal Fluid Leak–Jeffrey Barrett Joseph Schachter, Prachi Mehndiratta

P5.10-001 Undertreatment of

P5.10-011 Features of episodic

Patients with Cluster Headache– Anusha Mannava, Jennifer Wax, Daniel Krashin, Jenna R. Kanter, Silvie Belaskova, Natalia Murinova

P5.10-002 Acute Headache

Diagnosis in the Emergency Department: Accuracy and Safety of an Artificial Intelligence System–Julian Nicol√°s Acosta, Francisco Dorr, Mar√≠a Teresa Goicochea, Diego Fern√°ndez Slezak, Mauricio Franco Farez

P5.10-003 Use of Traditional

Medicine for Primary Headache Disorders in Kuwait.–Fatemah Alshawaf, Jasem Yousef AlHashel, Samar Farouk, Raed Alroughani

P5.10-004 Filling the Gap: CSF

Fistula as a Presentation of Intracranial Hypertension–Aimee Szewka, Gregory Fenton, Bobby Tajudeen, Milena Stosic

P5.10-005 An Interdisciplinary

Approach Between Neurology and Neurosurgery for the Treatment of Headaches in the Setting of Aqueductal Stenosis–Virginia Baker, Nawaz Hack, Laurence Davidson

P5.10-006 Severity of Post-

traumatic Headache in relation to Severity of TBI, PTSD and severe depression in Veterans of recent wars–James R. Couch, Blair Apple, Kenneth Stewart

P5.10-007 One and Done: A Case

212 2019 AAN Annual Meeting

Thursday, May 9 11:30 a.m.–6:30 p.m.

Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia–Paul G. Mathew, Umer Najib, Shaoleen Khaled, Regina Krel

cluster headache in the real world setting: clinical characteristics from a large, multi-national, crosssectional survey–James Martinez, J. Scott Andrews, James Jackson, Russell Nichols, Sarah Cotton, Antje Tockhorn-Heidenreich, James Carroll, Zoe Phillips

P5.10-012 Trend of Cluster

Headache Hospitalizations and their Associated Outcomes, a National Four Year Retrospective Review.–Matthew Chung, Chirag Narshibhai Savani, Varun Kumar, Tigran Kesayan, Luiz De Souza, Jose R. Rodriguez, James Ray Ghattas, Grace Kim, Martin Anthony Myers, Charles W. Brock

P5.10-013 Intravenous

Fosphenytoin as Rescue Treatment in Trigeminal Neuralgia Crisis–Susana Schnell, Mariano Marrodan, Maria T. Goicochea, Lucas Bonamico

P5.10-014 Assessment and

Management of Patients with Headache Referred to a General Neurology Consultation Service– Conor Fearon, Kevin Moloney, Albi J. Chalissery, Damien Ferguson, Patrick Brian Moloney, Janice M. Redmond

P5.10-015 Acute and preventive treatment patterns in episodic cluster headache: findings from the United States, United Kingdom and Germany–Russell Nichols, J. Scott Andrews, James Jackson, Sarah Cotton, Antje Tockhorn-Heidenreich, Zoe Phillips, James Carroll, James Martinez

P5.10-016 Idiopathic Orbital

Inflammation Presenting as Hemicrania Continua–Jaclyn D. Duvall, Narayan R. Kissoon, John Chen

P5.10-017 Predictors of 30-

Day Readmission Post Index Hospitalization for Cluster Headache: 5 Years National Estimate–Grace Kim, Chirag Narshibhai Savani, Varun Kumar, Matthew Chung, Tigran Kesayan, Jose R. Rodriguez, James Ray Ghattas, Luiz De Souza, Martin Anthony Myers, Charles W. Brock

P5.10-018 Accuracy of

Pre-Headache Clinic SUNCT Diagnosis: A Cautionary Tale– Jennifer Wax, Anusha Mannava, Jenna R. Kanter, Daniel Krashin, Natalia Murinova

P5.10-019 Healthcare resource

use and humanistic burden associated with attack frequency in episodic cluster headache–J. Scott Andrews, Antje TockhornHeidenreich, James Jackson, Russell Nichols, Sarah Cotton, Zoe Phillips, James Carroll, James Martinez

P5.10-020 Medical Cannabis

Treatment in Patients with Trigeminal Neuralgia–Laszlo Mechtler, Paul B. Hart, Vincent Harry Bargnes, Nicolas Saikali

P5.10-021 Persistent

Neurological Deficits in a Patient with Hemiplegic Migraine Revealing Diffuse Astrocytoma– Aarushi Suneja, Ashhar Ali

P5.10-022 Hypnic Headache:

Characteristics and Treatment Modalities in An Academic Headache Center–Jennifer Wax, Anusha Mannava, Silvie Belaskova, Daniel Krashin, Natalia Murinova

P5.10-023 Sex-induced

Headache Associated with Moyamoya Angiopathy: A Case Story and Literature Review– ShuTing Chen, Jr-Wei Wu

P5.10-024 Diagnostic Delay in

Patients Prior to Being Seen in Headache Clinic–Pooja Puvvadi, Melissa Schorn, Sau Mui ChanGoh, Silvie Belaskova, Daniel Krashin, Natalia Murinova

P5.10-025 One-Month Feasibility

of Progressive Muscle Relaxation (PMR) via Smartphone Application for Post Traumatic Headache (PTH) Patients–Saima Usmani, Sandra India Aldana, Emma Ortega, Christian Kasianko, Zoe Weiss, Laura J. Balcer, Mia T. Minen

P5.10-026 Marijuana Use In

Headache In a University–Based Headache Clinic–Melissa Schorn, Daniel Krashin, Anusha Mannava, Silvie Belaskova, Natalia Murinova

P5.10-027 A Survey Comparing

Neurology and Internal Medicine Residents’ Approaches to Headache Management–Vanessa Cooper, Jason J. Sico

POSTER SESSIONS

PUBLICATION CODE KEY Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Board Number

P5.10-028 Undertreatment of

Headache Associated with Sexual Activity–Ami Zarrillo Cuneo, Daniel Krashin, Natalia Murinova

Thursday

Check Out a Special Poster Session During the Friday Grand Finale! More details on specific posters coming soon, so check AAN.com/view/AM19Sci for the latest information.

AAN.com/view/AM19Sci 213

Thank You

2O19 Industry Roundtable Members* The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.

YEAR ANNIVERSARY

$50,000 Members

$40,000 Members

$25,000 Members

• Avanir Pharmaceuticals, Inc.

• Adamas Pharmaceuticals

• IPSEN Biopharmaceuticals Inc.

• Alexion Pharmaceuticals, Inc.

• Mitsubishi Tanabe Pharma

• Akcea Therapeutics

• Medtronic, Inc.

• Neurelis, Inc.

• Allergan, Inc.

• Merck & Co., Inc.

• Ovid Therapeutics

• Amneal Specialty, a division

• SK life science, a subsidiary

• Philips

America, Inc.

of Amneal Pharmaceuticals LLC • CSL Behring

$10,000 Members

of SK biopharmaceuticals

*Commitments as of February 4, 2019

71ST ANNUAL MEETING EXHIBITORS Abbott AbbVie, Inc. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Acorda Therapeutics Actelion Pharma Adamas Pharmaceuticals Inc. Advanced Brain Monitoring, Inc. Advocate Aurora Health AKCEA THERAPEUTICS Alder Biopharmaceuticals, Inc. Alexion Alexion Pharmaceuticals Allegheny Health Network Allergan Medical Affairs Allergan, Inc. Alnylam Pharmaceuticals Alzheimer’s Association AMBU, Inc. American Board of Psychiatry and Neurology (ABPN) American Headache Society Amgen / Novartis Amneal Pharmaceuticals APBD Research Foundation Aquestive Therapeutics, Inc. Aquestive Medical Affairs Arbor Pharmaceuticals, LLC argenx Aspen Medical Products Association for Frontotemporal Degeneration Avanir Pharmaceuticals, Inc AveXis, Inc. Axiva Health Solutions Bellin Health Biogen Biohaven Pharmaceutical BioSensics BKIN Technologies Ltd Boston Scientific BrainCheck BrianScope, LLC BriovaRx Infusion Services Cadwell Industries, Inc. Cambridge University Press Catalyst Pharmaceuticals, Inc Medical Affairs Catalyst Pharmaceuticals, Inc. CEFALY Technology Celgene Corporation CHRISTUS Health Coalition For Headache And Migraine Patients (CHAMP) Cognision Community Health Systems CompHealth Compumedics Neuroscan Corinthian Reference Lab CSL Behring Cure SMA

Cure VCP Disease, Inc. DEFEAT MSA DEMOS MEDICAL DENT Neuroscience Research Institute DynaMed Plus/EBSCO Health Dysautonomia Internationa Education Commission for Foreign Medical Graduates Eisai Inc. electroCore, Inc. Lilly USA, LLC Elsevier EMD Serono EMS BIOMEDICAL eNeura Inc. epocrates European Academy of Neurology (EAN) Evoke Neuroscience Frontiers in Neurology Guillain-Barre/CIDP Foundation International GE Healthcare Genenetech a Member of the Roche Group Global Kinetics Corporation Great Lakes NeuroTechnologies Inc. Greenwich Biosciences, Inc. Hayes Healthcare HCA Healix, LLC Hydrocephalus Association icometrix Impel NeuroPharma Indiana University Health Insightec Intermountain Healthcare International Essential Tremor Foundation International Parkinson and Movement Disorder Society Invitae Ipsen Biopharmaceuticals, Inc. Jackson & Coker LT Jari Electrode Supply Jazz Pharmaceuticals, Inc. Kaiser Permanente Karger Publishers KEGO King-Devick technologies, inc. KRONUS, Inc. LabCorp Lewy Body Dementia Association Lifelines Neuro LivaNova LocumTenens.com Lundbeck Managing Epilepsy Well Network Mayo Clinic Mayo Clinic Laboratories

McKesson MDocHaus Med Care Pharmaceuticals Medday Pharmaceuticals Brainwork MedLink Neurology Medscape Neurology Medtronic Merck & Co., Inc. Merz Neurosciences Metro Health - University of Michigan Health Micromedical by Interacoustics Midland Health Mitsubishi Tanabe Pharma America, Inc. MoMed Inc. MotherToBaby MULTIGON INDUSTRIES,INC. Multiple Sclerosis Association of America Multiple Sclerosis Foundation Mylan Inc. National Institute of Neurological Disorders and Stroke (NINDS) National Prion Disease Pathology Surveillance Center Natus Neuro Neurelis, Inc. Neurocrine Biosciences, Inc. Neurocritical Care Society Neurology Advisor Neurology Live MDedge/Neurology NeuroPace Neurovirtual Nihon Kohden America Novartis Ochsner Health System Ohio State University-Dept of Neurology option care Oxford University Press PeaceHealth Penn State Health PHARNEXT Philips Neuro Piramal Critical Care PracticeLink Promius Pharma ProtoKinetics Gait Analysis Walkways Provider Solutions + Development PTC Therapeutics Quanterix Corporation Quest Diagnostics RosmanSearch, Inc. Saint Luke’s Marion Bloch Neuroscience Institute Sanofi Genzyme - Rare Sanofi Genzyme

Saol Therapeutics Sarepta Therapeutics Sensonics International SK life science SoutheastHEALTH Spectrum Health Medical Group Springer Nature STAFF CARE Stealth BioTherapeutics Sunovion Pharmaceuticals Inc. Sunovion Medical Affairs Sunovion Pharmaceuticals Trokendi XR Oxtellar XR Tenet Healthcare Teva Pharmaceuticals JAMA Network Theranica Bio-Electronics LTD Tower Health United Council for Neurologic Subspecialties University of Florida Health Upsher-Smith Laboratories, LLC US WorldMeds UW Medicine Valley Medical Center Variantyx Inc Vituity Wolters Kluwer Zeto Zosano Pharma

*As of January 24, 2019 AAN.com/view/AM19Sci 215

2019 AWARD RECIPIENTS

The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy, fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey. The American Academy of Neurology thanks the American Brain Foundation for its philanthropic support of the American Academy of Neurology’s awards program.

A.B. BAKER AWARD FOR LIFETIME ACHIEVEMENT IN NEUROLOGIC EDUCATION

ASSOCIATION OF INDIAN NEUROLOGISTS IN AMERICA LIFETIME ACHIEVEMENT AWARD

Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals. Recipient: Steven L. Lewis, MD, FAAN Allentown, PA

Sponsored by the American Brain Foundation. Recipient: Ram Ayyar, MBBS, MD, MRCP, FAAN Miami, FL AINA Annual Meeting Monday, May 6, 6:00 p.m.

ADVANCED PRACTICE PROVIDER SCHOLARSHIP Sponsored by the AAN Practice Committee. Recipients: Mary Epperson, RN, BSN, MSN, CPNP St. Louis, MO Christa S. Cooper, PA-C, MMS, MPH Chicago, IL

ALLIANCE AWARDS Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Founders

Recipient:

Lily Zhou, BHSc, MD Ottawa, ON, Canada S40: Stroke Risk Factors and Epidemiology Wednesday, May 8, 3:30 p.m.

S. Weir Mitchell Recipient:

Andrew Findlay, MD St. Louis, MO S23: Genetic Muscle Disorders Monday, May 6, 3:30 p.m.

AMERICAN ACADEMY OF NEUROLOGY PRESIDENT’S AWARD This award is given by the American Academy of Neurology President for outstanding service to the American Academy of Neurology and the profession of neurology. Recipient: Lisa M. DeAngelis, MD, FAAN New York, NY

AMERICAN BRAIN FOUNDATION BOARD CHAIR’S AWARD Sponsored by the American Brain Foundation. Recipient: Edgar J. Kenton III, MD, FAAN, FAHA, given posthumously Philadelphia, PA Commitment to Cures Wednesday, May 8, 6:00 p.m.

216 2019 AAN Annual Meeting

AWARD FOR CREATIVE EXPRESSION OF HUMAN VALUES IN NEUROLOGY This award is sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society. Recipient: Ludwig Gutmann, MD, FAAN Iowa City, IA The Intolerable Burden

BRUCE S. SCHOENBERG INTERNATIONAL AWARD IN NEUROEPIDEMIOLOGY Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc. Recipient: This award was not given for 2019

CHILD NEUROLOGY NEUROSCIENCE RESEARCH PRIZE Sponsored by the American Academy of Neurology and the Child Neurology Society. Recipient: Shan Lateef Alexandria, VA Child Neurology Society Meeting October 23 - 26, 2019 Charlotte, NC

COMMITMENT TO CURES AWARD Sponsored by the American Brain Foundation. Recipient: Jeffrey Lurie Philadelphia, PA Commitment to Cures Wednesday, May 8, 6:00 p.m.

DREIFUSS-PENRY EPILEPSY AWARD Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Neuroscience; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma. Recipient: Daniel Friedman, MD, MS New York, NY S36: Epilepsy/Clinical Neurophysiology (EEG) II Wednesday, May 8, 1:00 p.m.

HAROLD WOLFF-JOHN GRAHAM AWARD Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals. Recipient: Jelena Pavlovic, MD, PhD New York, NY S20: Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine Monday, May 6, 3:30 p.m.

INTERNATIONAL SCHOLARSHIP AWARD Sponsored by the American Academy of Neurology. Recipients: Dona-Hui Ao, MD Beijing, China Babawale Arabambi, MBBS, FWACP Lagos, Nigeria Marjorie Anne Bagnas, MD Manila, Philippines Abiodun Bello, MBBS, FWACP Ilorin, Nigeria Catalina Bensi, MD Buenos Aires, Argentina Fabricio Castro de Borba, MD São Paulo, Brazil Filipe Brogueira Rodrigues, MD, MSc London, United Kingdom Avinash Chandra, MD Kathmandu, India Marienke de Bruijn, MD Tilburg, Netherlands Guillermo Delgado-Garcia, MD Mexico City, Mexico Lingling Ding, MD Beijing, China Victoria Carla Fernandez, MD Buenos Aires, Argentina Divyani Garg, MBBS, MD New Delhi, India Alicia Gonzalez-Martinez, MD Madrid, Spain Wijoyo Halim, MD Palu, Indonesia

Calandri Ismael, MD Buenos Aires, Argentina Joyce Jimenez-Zambrano, MD Guayaquil, Ecuador Marilise Katsurayama, MD São Paulo, Brazil Ravish Keni, MBBS, MD Thiruvananthapuramm, India Priyanka Madaan, MD, DM Chandigarh, India Mark Willy Mondia, MD Manila, Philippines Tshering Pem, MBBS Thimphu, Bhutan Chintan Prajapati, MBBS, MD New Delhi, India Ahmed Effat Saied, MD, MSc Mansoura, Egypt Lucas Scárdua Silva, MD Campinas, Brazil Salma Suhana, MBBS, MD Davanagere, India Satish Wagh, MD Puducherry, India Sonam Yangzom, MBBS Thimphu, Bhutan Florencia Yorio, MD Buenos Aires, Argentina Stanley Zimba, MBChB, MMed Lusaka, Zambia

IRWIN SCHATZ AWARD FOR AUTONOMIC DISORDERS Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc. Recipient: Roy Freeman, MD Boston, MA S18: Autonomic Disorders Monday, May 6, 3:30 p.m.

JOHN DYSTEL PRIZE FOR MULTIPLE SCLEROSIS RESEARCH Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society. Recipient: Anne Cross, MD St. Louis, MO The Grand Experience Wednesday, May 8, 3:30 p.m.

JON STOLK AWARD IN MOVEMENT DISORDERS FOR YOUNG INVESTIGATORS Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma. Recipient: Sheng-Han Kuo, MD New York, NY S41: Imaging in Movement Disorders Wednesday, May 8, 3:30 p.m.

KENNETH M. VISTE JR., MD PATIENT ADVOCATE OF THE YEAR AWARD Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends, and patients. Recipient: Aaron L. Berkowitz, MD, PhD Boston, MA

LAWRENCE C. MCHENRY AWARD: AN AWARD FOR THE HISTORY OF NEUROLOGY Sponsored by the American Academy of Neurology. Recipient: Stefano Sandrone, PhD Milan, Italy S44: History of Neurology Thursday, May 9, 1:00 p.m.

AAN.com/view/AM19Sci 217

2019 AWARD RECIPIENTS MEDICAL STUDENT ESSAY AWARDS Sponsored by the American Academy of Neurology.

Extended Neuroscience Award Recipient:

Laura McGarry New York, NY Poster Session 2 Monday, May 6, 11:30 a.m.

G. Milton Shy Award in Clinical Neurology Recipient:

Audrey Leasure New Haven, CT Poster Session 2 Monday, May 6, 11:30 a.m.

Roland P. Mackay Award in Historical Aspects Recipient:

Stephanie Roses Durham, NC Poster Session 2 Monday, May 6, 11:30 a.m.

Saul R. Korey Award in Experimental Neurology Recipient:

Sona Mistry, MSc Sheffield, United Kingdom Poster Session 2 Monday, May 6, 11:30 a.m.

MICHAEL S. PESSIN STROKE LEADERSHIP PRIZE Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues. Recipient: Alessandro Biffi, MD Boston, MA S22: Stroke Genetics, Cellular Responses, and Animal Models Monday, May 6, 3:30 p.m.

MITCHELL B. MAX AWARD FOR NEUROPATHIC PAIN Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max. Recipient: Troels Staehelin Jensen, MD, DMSc Aarhus, Denmark S24: Lost Connections: From Functional Connectivity to Needs in Pain and Palliative Care Tuesday, May 7, 1:00 p.m.

MOVEMENT DISORDERS RESEARCH AWARD Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation. Recipient: Guenther Deuschl, MD, PhD Kiel, Germany S16: Huntington’s Disease: From Bench to Clinical Trials Monday, May 6, 1:00 p.m. 218 2019 AAN Annual Meeting

MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha. Recipient: James H. Bower, MD Rochester, MN Global Health Section Meeting Monday, May 6, 8:15 a.m.

NEUROENDOCRINE RESEARCH AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog. Recipient: Dena Dubal, MD San Francisco, CA Neuroendocrinology Section Meeting

NEURO-ONCOLOGY INVESTIGATOR AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner. Recipient: Jorg Dietrich, MD, PhD Boston, MA S14: Translational and Clinical Advances in Neuro-Oncology Monday, May 6, 1:00 p.m.

NEURO-ONCOLOGY SCIENTIFIC AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung. Recipient: Andreas von Deimling, MD Heidelberg, Germany S14: Translational and Clinical Advances in Neuro-Oncology Monday, May 6, 1:11 p.m.

NEUROSCIENCE RESEARCH PRIZE Funded by the American Academy of Neurology. Recipients: Rachel Chernoff Armonk, NY Poster Session 1 Sunday, May 5, 11:30 a.m. Kevin Zhong Basking Ridge, NJ Poster Session 1 Sunday, May 5, 11:30 a.m. Caleb Shi Hackensack, NJ Poster Session 1 Sunday, May 5, 11:30 a.m.

NORMAN GESCHWIND PRIZE IN BEHAVIORAL NEUROLOGY

SHEILA ESSEY AWARD: AN AWARD FOR ALS RESEARCH

Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology. Recipient: Sonja Scholz, MD Bethesda, MD S13: Behavioral and Cognitive Neurology: Behavioral Neurology, Aging, and Dementia Monday, May 6, 1:00 p.m.

Sponsored by the American Academy of Neurology, the American Brain Foundation and the ALS Association and supported through the philanthropy of the Essey Family and the ALS Association. Recipient: Aaron Gitler, PhD Stanford, CA The Grand Experience Tuesday, May 7, 3:30 p.m.

SLEEP SCIENCE AWARD POTAMKIN PRIZE FOR RESEARCH IN PICK’S, ALZHEIMER’S, AND RELATED DISEASES Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family Recipient: Randall Bateman, MD St. Louis, MO The Grand Experience Monday, May 6, 3:30 p.m.

PUBLIC LEADERSHIP IN NEUROLOGY AWARD Sponsored by the American Brain Foundation. Recipient: Ann Romney Salt Lake City, UT Commitment to Cures Wednesday, May 8, 6:00 p.m.

Sponsored by the American Academy of Neurology and the American Academy of Neurology Sleep Section and endowed by Cephalon, Inc. Recipient: Clifford Saper, MD, PhD Boston, MA S46: Sleep Science and Therapy Updates Thursday, May 9, 1:00 p.m.

WAYNE A. HENING SLEEP MEDICINE INVESTIGATOR AWARD Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening. Recipient: Diego Carvalho, MD Rochester, MN S46: Sleep Science and Therapy Updates Thursday, May 9, 1:22 p.m.

SAFETY AND QUALITY AWARD Sponsored by the American Academy of Neurology. Recipients: Monisha A. Kumar, MD David G. Coughlin, MD Philadelphia, PA Green Sheet Tool to Limit Unplanned ICU Readmission Danielle Larson, MD Chicago, IL Development of a Parkinson’s DiseaseSpecific Admission Order Set and Its Impact on Inpatient Medication Administration Elanagan Nagarajan, MD Columbia, MO Hematoma Risk After Needle EMG in Patients with Newer Anticoagulation Minh-Thuy Nguyen Boston, MA Improving Stroke Education in Spanish speaking Patients

AAN.com/view/AM19Sci 219

2019 RESEARCH PROGRAM RECIPIENTS Career Development Award Funded by the American Academy of Neurology. Recipients: Shouri Lahiri, MD Cedars-Sinai Medical Center Susanna Mierau, PhD, MD University of Cambridge

Clinical Research Training Scholarship Funded by the American Academy of Neurology. Recipients: Prashanth Ramachandran, MBBS University of California, San Francisco Karisa Schreck, MD, PhD Johns Hopkins University Jennifer Kim, MD, PhD Massachusetts General Hospital, Brigham, Harvard

Clinical Research Training Scholarship in ALS Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Jennifer Marsella, MD University of Rochester

Clinical Research Training Scholarship in Headache Funded by the International Headache Society and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Faisal Amin, MD, PhD Rigshospitalet

Clinical Research Training Scholarship in Multiple Sclerosis Funded by the Consortium of Multiple Sclerosis Centers, Biogen, and American Brain Foundation in collaboration with the American Brain Foundation. Recipient: Omar Al-Louzi, MD National Institutes of Health

Clinical Research Training Scholarship in Muscular Dystrophy Funded by the Muscular Dystrophy Association and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: This award was not given for 2019

220 2019 AAN Annual Meeting

Clinical Research Training Scholarship in Neuromuscular Disease Funded by the Muscle Study Group and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Reza Seyedsadjadi, MD Massachusetts General Hospital, Brigham, Harvard

Clinical Research Training Scholarship in Parkinson’s Disease Funded by the Parkinson’s Foundation and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: David Coughlin, MD University of Pennsylvania

Clinical Research Training Scholarship in Parkinson’s Disease Funded by the Parkinson’s Foundation and American Brain Foundation in collaboration with the American Academy of Neurology. Supported in part by a grant from AbbVie. Recipient: Anna Goodheart, MD Massachusetts General Hospital, Brigham, Harvard

Clinical Research Training Scholarship in Tourette Syndrome Funded by the Tourette Association of America and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Jennifer Vermilion, MD University of Rochester

Clinician Scientist Development Award in Interventional Neurology Funded by the Society of Vascular and Interventional Neurology and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Kevin Keenan, MD University of California, San Francisco

Clinician Scientist Development Award in Myasthenia Gravis Funded by the Myasthenia Gravis Foundation of America and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Shruti Raja, MD Duke University Medical Center

Lawrence M. Brass Stroke Research Award Funded by the American Heart Association and American Stroke Association and the American Brain Foundation. Recipient: Jiang Xiaoyan, MD, PhD University of Pittsburgh

McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory Loss

Susan S. Spencer Clinical Research Training Scholarship in Epilepsy Funded by the American Epilepsy Society, Epilepsy Foundation, and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Lisseth Burbano, MD Florey Institute of Neuroscience and Mental Health

Funded by the McKnight Brain Research Foundation through the American Brain Foundation, and the American Academy of Neurology. Recipients: Sanaz Sedaghat, PhD Feinberg School of Medicine, Northwestern University Christian Camargo, MD University of Miami School of Medicine

Neuroscience Research Training Scholarship Funded by the American Academy of Neurology. Recipients: Gary Ho, MD, PhD Massachusetts General Hospital, Brigham, Harvard Victoria Ho, MD, PhD UCLA Kellen Winden, MD, PhD Children’s Hospital Boston

Practice Research Training Scholarship Funded by the American Academy of Neurology. Recipient: Elan Guterman, MD University of California, San Francisco

Richard Olney Clinician Scientist Development Award in ALS Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Suma Babu, MD Massachusetts General Hospital, Brigham, Harvard

Robert W. Katzman, MD, Clinical Research Training Scholarship in Alzheimer’s and Dementia Research Funded by the Alzheimer’s Association and American Brain Foundation in collaboration with the American Academy of Neurology. Recipient: Hyun-Sik Yang, MD Massachusetts General Hospital, Brigham, Harvard

AAN.com/view/AM19Sci 221

GENERAL INFORMATION Accreditation/CME/Core Competencies

Core Competencies The AANI develops its activities/educational interventions in the context of the desirable physician attributes; specifically, of the Accreditation Council for Graduate Medical Education (ACGME) Core Competencies which include:

Patient Care

Accreditation

Medical Knowledge

The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Interpersonal and Communication Skills Practice-based Learning and Improvement Professionalism Systems-based Practice

The American Academy of Neurology Institute designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annual Meeting CME offerings, at the program and lecture level, are identified according to these competencies. Through identifying individual programs by competencies, attendees can easily identify and attend programs that meet each core competency. For more information on the definitions of the ACGME core competencies, please visit ACGME.org.

*See individual program descriptions in this booklet for the maximum number of credits per program.

AMA CME Definition/Educational Content of Certified CME

AMA Credit Designation

CME/Participation Records AANI has mechanisms in place to record, and when authorized by the participating physician, verify participation in the CME activity. To receive CME for the Annual Meeting live program, participants must: (1) Have their badge printed on-site and be verified as eligible for credit; (2) Attend the program(s); and (3) Submit the evaluation form for the program(s). CME is given only when all three steps are completed. AAN member CME and participation transcripts are available approximately four to six weeks following the close of the meeting via the AAN’s NeuroTracker™ at AAN.com/view/NeuroTracker. Nonmembers’ CME credits and participation transcripts will be sent automatically via email.

The AMA HOD and the Council on Medical Education have defined continuing medical education as follows: CME consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is the body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. (HOD policy #300.988)

Certified CME is defined as: 1

Nonpromotional learning activities certified for credit prior to the activity by an organization authorized by the credit system owner, or

Nonpromotional learning activities for which the credit system owner directly awards credit

ABPN Statement The American Board of Psychiatry and Neurology has reviewed the AAN Annual Meeting and has approved this product as a part of a comprehensive lifelong learning program which is mandated by the ABMS as a necessary component of maintenance of certification.

222 2019 AAN Annual Meeting

Accredited CME providers may certify nonclinical subjects (e.g., office management, patient-physician communications, faculty development) for AMA PRA Category 1 Credit™ as long as these are appropriate to a physician audience and benefit the profession, patient care, or public health. CME activities may describe or explain complementary and alternative health care practices. As with any CME activity,

these need to include discussion of the existing level of scientific evidence that supports the practices. However, education that advocates specific alternative therapies or teaches how to perform associated procedures, without scientific evidence or general acceptance among the profession that supports their efficacy and safety, cannot be certified for AMA PRA Category 1 Creditâ&#x201E;˘.

Content Validation The AANI, as an ACCME accredited provider, is responsible for validating the clinical content of CME activities that it provides. Specifically, (1) All the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. (2) All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Disclaimers/Disclosures Disclaimer The primary purpose of the Annual Meeting is to meet the educational needs of its members and address practice gaps by providing practice oriented and scientifically based educational activities that will maintain and advance competence and performance in the field of neurology. A diversity of opinions exists in the medical field and the views of the Annual Meeting faculty do not represent those of the AAN/AANI or constitute endorsement by the AAN/AANI. The AAN/AANI disclaims any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed at the Annual Meeting. The activities conducted and content distributed at the Annual Meeting are for educational purposes only and do not constitute standard of care or substitute for professional medical advice, diagnosis, or treatment. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the content provided is voluntary. The AAN/AANI provide this information on an â&#x20AC;&#x153;as isâ&#x20AC;? basis and makes no warranty, expressed or implied, regarding the information. The AAN/ AANI specifically disclaim any warranties of merchantability or fitness for a particular use or purpose. The AAN/AANI assume no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. Attendee assumes any and all liability associated with attendance/participation at the Annual Meeting.

Relationship Disclosure and Conflict of Interest Resolution According to AANI and ACCME policies, everyone who is in a position to control the content of an education activity must disclose financial relationships with any commercial interest to the provider. An individual who refuses to disclose relevant financial relationships is disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. In addition, the AANI must implement a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The resolution of conflict is handled by the Science Committee and the Conference Subcommittee. Disclosures for everyone in the position to control Annual Meeting content can be found on the AAN Annual Meeting website and the AAN Conferences Mobile App. In addition, education and science faculty disclosures can also be found in the syllabi, slides, handouts, and/or are given verbally from the podium.

Unlabeled Use Disclosure The AANI requires all Annual Meeting presenters to disclose if a therapy/product is not labeled for the use being discussed or if the therapy/product is still investigational. Unlabeled use disclosures can be found in the program materials.

Grants Some Annual Meeting education and scientific programs are supported in part by educational grants from commercial entities. Disclosure of the educational grant is done through acknowledgment statements on the program materials, signs outside of the room, and verbally from the podium. Although educational grants are received, all programs are developed and implemented solely by the Education Committee and Science Committee. The terms, conditions, and purposes of the commercial support are documented in a written agreement between the AANI and commercial supporter. The AAN uses grant funds to support and enhance existing, as well as new, education programs.

Cancelled or Closed Programs Programs may be closed due to reaching maximum capacity or cancelled due to insufficient enrollment. In the event of cancellation, registration for the cancelled course will be fully refunded for courses that have a separate registration fee. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration closure or cancellation.

AAN.com/view/AM19Sci 223

Cancellations/Refunds of Registration

Mothers/Family Room

Until March 7, 2019—Refund less $100 administrative fee March 8–April 11, 2019—Refund less $200 administrative fee After April 11, 2019—No refund All cancellations must be submitted in writing to aanam. cmrushelp.com or faxed to (415) 293-4071. No-shows will not receive a refund. Name substitutions are not permitted. No refunds will be processed for amounts of $20 or less.

Includes a private area for nursing mothers, changing stations, lounge area, and livestreams of select programs. The Pennsylvania Convention Center also has two additional private pods for nursing mothers.

Services Luggage Check Information about luggage check at the convention center will be available closer to the Annual Meeting.

Transportation Due to the proximity of the hotels to the Pennsylvania Convention Center, the AAN will provide shuttle service only for select hotels.* The housing website indicates whether a hotel is walkable or within the shuttle zone. Please refer to this information when making your housing selection. For attendees booking outside the official AAN housing block, shuttle access may be purchased for an additional fee. *Attendees of The Philly Spectacular—at Reading Terminal Market on the evening of Sunday, May 5 will have shuttle transportation to their hotel after the event included as part of their event ticket if the hotel is booked through the AAN.

Shuttle Bus Pass Complimentary shuttle buses will only be available to those who have made their reservations within the official AAN housing block and will be indicated on name badges. Attendees staying outside of the official AAN block may purchase a shuttle bus pass from the AAN for $15/day.

Wireless Connection Wireless Internet will be available at the Pennsylvania Convention Center.

First Aid Station First Aid stations are located within the Pennsylvania Convention Center. The stations are staffed by licensed medical professionals and fully equipped with supplies, including automatic external defibrillators. The stations are operational throughout the duration of the Annual Meeting.

Prayer Room A prayer room will be available in the Pennsylvania Convention Center for attendees looking for a quiet space for thought, reflection, and prayer.

224 2019 AAN Annual Meeting

Guidelines Meetings Anti-Harassment Policy The AAN is committed to providing a meeting environment that is free from all forms of discrimination and harassment. The Meetings Anti-Harassment Policy promotes the AAN’s values by defining the expectations for all participants at any AAN meeting and related social events. Violations of this Policy may be reported to Member Services at (800) 879-1960, memberservices@aan.com, or to Academy staff on-site at the Annual Meeting.

Photography and Recording of Programs The AAN strictly prohibits all unauthorized photography (flash, digital, or otherwise), audio, and/or video recording during the Annual Meeting. Photography is allowed only in the Poster Sessions.

Consent to Use of Images All portions of the Annual Meeting may be photographed, videotaped, or recorded for future rebroadcast, distribution, promotion, or other commercial purpose. By attending the Annual Meeting you are consenting to being recorded, photographed, and videotaped without acknowledgment, payment, or remuneration of any kind. Any recordings, photographs, or videos of any nature are the sole property of AAN and its successors and assignees.

Cell Phones The AAN requests that attendees turn cellular phones and pagers to vibrate mode upon entering all Annual Meeting programs.

Language The official language of the Annual Meeting is English. No simultaneous translation is available.

No Smoking The Pennsylvania Convention Center is a nonsmoking facility. For the health and comfort of everyone, smoking is prohibited at Annual Meeting functions, which include all education and scientific activities and social functions.

AAN Press Room Only authorized media may use the Press Room at the Annual Meeting. Journalists must check in at the Press Room and provide proper credentials. For more information, email Renee Tessman at rtessman@aan.com or call (612) 928-6137.

Enhance Your Annual Meeting Experience with Annual Meeting On Demand This comprehensive, CME-accredited digital library offers*:

New for 2019! • Lower Price – By moving Annual Meeting On Demand to the AAN’s Online Learning Center, we’ve been able to lower the purchase price. • Simplified, Convenient Access – Access through the Online Learning Center, along with other AAN learning content. Note, with the move to an online offering, hard drives will not be provided.

• Complimentary Earbuds – Pre-order before the Annual Meeting and receive free wireless earbuds. • Be sure to visit the eLearning Innovation and Networking space at the Annual Meeting for any Annual Meeting On Demand or other online learning questions!

Gold Registration = Best Value! Upgrade to Gold Registration and receive all sessions at the meeting* as well as access to Annual Meeting On Demand so you don’t miss out on concurrent sessions.

Not attending the 2019 Annual Meeting? You can still purchase online and receive a special discount if you order by May 10, 2019.

BY MARCH 7, 2019

MARCH 8APRIL 11, 2019

AFTER APRIL 11, 2019

STUDENT MEMBERS AND NONMEMBER STUDENTS

$99

HONORARY AND SENIOR MEMBERS

$279

INTERN AND JUNIOR MEMBERS

$369

$399

$459

Gold Registration

NON-PHYSICIAN MEMBERS (ADVANCED PRACTICE PROVIDER, BUSINESS ADMINISTRATOR, RESEARCHER)

$544

$594

$694

NEUROLOGIST AND PHYSICIAN AFFILIATE MEMBERS

$1,024

$1,109

$1,284

NONMEMBERS

$1,689

$1,834

$2,129

*Specific presentations within a session may not be available based on permissions granted by the presenter.

AAN.com/view/AMOD2019

Non-attendee Pricing STUDENT MEMBERS/NONMEMBERS, INTERN, JUNIOR, AND NON-PHYSICIAN MEMBERS

$179

NEUROLOGIST AND PHYSICIAN AFFILIATE, HONORARY, AND SENIOR MEMBERS

$479

NONMEMBERS

$779

HOTELS AND RESERVATIONS Why Book a Hotel Room Through the AAN? Shuttle bus service is complimentary to those who book within the block (a $15/day value!) Greater networking opportunities Pre-vetted hotels with discounted rates and easy-tomodify reservations Friendly booking terms: No change fees or full prepayment upon booking Housing representatives are available in advance and on-site for assistance with official hotels Discounted hotel rates are available until April 2, 2019, or until the block is filled. After this date, reservations are subject to availability.

Save on Hotel Reservations Annual Meeting hotel reservations are processed by the AAN’s official housing vendor, Convention Management Resources (CMR). Online booking allows you to: Take advantage of the AAN’s discounted hotel rates View room descriptions, photos, and availability Access maps of hotel proximity to Annual Meeting locations AAN Online Hotel Reservations are available: Online: AAN.com/view/BookHotel Phone: US/Canada (800) 676-4226 International (415) 979-2283 Monday–Friday: 6:00 a.m.–6:00 p.m. PT

Group Accommodations Deadline: March 1, 2019 Blocks of 10 or more sleeping rooms are considered a group. Submit your request at aanam.cmrushelp.com and you will be contacted by an AAN Housing Consultant.

226 2019 AAN Annual Meeting

Look for this seal to ensure you are booking through the AAN’s official housing vendor, CMR, and avoid fraudulent sites by only booking on sites where you see this seal.

DESIGNED TO DEVELOP YOUR SKILLS FOR SUCCESS

“

The secret to great leadership is cultivating a multi-dimensional skill set. Honed over time, these skills offer the opportunity to successfully navigate and drive positive change in health care.

–Terrence L. Cascino, MD, FAAN

AAN Past President, Chair, Leadership Development Committee

World-renowned consultants and physician leaders in the field of neurology have collaborated to create a full complement of Leadership University programs for the 2019 Annual Meeting. Look for the Leadership Univeristy icon L throughout this program to choose courses that take your career to the next level.

PERSONAL DEVELOPMENT L Strengths Spotting: Using Strengths to Help

Improve Communication with Patients, Colleagues, and Leaders

L Team Building in Medicine: How to

Incorporate Strengths Training into Medical Teams

COMMUNICATION L Women in Leadership L Mitigating the Impact of Unconscious

Bias Workshop

L Women in Leadership: 2019, Why Are We Still

Talking About This?

RESILIENCE L Leadership Challenges in Practice L The Doctor’s Lounge: Helping Physician’s

in Mid-career Renew and Repurpose Their Work/Lives Proposed

FUNDAMENTALS L Educators’ Leadership Program L Chief Resident Leadership Program

WELLNESS L Leadership in the Era of Burnout: A

Practical Approach to Becoming a True Physician Leader

HOTELS AND AMENITIES

Choose from a variety of hotels with excellent amenities, including complimentary internet* and convenient access to the Annual Meeting and Philly’s neighborhoods. Lowest Available Rate**

Distance to Pennsylvania Convention Center

In-House Restaurant

On Shuttle Route

Philadelphia Marriott Downtown 1201 Market Street Philadelphia, PA 19107

$285

1 Block



Walkable

Aloft Philadelphia Downtown 101 North Broad Street Philadelphia, PA 19107

$274

1 Block

Walkable

$199

2 Blocks

Walkable

Best Western Plus Philadelphia Convention Center 1225 Vine Street Philadelphia, PA 19107 Cambria Hotel & Suites Philadelphia Downtown Center City 219 South Broad Street Philadelphia, PA 19107

$185

3 Blocks



Shuttle

Courtyard Philadelphia Downtown 21 North Juniper Street Philadelphia, PA 19107

$249

1.5 Blocks



Walkable

$259

5 Blocks



Shuttle

DoubleTree Hotel Philadelphia Center City 237 Broad Street Philadelphia, PA 19107 Embassy Suites Philadelphia Center City 1776 Benjamin Franklin Parkway Philadelphia, PA 19103

$266

6 Blocks



Shuttle

Fairfield Inn & Suites Philadelphia Downtown/Center City 261 South 13th Street Philadelphia, PA 19107

$229

5 Blocks



Shuttle

Four Points by Sheraton Philadelphia Center City 1201 Race Street Philadelphia, PA 19107 Hampton Inn Philadelphia Center City - Convention Center 1301 Race Street Philadelphia, PA 19107 Hilton Garden Inn Philadelphia Center City 1100 Arch Street Philadelphia, PA 19107

$209

1 Block



Walkable

$268

1 Block



Walkable

$249

1 Block



Walkable



Shuttle

Official Hotel Name / Hotel Address

9 10

$249

1.6 Miles

Hilton Philadelphia at Penn's Landing 201 South Columbus Boulevard Philadelphia, PA 19106 Holiday Inn Express Philadelphia - Midtown 1305 Walnut Street Philadelphia, PA 19107

$221

4 Blocks

Shuttle

Holiday Inn Express Philadelphia East - Penns Landing 100 North Christopher Columbus Boulevard Philadelphia, PA 19106

$189

1.5 Miles

Shuttle

Home2 Suites Philadelphia – Center City 1200 Arch Street Philadelphia, PA 19107 Homewood Suites by Hilton University City Philadelphia 4109 Walnut Street Philadelphia, PA 19104 Hotel Monaco Philadelphia 433 Chestnut Street Philadelphia, PA 19106 Hotel Palomar Philadelphia 117 South 17th Street Philadelphia, PA 19103

$275

1 Block

Walkable

$259

2.5 Miles

Shuttle

$329

7 Blocks



Shuttle

$299

10 Blocks



Shuttle

Le Meridien Philadelphia 1421 Arch Street Philadelphia, PA 19102 Loews Philadelphia Hotel 1200 Market Street Philadelphia, PA 19107

$363

1 Block



Walkable

$259

1 Block



Walkable

Philadelphia 201 Hotel, a Marriott Supported Hotel 201 North 17th Street Philadelphia, PA 19103 Renaissance Philadelphia Downtown 401 Chestnut Street Philadelphia, PA 19106

$229

5 Blocks



Shuttle

$289

8 Blocks



Shuttle

$259

2 Blocks

$321

3 Blocks



Walkable

Residence Inn Philadelphia Center City 1 East Penn Square Philadelphia, PA 19107 Ritz-Carlton Philadelphia 10 Avenue of the Arts Philadelphia, PA 19102 Sheraton Philadelphia Society Hill Hotel 1 Dock Street Philadelphia, PA 19106-3996

$219

1.3 Miles



Shuttle

Sheraton Philadelphia University City Hotel 3549 Chestnut Street Philadelphia, PA 19104

$179

2 Miles



Shuttle

Sofitel Philadelphia 120 South 17th Street Philadelphia, PA 19103

$300

7 Blocks



Shuttle

Sonesta Philadelphia Downtown Rittenhouse Square 1800 Market Street Philadelphia, PA 19103

$279

5 Blocks



Shuttle

15 16 17 18 19 20 21 22 23

Walkable

*All hotels booked through the AAN include complimentary internet except the Philadelphia Marriott Downtown. **Availability may be limited; other room categories may be available at a higher rate. Rates do not include hotel tax. Rates include an $8 per night assessment fee to offset the expense of the meeting. For deposit and other information, visit AAN.com/view/BookHotel.

228 2019 AAN Annual Meeting

The Bellevue Hotel, Hyatt Unbound Collection 200 South Broad Street Philadelphia, PA 19102

$309

7 Blocks



Shuttle

The Logan Philadelphia, Curio Collection by Hilton 1 Logan Square Philadelphia, PA 19103

$309

6 Blocks



Shuttle

The Study at University City 20 South 33rd Street Philadelphia, PA 19104

$256

2 Miles



Shuttle

The Warwick Hotel Rittenhouse Square 220 South 17th Street Philadelphia, PA 19103-6179

$253

8 Blocks



Shuttle

The Windsor Suites Philadelphia 1700 Benjamin Franklin Parkway Philadelphia, PA 19103 Westin Philadelphia 99 South 17th Street Philadelphia, PA 19103 Wyndham Philadelphia Historic District 400 Arch Street Philadelphia, PA 19106

$224

4 Blocks



Shuttle

$355

8 Blocks



Shuttle

$199

8 Blocks



Shuttle

Convention Center Anchored by the Pennsylvania Convention Center, this bustling district is a go-to for architecture and history buffs, and art and food lovers.

Rittenhouse Square Enjoy public art, upscale shopping, al fresco dining, and Civil-War era mansions—all near a tree-filled public park in Center City Philadelphia.

Old City/Society Hill Home to more historic buildings from the American colonial and federal periods than anywhere else in the United States, this area boasts a vibrant arts scene.

University City A hub for higher education, this neighborhood is home to top universities, including University of Pennsylvania and Drexel University. Washington Square District Lively dining spots, vibrant nightlife, and plenty of LGBT-friendly establishments fill this quaint, historic neighborhood.

33 Chestnut St

26 17

m St

11th St

2nd St

INDEPENDENCE i NATIONAL HISTORICAL PARK

Sansom St

Walnut St Locust St

WASHINGTON SQUARE

SOCIETY HILL

Spruce St

24 Locust St

CITY PARK

2nd St

3rd St

4th St

5th St

6th St

7th St

th St

12th St h St

Broad St

iper St

AAN.com/view/AM19Sci 229

Pine St Lombard St

Delaware E

Lombard St

PENN'S LANDING

er Colu Christoph

Lombard St

mbus

16 21

Chestnut St THOMAS JEFFERSON UNIVERSITY

UNIVERSITY OF THE ARTS

Pine St

C hristopher Colu

3rd St 3rd St

5th St

6th St

8th St

9th St

7th St

Spruce St

Market St S

t ck S

Locust St

RITTENHOUSE

Delaware Av

4th St

5th St

6th St

8th St

9th St

10th St

11th St

12th St

13th St

MARKET EAST STATION

PHILADELPHIA

Walnut St

Sansom St

RITTENHOUSE SQUARE

S. Penn Sq

OLD CITY

Front St

Market St

CITY HALL

1 14

Arch St

Front St

4Filbert St

Cherry St

2nd St

JFK PLAZA

676

Race St

4th St

Arch St

DELA

New St

FRANKLIN SQUARE

CHINATOWN

Callowhill St

676 Vine St

10th St

17th St

Cherry St

Wood St

12th St

611

Race St

Kennedy Bl

Juniper St

20 18th St

19th St

20th St

21st St

22nd St

Arch St

15th St

LOGAN SQUARE

ce St

ry St

Wood St

Vine Street Expwy

Broad St

Winter St

676

15th St

Wood St

16th St

Willow St

Callowhill St

16th St

18th St

20th St

Noble S

in P

nkl

wn into nkl

Fra

American St

5th St

Buttonwood St

Noble St

min

6th St

7th St

8th St

10th St

Percy St

11th St

12th St

Front St

34th St

35th St

Spring Garden St

UNIVERSITY CITY ill St ll hhill Callowhill Callowh C

nja

Green St

Poplar St

Brown St

Spring Garden St

S Walnut St

Hamilton St

Green St

36th St

ng Garden G d St Spring

15th St

16th St

17th St

Chestnut St

ndywinee St Brandywine

18th St

19th St

21st St

en St Green

Fairmount

Broad St

Wallace St

Mt. Vernon St

Pennsylvania Convention Center Pennsylvania Convention Center

13th St

North St

Orianna S

nt Av

2nd St

Brown S

Fairmou

3rd St

Parkway/Museums District Modeled after the Champs-Élysées, the Benjamin Franklin Parkway is home to some of the nation’s most iconic museums and institutions.

On Shuttle Route

22nd St

Distance to Pennsylvania In-House Convention Center Restaurant

Lowest Available Rate**

Official Hotel Name / Hotel Address

INDUSTRY THERAPEUTIC UPDATES* Saturday, May 4

Monday, May 6 |

Tuesday, May 7

Join industry representatives for unique opportunities to learn about current therapies and projects in the industry pipeline. Registration for these informational sessions is free and open to all registered Annual Meeting attendees.

Saturday, May 4 Novartis Pharmaceuticals Location: Philadelphia Marriott Downtown Room: Liberty Ballroom

Monday, May 6 Avanir Pharmaceuticals, Inc. Location: Philadelphia 201 Hotel Room: Liberty Ballroom B Alexion Pharmaceuticals Location: Philadelphia 201 Hotel Room: Independence Ballroom Biogen Location: Loews Philadelphia Hotel Room: Millennium Hall Biogen Location: Philadelphia 201 Hotel Room: Liberty Ballroom A

EMD Serono, Inc. Location: Philadelphia Marriott Downtown Room: Liberty Ballroom Genentech Location: Philadelphia Marriott Downtown Room: Independence Ballroom Genentech Location: Philadelphia 201 Hotel Room: Philadelphia Ballroom

Novartis Pharmaceuticals Location: Loews Philadelphia Hotel Room: Congress Hall Sunovion Pharmaceuticals Inc. Location: Loews Philadelphia Hotel Room: Commonwealth Ballroom Teva CNS Location: Philadelphia 201 Hotel Room: Freedom Ballroom

RSVP is recommended for these events. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events. Please visit AAN.com/view/ITU for more information and to RSVP.

Wednesday, May 8

Starting at 7:00 p.m.

Tuesday, May 7 AbbVie, Inc. Location: Philadelphia 201 Hotel Room: Liberty B Ballroom

Lundbeck Location: Philadelphia Marriott Downtown Room: Liberty Ballroom

Acorda Therapeutics Inc. Location: Loews Philadelphia Hotel Room: Commonwealth Ballroom

Merck & Co., Inc. Location: Philadelphia 201 Hotel Room: Freedom Ballroom

Akcea Therapeutics Location: Philadelphia 201 Hotel Room: Liberty A Ballroom

Novartis Pharmaceuticals Location: Loews Philadelphia Hotel Room: Millennium Hall

Biogen Location: Philadelphia Marriott Downtown Room: Independence Ballroom

Teva CNS Location: Loews Philadelphia Hotel Room: Congress Hall

EMD Serono, Inc. Location: Philadelphia 201 Hotel Room: Philadelphia Ballroom

Wednesday, May 8 AveXis, Inc. Location: Philadelphia Marriott Downtown Room: Liberty Ballroom

Sanofi Genzyme A New Look at Gender-based Issues Throughout the MS Continuum Location: Philadelphia Marriott Downtown Room: Grand Ballroom

*As of January 31, 2019. Subject to Change.

With hereditary transthyretin-mediated (hATTR) amyloidosis...

Patients and their families face a future of functional decline1-3

Important Safety Information Infusion-Related Reactions (IRRs) In a controlled clinical study, 19% of ONPATTROtreated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache. To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. References: 1. Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013; 8:31. 2. Coutinho P, Martins da Silva A, Lopes Lima JL, et al. Amyloid and amyloidosis: Proceedings of the Third International Symposium on Amyloidosis, Póvoa de Varzim, Portugal, 23-28 September 1979. Amsterdam: Excerpta Medica; 1980:88-98. 3. Vinik EJ, Vinik AI, Paulson JF, et al. J Peripher Nerv Syst. 2014;19:104-119. 4. ONPATTRO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2018. 5. Adams D, Coelho T, Obici L, et al. Neurology. 2015;85(8):675-682. 6. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. N Engl J Med. 2018;379(1):11-21. 7. Center for Drug Evaluation and Research. NDA 210922—patisiran—cross-discipline team leader review. U.S. Department of Health and Human Services, Food and Drug Administration; 2018.

Reduced Serum Vitamin A Levels and Recommended Supplementation ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness). Adverse Reactions The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%). Please see brief summary of full Prescribing Information following this ad.

ONPATTRO® (patisiran) can reverse polyneuropathy manifestations of the disease4 A novel RNAi-based approach that may transform the future for your patients1,4-6 ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

At 18 months, ONPATTRO demonstrated: Study Design The efficacy of ONPATTRO was demonstrated in a randomized, double-blind, placebo-controlled, multicenter clinical trial in adults with hATTR amyloidosis with polyneuropathy. Patients were randomized to receive ONPATTRO 0.3 mg/kg (N=148) or placebo (N=77) via intravenous infusion once every 3 weeks for 18 months. Primary endpoint: The modified Neuropathy Impairment Score + 7 (mNIS+7) is an objective 304-point assessment of neuropathy that measures cranial nerve function, muscle strength, reflexes, postural blood pressure, quantitative sensory testing, and peripheral nerve electrophysiology. Key secondary endpoint: The Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) scale is a patient-reported assessment that evaluates neuropathy in the following domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy (score range -4 to 136). Select secondary endpoint: The Composite Autonomic Symptom Score 31 (COMPASS 31) is a patient-reported questionnaire that evaluates 6 autonomic domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor (score range 0 to 100).

Reversal in neuropathy impairment4 • Mean change from baseline in mNIS+7 of -6.0 points vs 28.0 with placebo, a treatment difference of -34 points (95% CI: -39.9, -28.1; p<0.001)

Improvement in quality of life4 • Mean change from baseline in Norfolk QoL-DN score of -6.7 points vs 14.4 with placebo, a treatment difference of -21.1 points (95% CI: -27.2, -15.0; p<0.001)

Reduction in autonomic symptoms6,7 • Mean change from baseline in COMPASS 31 of -5.3 points vs 2.2 with placebo, a treatment difference of -7.5 points (95% CI: -11.9, -3.2; p<0.001) CI=confidence interval; RNA=ribonucleic acid; RNAi=RNA interference.

Visit Booth #2401 to find out more.

THANK YOU

2O19 ANNUAL MEETING SUPPORTERS* The American Academy of Neurology (AAN) thanks the following companies, foundations, and organizations for their demonstrated vision, commitment, and strong support of programs which find answers and improve lives through neurologic education and research. AbbVie, Inc.

Door Drop Inserts Exhibit Hall Passport Industry Therapeutic Update Onsite Exhibit Guide Advertisement

ACADIA Pharmaceuticals Inc. Diversity Leadership Program Emerging Leaders Program Women Leading in Neurology Leadership Program

Acorda Therapeutics, Inc.

Exhibit Hall Passport Exhibit Hall Presentation Stage Industry Therapeutic Update On-site Guide Advertisement

Adamas Pharmaceuticals, Inc. Door Drop Inserts Exhibit Hall Passport Onsite Exhibit Guide Advertisement

Akcea Therapeutics Industry Therapeutic Update

Alexion Pharmaceuticals Industry Therapeutic Update

Alnylam Pharmaceuticals AANextra Advertisment Science Program Advertisement

Allergan, Inc. Leadership Program Transforming Leaders Program Women Leading in Neurology Leadership Program

The Allergan Foundation Medical Student Diversity Program: Annual Meeting Scholarship

Amgen and Novartis Pharmaceuticals Corporation

Industry Therapeutic Update Exhibit Hall Buzz Café Exhibit Hall 20’ x 20’ Charging Hub Exhibit Hall Passport Door Drop Bag Sponsorship On-site Guide Advertisement

Arbor Pharmaceuticals

5K Run/1K Walk for Brain Research Exhibit Hall Footprints Exhibit Hall Passport Exhibit Hall Trifold Map

Avanir Pharmaceuticals, Inc. Brain Health Fair Silver Sponsor Industry Therapeutic Update Science Program Advertisement

AveXis, Inc.

5K Run/1K Walk for Brain Research AANextra Advertisement Door Drop Insert Exhibit Hall Charging Lounge Exhibit Hall Footprints Exhibit Hall Presentation Stage Exhibit Hall Tabletop Graphics Industry Therapeutic Update On-site Guide Advertisement

Biogen

5K Run/1K Walk for Brain Research AANextra Advertisement Door Drop Inserts Exhibit Hall 20’ x 20’ Charging Hub Exhibit Hall Aisle Carpet Exhibit Hall Overhead Exit Banner Exhibit Hall Passport Exhibit Hall Pillar Marketing Exhibit Hall Presentation Stages Exhibit Hall Street Lamps Exhibit Hall Table Top Graphics Hotel Key Cards & Card Sleeves Industry Therapeutic Updates On-site Guide Advertisements Poster Hall Charging Hub

Boston Scientific On-site Guide Advertisement

Celgene Corporation

5K Run/1K Walk for Brain Research AANextra Advertisement Brain Health Fair Platinum Sponsor Cell Charging Station Exhibit Hall 20’ x 20’ Charging Hub Exhibit Hall Aisle Carpet Exhibit Hall Footprints Exhibit Hall Pillar Marketing Exhibit Hall Tabletop Graphics Exhibit Hall Wayfinding Map General Support of the Annual Meeting On-site Guide Advertisement Poster Hall Charging Hub

CSL Behring

AANextra Advertisement Door Drop Bag Sponsorship Exhibit Hall Passport Exhibit Hall Pillar Marketing

Cure SMA Exhibit Hall Passport

Eisai Inc. C108 Clinical Epilepsy II: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly Brain Health Fair Silver Sponsorship Door Drop Inserts Exhibit Hall Passport

EMD Serono, Inc.

5K Run/1K Walk for Brain Research AANextra Advertisement Door Drop Inserts Exhibit Hall 20’ x 20’ Charging Hub Exhibit Hall Aisle Carpet Exhibit Hall Digital Billboard Exhibit Hall Entrance Wall Clings Exhibit Hall Floor Entrance Graphics Exhibit Hall Footprints Exhibit Hall Networking Reception Exhibit Hall Passport Exhibit Hall Pillar Marketing Exhibit Hall Presentation Stage Exhibit Hall Tabletop Graphics Industry Therapeutic Updates Mobile App Sponsor On-site Guide Advertisements

Genentech, a member of the Roche Group

5K Run/1K Walk for Brain Research AANextra Advertisement Door Drop Inserts Exhibit Hall Pillar Marketing Exhibit Hall Presentation Stage Exhibit Hall Tabletop Graphics Industry Therapeutic Updates On-site Guide Advertisement Wi-Fi Access on Shuttle Buses

Greenwich Biosciences, Inc.

5K Run/1K Walk for Brain Research AANextra Advertisement Brain Health Fair Silver Sponsorship Exhibit Hall Footprints Fellows Scholarship Fund Science Program Advertisement

Jazz Pharmaceuticals, Inc. C55: Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence C198: Integrating Sleep Medicine Concepts into Your Child Neurology Practice

Lundbeck, LLC Industry Therapeutic Update

Merck & Co., Inc. Industry Therapeutic Update

Neurocrine Biosciences AANextra Advertisement Door Drop Insert Transforming Leaders Program

Nihon Kohden America, Inc. Exhibit Hall Passport

Novartis Pharmaceuticals Corporation

Exhibit Hall 20’ x 20’ Charging Hubs Exhibit Hall Buzz Cafés Exhibit Hall Park Benches Exhibit Hall Passport Exhibit Hall Presentation Stage Exhibit Hall Tabletop Graphics Industry Therapeutic Updates On-site Guide Advertisement

Promius Pharmaceuticals Cell Phone Charging Locker

Sanofi Genzyme

Door Drop Insert Diversity Leadership Program Emerging Leaders Program Industry Therapeutic Update On-site Guide Advertisement Transforming Leaders Program Women Leading in Neurology Leadership Program

sk life science, a subsidiary of SK biopharmaceuticals Exhibit Hall Passport

Sunovion Pharmaceuticals Inc.

5K Run/1K Walk for Brain Research AANextra Advertisement Brain Health Fair Silver Sponsor Door Drop Inserts Exhibit Hall Aisle Carpet Exhibit Hall Charging Lounge Exhibit Hall Opening Luncheon Exhibit Hall Passport Exhibit Hall Tabletop Graphics Industry Therapeutic Update

Supernus Pharmaceuticals, Inc.

Brain Health Fair Silver Sponsor Diversity Leadership Program Door Drop Inserts Emerging Leaders Program Exhibit Hall Passport On-site Guide Advertisement

Teva CNS

AANextra Advertisement Door Drop Insert Industry Therapeutic Updates On-site Guide Advertisement

UCB Inc. Women Leading in Neurology Leadership Program

Variantyx Inc. Exhibit Hall Passport

Wolters Kluwer Health, AAN Publishing Partner for: Neurology®, Neurology® Clinical Practice, Neurology® Neuroimmunology & Neuroinflammation, Neurology® Genetics, Continuum®, Neurology Today®, and Brain & Life®

Annual Meeting Book Bags Brain Health Fair Book Bags Cell Phone Charging Locker Convention Center Wi-Fi Access Exhibit Hall Passport Posters Online Residents and Fellows Scholarship Fund

*As of January 25, 2019

TRAVEL INFORMATION The Annual Meeting offers several money-saving options on travel reservations. For 2 to 10 percent discounted airline tickets, use the below discount codes when booking directly through Delta or United Airlines. Please note, flights booked with United Airlines will need to provide both the discount code and the agreement code. Airline/Rental Car

Discount Code/Contract ID

Phone Number

Website

Delta United

NY2EQ ZFR2755632

(800) 328-1111 (800) 428-1122

Delta.com United.com

Alamo Hertz

LEADERS 1170024

(844) 354-6962 (800) 654-3131

Alamo.com Hertz.com

TRAVEL TIPS Travel Documents/Passports and Entry Requirements Non-US visitors must have valid travel documents/passports to enter Philadelphia to provide proof of their citizenship. Document requirements vary depending on your country of origin, citizenship, the reason for your visit, and the length of your stay, and may include passport or a birth certificate, photo ID, and/or a visa. For more information, or to request a Letter of Announcement for the 2019 Annual Meeting, visit AAN.com/view/AMinfo.

Currency Philadelphia’s currency is the US dollar; currency exchange is available at banks and kiosks throughout the city and at the airport. Cash machines/ ATMs are available in most banks, hotels, and shopping centers. For denominations under one dollar, the currency is coins.

Customs and Immigration From an international point of arrival, upon arriving in Philadelphia, you will be required to go through a US Customs and Border Protection (CBP) inspection. Before you land, your flight crew will distribute an Immigration and Customs Declaration Form for you to complete; forms are also available at the airport upon your arrival. You will need to present this form, along with your passport, visa (if any), and return tickets to the CBP officer.

Health Insurance Be sure to check with your health insurance provider about policy coverage away from home—particularly if you’re insured by an HMO and/or Medicare/Medicaid.

Airport and Luggage The Philadelphia, PA, area is served by the Philadelphia International Airport (PHL) which is 10 miles from the Pennsylvania Convention Center. Restrictions for carry-on baggage and weight and size limits for checked baggage are different for international flights than for domestic flights. Be sure to check with your individual carrier as to weight and measurement restrictions and associated costs for overages.

238 2019 AAN Annual Meeting

Measurements Philadelphia uses the United States customary system for weights and measurements. If you choose to drive in Philadelphia be aware the speed limits are posted in miles per hour.

Medication If you are entering Philadelphia with prescription drugs and syringes: keep the medication in its original, labeled container; include medical certificate with syringes showing they are for medical use and have them declared to US Customs officials; bring an extra prescription in case your medication is lost and/or to attest to your need to take such prescriptions; and carry the generic name of prescription medicines.

Mobile Phone Service Contact your service provider directly to inquire if service is available and/or the applicable rates.

Time Zone Philadelphia is in the Eastern Time Zone. In May, it will be the same time as New York, one hour ahead of Chicago, three hours ahead of Los Angeles, five hours behind London, and 13 hours behind Tokyo. For more information, visit AAN.com/view/AMinfo.

Weather/Attire May brings warm temperatures to Philadelphia. Daily maximum temperatures usually range from 70 to 75 degrees Fahrenheit. The minimum temperature usually falls between 50 and 55 degrees Fahrenheit. The AAN promotes business casual attire for the duration of the meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary.

AAN.com/view/AM19Sci 239

240 2019 AAN Annual Meeting

AAN.com/view/AM19Sci 241

THE FINAL ACT:

SEE YOU AT THE CLOSING PARTY! Experience the power of flower!

Friday, May 10 5:30 p.m. – 7:00 p.m. Pennsylvania Convention Center–Ballroom B An amazing week calls for an amazing after party. This year’s closing celebration theme is a unique floral May Day extravaganza where you can enjoy: • Live music by the Philadelphia String Quartet • Special botanical guests • Refreshments and libations • Floral selfie wall • And more!

LOVE

KINDNESS

One FREE ticket for registered conference attendees. Tickets for additional guests can be purchased through registration for $50.

HOPE

We’ve pulled out all the stops for the last day

Grand Friday

Finale

Don’t Miss the Friday Grand Finale

SCHEDULE

An amazing week deserves an amazing finish. Get ready for a tour de force of engaging events, fun activities, and insightful presentations throughout the entire day. Oh, and did we mention the May Day Closing Party? This will definitely be a day to remember.

9:15 a.m. - 11:30 a.m.

Neurology Year in Review Plenary Session highlighting the latest research from the past year within a specific subspecialty topic

11:30 a.m. - 1:00 p.m. Innovation Lunch with a unique, cross-subspecialty session focused on neuroimaging 1:00 p.m. - 3:00 p.m. • Four major scientific sessions including MS, neuromuscular, stroke, and headache – selected to appeal to a wide variety of attendees • Four update programs covering movement disorders, aging/dementia, epilepsy, and neuro-ophthalmology/neuro-otology 3:30 p.m. - 4:30 p.m. Education Blitz Programs - Quick-fire education programming for those hungry for more learning opportunities covering child concussion, normal pressure hydrocephalus, emerging infectious diseases, evolution of autoimmune neurology, MS, and sleep 5:00 p.m. Closing Party Celebrating May Day

2O19 AAN Annual Meeting Science Program

201 Chicago Avenue Minneapolis, MN 55415

72nd AAN Annual Meeting

73rd AAN Annual Meeting

74th AAN Annual Meeting

Toronto, Ontario, Canada April 25–May 1, 2020

San Francisco, CA April 17–April 23, 2021

Seattle, WA April 2–8, 2022

AAN Member Services: (800) 879-1960

Use #AANAM and follow the AAN

AMERICAN ACADEMY OF NEUROLOGY

Future AAN Annual Meeting Dates and Locations